data_1sro_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1sro _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.474 HG21 ' HG2' ' A' ' 59' ' ' LYS . 40.6 t . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.622 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 15.2 m-85 -136.17 129.19 31.32 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.967 -1.083 . . . . 0.0 110.386 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.5 m -76.91 102.06 6.21 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 178.264 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -83.14 113.81 3.74 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 119.813 -1.184 . . . . 0.0 110.73 -178.262 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.525 ' O ' HG12 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -89.31 153.87 20.54 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 178.697 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.551 ' CG2' HD12 ' A' ' 50' ' ' LEU . 77.1 t -87.43 116.11 29.12 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 O-C-N 120.759 -1.213 . . . . 0.0 109.116 -179.572 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.519 ' O ' ' CD ' ' A' ' 15' ' ' ARG . 0.2 OUTLIER -126.72 7.24 6.8 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.386 -0.821 . . . . 0.0 109.473 -179.396 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.519 ' CD ' ' O ' ' A' ' 14' ' ' THR . 1.9 mtp180 -178.26 149.52 0.53 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.304 -0.872 . . . . 0.0 109.575 179.692 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 33.6 mt -140.9 157.16 22.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.656 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -135.78 152.93 31.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.858 -1.151 . . . . 0.0 110.057 -179.395 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -58.62 -41.44 85.93 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.721 -1.237 . . . . 0.0 109.035 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.656 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 17.3 p90 -90.41 28.68 1.41 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.363 -0.836 . . . . 0.0 110.33 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.637 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 151.72 -152.29 24.07 Favored Glycine 0 N--CA 1.491 2.326 0 C-N-CA 119.073 -1.537 . . . . 0.0 111.018 -179.607 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.475 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -151.75 147.11 26.29 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.125 -1.221 . . . . 0.0 108.938 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.629 ' CE1' HD12 ' A' ' 32' ' ' LEU . 8.8 m-30 -106.93 158.66 16.85 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 179.642 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.565 ' CG2' ' CG2' ' A' ' 33' ' ' VAL . 31.8 t -147.61 161.92 7.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.035 -1.041 . . . . 0.0 109.858 -179.154 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.543 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -139.74 150.34 44.68 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.103 -0.998 . . . . 0.0 109.436 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.537 ' CG1' ' O ' ' A' ' 29' ' ' LYS . 4.5 pt . . . . . 0 N--CA 1.494 1.726 0 O-C-N 120.823 -1.173 . . . . 0.0 109.706 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.537 ' O ' ' CG1' ' A' ' 25' ' ' ILE . 14.7 mtpt . . . . . 0 N--CA 1.489 1.476 0 CA-C-O 121.445 0.64 . . . . 0.0 109.389 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.543 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 1.1 mt-10 -130.34 158.8 38.83 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.061 -1.024 . . . . 0.0 110.356 -179.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 23' ' ' VAL . . . -108.68 -173.73 21.48 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 179.328 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.629 HD12 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.26 123.21 8.76 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.853 -1.381 . . . . 0.0 110.682 179.751 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.565 ' CG2' ' CG2' ' A' ' 23' ' ' VAL . 60.8 t -97.67 62.16 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 177.662 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.487 ' HB3' ' HG3' ' A' ' 37' ' ' GLN . 3.3 t-80 -48.39 159.49 0.21 Allowed 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.692 -1.255 . . . . 0.0 108.147 -179.623 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.547 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 3.1 tp -48.58 -50.35 12.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.587 0 O-C-N 121.099 -1.001 . . . . 0.0 110.09 -179.121 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 5.3 m -81.57 41.22 0.62 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.182 -0.949 . . . . 0.0 110.424 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.487 ' HG3' ' HB3' ' A' ' 34' ' ' HIS . 40.3 mt-30 -150.69 53.0 0.88 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.847 -1.158 . . . . 0.0 110.245 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.633 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.6 mp -119.09 -98.92 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.928 -1.107 . . . . 0.0 109.936 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.503 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.302 -1.469 0 O-C-N 121.315 -0.866 . . . . 0.0 109.641 -179.424 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.626 ' CG2' ' CZ ' ' A' ' 49' ' ' TYR . 80.4 t . . . . . 0 N--CA 1.487 1.401 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.425 ' C ' ' O ' ' A' ' 43' ' ' VAL . 0.0 OUTLIER -43.73 -26.66 0.26 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.38 -0.825 . . . . 0.0 108.896 179.849 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.459 ' O ' HG11 ' A' ' 43' ' ' VAL . 0.1 OUTLIER -109.83 114.33 27.8 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.495 -0.753 . . . . 0.0 108.988 179.479 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.535 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -78.16 -24.14 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.141 -0.975 . . . . 0.0 108.62 179.747 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 3.7 p -76.22 1.61 15.45 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.44 -0.787 . . . . 0.0 109.344 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.429 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 14.4 m-20 -96.05 -40.35 9.29 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.111 -0.993 . . . . 0.0 108.926 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.633 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 9.5 m-85 -89.56 -28.77 19.36 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.487 -0.758 . . . . 0.0 109.019 179.715 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.551 HD12 ' CG2' ' A' ' 13' ' ' VAL . 0.1 OUTLIER -102.75 134.74 45.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.504 -0.748 . . . . 0.0 109.537 -179.842 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.507 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 1.9 tt0 -140.39 143.03 35.45 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.59 -0.694 . . . . 0.0 109.314 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 39.1 mtm -67.54 93.77 0.38 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.179 -0.951 . . . . 0.0 109.441 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.69 -18.91 4.81 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' GLN . . . . . 0.449 ' O ' HG22 ' A' ' 13' ' ' VAL . 11.6 mm-40 -79.7 124.86 28.96 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.328 -1.101 . . . . 0.0 109.637 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -106.27 117.78 34.94 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.257 -0.902 . . . . 0.0 109.109 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.446 HG22 HG12 ' A' ' 73' ' ' ILE . 33.8 m -118.98 151.76 50.85 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.134 -0.979 . . . . 0.0 109.836 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 56' ' ' VAL . 36.0 Cg_endo -78.87 142.57 17.72 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.695 2.264 . . . . 0.0 110.509 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.484 ' CG2' ' HB3' ' A' ' 71' ' ' LEU . 0.9 OUTLIER -141.67 -177.22 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.211 -0.931 . . . . 0.0 109.354 179.622 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.474 ' HG2' HG21 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -134.03 128.73 34.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.283 -0.886 . . . . 0.0 109.475 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.622 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 62.0 t . . . . . 0 N--CA 1.491 1.597 0 O-C-N 121.266 -0.896 . . . . 0.0 109.037 179.504 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.484 ' HB3' ' CG2' ' A' ' 58' ' ' VAL . 15.1 mt . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -118.21 106.64 13.03 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.341 -0.849 . . . . 0.0 109.871 -179.618 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.446 HG12 HG22 ' A' ' 56' ' ' VAL . 0.1 OUTLIER -58.77 139.12 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.269 -0.894 . . . . 0.0 109.001 179.865 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 2.4 mmtm . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.26 -0.9 . . . . 0.0 109.281 179.803 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.457 HG11 ' O ' ' A' ' 58' ' ' VAL . 48.1 t . . . . . 0 N--CA 1.489 1.486 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.519 ' CE1' HG22 ' A' ' 60' ' ' VAL . 3.0 m-85 -110.31 179.92 3.95 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.156 -0.965 . . . . 0.0 109.392 179.775 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.464 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 3.5 m -136.65 107.58 6.68 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 178.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.486 ' HA2' ' O ' ' A' ' 24' ' ' ALA . . . -109.82 141.6 16.2 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.065 -1.541 . . . . 0.0 110.331 -178.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.497 ' O ' HG11 ' A' ' 23' ' ' VAL . 27.4 mtpt -89.15 163.73 15.32 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 178.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.541 ' CG1' HD21 ' A' ' 50' ' ' LEU . 95.3 t -87.43 102.02 11.94 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.542 ' CG2' ' HB1' ' A' ' 24' ' ' ALA . 1.2 p -106.12 -11.67 16.02 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.478 -0.764 . . . . 0.0 110.186 -178.62 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.539 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -161.2 156.33 24.07 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.954 -1.091 . . . . 0.0 110.455 -179.781 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.461 ' HA ' ' HA ' ' A' ' 21' ' ' ALA . 24.1 mt -147.61 142.77 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.161 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.685 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 1.5 m -120.79 157.82 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.898 -1.126 . . . . 0.0 110.186 -178.771 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.2 -39.41 86.46 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.807 -1.183 . . . . 0.0 109.459 179.097 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.685 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 10.1 p90 -95.16 27.06 3.4 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.14 -0.975 . . . . 0.0 110.222 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.63 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 158.29 -157.43 28.31 Favored Glycine 0 N--CA 1.49 2.244 0 C-N-CA 118.936 -1.602 . . . . 0.0 110.802 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.488 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -149.23 145.4 27.1 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.215 -1.168 . . . . 0.0 109.154 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.641 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 10.3 m-30 -106.5 158.4 16.94 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.467 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.534 ' CG2' HG22 ' A' ' 33' ' ' VAL . 32.3 t -148.87 164.95 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.067 -1.02 . . . . 0.0 109.533 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.564 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -133.76 152.93 52.01 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.032 -1.043 . . . . 0.0 109.998 -179.478 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.488 HG13 ' O ' ' A' ' 29' ' ' LYS . 2.0 pt . . . . . 0 N--CA 1.494 1.74 0 O-C-N 120.666 -1.271 . . . . 0.0 109.429 179.362 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.488 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.464 0 CA-C-O 121.716 0.77 . . . . 0.0 109.8 . . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.564 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 13.8 mt-10 -134.6 154.08 51.66 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.925 -1.109 . . . . 0.0 110.222 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.46 ' O ' ' O ' ' A' ' 23' ' ' VAL . . . -101.06 -175.99 29.12 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 108.478 -1.849 . . . . 0.0 108.478 179.307 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.641 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.17 119.31 6.76 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.979 -1.306 . . . . 0.0 110.73 179.429 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.611 ' CG1' ' CD1' ' A' ' 50' ' ' LEU . 41.3 t -95.93 62.21 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 177.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.519 ' O ' ' CD1' ' A' ' 38' ' ' ILE . 3.9 t-160 -49.37 160.12 0.27 Allowed 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.898 -1.127 . . . . 0.0 108.46 -179.49 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.567 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.9 tp -52.2 -49.58 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.236 -0.915 . . . . 0.0 110.286 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.408 ' C ' ' CG ' ' A' ' 37' ' ' GLN . 0.4 OUTLIER -81.28 41.34 0.6 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.16 -0.963 . . . . 0.0 110.582 -179.331 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.457 ' HG3' ' HB3' ' A' ' 34' ' ' HIS . 30.7 mt-30 -150.65 33.38 0.62 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.766 -1.209 . . . . 0.0 110.42 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.641 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.5 mp -108.72 -96.29 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.815 -1.178 . . . . 0.0 110.157 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.477 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.3 -1.55 0 O-C-N 121.361 -0.837 . . . . 0.0 110.326 -178.922 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.633 HG23 ' CD2' ' A' ' 49' ' ' TYR . 5.5 t . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 121.15 0.5 . . . . 0.0 110.245 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.406 ' C ' ' O ' ' A' ' 43' ' ' VAL . 2.3 mp0 -47.85 -26.01 1.5 Allowed 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 178.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.456 ' O ' HG11 ' A' ' 43' ' ' VAL . 0.1 OUTLIER -127.86 124.65 38.04 Favored 'General case' 0 N--CA 1.487 1.375 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.453 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.549 HG23 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -70.23 -25.74 28.02 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.355 -0.841 . . . . 0.0 109.119 -179.507 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.448 HG21 HG23 ' A' ' 16' ' ' ILE . 3.4 p -75.43 5.28 5.98 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.431 -0.793 . . . . 0.0 109.878 179.598 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.431 ' CG ' ' HB2' ' A' ' 45' ' ' LYS . 12.5 m-20 -101.14 -34.7 9.59 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.008 -1.057 . . . . 0.0 108.677 179.534 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.641 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 6.3 m-85 -89.51 -34.07 16.53 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.524 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.611 ' CD1' ' CG1' ' A' ' 33' ' ' VAL . 0.0 OUTLIER -102.57 154.4 19.16 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.173 -1.011 . . . . 0.0 110.366 179.783 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.459 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.6 OUTLIER -142.95 133.83 25.47 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.487 -0.758 . . . . 0.0 109.13 179.982 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' MET . . . . . 0.459 ' HA ' HG13 ' A' ' 13' ' ' VAL . 3.9 mtt -63.99 100.44 0.31 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.258 -0.901 . . . . 0.0 109.847 -179.771 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 129.97 -24.84 4.47 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' GLN . . . . . 0.404 ' HA ' ' OE1' ' A' ' 54' ' ' GLN . 13.2 mm100 -78.87 158.48 28.1 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.232 -1.158 . . . . 0.0 109.786 -179.785 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -110.61 111.66 23.04 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.328 -0.857 . . . . 0.0 109.026 179.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.48 ' CG2' ' O ' ' A' ' 56' ' ' VAL . 6.8 m -103.24 121.99 46.84 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.184 -0.947 . . . . 0.0 110.108 -179.424 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.464 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.5 Cg_endo -80.84 146.71 16.61 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 C-N-CA 122.559 2.173 . . . . 0.0 110.077 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.526 ' CG2' ' HB3' ' A' ' 71' ' ' LEU . 1.0 OUTLIER -140.01 -168.77 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.06 -1.025 . . . . 0.0 109.655 -179.994 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 14.9 mtpt -131.23 119.61 22.06 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.401 -0.812 . . . . 0.0 109.493 179.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.519 HG22 ' CE1' ' A' ' 9' ' ' TYR . 95.9 t . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.526 ' HB3' ' CG2' ' A' ' 58' ' ' VAL . 96.5 mt . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 121.459 0.647 . . . . 0.0 110.043 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -117.16 113.55 22.41 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.508 -0.745 . . . . 0.0 109.571 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.483 HD12 HG23 ' A' ' 33' ' ' VAL . 0.6 OUTLIER -47.56 122.81 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.349 -0.844 . . . . 0.0 109.264 179.927 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.442 ' HB3' ' O ' ' A' ' 57' ' ' PRO . 4.2 ttpp . . . . . 0 N--CA 1.488 1.451 0 O-C-N 121.19 -0.944 . . . . 0.0 108.939 179.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.467 HG23 ' CG ' ' A' ' 59' ' ' LYS . 54.9 t . . . . . 0 N--CA 1.489 1.48 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.561 ' CE1' ' CG2' ' A' ' 60' ' ' VAL . 2.9 m-85 -106.52 -179.4 3.93 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.119 -0.988 . . . . 0.0 110.071 -178.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.8 m -129.04 105.52 8.25 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 178.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.417 ' HA2' ' O ' ' A' ' 24' ' ' ALA . . . -108.16 132.21 11.0 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 119.318 -1.42 . . . . 0.0 111.254 -177.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.504 ' O ' HG11 ' A' ' 23' ' ' VAL . 0.3 OUTLIER -91.39 158.83 16.3 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 178.348 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.54 HG23 ' CD2' ' A' ' 50' ' ' LEU . 61.2 t -87.82 97.02 6.2 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 O-C-N 120.858 -1.151 . . . . 0.0 109.045 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.513 ' CG2' ' CB ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -101.37 -5.78 24.93 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.527 -0.733 . . . . 0.0 109.817 -179.255 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.536 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -164.95 153.71 12.37 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.122 -0.986 . . . . 0.0 110.113 -179.693 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.475 HG23 ' CG2' ' A' ' 47' ' ' THR . 7.7 mt -141.58 152.92 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 178.842 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.634 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -132.33 151.27 34.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.903 -1.123 . . . . 0.0 109.907 -179.011 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -58.41 -38.78 78.09 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.735 -1.228 . . . . 0.0 108.835 179.203 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.634 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 23.3 p90 -92.57 30.13 1.59 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.504 -0.748 . . . . 0.0 109.943 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.632 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 149.54 -150.99 23.16 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 119.114 -1.517 . . . . 0.0 111.219 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.489 ' CB ' ' HB ' ' A' ' 33' ' ' VAL . . . -152.58 144.9 23.98 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.094 -1.239 . . . . 0.0 109.158 -179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.63 ' CE1' HD12 ' A' ' 32' ' ' LEU . 10.3 m-30 -106.29 142.38 36.07 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.306 -0.872 . . . . 0.0 108.881 179.566 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.573 ' CG2' ' CG2' ' A' ' 33' ' ' VAL . 40.8 t -132.91 163.02 39.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 120.902 -1.124 . . . . 0.0 109.643 -179.444 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.513 ' CB ' ' CG2' ' A' ' 14' ' ' THR . . . -130.15 153.24 48.73 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.103 -0.998 . . . . 0.0 109.65 -179.608 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.459 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.8 pt . . . . . 0 N--CA 1.492 1.645 0 O-C-N 120.984 -1.072 . . . . 0.0 109.417 179.825 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.459 ' O ' HG13 ' A' ' 25' ' ' ILE . 16.5 mmtt . . . . . 0 N--CA 1.488 1.464 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.505 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 1.2 mt-10 -136.81 150.75 48.51 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.973 -1.079 . . . . 0.0 110.102 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 23' ' ' VAL . . . -102.33 -177.19 27.54 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 108.137 -1.985 . . . . 0.0 108.137 179.03 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.63 HD12 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -149.53 116.76 6.05 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.694 -1.474 . . . . 0.0 110.431 179.119 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.574 HG22 ' CD1' ' A' ' 50' ' ' LEU . 93.3 t -90.85 59.93 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 178.049 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.502 ' HB3' ' HG3' ' A' ' 37' ' ' GLN . 3.6 t-80 -48.73 157.28 0.39 Allowed 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.55 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.8 tp -47.19 -47.76 9.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.089 -1.007 . . . . 0.0 110.119 -179.207 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.408 ' C ' ' CG ' ' A' ' 37' ' ' GLN . 56.7 p -81.18 39.41 0.51 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.064 -1.023 . . . . 0.0 110.791 -179.463 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.502 ' HG3' ' HB3' ' A' ' 34' ' ' HIS . 12.4 mt-30 -150.52 53.42 0.89 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.646 -1.283 . . . . 0.0 110.664 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.623 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.7 mp -126.25 -96.31 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.952 -1.093 . . . . 0.0 109.529 179.24 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.527 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.302 -1.469 0 O-C-N 121.411 -0.806 . . . . 0.0 109.195 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.643 ' CG1' ' CD1' ' A' ' 49' ' ' TYR . 54.6 t . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 108.976 -0.749 . . . . 0.0 108.976 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.433 ' C ' ' O ' ' A' ' 43' ' ' VAL . 16.8 mt-10 -40.99 -28.05 0.07 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.558 -0.714 . . . . 0.0 110.314 -179.399 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.492 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.1 OUTLIER -142.63 138.51 30.76 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.961 -1.087 . . . . 0.0 110.206 -179.697 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.54 HG23 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -80.61 -26.47 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.356 -0.84 . . . . 0.0 108.845 179.514 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.475 ' CG2' HG23 ' A' ' 16' ' ' ILE . 47.3 p -78.47 5.12 11.45 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.317 -0.864 . . . . 0.0 109.023 179.056 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.445 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 4.1 m-20 -104.48 -30.76 9.83 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.328 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.643 ' CD1' ' CG1' ' A' ' 43' ' ' VAL . 17.8 m-85 -90.25 -33.98 15.94 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.574 ' CD1' HG22 ' A' ' 33' ' ' VAL . 3.5 mt -108.1 151.78 25.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.194 -0.941 . . . . 0.0 110.005 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.502 ' CB ' ' HG3' ' A' ' 54' ' ' GLN . 0.1 OUTLIER -136.93 138.52 40.72 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 179.033 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 23.4 mtt -62.6 91.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.003 -1.06 . . . . 0.0 109.839 -179.523 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 137.52 -22.59 3.17 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 119.732 -1.223 . . . . 0.0 110.388 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' GLN . . . . . 0.502 ' HG3' ' CB ' ' A' ' 51' ' ' GLN . 6.5 mm-40 -77.28 145.29 37.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.055 -1.262 . . . . 0.0 110.074 -179.377 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -113.19 127.26 56.13 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.475 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.417 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 15.9 m -132.45 142.37 44.66 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.02 -1.05 . . . . 0.0 110.032 -179.524 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.447 ' O ' ' HB2' ' A' ' 74' ' ' LYS . 36.9 Cg_endo -80.27 129.42 7.66 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.665 2.244 . . . . 0.0 110.335 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.428 ' HB ' ' C ' ' A' ' 72' ' ' SER . 0.8 OUTLIER -120.6 -170.5 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.19 -0.944 . . . . 0.0 109.317 179.753 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.467 ' CG ' HG23 ' A' ' 8' ' ' VAL . 0.1 OUTLIER -132.12 141.83 49.28 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.257 -0.902 . . . . 0.0 109.319 179.883 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.561 ' CG2' ' CE1' ' A' ' 9' ' ' TYR . 26.5 t . . . . . 0 N--CA 1.492 1.645 0 O-C-N 121.449 -0.782 . . . . 0.0 109.139 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.447 HD22 ' HA ' ' A' ' 60' ' ' VAL . 17.5 mt . . . . . 0 N--CA 1.489 1.51 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.431 ' O ' ' C ' ' A' ' 73' ' ' ILE . 0.6 OUTLIER -134.11 117.14 16.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.105 -0.997 . . . . 0.0 110.302 -179.262 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.431 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.1 OUTLIER -44.07 131.89 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.299 -0.876 . . . . 0.0 108.962 179.691 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.447 ' HB2' ' O ' ' A' ' 57' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.602 0 O-C-N 121.215 -0.928 . . . . 0.0 110.137 -179.374 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.508 ' CG1' ' O ' ' A' ' 58' ' ' VAL . 93.5 t . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.485 ' N ' HG11 ' A' ' 8' ' ' VAL . 9.2 m-85 -118.69 -168.19 1.5 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.302 -0.874 . . . . 0.0 109.758 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.484 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 34.3 m -166.21 127.81 1.83 Allowed 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.443 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' A' ' 55' ' ' GLU . . . -149.53 -177.84 23.97 Favored Glycine 0 N--CA 1.489 2.202 0 C-N-CA 118.44 -1.838 . . . . 0.0 111.266 -178.636 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.526 ' O ' HG12 ' A' ' 23' ' ' VAL . 15.6 mtpt -104.45 168.27 9.2 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.808 -0.819 . . . . 0.0 108.929 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.534 ' CG2' HD12 ' A' ' 50' ' ' LEU . 72.4 t -87.98 101.37 11.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 O-C-N 121.156 -0.965 . . . . 0.0 108.423 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.534 ' CG2' ' HB1' ' A' ' 24' ' ' ALA . 1.1 p -111.11 11.12 21.96 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.275 -0.89 . . . . 0.0 110.286 -178.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.528 ' CG ' ' O ' ' A' ' 14' ' ' THR . 0.0 OUTLIER -175.29 147.01 0.86 Allowed 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.956 -1.09 . . . . 0.0 110.255 179.75 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 17.2 mt -139.28 151.71 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.068 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.649 HG21 ' N ' ' A' ' 20' ' ' GLY . 0.7 OUTLIER -129.61 154.05 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.765 -1.209 . . . . 0.0 110.088 -179.089 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -59.13 -41.7 88.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.866 -1.147 . . . . 0.0 109.327 179.173 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.645 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 14.0 p90 -91.3 27.14 2.0 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.313 -0.867 . . . . 0.0 110.22 -179.716 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.649 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 155.22 -153.58 24.88 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.898 -1.62 . . . . 0.0 111.063 -179.365 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.517 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -150.33 144.71 25.69 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.063 -1.257 . . . . 0.0 109.007 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.652 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 11.1 m-30 -108.41 162.11 14.41 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.401 -0.812 . . . . 0.0 109.214 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.537 ' CG1' ' N ' ' A' ' 24' ' ' ALA . 3.5 t -150.63 166.81 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.166 -0.958 . . . . 0.0 109.433 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.537 ' N ' ' CG1' ' A' ' 23' ' ' VAL . . . -132.79 145.24 50.83 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.209 -0.932 . . . . 0.0 108.856 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.534 ' CD1' ' HB2' ' A' ' 29' ' ' LYS . 7.7 pt . . . . . 0 N--CA 1.496 1.84 0 O-C-N 120.547 -1.346 . . . . 0.0 109.653 -179.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.534 ' HB2' ' CD1' ' A' ' 25' ' ' ILE . 5.8 mmtm . . . . . 0 N--CA 1.49 1.529 0 CA-C-O 121.774 0.797 . . . . 0.0 109.68 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.534 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 7.3 pt-20 -128.01 157.47 40.55 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 120.867 -1.146 . . . . 0.0 110.474 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.523 ' HA2' ' CD1' ' A' ' 71' ' ' LEU . . . -105.83 -175.79 23.83 Favored Glycine 0 N--CA 1.487 2.042 0 N-CA-C 108.337 -1.905 . . . . 0.0 108.337 179.298 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.652 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.79 121.29 7.4 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 120.746 -1.444 . . . . 0.0 111.542 -179.794 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.533 HG21 ' CG2' ' A' ' 23' ' ' VAL . 26.0 t -95.86 62.9 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 176.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 3.7 t-160 -48.08 155.02 0.5 Allowed 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.885 -1.135 . . . . 0.0 108.883 -179.274 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.522 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 3.0 tp -45.84 -52.09 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.218 -0.926 . . . . 0.0 110.315 -179.431 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.417 ' C ' ' HG3' ' A' ' 37' ' ' GLN . 0.0 OUTLIER -81.52 42.96 0.71 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.294 -0.879 . . . . 0.0 110.524 -179.33 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.461 ' C ' ' CD1' ' A' ' 38' ' ' ILE . 68.3 mt-30 -150.83 53.38 0.87 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.859 -1.151 . . . . 0.0 110.036 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.635 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.7 mp -124.53 -96.01 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.926 -1.109 . . . . 0.0 110.376 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.544 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.3 -1.554 0 O-C-N 121.492 -0.755 . . . . 0.0 109.674 -178.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.64 HG23 ' CD2' ' A' ' 49' ' ' TYR . 60.2 t . . . . . 0 N--CA 1.486 1.36 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.433 ' C ' ' O ' ' A' ' 43' ' ' VAL . 3.6 mm-40 -45.06 -25.05 0.29 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.224 -0.922 . . . . 0.0 108.744 179.633 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.475 ' O ' HG11 ' A' ' 43' ' ' VAL . 25.0 mmtp -119.66 122.7 42.09 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.537 -0.727 . . . . 0.0 109.157 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.511 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -78.98 -24.54 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.271 -0.893 . . . . 0.0 108.842 179.812 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 72.5 p -75.9 4.4 8.25 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.449 -0.782 . . . . 0.0 109.723 179.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -102.75 -38.16 7.57 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.135 -0.978 . . . . 0.0 109.183 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.64 ' CD2' HG23 ' A' ' 43' ' ' VAL . 9.9 m-85 -89.43 -33.55 16.78 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.349 -0.844 . . . . 0.0 109.104 179.669 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.534 HD12 ' CG2' ' A' ' 13' ' ' VAL . 0.1 OUTLIER -98.86 135.54 40.15 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.412 -0.805 . . . . 0.0 109.443 -179.793 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.47 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.0 OUTLIER -138.89 122.5 17.41 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.556 -0.715 . . . . 0.0 109.6 -179.84 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' MET . . . . . 0.504 ' CG ' ' O ' ' A' ' 52' ' ' MET . 5.1 ptm -48.6 105.79 0.09 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.317 -0.864 . . . . 0.0 109.947 -179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 133.92 -43.55 1.26 Allowed Glycine 0 N--CA 1.492 2.398 0 C-N-CA 119.832 -1.175 . . . . 0.0 110.471 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 15.8 mt-30 -69.32 146.15 52.43 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.01 -1.288 . . . . 0.0 110.107 -179.399 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . 0.489 ' HA ' ' O ' ' A' ' 11' ' ' GLY . 0.4 OUTLIER -122.53 140.08 53.18 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.355 -0.841 . . . . 0.0 109.115 179.526 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.403 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 24.8 m -146.73 155.95 48.37 Favored Pre-proline 0 N--CA 1.487 1.424 0 O-C-N 121.164 -0.96 . . . . 0.0 110.052 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.484 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 37.2 Cg_endo -83.37 146.9 12.51 Favored 'Trans proline' 0 C--N 1.314 -1.261 0 C-N-CA 123.161 2.574 . . . . 0.0 110.428 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.542 ' CG2' ' HB3' ' A' ' 71' ' ' LEU . 1.0 OUTLIER -141.29 -168.61 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.186 -0.946 . . . . 0.0 109.287 179.368 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 17.2 mtmt -134.3 134.14 41.54 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.385 -0.822 . . . . 0.0 109.779 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.472 ' CG2' ' CE1' ' A' ' 9' ' ' TYR . 47.6 t . . . . . 0 N--CA 1.493 1.721 0 O-C-N 121.392 -0.818 . . . . 0.0 109.197 179.632 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.542 ' HB3' ' CG2' ' A' ' 58' ' ' VAL . 13.6 mt . . . . . 0 N--CA 1.487 1.376 0 CA-C-O 121.469 0.652 . . . . 0.0 109.607 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.423 ' O ' ' C ' ' A' ' 73' ' ' ILE . 0.3 OUTLIER -133.43 107.65 8.19 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.442 -0.786 . . . . 0.0 109.724 -179.636 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.423 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.0 OUTLIER -44.92 140.31 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.249 -0.907 . . . . 0.0 108.77 179.713 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.419 ' HD3' ' HB2' ' A' ' 57' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.634 0 O-C-N 121.15 -0.969 . . . . 0.0 109.424 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.511 ' HA ' ' HA ' ' A' ' 59' ' ' LYS . 68.1 t . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.609 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 14.0 m-85 -143.94 128.42 17.99 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.023 -1.048 . . . . 0.0 110.355 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -91.06 115.62 28.16 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 178.15 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.456 ' O ' HG21 ' A' ' 56' ' ' VAL . . . -113.6 141.3 16.87 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 119.119 -1.515 . . . . 0.0 110.626 -178.362 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.511 ' O ' HG11 ' A' ' 23' ' ' VAL . 0.8 OUTLIER -89.56 162.07 15.86 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 178.724 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.54 ' CG1' HD11 ' A' ' 50' ' ' LEU . 58.2 t -87.86 105.39 15.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 120.986 -1.072 . . . . 0.0 108.368 179.616 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.527 ' O ' ' CD ' ' A' ' 15' ' ' ARG . 0.7 OUTLIER -111.7 -0.8 15.89 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.262 -0.899 . . . . 0.0 110.218 -178.859 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.527 ' CD ' ' O ' ' A' ' 14' ' ' THR . 0.3 OUTLIER -168.05 152.42 6.34 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.902 -1.123 . . . . 0.0 110.314 179.97 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.431 ' HA ' ' HA ' ' A' ' 21' ' ' ALA . 56.6 mt -145.37 150.03 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 179.058 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.687 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 1.2 m -126.93 156.33 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 120.932 -1.105 . . . . 0.0 109.813 -179.076 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -60.37 -37.89 82.18 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.784 -1.197 . . . . 0.0 109.455 179.208 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.687 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 13.9 p90 -94.56 26.43 3.47 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.244 -0.91 . . . . 0.0 110.379 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.633 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 155.54 -154.08 25.25 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.481 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.492 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -152.27 146.23 25.25 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.043 -1.269 . . . . 0.0 109.439 -179.558 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.643 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 12.4 m-30 -108.04 158.54 17.31 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.354 -0.842 . . . . 0.0 109.145 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.593 ' CG2' ' CG2' ' A' ' 33' ' ' VAL . 7.7 t -145.85 163.75 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.166 -0.959 . . . . 0.0 109.151 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.55 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -137.1 146.55 45.25 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.017 -1.052 . . . . 0.0 110.119 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.492 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.1 pt . . . . . 0 N--CA 1.494 1.735 0 O-C-N 120.779 -1.201 . . . . 0.0 108.667 178.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.492 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.512 0 CA-C-O 121.548 0.69 . . . . 0.0 109.514 . . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.55 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 3.5 pt-20 -134.68 153.4 52.01 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 120.847 -1.158 . . . . 0.0 110.224 -179.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -102.57 -173.51 27.0 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 108.504 -1.839 . . . . 0.0 108.504 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.643 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.31 119.02 6.55 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.993 -1.298 . . . . 0.0 110.692 179.514 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.593 ' CG2' ' CG2' ' A' ' 23' ' ' VAL . 8.4 t -96.59 63.56 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 177.588 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.53 ' HB3' ' CG ' ' A' ' 37' ' ' GLN . 4.4 t-80 -47.7 166.08 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.308 0 O-C-N 120.879 -1.138 . . . . 0.0 108.279 -179.594 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.566 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.2 OUTLIER -55.19 -55.33 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.136 -0.977 . . . . 0.0 110.296 -179.256 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.407 ' O ' ' CD ' ' A' ' 37' ' ' GLN . 92.6 p -82.31 42.57 0.75 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.018 -1.051 . . . . 0.0 110.334 -179.734 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.53 ' CG ' ' HB3' ' A' ' 34' ' ' HIS . 20.8 mm-40 -145.27 44.46 1.32 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.938 -1.101 . . . . 0.0 109.598 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.631 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.8 mp -119.33 -91.66 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.253 -0.904 . . . . 0.0 108.978 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.59 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.298 -1.654 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.616 ' CG1' ' CD1' ' A' ' 49' ' ' TYR . 39.6 t . . . . . 0 N--CA 1.482 1.132 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 25.5 tp10 -46.49 -22.5 0.27 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.151 -0.968 . . . . 0.0 109.244 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.539 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 28.9 mttp -119.68 109.12 15.27 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.386 -0.821 . . . . 0.0 109.246 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.546 HG22 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -77.52 -22.87 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.232 -0.918 . . . . 0.0 108.781 179.842 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 18.6 p -76.99 2.57 14.48 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.449 -0.782 . . . . 0.0 109.216 179.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -101.42 -33.68 9.89 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.1 -1.0 . . . . 0.0 109.264 179.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.631 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 6.6 m-85 -94.98 -30.78 13.94 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.575 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.54 HD11 ' CG1' ' A' ' 13' ' ' VAL . 0.2 OUTLIER -105.61 140.73 38.24 Favored 'General case' 0 N--CA 1.488 1.454 0 CA-C-O 121.536 0.684 . . . . 0.0 109.35 -179.731 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.505 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 2.0 tm0? -148.61 124.38 10.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.462 -0.774 . . . . 0.0 109.301 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' MET . . . . . 0.478 ' HA ' HG13 ' A' ' 13' ' ' VAL . 56.8 mtp -48.8 112.65 0.64 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.288 -0.883 . . . . 0.0 109.924 -179.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 113.11 -44.85 1.42 Allowed Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' GLN . . . . . 0.42 ' O ' HG22 ' A' ' 13' ' ' VAL . 15.5 mm100 -56.92 102.96 0.09 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.147 -1.208 . . . . 0.0 109.586 -179.727 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -65.18 137.14 57.43 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.188 -0.945 . . . . 0.0 109.125 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.456 HG21 ' O ' ' A' ' 11' ' ' GLY . 16.7 m -135.48 132.13 19.7 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.229 -0.919 . . . . 0.0 109.841 -179.767 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.442 ' HG2' ' HG3' ' A' ' 74' ' ' LYS . 36.4 Cg_endo -79.96 142.63 15.72 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.461 2.107 . . . . 0.0 110.129 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.54 ' CG2' ' HB3' ' A' ' 71' ' ' LEU . 0.9 OUTLIER -141.43 -173.74 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.232 -0.917 . . . . 0.0 109.246 179.665 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.511 ' HA ' ' HA ' ' A' ' 8' ' ' VAL . 9.0 mtmm -142.35 111.26 6.33 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.295 -0.878 . . . . 0.0 110.248 -179.71 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.609 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 61.5 t . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.857 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.54 ' HB3' ' CG2' ' A' ' 58' ' ' VAL . 0.3 OUTLIER . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 . . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.419 ' HB2' ' O ' ' A' ' 59' ' ' LYS . 0.6 OUTLIER -109.85 111.71 23.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.197 -0.94 . . . . 0.0 110.219 -179.231 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.471 ' CD1' ' O ' ' A' ' 37' ' ' GLN . 1.2 mp -56.96 128.21 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.181 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.442 ' HG3' ' HG2' ' A' ' 57' ' ' PRO . 0.6 OUTLIER . . . . . 0 N--CA 1.494 1.751 0 O-C-N 121.357 -0.84 . . . . 0.0 110.351 -179.136 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.8 t . . . . . 0 N--CA 1.489 1.491 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.673 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 4.6 m-85 -122.28 133.21 54.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.043 -1.035 . . . . 0.0 109.998 -179.598 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.3 m -83.87 103.29 13.02 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.546 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.31 119.82 5.11 Favored Glycine 0 N--CA 1.487 2.056 0 C-N-CA 119.884 -1.151 . . . . 0.0 110.737 -178.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.539 ' O ' HG12 ' A' ' 23' ' ' VAL . 2.0 mtmt -89.29 148.46 23.55 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 178.77 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.515 ' CB ' ' O ' ' A' ' 51' ' ' GLN . 3.8 t -86.85 117.6 31.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 O-C-N 120.597 -1.314 . . . . 0.0 108.656 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.493 ' OG1' ' HD3' ' A' ' 15' ' ' ARG . 1.5 p -128.16 -3.41 5.67 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.419 -0.801 . . . . 0.0 109.933 -178.596 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.493 ' HD3' ' OG1' ' A' ' 14' ' ' THR . 0.0 OUTLIER -173.77 150.57 1.71 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.128 -0.982 . . . . 0.0 109.872 179.396 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.512 HG22 HD11 ' A' ' 16' ' ' ILE . 18.0 mt -136.31 161.49 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.374 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.639 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -139.97 153.34 22.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 120.59 -1.319 . . . . 0.0 110.623 -179.009 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -59.22 -41.19 88.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.766 -1.209 . . . . 0.0 109.376 179.093 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.639 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 14.3 p90 -90.99 28.42 1.58 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.356 -0.84 . . . . 0.0 110.096 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.608 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 149.7 -149.28 21.2 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.08 -1.533 . . . . 0.0 110.834 -179.717 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.569 ' HB2' ' CD1' ' A' ' 50' ' ' LEU . . . -153.64 147.79 25.73 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 120.967 -1.313 . . . . 0.0 109.263 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.644 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 11.9 m-30 -106.7 158.35 17.03 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.4 -0.813 . . . . 0.0 109.083 179.641 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 12' ' ' LYS . 15.6 t -150.12 162.11 4.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.291 -0.881 . . . . 0.0 109.185 -179.464 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.543 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -133.57 136.5 44.97 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.147 -0.97 . . . . 0.0 109.494 -179.631 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.465 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.7 pt . . . . . 0 N--CA 1.492 1.671 0 O-C-N 120.917 -1.115 . . . . 0.0 109.47 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.465 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 121.423 0.63 . . . . 0.0 109.501 . . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.543 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -120.49 149.83 41.78 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.804 -1.185 . . . . 0.0 110.46 -179.57 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.471 ' O ' ' O ' ' A' ' 23' ' ' VAL . . . -102.69 -178.1 26.99 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.198 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.644 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -148.56 119.79 7.8 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.863 -1.375 . . . . 0.0 110.67 179.744 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.522 ' HB ' ' HB2' ' A' ' 21' ' ' ALA . 59.4 t -94.4 62.26 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 177.776 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.438 ' HB3' ' HG3' ' A' ' 37' ' ' GLN . 4.0 t-80 -50.16 159.39 0.45 Allowed 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.888 -1.132 . . . . 0.0 108.637 -179.53 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.535 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 1.6 tp -48.53 -52.94 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.169 -0.957 . . . . 0.0 110.342 -179.614 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 1.9 t -81.84 44.85 0.86 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.12 -0.987 . . . . 0.0 110.536 -179.448 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.451 ' C ' HD13 ' A' ' 38' ' ' ILE . 46.8 mt-30 -150.36 37.03 0.67 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.783 -1.198 . . . . 0.0 109.88 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.622 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.8 mp -114.77 -96.69 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.932 -1.105 . . . . 0.0 110.285 -179.58 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.531 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.301 -1.512 0 O-C-N 121.447 -0.783 . . . . 0.0 109.43 -179.17 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.621 ' CG1' ' CD1' ' A' ' 49' ' ' TYR . 59.1 t . . . . . 0 N--CA 1.494 1.728 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.446 ' C ' ' O ' ' A' ' 43' ' ' VAL . 20.9 tp10 -38.57 -29.27 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.569 -0.707 . . . . 0.0 110.538 -179.264 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.469 ' N ' ' O ' ' A' ' 43' ' ' VAL . 3.5 mttm -133.03 132.37 41.75 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.915 -1.115 . . . . 0.0 109.978 -179.552 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.522 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -79.65 -25.74 12.35 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 179.18 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' THR . . . . . 0.454 HG21 HG22 ' A' ' 16' ' ' ILE . 10.5 p -77.2 4.45 10.44 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.653 -0.654 . . . . 0.0 109.355 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.463 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 2.8 m-20 -106.53 -30.16 9.22 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.147 -0.97 . . . . 0.0 108.621 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.622 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 19.0 m-85 -92.14 -30.91 15.71 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.576 -0.703 . . . . 0.0 109.264 179.764 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.569 ' CD1' ' HB2' ' A' ' 21' ' ' ALA . 0.6 OUTLIER -106.08 143.48 34.15 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.633 179.857 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.515 ' O ' ' CB ' ' A' ' 13' ' ' VAL . 4.1 tt0 -130.69 129.69 42.92 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.273 -0.892 . . . . 0.0 108.999 179.455 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' MET . . . . . 0.442 ' HA ' HG13 ' A' ' 13' ' ' VAL . 10.2 mtt -63.57 118.33 8.04 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.142 -0.973 . . . . 0.0 109.674 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 105.12 -23.05 31.66 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' GLN . . . . . 0.49 ' CG ' ' HB3' ' A' ' 51' ' ' GLN . 4.9 mt-30 -73.31 -172.61 1.17 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.23 -1.159 . . . . 0.0 109.647 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . 0.417 ' HG2' ' HA ' ' A' ' 12' ' ' LYS . 5.6 mt-10 -156.76 128.75 7.29 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.214 -0.929 . . . . 0.0 109.518 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 14.6 m -128.5 145.63 56.71 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.223 -0.923 . . . . 0.0 109.721 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -79.79 139.93 14.28 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.644 2.229 . . . . 0.0 110.155 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.47 HG21 ' O ' ' A' ' 9' ' ' TYR . 1.0 OUTLIER -142.49 -177.96 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.162 -0.961 . . . . 0.0 109.777 -179.844 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.417 ' N ' HG22 ' A' ' 58' ' ' VAL . 5.3 mttm -127.0 116.52 20.88 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.443 -0.786 . . . . 0.0 109.465 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.673 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 13.6 t . . . . . 0 C--N 1.302 -1.459 0 O-C-N 121.166 -0.959 . . . . 0.0 109.353 179.704 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.429 HD11 ' HA3' ' A' ' 31' ' ' GLY . 12.0 mt . . . . . 0 N--CA 1.486 1.361 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.25 90.01 3.17 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.199 -0.938 . . . . 0.0 110.071 -179.333 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -50.27 133.23 10.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.328 -0.858 . . . . 0.0 108.983 179.752 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 4.1 tttp . . . . . 0 N--CA 1.492 1.661 0 O-C-N 121.232 -0.918 . . . . 0.0 109.33 -179.932 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.6 t . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.637 ' CE1' ' CG2' ' A' ' 60' ' ' VAL . 10.3 m-85 -119.53 -177.24 3.33 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.142 -0.974 . . . . 0.0 109.975 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.58 111.86 6.29 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 178.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -125.09 153.34 17.94 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.009 -1.567 . . . . 0.0 110.809 -178.224 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.493 ' O ' HG11 ' A' ' 23' ' ' VAL . 16.1 mttm -95.93 166.07 11.96 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 178.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.522 ' CG1' HD11 ' A' ' 50' ' ' LEU . 79.3 t -88.46 105.23 15.45 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 121.062 -1.023 . . . . 0.0 108.323 179.404 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.544 ' CG2' ' HB1' ' A' ' 24' ' ' ALA . 1.7 p -117.57 6.27 12.48 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.269 -0.895 . . . . 0.0 110.077 -179.014 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.53 ' CD ' ' O ' ' A' ' 14' ' ' THR . 0.0 OUTLIER -169.69 149.25 3.8 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.08 -1.013 . . . . 0.0 109.935 179.867 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.435 ' C ' HG11 ' A' ' 17' ' ' VAL . 19.5 mt -141.99 163.49 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 179.479 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.666 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -143.48 153.41 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.8 -1.188 . . . . 0.0 110.205 -179.43 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -58.21 -42.7 86.8 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.784 -1.198 . . . . 0.0 109.324 179.276 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.666 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 12.1 p90 -90.61 29.42 1.31 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.217 -0.927 . . . . 0.0 110.351 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.609 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 150.47 -152.08 24.01 Favored Glycine 0 N--CA 1.494 2.54 0 C-N-CA 119.102 -1.523 . . . . 0.0 110.936 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.543 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -152.78 148.81 27.66 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.992 -1.299 . . . . 0.0 108.979 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.644 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 11.1 m-30 -107.81 163.81 12.79 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.345 -0.847 . . . . 0.0 108.753 179.571 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.594 ' CG2' ' CG2' ' A' ' 33' ' ' VAL . 22.7 t -149.5 165.49 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.093 -1.004 . . . . 0.0 109.204 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.562 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -132.42 141.44 48.86 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.057 -1.027 . . . . 0.0 110.592 -179.108 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.495 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.1 pt . . . . . 0 N--CA 1.491 1.585 0 O-C-N 121.079 -1.013 . . . . 0.0 108.81 179.083 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.495 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.3 OUTLIER . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 121.4 0.619 . . . . 0.0 109.625 . . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.562 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 1.4 pp20? -133.14 149.42 52.08 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 120.924 -1.11 . . . . 0.0 110.328 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.473 ' HA3' HD11 ' A' ' 71' ' ' LEU . . . -98.08 -172.68 32.79 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 108.251 -1.939 . . . . 0.0 108.251 179.194 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.644 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.65 119.76 6.74 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 120.842 -1.387 . . . . 0.0 111.047 179.737 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.594 ' CG2' ' CG2' ' A' ' 23' ' ' VAL . 49.3 t -95.47 61.3 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.32 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.446 ' HB2' HD21 ' A' ' 32' ' ' LEU . 3.6 t-80 -49.11 160.82 0.18 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.846 -1.159 . . . . 0.0 108.331 -179.373 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.539 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.6 tp -52.96 -41.29 40.11 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 121.029 -1.045 . . . . 0.0 109.986 -179.731 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.467 ' O ' ' HG2' ' A' ' 37' ' ' GLN . 49.9 m -81.59 30.29 0.36 Allowed 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.086 -1.009 . . . . 0.0 110.922 -179.425 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.467 ' HG2' ' O ' ' A' ' 36' ' ' SER . 6.3 mt-30 -149.22 65.32 1.02 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.653 -1.28 . . . . 0.0 110.174 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.641 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.6 mp -123.54 -99.37 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 120.87 -1.144 . . . . 0.0 109.843 179.489 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.527 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.302 -1.476 0 O-C-N 121.16 -0.962 . . . . 0.0 109.33 -179.544 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.593 HG23 ' CD2' ' A' ' 49' ' ' TYR . 72.4 t . . . . . 0 N--CA 1.494 1.739 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 29.4 mp0 -45.01 -31.0 1.15 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.344 -0.847 . . . . 0.0 109.397 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.476 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 0.3 OUTLIER -112.17 114.78 27.79 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.202 -0.936 . . . . 0.0 109.386 179.873 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.539 HG22 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -73.18 -22.66 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.746 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 3.0 p -77.31 4.41 10.76 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.535 -0.728 . . . . 0.0 109.387 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.476 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 2.4 m-20 -103.93 -29.89 10.66 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.156 -0.965 . . . . 0.0 108.75 179.566 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.641 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 32.3 m-85 -96.49 -30.11 13.52 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.616 -0.678 . . . . 0.0 109.337 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.522 HD11 ' CG1' ' A' ' 13' ' ' VAL . 0.1 OUTLIER -104.07 133.98 48.1 Favored 'General case' 0 N--CA 1.489 1.497 0 CA-C-O 121.816 0.817 . . . . 0.0 109.774 -179.695 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.487 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.0 OUTLIER -136.21 123.49 21.85 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.912 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' MET . . . . . 0.494 ' HA ' HG13 ' A' ' 13' ' ' VAL . 3.1 mtt -52.44 110.01 0.45 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.18 -0.95 . . . . 0.0 110.772 -179.189 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 122.54 -9.87 9.25 Favored Glycine 0 N--CA 1.496 2.648 0 C-N-CA 119.894 -1.146 . . . . 0.0 110.606 178.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -80.96 175.66 10.5 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.146 -1.208 . . . . 0.0 110.174 -179.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -142.72 117.72 10.01 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.3 m -135.95 145.42 52.54 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 120.993 -1.067 . . . . 0.0 110.635 -179.207 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.475 ' HG2' ' CD ' ' A' ' 74' ' ' LYS . 37.2 Cg_endo -82.98 155.64 15.07 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 C-N-CA 122.873 2.382 . . . . 0.0 109.486 178.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.506 ' CG2' ' HB3' ' A' ' 71' ' ' LEU . 1.2 m -150.48 -173.74 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.823 -1.173 . . . . 0.0 110.206 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -123.18 129.2 51.09 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 179.628 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.637 ' CG2' ' CE1' ' A' ' 9' ' ' TYR . 89.0 t . . . . . 0 N--CA 1.49 1.534 0 O-C-N 121.27 -0.894 . . . . 0.0 110.071 -179.375 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.506 ' HB3' ' CG2' ' A' ' 58' ' ' VAL . 12.6 mt . . . . . 0 N--CA 1.488 1.434 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.466 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.4 OUTLIER -115.79 109.61 17.9 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.301 -0.875 . . . . 0.0 109.781 -179.572 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.533 ' CG2' ' O ' ' A' ' 38' ' ' ILE . 0.1 OUTLIER -42.4 126.32 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.364 -0.835 . . . . 0.0 108.925 179.918 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.475 ' CD ' ' HG2' ' A' ' 57' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.444 0 O-C-N 121.167 -0.958 . . . . 0.0 109.46 -179.66 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.501 HG11 ' N ' ' A' ' 9' ' ' TYR . 72.9 t . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.594 ' CE1' ' CG2' ' A' ' 60' ' ' VAL . 14.7 m-85 -133.96 -171.56 2.77 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.033 -1.042 . . . . 0.0 110.225 -179.62 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.411 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 24.8 m -159.29 120.45 3.26 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 179.243 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.524 ' CA ' ' O ' ' A' ' 24' ' ' ALA . . . -131.92 164.59 23.66 Favored Glycine 0 N--CA 1.49 2.27 0 C-N-CA 118.759 -1.686 . . . . 0.0 111.077 -178.323 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.541 ' O ' HG12 ' A' ' 23' ' ' VAL . 0.3 OUTLIER -101.76 168.37 9.49 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.385 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.475 HG23 HD21 ' A' ' 50' ' ' LEU . 96.0 t -88.01 99.34 8.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.656 0 O-C-N 120.719 -1.238 . . . . 0.0 108.475 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.509 ' CG2' ' CB ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -105.24 -3.1 23.27 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.351 -0.843 . . . . 0.0 110.191 -178.8 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.546 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 1.8 mpp_? -165.82 155.44 12.28 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.946 -1.096 . . . . 0.0 110.19 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.422 ' C ' HG11 ' A' ' 17' ' ' VAL . 21.3 mt -144.43 157.89 15.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 179.575 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.656 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -140.09 155.85 24.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 120.664 -1.273 . . . . 0.0 110.196 -178.995 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -60.69 -41.21 94.68 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.63 -1.294 . . . . 0.0 109.456 179.472 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.656 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 12.4 p90 -89.73 24.61 2.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.186 -0.947 . . . . 0.0 110.039 -179.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.617 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 154.76 -149.07 20.27 Favored Glycine 0 N--CA 1.493 2.445 0 C-N-CA 119.166 -1.492 . . . . 0.0 110.958 -179.682 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.502 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -154.94 148.05 24.79 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.217 -1.166 . . . . 0.0 108.465 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.644 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 10.9 m-30 -108.75 160.88 15.61 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 179.693 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.554 ' CG2' HG22 ' A' ' 33' ' ' VAL . 3.2 t -150.82 165.33 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.08 -1.012 . . . . 0.0 109.335 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.527 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -127.08 150.46 49.46 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.066 -1.021 . . . . 0.0 109.864 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.482 HG13 ' O ' ' A' ' 29' ' ' LYS . 0.8 OUTLIER . . . . . 0 N--CA 1.493 1.704 0 O-C-N 121.102 -0.999 . . . . 0.0 109.397 179.646 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.482 ' O ' HG13 ' A' ' 25' ' ' ILE . 20.8 mmmt . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 121.632 0.73 . . . . 0.0 109.319 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.527 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -129.7 151.95 49.73 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 120.887 -1.133 . . . . 0.0 110.448 -179.305 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.421 ' CA ' HD13 ' A' ' 71' ' ' LEU . . . -99.17 -174.53 31.57 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 179.191 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.644 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.23 121.81 8.0 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.764 -1.433 . . . . 0.0 111.46 179.946 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.572 ' CG1' ' CD1' ' A' ' 73' ' ' ILE . 52.7 t -94.44 62.37 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 177.274 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.494 ' CB ' ' OE1' ' A' ' 37' ' ' GLN . 3.3 t-80 -50.43 155.13 1.1 Allowed 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.862 -1.149 . . . . 0.0 108.804 -179.37 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.519 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 4.1 tp -46.64 -49.92 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.361 -0.837 . . . . 0.0 110.765 -179.528 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.5 41.84 0.65 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.952 -1.093 . . . . 0.0 110.524 -179.434 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.494 ' OE1' ' CB ' ' A' ' 34' ' ' HIS . 17.2 mt-30 -150.38 51.44 0.89 Allowed 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.875 -1.141 . . . . 0.0 110.016 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.639 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.7 mp -127.27 -96.5 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 120.935 -1.103 . . . . 0.0 110.312 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.548 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.496 0 O-C-N 121.563 -0.711 . . . . 0.0 109.899 -179.01 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.622 ' CG1' ' CD1' ' A' ' 49' ' ' TYR . 54.1 t . . . . . 0 N--CA 1.492 1.652 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 71.7 tt0 -45.26 -26.36 0.49 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.434 -0.791 . . . . 0.0 110.13 -179.295 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.499 ' O ' HG11 ' A' ' 43' ' ' VAL . 0.8 OUTLIER -131.54 131.64 43.53 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.067 -1.021 . . . . 0.0 109.991 -179.6 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.526 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -80.04 -26.2 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.992 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 7.3 p -80.36 6.58 11.72 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 178.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -105.3 -25.01 12.59 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 179.23 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.639 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 26.0 m-85 -97.57 -33.61 11.28 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 179.74 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.509 HD13 ' CG2' ' A' ' 33' ' ' VAL . 0.7 OUTLIER -104.38 143.08 33.48 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.198 -0.939 . . . . 0.0 109.449 179.292 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.452 ' HB3' ' HG3' ' A' ' 54' ' ' GLN . 1.3 tm0? -133.86 134.94 43.34 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 7.0 mtt -54.99 102.54 0.07 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.142 -0.973 . . . . 0.0 109.733 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 126.84 -38.09 2.25 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 119.784 -1.198 . . . . 0.0 110.186 179.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' GLN . . . . . 0.452 ' HG3' ' HB3' ' A' ' 51' ' ' GLN . 19.3 mm-40 -59.58 128.95 39.58 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.24 -1.153 . . . . 0.0 110.056 -179.579 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . 0.463 ' HA ' ' HA ' ' A' ' 12' ' ' LYS . 61.8 mt-10 -108.89 131.96 54.5 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.34 -0.85 . . . . 0.0 108.9 179.375 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 17.1 m -137.34 153.44 74.71 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.086 -1.009 . . . . 0.0 110.177 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.429 ' HB2' ' HD3' ' A' ' 74' ' ' LYS . 36.9 Cg_endo -79.69 155.89 24.2 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.937 2.425 . . . . 0.0 110.09 179.57 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.541 ' CG2' ' HB3' ' A' ' 71' ' ' LEU . 1.0 OUTLIER -147.94 -174.73 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.047 -1.033 . . . . 0.0 109.469 179.927 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 1.7 mttp -136.38 119.97 17.12 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.452 -0.78 . . . . 0.0 109.384 179.854 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.594 ' CG2' ' CE1' ' A' ' 9' ' ' TYR . 60.8 t . . . . . 0 N--CA 1.492 1.654 0 O-C-N 121.303 -0.873 . . . . 0.0 109.281 179.824 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.541 ' HB3' ' CG2' ' A' ' 58' ' ' VAL . 23.5 mt . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 121.357 0.599 . . . . 0.0 109.6 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.477 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.5 OUTLIER -100.38 123.5 44.68 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.39 -0.819 . . . . 0.0 109.737 -179.594 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.572 ' CD1' ' CG1' ' A' ' 33' ' ' VAL . 0.0 OUTLIER -63.3 123.65 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.418 -0.801 . . . . 0.0 109.226 179.988 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.429 ' HD3' ' HB2' ' A' ' 57' ' ' PRO . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.925 . . . . 0.0 109.397 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.455 ' HA ' ' O ' ' A' ' 58' ' ' VAL . 78.8 t . . . . . 0 N--CA 1.489 1.482 0 CA-C-O 121.309 0.576 . . . . 0.0 109.801 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.464 ' CE1' ' CG2' ' A' ' 60' ' ' VAL . 5.1 m-85 -92.18 -168.74 2.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.325 -0.859 . . . . 0.0 109.148 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 21.3 m -151.48 115.85 5.07 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 178.69 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.536 ' CA ' ' O ' ' A' ' 24' ' ' ALA . . . -129.16 152.8 19.57 Favored Glycine 0 N--CA 1.487 2.035 0 C-N-CA 119.148 -1.501 . . . . 0.0 110.844 -178.57 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.505 ' O ' HG11 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -93.61 167.7 11.5 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.006 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.528 ' CG2' HD22 ' A' ' 50' ' ' LEU . 58.4 t -88.35 106.28 16.43 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.754 0 C-N-CA 119.164 -1.014 . . . . 0.0 108.34 179.736 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.557 ' CG2' ' CB ' ' A' ' 24' ' ' ALA . 0.5 OUTLIER -111.07 -3.28 15.55 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.341 -0.85 . . . . 0.0 110.226 -178.577 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.548 ' CD ' ' OG1' ' A' ' 14' ' ' THR . 0.0 OUTLIER -173.45 150.73 1.86 Allowed 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.98 -1.075 . . . . 0.0 110.007 179.479 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.515 HG21 ' N ' ' A' ' 17' ' ' VAL . 13.1 mt -136.73 161.38 36.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.525 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.658 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.9 OUTLIER -138.65 153.89 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 120.653 -1.28 . . . . 0.0 110.225 -179.63 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -58.59 -43.69 89.61 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.771 -1.205 . . . . 0.0 109.495 179.196 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.658 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 11.6 p90 -89.98 27.9 1.49 Allowed 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.22 -0.925 . . . . 0.0 110.251 -179.54 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.629 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 153.67 -153.68 25.0 Favored Glycine 0 N--CA 1.492 2.375 0 C-N-CA 118.914 -1.613 . . . . 0.0 111.249 -179.731 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.468 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -151.75 147.69 26.99 Favored 'General case' 0 C--N 1.305 -1.349 0 O-C-N 121.109 -1.23 . . . . 0.0 109.056 -179.737 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.646 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 12.2 m-30 -108.25 160.12 16.09 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.543 ' CG1' ' N ' ' A' ' 24' ' ' ALA . 24.0 t -150.41 166.58 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.06 -1.025 . . . . 0.0 109.666 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.557 ' CB ' ' CG2' ' A' ' 14' ' ' THR . . . -130.99 144.99 51.89 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.183 -0.948 . . . . 0.0 109.714 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.462 HG13 ' O ' ' A' ' 29' ' ' LYS . 2.2 pt . . . . . 0 N--CA 1.494 1.731 0 O-C-N 120.906 -1.121 . . . . 0.0 109.399 179.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.462 ' O ' HG13 ' A' ' 25' ' ' ILE . 56.2 mmtt . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.535 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 10.7 pt-20 -124.47 152.75 42.97 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 120.918 -1.114 . . . . 0.0 110.975 -179.35 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.448 ' CA ' HD13 ' A' ' 71' ' ' LEU . . . -100.72 -176.54 29.62 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 108.359 -1.896 . . . . 0.0 108.359 179.165 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.646 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.26 120.88 7.48 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.863 -1.375 . . . . 0.0 110.913 179.645 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.62 ' CG1' ' CD1' ' A' ' 50' ' ' LEU . 61.8 t -96.19 63.11 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 177.712 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.425 ' HB3' ' HG3' ' A' ' 37' ' ' GLN . 3.1 t-80 -50.45 156.62 0.84 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.837 -1.165 . . . . 0.0 108.623 -179.48 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.543 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.2 OUTLIER -46.65 -48.97 6.85 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.113 -0.992 . . . . 0.0 109.575 -179.793 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 4.9 p -81.59 40.39 0.58 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.287 -0.883 . . . . 0.0 110.389 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.428 ' C ' HD13 ' A' ' 38' ' ' ILE . 71.4 mt-30 -148.93 30.63 0.79 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.714 -1.241 . . . . 0.0 110.069 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.65 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.8 mp -104.65 -96.32 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.016 -1.053 . . . . 0.0 109.602 179.68 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.533 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.3 -1.585 0 O-C-N 121.463 -0.773 . . . . 0.0 109.502 -179.588 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.605 HG23 ' CD2' ' A' ' 49' ' ' TYR . 87.4 t . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.434 ' C ' ' O ' ' A' ' 43' ' ' VAL . 0.4 OUTLIER -45.33 -27.22 0.63 Allowed 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 179.568 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.426 ' O ' HG11 ' A' ' 43' ' ' VAL . 0.0 OUTLIER -115.44 113.44 23.72 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 179.239 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.52 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -73.67 -25.35 20.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 -179.981 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 61.1 p -77.68 5.72 8.73 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.471 -0.768 . . . . 0.0 109.414 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.421 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 13.3 m-20 -101.29 -32.7 10.37 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 179.292 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.65 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 19.5 m-85 -90.43 -36.23 14.69 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 179.502 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.62 ' CD1' ' CG1' ' A' ' 33' ' ' VAL . 0.0 OUTLIER -101.61 158.01 16.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.292 -0.88 . . . . 0.0 110.527 179.789 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.414 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 16.8 tp60 -149.35 127.6 12.11 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.503 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' MET . . . . . 0.406 ' HA ' HG13 ' A' ' 13' ' ' VAL . 5.6 mtt -59.69 111.82 1.58 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.124 -0.985 . . . . 0.0 110.19 -179.463 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 120.8 -25.43 7.19 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 119.874 -1.155 . . . . 0.0 110.383 179.301 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 9.6 mt-30 -74.95 177.09 6.57 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.082 -1.246 . . . . 0.0 110.323 -179.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -139.13 126.53 21.59 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.76 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.2 m -138.01 144.98 45.97 Favored Pre-proline 0 N--CA 1.489 1.505 0 O-C-N 120.947 -1.096 . . . . 0.0 110.5 -179.293 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 37.1 Cg_endo -81.81 153.11 17.2 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 122.951 2.434 . . . . 0.0 110.117 179.418 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 8' ' ' VAL . 0.8 OUTLIER -144.39 -168.86 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.1 -1.0 . . . . 0.0 109.344 179.457 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.431 ' HE3' ' CD ' ' A' ' 74' ' ' LYS . 5.6 mttt -133.87 136.85 44.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.33 -0.856 . . . . 0.0 109.298 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.464 ' CG2' ' CE1' ' A' ' 9' ' ' TYR . 86.2 t . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.35 -0.844 . . . . 0.0 109.025 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.448 HD13 ' CA ' ' A' ' 31' ' ' GLY . 20.8 mt . . . . . 0 N--CA 1.489 1.516 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.445 ' O ' ' C ' ' A' ' 73' ' ' ILE . 2.1 m -125.73 117.01 22.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.289 -0.882 . . . . 0.0 109.744 -179.69 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.445 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.1 OUTLIER -44.22 136.91 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.274 -0.891 . . . . 0.0 108.785 179.68 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.431 ' CD ' ' HE3' ' A' ' 59' ' ' LYS . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.475 0 O-C-N 121.191 -0.943 . . . . 0.0 109.532 -179.714 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.8 t . . . . . 0 N--CA 1.491 1.583 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . . . . . . . . . 13.3 m-85 -116.64 -174.25 2.53 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.173 -0.954 . . . . 0.0 110.239 -179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.444 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 5.5 m -155.89 111.77 3.05 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 179.258 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.434 ' CA ' ' O ' ' A' ' 24' ' ' ALA . . . -126.58 153.66 18.85 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 118.906 -1.616 . . . . 0.0 111.04 -178.095 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.494 ' O ' HG11 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -89.71 164.12 14.82 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 179.128 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.471 ' HB ' ' O ' ' A' ' 51' ' ' GLN . 99.4 t -88.08 95.96 5.56 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 O-C-N 120.753 -1.217 . . . . 0.0 108.336 179.703 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.544 ' OG1' ' CD ' ' A' ' 15' ' ' ARG . 1.1 p -96.53 -1.9 46.17 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.5 -0.75 . . . . 0.0 109.865 -178.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.544 ' CD ' ' OG1' ' A' ' 14' ' ' THR . 0.0 OUTLIER -173.37 143.21 1.06 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.174 -0.954 . . . . 0.0 109.687 179.982 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.44 HD11 HG22 ' A' ' 16' ' ' ILE . 8.8 mt -131.56 159.16 43.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 179.323 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.652 HG21 ' N ' ' A' ' 20' ' ' GLY . 0.8 OUTLIER -135.44 153.83 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 120.634 -1.291 . . . . 0.0 110.42 -178.474 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -61.3 -39.69 91.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.569 -1.332 . . . . 0.0 109.376 179.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.639 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 15.5 p90 -90.86 23.42 3.15 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.364 -0.835 . . . . 0.0 110.107 -179.736 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.652 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 155.16 -152.28 23.81 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 119.214 -1.47 . . . . 0.0 110.822 -179.402 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.521 ' CB ' ' HB ' ' A' ' 33' ' ' VAL . . . -151.42 145.01 24.94 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 120.759 -1.436 . . . . 0.0 109.31 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.641 ' CE1' HD12 ' A' ' 32' ' ' LEU . 12.4 m-30 -107.18 156.78 18.46 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.55 ' CG2' HG22 ' A' ' 33' ' ' VAL . 7.2 t -150.44 162.13 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.045 -1.035 . . . . 0.0 109.793 -179.533 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.525 ' HB1' ' CG2' ' A' ' 14' ' ' THR . . . -128.17 144.49 51.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.283 -0.886 . . . . 0.0 109.06 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.492 ' CG1' ' O ' ' A' ' 29' ' ' LYS . 1.8 pt . . . . . 0 N--CA 1.494 1.745 0 O-C-N 120.775 -1.203 . . . . 0.0 109.915 -179.794 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.492 ' O ' ' CG1' ' A' ' 25' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.428 0 CA-C-O 121.653 0.739 . . . . 0.0 109.683 . . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.524 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 0.3 OUTLIER -128.44 149.11 50.71 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.937 -1.102 . . . . 0.0 110.092 -179.661 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -98.7 -178.3 32.3 Favored Glycine 0 N--CA 1.486 2.02 0 N-CA-C 108.216 -1.954 . . . . 0.0 108.216 179.106 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.641 HD12 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -148.87 116.53 6.24 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 120.827 -1.396 . . . . 0.0 110.541 179.604 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.55 HG22 ' CG2' ' A' ' 23' ' ' VAL . 91.9 t -89.95 59.35 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 177.75 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.494 ' O ' ' CD1' ' A' ' 38' ' ' ILE . 4.5 t-80 -47.28 156.19 0.27 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 120.739 -1.225 . . . . 0.0 108.551 -179.463 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.551 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.2 OUTLIER -49.81 -47.25 22.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.163 -0.96 . . . . 0.0 109.49 -179.713 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.418 ' C ' ' HG2' ' A' ' 37' ' ' GLN . 0.3 OUTLIER -81.22 39.79 0.53 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.413 -0.804 . . . . 0.0 110.399 -179.925 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.418 ' HG2' ' C ' ' A' ' 36' ' ' SER . 47.1 mm-40 -147.98 34.15 0.83 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.934 -1.104 . . . . 0.0 109.27 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.634 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.6 mp -112.48 -97.11 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.248 -0.908 . . . . 0.0 109.916 -179.613 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.531 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.301 -1.524 0 O-C-N 121.311 -0.868 . . . . 0.0 109.825 -179.402 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.61 ' CG1' ' CD1' ' A' ' 49' ' ' TYR . 2.5 t . . . . . 0 N--CA 1.481 1.075 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.451 ' C ' ' O ' ' A' ' 43' ' ' VAL . 3.2 mp0 -40.32 -25.06 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.639 -0.663 . . . . 0.0 109.923 -179.59 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.538 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.8 OUTLIER -151.28 121.56 7.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.146 -0.971 . . . . 0.0 110.021 -179.813 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.542 HG23 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -71.71 -26.92 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 178.959 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 58.6 p -79.14 6.02 10.64 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.461 ' OD2' ' HB2' ' A' ' 45' ' ' LYS . 26.6 m-20 -106.25 -26.9 11.34 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 179.204 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.634 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 12.9 m-85 -92.54 -34.83 13.9 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.247 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.525 ' CD1' ' CG2' ' A' ' 33' ' ' VAL . 4.6 mt -109.57 152.9 24.9 Favored 'General case' 0 N--CA 1.492 1.635 0 C-N-CA 119.473 -0.891 . . . . 0.0 109.752 179.637 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.471 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.9 OUTLIER -128.19 138.68 52.58 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.39 -0.819 . . . . 0.0 108.982 179.437 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' MET . . . . . 0.442 ' HA ' HG13 ' A' ' 13' ' ' VAL . 22.6 mtp -63.17 114.19 3.61 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.217 -0.927 . . . . 0.0 109.716 -179.719 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 109.38 -23.85 21.72 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' GLN . . . . . 0.433 ' HG3' ' HB3' ' A' ' 51' ' ' GLN . 1.5 mt-30 -74.5 147.78 41.57 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.098 -1.236 . . . . 0.0 109.791 -179.718 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . 0.458 ' HA ' ' HA ' ' A' ' 12' ' ' LYS . 0.3 OUTLIER -107.06 146.95 30.57 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.329 -0.857 . . . . 0.0 109.37 179.889 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.436 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 18.8 m -150.6 140.03 13.52 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.079 -1.013 . . . . 0.0 109.944 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.444 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 37.2 Cg_endo -82.96 151.85 14.33 Favored 'Trans proline' 0 C--N 1.315 -1.21 0 C-N-CA 122.786 2.324 . . . . 0.0 110.137 179.311 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.505 ' CG2' ' HB3' ' A' ' 71' ' ' LEU . 0.9 OUTLIER -147.72 -171.22 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.167 -0.958 . . . . 0.0 109.299 179.511 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 10.8 mttt -138.59 121.7 16.84 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.079 -1.013 . . . . 0.0 109.955 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . . . . . . . . . 35.2 t . . . . . 0 N--CA 1.492 1.662 0 O-C-N 121.294 -0.879 . . . . 0.0 108.944 179.251 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.565 ' CD2' ' N ' ' A' ' 71' ' ' LEU . 2.4 mm? . . . . . 0 N--CA 1.489 1.503 0 CA-C-O 121.546 0.689 . . . . 0.0 109.935 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -119.33 112.71 19.78 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.522 -0.736 . . . . 0.0 109.366 -179.87 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.442 ' O ' ' C ' ' A' ' 74' ' ' LYS . 0.1 OUTLIER -55.63 136.08 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.271 -0.893 . . . . 0.0 109.336 -179.67 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.442 ' C ' ' O ' ' A' ' 73' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.727 0 O-C-N 121.351 -0.843 . . . . 0.0 109.814 -179.481 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 24.1 t . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.588 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 4.2 m-85 -110.87 130.69 55.51 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.124 -0.985 . . . . 0.0 110.012 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 11.0 m -80.45 100.49 8.53 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.335 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.47 126.0 7.25 Favored Glycine 0 N--CA 1.487 2.072 0 C-N-CA 119.87 -1.157 . . . . 0.0 110.487 -178.539 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.521 ' O ' HG12 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -89.75 148.12 23.44 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.794 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.509 ' CG1' ' CD1' ' A' ' 50' ' ' LEU . 22.8 t -87.85 112.21 23.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 120.568 -1.332 . . . . 0.0 108.97 -179.648 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.527 HG22 ' CB ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -122.8 -6.09 8.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.437 -0.789 . . . . 0.0 110.216 -178.916 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.465 ' HD2' ' O ' ' A' ' 14' ' ' THR . 0.9 OUTLIER -164.68 153.66 12.93 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.916 -1.115 . . . . 0.0 110.06 -179.949 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.468 HG21 ' HB3' ' A' ' 21' ' ' ALA . 12.2 mt -141.08 161.57 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 179.438 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.644 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -140.15 153.44 22.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 120.881 -1.137 . . . . 0.0 109.982 -179.58 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -58.45 -41.78 85.9 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.778 -1.202 . . . . 0.0 109.145 179.405 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.644 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 15.5 p90 -90.3 29.31 1.27 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.381 -0.825 . . . . 0.0 110.077 -179.743 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.6 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 149.81 -148.86 20.57 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 118.964 -1.589 . . . . 0.0 110.976 -179.766 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.49 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -154.94 148.83 25.66 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.233 -1.157 . . . . 0.0 108.917 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.649 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 10.5 m-30 -106.94 162.46 13.81 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.339 -0.851 . . . . 0.0 108.954 179.682 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.598 ' CG2' ' CG2' ' A' ' 33' ' ' VAL . 22.5 t -149.03 160.87 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.08 -1.013 . . . . 0.0 109.64 -179.64 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.541 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -133.8 135.92 44.14 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.306 -0.871 . . . . 0.0 109.55 -179.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.461 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.2 pt . . . . . 0 N--CA 1.493 1.683 0 O-C-N 120.818 -1.176 . . . . 0.0 109.509 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.461 ' O ' HG13 ' A' ' 25' ' ' ILE . 4.4 mtmt . . . . . 0 N--CA 1.488 1.442 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.541 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 6.4 mt-10 -127.48 150.87 49.47 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.741 -1.224 . . . . 0.0 111.004 -179.151 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -102.33 -172.96 27.25 Favored Glycine 0 N--CA 1.488 2.104 0 N-CA-C 108.22 -1.952 . . . . 0.0 108.22 178.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.649 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.14 121.8 8.05 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.737 -1.449 . . . . 0.0 110.951 179.743 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.598 ' CG2' ' CG2' ' A' ' 23' ' ' VAL . 61.1 t -95.3 61.36 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 177.523 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.426 ' HB2' HD21 ' A' ' 32' ' ' LEU . 2.6 t-80 -48.88 158.13 0.35 Allowed 'General case' 0 C--N 1.304 -1.37 0 O-C-N 120.893 -1.13 . . . . 0.0 108.653 -179.462 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.528 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.9 tp -46.66 -51.01 5.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.188 -0.945 . . . . 0.0 109.864 -179.464 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 42.6 p -81.99 44.51 0.85 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.302 -0.874 . . . . 0.0 110.372 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.452 ' C ' HD13 ' A' ' 38' ' ' ILE . 3.6 mm100 -144.29 33.61 1.2 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.903 -1.123 . . . . 0.0 110.214 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.612 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.6 mp -120.29 -98.49 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.833 -1.167 . . . . 0.0 110.214 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.508 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.302 -1.476 0 O-C-N 121.459 -0.776 . . . . 0.0 109.45 -179.206 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.633 ' CG1' ' CD1' ' A' ' 49' ' ' TYR . 58.7 t . . . . . 0 N--CA 1.487 1.387 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 43' ' ' VAL . 14.0 mt-10 -45.78 -24.27 0.36 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.354 -0.841 . . . . 0.0 108.988 179.488 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.471 ' O ' HG11 ' A' ' 43' ' ' VAL . 4.7 mmtp -134.97 123.71 23.76 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.327 -0.858 . . . . 0.0 109.4 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.527 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -73.68 -23.47 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 O-C-N 121.131 -0.981 . . . . 0.0 108.643 179.647 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 8.3 p -75.4 1.39 14.03 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.482 -0.761 . . . . 0.0 109.389 179.198 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.432 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 0.9 OUTLIER -102.17 -35.59 8.84 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.149 -0.969 . . . . 0.0 109.245 -179.999 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.633 ' CD1' ' CG1' ' A' ' 43' ' ' VAL . 3.9 m-85 -90.83 -28.72 18.0 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.35 -0.844 . . . . 0.0 108.972 179.791 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.509 ' CD1' ' CG1' ' A' ' 13' ' ' VAL . 0.2 OUTLIER -109.72 140.9 43.06 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.495 -0.753 . . . . 0.0 109.565 -179.575 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.486 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 2.3 mp0 -150.62 131.93 14.57 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.398 -0.814 . . . . 0.0 109.476 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' MET . . . . . 0.493 ' HA ' HG13 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -61.84 107.61 0.87 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.273 -0.892 . . . . 0.0 109.955 -179.929 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 132.33 -31.97 2.91 Favored Glycine 0 N--CA 1.491 2.321 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.306 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' GLN . . . . . 0.479 ' O ' HG22 ' A' ' 13' ' ' VAL . 6.2 mt-30 -80.3 162.28 24.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.033 -1.275 . . . . 0.0 109.818 -179.668 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -125.28 138.66 54.09 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.518 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.406 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 17.2 m -140.58 143.92 34.44 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.017 -1.052 . . . . 0.0 110.008 -179.461 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.446 ' O ' HG11 ' A' ' 58' ' ' VAL . 36.3 Cg_endo -79.05 145.93 19.85 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.59 2.193 . . . . 0.0 110.241 179.704 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.48 HG21 ' O ' ' A' ' 9' ' ' TYR . 1.0 OUTLIER -148.21 -174.84 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.196 -0.94 . . . . 0.0 109.901 -179.878 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 3.0 mtpt -123.51 135.66 54.15 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.52 -0.737 . . . . 0.0 109.239 179.606 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.588 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 96.1 t . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.33 -0.856 . . . . 0.0 109.229 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.457 HD23 ' HB2' ' A' ' 9' ' ' TYR . 31.3 mt . . . . . 0 N--CA 1.487 1.423 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.456 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.4 OUTLIER -123.24 108.08 12.41 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.273 -0.892 . . . . 0.0 110.049 -179.259 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -48.61 140.83 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.227 -0.921 . . . . 0.0 108.911 179.886 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 11.3 mmtt . . . . . 0 N--CA 1.491 1.611 0 O-C-N 121.318 -0.864 . . . . 0.0 109.744 -179.684 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.46 HG21 ' HG2' ' A' ' 59' ' ' LYS . 41.3 t . . . . . 0 N--CA 1.492 1.633 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.577 ' CD2' HD11 ' A' ' 25' ' ' ILE . 2.8 m-30 -114.75 135.12 54.52 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.154 -0.966 . . . . 0.0 110.158 -179.335 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -73.82 100.74 3.54 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 177.448 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -82.26 122.73 5.82 Favored Glycine 0 N--CA 1.488 2.119 0 C-N-CA 120.009 -1.091 . . . . 0.0 111.368 -177.302 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.484 ' O ' HG12 ' A' ' 23' ' ' VAL . 2.4 mttt -96.07 143.24 27.39 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 177.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.528 ' CG1' HD21 ' A' ' 50' ' ' LEU . 24.9 t -88.1 107.66 17.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 120.802 -1.186 . . . . 0.0 108.934 -179.648 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.527 ' CG2' ' HB1' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -116.93 -7.95 11.34 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.454 -0.778 . . . . 0.0 109.813 -179.07 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.465 ' HD2' ' O ' ' A' ' 14' ' ' THR . 0.9 OUTLIER -161.48 148.22 14.45 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.054 -1.029 . . . . 0.0 110.158 -179.899 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.443 HG22 HD11 ' A' ' 16' ' ' ILE . 11.8 mt -137.05 157.38 35.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 179.005 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.651 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -136.3 153.4 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 120.749 -1.22 . . . . 0.0 110.034 -179.192 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -59.07 -41.94 89.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.69 -1.257 . . . . 0.0 109.331 179.228 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.651 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 12.9 p90 -91.16 27.24 1.93 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.3 -0.875 . . . . 0.0 110.361 -179.525 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.647 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 154.4 -154.9 25.83 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 118.895 -1.621 . . . . 0.0 110.829 -179.505 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.501 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -148.45 143.97 27.1 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.042 -1.27 . . . . 0.0 108.853 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.639 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 10.0 m-30 -105.94 154.77 20.11 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.254 -0.904 . . . . 0.0 108.825 179.748 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.52 HG11 ' N ' ' A' ' 24' ' ' ALA . 35.2 t -144.04 161.81 15.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.066 -1.021 . . . . 0.0 109.783 -179.273 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.527 ' HB1' ' CG2' ' A' ' 14' ' ' THR . . . -137.2 148.81 46.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.157 -0.964 . . . . 0.0 109.515 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.577 HD11 ' CD2' ' A' ' 9' ' ' TYR . 2.7 pt . . . . . 0 N--CA 1.492 1.673 0 O-C-N 121.006 -1.059 . . . . 0.0 109.044 179.642 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.477 ' HB2' HD13 ' A' ' 25' ' ' ILE . 1.7 mtpp . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.52 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 17.3 mt-10 -134.99 153.46 52.08 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.998 -1.063 . . . . 0.0 110.334 -179.786 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.522 ' HA3' ' CD1' ' A' ' 71' ' ' LEU . . . -107.3 -175.78 22.64 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 179.43 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.639 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.49 119.29 6.6 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.875 -1.368 . . . . 0.0 110.736 179.72 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.612 ' CG1' ' CD1' ' A' ' 50' ' ' LEU . 96.3 t -93.84 61.14 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.543 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 177.71 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.408 ' HB2' HD21 ' A' ' 32' ' ' LEU . 6.6 t-80 -47.7 156.45 0.31 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.906 -1.122 . . . . 0.0 108.417 -179.571 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.524 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 3.1 tp -49.62 -43.37 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.154 -0.966 . . . . 0.0 110.321 -179.536 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -81.25 34.29 0.36 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.182 -0.949 . . . . 0.0 110.94 -179.34 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.438 ' C ' HD13 ' A' ' 38' ' ' ILE . 71.4 mt-30 -150.81 58.4 0.92 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.709 -1.244 . . . . 0.0 110.14 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.628 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.7 mp -122.08 -97.86 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 120.984 -1.073 . . . . 0.0 109.569 179.746 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.532 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.298 -0.876 . . . . 0.0 109.382 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.64 ' CG2' ' CZ ' ' A' ' 49' ' ' TYR . 66.9 t . . . . . 0 N--CA 1.488 1.443 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.428 ' O ' ' HG3' ' A' ' 44' ' ' GLU . 13.8 tp10 -45.38 -26.59 0.56 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.162 -0.961 . . . . 0.0 108.467 179.662 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.471 ' O ' HG11 ' A' ' 43' ' ' VAL . 4.2 mptt -108.0 105.63 15.5 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.28 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.544 HG23 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -75.22 -25.52 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.399 -0.813 . . . . 0.0 109.09 -179.681 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 62.7 p -77.55 6.22 7.55 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.413 -0.805 . . . . 0.0 109.464 179.181 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.459 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 58.9 m-20 -101.7 -32.32 10.37 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.426 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.64 ' CZ ' ' CG2' ' A' ' 43' ' ' VAL . 15.9 m-85 -92.45 -34.85 13.95 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.494 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.612 ' CD1' ' CG1' ' A' ' 33' ' ' VAL . 0.0 OUTLIER -100.0 156.62 17.06 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.322 -0.861 . . . . 0.0 110.571 -179.854 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.494 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 61.8 mt-30 -146.85 126.57 13.42 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' MET . . . . . 0.525 ' CG ' ' O ' ' A' ' 52' ' ' MET . 3.2 ptp -60.81 98.59 0.07 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.15 -0.969 . . . . 0.0 109.94 -179.654 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 132.21 -25.44 3.86 Favored Glycine 0 N--CA 1.493 2.45 0 C-N-CA 119.719 -1.229 . . . . 0.0 110.368 179.467 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 89.0 mm-40 -79.19 150.49 31.65 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.105 -1.232 . . . . 0.0 110.402 -179.358 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -116.9 113.71 22.84 Favored 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.088 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.423 ' O ' HG21 ' A' ' 56' ' ' VAL . 17.7 m -115.24 150.23 44.06 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.107 -0.996 . . . . 0.0 110.121 -179.205 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -78.5 126.91 7.79 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.675 2.25 . . . . 0.0 110.24 179.744 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.493 HG21 ' O ' ' A' ' 9' ' ' TYR . 1.3 m -131.9 -172.74 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.148 -0.97 . . . . 0.0 109.722 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.46 ' HG2' HG21 ' A' ' 8' ' ' VAL . 9.8 mtmt -133.12 116.87 16.82 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.6 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.488 HG21 ' CG ' ' A' ' 9' ' ' TYR . 52.6 t . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.344 -0.848 . . . . 0.0 109.217 -179.744 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.522 ' CD1' ' HA3' ' A' ' 31' ' ' GLY . 11.1 mt . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.249 0.547 . . . . 0.0 109.633 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.45 ' HB2' ' O ' ' A' ' 59' ' ' LYS . 0.6 OUTLIER -115.95 93.68 4.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.301 -0.874 . . . . 0.0 109.838 -179.85 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.467 ' O ' ' O ' ' A' ' 74' ' ' LYS . 0.1 OUTLIER -48.8 141.14 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.202 -0.936 . . . . 0.0 109.251 179.762 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.467 ' O ' ' O ' ' A' ' 73' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.686 0 O-C-N 121.311 -0.868 . . . . 0.0 109.673 -179.789 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.495 ' CG1' ' O ' ' A' ' 58' ' ' VAL . 97.3 t . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.538 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 6.4 m-85 -119.41 126.65 51.88 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.858 -1.151 . . . . 0.0 110.525 -179.673 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.429 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 0.2 OUTLIER -95.31 127.34 41.28 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 178.352 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -127.62 150.14 18.15 Favored Glycine 0 N--CA 1.486 2.025 0 C-N-CA 118.834 -1.651 . . . . 0.0 110.953 -178.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.507 ' O ' HG11 ' A' ' 23' ' ' VAL . 0.1 OUTLIER -89.8 163.21 15.14 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 178.624 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.535 ' CB ' ' O ' ' A' ' 51' ' ' GLN . 69.8 t -88.42 107.9 18.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 O-C-N 121.006 -1.059 . . . . 0.0 108.445 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.533 ' CG2' ' HB1' ' A' ' 24' ' ' ALA . 1.3 p -118.51 -0.52 11.38 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.544 -0.862 . . . . 0.0 110.167 -178.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.478 ' HG3' ' O ' ' A' ' 14' ' ' THR . 0.0 OUTLIER -167.96 148.04 4.95 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.987 -1.071 . . . . 0.0 109.985 179.739 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 30.6 mt -140.31 157.38 24.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.232 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.655 HG21 ' N ' ' A' ' 20' ' ' GLY . 0.6 OUTLIER -135.38 152.98 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.918 -1.114 . . . . 0.0 109.751 -179.321 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -60.41 -39.08 86.08 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.631 -1.293 . . . . 0.0 109.218 179.458 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.636 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 18.4 p90 -91.86 24.92 2.96 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.497 -0.752 . . . . 0.0 110.073 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.655 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 156.07 -152.78 24.19 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.881 -179.188 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.496 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -151.91 145.65 25.05 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.853 -1.38 . . . . 0.0 108.843 179.636 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.648 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 10.3 m-30 -107.26 160.37 15.65 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.35 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.548 ' CG1' ' N ' ' A' ' 24' ' ' ALA . 14.3 t -149.99 167.67 2.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.009 -1.057 . . . . 0.0 109.536 -179.228 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.561 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -131.62 147.43 52.52 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.137 -0.977 . . . . 0.0 109.278 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.492 HG13 ' O ' ' A' ' 29' ' ' LYS . 0.5 OUTLIER . . . . . 0 N--CA 1.493 1.716 0 O-C-N 120.561 -1.337 . . . . 0.0 109.808 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.492 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.373 0.606 . . . . 0.0 109.807 . . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.561 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 7.2 mt-10 -120.18 153.05 36.81 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 120.814 -1.179 . . . . 0.0 110.811 -179.393 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.448 ' HA3' ' CD1' ' A' ' 71' ' ' LEU . . . -99.1 -172.8 31.39 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 108.555 -1.818 . . . . 0.0 108.555 179.061 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.648 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.83 120.19 6.85 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.824 -1.397 . . . . 0.0 111.082 179.6 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.534 ' CG2' ' CG2' ' A' ' 23' ' ' VAL . 48.6 t -95.15 61.79 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 177.276 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.415 ' HB2' HD21 ' A' ' 32' ' ' LEU . 3.1 t-160 -48.77 157.1 0.41 Allowed 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.785 -1.197 . . . . 0.0 108.908 -179.131 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.539 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.4 OUTLIER -49.62 -47.09 21.3 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.297 -0.877 . . . . 0.0 110.237 -179.58 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.442 ' O ' ' CD ' ' A' ' 37' ' ' GLN . 0.6 OUTLIER -80.48 33.33 0.3 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.251 -0.906 . . . . 0.0 110.972 -179.133 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.448 ' C ' HD13 ' A' ' 38' ' ' ILE . 44.7 mm-40 -148.26 57.99 1.08 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.823 -1.173 . . . . 0.0 109.735 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.626 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.5 mp -116.84 -99.56 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 120.942 -1.099 . . . . 0.0 110.075 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.536 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.304 -1.408 0 O-C-N 121.272 -0.892 . . . . 0.0 109.649 -179.341 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.626 ' CG1' ' CD1' ' A' ' 49' ' ' TYR . 72.1 t . . . . . 0 N--CA 1.485 1.324 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -44.4 -24.95 0.21 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.349 -0.844 . . . . 0.0 109.032 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.464 ' HD2' ' OD2' ' A' ' 48' ' ' ASP . 68.7 mttt -110.8 104.44 13.07 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.454 -0.779 . . . . 0.0 109.14 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.573 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -72.19 -23.34 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.194 -0.941 . . . . 0.0 108.552 179.857 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 24.2 p -77.87 4.0 13.02 Favored 'General case' 0 C--N 1.3 -1.549 0 C-N-CA 119.827 -0.749 . . . . 0.0 109.294 179.21 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.464 ' OD2' ' HD2' ' A' ' 45' ' ' LYS . 1.8 m-20 -102.42 -33.78 9.41 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.151 -0.968 . . . . 0.0 108.824 179.598 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.626 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 23.5 m-85 -92.88 -33.05 14.37 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.449 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.532 HD12 ' CG2' ' A' ' 13' ' ' VAL . 0.2 OUTLIER -102.23 138.19 39.49 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.973 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.535 ' O ' ' CB ' ' A' ' 13' ' ' VAL . 0.0 OUTLIER -142.32 142.35 32.5 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.48 -0.763 . . . . 0.0 109.41 -179.788 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' MET . . . . . 0.471 ' HA ' HG13 ' A' ' 13' ' ' VAL . 0.1 OUTLIER -59.6 131.49 51.09 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.353 -0.842 . . . . 0.0 110.666 -179.394 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 90.45 -16.75 56.99 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' GLN . . . . . 0.412 ' CD ' ' HB2' ' A' ' 51' ' ' GLN . 6.7 mt-30 -70.46 169.4 14.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.173 -1.192 . . . . 0.0 109.886 -179.642 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . 0.467 ' OE1' ' HE3' ' A' ' 12' ' ' LYS . 3.2 mt-10 -139.7 132.87 29.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.193 -0.942 . . . . 0.0 108.556 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.1 m -141.05 136.83 16.34 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 120.916 -1.115 . . . . 0.0 110.402 -179.4 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.3 Cg_endo -80.2 144.4 16.48 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 C-N-CA 122.524 2.149 . . . . 0.0 109.065 178.785 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.495 ' O ' ' CG1' ' A' ' 8' ' ' VAL . 1.5 m -144.13 -174.8 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 120.918 -1.114 . . . . 0.0 110.062 -179.612 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 4.1 mttt -121.9 135.14 54.87 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.516 -0.74 . . . . 0.0 109.357 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.538 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 58.9 t . . . . . 0 N--CA 1.49 1.526 0 O-C-N 121.275 -0.891 . . . . 0.0 109.002 179.734 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.448 ' CD1' ' HA3' ' A' ' 31' ' ' GLY . 20.6 mt . . . . . 0 N--CA 1.488 1.463 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.407 ' C ' ' HB ' ' A' ' 58' ' ' VAL . 0.4 OUTLIER -121.28 101.46 7.65 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.15 -0.969 . . . . 0.0 110.08 -179.622 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.526 ' CG2' ' O ' ' A' ' 38' ' ' ILE . 0.1 OUTLIER -45.28 137.96 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.2 -0.937 . . . . 0.0 108.96 179.838 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.589 0 O-C-N 121.404 -0.81 . . . . 0.0 109.871 -179.75 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.418 HG12 ' O ' ' A' ' 58' ' ' VAL . 89.9 t . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.44 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 4.0 m-85 -107.78 179.33 4.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.183 -0.948 . . . . 0.0 110.031 -179.501 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -121.19 101.19 7.49 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 178.012 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.79 115.95 4.35 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 119.85 -1.167 . . . . 0.0 111.099 -177.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.509 ' O ' HG12 ' A' ' 23' ' ' VAL . 5.7 mtmt -88.66 152.04 22.07 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 107.208 -1.404 . . . . 0.0 107.208 178.075 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.498 ' HB ' ' O ' ' A' ' 51' ' ' GLN . 34.9 t -87.34 110.76 20.97 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 O-C-N 120.751 -1.218 . . . . 0.0 109.142 -179.07 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.529 ' O ' ' CG ' ' A' ' 15' ' ' ARG . 0.5 OUTLIER -120.7 5.2 10.54 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.442 -0.786 . . . . 0.0 109.807 -179.227 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.529 ' CG ' ' O ' ' A' ' 14' ' ' THR . 3.5 mpp_? -176.15 152.5 1.16 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.047 -1.033 . . . . 0.0 110.225 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.507 HD12 HG22 ' A' ' 16' ' ' ILE . 35.0 mt -142.19 159.01 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 179.209 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.624 HG21 ' N ' ' A' ' 20' ' ' GLY . 0.7 OUTLIER -137.19 153.65 29.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 120.82 -1.175 . . . . 0.0 109.872 -179.243 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -59.13 -40.06 84.29 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.873 -1.142 . . . . 0.0 109.12 179.248 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.623 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 20.1 p90 -91.66 27.71 1.96 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.431 -0.793 . . . . 0.0 110.148 -179.739 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.624 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 151.82 -148.64 19.87 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 119.033 -1.556 . . . . 0.0 110.899 -179.559 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.503 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -155.32 148.46 24.71 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.241 -1.153 . . . . 0.0 108.846 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.652 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 11.6 m-30 -107.92 160.9 15.41 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.58 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.515 HG11 ' N ' ' A' ' 24' ' ' ALA . 20.4 t -149.39 162.25 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.129 -0.982 . . . . 0.0 109.49 -179.522 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.525 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -133.73 145.44 49.86 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.122 -0.986 . . . . 0.0 109.811 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.461 HG13 ' O ' ' A' ' 29' ' ' LYS . 3.2 pt . . . . . 0 N--CA 1.493 1.675 0 O-C-N 121.065 -1.022 . . . . 0.0 109.273 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.461 ' O ' HG13 ' A' ' 25' ' ' ILE . 2.5 mmmt . . . . . 0 N--CA 1.492 1.636 0 CA-C-O 121.213 0.53 . . . . 0.0 109.776 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.525 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -132.56 151.44 51.93 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.155 -0.966 . . . . 0.0 110.43 -179.861 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.533 ' CA ' HD13 ' A' ' 71' ' ' LEU . . . -104.72 -175.64 24.81 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 179.309 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.652 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -149.43 120.59 7.78 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.846 -1.385 . . . . 0.0 110.724 179.753 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.528 HG22 ' CD1' ' A' ' 50' ' ' LEU . 88.3 t -93.67 60.1 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 177.85 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.42 ' C ' ' O ' ' A' ' 33' ' ' VAL . 5.6 t-80 -47.6 158.42 0.19 Allowed 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.779 -1.201 . . . . 0.0 108.383 -179.533 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.539 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.8 tp -47.76 -52.94 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.081 -1.012 . . . . 0.0 110.07 -179.276 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.439 ' C ' ' HG2' ' A' ' 37' ' ' GLN . 0.0 OUTLIER -81.48 39.41 0.53 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.091 -1.005 . . . . 0.0 110.375 -179.631 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.454 ' C ' HD13 ' A' ' 38' ' ' ILE . 11.9 mm100 -144.83 50.41 1.26 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.926 -1.109 . . . . 0.0 109.641 -179.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.648 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.6 mp -120.08 -99.79 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 120.765 -1.209 . . . . 0.0 110.675 -179.484 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.511 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . . . . . . 0 N--CA 1.488 1.438 0 O-C-N 121.211 -0.931 . . . . 0.0 110.269 -178.622 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.613 ' CG2' ' CZ ' ' A' ' 49' ' ' TYR . 24.4 t . . . . . 0 N--CA 1.485 1.308 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -46.97 -22.06 0.28 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.328 -0.858 . . . . 0.0 109.718 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.541 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.5 OUTLIER -128.28 117.78 22.09 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.113 -0.992 . . . . 0.0 109.858 -179.805 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.538 HG22 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -77.65 -25.81 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.199 -0.938 . . . . 0.0 108.701 179.485 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 63.5 p -77.1 3.73 11.85 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.383 -0.823 . . . . 0.0 109.307 179.237 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.404 ' OD2' ' CB ' ' A' ' 45' ' ' LYS . 99.1 m-20 -101.86 -24.36 14.04 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.482 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.648 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 22.1 m-85 -100.29 -25.87 14.1 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.733 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.528 ' CD1' HG22 ' A' ' 33' ' ' VAL . 0.2 OUTLIER -111.25 142.74 43.06 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.909 . . . . 0.0 109.391 179.465 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.498 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.2 OUTLIER -141.72 133.41 27.07 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.537 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 9.9 mtm -54.78 97.49 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.137 -0.977 . . . . 0.0 110.077 -179.487 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.9 -36.0 2.51 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 119.847 -1.168 . . . . 0.0 110.304 179.341 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 5.2 mm-40 -57.5 162.47 2.89 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.066 -1.256 . . . . 0.0 109.695 -179.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . 0.404 ' HG3' ' HA ' ' A' ' 12' ' ' LYS . 0.7 OUTLIER -137.55 125.93 23.34 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.412 -0.805 . . . . 0.0 109.184 179.819 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.0 m -130.25 139.26 35.09 Favored Pre-proline 0 N--CA 1.488 1.451 0 O-C-N 121.063 -1.023 . . . . 0.0 109.606 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.453 ' O ' ' HB2' ' A' ' 74' ' ' LYS . 35.5 Cg_endo -78.44 134.13 12.33 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.503 2.135 . . . . 0.0 110.352 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.47 ' CG2' ' HB3' ' A' ' 71' ' ' LEU . 0.9 OUTLIER -127.41 179.17 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.152 -0.968 . . . . 0.0 109.782 -179.922 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -117.01 122.19 43.51 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.639 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.44 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 91.2 t . . . . . 0 N--CA 1.49 1.552 0 O-C-N 121.189 -0.944 . . . . 0.0 109.528 -179.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.533 HD13 ' CA ' ' A' ' 31' ' ' GLY . 81.4 mt . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.41 ' O ' ' C ' ' A' ' 73' ' ' ILE . 0.3 OUTLIER -121.32 97.21 5.41 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.115 -0.99 . . . . 0.0 110.362 -179.204 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.456 HG23 ' O ' ' A' ' 38' ' ' ILE . 0.2 OUTLIER -42.67 123.02 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.317 -0.864 . . . . 0.0 109.099 179.605 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.453 ' HB2' ' O ' ' A' ' 57' ' ' PRO . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.614 0 O-C-N 121.208 -0.933 . . . . 0.0 109.768 -179.651 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.481 ' HA ' ' O ' ' A' ' 58' ' ' VAL . 55.3 t . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.646 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 3.0 m-85 -104.75 129.72 52.94 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.085 -1.009 . . . . 0.0 109.956 -179.561 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.5 m -74.49 98.08 3.25 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 178.398 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -77.73 120.45 5.51 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 -178.396 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.516 ' O ' ' CG1' ' A' ' 23' ' ' VAL . 0.0 OUTLIER -92.47 150.51 20.74 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.71 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.54 ' CG1' HD11 ' A' ' 50' ' ' LEU . 20.7 t -89.49 106.12 16.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 120.908 -1.12 . . . . 0.0 108.991 -179.905 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.553 ' CG2' ' HB1' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -120.59 3.06 10.71 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.234 -0.916 . . . . 0.0 109.67 -179.506 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.514 ' CG ' ' O ' ' A' ' 14' ' ' THR . 5.0 mpp_? -173.31 153.48 2.43 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.174 -0.954 . . . . 0.0 109.821 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.442 HG21 ' N ' ' A' ' 17' ' ' VAL . 14.7 mt -140.84 159.76 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.562 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.651 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -139.67 155.55 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 120.822 -1.174 . . . . 0.0 110.285 -179.746 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -59.06 -44.48 91.84 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.967 -1.083 . . . . 0.0 109.803 179.449 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.651 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 8.2 p90 -90.42 24.62 2.53 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.107 -0.996 . . . . 0.0 110.377 -179.389 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.629 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 158.4 -152.28 23.41 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 118.977 -1.582 . . . . 0.0 111.044 -179.583 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.499 ' CB ' ' HB ' ' A' ' 33' ' ' VAL . . . -151.36 146.9 26.32 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.214 -1.168 . . . . 0.0 108.906 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.63 ' CE1' HD12 ' A' ' 32' ' ' LEU . 10.3 m-30 -106.73 157.93 17.35 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.259 -0.901 . . . . 0.0 108.992 179.754 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.647 HG11 ' N ' ' A' ' 24' ' ' ALA . 42.3 t -150.58 154.66 8.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 120.945 -1.097 . . . . 0.0 109.674 -178.834 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.647 ' N ' HG11 ' A' ' 23' ' ' VAL . . . -121.87 138.21 54.48 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.89 -1.131 . . . . 0.0 109.319 179.662 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.466 HG13 ' O ' ' A' ' 29' ' ' LYS . 2.5 pt . . . . . 0 N--CA 1.494 1.733 0 O-C-N 121.166 -0.958 . . . . 0.0 109.239 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.466 ' O ' HG13 ' A' ' 25' ' ' ILE . 4.7 mttm . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.505 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 0.4 OUTLIER -119.28 141.13 49.24 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.063 -1.023 . . . . 0.0 110.067 -179.757 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.53 ' HA3' ' CD1' ' A' ' 71' ' ' LEU . . . -91.93 -177.7 42.21 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.03 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.63 HD12 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -149.93 120.14 7.29 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 120.796 -1.414 . . . . 0.0 110.842 179.687 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.499 ' HB ' ' CB ' ' A' ' 21' ' ' ALA . 93.4 t -92.84 60.1 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 177.714 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.461 ' HB2' HD21 ' A' ' 32' ' ' LEU . 3.0 t-80 -48.76 156.51 0.47 Allowed 'General case' 0 N--CA 1.486 1.346 0 O-C-N 120.895 -1.128 . . . . 0.0 108.681 -179.375 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.537 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.7 tp -48.45 -48.92 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.296 -0.878 . . . . 0.0 110.623 -179.385 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.463 ' O ' ' HG2' ' A' ' 37' ' ' GLN . 0.5 OUTLIER -81.25 40.93 0.58 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.145 -0.972 . . . . 0.0 110.693 -179.396 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.463 ' HG2' ' O ' ' A' ' 36' ' ' SER . 12.0 mt-30 -150.95 51.73 0.86 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.713 -1.242 . . . . 0.0 110.047 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.651 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.7 mp -123.04 -97.91 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.886 -1.134 . . . . 0.0 110.094 -179.889 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.534 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.302 -1.499 0 O-C-N 121.432 -0.792 . . . . 0.0 108.999 -179.493 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.601 ' HA ' ' CE1' ' A' ' 49' ' ' TYR . 50.1 t . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 43' ' ' VAL . 29.3 tt0 -41.83 -29.53 0.21 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.371 -0.83 . . . . 0.0 109.982 -179.61 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.483 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 1.1 mmtp -150.45 141.8 23.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.077 -1.015 . . . . 0.0 109.792 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.541 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -74.12 -25.82 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 O-C-N 121.202 -0.936 . . . . 0.0 108.664 179.413 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.8 p -78.38 3.18 16.38 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.745 -0.782 . . . . 0.0 109.108 179.372 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.421 ' OD2' ' HB2' ' A' ' 45' ' ' LYS . 4.7 m-20 -101.82 -29.4 11.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.171 -0.956 . . . . 0.0 108.749 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.651 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 20.4 m-85 -98.29 -27.5 14.1 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.571 -0.705 . . . . 0.0 109.129 179.765 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.54 HD11 ' CG1' ' A' ' 13' ' ' VAL . 0.2 OUTLIER -104.9 141.03 37.26 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.603 -0.686 . . . . 0.0 109.35 -179.73 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.537 ' HB3' ' CG ' ' A' ' 54' ' ' GLN . 43.6 tt0 -136.46 132.34 35.24 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.488 -0.757 . . . . 0.0 109.641 -179.712 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' MET . . . . . 0.481 ' HA ' HG13 ' A' ' 13' ' ' VAL . 4.7 mtt -65.26 112.11 3.31 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.354 -0.841 . . . . 0.0 109.605 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 113.71 -23.07 13.78 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' GLN . . . . . 0.537 ' CG ' ' HB3' ' A' ' 51' ' ' GLN . 57.0 mm-40 -79.37 167.5 20.78 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.251 -1.147 . . . . 0.0 109.583 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . 0.5 ' N ' ' OE1' ' A' ' 55' ' ' GLU . 1.3 mp0 -133.36 147.59 51.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.312 -0.867 . . . . 0.0 109.177 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 19.1 m -144.74 141.21 17.27 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.156 -0.965 . . . . 0.0 109.771 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.54 126.39 7.45 Favored 'Trans proline' 0 C--N 1.312 -1.391 0 C-N-CA 122.575 2.183 . . . . 0.0 110.238 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.481 ' O ' ' HA ' ' A' ' 8' ' ' VAL . 1.0 OUTLIER -132.31 -170.98 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.191 -0.943 . . . . 0.0 109.516 179.843 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.473 ' CG ' HG21 ' A' ' 8' ' ' VAL . 29.6 mtpt -134.43 127.01 30.68 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.414 -0.804 . . . . 0.0 109.459 179.801 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.646 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 26.2 t . . . . . 0 N--CA 1.489 1.504 0 O-C-N 121.281 -0.887 . . . . 0.0 109.018 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.53 ' CD1' ' HA3' ' A' ' 31' ' ' GLY . 18.8 mt . . . . . 0 N--CA 1.487 1.42 0 CA-C-O 121.358 0.599 . . . . 0.0 109.549 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.443 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.3 OUTLIER -114.67 106.7 14.54 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.375 -0.828 . . . . 0.0 109.565 -179.742 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -65.84 135.24 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.261 -0.899 . . . . 0.0 109.229 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.471 0 O-C-N 121.315 -0.866 . . . . 0.0 109.228 179.715 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.524 HG11 ' N ' ' A' ' 9' ' ' TYR . 71.6 t . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.524 ' N ' HG11 ' A' ' 8' ' ' VAL . 11.5 m-85 -136.53 129.51 31.06 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.059 -1.026 . . . . 0.0 110.77 -179.521 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.454 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 0.4 OUTLIER -97.58 112.05 24.07 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.149 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -113.48 151.97 18.16 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.134 -1.508 . . . . 0.0 110.59 -178.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.525 ' HG2' ' CG ' ' A' ' 55' ' ' GLU . 3.4 mtmm -89.63 162.32 15.68 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.876 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.5 HG13 ' HA ' ' A' ' 52' ' ' MET . 60.3 t -88.16 97.56 6.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 120.994 -1.066 . . . . 0.0 108.203 179.651 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.511 HG22 ' CB ' ' A' ' 24' ' ' ALA . 1.6 p -103.43 -4.64 23.8 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.475 -0.765 . . . . 0.0 110.426 -178.642 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.526 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -163.37 153.8 15.96 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.913 -1.117 . . . . 0.0 110.584 -179.699 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.449 HG22 HD11 ' A' ' 16' ' ' ILE . 19.8 mt -143.21 155.41 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 178.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.645 HG21 ' N ' ' A' ' 20' ' ' GLY . 0.6 OUTLIER -135.54 154.96 35.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.837 -1.164 . . . . 0.0 110.055 -178.934 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 12.0 t0 -60.5 -40.44 91.41 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.687 -1.258 . . . . 0.0 109.323 179.43 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.643 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 15.5 p90 -90.2 23.14 2.98 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.356 -0.84 . . . . 0.0 110.289 -179.743 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.645 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 156.23 -149.42 20.35 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 119.294 -1.432 . . . . 0.0 110.975 -179.654 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.536 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -153.54 146.85 24.79 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.042 -1.27 . . . . 0.0 108.99 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.647 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 11.2 m-30 -109.35 155.89 20.67 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.395 -0.816 . . . . 0.0 109.175 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.591 ' CG2' ' CG2' ' A' ' 33' ' ' VAL . 7.0 t -144.23 168.23 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 120.93 -1.106 . . . . 0.0 109.145 179.795 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.566 ' N ' ' CG1' ' A' ' 23' ' ' VAL . . . -138.05 150.92 47.36 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.06 -1.025 . . . . 0.0 110.743 -179.328 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.459 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.8 pt . . . . . 0 N--CA 1.492 1.661 0 O-C-N 121.182 -0.949 . . . . 0.0 108.951 179.315 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.459 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 . . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.534 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 5.2 mp0 -131.78 155.04 48.44 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 120.84 -1.162 . . . . 0.0 111.081 -179.468 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.464 ' HA3' HD11 ' A' ' 71' ' ' LEU . . . -105.72 -174.0 23.82 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 108.352 -1.899 . . . . 0.0 108.352 179.141 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.647 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.51 122.89 8.42 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.716 -1.461 . . . . 0.0 111.054 179.674 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.591 ' CG2' ' CG2' ' A' ' 23' ' ' VAL . 14.9 t -99.62 64.73 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 177.333 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.452 ' HB3' ' HG3' ' A' ' 37' ' ' GLN . 3.6 t-80 -49.58 162.23 0.17 Allowed 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.835 -1.165 . . . . 0.0 108.746 -179.474 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.557 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.3 OUTLIER -52.79 -52.05 31.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.214 -0.929 . . . . 0.0 110.329 -179.269 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.445 ' C ' ' HG2' ' A' ' 37' ' ' GLN . 11.5 m -81.42 32.46 0.35 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 120.994 -1.066 . . . . 0.0 110.764 -179.351 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.452 ' HG3' ' HB3' ' A' ' 34' ' ' HIS . 0.3 OUTLIER -138.24 48.24 1.97 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.695 -1.253 . . . . 0.0 109.978 -179.955 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.64 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.5 mp -119.39 -99.39 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 120.956 -1.09 . . . . 0.0 110.019 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.538 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.302 -1.476 0 O-C-N 121.317 -0.864 . . . . 0.0 109.09 -179.266 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.615 ' HA ' ' CE1' ' A' ' 49' ' ' TYR . 90.0 t . . . . . 0 N--CA 1.493 1.723 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.412 ' C ' ' O ' ' A' ' 43' ' ' VAL . 11.1 mt-10 -41.31 -30.66 0.19 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.556 -0.715 . . . . 0.0 109.506 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.479 ' O ' HG11 ' A' ' 43' ' ' VAL . 14.1 mttt -122.21 130.05 52.83 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.35 -0.844 . . . . 0.0 109.066 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.518 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -78.62 -24.31 13.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.19 -0.944 . . . . 0.0 108.932 -179.976 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 3.2 p -76.78 4.38 9.81 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.328 -0.858 . . . . 0.0 109.48 179.388 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.476 ' N ' ' OD1' ' A' ' 48' ' ' ASP . 2.0 m-20 -99.55 -37.43 9.17 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.156 -0.965 . . . . 0.0 108.727 179.515 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.64 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 18.0 m-85 -90.19 -32.69 16.5 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.683 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.509 ' CD1' HG22 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -99.21 140.38 33.45 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.532 -0.73 . . . . 0.0 109.223 179.938 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.457 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 45.6 mt-30 -136.35 112.56 9.8 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.463 -0.773 . . . . 0.0 109.253 -179.821 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' MET . . . . . 0.5 ' HA ' HG13 ' A' ' 13' ' ' VAL . 0.7 OUTLIER -52.49 94.59 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.277 -0.889 . . . . 0.0 110.176 -179.769 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 143.37 -38.88 1.35 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.771 -1.204 . . . . 0.0 110.428 179.508 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 22.4 mt-30 -77.36 169.17 18.8 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.128 -1.219 . . . . 0.0 109.782 -179.42 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . 0.525 ' CG ' ' HG2' ' A' ' 12' ' ' LYS . 3.6 mt-10 -122.81 125.32 45.22 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.297 -0.877 . . . . 0.0 109.217 179.739 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.419 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 22.9 m -117.49 142.64 30.73 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.187 -0.946 . . . . 0.0 109.97 -179.68 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.454 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.3 Cg_endo -80.28 153.66 21.43 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 122.753 2.302 . . . . 0.0 110.105 179.669 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.535 ' CG2' HD23 ' A' ' 71' ' ' LEU . 0.9 OUTLIER -150.47 -170.27 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.169 -0.957 . . . . 0.0 109.63 179.8 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.441 ' HA ' ' HA ' ' A' ' 8' ' ' VAL . 7.7 mtpt -140.75 124.44 17.03 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.398 -0.814 . . . . 0.0 109.663 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.419 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 43.0 t . . . . . 0 N--CA 1.491 1.579 0 O-C-N 121.415 -0.803 . . . . 0.0 108.991 179.365 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.535 HD23 ' CG2' ' A' ' 58' ' ' VAL . 52.8 mt . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 121.532 0.682 . . . . 0.0 110.112 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 73' ' ' ILE . 0.3 OUTLIER -124.36 116.58 22.82 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.481 -0.762 . . . . 0.0 110.028 -179.725 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.523 HD12 ' CG1' ' A' ' 33' ' ' VAL . 1.3 mp -46.43 134.97 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.079 -1.013 . . . . 0.0 108.511 179.368 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.649 0 O-C-N 121.157 -0.964 . . . . 0.0 109.976 -179.334 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.445 HG23 ' HE3' ' A' ' 59' ' ' LYS . 75.8 t . . . . . 0 N--CA 1.493 1.693 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.578 ' CD1' HG22 ' A' ' 60' ' ' VAL . 4.4 m-30 -105.22 129.47 53.59 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.113 -0.992 . . . . 0.0 110.066 -178.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.6 m -77.0 102.39 6.42 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 178.628 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -80.21 116.2 4.21 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.933 -1.127 . . . . 0.0 110.373 -178.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.542 ' O ' HG12 ' A' ' 23' ' ' VAL . 9.1 mttt -89.16 149.97 22.9 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.655 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.546 ' CG2' ' CD2' ' A' ' 50' ' ' LEU . 85.8 t -86.83 106.69 16.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 120.956 -1.09 . . . . 0.0 109.059 -179.292 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.547 ' CG2' ' HB1' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -113.99 -25.43 8.57 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.529 -0.732 . . . . 0.0 109.21 -179.492 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.513 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 5.6 mtp180 -143.86 152.23 40.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.262 -0.899 . . . . 0.0 109.967 179.762 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.7 mt -139.85 154.42 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.249 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.645 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -134.83 154.3 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 120.782 -1.199 . . . . 0.0 110.313 -178.835 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -59.28 -42.81 92.12 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.796 -1.19 . . . . 0.0 109.539 179.298 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.645 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 9.9 p90 -90.73 27.28 1.81 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.17 -0.956 . . . . 0.0 110.065 -179.766 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.636 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 154.85 -153.01 24.49 Favored Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.012 -1.566 . . . . 0.0 111.141 -179.488 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.509 ' CB ' HG13 ' A' ' 46' ' ' VAL . . . -150.02 143.81 25.41 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.057 -1.26 . . . . 0.0 109.075 -179.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.626 ' CE1' HD12 ' A' ' 32' ' ' LEU . 9.5 m-30 -104.27 160.79 14.59 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.174 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.545 ' CG2' HG22 ' A' ' 33' ' ' VAL . 24.9 t -151.09 159.42 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.841 -1.162 . . . . 0.0 110.514 -178.613 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.547 ' HB1' ' CG2' ' A' ' 14' ' ' THR . . . -138.14 143.04 40.14 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.24 -0.912 . . . . 0.0 109.142 179.618 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.537 ' CG1' ' O ' ' A' ' 29' ' ' LYS . 11.9 pt . . . . . 0 N--CA 1.494 1.728 0 O-C-N 120.825 -1.172 . . . . 0.0 109.001 179.742 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.537 ' O ' ' CG1' ' A' ' 25' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.895 0.855 . . . . 0.0 110.088 . . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.484 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 1.4 pm0 -136.04 156.6 48.49 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.059 -1.026 . . . . 0.0 110.194 -179.505 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.486 ' HA3' ' CD1' ' A' ' 71' ' ' LEU . . . -112.4 176.7 18.03 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 108.798 -1.721 . . . . 0.0 108.798 179.496 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.626 HD12 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -140.98 119.45 12.29 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.986 -1.302 . . . . 0.0 110.074 179.285 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.598 ' CG1' ' CD1' ' A' ' 50' ' ' LEU . 47.0 t -94.02 62.3 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.099 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 3.4 t-80 -48.56 156.18 0.47 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.857 -1.152 . . . . 0.0 108.712 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.536 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 3.2 tp -45.52 -53.96 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.365 -0.834 . . . . 0.0 110.899 -179.117 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.432 ' O ' ' HG2' ' A' ' 37' ' ' GLN . 5.3 t -81.27 41.4 0.6 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.049 -1.032 . . . . 0.0 110.633 -179.254 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.467 ' C ' ' CD1' ' A' ' 38' ' ' ILE . 43.5 mt-30 -150.8 61.45 0.93 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.782 -1.199 . . . . 0.0 110.598 -179.843 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.589 HG23 ' CD2' ' A' ' 49' ' ' TYR . 1.9 mp -129.37 -95.56 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 120.849 -1.157 . . . . 0.0 109.684 179.372 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.539 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.3 -1.552 0 O-C-N 121.555 -0.715 . . . . 0.0 109.752 -179.251 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.626 HG21 ' CZ ' ' A' ' 49' ' ' TYR . 75.7 t . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . 0.453 ' C ' ' O ' ' A' ' 43' ' ' VAL . 0.3 OUTLIER -40.71 -32.24 0.2 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.631 -0.668 . . . . 0.0 109.621 -179.99 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.467 ' HD2' ' OD2' ' A' ' 48' ' ' ASP . 2.7 mtmp? -111.69 118.23 35.08 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.417 -0.802 . . . . 0.0 109.514 -179.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.51 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -74.93 -26.59 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 179.509 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 7.9 p -78.93 5.36 11.76 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.36 -0.838 . . . . 0.0 109.176 179.215 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.467 ' OD2' ' HD2' ' A' ' 45' ' ' LYS . 3.2 m-20 -98.43 -37.24 9.68 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 179.383 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.626 ' CZ ' HG21 ' A' ' 43' ' ' VAL . 15.9 m-85 -90.28 -34.01 15.91 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.626 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.598 ' CD1' ' CG1' ' A' ' 33' ' ' VAL . 0.0 OUTLIER -110.66 148.11 32.92 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.354 -0.841 . . . . 0.0 110.395 179.886 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.464 ' O ' ' CG1' ' A' ' 13' ' ' VAL . 2.3 tt0 -150.62 147.03 26.91 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.57 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 8.2 mtp -65.84 88.05 0.1 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.098 -1.001 . . . . 0.0 109.743 -179.593 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 145.19 -20.81 1.92 Allowed Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.725 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 19.7 mm-40 -80.86 168.86 18.28 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.309 -1.112 . . . . 0.0 110.008 -179.733 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -144.04 116.77 8.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.387 -0.821 . . . . 0.0 109.097 179.684 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.5 m -114.41 142.31 27.92 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.13 -0.981 . . . . 0.0 109.359 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -78.93 142.39 17.45 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.351 2.034 . . . . 0.0 110.322 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.426 HG21 ' O ' ' A' ' 9' ' ' TYR . 0.8 OUTLIER -138.1 174.96 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.333 -0.855 . . . . 0.0 109.32 -179.886 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.445 ' HE3' HG23 ' A' ' 8' ' ' VAL . 0.1 OUTLIER -126.64 111.16 14.0 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.284 -0.885 . . . . 0.0 109.381 179.511 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.578 HG22 ' CD1' ' A' ' 9' ' ' TYR . 80.4 t . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.524 -0.735 . . . . 0.0 109.077 179.707 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.486 ' CD1' ' HA3' ' A' ' 31' ' ' GLY . 22.5 mt . . . . . 0 N--CA 1.488 1.445 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.49 99.07 8.61 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.448 -0.782 . . . . 0.0 110.498 -178.927 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.471 ' O ' ' C ' ' A' ' 74' ' ' LYS . 15.5 mm -51.69 137.95 9.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.316 -0.865 . . . . 0.0 109.295 179.697 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.471 ' C ' ' O ' ' A' ' 73' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.497 1.897 0 O-C-N 121.587 -0.696 . . . . 0.0 110.102 -179.835 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.523 ' CG1' ' O ' ' A' ' 58' ' ' VAL . 75.9 t . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.629 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 11.0 m-85 -120.87 127.7 52.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.036 -1.04 . . . . 0.0 110.502 -179.287 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' THR . . . . . 0.462 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 5.6 m -97.04 109.22 22.02 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 178.501 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -110.77 150.1 17.74 Favored Glycine 0 N--CA 1.487 2.095 0 C-N-CA 119.472 -1.347 . . . . 0.0 110.495 -178.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.468 ' O ' HG11 ' A' ' 23' ' ' VAL . 0.8 OUTLIER -89.81 163.02 15.21 Favored 'General case' 0 C--N 1.304 -1.394 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 179.08 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.544 HG23 ' CD2' ' A' ' 50' ' ' LEU . 41.6 t -89.0 103.27 13.8 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 O-C-N 121.096 -1.002 . . . . 0.0 108.754 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.534 ' CG2' ' CB ' ' A' ' 24' ' ' ALA . 0.5 OUTLIER -106.6 -12.46 15.57 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.282 -0.886 . . . . 0.0 109.779 -179.198 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.484 ' HD2' ' O ' ' A' ' 14' ' ' THR . 0.5 OUTLIER -159.26 153.9 24.42 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.054 -1.029 . . . . 0.0 110.41 -179.662 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.451 HG22 HD11 ' A' ' 16' ' ' ILE . 11.1 mt -139.69 157.65 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 179.255 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.664 HG21 ' N ' ' A' ' 20' ' ' GLY . 0.8 OUTLIER -137.75 153.7 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 120.697 -1.252 . . . . 0.0 110.128 -178.947 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.69 -40.66 93.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.594 -1.316 . . . . 0.0 109.232 179.186 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.647 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 16.3 p90 -90.04 24.17 2.55 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.273 -0.892 . . . . 0.0 110.19 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.664 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 155.82 -153.5 24.8 Favored Glycine 0 N--CA 1.494 2.506 0 C-N-CA 119.091 -1.528 . . . . 0.0 111.272 -179.405 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.497 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -149.78 145.35 26.58 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.116 -1.226 . . . . 0.0 108.931 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.632 ' CE1' HD12 ' A' ' 32' ' ' LEU . 10.2 m-30 -107.78 145.25 33.81 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.337 -0.852 . . . . 0.0 109.232 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.539 ' CG2' ' CG2' ' A' ' 33' ' ' VAL . 48.9 t -133.33 167.52 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.134 -0.979 . . . . 0.0 109.597 -179.681 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.545 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -136.64 135.29 38.17 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.884 -1.135 . . . . 0.0 110.78 -179.42 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.496 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.1 pt . . . . . 0 N--CA 1.494 1.75 0 O-C-N 120.94 -1.1 . . . . 0.0 108.863 178.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.496 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 . . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.545 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 4.6 pt-20 -111.08 150.48 29.31 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.771 -1.206 . . . . 0.0 109.988 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.427 ' O ' ' O ' ' A' ' 23' ' ' VAL . . . -97.95 -175.4 33.47 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 108.03 -2.028 . . . . 0.0 108.03 178.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.632 HD12 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -151.13 121.04 7.09 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 120.89 -1.359 . . . . 0.0 111.39 179.645 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.539 ' CG2' ' CG2' ' A' ' 23' ' ' VAL . 71.8 t -94.67 61.81 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 177.286 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.517 ' O ' ' CD1' ' A' ' 38' ' ' ILE . 3.1 t-80 -49.54 152.83 1.27 Allowed 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.89 -1.131 . . . . 0.0 108.814 -179.165 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.526 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.4 OUTLIER -46.96 -49.01 7.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.372 -0.83 . . . . 0.0 109.982 -179.591 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.436 ' C ' ' HG2' ' A' ' 37' ' ' GLN . 0.3 OUTLIER -81.6 40.42 0.58 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.21 -0.931 . . . . 0.0 110.327 -179.819 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.458 ' OE1' ' HA ' ' A' ' 37' ' ' GLN . 14.7 mm-40 -147.88 31.9 0.86 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.849 -1.157 . . . . 0.0 109.388 -179.878 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.634 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.6 mp -111.22 -98.74 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 O-C-N 121.13 -0.981 . . . . 0.0 109.992 -179.581 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.515 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.511 0 O-C-N 121.323 -0.861 . . . . 0.0 109.38 -179.706 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.61 ' CG1' ' CD1' ' A' ' 49' ' ' TYR . 24.1 t . . . . . 0 N--CA 1.486 1.375 0 CA-C-O 121.426 0.631 . . . . 0.0 109.553 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -49.02 -22.61 0.92 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.442 -0.786 . . . . 0.0 109.426 179.619 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.539 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 1.3 mmpt? -130.11 113.05 14.03 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.315 -0.866 . . . . 0.0 109.945 -179.58 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.516 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -76.64 -26.05 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.233 -0.917 . . . . 0.0 108.839 179.563 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 52.9 p -76.56 3.74 10.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.838 . . . . 0.0 109.35 179.396 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.464 ' OD2' ' CB ' ' A' ' 45' ' ' LYS . 98.5 m-20 -103.88 -30.26 10.46 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.143 -0.973 . . . . 0.0 108.515 179.716 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.634 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 16.3 m-85 -91.24 -31.58 16.09 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 179.501 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.544 ' CD2' HG23 ' A' ' 13' ' ' VAL . 1.3 mt -108.23 155.22 20.71 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.278 -0.889 . . . . 0.0 109.418 179.446 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.487 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 5.9 tp60 -141.53 138.43 32.72 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.321 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 9.4 mtt -63.3 112.82 2.87 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.144 -0.973 . . . . 0.0 109.908 -179.497 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 108.3 -22.66 26.53 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' GLN . . . . . 0.47 ' CG ' ' HB3' ' A' ' 51' ' ' GLN . 35.3 mt-30 -68.94 162.6 26.34 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.173 -1.193 . . . . 0.0 109.89 -179.757 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . 0.423 ' C ' HG11 ' A' ' 56' ' ' VAL . 1.1 mt-10 -114.32 141.82 47.11 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.359 -0.838 . . . . 0.0 109.033 179.6 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . 0.423 HG11 ' C ' ' A' ' 55' ' ' GLU . 31.7 m -144.13 131.04 10.31 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 120.948 -1.095 . . . . 0.0 110.25 -179.823 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.462 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.6 Cg_endo -80.65 154.14 20.51 Favored 'Trans proline' 0 C--N 1.316 -1.176 0 C-N-CA 122.65 2.233 . . . . 0.0 109.765 179.405 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.523 ' O ' ' CG1' ' A' ' 8' ' ' VAL . 0.9 OUTLIER -150.89 -169.73 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.035 -1.041 . . . . 0.0 109.625 179.733 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.492 ' CE ' HG21 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -135.68 138.53 42.89 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.469 -0.769 . . . . 0.0 109.205 179.557 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.629 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 5.1 t . . . . . 0 N--CA 1.49 1.551 0 O-C-N 121.334 -0.854 . . . . 0.0 108.853 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . . . . . . . . . 19.4 mt . . . . . 0 N--CA 1.489 1.525 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.16 117.55 20.96 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.509 -0.744 . . . . 0.0 110.001 -179.145 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.449 HD13 HG12 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -56.07 133.05 20.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.223 -0.923 . . . . 0.0 109.037 179.883 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.707 0 O-C-N 121.467 -0.771 . . . . 0.0 110.05 -179.302 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 23.9 t . . . . . 0 N--CA 1.487 1.425 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.673 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 4.0 m-85 -122.64 136.79 54.98 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.037 -1.04 . . . . 0.0 110.195 -178.848 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 7.0 m -90.34 102.66 15.39 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 178.125 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.441 ' HA3' HG13 ' A' ' 23' ' ' VAL . . . -79.54 128.39 8.51 Favored Glycine 0 N--CA 1.488 2.114 0 C-N-CA 119.843 -1.17 . . . . 0.0 110.794 -178.197 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.537 ' O ' HG12 ' A' ' 23' ' ' VAL . 6.1 mttt -89.08 147.61 24.14 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 178.29 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.472 HG13 ' HA ' ' A' ' 52' ' ' MET . 17.1 t -86.42 104.2 13.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 O-C-N 120.384 -1.447 . . . . 0.0 108.708 -179.289 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.532 ' O ' ' CD ' ' A' ' 15' ' ' ARG . 1.5 p -111.29 -9.15 14.3 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.697 -0.627 . . . . 0.0 109.858 -178.888 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.532 ' CD ' ' O ' ' A' ' 14' ' ' THR . 1.1 mpp_? -166.76 157.82 12.41 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.026 -1.046 . . . . 0.0 110.256 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.412 ' HA ' ' HA ' ' A' ' 21' ' ' ALA . 14.7 mt -144.1 153.66 15.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.057 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.666 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.9 OUTLIER -133.67 155.46 40.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.835 -1.165 . . . . 0.0 109.884 -179.413 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -59.34 -41.74 89.89 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.753 -1.217 . . . . 0.0 109.345 179.444 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.666 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 12.8 p90 -91.33 26.56 2.2 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.346 -0.846 . . . . 0.0 110.296 -179.609 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.622 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 156.25 -152.99 24.37 Favored Glycine 0 N--CA 1.493 2.456 0 C-N-CA 119.108 -1.52 . . . . 0.0 111.174 -179.669 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.508 ' CB ' ' HB ' ' A' ' 33' ' ' VAL . . . -152.24 144.54 23.99 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.259 -1.142 . . . . 0.0 109.017 -179.657 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.623 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 9.6 m-30 -105.28 152.72 22.55 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.171 -0.956 . . . . 0.0 109.244 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.537 HG12 ' O ' ' A' ' 12' ' ' LYS . 35.5 t -145.35 162.95 12.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.266 -0.896 . . . . 0.0 109.385 -179.476 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.528 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -135.18 130.72 35.79 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.852 -1.155 . . . . 0.0 110.089 -179.066 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.497 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.673 0 O-C-N 120.938 -1.101 . . . . 0.0 109.157 179.504 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.497 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.433 0.635 . . . . 0.0 109.421 . . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.528 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 2.8 mt-10 -105.91 148.46 27.59 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 120.725 -1.234 . . . . 0.0 109.628 179.772 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 23' ' ' VAL . . . -98.97 -179.36 31.71 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 108.452 -1.859 . . . . 0.0 108.452 179.342 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.623 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.64 117.37 5.82 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 120.814 -1.404 . . . . 0.0 110.652 179.577 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.525 ' CG2' HG23 ' A' ' 23' ' ' VAL . 30.1 t -91.23 61.06 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 177.51 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.492 ' HB2' HD21 ' A' ' 32' ' ' LEU . 3.7 t-80 -50.73 156.28 0.98 Allowed 'General case' 0 C--N 1.304 -1.394 0 O-C-N 120.964 -1.085 . . . . 0.0 108.624 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.537 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.9 OUTLIER -48.87 -47.35 16.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.171 -0.956 . . . . 0.0 109.789 -179.954 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.478 ' O ' ' HG2' ' A' ' 37' ' ' GLN . 37.4 t -81.42 40.2 0.56 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.158 -0.964 . . . . 0.0 110.647 -179.498 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.488 ' HG3' ' HB3' ' A' ' 34' ' ' HIS . 35.9 mt-30 -150.51 43.35 0.84 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.851 -1.155 . . . . 0.0 110.032 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.648 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.6 mp -120.68 -98.97 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.086 -1.008 . . . . 0.0 109.521 179.719 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.529 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.301 -1.534 0 O-C-N 121.244 -0.91 . . . . 0.0 109.636 -179.725 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.613 HG23 ' CG ' ' A' ' 49' ' ' TYR . 17.7 t . . . . . 0 N--CA 1.484 1.263 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -44.91 -21.33 0.05 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.544 -0.722 . . . . 0.0 110.316 -179.686 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.539 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 5.7 mttt -139.1 117.5 12.01 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.013 -1.054 . . . . 0.0 110.191 -179.433 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.494 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -72.52 -27.61 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.38 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 81.9 p -75.97 1.26 15.79 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.798 -0.761 . . . . 0.0 109.15 179.439 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.456 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 2.1 m-20 -97.71 -35.35 10.59 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.291 -0.881 . . . . 0.0 109.041 179.696 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.648 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 7.0 m-85 -91.46 -27.38 18.31 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.404 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.475 HD22 ' CG2' ' A' ' 33' ' ' VAL . 0.2 OUTLIER -104.46 140.31 38.13 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 179.598 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.476 ' HB3' ' HB2' ' A' ' 54' ' ' GLN . 4.1 tp-100 -132.41 124.46 28.69 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.198 -0.939 . . . . 0.0 109.788 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' MET . . . . . 0.472 ' HA ' HG13 ' A' ' 13' ' ' VAL . 23.6 ptp -58.42 130.07 45.01 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.381 -0.824 . . . . 0.0 109.869 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 93.86 -31.17 6.75 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 179.598 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' GLN . . . . . 0.476 ' HB2' ' HB3' ' A' ' 51' ' ' GLN . 56.8 mt-30 -77.97 -172.94 2.91 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.129 -1.218 . . . . 0.0 109.817 -179.62 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -143.56 157.06 44.72 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.441 -0.787 . . . . 0.0 108.943 179.704 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -140.0 140.91 25.29 Favored Pre-proline 0 C--N 1.303 -1.423 0 O-C-N 121.143 -0.973 . . . . 0.0 109.581 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.453 ' O ' ' HB3' ' A' ' 74' ' ' LYS . 36.3 Cg_endo -79.24 130.38 9.17 Favored 'Trans proline' 0 C--N 1.311 -1.403 0 C-N-CA 122.438 2.092 . . . . 0.0 109.9 179.551 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.459 HG21 ' O ' ' A' ' 9' ' ' TYR . 1.1 m -143.18 -170.02 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.087 -1.008 . . . . 0.0 109.99 -179.631 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.5 OUTLIER -135.08 126.81 29.12 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.672 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.673 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 36.2 t . . . . . 0 N--CA 1.488 1.473 0 O-C-N 121.278 -0.889 . . . . 0.0 109.306 -179.757 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.486 ' CD2' ' N ' ' A' ' 71' ' ' LEU . 3.4 mm? . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.24 0.543 . . . . 0.0 109.654 . . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.407 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.4 OUTLIER -112.14 106.26 14.83 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.393 -0.817 . . . . 0.0 109.704 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.483 HD12 ' CG1' ' A' ' 33' ' ' VAL . 0.9 OUTLIER -52.02 144.19 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.108 -0.995 . . . . 0.0 109.303 -179.871 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.453 ' HB3' ' O ' ' A' ' 57' ' ' PRO . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.371 -0.831 . . . . 0.0 109.843 -179.692 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' VAL . . . . . 0.402 HG11 ' O ' ' A' ' 58' ' ' VAL . 71.3 t . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' TYR . . . . . 0.462 ' CD1' HG22 ' A' ' 60' ' ' VAL . 3.1 m-85 -106.27 -174.67 2.59 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.147 -0.97 . . . . 0.0 109.836 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 11.4 m -147.28 110.79 4.92 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.419 ' CA ' ' O ' ' A' ' 24' ' ' ALA . . . -121.26 143.24 15.96 Favored Glycine 0 N--CA 1.488 2.122 0 C-N-CA 118.868 -1.634 . . . . 0.0 110.908 -178.194 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' LYS . . . . . 0.486 ' O ' HG11 ' A' ' 23' ' ' VAL . 8.8 mttp -90.43 165.58 13.75 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' VAL . . . . . 0.507 ' CG1' HD11 ' A' ' 50' ' ' LEU . 39.1 t -88.27 102.89 13.16 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.744 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.487 179.426 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' THR . . . . . 0.539 ' CG2' ' CB ' ' A' ' 24' ' ' ALA . 0.1 OUTLIER -101.75 -7.98 22.11 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.292 -0.88 . . . . 0.0 109.494 -179.351 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' ARG . . . . . 0.504 ' CG ' ' C ' ' A' ' 14' ' ' THR . 0.0 OUTLIER -167.64 147.24 5.02 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.151 -0.968 . . . . 0.0 109.613 -179.599 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' ILE . . . . . 0.405 ' C ' HG11 ' A' ' 17' ' ' VAL . 62.1 mt -131.13 163.34 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' VAL . . . . . 0.655 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -138.82 154.38 26.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 120.726 -1.234 . . . . 0.0 110.425 -179.559 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -59.23 -43.16 92.34 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.843 -1.161 . . . . 0.0 109.812 179.531 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' PHE . . . . . 0.655 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 6.4 p90 -92.12 25.6 2.81 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.249 -0.907 . . . . 0.0 110.266 -179.384 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' GLY . . . . . 0.643 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 157.66 -154.79 25.84 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 119.033 -1.556 . . . . 0.0 110.98 -179.71 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' ALA . . . . . 0.493 ' HB1' HG13 ' A' ' 46' ' ' VAL . . . -149.61 145.97 27.05 Favored 'General case' 0 N--CA 1.486 1.345 0 O-C-N 121.089 -1.242 . . . . 0.0 108.995 -179.759 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' PHE . . . . . 0.643 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 10.8 m-30 -106.87 158.2 17.19 Favored 'General case' 0 C--N 1.298 -1.672 0 O-C-N 121.316 -0.865 . . . . 0.0 108.738 179.481 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' VAL . . . . . 0.578 ' CG2' ' CG2' ' A' ' 33' ' ' VAL . 37.6 t -148.34 166.34 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.069 -1.02 . . . . 0.0 109.755 -179.507 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' ALA . . . . . 0.542 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -137.91 144.65 41.4 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.287 -0.883 . . . . 0.0 109.539 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ILE . . . . . 0.535 ' CG1' ' O ' ' A' ' 29' ' ' LYS . 5.5 pt . . . . . 0 N--CA 1.494 1.771 0 O-C-N 120.625 -1.297 . . . . 0.0 108.562 179.253 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' LYS . . . . . 0.535 ' O ' ' CG1' ' A' ' 25' ' ' ILE . 0.4 OUTLIER . . . . . 0 N--CA 1.492 1.674 0 CA-C-O 121.684 0.754 . . . . 0.0 110.06 . . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' GLU . . . . . 0.542 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 12.6 mp0 -123.39 153.24 40.65 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.836 -1.165 . . . . 0.0 110.109 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' A' ' 23' ' ' VAL . . . -103.67 -175.48 25.92 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 108.8 -1.72 . . . . 0.0 108.8 179.521 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' LEU . . . . . 0.643 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.57 119.82 6.81 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.97 -1.312 . . . . 0.0 110.552 179.624 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . 0.578 ' CG2' ' CG2' ' A' ' 23' ' ' VAL . 25.2 t -96.84 63.21 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 177.736 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' HIS . . . . . 0.532 ' O ' ' CD1' ' A' ' 38' ' ' ILE . 7.7 t-80 -48.64 162.57 0.1 Allowed 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.741 -1.224 . . . . 0.0 108.359 -179.627 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.558 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.4 OUTLIER -55.5 -45.79 78.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.012 -1.055 . . . . 0.0 110.53 -179.49 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' SER . . . . . 0.466 ' C ' ' HG2' ' A' ' 37' ' ' GLN . 0.9 OUTLIER -80.05 23.77 0.45 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.153 -0.967 . . . . 0.0 110.795 -179.338 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' GLN . . . . . 0.533 ' O ' ' CD1' ' A' ' 73' ' ' ILE . 3.4 mm100 -138.74 64.18 1.49 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.883 -1.136 . . . . 0.0 109.293 179.546 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ILE . . . . . 0.633 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.8 mp -129.35 -94.59 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.042 -1.036 . . . . 0.0 109.704 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' ALA . . . . . 0.546 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.3 -1.544 0 O-C-N 121.455 -0.778 . . . . 0.0 109.852 -179.346 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' VAL . . . . . 0.647 ' CG1' ' CD1' ' A' ' 49' ' ' TYR . 44.3 t . . . . . 0 N--CA 1.482 1.154 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -53.98 -19.02 4.06 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.365 -0.834 . . . . 0.0 109.114 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' LYS . . . . . 0.543 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.2 OUTLIER -121.68 108.19 13.25 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.436 -0.79 . . . . 0.0 109.748 -179.569 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' VAL . . . . . 0.519 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -76.3 -24.76 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.331 -0.856 . . . . 0.0 109.179 179.972 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.2 p -78.28 5.95 9.28 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.364 -0.835 . . . . 0.0 109.541 179.873 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' ASP . . . . . 0.434 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 10.2 m-20 -104.35 -37.59 7.17 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.136 -0.977 . . . . 0.0 108.716 179.548 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' TYR . . . . . 0.647 ' CD1' ' CG1' ' A' ' 43' ' ' VAL . 11.7 m-85 -89.84 -38.01 14.05 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.532 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' LEU . . . . . 0.507 HD11 ' CG1' ' A' ' 13' ' ' VAL . 0.2 OUTLIER -96.45 136.02 37.52 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.435 -0.791 . . . . 0.0 109.301 -179.931 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' GLN . . . . . 0.503 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.9 OUTLIER -129.72 132.57 46.66 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.659 -0.651 . . . . 0.0 109.372 -179.517 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 11.5 mtt -57.31 113.52 1.79 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.313 -0.867 . . . . 0.0 109.661 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 106.14 -34.09 6.0 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.636 -1.385 . . . . 0.0 109.636 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 6.9 mt-30 -54.4 143.02 24.94 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.32 -1.106 . . . . 0.0 110.025 -179.722 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -104.15 129.39 51.88 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.313 -0.867 . . . . 0.0 108.898 179.368 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.2 m -132.78 134.48 24.65 Favored Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 120.99 -1.069 . . . . 0.0 110.085 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' PRO . . . . . 0.474 ' O ' ' HB2' ' A' ' 74' ' ' LYS . 37.0 Cg_endo -81.72 143.51 13.38 Favored 'Trans proline' 0 C--N 1.314 -1.283 0 C-N-CA 122.705 2.27 . . . . 0.0 110.015 179.341 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 72' ' ' SER . 0.9 OUTLIER -135.31 -177.87 2.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.062 -1.024 . . . . 0.0 109.322 179.676 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . 0.494 ' HB2' ' CB ' ' A' ' 72' ' ' SER . 0.0 OUTLIER -131.72 110.78 11.13 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.277 -0.889 . . . . 0.0 109.212 179.737 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' VAL . . . . . 0.462 HG22 ' CD1' ' A' ' 9' ' ' TYR . 25.1 t . . . . . 0 N--CA 1.492 1.647 0 O-C-N 121.374 -0.829 . . . . 0.0 109.112 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' LEU . . . . . 0.416 ' HB3' ' CG2' ' A' ' 58' ' ' VAL . 23.4 mt . . . . . 0 N--CA 1.489 1.48 0 CA-C-O 121.352 0.596 . . . . 0.0 109.477 . . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' SER . . . . . 0.494 ' CB ' ' HB2' ' A' ' 59' ' ' LYS . 0.3 OUTLIER -100.66 110.63 22.77 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.336 -0.852 . . . . 0.0 109.546 179.931 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' ILE . . . . . 0.533 ' CD1' ' O ' ' A' ' 37' ' ' GLN . 1.9 mp -62.68 127.11 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.496 -0.752 . . . . 0.0 109.733 -179.738 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' LYS . . . . . 0.474 ' HB2' ' O ' ' A' ' 57' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.602 0 O-C-N 121.301 -0.874 . . . . 0.0 109.29 179.666 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.487 ' O ' ' HG2' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.487 ' HG2' ' O ' ' A' ' 1' ' ' ALA . 1.3 pt-20 41.05 -166.51 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.659 -0.651 . . . . 0.0 109.837 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.546 ' CG2' ' OH ' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -141.34 -167.44 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.145 -0.972 . . . . 0.0 109.588 -179.301 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -121.73 141.55 51.07 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.425 -0.797 . . . . 0.0 109.053 179.376 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.49 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 2.6 t -80.14 161.66 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.179 -0.951 . . . . 0.0 109.74 -179.655 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.49 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 95.97 -7.02 67.17 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 1.1 ttm180 -98.44 168.14 10.39 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.3 -1.118 . . . . 0.0 109.646 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.474 HG21 ' HG2' ' A' ' 59' ' ' LYS . 40.6 t -89.87 150.83 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.371 -0.831 . . . . 0.0 108.899 179.758 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.622 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 15.2 m-85 -136.17 129.19 31.32 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.967 -1.083 . . . . 0.0 110.386 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.5 m -76.91 102.06 6.21 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 178.264 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -83.14 113.81 3.74 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 119.813 -1.184 . . . . 0.0 110.73 -178.262 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.525 ' O ' HG12 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -89.31 153.87 20.54 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 178.697 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.551 ' CG2' HD12 ' A' ' 50' ' ' LEU . 77.1 t -87.43 116.11 29.12 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 O-C-N 120.759 -1.213 . . . . 0.0 109.116 -179.572 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.519 ' O ' ' CD ' ' A' ' 15' ' ' ARG . 0.2 OUTLIER -126.72 7.24 6.8 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.386 -0.821 . . . . 0.0 109.473 -179.396 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.519 ' CD ' ' O ' ' A' ' 14' ' ' THR . 1.9 mtp180 -178.26 149.52 0.53 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.304 -0.872 . . . . 0.0 109.575 179.692 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 33.6 mt -140.9 157.16 22.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.487 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.656 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -135.78 152.93 31.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.858 -1.151 . . . . 0.0 110.057 -179.395 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -58.62 -41.44 85.93 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.721 -1.237 . . . . 0.0 109.035 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.656 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 17.3 p90 -90.41 28.68 1.41 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.363 -0.836 . . . . 0.0 110.33 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.637 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 151.72 -152.29 24.07 Favored Glycine 0 N--CA 1.491 2.326 0 C-N-CA 119.073 -1.537 . . . . 0.0 111.018 -179.607 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.475 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -151.75 147.11 26.29 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.125 -1.221 . . . . 0.0 108.938 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.629 ' CE1' HD12 ' A' ' 32' ' ' LEU . 8.8 m-30 -106.93 158.66 16.85 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 179.642 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.565 ' CG2' ' CG2' ' A' ' 33' ' ' VAL . 31.8 t -147.61 161.92 7.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.035 -1.041 . . . . 0.0 109.858 -179.154 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.543 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -139.74 150.34 44.68 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.103 -0.998 . . . . 0.0 109.436 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.537 ' CG1' ' O ' ' A' ' 29' ' ' LYS . 4.5 pt -112.53 -0.98 9.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 120.823 -1.173 . . . . 0.0 109.706 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 69.31 146.98 0.23 Allowed Glycine 0 N--CA 1.49 2.233 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 106.36 -3.59 37.43 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 110.73 1.95 28.89 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.537 ' O ' ' CG1' ' A' ' 25' ' ' ILE . 14.7 mtpt -129.42 143.55 50.89 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.194 -1.18 . . . . 0.0 109.389 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.543 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 1.1 mt-10 -130.34 158.8 38.83 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.061 -1.024 . . . . 0.0 110.356 -179.678 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 23' ' ' VAL . . . -108.68 -173.73 21.48 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 179.328 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.629 HD12 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.26 123.21 8.76 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.853 -1.381 . . . . 0.0 110.682 179.751 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.565 ' CG2' ' CG2' ' A' ' 23' ' ' VAL . 60.8 t -97.67 62.16 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 177.662 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.487 ' HB3' ' HG3' ' A' ' 37' ' ' GLN . 3.3 t-80 -48.39 159.49 0.21 Allowed 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.692 -1.255 . . . . 0.0 108.147 -179.623 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.547 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 3.1 tp -48.58 -50.35 12.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.587 0 O-C-N 121.099 -1.001 . . . . 0.0 110.09 -179.121 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 5.3 m -81.57 41.22 0.62 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.182 -0.949 . . . . 0.0 110.424 -179.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.487 ' HG3' ' HB3' ' A' ' 34' ' ' HIS . 40.3 mt-30 -150.69 53.0 0.88 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.847 -1.158 . . . . 0.0 110.245 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.633 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.6 mp -119.09 -98.92 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.928 -1.107 . . . . 0.0 109.936 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.503 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . -126.42 162.28 25.94 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.315 -0.866 . . . . 0.0 109.641 -179.424 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -47.3 -33.1 5.29 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.225 -0.922 . . . . 0.0 109.09 179.594 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -66.74 141.88 57.58 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.277 -0.889 . . . . 0.0 109.39 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 80.0 mtp180 -61.07 114.64 3.22 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.22 -0.925 . . . . 0.0 109.531 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.626 ' CG2' ' CZ ' ' A' ' 49' ' ' TYR . 80.4 t -101.99 55.0 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.263 -0.898 . . . . 0.0 108.861 179.591 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.425 ' C ' ' O ' ' A' ' 43' ' ' VAL . 0.0 OUTLIER -43.73 -26.66 0.26 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.38 -0.825 . . . . 0.0 108.896 179.849 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.459 ' O ' HG11 ' A' ' 43' ' ' VAL . 0.1 OUTLIER -109.83 114.33 27.8 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.495 -0.753 . . . . 0.0 108.988 179.479 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.535 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -78.16 -24.14 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.141 -0.975 . . . . 0.0 108.62 179.747 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 3.7 p -76.22 1.61 15.45 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.44 -0.787 . . . . 0.0 109.344 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.429 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 14.4 m-20 -96.05 -40.35 9.29 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.111 -0.993 . . . . 0.0 108.926 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.633 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 9.5 m-85 -89.56 -28.77 19.36 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.487 -0.758 . . . . 0.0 109.019 179.715 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.551 HD12 ' CG2' ' A' ' 13' ' ' VAL . 0.1 OUTLIER -102.75 134.74 45.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.504 -0.748 . . . . 0.0 109.537 -179.842 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.507 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 1.9 tt0 -140.39 143.03 35.45 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.59 -0.694 . . . . 0.0 109.314 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 39.1 mtm -67.54 93.77 0.38 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.179 -0.951 . . . . 0.0 109.441 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.69 -18.91 4.81 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . 0.449 ' O ' HG22 ' A' ' 13' ' ' VAL . 11.6 mm-40 -79.7 124.86 28.96 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.328 -1.101 . . . . 0.0 109.637 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -106.27 117.78 34.94 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.257 -0.902 . . . . 0.0 109.109 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.497 HG13 ' CB ' ' A' ' 76' ' ' ALA . 33.8 m -118.98 151.76 50.85 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.134 -0.979 . . . . 0.0 109.836 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.401 ' HD3' ' HA ' ' A' ' 56' ' ' VAL . 36.0 Cg_endo -78.87 142.57 17.72 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.695 2.264 . . . . 0.0 110.509 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.484 ' CG2' ' HB3' ' A' ' 71' ' ' LEU . 0.9 OUTLIER -141.67 -177.22 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.211 -0.931 . . . . 0.0 109.354 179.622 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.488 ' O ' ' N ' ' A' ' 61' ' ' LEU . 0.0 OUTLIER -134.03 128.73 34.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.283 -0.886 . . . . 0.0 109.475 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.622 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 62.0 t -55.21 89.53 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.266 -0.896 . . . . 0.0 109.037 179.504 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.591 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 10.3 tp -57.05 -34.8 68.59 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.35 -0.843 . . . . 0.0 108.879 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.591 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 0.1 OUTLIER 151.58 177.95 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.059 0 CA-C-O 121.332 0.587 . . . . 0.0 109.537 179.586 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 60.3 t -143.17 106.27 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.365 -0.834 . . . . 0.0 109.387 179.568 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.8 p30 -63.16 -172.07 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.255 -0.903 . . . . 0.0 109.784 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 16.9 mtm180 -75.52 -1.12 22.79 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.367 -0.833 . . . . 0.0 109.587 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -91.05 8.75 33.87 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.131 -0.981 . . . . 0.0 109.509 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 56.18 28.11 53.59 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.416 ' O ' ' C ' ' A' ' 69' ' ' ILE . 35.0 mmm-85 -90.82 84.41 5.82 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.285 -1.127 . . . . 0.0 109.351 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.477 ' HB ' ' O ' ' A' ' 30' ' ' GLU . 4.3 mt -42.83 105.34 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.325 -0.859 . . . . 0.0 109.788 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.428 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 0.7 OUTLIER -90.99 94.5 9.67 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.249 -0.907 . . . . 0.0 109.359 179.754 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.484 ' HB3' ' CG2' ' A' ' 58' ' ' VAL . 15.1 mt -89.82 151.51 21.74 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.176 -0.953 . . . . 0.0 109.23 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.427 ' OG ' HD11 ' A' ' 61' ' ' LEU . 0.6 OUTLIER -118.21 106.64 13.03 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.341 -0.849 . . . . 0.0 109.871 -179.618 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.446 HG12 HG22 ' A' ' 56' ' ' VAL . 0.1 OUTLIER -58.77 139.12 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.269 -0.894 . . . . 0.0 109.001 179.865 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 2.4 mmtm -74.28 -94.9 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.26 -0.9 . . . . 0.0 109.281 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -156.82 45.35 0.4 Allowed 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.29 -0.881 . . . . 0.0 109.45 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.497 ' CB ' HG13 ' A' ' 56' ' ' VAL . . . . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 118.029 -0.986 . . . . 0.0 109.476 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.295 0.569 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.478 ' O ' ' HB ' ' A' ' 3' ' ' ILE . 0.1 OUTLIER -141.39 172.73 12.27 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 109.645 -179.949 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.522 HD12 ' CD ' ' A' ' 7' ' ' ARG . 0.3 OUTLIER 170.38 129.24 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 O-C-N 121.444 -0.785 . . . . 0.0 109.323 -179.46 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -142.3 -160.1 1.05 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.369 -0.832 . . . . 0.0 109.297 179.908 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.57 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 3.2 t -71.77 167.62 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.177 -0.952 . . . . 0.0 109.087 179.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.57 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 77.42 2.11 78.49 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.67 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.522 ' CD ' HD12 ' A' ' 3' ' ' ILE . 0.4 OUTLIER -102.08 169.85 8.48 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.269 -1.136 . . . . 0.0 109.291 179.901 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.457 HG11 ' O ' ' A' ' 58' ' ' VAL . 48.1 t -101.29 134.55 41.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.198 -0.939 . . . . 0.0 109.385 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.519 ' CE1' HG22 ' A' ' 60' ' ' VAL . 3.0 m-85 -110.31 179.92 3.95 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.156 -0.965 . . . . 0.0 109.392 179.775 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.464 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 3.5 m -136.65 107.58 6.68 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 178.94 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.486 ' HA2' ' O ' ' A' ' 24' ' ' ALA . . . -109.82 141.6 16.2 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.065 -1.541 . . . . 0.0 110.331 -178.743 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.497 ' O ' HG11 ' A' ' 23' ' ' VAL . 27.4 mtpt -89.15 163.73 15.32 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 178.939 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.541 ' CG1' HD21 ' A' ' 50' ' ' LEU . 95.3 t -87.43 102.02 11.94 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.542 ' CG2' ' HB1' ' A' ' 24' ' ' ALA . 1.2 p -106.12 -11.67 16.02 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.478 -0.764 . . . . 0.0 110.186 -178.62 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.539 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -161.2 156.33 24.07 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.954 -1.091 . . . . 0.0 110.455 -179.781 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.461 ' HA ' ' HA ' ' A' ' 21' ' ' ALA . 24.1 mt -147.61 142.77 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.161 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.685 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 1.5 m -120.79 157.82 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.898 -1.126 . . . . 0.0 110.186 -178.771 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.2 -39.41 86.46 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.807 -1.183 . . . . 0.0 109.459 179.097 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.685 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 10.1 p90 -95.16 27.06 3.4 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.14 -0.975 . . . . 0.0 110.222 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.63 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 158.29 -157.43 28.31 Favored Glycine 0 N--CA 1.49 2.244 0 C-N-CA 118.936 -1.602 . . . . 0.0 110.802 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.488 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -149.23 145.4 27.1 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.215 -1.168 . . . . 0.0 109.154 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.641 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 10.3 m-30 -106.5 158.4 16.94 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.467 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.534 ' CG2' HG22 ' A' ' 33' ' ' VAL . 32.3 t -148.87 164.95 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.067 -1.02 . . . . 0.0 109.533 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.564 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -133.76 152.93 52.01 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.032 -1.043 . . . . 0.0 109.998 -179.478 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.488 HG13 ' O ' ' A' ' 29' ' ' LYS . 2.0 pt -118.0 -99.78 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 120.666 -1.271 . . . . 0.0 109.429 179.362 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -63.83 -127.59 0.01 OUTLIER Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -117.97 -38.11 0.84 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -99.89 1.81 56.71 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.488 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER -127.53 143.23 51.21 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.184 -1.186 . . . . 0.0 109.8 179.949 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.564 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 13.8 mt-10 -134.6 154.08 51.66 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.925 -1.109 . . . . 0.0 110.222 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.46 ' O ' ' O ' ' A' ' 23' ' ' VAL . . . -101.06 -175.99 29.12 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 108.478 -1.849 . . . . 0.0 108.478 179.307 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.641 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.17 119.31 6.76 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.979 -1.306 . . . . 0.0 110.73 179.429 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.611 ' CG1' ' CD1' ' A' ' 50' ' ' LEU . 41.3 t -95.93 62.21 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 177.907 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.519 ' O ' ' CD1' ' A' ' 38' ' ' ILE . 3.9 t-160 -49.37 160.12 0.27 Allowed 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.898 -1.127 . . . . 0.0 108.46 -179.49 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.567 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.9 tp -52.2 -49.58 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.236 -0.915 . . . . 0.0 110.286 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.408 ' C ' ' CG ' ' A' ' 37' ' ' GLN . 0.4 OUTLIER -81.28 41.34 0.6 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.16 -0.963 . . . . 0.0 110.582 -179.331 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.457 ' HG3' ' HB3' ' A' ' 34' ' ' HIS . 30.7 mt-30 -150.65 33.38 0.62 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.766 -1.209 . . . . 0.0 110.42 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.641 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.5 mp -108.72 -96.29 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.815 -1.178 . . . . 0.0 110.157 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.568 ' O ' ' CB ' ' A' ' 40' ' ' ASP . . . -92.76 47.05 1.26 Allowed 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.361 -0.837 . . . . 0.0 110.326 -178.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.568 ' CB ' ' O ' ' A' ' 39' ' ' ALA . 6.5 t70 83.01 -45.65 0.13 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.596 -0.69 . . . . 0.0 110.495 179.125 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.479 ' O ' ' O ' ' A' ' 42' ' ' ARG . 0.0 OUTLIER -166.61 -33.41 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.88 -1.137 . . . . 0.0 110.043 -179.707 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.5 ' O ' ' HB ' ' A' ' 43' ' ' VAL . 9.2 mtp180 -56.66 -159.37 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.168 -0.958 . . . . 0.0 109.652 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.633 HG23 ' CD2' ' A' ' 49' ' ' TYR . 5.5 t 80.05 55.28 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.605 -0.684 . . . . 0.0 110.245 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.406 ' C ' ' O ' ' A' ' 43' ' ' VAL . 2.3 mp0 -47.85 -26.01 1.5 Allowed 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 178.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.456 ' O ' HG11 ' A' ' 43' ' ' VAL . 0.1 OUTLIER -127.86 124.65 38.04 Favored 'General case' 0 N--CA 1.487 1.375 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.453 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.549 HG23 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -70.23 -25.74 28.02 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.355 -0.841 . . . . 0.0 109.119 -179.507 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.448 HG21 HG23 ' A' ' 16' ' ' ILE . 3.4 p -75.43 5.28 5.98 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.431 -0.793 . . . . 0.0 109.878 179.598 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.431 ' CG ' ' HB2' ' A' ' 45' ' ' LYS . 12.5 m-20 -101.14 -34.7 9.59 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.008 -1.057 . . . . 0.0 108.677 179.534 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.641 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 6.3 m-85 -89.51 -34.07 16.53 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.524 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.611 ' CD1' ' CG1' ' A' ' 33' ' ' VAL . 0.0 OUTLIER -102.57 154.4 19.16 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.173 -1.011 . . . . 0.0 110.366 179.783 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.459 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.6 OUTLIER -142.95 133.83 25.47 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.487 -0.758 . . . . 0.0 109.13 179.982 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' MET . . . . . 0.459 ' HA ' HG13 ' A' ' 13' ' ' VAL . 3.9 mtt -63.99 100.44 0.31 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.258 -0.901 . . . . 0.0 109.847 -179.771 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 129.97 -24.84 4.47 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . 0.404 ' HA ' ' OE1' ' A' ' 54' ' ' GLN . 13.2 mm100 -78.87 158.48 28.1 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.232 -1.158 . . . . 0.0 109.786 -179.785 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -110.61 111.66 23.04 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.328 -0.857 . . . . 0.0 109.026 179.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.48 ' CG2' ' O ' ' A' ' 56' ' ' VAL . 6.8 m -103.24 121.99 46.84 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.184 -0.947 . . . . 0.0 110.108 -179.424 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.509 ' HG2' ' CB ' ' A' ' 76' ' ' ALA . 36.5 Cg_endo -80.84 146.71 16.61 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 C-N-CA 122.559 2.173 . . . . 0.0 110.077 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.526 ' CG2' ' HB3' ' A' ' 71' ' ' LEU . 1.0 OUTLIER -140.01 -168.77 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.06 -1.025 . . . . 0.0 109.655 -179.994 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.512 ' O ' ' N ' ' A' ' 61' ' ' LEU . 14.9 mtpt -131.23 119.61 22.06 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.401 -0.812 . . . . 0.0 109.493 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.519 HG22 ' CE1' ' A' ' 9' ' ' TYR . 95.9 t -54.37 89.19 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.418 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.514 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 9.5 tp -68.72 -24.54 64.48 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.339 -0.85 . . . . 0.0 110.034 -179.249 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.514 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 0.5 OUTLIER 166.15 133.88 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.001 -1.062 . . . . 0.0 110.854 179.79 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.463 HG11 ' O ' ' A' ' 67' ' ' GLY . 36.9 t -150.98 -96.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 178.804 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.444 ' O ' ' O ' ' A' ' 63' ' ' VAL . 5.2 p-10 40.73 -162.45 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.069 -1.019 . . . . 0.0 110.234 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 33.1 mmt180 -51.03 -62.81 1.39 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.336 -0.852 . . . . 0.0 109.027 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -89.89 90.37 8.15 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.279 -0.888 . . . . 0.0 108.842 179.443 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.463 ' O ' HG11 ' A' ' 63' ' ' VAL . . . 167.78 100.76 0.14 Allowed Glycine 0 N--CA 1.486 1.978 0 N-CA-C 108.592 -1.803 . . . . 0.0 108.592 -179.413 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 68.8 mtp180 -88.95 79.51 7.29 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.523 -0.986 . . . . 0.0 109.726 -179.307 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.539 ' CG2' ' O ' ' A' ' 69' ' ' ILE . 12.7 mm 50.05 71.64 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.466 -0.771 . . . . 0.0 110.216 179.526 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.473 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 0.0 OUTLIER -97.62 76.37 2.51 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.961 -1.087 . . . . 0.0 108.07 178.755 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.526 ' HB3' ' CG2' ' A' ' 58' ' ' VAL . 96.5 mt -88.96 153.41 21.05 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.329 -0.857 . . . . 0.0 110.043 -178.765 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -117.16 113.55 22.41 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.508 -0.745 . . . . 0.0 109.571 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.483 HD12 HG23 ' A' ' 33' ' ' VAL . 0.6 OUTLIER -47.56 122.81 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.349 -0.844 . . . . 0.0 109.264 179.927 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.442 ' HB3' ' O ' ' A' ' 57' ' ' PRO . 4.2 ttpp -79.29 -16.57 56.19 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.19 -0.944 . . . . 0.0 108.939 179.431 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 67.52 42.4 2.13 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -179.572 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.509 ' CB ' ' HG2' ' A' ' 57' ' ' PRO . . . . . . . . 0 N--CA 1.488 1.457 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.453 -179.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.302 0.572 . . . . 0.0 109.473 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.507 ' O ' ' CB ' ' A' ' 3' ' ' ILE . 64.3 mt-10 47.69 -125.32 1.72 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.199 -0.938 . . . . 0.0 109.404 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.507 ' CB ' ' O ' ' A' ' 2' ' ' GLU . 0.3 OUTLIER 75.09 146.01 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 120.674 -1.267 . . . . 0.0 108.879 -179.652 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -142.02 176.81 8.66 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.095 -1.003 . . . . 0.0 109.959 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.577 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 2.7 t -79.97 169.52 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.363 -0.836 . . . . 0.0 109.146 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.577 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 73.98 16.91 79.34 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.333 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.426 ' CD ' ' N ' ' A' ' 8' ' ' VAL . 0.1 OUTLIER -116.12 152.69 33.16 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.564 -0.963 . . . . 0.0 109.061 -179.61 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.467 HG23 ' CG ' ' A' ' 59' ' ' LYS . 54.9 t -88.65 129.95 38.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 179.357 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.561 ' CE1' ' CG2' ' A' ' 60' ' ' VAL . 2.9 m-85 -106.52 -179.4 3.93 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.119 -0.988 . . . . 0.0 110.071 -178.731 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.8 m -129.04 105.52 8.25 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 178.181 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.417 ' HA2' ' O ' ' A' ' 24' ' ' ALA . . . -108.16 132.21 11.0 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 119.318 -1.42 . . . . 0.0 111.254 -177.747 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.504 ' O ' HG11 ' A' ' 23' ' ' VAL . 0.3 OUTLIER -91.39 158.83 16.3 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 178.348 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.54 HG23 ' CD2' ' A' ' 50' ' ' LEU . 61.2 t -87.82 97.02 6.2 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 O-C-N 120.858 -1.151 . . . . 0.0 109.045 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.513 ' CG2' ' CB ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -101.37 -5.78 24.93 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.527 -0.733 . . . . 0.0 109.817 -179.255 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.536 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -164.95 153.71 12.37 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.122 -0.986 . . . . 0.0 110.113 -179.693 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.475 HG23 ' CG2' ' A' ' 47' ' ' THR . 7.7 mt -141.58 152.92 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 178.842 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.634 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -132.33 151.27 34.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.903 -1.123 . . . . 0.0 109.907 -179.011 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -58.41 -38.78 78.09 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.735 -1.228 . . . . 0.0 108.835 179.203 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.634 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 23.3 p90 -92.57 30.13 1.59 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.504 -0.748 . . . . 0.0 109.943 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.632 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 149.54 -150.99 23.16 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 119.114 -1.517 . . . . 0.0 111.219 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.489 ' CB ' ' HB ' ' A' ' 33' ' ' VAL . . . -152.58 144.9 23.98 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.094 -1.239 . . . . 0.0 109.158 -179.877 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.63 ' CE1' HD12 ' A' ' 32' ' ' LEU . 10.3 m-30 -106.29 142.38 36.07 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.306 -0.872 . . . . 0.0 108.881 179.566 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.573 ' CG2' ' CG2' ' A' ' 33' ' ' VAL . 40.8 t -132.91 163.02 39.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 120.902 -1.124 . . . . 0.0 109.643 -179.444 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.513 ' CB ' ' CG2' ' A' ' 14' ' ' THR . . . -130.15 153.24 48.73 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.103 -0.998 . . . . 0.0 109.65 -179.608 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.459 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.8 pt -120.15 -105.25 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 120.984 -1.072 . . . . 0.0 109.417 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -83.62 161.28 38.49 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -52.55 107.47 0.52 Allowed Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 116.36 -50.48 0.78 Allowed Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.459 ' O ' HG13 ' A' ' 25' ' ' ILE . 16.5 mmtt -87.03 142.53 27.87 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.222 -1.164 . . . . 0.0 109.261 179.85 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.505 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 1.2 mt-10 -136.81 150.75 48.51 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.973 -1.079 . . . . 0.0 110.102 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.473 ' O ' ' O ' ' A' ' 23' ' ' VAL . . . -102.33 -177.19 27.54 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 108.137 -1.985 . . . . 0.0 108.137 179.03 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.63 HD12 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -149.53 116.76 6.05 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.694 -1.474 . . . . 0.0 110.431 179.119 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.574 HG22 ' CD1' ' A' ' 50' ' ' LEU . 93.3 t -90.85 59.93 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 178.049 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.502 ' HB3' ' HG3' ' A' ' 37' ' ' GLN . 3.6 t-80 -48.73 157.28 0.39 Allowed 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.55 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.8 tp -47.19 -47.76 9.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.089 -1.007 . . . . 0.0 110.119 -179.207 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.408 ' C ' ' CG ' ' A' ' 37' ' ' GLN . 56.7 p -81.18 39.41 0.51 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.064 -1.023 . . . . 0.0 110.791 -179.463 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.502 ' HG3' ' HB3' ' A' ' 34' ' ' HIS . 12.4 mt-30 -150.52 53.42 0.89 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.646 -1.283 . . . . 0.0 110.664 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.623 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.7 mp -126.25 -96.31 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.952 -1.093 . . . . 0.0 109.529 179.24 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.537 ' O ' ' CB ' ' A' ' 40' ' ' ASP . . . -97.31 54.67 1.22 Allowed 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.411 -0.806 . . . . 0.0 109.195 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.537 ' CB ' ' O ' ' A' ' 39' ' ' ALA . 11.1 t0 83.13 -42.57 0.1 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.793 -0.567 . . . . 0.0 109.663 -179.631 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.498 ' HB2' ' O ' ' A' ' 40' ' ' ASP . 0.0 OUTLIER 166.54 -21.61 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.198 -0.939 . . . . 0.0 109.938 -179.945 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.453 ' O ' ' OH ' ' A' ' 49' ' ' TYR . 0.0 OUTLIER -77.11 76.87 3.66 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.096 -1.002 . . . . 0.0 110.419 -179.14 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.643 ' CG1' ' CD1' ' A' ' 49' ' ' TYR . 54.6 t -142.45 74.75 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 108.976 178.91 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.433 ' C ' ' O ' ' A' ' 43' ' ' VAL . 16.8 mt-10 -40.99 -28.05 0.07 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.558 -0.714 . . . . 0.0 110.314 -179.399 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.492 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.1 OUTLIER -142.63 138.51 30.76 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.961 -1.087 . . . . 0.0 110.206 -179.697 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.54 HG23 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -80.61 -26.47 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.356 -0.84 . . . . 0.0 108.845 179.514 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.475 ' CG2' HG23 ' A' ' 16' ' ' ILE . 47.3 p -78.47 5.12 11.45 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.317 -0.864 . . . . 0.0 109.023 179.056 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.445 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 4.1 m-20 -104.48 -30.76 9.83 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.328 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.643 ' CD1' ' CG1' ' A' ' 43' ' ' VAL . 17.8 m-85 -90.25 -33.98 15.94 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.574 ' CD1' HG22 ' A' ' 33' ' ' VAL . 3.5 mt -108.1 151.78 25.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.194 -0.941 . . . . 0.0 110.005 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.502 ' CB ' ' HG3' ' A' ' 54' ' ' GLN . 0.1 OUTLIER -136.93 138.52 40.72 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 179.033 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 23.4 mtt -62.6 91.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.003 -1.06 . . . . 0.0 109.839 -179.523 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 137.52 -22.59 3.17 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 119.732 -1.223 . . . . 0.0 110.388 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . 0.502 ' HG3' ' CB ' ' A' ' 51' ' ' GLN . 6.5 mm-40 -77.28 145.29 37.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.055 -1.262 . . . . 0.0 110.074 -179.377 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -113.19 127.26 56.13 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.475 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.417 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 15.9 m -132.45 142.37 44.66 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.02 -1.05 . . . . 0.0 110.032 -179.524 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.447 ' O ' ' HB2' ' A' ' 74' ' ' LYS . 36.9 Cg_endo -80.27 129.42 7.66 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.665 2.244 . . . . 0.0 110.335 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.428 ' HB ' ' C ' ' A' ' 72' ' ' SER . 0.8 OUTLIER -120.6 -170.5 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.19 -0.944 . . . . 0.0 109.317 179.753 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.467 ' CG ' HG23 ' A' ' 8' ' ' VAL . 0.1 OUTLIER -132.12 141.83 49.28 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.257 -0.902 . . . . 0.0 109.319 179.883 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.561 ' CG2' ' CE1' ' A' ' 9' ' ' TYR . 26.5 t -68.76 87.82 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.449 -0.782 . . . . 0.0 109.139 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.547 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 0.5 OUTLIER -56.51 -29.45 61.86 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.345 -0.847 . . . . 0.0 109.388 -179.888 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.547 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 1.0 OUTLIER 160.96 164.36 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.359 -0.838 . . . . 0.0 110.279 179.644 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 66' ' ' GLN . 50.5 t -150.13 -48.98 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.491 -0.756 . . . . 0.0 109.359 179.595 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 63' ' ' VAL . 0.5 OUTLIER -44.36 -61.26 1.58 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.199 -0.938 . . . . 0.0 109.483 179.993 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.38 -52.87 63.75 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.088 -1.008 . . . . 0.0 108.689 179.506 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . 0.466 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 0.0 OUTLIER -108.49 107.39 17.89 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 179.272 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -74.6 3.47 41.96 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 -179.335 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.48 ' O ' ' O ' ' A' ' 69' ' ' ILE . 0.0 OUTLIER -89.6 41.74 1.06 Allowed 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.953 -1.322 . . . . 0.0 109.352 179.885 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.522 ' CG2' ' HG ' ' A' ' 71' ' ' LEU . 63.2 mt 39.35 94.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.827 -0.545 . . . . 0.0 110.121 179.491 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.469 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 8.9 mmm180 -89.74 79.55 6.72 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.007 -1.058 . . . . 0.0 109.854 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.522 ' HG ' ' CG2' ' A' ' 69' ' ' ILE . 17.5 mt -91.11 147.38 23.11 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.217 -0.927 . . . . 0.0 108.78 179.435 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.431 ' O ' ' C ' ' A' ' 73' ' ' ILE . 0.6 OUTLIER -134.11 117.14 16.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.105 -0.997 . . . . 0.0 110.302 -179.262 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.431 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.1 OUTLIER -44.07 131.89 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.299 -0.876 . . . . 0.0 108.962 179.691 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.447 ' HB2' ' O ' ' A' ' 57' ' ' PRO . 0.0 OUTLIER -71.82 177.3 4.3 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.215 -0.928 . . . . 0.0 110.137 -179.374 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -49.85 -43.83 49.18 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.465 -0.772 . . . . 0.0 109.574 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 117.94 -1.029 . . . . 0.0 109.372 -179.867 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 29.9 mp0 -142.2 -166.84 2.33 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.363 -0.836 . . . . 0.0 109.001 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.534 ' CG2' ' OH ' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -123.4 -169.71 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.014 -1.054 . . . . 0.0 109.361 179.971 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -149.47 134.19 17.77 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.379 -0.826 . . . . 0.0 109.212 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.495 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 4.2 t -60.87 162.94 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.256 -0.902 . . . . 0.0 109.465 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.495 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 80.87 2.34 90.18 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.23 -1.548 . . . . 0.0 109.23 -179.593 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.521 ' HG2' ' N ' ' A' ' 8' ' ' VAL . 28.2 ttt85 -102.01 160.34 14.59 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.292 -1.122 . . . . 0.0 109.609 -179.778 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.521 ' N ' ' HG2' ' A' ' 7' ' ' ARG . 93.5 t -96.9 142.95 13.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.243 -0.911 . . . . 0.0 109.369 179.763 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.534 ' OH ' ' CG2' ' A' ' 3' ' ' ILE . 9.2 m-85 -118.69 -168.19 1.5 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.302 -0.874 . . . . 0.0 109.758 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.484 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 34.3 m -166.21 127.81 1.83 Allowed 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.443 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.489 ' O ' ' HA ' ' A' ' 55' ' ' GLU . . . -149.53 -177.84 23.97 Favored Glycine 0 N--CA 1.489 2.202 0 C-N-CA 118.44 -1.838 . . . . 0.0 111.266 -178.636 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.526 ' O ' HG12 ' A' ' 23' ' ' VAL . 15.6 mtpt -104.45 168.27 9.2 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.808 -0.819 . . . . 0.0 108.929 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.534 ' CG2' HD12 ' A' ' 50' ' ' LEU . 72.4 t -87.98 101.37 11.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 O-C-N 121.156 -0.965 . . . . 0.0 108.423 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.534 ' CG2' ' HB1' ' A' ' 24' ' ' ALA . 1.1 p -111.11 11.12 21.96 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.275 -0.89 . . . . 0.0 110.286 -178.814 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.528 ' CG ' ' O ' ' A' ' 14' ' ' THR . 0.0 OUTLIER -175.29 147.01 0.86 Allowed 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.956 -1.09 . . . . 0.0 110.255 179.75 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 17.2 mt -139.28 151.71 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.068 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.649 HG21 ' N ' ' A' ' 20' ' ' GLY . 0.7 OUTLIER -129.61 154.05 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.765 -1.209 . . . . 0.0 110.088 -179.089 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -59.13 -41.7 88.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.866 -1.147 . . . . 0.0 109.327 179.173 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.645 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 14.0 p90 -91.3 27.14 2.0 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.313 -0.867 . . . . 0.0 110.22 -179.716 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.649 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 155.22 -153.58 24.88 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.898 -1.62 . . . . 0.0 111.063 -179.365 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.517 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -150.33 144.71 25.69 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.063 -1.257 . . . . 0.0 109.007 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.652 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 11.1 m-30 -108.41 162.11 14.41 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.401 -0.812 . . . . 0.0 109.214 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.537 ' CG1' ' N ' ' A' ' 24' ' ' ALA . 3.5 t -150.63 166.81 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.166 -0.958 . . . . 0.0 109.433 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.537 ' N ' ' CG1' ' A' ' 23' ' ' VAL . . . -132.79 145.24 50.83 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.209 -0.932 . . . . 0.0 108.856 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.534 ' CD1' ' HB2' ' A' ' 29' ' ' LYS . 7.7 pt -98.83 -20.47 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 120.547 -1.346 . . . . 0.0 109.653 -179.829 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.11 -8.42 57.67 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -89.54 34.18 4.11 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.437 ' C ' ' HG2' ' A' ' 29' ' ' LYS . . . 87.79 -1.23 85.21 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.634 -1.387 . . . . 0.0 109.634 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.534 ' HB2' ' CD1' ' A' ' 25' ' ' ILE . 5.8 mmtm -140.68 174.55 10.41 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.193 -1.181 . . . . 0.0 109.68 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.534 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 7.3 pt-20 -128.01 157.47 40.55 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 120.867 -1.146 . . . . 0.0 110.474 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.523 ' HA2' ' CD1' ' A' ' 71' ' ' LEU . . . -105.83 -175.79 23.83 Favored Glycine 0 N--CA 1.487 2.042 0 N-CA-C 108.337 -1.905 . . . . 0.0 108.337 179.298 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.652 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.79 121.29 7.4 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 120.746 -1.444 . . . . 0.0 111.542 -179.794 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.533 HG21 ' CG2' ' A' ' 23' ' ' VAL . 26.0 t -95.86 62.9 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 176.922 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 3.7 t-160 -48.08 155.02 0.5 Allowed 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.885 -1.135 . . . . 0.0 108.883 -179.274 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.522 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 3.0 tp -45.84 -52.09 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.218 -0.926 . . . . 0.0 110.315 -179.431 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.417 ' C ' ' HG3' ' A' ' 37' ' ' GLN . 0.0 OUTLIER -81.52 42.96 0.71 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.294 -0.879 . . . . 0.0 110.524 -179.33 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.461 ' C ' ' CD1' ' A' ' 38' ' ' ILE . 68.3 mt-30 -150.83 53.38 0.87 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.859 -1.151 . . . . 0.0 110.036 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.635 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.7 mp -124.53 -96.01 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.926 -1.109 . . . . 0.0 110.376 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.544 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . -95.09 -39.9 9.9 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.492 -0.755 . . . . 0.0 109.674 -178.845 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.488 ' O ' ' HB2' ' A' ' 41' ' ' LYS . 9.9 p-10 174.74 -40.66 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.418 -0.801 . . . . 0.0 109.475 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.488 ' HB2' ' O ' ' A' ' 40' ' ' ASP . 0.2 OUTLIER 172.23 -18.39 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.288 -0.883 . . . . 0.0 110.793 -179.763 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.43 6.93 4.01 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.821 -1.174 . . . . 0.0 110.51 -179.3 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.64 HG23 ' CD2' ' A' ' 49' ' ' TYR . 60.2 t -86.76 52.55 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 O-C-N 120.925 -1.109 . . . . 0.0 109.242 179.659 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.433 ' C ' ' O ' ' A' ' 43' ' ' VAL . 3.6 mm-40 -45.06 -25.05 0.29 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.224 -0.922 . . . . 0.0 108.744 179.633 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.475 ' O ' HG11 ' A' ' 43' ' ' VAL . 25.0 mmtp -119.66 122.7 42.09 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.537 -0.727 . . . . 0.0 109.157 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.511 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -78.98 -24.54 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.271 -0.893 . . . . 0.0 108.842 179.812 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 72.5 p -75.9 4.4 8.25 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.449 -0.782 . . . . 0.0 109.723 179.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -102.75 -38.16 7.57 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.135 -0.978 . . . . 0.0 109.183 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.64 ' CD2' HG23 ' A' ' 43' ' ' VAL . 9.9 m-85 -89.43 -33.55 16.78 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.349 -0.844 . . . . 0.0 109.104 179.669 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.534 HD12 ' CG2' ' A' ' 13' ' ' VAL . 0.1 OUTLIER -98.86 135.54 40.15 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.412 -0.805 . . . . 0.0 109.443 -179.793 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.47 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.0 OUTLIER -138.89 122.5 17.41 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.556 -0.715 . . . . 0.0 109.6 -179.84 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' MET . . . . . 0.504 ' CG ' ' O ' ' A' ' 52' ' ' MET . 5.1 ptm -48.6 105.79 0.09 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.317 -0.864 . . . . 0.0 109.947 -179.925 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 133.92 -43.55 1.26 Allowed Glycine 0 N--CA 1.492 2.398 0 C-N-CA 119.832 -1.175 . . . . 0.0 110.471 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 15.8 mt-30 -69.32 146.15 52.43 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.01 -1.288 . . . . 0.0 110.107 -179.399 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . 0.489 ' HA ' ' O ' ' A' ' 11' ' ' GLY . 0.4 OUTLIER -122.53 140.08 53.18 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.355 -0.841 . . . . 0.0 109.115 179.526 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.403 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 24.8 m -146.73 155.95 48.37 Favored Pre-proline 0 N--CA 1.487 1.424 0 O-C-N 121.164 -0.96 . . . . 0.0 110.052 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.484 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 37.2 Cg_endo -83.37 146.9 12.51 Favored 'Trans proline' 0 C--N 1.314 -1.261 0 C-N-CA 123.161 2.574 . . . . 0.0 110.428 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.542 ' CG2' ' HB3' ' A' ' 71' ' ' LEU . 1.0 OUTLIER -141.29 -168.61 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.186 -0.946 . . . . 0.0 109.287 179.368 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 17.2 mtmt -134.3 134.14 41.54 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.385 -0.822 . . . . 0.0 109.779 179.979 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.472 ' CG2' ' CE1' ' A' ' 9' ' ' TYR . 47.6 t -63.49 87.43 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.392 -0.818 . . . . 0.0 109.197 179.632 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.575 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 4.9 tp -53.56 -37.78 63.24 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.644 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.575 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 2.7 pt-20 153.4 167.66 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.064 0 CA-C-O 121.765 0.793 . . . . 0.0 110.14 179.374 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.528 ' CG2' ' HA ' ' A' ' 69' ' ' ILE . 49.1 t -151.52 130.29 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 O-C-N 121.494 -0.753 . . . . 0.0 109.37 179.155 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.424 ' O ' ' C ' ' A' ' 65' ' ' ARG . 14.6 p-10 -154.09 -177.38 6.38 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.236 -0.915 . . . . 0.0 109.382 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . 0.424 ' C ' ' O ' ' A' ' 64' ' ' ASP . 9.3 ptm180 -44.13 -44.26 7.53 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.186 -0.946 . . . . 0.0 108.973 179.837 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -105.35 57.13 0.68 Allowed 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 179.15 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.452 ' O ' HG12 ' A' ' 63' ' ' VAL . . . -175.08 92.41 0.09 OUTLIER Glycine 0 N--CA 1.489 2.202 0 N-CA-C 108.989 -1.645 . . . . 0.0 108.989 -179.662 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 4.3 mtt180 -88.54 100.08 12.8 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.25 -1.147 . . . . 0.0 108.989 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.528 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 61.2 mt 52.42 78.42 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.474 -0.766 . . . . 0.0 109.511 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.475 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 26.2 mmm180 -89.72 87.68 7.09 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.841 -1.162 . . . . 0.0 108.62 179.517 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.542 ' HB3' ' CG2' ' A' ' 58' ' ' VAL . 13.6 mt -89.16 163.64 15.35 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.324 -0.86 . . . . 0.0 109.607 -179.305 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.423 ' O ' ' C ' ' A' ' 73' ' ' ILE . 0.3 OUTLIER -133.43 107.65 8.19 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.442 -0.786 . . . . 0.0 109.724 -179.636 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.47 ' O ' ' HB1' ' A' ' 76' ' ' ALA . 0.0 OUTLIER -44.92 140.31 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.249 -0.907 . . . . 0.0 108.77 179.713 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.419 ' HD3' ' HB2' ' A' ' 57' ' ' PRO . 0.0 OUTLIER -50.58 170.6 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.15 -0.969 . . . . 0.0 109.424 179.973 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 46.51 61.85 2.58 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.149 -0.969 . . . . 0.0 109.048 -179.802 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.47 ' HB1' ' O ' ' A' ' 73' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.419 -179.646 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.518 0 CA-C-O 121.254 0.549 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.5 mp0 -95.7 -169.32 1.93 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.272 -0.893 . . . . 0.0 109.605 -179.921 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.524 ' HA ' ' OH ' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -124.11 115.5 45.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 C-N-CA 119.472 -0.891 . . . . 0.0 110.21 -179.092 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -117.8 147.95 42.54 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 179.582 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.466 ' HA ' HG13 ' A' ' 60' ' ' VAL . 14.8 t -69.54 159.77 5.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 O-C-N 120.991 -1.068 . . . . 0.0 109.577 -179.745 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.459 ' N ' HG11 ' A' ' 5' ' ' VAL . . . 71.06 7.32 62.36 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 108.998 -1.641 . . . . 0.0 108.998 -179.38 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.77 178.6 5.86 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.284 -1.127 . . . . 0.0 109.67 -179.818 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.511 ' HA ' ' HA ' ' A' ' 59' ' ' LYS . 68.1 t -114.97 144.84 21.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.305 -0.872 . . . . 0.0 109.448 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.609 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 14.0 m-85 -143.94 128.42 17.99 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.023 -1.048 . . . . 0.0 110.355 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -91.06 115.62 28.16 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 178.15 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.456 ' O ' HG21 ' A' ' 56' ' ' VAL . . . -113.6 141.3 16.87 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 119.119 -1.515 . . . . 0.0 110.626 -178.362 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.511 ' O ' HG11 ' A' ' 23' ' ' VAL . 0.8 OUTLIER -89.56 162.07 15.86 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 178.724 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.54 ' CG1' HD11 ' A' ' 50' ' ' LEU . 58.2 t -87.86 105.39 15.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 120.986 -1.072 . . . . 0.0 108.368 179.616 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.527 ' O ' ' CD ' ' A' ' 15' ' ' ARG . 0.7 OUTLIER -111.7 -0.8 15.89 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.262 -0.899 . . . . 0.0 110.218 -178.859 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.527 ' CD ' ' O ' ' A' ' 14' ' ' THR . 0.3 OUTLIER -168.05 152.42 6.34 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.902 -1.123 . . . . 0.0 110.314 179.97 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.431 ' HA ' ' HA ' ' A' ' 21' ' ' ALA . 56.6 mt -145.37 150.03 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 179.058 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.687 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 1.2 m -126.93 156.33 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 120.932 -1.105 . . . . 0.0 109.813 -179.076 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -60.37 -37.89 82.18 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.784 -1.197 . . . . 0.0 109.455 179.208 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.687 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 13.9 p90 -94.56 26.43 3.47 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.244 -0.91 . . . . 0.0 110.379 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.633 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 155.54 -154.08 25.25 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.481 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.492 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -152.27 146.23 25.25 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.043 -1.269 . . . . 0.0 109.439 -179.558 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.643 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 12.4 m-30 -108.04 158.54 17.31 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.354 -0.842 . . . . 0.0 109.145 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.593 ' CG2' ' CG2' ' A' ' 33' ' ' VAL . 7.7 t -145.85 163.75 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.166 -0.959 . . . . 0.0 109.151 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.55 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -137.1 146.55 45.25 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.017 -1.052 . . . . 0.0 110.119 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.492 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.1 pt -106.77 22.22 3.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 120.779 -1.201 . . . . 0.0 108.667 178.985 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 147.66 -143.27 11.01 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -111.75 9.24 27.85 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -118.96 -67.78 0.31 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.492 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER -97.66 151.11 20.44 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.234 -1.157 . . . . 0.0 109.514 -179.97 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.55 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 3.5 pt-20 -134.68 153.4 52.01 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 120.847 -1.158 . . . . 0.0 110.224 -179.855 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -102.57 -173.51 27.0 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 108.504 -1.839 . . . . 0.0 108.504 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.643 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.31 119.02 6.55 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.993 -1.298 . . . . 0.0 110.692 179.514 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.593 ' CG2' ' CG2' ' A' ' 23' ' ' VAL . 8.4 t -96.59 63.56 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 177.588 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.53 ' HB3' ' CG ' ' A' ' 37' ' ' GLN . 4.4 t-80 -47.7 166.08 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.308 0 O-C-N 120.879 -1.138 . . . . 0.0 108.279 -179.594 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.566 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.2 OUTLIER -55.19 -55.33 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.136 -0.977 . . . . 0.0 110.296 -179.256 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.407 ' O ' ' CD ' ' A' ' 37' ' ' GLN . 92.6 p -82.31 42.57 0.75 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.018 -1.051 . . . . 0.0 110.334 -179.734 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.53 ' CG ' ' HB3' ' A' ' 34' ' ' HIS . 20.8 mm-40 -145.27 44.46 1.32 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.938 -1.101 . . . . 0.0 109.598 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.631 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.8 mp -119.33 -91.66 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.253 -0.904 . . . . 0.0 108.978 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.59 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . -118.93 157.79 27.0 Favored 'General case' 0 C--N 1.298 -1.654 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 39' ' ' ALA . 0.2 OUTLIER -43.06 -49.97 6.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.315 -0.866 . . . . 0.0 109.568 -179.674 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.41 ' O ' ' C ' ' A' ' 42' ' ' ARG . 0.0 OUTLIER -58.52 120.66 9.23 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.161 -0.962 . . . . 0.0 109.141 179.806 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.41 ' C ' ' O ' ' A' ' 41' ' ' LYS . 0.0 OUTLIER -44.35 123.97 3.8 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.316 -0.865 . . . . 0.0 109.601 -179.901 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.616 ' CG1' ' CD1' ' A' ' 49' ' ' TYR . 39.6 t -94.23 70.72 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 179.314 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 25.5 tp10 -46.49 -22.5 0.27 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.151 -0.968 . . . . 0.0 109.244 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.539 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 28.9 mttp -119.68 109.12 15.27 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.386 -0.821 . . . . 0.0 109.246 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.546 HG22 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -77.52 -22.87 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.232 -0.918 . . . . 0.0 108.781 179.842 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 18.6 p -76.99 2.57 14.48 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.449 -0.782 . . . . 0.0 109.216 179.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 1.7 m-20 -101.42 -33.68 9.89 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.1 -1.0 . . . . 0.0 109.264 179.829 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.631 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 6.6 m-85 -94.98 -30.78 13.94 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.575 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.54 HD11 ' CG1' ' A' ' 13' ' ' VAL . 0.2 OUTLIER -105.61 140.73 38.24 Favored 'General case' 0 N--CA 1.488 1.454 0 CA-C-O 121.536 0.684 . . . . 0.0 109.35 -179.731 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.505 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 2.0 tm0? -148.61 124.38 10.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.462 -0.774 . . . . 0.0 109.301 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' MET . . . . . 0.478 ' HA ' HG13 ' A' ' 13' ' ' VAL . 56.8 mtp -48.8 112.65 0.64 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.288 -0.883 . . . . 0.0 109.924 -179.755 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 113.11 -44.85 1.42 Allowed Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . 0.42 ' O ' HG22 ' A' ' 13' ' ' VAL . 15.5 mm100 -56.92 102.96 0.09 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.147 -1.208 . . . . 0.0 109.586 -179.727 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -65.18 137.14 57.43 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.188 -0.945 . . . . 0.0 109.125 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.456 HG21 ' O ' ' A' ' 11' ' ' GLY . 16.7 m -135.48 132.13 19.7 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.229 -0.919 . . . . 0.0 109.841 -179.767 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.442 ' HG2' ' HG3' ' A' ' 74' ' ' LYS . 36.4 Cg_endo -79.96 142.63 15.72 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.461 2.107 . . . . 0.0 110.129 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.54 ' CG2' ' HB3' ' A' ' 71' ' ' LEU . 0.9 OUTLIER -141.43 -173.74 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.232 -0.917 . . . . 0.0 109.246 179.665 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.536 ' O ' ' N ' ' A' ' 61' ' ' LEU . 9.0 mtmm -142.35 111.26 6.33 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.295 -0.878 . . . . 0.0 110.248 -179.71 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.609 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 61.5 t -45.57 94.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.857 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.536 ' N ' ' O ' ' A' ' 59' ' ' LYS . 4.6 tp -75.89 -26.84 57.39 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.331 -0.855 . . . . 0.0 109.866 -178.991 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.523 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 8.9 pt-20 162.73 -171.88 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.378 -0.827 . . . . 0.0 110.427 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.505 ' O ' ' N ' ' A' ' 67' ' ' GLY . 49.0 t -143.49 -42.68 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 179.644 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.447 ' O ' ' C ' ' A' ' 65' ' ' ARG . 0.3 OUTLIER -45.46 -45.94 13.34 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.405 -0.81 . . . . 0.0 109.926 -179.948 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . 0.447 ' C ' ' O ' ' A' ' 64' ' ' ASP . 11.2 ttm180 -41.71 -70.84 0.09 Allowed 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.293 -0.879 . . . . 0.0 109.677 -179.772 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -97.25 -52.23 3.9 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.228 -0.92 . . . . 0.0 109.248 179.864 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.505 ' N ' ' O ' ' A' ' 63' ' ' VAL . . . 110.88 -17.99 26.96 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.144 -1.583 . . . . 0.0 109.144 -179.81 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.47 ' O ' ' HB ' ' A' ' 69' ' ' ILE . 0.0 OUTLIER -98.31 51.87 1.02 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.398 -1.06 . . . . 0.0 108.895 179.514 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.521 HG22 ' CD2' ' A' ' 71' ' ' LEU . 4.0 mt 62.13 109.28 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 121.493 -0.755 . . . . 0.0 109.392 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.5 ' CB ' ' O ' ' A' ' 62' ' ' GLU . 0.0 OUTLIER -106.09 92.62 4.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.458 -0.776 . . . . 0.0 109.376 179.947 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.54 ' HB3' ' CG2' ' A' ' 58' ' ' VAL . 0.3 OUTLIER -94.74 154.53 17.25 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.324 -0.86 . . . . 0.0 109.366 -179.94 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.468 ' OG ' HD11 ' A' ' 61' ' ' LEU . 0.6 OUTLIER -109.85 111.71 23.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.197 -0.94 . . . . 0.0 110.219 -179.231 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.471 ' CD1' ' O ' ' A' ' 37' ' ' GLN . 1.2 mp -56.96 128.21 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.181 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.442 ' HG3' ' HG2' ' A' ' 57' ' ' PRO . 0.6 OUTLIER -39.44 -59.33 1.1 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.357 -0.84 . . . . 0.0 110.351 -179.136 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -48.27 -45.67 34.93 Favored 'General case' 0 C--N 1.292 -1.898 0 O-C-N 121.498 -0.752 . . . . 0.0 109.439 -179.84 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.467 ' HB1' ' O ' ' A' ' 73' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 118.055 -0.974 . . . . 0.0 109.622 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.459 ' O ' ' O ' ' A' ' 3' ' ' ILE . 8.6 mt-10 54.43 40.9 32.14 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.246 -0.909 . . . . 0.0 109.381 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.466 HG21 ' OH ' ' A' ' 9' ' ' TYR . 0.3 OUTLIER 62.26 127.14 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.233 -0.917 . . . . 0.0 108.806 179.768 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.44 ' O ' ' HG3' ' A' ' 7' ' ' ARG . 1.6 pt-20 -129.17 -150.96 0.46 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.272 -0.892 . . . . 0.0 109.922 -179.408 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.516 ' CG2' HG13 ' A' ' 60' ' ' VAL . 2.2 t -80.36 163.55 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.351 -0.843 . . . . 0.0 109.714 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.504 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 90.08 13.97 59.77 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.44 ' HG3' ' O ' ' A' ' 4' ' ' GLU . 0.1 OUTLIER -133.79 -173.87 3.36 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.086 -1.243 . . . . 0.0 109.643 -179.333 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.8 t -90.05 134.13 29.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.192 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.673 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 4.6 m-85 -122.28 133.21 54.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.043 -1.035 . . . . 0.0 109.998 -179.598 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.3 m -83.87 103.29 13.02 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.546 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.31 119.82 5.11 Favored Glycine 0 N--CA 1.487 2.056 0 C-N-CA 119.884 -1.151 . . . . 0.0 110.737 -178.495 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.539 ' O ' HG12 ' A' ' 23' ' ' VAL . 2.0 mtmt -89.29 148.46 23.55 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 178.77 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.515 ' CB ' ' O ' ' A' ' 51' ' ' GLN . 3.8 t -86.85 117.6 31.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 O-C-N 120.597 -1.314 . . . . 0.0 108.656 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.493 ' OG1' ' HD3' ' A' ' 15' ' ' ARG . 1.5 p -128.16 -3.41 5.67 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.419 -0.801 . . . . 0.0 109.933 -178.596 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.493 ' HD3' ' OG1' ' A' ' 14' ' ' THR . 0.0 OUTLIER -173.77 150.57 1.71 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.128 -0.982 . . . . 0.0 109.872 179.396 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.512 HG22 HD11 ' A' ' 16' ' ' ILE . 18.0 mt -136.31 161.49 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.374 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.639 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -139.97 153.34 22.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 120.59 -1.319 . . . . 0.0 110.623 -179.009 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -59.22 -41.19 88.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.766 -1.209 . . . . 0.0 109.376 179.093 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.639 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 14.3 p90 -90.99 28.42 1.58 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.356 -0.84 . . . . 0.0 110.096 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.608 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 149.7 -149.28 21.2 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.08 -1.533 . . . . 0.0 110.834 -179.717 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.569 ' HB2' ' CD1' ' A' ' 50' ' ' LEU . . . -153.64 147.79 25.73 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 120.967 -1.313 . . . . 0.0 109.263 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.644 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 11.9 m-30 -106.7 158.35 17.03 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.4 -0.813 . . . . 0.0 109.083 179.641 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.539 HG12 ' O ' ' A' ' 12' ' ' LYS . 15.6 t -150.12 162.11 4.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.291 -0.881 . . . . 0.0 109.185 -179.464 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.543 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -133.57 136.5 44.97 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.147 -0.97 . . . . 0.0 109.494 -179.631 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.465 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.7 pt -110.87 51.81 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 120.917 -1.115 . . . . 0.0 109.47 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 120.71 -166.85 13.84 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -104.06 20.21 41.37 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -126.16 -36.79 0.52 Allowed Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.465 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.6 OUTLIER -134.21 146.04 49.75 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.157 -1.201 . . . . 0.0 109.501 -179.787 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.543 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -120.49 149.83 41.78 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.804 -1.185 . . . . 0.0 110.46 -179.57 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.471 ' O ' ' O ' ' A' ' 23' ' ' VAL . . . -102.69 -178.1 26.99 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.198 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.644 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -148.56 119.79 7.8 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.863 -1.375 . . . . 0.0 110.67 179.744 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.522 ' HB ' ' HB2' ' A' ' 21' ' ' ALA . 59.4 t -94.4 62.26 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 177.776 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.438 ' HB3' ' HG3' ' A' ' 37' ' ' GLN . 4.0 t-80 -50.16 159.39 0.45 Allowed 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.888 -1.132 . . . . 0.0 108.637 -179.53 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.535 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 1.6 tp -48.53 -52.94 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.169 -0.957 . . . . 0.0 110.342 -179.614 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 1.9 t -81.84 44.85 0.86 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.12 -0.987 . . . . 0.0 110.536 -179.448 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.451 ' C ' HD13 ' A' ' 38' ' ' ILE . 46.8 mt-30 -150.36 37.03 0.67 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.783 -1.198 . . . . 0.0 109.88 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.622 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.8 mp -114.77 -96.69 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.932 -1.105 . . . . 0.0 110.285 -179.58 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.541 ' O ' ' CB ' ' A' ' 40' ' ' ASP . . . -97.46 51.75 1.09 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.447 -0.783 . . . . 0.0 109.43 -179.17 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.541 ' CB ' ' O ' ' A' ' 39' ' ' ALA . 5.0 m-20 82.28 -41.88 0.13 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.782 -0.574 . . . . 0.0 110.106 179.843 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.442 ' CB ' ' O ' ' A' ' 40' ' ' ASP . 0.0 OUTLIER 171.05 -22.95 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.883 -1.136 . . . . 0.0 110.767 -179.691 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.49 ' O ' ' OH ' ' A' ' 49' ' ' TYR . 1.6 mtm180 -79.49 77.98 6.03 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.878 -1.139 . . . . 0.0 110.974 -178.912 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.621 ' CG1' ' CD1' ' A' ' 49' ' ' TYR . 59.1 t -144.32 63.73 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.313 -0.867 . . . . 0.0 108.756 178.68 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.446 ' C ' ' O ' ' A' ' 43' ' ' VAL . 20.9 tp10 -38.57 -29.27 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.569 -0.707 . . . . 0.0 110.538 -179.264 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.469 ' N ' ' O ' ' A' ' 43' ' ' VAL . 3.5 mttm -133.03 132.37 41.75 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.915 -1.115 . . . . 0.0 109.978 -179.552 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.522 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -79.65 -25.74 12.35 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 179.18 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' THR . . . . . 0.454 HG21 HG22 ' A' ' 16' ' ' ILE . 10.5 p -77.2 4.45 10.44 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.653 -0.654 . . . . 0.0 109.355 179.325 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.463 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 2.8 m-20 -106.53 -30.16 9.22 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.147 -0.97 . . . . 0.0 108.621 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.622 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 19.0 m-85 -92.14 -30.91 15.71 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.576 -0.703 . . . . 0.0 109.264 179.764 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.569 ' CD1' ' HB2' ' A' ' 21' ' ' ALA . 0.6 OUTLIER -106.08 143.48 34.15 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.633 179.857 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.515 ' O ' ' CB ' ' A' ' 13' ' ' VAL . 4.1 tt0 -130.69 129.69 42.92 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.273 -0.892 . . . . 0.0 108.999 179.455 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' MET . . . . . 0.442 ' HA ' HG13 ' A' ' 13' ' ' VAL . 10.2 mtt -63.57 118.33 8.04 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.142 -0.973 . . . . 0.0 109.674 -179.895 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 105.12 -23.05 31.66 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . 0.49 ' CG ' ' HB3' ' A' ' 51' ' ' GLN . 4.9 mt-30 -73.31 -172.61 1.17 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.23 -1.159 . . . . 0.0 109.647 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . 0.417 ' HG2' ' HA ' ' A' ' 12' ' ' LYS . 5.6 mt-10 -156.76 128.75 7.29 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.214 -0.929 . . . . 0.0 109.518 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 14.6 m -128.5 145.63 56.71 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.223 -0.923 . . . . 0.0 109.721 -179.89 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 36.3 Cg_endo -79.79 139.93 14.28 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.644 2.229 . . . . 0.0 110.155 179.718 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.47 HG21 ' O ' ' A' ' 9' ' ' TYR . 1.0 OUTLIER -142.49 -177.96 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.162 -0.961 . . . . 0.0 109.777 -179.844 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.417 ' N ' HG22 ' A' ' 58' ' ' VAL . 5.3 mttm -127.0 116.52 20.88 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.443 -0.786 . . . . 0.0 109.465 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.673 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 13.6 t -51.31 99.34 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.166 -0.959 . . . . 0.0 109.353 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.611 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 9.8 tp -75.74 -16.01 60.2 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.327 -0.858 . . . . 0.0 109.573 -179.666 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.611 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 2.3 tt0 92.71 -175.83 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 0.9 OUTLIER -122.24 -167.19 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.993 -1.067 . . . . 0.0 109.852 -179.457 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 9.6 p-10 -135.33 -139.83 0.17 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.376 -0.827 . . . . 0.0 109.64 -179.635 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 3.0 tpm_? -67.43 -29.34 68.8 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.146 -0.971 . . . . 0.0 109.901 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . 0.434 ' HB3' ' HG2' ' A' ' 68' ' ' ARG . 2.8 tt0 -89.64 -174.12 4.2 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.003 -1.06 . . . . 0.0 109.434 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -109.86 45.69 1.28 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.47 ' HB2' ' NH1' ' A' ' 70' ' ' ARG . 9.6 mmm180 -105.03 91.51 3.83 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.149 -1.206 . . . . 0.0 109.448 179.816 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 2.4 mt -47.37 120.0 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.129 -0.982 . . . . 0.0 109.362 179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.486 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 7.1 mmt-85 -94.5 100.57 12.53 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.208 -0.933 . . . . 0.0 109.718 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.429 HD11 ' HA3' ' A' ' 31' ' ' GLY . 12.0 mt -90.7 146.36 24.07 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 121.264 -0.897 . . . . 0.0 108.725 179.612 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.25 90.01 3.17 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.199 -0.938 . . . . 0.0 110.071 -179.333 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -50.27 133.23 10.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.328 -0.858 . . . . 0.0 108.983 179.752 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.411 ' O ' ' C ' ' A' ' 75' ' ' GLU . 4.1 tttp -73.98 167.51 21.35 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.232 -0.918 . . . . 0.0 109.33 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.411 ' C ' ' O ' ' A' ' 74' ' ' LYS . 5.1 mt-10 -45.06 -40.11 6.39 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.198 -0.939 . . . . 0.0 109.385 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 117.927 -1.035 . . . . 0.0 109.514 179.993 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 121.254 0.549 . . . . 0.0 109.539 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER 51.86 -171.64 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.207 -0.933 . . . . 0.0 109.465 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.563 ' CB ' ' OH ' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -130.72 -161.63 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 O-C-N 121.346 -0.846 . . . . 0.0 109.26 -179.499 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -134.9 135.65 41.74 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.312 -0.868 . . . . 0.0 109.013 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.418 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 4.0 t -67.24 157.45 6.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.194 -0.941 . . . . 0.0 109.35 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.418 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 85.24 -5.74 82.06 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 109.001 -1.64 . . . . 0.0 109.001 -179.391 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 5.4 ttm180 -85.04 159.41 20.22 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.21 -1.171 . . . . 0.0 109.519 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.6 t -92.08 138.69 19.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.154 -0.966 . . . . 0.0 109.465 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.637 ' CE1' ' CG2' ' A' ' 60' ' ' VAL . 10.3 m-85 -119.53 -177.24 3.33 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.142 -0.974 . . . . 0.0 109.975 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.58 111.86 6.29 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 178.885 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -125.09 153.34 17.94 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.009 -1.567 . . . . 0.0 110.809 -178.224 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.493 ' O ' HG11 ' A' ' 23' ' ' VAL . 16.1 mttm -95.93 166.07 11.96 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 178.938 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.522 ' CG1' HD11 ' A' ' 50' ' ' LEU . 79.3 t -88.46 105.23 15.45 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 121.062 -1.023 . . . . 0.0 108.323 179.404 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.544 ' CG2' ' HB1' ' A' ' 24' ' ' ALA . 1.7 p -117.57 6.27 12.48 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.269 -0.895 . . . . 0.0 110.077 -179.014 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.53 ' CD ' ' O ' ' A' ' 14' ' ' THR . 0.0 OUTLIER -169.69 149.25 3.8 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.08 -1.013 . . . . 0.0 109.935 179.867 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.435 ' C ' HG11 ' A' ' 17' ' ' VAL . 19.5 mt -141.99 163.49 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 179.479 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.666 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -143.48 153.41 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.8 -1.188 . . . . 0.0 110.205 -179.43 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -58.21 -42.7 86.8 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.784 -1.198 . . . . 0.0 109.324 179.276 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.666 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 12.1 p90 -90.61 29.42 1.31 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.217 -0.927 . . . . 0.0 110.351 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.609 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 150.47 -152.08 24.01 Favored Glycine 0 N--CA 1.494 2.54 0 C-N-CA 119.102 -1.523 . . . . 0.0 110.936 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.543 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -152.78 148.81 27.66 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.992 -1.299 . . . . 0.0 108.979 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.644 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 11.1 m-30 -107.81 163.81 12.79 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.345 -0.847 . . . . 0.0 108.753 179.571 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.594 ' CG2' ' CG2' ' A' ' 33' ' ' VAL . 22.7 t -149.5 165.49 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.093 -1.004 . . . . 0.0 109.204 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.562 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -132.42 141.44 48.86 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.057 -1.027 . . . . 0.0 110.592 -179.108 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.495 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.1 pt -110.91 -93.0 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.079 -1.013 . . . . 0.0 108.81 179.083 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -70.38 -163.34 4.5 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.321 -1.511 . . . . 0.0 109.321 179.547 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.42 -23.98 48.85 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.848 -1.301 . . . . 0.0 109.848 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -115.03 -13.91 8.85 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 -179.741 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.495 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.3 OUTLIER -104.95 142.7 34.3 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.121 -1.223 . . . . 0.0 109.625 -179.973 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.562 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 1.4 pp20? -133.14 149.42 52.08 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 120.924 -1.11 . . . . 0.0 110.328 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.473 ' HA3' HD11 ' A' ' 71' ' ' LEU . . . -98.08 -172.68 32.79 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 108.251 -1.939 . . . . 0.0 108.251 179.194 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.644 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.65 119.76 6.74 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 120.842 -1.387 . . . . 0.0 111.047 179.737 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.594 ' CG2' ' CG2' ' A' ' 23' ' ' VAL . 49.3 t -95.47 61.3 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.32 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.446 ' HB2' HD21 ' A' ' 32' ' ' LEU . 3.6 t-80 -49.11 160.82 0.18 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.846 -1.159 . . . . 0.0 108.331 -179.373 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.539 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.6 tp -52.96 -41.29 40.11 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 121.029 -1.045 . . . . 0.0 109.986 -179.731 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.467 ' O ' ' HG2' ' A' ' 37' ' ' GLN . 49.9 m -81.59 30.29 0.36 Allowed 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.086 -1.009 . . . . 0.0 110.922 -179.425 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.467 ' HG2' ' O ' ' A' ' 36' ' ' SER . 6.3 mt-30 -149.22 65.32 1.02 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.653 -1.28 . . . . 0.0 110.174 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.641 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.6 mp -123.54 -99.37 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 120.87 -1.144 . . . . 0.0 109.843 179.489 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.527 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . -111.92 -142.49 0.38 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.16 -0.962 . . . . 0.0 109.33 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.475 ' O ' ' CB ' ' A' ' 41' ' ' LYS . 2.2 t70 -43.65 -51.88 6.76 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.128 -0.982 . . . . 0.0 109.721 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.475 ' CB ' ' O ' ' A' ' 40' ' ' ASP . 0.8 OUTLIER 165.7 -22.62 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.248 -0.907 . . . . 0.0 109.985 -179.703 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.461 ' O ' ' OH ' ' A' ' 49' ' ' TYR . 1.7 mmp_? -77.18 77.24 3.72 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.127 -0.983 . . . . 0.0 110.676 -179.119 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.593 HG23 ' CD2' ' A' ' 49' ' ' TYR . 72.4 t -137.51 49.74 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.117 -0.989 . . . . 0.0 108.874 178.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 29.4 mp0 -45.01 -31.0 1.15 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.344 -0.847 . . . . 0.0 109.397 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.476 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 0.3 OUTLIER -112.17 114.78 27.79 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.202 -0.936 . . . . 0.0 109.386 179.873 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.539 HG22 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -73.18 -22.66 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.746 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 3.0 p -77.31 4.41 10.76 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.535 -0.728 . . . . 0.0 109.387 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.476 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 2.4 m-20 -103.93 -29.89 10.66 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.156 -0.965 . . . . 0.0 108.75 179.566 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.641 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 32.3 m-85 -96.49 -30.11 13.52 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.616 -0.678 . . . . 0.0 109.337 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.522 HD11 ' CG1' ' A' ' 13' ' ' VAL . 0.1 OUTLIER -104.07 133.98 48.1 Favored 'General case' 0 N--CA 1.489 1.497 0 CA-C-O 121.816 0.817 . . . . 0.0 109.774 -179.695 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.487 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.0 OUTLIER -136.21 123.49 21.85 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.912 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' MET . . . . . 0.494 ' HA ' HG13 ' A' ' 13' ' ' VAL . 3.1 mtt -52.44 110.01 0.45 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.18 -0.95 . . . . 0.0 110.772 -179.189 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 122.54 -9.87 9.25 Favored Glycine 0 N--CA 1.496 2.648 0 C-N-CA 119.894 -1.146 . . . . 0.0 110.606 178.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -80.96 175.66 10.5 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.146 -1.208 . . . . 0.0 110.174 -179.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -142.72 117.72 10.01 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.564 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.3 m -135.95 145.42 52.54 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 120.993 -1.067 . . . . 0.0 110.635 -179.207 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.475 ' HG2' ' CD ' ' A' ' 74' ' ' LYS . 37.2 Cg_endo -82.98 155.64 15.07 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 C-N-CA 122.873 2.382 . . . . 0.0 109.486 178.806 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.506 ' CG2' ' HB3' ' A' ' 71' ' ' LEU . 1.2 m -150.48 -173.74 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.823 -1.173 . . . . 0.0 110.206 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -123.18 129.2 51.09 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 179.628 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.637 ' CG2' ' CE1' ' A' ' 9' ' ' TYR . 89.0 t -59.38 91.55 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.27 -0.894 . . . . 0.0 110.071 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.599 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 14.2 tp -60.17 -18.31 47.04 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.245 -0.909 . . . . 0.0 109.228 179.593 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.599 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 1.6 pt-20 97.89 -161.79 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.149 0 CA-C-O 121.676 0.75 . . . . 0.0 109.901 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.542 ' N ' ' CG ' ' A' ' 62' ' ' GLU . 41.4 t -140.68 119.24 10.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 65' ' ' ARG . 20.8 p-10 -97.17 -158.07 0.64 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.222 -0.924 . . . . 0.0 109.255 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . 0.425 ' C ' ' O ' ' A' ' 64' ' ' ASP . 4.5 mtp85 -44.3 -75.4 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.249 -0.907 . . . . 0.0 108.876 179.727 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 4.2 pt20 -103.26 123.94 47.69 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.245 -0.909 . . . . 0.0 108.799 179.087 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.402 ' O ' ' CG1' ' A' ' 63' ' ' VAL . . . 151.07 104.66 0.29 Allowed Glycine 0 N--CA 1.487 2.069 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 -179.58 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.5 ptm180 -88.42 125.42 34.72 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.399 -1.059 . . . . 0.0 109.279 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.524 HG22 HD11 ' A' ' 69' ' ' ILE . 21.7 mt 45.15 86.43 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.392 -0.817 . . . . 0.0 109.182 -179.639 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.512 ' HG2' ' CD2' ' A' ' 61' ' ' LEU . 4.0 tpt180 -89.51 88.21 7.35 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.028 -1.045 . . . . 0.0 109.554 -179.8 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.506 ' HB3' ' CG2' ' A' ' 58' ' ' VAL . 12.6 mt -89.87 140.74 29.31 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.137 -0.977 . . . . 0.0 109.057 179.69 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.466 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.4 OUTLIER -115.79 109.61 17.9 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.301 -0.875 . . . . 0.0 109.781 -179.572 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.533 ' CG2' ' O ' ' A' ' 38' ' ' ILE . 0.1 OUTLIER -42.4 126.32 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.364 -0.835 . . . . 0.0 108.925 179.918 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.475 ' CD ' ' HG2' ' A' ' 57' ' ' PRO . 0.0 OUTLIER -61.94 -158.32 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.167 -0.958 . . . . 0.0 109.46 -179.66 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 4.2 tp10 -101.72 47.41 0.9 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.343 -0.848 . . . . 0.0 109.615 -179.762 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 118.078 -0.963 . . . . 0.0 109.358 179.951 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.426 ' O ' ' HB2' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.426 ' HB2' ' O ' ' A' ' 1' ' ' ALA . 2.9 mm-40 67.34 -176.13 0.2 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.162 -0.961 . . . . 0.0 109.537 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.539 ' CB ' ' OH ' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -130.37 -161.08 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 O-C-N 121.297 -0.877 . . . . 0.0 109.578 -179.564 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -127.64 116.63 20.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.36 -0.837 . . . . 0.0 109.01 179.8 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.53 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 20.1 t -52.06 164.56 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.177 -0.952 . . . . 0.0 109.67 -179.706 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.53 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 85.29 -4.89 84.89 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -179.486 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.418 ' O ' HG22 ' A' ' 60' ' ' VAL . 60.2 ttt-85 -95.51 157.77 15.75 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.262 -1.14 . . . . 0.0 109.724 -179.827 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.501 HG11 ' N ' ' A' ' 9' ' ' TYR . 72.9 t -90.45 153.93 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.306 -0.871 . . . . 0.0 109.368 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.594 ' CE1' ' CG2' ' A' ' 60' ' ' VAL . 14.7 m-85 -133.96 -171.56 2.77 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.033 -1.042 . . . . 0.0 110.225 -179.62 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.411 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 24.8 m -159.29 120.45 3.26 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 179.243 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.524 ' CA ' ' O ' ' A' ' 24' ' ' ALA . . . -131.92 164.59 23.66 Favored Glycine 0 N--CA 1.49 2.27 0 C-N-CA 118.759 -1.686 . . . . 0.0 111.077 -178.323 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.541 ' O ' HG12 ' A' ' 23' ' ' VAL . 0.3 OUTLIER -101.76 168.37 9.49 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.385 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.475 HG23 HD21 ' A' ' 50' ' ' LEU . 96.0 t -88.01 99.34 8.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.656 0 O-C-N 120.719 -1.238 . . . . 0.0 108.475 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.509 ' CG2' ' CB ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -105.24 -3.1 23.27 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.351 -0.843 . . . . 0.0 110.191 -178.8 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.546 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 1.8 mpp_? -165.82 155.44 12.28 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.946 -1.096 . . . . 0.0 110.19 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.422 ' C ' HG11 ' A' ' 17' ' ' VAL . 21.3 mt -144.43 157.89 15.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 179.575 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.656 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -140.09 155.85 24.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 120.664 -1.273 . . . . 0.0 110.196 -178.995 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -60.69 -41.21 94.68 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.63 -1.294 . . . . 0.0 109.456 179.472 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.656 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 12.4 p90 -89.73 24.61 2.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.186 -0.947 . . . . 0.0 110.039 -179.774 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.617 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 154.76 -149.07 20.27 Favored Glycine 0 N--CA 1.493 2.445 0 C-N-CA 119.166 -1.492 . . . . 0.0 110.958 -179.682 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.502 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -154.94 148.05 24.79 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.217 -1.166 . . . . 0.0 108.465 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.644 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 10.9 m-30 -108.75 160.88 15.61 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 179.693 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.554 ' CG2' HG22 ' A' ' 33' ' ' VAL . 3.2 t -150.82 165.33 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.08 -1.012 . . . . 0.0 109.335 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.527 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -127.08 150.46 49.46 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.066 -1.021 . . . . 0.0 109.864 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.482 HG13 ' O ' ' A' ' 29' ' ' LYS . 0.8 OUTLIER -113.32 24.13 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.102 -0.999 . . . . 0.0 109.397 179.646 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 128.83 -165.65 21.57 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -92.26 89.47 1.4 Allowed Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 158.34 -58.96 0.34 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.482 ' O ' HG13 ' A' ' 25' ' ' ILE . 20.8 mmmt -119.7 153.7 35.21 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.362 -1.081 . . . . 0.0 109.319 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.527 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -129.7 151.95 49.73 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 120.887 -1.133 . . . . 0.0 110.448 -179.305 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.421 ' CA ' HD13 ' A' ' 71' ' ' LEU . . . -99.17 -174.53 31.57 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 179.191 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.644 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.23 121.81 8.0 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.764 -1.433 . . . . 0.0 111.46 179.946 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.572 ' CG1' ' CD1' ' A' ' 73' ' ' ILE . 52.7 t -94.44 62.37 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 177.274 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.494 ' CB ' ' OE1' ' A' ' 37' ' ' GLN . 3.3 t-80 -50.43 155.13 1.1 Allowed 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.862 -1.149 . . . . 0.0 108.804 -179.37 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.519 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 4.1 tp -46.64 -49.92 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.361 -0.837 . . . . 0.0 110.765 -179.528 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -81.5 41.84 0.65 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.952 -1.093 . . . . 0.0 110.524 -179.434 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.494 ' OE1' ' CB ' ' A' ' 34' ' ' HIS . 17.2 mt-30 -150.38 51.44 0.89 Allowed 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.875 -1.141 . . . . 0.0 110.016 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.639 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.7 mp -127.27 -96.5 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 120.935 -1.103 . . . . 0.0 110.312 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.561 ' O ' ' CB ' ' A' ' 40' ' ' ASP . . . -100.11 53.12 0.9 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.563 -0.711 . . . . 0.0 109.899 -179.01 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.561 ' CB ' ' O ' ' A' ' 39' ' ' ALA . 11.7 t0 82.54 -44.92 0.15 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.787 -0.571 . . . . 0.0 109.967 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.451 ' HB2' ' O ' ' A' ' 40' ' ' ASP . 0.1 OUTLIER 172.97 -25.59 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.035 -1.041 . . . . 0.0 110.572 -179.62 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.507 ' O ' ' OH ' ' A' ' 49' ' ' TYR . 0.1 OUTLIER -76.43 78.58 3.15 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.136 -0.977 . . . . 0.0 110.846 -178.763 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.622 ' CG1' ' CD1' ' A' ' 49' ' ' TYR . 54.1 t -144.61 67.03 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 178.512 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 71.7 tt0 -45.26 -26.36 0.49 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.434 -0.791 . . . . 0.0 110.13 -179.295 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.499 ' O ' HG11 ' A' ' 43' ' ' VAL . 0.8 OUTLIER -131.54 131.64 43.53 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.067 -1.021 . . . . 0.0 109.991 -179.6 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.526 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -80.04 -26.2 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.992 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 7.3 p -80.36 6.58 11.72 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 178.926 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -105.3 -25.01 12.59 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 179.23 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.639 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 26.0 m-85 -97.57 -33.61 11.28 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 179.74 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.509 HD13 ' CG2' ' A' ' 33' ' ' VAL . 0.7 OUTLIER -104.38 143.08 33.48 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.198 -0.939 . . . . 0.0 109.449 179.292 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.452 ' HB3' ' HG3' ' A' ' 54' ' ' GLN . 1.3 tm0? -133.86 134.94 43.34 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 7.0 mtt -54.99 102.54 0.07 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.142 -0.973 . . . . 0.0 109.733 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 126.84 -38.09 2.25 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 119.784 -1.198 . . . . 0.0 110.186 179.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . 0.452 ' HG3' ' HB3' ' A' ' 51' ' ' GLN . 19.3 mm-40 -59.58 128.95 39.58 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.24 -1.153 . . . . 0.0 110.056 -179.579 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . 0.463 ' HA ' ' HA ' ' A' ' 12' ' ' LYS . 61.8 mt-10 -108.89 131.96 54.5 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.34 -0.85 . . . . 0.0 108.9 179.375 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 17.1 m -137.34 153.44 74.71 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.086 -1.009 . . . . 0.0 110.177 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.429 ' HB2' ' HD3' ' A' ' 74' ' ' LYS . 36.9 Cg_endo -79.69 155.89 24.2 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.937 2.425 . . . . 0.0 110.09 179.57 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.541 ' CG2' ' HB3' ' A' ' 71' ' ' LEU . 1.0 OUTLIER -147.94 -174.73 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.047 -1.033 . . . . 0.0 109.469 179.927 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.467 ' O ' ' N ' ' A' ' 61' ' ' LEU . 1.7 mttp -136.38 119.97 17.12 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.452 -0.78 . . . . 0.0 109.384 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.594 ' CG2' ' CE1' ' A' ' 9' ' ' TYR . 60.8 t -48.39 95.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.303 -0.873 . . . . 0.0 109.281 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.662 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 11.7 tp -74.46 -27.31 60.53 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.38 -0.825 . . . . 0.0 109.351 -179.655 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.662 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 8.2 tp10 136.42 158.28 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.342 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.544 ' N ' ' HG3' ' A' ' 62' ' ' GLU . 6.3 t -88.66 129.5 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.034 -1.041 . . . . 0.0 109.089 179.84 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 48.8 p-10 -69.38 -176.09 0.91 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.303 -0.873 . . . . 0.0 109.978 -179.579 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -73.73 -4.41 34.35 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.406 -0.809 . . . . 0.0 109.717 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . 0.441 ' O ' ' HG3' ' A' ' 66' ' ' GLN . 1.0 OUTLIER -90.17 9.02 30.03 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.175 -0.953 . . . . 0.0 109.4 -179.957 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 70.2 6.7 58.14 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.472 ' O ' HG11 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -92.15 152.08 20.07 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.171 -1.193 . . . . 0.0 109.315 179.897 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.458 HD11 ' O ' ' A' ' 30' ' ' GLU . 0.8 OUTLIER -83.25 121.13 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.227 -0.92 . . . . 0.0 109.881 -179.56 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.448 ' CB ' ' O ' ' A' ' 62' ' ' GLU . 2.4 tpt180 -89.77 97.39 11.16 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.24 -0.913 . . . . 0.0 109.039 179.593 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.541 ' HB3' ' CG2' ' A' ' 58' ' ' VAL . 23.5 mt -89.59 143.48 26.78 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 121.304 -0.873 . . . . 0.0 109.6 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.477 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.5 OUTLIER -100.38 123.5 44.68 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.39 -0.819 . . . . 0.0 109.737 -179.594 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.572 ' CD1' ' CG1' ' A' ' 33' ' ' VAL . 0.0 OUTLIER -63.3 123.65 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.418 -0.801 . . . . 0.0 109.226 179.988 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.429 ' HD3' ' HB2' ' A' ' 57' ' ' PRO . 0.1 OUTLIER -67.14 178.82 1.33 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.925 . . . . 0.0 109.397 179.859 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -87.72 42.48 1.05 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.362 -0.836 . . . . 0.0 109.616 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.526 0 CA-C-O 118.044 -0.979 . . . . 0.0 109.512 179.879 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.468 ' O ' ' O ' ' A' ' 3' ' ' ILE . 3.1 tt0 -92.09 80.46 5.1 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.298 -0.876 . . . . 0.0 109.739 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.469 HG22 ' N ' ' A' ' 4' ' ' GLU . 0.4 OUTLIER -45.17 169.77 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.196 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.469 ' N ' HG22 ' A' ' 3' ' ' ILE . 0.6 OUTLIER -123.73 140.36 53.06 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.006 -1.059 . . . . 0.0 109.604 -179.87 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.541 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 24.1 t -67.4 165.42 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.232 -0.917 . . . . 0.0 109.332 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.541 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 75.6 1.61 66.6 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 108.886 -1.686 . . . . 0.0 108.886 -179.295 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.456 ' HD3' HD13 ' A' ' 3' ' ' ILE . 2.4 ttt180 -81.86 170.15 16.0 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.277 -1.131 . . . . 0.0 109.429 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.455 ' HA ' ' O ' ' A' ' 58' ' ' VAL . 78.8 t -108.54 115.85 50.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.185 -0.947 . . . . 0.0 109.801 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.464 ' CE1' ' CG2' ' A' ' 60' ' ' VAL . 5.1 m-85 -92.18 -168.74 2.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.325 -0.859 . . . . 0.0 109.148 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.508 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 21.3 m -151.48 115.85 5.07 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 178.69 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.536 ' CA ' ' O ' ' A' ' 24' ' ' ALA . . . -129.16 152.8 19.57 Favored Glycine 0 N--CA 1.487 2.035 0 C-N-CA 119.148 -1.501 . . . . 0.0 110.844 -178.57 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.505 ' O ' HG11 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -93.61 167.7 11.5 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.006 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.528 ' CG2' HD22 ' A' ' 50' ' ' LEU . 58.4 t -88.35 106.28 16.43 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.754 0 C-N-CA 119.164 -1.014 . . . . 0.0 108.34 179.736 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.557 ' CG2' ' CB ' ' A' ' 24' ' ' ALA . 0.5 OUTLIER -111.07 -3.28 15.55 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.341 -0.85 . . . . 0.0 110.226 -178.577 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.548 ' CD ' ' OG1' ' A' ' 14' ' ' THR . 0.0 OUTLIER -173.45 150.73 1.86 Allowed 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.98 -1.075 . . . . 0.0 110.007 179.479 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.515 HG21 ' N ' ' A' ' 17' ' ' VAL . 13.1 mt -136.73 161.38 36.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.525 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.658 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.9 OUTLIER -138.65 153.89 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 120.653 -1.28 . . . . 0.0 110.225 -179.63 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -58.59 -43.69 89.61 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.771 -1.205 . . . . 0.0 109.495 179.196 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.658 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 11.6 p90 -89.98 27.9 1.49 Allowed 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.22 -0.925 . . . . 0.0 110.251 -179.54 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.629 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 153.67 -153.68 25.0 Favored Glycine 0 N--CA 1.492 2.375 0 C-N-CA 118.914 -1.613 . . . . 0.0 111.249 -179.731 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.468 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -151.75 147.69 26.99 Favored 'General case' 0 C--N 1.305 -1.349 0 O-C-N 121.109 -1.23 . . . . 0.0 109.056 -179.737 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.646 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 12.2 m-30 -108.25 160.12 16.09 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.543 ' CG1' ' N ' ' A' ' 24' ' ' ALA . 24.0 t -150.41 166.58 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.06 -1.025 . . . . 0.0 109.666 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.557 ' CB ' ' CG2' ' A' ' 14' ' ' THR . . . -130.99 144.99 51.89 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.183 -0.948 . . . . 0.0 109.714 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.462 HG13 ' O ' ' A' ' 29' ' ' LYS . 2.2 pt -116.18 45.31 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.906 -1.121 . . . . 0.0 109.399 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 125.58 -162.36 19.84 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.731 -1.348 . . . . 0.0 109.731 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -107.19 48.49 0.95 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -160.02 -46.88 0.02 OUTLIER Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.462 ' O ' HG13 ' A' ' 25' ' ' ILE . 56.2 mmtt -121.21 149.29 43.06 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.406 -1.055 . . . . 0.0 108.833 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.535 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 10.7 pt-20 -124.47 152.75 42.97 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 120.918 -1.114 . . . . 0.0 110.975 -179.35 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.448 ' CA ' HD13 ' A' ' 71' ' ' LEU . . . -100.72 -176.54 29.62 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 108.359 -1.896 . . . . 0.0 108.359 179.165 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.646 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.26 120.88 7.48 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.863 -1.375 . . . . 0.0 110.913 179.645 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.62 ' CG1' ' CD1' ' A' ' 50' ' ' LEU . 61.8 t -96.19 63.11 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 177.712 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.425 ' HB3' ' HG3' ' A' ' 37' ' ' GLN . 3.1 t-80 -50.45 156.62 0.84 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.837 -1.165 . . . . 0.0 108.623 -179.48 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.543 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.2 OUTLIER -46.65 -48.97 6.85 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.113 -0.992 . . . . 0.0 109.575 -179.793 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 4.9 p -81.59 40.39 0.58 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.287 -0.883 . . . . 0.0 110.389 -179.841 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.428 ' C ' HD13 ' A' ' 38' ' ' ILE . 71.4 mt-30 -148.93 30.63 0.79 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.714 -1.241 . . . . 0.0 110.069 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.65 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.8 mp -104.65 -96.32 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.016 -1.053 . . . . 0.0 109.602 179.68 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.533 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . -109.23 -150.71 0.46 Allowed 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.463 -0.773 . . . . 0.0 109.502 -179.588 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.486 ' O ' ' HB2' ' A' ' 41' ' ' LYS . 8.7 m-20 -46.35 -56.68 5.49 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.31 -0.869 . . . . 0.0 109.891 -179.796 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.486 ' HB2' ' O ' ' A' ' 40' ' ' ASP . 22.4 tttt 170.65 -7.53 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.298 -0.876 . . . . 0.0 111.046 -179.716 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 2.2 mtm105 -80.73 41.31 0.56 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.742 -1.224 . . . . 0.0 110.583 -179.449 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.605 HG23 ' CD2' ' A' ' 49' ' ' TYR . 87.4 t -106.09 47.5 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 120.749 -1.219 . . . . 0.0 109.466 179.494 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.434 ' C ' ' O ' ' A' ' 43' ' ' VAL . 0.4 OUTLIER -45.33 -27.22 0.63 Allowed 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 179.568 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.426 ' O ' HG11 ' A' ' 43' ' ' VAL . 0.0 OUTLIER -115.44 113.44 23.72 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 179.239 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.52 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -73.67 -25.35 20.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 -179.981 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 61.1 p -77.68 5.72 8.73 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.471 -0.768 . . . . 0.0 109.414 179.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.421 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 13.3 m-20 -101.29 -32.7 10.37 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 179.292 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.65 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 19.5 m-85 -90.43 -36.23 14.69 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 179.502 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.62 ' CD1' ' CG1' ' A' ' 33' ' ' VAL . 0.0 OUTLIER -101.61 158.01 16.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.292 -0.88 . . . . 0.0 110.527 179.789 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.414 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 16.8 tp60 -149.35 127.6 12.11 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.503 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' MET . . . . . 0.406 ' HA ' HG13 ' A' ' 13' ' ' VAL . 5.6 mtt -59.69 111.82 1.58 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.124 -0.985 . . . . 0.0 110.19 -179.463 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 120.8 -25.43 7.19 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 119.874 -1.155 . . . . 0.0 110.383 179.301 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 9.6 mt-30 -74.95 177.09 6.57 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.082 -1.246 . . . . 0.0 110.323 -179.434 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -139.13 126.53 21.59 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.76 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.2 m -138.01 144.98 45.97 Favored Pre-proline 0 N--CA 1.489 1.505 0 O-C-N 120.947 -1.096 . . . . 0.0 110.5 -179.293 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 37.1 Cg_endo -81.81 153.11 17.2 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 122.951 2.434 . . . . 0.0 110.117 179.418 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.455 ' O ' ' HA ' ' A' ' 8' ' ' VAL . 0.8 OUTLIER -144.39 -168.86 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.1 -1.0 . . . . 0.0 109.344 179.457 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.431 ' HE3' ' CD ' ' A' ' 74' ' ' LYS . 5.6 mttt -133.87 136.85 44.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.33 -0.856 . . . . 0.0 109.298 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.464 ' CG2' ' CE1' ' A' ' 9' ' ' TYR . 86.2 t -65.39 86.87 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.35 -0.844 . . . . 0.0 109.025 179.675 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.511 ' O ' ' HB2' ' A' ' 62' ' ' GLU . 4.6 tp -56.32 -33.3 65.46 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.449 -0.782 . . . . 0.0 109.401 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.511 ' HB2' ' O ' ' A' ' 61' ' ' LEU . 0.8 OUTLIER 167.62 157.76 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.468 -0.77 . . . . 0.0 110.118 -179.952 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.491 ' HA ' ' O ' ' A' ' 66' ' ' GLN . 46.6 t -150.15 -52.44 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.473 -0.767 . . . . 0.0 109.21 179.162 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.425 ' C ' ' O ' ' A' ' 63' ' ' VAL . 0.5 OUTLIER -44.47 -50.81 9.22 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.301 -0.875 . . . . 0.0 109.324 -179.937 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . 0.523 ' CB ' ' OE1' ' A' ' 66' ' ' GLN . 0.1 OUTLIER -68.01 -37.32 81.29 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.239 -0.913 . . . . 0.0 108.913 179.597 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . 0.523 ' OE1' ' CB ' ' A' ' 65' ' ' ARG . 2.0 pm0 -128.37 112.76 14.76 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.479 -0.763 . . . . 0.0 109.08 179.598 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -74.39 5.32 28.95 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 -179.498 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.471 ' O ' ' O ' ' A' ' 69' ' ' ILE . 7.9 mtt180 -89.79 39.17 0.94 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.746 -1.444 . . . . 0.0 109.496 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.471 ' O ' ' O ' ' A' ' 68' ' ' ARG . 61.9 mt 36.87 95.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 CA-C-O 121.181 0.515 . . . . 0.0 110.437 179.445 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 10.0 tpt180 -89.88 81.5 6.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.16 -0.963 . . . . 0.0 109.625 179.777 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.448 HD13 ' CA ' ' A' ' 31' ' ' GLY . 20.8 mt -92.23 143.75 26.1 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.214 -0.929 . . . . 0.0 109.276 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.445 ' O ' ' C ' ' A' ' 73' ' ' ILE . 2.1 m -125.73 117.01 22.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.289 -0.882 . . . . 0.0 109.744 -179.69 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.445 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.1 OUTLIER -44.22 136.91 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.274 -0.891 . . . . 0.0 108.785 179.68 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.431 ' CD ' ' HE3' ' A' ' 59' ' ' LYS . 0.1 OUTLIER -48.12 170.99 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.191 -0.943 . . . . 0.0 109.532 -179.714 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER 46.7 44.03 13.43 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.248 -0.908 . . . . 0.0 109.466 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 118.011 -0.995 . . . . 0.0 109.41 179.823 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.44 ' O ' ' O ' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' A' ' 1' ' ' ALA . 4.6 mt-10 49.15 -178.13 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.207 -0.933 . . . . 0.0 109.72 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.491 ' HB ' ' OH ' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -127.48 -164.52 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 121.399 -0.813 . . . . 0.0 109.66 -179.511 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -126.25 119.13 26.64 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.496 -0.753 . . . . 0.0 109.201 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.413 HG11 HG13 ' A' ' 60' ' ' VAL . 3.0 t -56.4 157.13 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.27 -0.894 . . . . 0.0 109.402 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 83.73 -1.31 88.92 Favored Glycine 0 N--CA 1.488 2.123 0 N-CA-C 109.137 -1.585 . . . . 0.0 109.137 -179.387 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 8.0 ttt85 -89.25 156.05 19.0 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.217 -1.166 . . . . 0.0 109.915 -179.802 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 40.8 t -93.39 134.95 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.439 -0.788 . . . . 0.0 109.265 179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.491 ' OH ' ' HB ' ' A' ' 3' ' ' ILE . 13.3 m-85 -116.64 -174.25 2.53 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.173 -0.954 . . . . 0.0 110.239 -179.825 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.444 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 5.5 m -155.89 111.77 3.05 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 179.258 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.434 ' CA ' ' O ' ' A' ' 24' ' ' ALA . . . -126.58 153.66 18.85 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 118.906 -1.616 . . . . 0.0 111.04 -178.095 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.494 ' O ' HG11 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -89.71 164.12 14.82 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 179.128 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.471 ' HB ' ' O ' ' A' ' 51' ' ' GLN . 99.4 t -88.08 95.96 5.56 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 O-C-N 120.753 -1.217 . . . . 0.0 108.336 179.703 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.544 ' OG1' ' CD ' ' A' ' 15' ' ' ARG . 1.1 p -96.53 -1.9 46.17 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.5 -0.75 . . . . 0.0 109.865 -178.945 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.544 ' CD ' ' OG1' ' A' ' 14' ' ' THR . 0.0 OUTLIER -173.37 143.21 1.06 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.174 -0.954 . . . . 0.0 109.687 179.982 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.44 HD11 HG22 ' A' ' 16' ' ' ILE . 8.8 mt -131.56 159.16 43.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 179.323 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.652 HG21 ' N ' ' A' ' 20' ' ' GLY . 0.8 OUTLIER -135.44 153.83 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 120.634 -1.291 . . . . 0.0 110.42 -178.474 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -61.3 -39.69 91.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.569 -1.332 . . . . 0.0 109.376 179.416 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.639 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 15.5 p90 -90.86 23.42 3.15 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.364 -0.835 . . . . 0.0 110.107 -179.736 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.652 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 155.16 -152.28 23.81 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 119.214 -1.47 . . . . 0.0 110.822 -179.402 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.521 ' CB ' ' HB ' ' A' ' 33' ' ' VAL . . . -151.42 145.01 24.94 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 120.759 -1.436 . . . . 0.0 109.31 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.641 ' CE1' HD12 ' A' ' 32' ' ' LEU . 12.4 m-30 -107.18 156.78 18.46 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.559 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.55 ' CG2' HG22 ' A' ' 33' ' ' VAL . 7.2 t -150.44 162.13 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.045 -1.035 . . . . 0.0 109.793 -179.533 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.525 ' HB1' ' CG2' ' A' ' 14' ' ' THR . . . -128.17 144.49 51.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.283 -0.886 . . . . 0.0 109.06 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.492 ' CG1' ' O ' ' A' ' 29' ' ' LYS . 1.8 pt -103.4 2.94 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 120.775 -1.203 . . . . 0.0 109.915 -179.794 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 118.1 175.15 16.69 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.711 -1.233 . . . . 0.0 110.248 179.386 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -55.71 93.55 0.02 OUTLIER Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.413 ' O ' ' HG2' ' A' ' 29' ' ' LYS . . . 165.52 -42.02 0.28 Allowed Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.492 ' O ' ' CG1' ' A' ' 25' ' ' ILE . 0.0 OUTLIER -173.31 171.9 3.92 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.328 -1.101 . . . . 0.0 109.683 179.631 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.524 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 0.3 OUTLIER -128.44 149.11 50.71 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.937 -1.102 . . . . 0.0 110.092 -179.661 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -98.7 -178.3 32.3 Favored Glycine 0 N--CA 1.486 2.02 0 N-CA-C 108.216 -1.954 . . . . 0.0 108.216 179.106 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.641 HD12 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -148.87 116.53 6.24 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 120.827 -1.396 . . . . 0.0 110.541 179.604 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.55 HG22 ' CG2' ' A' ' 23' ' ' VAL . 91.9 t -89.95 59.35 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 177.75 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.494 ' O ' ' CD1' ' A' ' 38' ' ' ILE . 4.5 t-80 -47.28 156.19 0.27 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 120.739 -1.225 . . . . 0.0 108.551 -179.463 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.551 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.2 OUTLIER -49.81 -47.25 22.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.163 -0.96 . . . . 0.0 109.49 -179.713 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.418 ' C ' ' HG2' ' A' ' 37' ' ' GLN . 0.3 OUTLIER -81.22 39.79 0.53 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.413 -0.804 . . . . 0.0 110.399 -179.925 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.418 ' HG2' ' C ' ' A' ' 36' ' ' SER . 47.1 mm-40 -147.98 34.15 0.83 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.934 -1.104 . . . . 0.0 109.27 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.634 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.6 mp -112.48 -97.11 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.248 -0.908 . . . . 0.0 109.916 -179.613 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.572 ' O ' ' CB ' ' A' ' 40' ' ' ASP . . . -100.42 16.31 24.95 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.311 -0.868 . . . . 0.0 109.825 -179.402 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.572 ' CB ' ' O ' ' A' ' 39' ' ' ALA . 7.5 t70 83.85 -57.43 0.13 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.751 -0.593 . . . . 0.0 109.7 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 18.9 mttm -59.78 -179.58 0.1 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.203 -0.936 . . . . 0.0 109.194 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.411 ' O ' ' N ' ' A' ' 44' ' ' GLU . 3.3 mmt180 -79.88 92.26 5.48 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.3 -0.875 . . . . 0.0 109.503 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.61 ' CG1' ' CD1' ' A' ' 49' ' ' TYR . 2.5 t -58.55 95.31 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 179.326 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.451 ' C ' ' O ' ' A' ' 43' ' ' VAL . 3.2 mp0 -40.32 -25.06 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.639 -0.663 . . . . 0.0 109.923 -179.59 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.538 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.8 OUTLIER -151.28 121.56 7.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.146 -0.971 . . . . 0.0 110.021 -179.813 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.542 HG23 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -71.71 -26.92 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 178.959 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 58.6 p -79.14 6.02 10.64 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.892 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.461 ' OD2' ' HB2' ' A' ' 45' ' ' LYS . 26.6 m-20 -106.25 -26.9 11.34 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 179.204 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.634 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 12.9 m-85 -92.54 -34.83 13.9 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.247 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.525 ' CD1' ' CG2' ' A' ' 33' ' ' VAL . 4.6 mt -109.57 152.9 24.9 Favored 'General case' 0 N--CA 1.492 1.635 0 C-N-CA 119.473 -0.891 . . . . 0.0 109.752 179.637 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.471 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.9 OUTLIER -128.19 138.68 52.58 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.39 -0.819 . . . . 0.0 108.982 179.437 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' MET . . . . . 0.442 ' HA ' HG13 ' A' ' 13' ' ' VAL . 22.6 mtp -63.17 114.19 3.61 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.217 -0.927 . . . . 0.0 109.716 -179.719 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 109.38 -23.85 21.72 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . 0.433 ' HG3' ' HB3' ' A' ' 51' ' ' GLN . 1.5 mt-30 -74.5 147.78 41.57 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.098 -1.236 . . . . 0.0 109.791 -179.718 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . 0.458 ' HA ' ' HA ' ' A' ' 12' ' ' LYS . 0.3 OUTLIER -107.06 146.95 30.57 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.329 -0.857 . . . . 0.0 109.37 179.889 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.436 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 18.8 m -150.6 140.03 13.52 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.079 -1.013 . . . . 0.0 109.944 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.444 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 37.2 Cg_endo -82.96 151.85 14.33 Favored 'Trans proline' 0 C--N 1.315 -1.21 0 C-N-CA 122.786 2.324 . . . . 0.0 110.137 179.311 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.505 ' CG2' ' HB3' ' A' ' 71' ' ' LEU . 0.9 OUTLIER -147.72 -171.22 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.167 -0.958 . . . . 0.0 109.299 179.511 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.523 ' O ' ' N ' ' A' ' 61' ' ' LEU . 10.8 mttt -138.59 121.7 16.84 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.079 -1.013 . . . . 0.0 109.955 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.413 HG13 HG11 ' A' ' 5' ' ' VAL . 35.2 t -51.04 91.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.294 -0.879 . . . . 0.0 108.944 179.251 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.537 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 6.5 tp -66.42 -26.76 67.38 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.506 -0.746 . . . . 0.0 109.646 -179.616 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.537 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 21.2 tt0 162.54 153.06 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.326 -0.859 . . . . 0.0 110.164 179.828 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.483 ' O ' ' O ' ' A' ' 64' ' ' ASP . 74.7 t -151.2 -87.77 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.289 -0.882 . . . . 0.0 109.26 179.133 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.483 ' O ' ' O ' ' A' ' 63' ' ' VAL . 2.1 p-10 41.58 -167.7 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.36 -0.838 . . . . 0.0 110.155 179.648 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 1.2 ttt-85 -64.65 -29.17 70.17 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.12 -0.987 . . . . 0.0 108.969 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -104.86 74.06 1.11 Allowed 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.391 -0.818 . . . . 0.0 108.955 179.542 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.481 ' O ' ' HA ' ' A' ' 63' ' ' VAL . . . 157.28 103.47 0.2 Allowed Glycine 0 N--CA 1.487 2.045 0 N-CA-C 109.114 -1.594 . . . . 0.0 109.114 -179.557 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.433 ' O ' ' CG ' ' A' ' 68' ' ' ARG . 0.0 OUTLIER -89.01 96.63 10.81 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.333 -1.098 . . . . 0.0 109.295 -179.818 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.5 HG21 ' CD2' ' A' ' 71' ' ' LEU . 42.4 mt 45.37 64.92 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.463 -0.773 . . . . 0.0 110.189 179.722 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.483 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 0.0 OUTLIER -90.01 83.89 6.13 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.025 -1.047 . . . . 0.0 108.905 179.342 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.565 ' CD2' ' N ' ' A' ' 71' ' ' LEU . 2.4 mm? -89.18 164.05 15.16 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.267 -0.896 . . . . 0.0 109.935 -179.314 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -119.33 112.71 19.78 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.522 -0.736 . . . . 0.0 109.366 -179.87 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.442 ' O ' ' C ' ' A' ' 74' ' ' LYS . 0.1 OUTLIER -55.63 136.08 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.271 -0.893 . . . . 0.0 109.336 -179.67 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.442 ' C ' ' O ' ' A' ' 73' ' ' ILE . 0.0 OUTLIER -41.48 -39.14 1.44 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.351 -0.843 . . . . 0.0 109.814 -179.481 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.475 ' O ' ' HA ' ' A' ' 39' ' ' ALA . 1.2 tt0 -90.72 45.85 1.29 Allowed 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 179.627 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.494 0 CA-C-O 118.032 -0.985 . . . . 0.0 109.412 -179.65 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 121.287 0.565 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -93.75 -159.55 0.7 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.184 -0.947 . . . . 0.0 109.315 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.609 ' N ' ' CD1' ' A' ' 3' ' ' ILE . 0.1 OUTLIER -144.86 -164.73 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 O-C-N 121.199 -0.938 . . . . 0.0 109.319 -179.655 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -149.1 152.2 35.75 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.308 -0.87 . . . . 0.0 109.475 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.567 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 6.5 t -61.16 168.4 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.205 -0.934 . . . . 0.0 109.042 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.567 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 70.74 10.33 67.29 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 108.935 -1.666 . . . . 0.0 108.935 -179.466 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -109.92 176.14 5.18 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.365 -1.079 . . . . 0.0 109.421 -179.888 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 24.1 t -91.37 123.58 43.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.199 -0.938 . . . . 0.0 109.011 179.621 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.588 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 4.2 m-85 -110.87 130.69 55.51 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.124 -0.985 . . . . 0.0 110.012 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 11.0 m -80.45 100.49 8.53 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.335 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.47 126.0 7.25 Favored Glycine 0 N--CA 1.487 2.072 0 C-N-CA 119.87 -1.157 . . . . 0.0 110.487 -178.539 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.521 ' O ' HG12 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -89.75 148.12 23.44 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.794 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.509 ' CG1' ' CD1' ' A' ' 50' ' ' LEU . 22.8 t -87.85 112.21 23.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 120.568 -1.332 . . . . 0.0 108.97 -179.648 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.527 HG22 ' CB ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -122.8 -6.09 8.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.437 -0.789 . . . . 0.0 110.216 -178.916 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.465 ' HD2' ' O ' ' A' ' 14' ' ' THR . 0.9 OUTLIER -164.68 153.66 12.93 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.916 -1.115 . . . . 0.0 110.06 -179.949 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.468 HG21 ' HB3' ' A' ' 21' ' ' ALA . 12.2 mt -141.08 161.57 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 179.438 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.644 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -140.15 153.44 22.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 120.881 -1.137 . . . . 0.0 109.982 -179.58 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -58.45 -41.78 85.9 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.778 -1.202 . . . . 0.0 109.145 179.405 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.644 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 15.5 p90 -90.3 29.31 1.27 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.381 -0.825 . . . . 0.0 110.077 -179.743 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.6 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 149.81 -148.86 20.57 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 118.964 -1.589 . . . . 0.0 110.976 -179.766 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.49 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -154.94 148.83 25.66 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.233 -1.157 . . . . 0.0 108.917 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.649 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 10.5 m-30 -106.94 162.46 13.81 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.339 -0.851 . . . . 0.0 108.954 179.682 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.598 ' CG2' ' CG2' ' A' ' 33' ' ' VAL . 22.5 t -149.03 160.87 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.08 -1.013 . . . . 0.0 109.64 -179.64 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.541 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -133.8 135.92 44.14 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.306 -0.871 . . . . 0.0 109.55 -179.843 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.461 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.2 pt -108.81 -97.28 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 120.818 -1.176 . . . . 0.0 109.509 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 27' ' ' GLY . . . 159.56 -58.05 0.32 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.411 ' C ' ' O ' ' A' ' 26' ' ' GLY . . . -43.93 -34.55 3.03 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.541 -1.423 . . . . 0.0 109.541 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.447 ' O ' ' CG ' ' A' ' 29' ' ' LYS . . . -122.58 -69.85 0.25 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.527 ' N ' HD13 ' A' ' 69' ' ' ILE . 4.4 mtmt -164.15 -107.7 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.232 -1.158 . . . . 0.0 109.674 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.541 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 6.4 mt-10 -127.48 150.87 49.47 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.741 -1.224 . . . . 0.0 111.004 -179.151 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -102.33 -172.96 27.25 Favored Glycine 0 N--CA 1.488 2.104 0 N-CA-C 108.22 -1.952 . . . . 0.0 108.22 178.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.649 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.14 121.8 8.05 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.737 -1.449 . . . . 0.0 110.951 179.743 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.598 ' CG2' ' CG2' ' A' ' 23' ' ' VAL . 61.1 t -95.3 61.36 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 177.523 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.426 ' HB2' HD21 ' A' ' 32' ' ' LEU . 2.6 t-80 -48.88 158.13 0.35 Allowed 'General case' 0 C--N 1.304 -1.37 0 O-C-N 120.893 -1.13 . . . . 0.0 108.653 -179.462 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.528 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.9 tp -46.66 -51.01 5.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.188 -0.945 . . . . 0.0 109.864 -179.464 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 42.6 p -81.99 44.51 0.85 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.302 -0.874 . . . . 0.0 110.372 -179.639 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.452 ' C ' HD13 ' A' ' 38' ' ' ILE . 3.6 mm100 -144.29 33.61 1.2 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.903 -1.123 . . . . 0.0 110.214 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.612 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.6 mp -120.29 -98.49 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.833 -1.167 . . . . 0.0 110.214 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.567 ' O ' ' CB ' ' A' ' 40' ' ' ASP . . . -98.05 41.12 1.14 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.459 -0.776 . . . . 0.0 109.45 -179.206 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.567 ' CB ' ' O ' ' A' ' 39' ' ' ALA . 16.7 t70 82.96 -62.92 0.12 Allowed 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 -179.499 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -168.79 -0.13 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.066 -1.021 . . . . 0.0 111.774 -179.492 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.451 ' O ' ' OH ' ' A' ' 49' ' ' TYR . 0.3 OUTLIER -81.45 20.41 0.88 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.518 -1.364 . . . . 0.0 110.357 -179.806 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.633 ' CG1' ' CD1' ' A' ' 49' ' ' TYR . 58.7 t -102.41 67.43 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 O-C-N 120.889 -1.132 . . . . 0.0 109.41 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 43' ' ' VAL . 14.0 mt-10 -45.78 -24.27 0.36 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.354 -0.841 . . . . 0.0 108.988 179.488 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.471 ' O ' HG11 ' A' ' 43' ' ' VAL . 4.7 mmtp -134.97 123.71 23.76 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.327 -0.858 . . . . 0.0 109.4 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.527 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -73.68 -23.47 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 O-C-N 121.131 -0.981 . . . . 0.0 108.643 179.647 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 8.3 p -75.4 1.39 14.03 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.482 -0.761 . . . . 0.0 109.389 179.198 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.432 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 0.9 OUTLIER -102.17 -35.59 8.84 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.149 -0.969 . . . . 0.0 109.245 -179.999 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.633 ' CD1' ' CG1' ' A' ' 43' ' ' VAL . 3.9 m-85 -90.83 -28.72 18.0 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.35 -0.844 . . . . 0.0 108.972 179.791 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.509 ' CD1' ' CG1' ' A' ' 13' ' ' VAL . 0.2 OUTLIER -109.72 140.9 43.06 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.495 -0.753 . . . . 0.0 109.565 -179.575 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.486 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 2.3 mp0 -150.62 131.93 14.57 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.398 -0.814 . . . . 0.0 109.476 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' MET . . . . . 0.493 ' HA ' HG13 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -61.84 107.61 0.87 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.273 -0.892 . . . . 0.0 109.955 -179.929 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 132.33 -31.97 2.91 Favored Glycine 0 N--CA 1.491 2.321 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.306 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . 0.479 ' O ' HG22 ' A' ' 13' ' ' VAL . 6.2 mt-30 -80.3 162.28 24.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.033 -1.275 . . . . 0.0 109.818 -179.668 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -125.28 138.66 54.09 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.518 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.406 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 17.2 m -140.58 143.92 34.44 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.017 -1.052 . . . . 0.0 110.008 -179.461 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.446 ' O ' HG11 ' A' ' 58' ' ' VAL . 36.3 Cg_endo -79.05 145.93 19.85 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.59 2.193 . . . . 0.0 110.241 179.704 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.48 HG21 ' O ' ' A' ' 9' ' ' TYR . 1.0 OUTLIER -148.21 -174.84 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.196 -0.94 . . . . 0.0 109.901 -179.878 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 3.0 mtpt -123.51 135.66 54.15 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.52 -0.737 . . . . 0.0 109.239 179.606 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.588 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 96.1 t -67.1 91.72 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.33 -0.856 . . . . 0.0 109.229 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.576 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 5.9 tp -65.11 -16.96 64.05 Favored 'General case' 0 C--N 1.305 -1.358 0 O-C-N 121.315 -0.866 . . . . 0.0 109.773 -179.552 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.576 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 20.6 mt-10 96.47 -176.83 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.239 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 -179.782 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.401 ' CG2' ' HA ' ' A' ' 69' ' ' ILE . 82.8 t -114.58 129.85 69.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.178 -0.951 . . . . 0.0 109.741 -179.606 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -119.75 -30.0 4.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.27 -0.894 . . . . 0.0 109.603 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.09 -79.59 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.209 -0.932 . . . . 0.0 109.436 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 1.1 tt0 -151.15 -45.82 0.12 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.106 -0.996 . . . . 0.0 109.105 179.786 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -162.43 24.95 0.22 Allowed Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.46 ' O ' ' HG3' ' A' ' 68' ' ' ARG . 0.1 OUTLIER -99.05 105.67 17.82 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.291 -1.123 . . . . 0.0 109.367 -179.907 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.527 HD13 ' N ' ' A' ' 29' ' ' LYS . 82.2 mt -47.64 120.53 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.203 -0.936 . . . . 0.0 109.606 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.548 ' CB ' ' O ' ' A' ' 62' ' ' GLU . 1.2 tpt180 -93.74 91.76 7.16 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.157 -0.964 . . . . 0.0 108.955 179.403 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.457 HD23 ' HB2' ' A' ' 9' ' ' TYR . 31.3 mt -89.51 150.19 22.56 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.34 -0.85 . . . . 0.0 109.024 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.456 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.4 OUTLIER -123.24 108.08 12.41 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.273 -0.892 . . . . 0.0 110.049 -179.259 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.457 HG21 ' HB1' ' A' ' 76' ' ' ALA . 0.0 OUTLIER -48.61 140.83 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.227 -0.921 . . . . 0.0 108.911 179.886 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 11.3 mmtt -47.19 151.53 0.68 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.318 -0.864 . . . . 0.0 109.744 -179.684 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 46.4 73.44 0.18 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.321 -0.862 . . . . 0.0 109.521 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.458 ' CB ' ' O ' ' A' ' 38' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.506 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.47 ' O ' ' O ' ' A' ' 3' ' ' ILE . 91.5 mt-10 -121.81 -22.4 5.79 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.19 -0.943 . . . . 0.0 109.839 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.49 HG22 ' N ' ' A' ' 4' ' ' GLU . 0.4 OUTLIER 53.52 170.96 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.298 -1.65 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 -179.821 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.49 ' N ' HG22 ' A' ' 3' ' ' ILE . 1.3 mt-10 -150.52 162.99 39.54 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.984 -1.072 . . . . 0.0 110.042 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.459 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 2.5 t -70.05 161.96 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.348 -0.845 . . . . 0.0 109.204 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.459 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 86.54 9.99 74.34 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 -179.585 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.408 ' HD3' ' CD1' ' A' ' 3' ' ' ILE . 1.7 ttt180 -107.53 178.18 4.61 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.29 -1.124 . . . . 0.0 109.437 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.46 HG21 ' HG2' ' A' ' 59' ' ' LYS . 41.3 t -90.0 127.65 42.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.199 -0.938 . . . . 0.0 108.82 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.577 ' CD2' HD11 ' A' ' 25' ' ' ILE . 2.8 m-30 -114.75 135.12 54.52 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.154 -0.966 . . . . 0.0 110.158 -179.335 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -73.82 100.74 3.54 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 177.448 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -82.26 122.73 5.82 Favored Glycine 0 N--CA 1.488 2.119 0 C-N-CA 120.009 -1.091 . . . . 0.0 111.368 -177.302 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.484 ' O ' HG12 ' A' ' 23' ' ' VAL . 2.4 mttt -96.07 143.24 27.39 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 177.988 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.528 ' CG1' HD21 ' A' ' 50' ' ' LEU . 24.9 t -88.1 107.66 17.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 120.802 -1.186 . . . . 0.0 108.934 -179.648 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.527 ' CG2' ' HB1' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -116.93 -7.95 11.34 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.454 -0.778 . . . . 0.0 109.813 -179.07 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.465 ' HD2' ' O ' ' A' ' 14' ' ' THR . 0.9 OUTLIER -161.48 148.22 14.45 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.054 -1.029 . . . . 0.0 110.158 -179.899 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.443 HG22 HD11 ' A' ' 16' ' ' ILE . 11.8 mt -137.05 157.38 35.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 179.005 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.651 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -136.3 153.4 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 120.749 -1.22 . . . . 0.0 110.034 -179.192 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -59.07 -41.94 89.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.69 -1.257 . . . . 0.0 109.331 179.228 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.651 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 12.9 p90 -91.16 27.24 1.93 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.3 -0.875 . . . . 0.0 110.361 -179.525 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.647 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 154.4 -154.9 25.83 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 118.895 -1.621 . . . . 0.0 110.829 -179.505 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.501 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -148.45 143.97 27.1 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.042 -1.27 . . . . 0.0 108.853 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.639 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 10.0 m-30 -105.94 154.77 20.11 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.254 -0.904 . . . . 0.0 108.825 179.748 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.52 HG11 ' N ' ' A' ' 24' ' ' ALA . 35.2 t -144.04 161.81 15.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.066 -1.021 . . . . 0.0 109.783 -179.273 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.527 ' HB1' ' CG2' ' A' ' 14' ' ' THR . . . -137.2 148.81 46.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.157 -0.964 . . . . 0.0 109.515 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.577 HD11 ' CD2' ' A' ' 9' ' ' TYR . 2.7 pt -126.47 161.59 32.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.006 -1.059 . . . . 0.0 109.044 179.642 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -79.37 143.79 26.34 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 124.04 2.14 8.59 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 87.5 29.23 22.33 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.477 ' HB2' HD13 ' A' ' 25' ' ' ILE . 1.7 mtpp -142.08 163.22 33.47 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.344 -1.092 . . . . 0.0 109.313 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.52 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 17.3 mt-10 -134.99 153.46 52.08 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.998 -1.063 . . . . 0.0 110.334 -179.786 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.522 ' HA3' ' CD1' ' A' ' 71' ' ' LEU . . . -107.3 -175.78 22.64 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 179.43 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.639 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.49 119.29 6.6 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.875 -1.368 . . . . 0.0 110.736 179.72 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.612 ' CG1' ' CD1' ' A' ' 50' ' ' LEU . 96.3 t -93.84 61.14 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.543 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 177.71 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.408 ' HB2' HD21 ' A' ' 32' ' ' LEU . 6.6 t-80 -47.7 156.45 0.31 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.906 -1.122 . . . . 0.0 108.417 -179.571 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.524 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 3.1 tp -49.62 -43.37 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.154 -0.966 . . . . 0.0 110.321 -179.536 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -81.25 34.29 0.36 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.182 -0.949 . . . . 0.0 110.94 -179.34 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.438 ' C ' HD13 ' A' ' 38' ' ' ILE . 71.4 mt-30 -150.81 58.4 0.92 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.709 -1.244 . . . . 0.0 110.14 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.628 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.7 mp -122.08 -97.86 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 120.984 -1.073 . . . . 0.0 109.569 179.746 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.532 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . -123.67 172.37 8.86 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.298 -0.876 . . . . 0.0 109.382 -179.809 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -51.62 -53.16 41.43 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.244 -0.91 . . . . 0.0 109.373 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -55.43 150.52 11.61 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.323 -0.861 . . . . 0.0 109.517 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 5.4 mmt180 -65.79 128.9 37.84 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.3 -0.875 . . . . 0.0 109.487 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.64 ' CG2' ' CZ ' ' A' ' 49' ' ' TYR . 66.9 t -108.65 55.75 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.287 -0.883 . . . . 0.0 109.046 179.641 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.428 ' O ' ' HG3' ' A' ' 44' ' ' GLU . 13.8 tp10 -45.38 -26.59 0.56 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.162 -0.961 . . . . 0.0 108.467 179.662 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.471 ' O ' HG11 ' A' ' 43' ' ' VAL . 4.2 mptt -108.0 105.63 15.5 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.28 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.544 HG23 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -75.22 -25.52 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.399 -0.813 . . . . 0.0 109.09 -179.681 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 62.7 p -77.55 6.22 7.55 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.413 -0.805 . . . . 0.0 109.464 179.181 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.459 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 58.9 m-20 -101.7 -32.32 10.37 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.426 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.64 ' CZ ' ' CG2' ' A' ' 43' ' ' VAL . 15.9 m-85 -92.45 -34.85 13.95 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.494 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.612 ' CD1' ' CG1' ' A' ' 33' ' ' VAL . 0.0 OUTLIER -100.0 156.62 17.06 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.322 -0.861 . . . . 0.0 110.571 -179.854 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.494 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 61.8 mt-30 -146.85 126.57 13.42 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' MET . . . . . 0.525 ' CG ' ' O ' ' A' ' 52' ' ' MET . 3.2 ptp -60.81 98.59 0.07 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.15 -0.969 . . . . 0.0 109.94 -179.654 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 132.21 -25.44 3.86 Favored Glycine 0 N--CA 1.493 2.45 0 C-N-CA 119.719 -1.229 . . . . 0.0 110.368 179.467 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 89.0 mm-40 -79.19 150.49 31.65 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.105 -1.232 . . . . 0.0 110.402 -179.358 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -116.9 113.71 22.84 Favored 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.088 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.423 ' O ' HG21 ' A' ' 56' ' ' VAL . 17.7 m -115.24 150.23 44.06 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.107 -0.996 . . . . 0.0 110.121 -179.205 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 36.2 Cg_endo -78.5 126.91 7.79 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.675 2.25 . . . . 0.0 110.24 179.744 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.493 HG21 ' O ' ' A' ' 9' ' ' TYR . 1.3 m -131.9 -172.74 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.148 -0.97 . . . . 0.0 109.722 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.524 ' O ' ' N ' ' A' ' 61' ' ' LEU . 9.8 mtmt -133.12 116.87 16.82 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.6 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.488 HG21 ' CG ' ' A' ' 9' ' ' TYR . 52.6 t -49.94 91.39 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.344 -0.848 . . . . 0.0 109.217 -179.744 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.592 ' O ' ' CG ' ' A' ' 62' ' ' GLU . 15.8 tp -64.93 -20.81 66.66 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.425 -0.797 . . . . 0.0 109.985 -179.379 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.592 ' CG ' ' O ' ' A' ' 61' ' ' LEU . 0.2 OUTLIER 89.35 -171.08 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.014 0 CA-C-O 121.219 0.533 . . . . 0.0 109.594 -179.73 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.512 ' CG2' ' O ' ' A' ' 68' ' ' ARG . 69.7 t -126.74 95.9 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.297 -0.877 . . . . 0.0 109.824 -179.759 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.425 ' C ' ' O ' ' A' ' 63' ' ' VAL . 0.0 OUTLIER -44.34 -73.15 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.236 -0.915 . . . . 0.0 108.886 179.498 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . 0.523 ' HG3' ' N ' ' A' ' 66' ' ' GLN . 8.2 ptm180 -76.47 -141.55 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.094 -1.004 . . . . 0.0 108.925 179.276 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . 0.523 ' N ' ' HG3' ' A' ' 65' ' ' ARG . 2.7 mt-30 -123.48 102.23 7.77 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.943 -1.098 . . . . 0.0 109.419 179.767 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -154.02 -100.02 0.18 Allowed Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.512 ' O ' ' CG2' ' A' ' 63' ' ' VAL . 0.1 OUTLIER -132.9 152.5 51.87 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.161 -1.199 . . . . 0.0 109.516 -179.893 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.469 ' HA ' HG22 ' A' ' 63' ' ' VAL . 1.3 mp -50.53 121.76 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.414 -0.804 . . . . 0.0 110.002 -179.529 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.455 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 7.4 mmt85 -90.38 116.31 28.23 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.2 -0.938 . . . . 0.0 109.106 179.408 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.522 ' CD1' ' HA3' ' A' ' 31' ' ' GLY . 11.1 mt -89.65 152.55 21.31 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.129 -0.982 . . . . 0.0 109.633 -179.754 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.45 ' HB2' ' O ' ' A' ' 59' ' ' LYS . 0.6 OUTLIER -115.95 93.68 4.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.301 -0.874 . . . . 0.0 109.838 -179.85 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.467 ' O ' ' O ' ' A' ' 74' ' ' LYS . 0.1 OUTLIER -48.8 141.14 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.202 -0.936 . . . . 0.0 109.251 179.762 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.467 ' O ' ' O ' ' A' ' 73' ' ' ILE . 0.1 OUTLIER -42.9 167.24 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.311 -0.868 . . . . 0.0 109.673 -179.789 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.464 ' CA ' ' OE1' ' A' ' 75' ' ' GLU . 0.1 OUTLIER 57.68 29.52 17.43 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.161 -0.962 . . . . 0.0 109.097 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.46 ' HB1' ' O ' ' A' ' 73' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.996 -1.002 . . . . 0.0 109.55 179.975 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.586 0 N-CA-C 109.419 -0.585 . . . . 0.0 109.419 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 2.4 tt0 60.21 -153.36 0.38 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.15 -0.969 . . . . 0.0 109.408 -179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.501 ' HB ' ' OH ' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -133.39 -161.73 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.171 -0.956 . . . . 0.0 109.611 -179.436 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.458 ' O ' ' HG3' ' A' ' 7' ' ' ARG . 1.3 tp10 -104.95 131.09 52.9 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.433 -0.792 . . . . 0.0 108.887 179.364 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.546 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 12.5 t -79.6 165.68 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.224 -0.923 . . . . 0.0 109.809 -179.532 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.546 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 96.37 -0.55 61.79 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 -179.753 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.458 ' HG3' ' O ' ' A' ' 4' ' ' GLU . 0.0 OUTLIER -110.33 164.13 12.97 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.147 -1.208 . . . . 0.0 109.593 -179.546 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.495 ' CG1' ' O ' ' A' ' 58' ' ' VAL . 97.3 t -90.18 135.52 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.345 -0.847 . . . . 0.0 108.756 179.388 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.538 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 6.4 m-85 -119.41 126.65 51.88 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.858 -1.151 . . . . 0.0 110.525 -179.673 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.429 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 0.2 OUTLIER -95.31 127.34 41.28 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 178.352 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -127.62 150.14 18.15 Favored Glycine 0 N--CA 1.486 2.025 0 C-N-CA 118.834 -1.651 . . . . 0.0 110.953 -178.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.507 ' O ' HG11 ' A' ' 23' ' ' VAL . 0.1 OUTLIER -89.8 163.21 15.14 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 178.624 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.535 ' CB ' ' O ' ' A' ' 51' ' ' GLN . 69.8 t -88.42 107.9 18.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 O-C-N 121.006 -1.059 . . . . 0.0 108.445 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.533 ' CG2' ' HB1' ' A' ' 24' ' ' ALA . 1.3 p -118.51 -0.52 11.38 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.544 -0.862 . . . . 0.0 110.167 -178.889 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.478 ' HG3' ' O ' ' A' ' 14' ' ' THR . 0.0 OUTLIER -167.96 148.04 4.95 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.987 -1.071 . . . . 0.0 109.985 179.739 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 30.6 mt -140.31 157.38 24.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.232 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.655 HG21 ' N ' ' A' ' 20' ' ' GLY . 0.6 OUTLIER -135.38 152.98 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.918 -1.114 . . . . 0.0 109.751 -179.321 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -60.41 -39.08 86.08 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.631 -1.293 . . . . 0.0 109.218 179.458 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.636 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 18.4 p90 -91.86 24.92 2.96 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.497 -0.752 . . . . 0.0 110.073 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.655 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 156.07 -152.78 24.19 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.881 -179.188 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.496 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -151.91 145.65 25.05 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.853 -1.38 . . . . 0.0 108.843 179.636 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.648 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 10.3 m-30 -107.26 160.37 15.65 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.35 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.548 ' CG1' ' N ' ' A' ' 24' ' ' ALA . 14.3 t -149.99 167.67 2.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.009 -1.057 . . . . 0.0 109.536 -179.228 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.561 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -131.62 147.43 52.52 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.137 -0.977 . . . . 0.0 109.278 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.492 HG13 ' O ' ' A' ' 29' ' ' LYS . 0.5 OUTLIER -109.54 -14.35 10.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 120.561 -1.337 . . . . 0.0 109.808 -179.995 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 25' ' ' ILE . . . 59.31 128.07 0.01 OUTLIER Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.37 2.02 58.61 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.491 ' O ' ' CB ' ' A' ' 29' ' ' LYS . . . -156.79 33.36 0.57 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.492 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER 74.71 -156.11 0.05 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.456 -1.026 . . . . 0.0 109.807 179.857 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.561 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 7.2 mt-10 -120.18 153.05 36.81 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 120.814 -1.179 . . . . 0.0 110.811 -179.393 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.448 ' HA3' ' CD1' ' A' ' 71' ' ' LEU . . . -99.1 -172.8 31.39 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 108.555 -1.818 . . . . 0.0 108.555 179.061 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.648 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.83 120.19 6.85 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.824 -1.397 . . . . 0.0 111.082 179.6 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.534 ' CG2' ' CG2' ' A' ' 23' ' ' VAL . 48.6 t -95.15 61.79 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 177.276 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.415 ' HB2' HD21 ' A' ' 32' ' ' LEU . 3.1 t-160 -48.77 157.1 0.41 Allowed 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.785 -1.197 . . . . 0.0 108.908 -179.131 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.539 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.4 OUTLIER -49.62 -47.09 21.3 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.297 -0.877 . . . . 0.0 110.237 -179.58 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.442 ' O ' ' CD ' ' A' ' 37' ' ' GLN . 0.6 OUTLIER -80.48 33.33 0.3 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.251 -0.906 . . . . 0.0 110.972 -179.133 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.448 ' C ' HD13 ' A' ' 38' ' ' ILE . 44.7 mm-40 -148.26 57.99 1.08 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.823 -1.173 . . . . 0.0 109.735 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.626 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.5 mp -116.84 -99.56 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 120.942 -1.099 . . . . 0.0 110.075 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.536 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . -117.37 43.55 2.31 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.272 -0.892 . . . . 0.0 109.649 -179.341 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.45 ' O ' ' OD1' ' A' ' 40' ' ' ASP . 2.1 p30 42.62 27.57 0.1 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.39 -0.819 . . . . 0.0 109.074 -179.55 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.437 ' N ' ' O ' ' A' ' 39' ' ' ALA . 1.8 ttmt -124.35 -178.68 4.18 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 3.8 mtp180 -77.35 77.5 3.88 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.205 -0.934 . . . . 0.0 109.639 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.626 ' CG1' ' CD1' ' A' ' 49' ' ' TYR . 72.1 t -87.73 49.58 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 O-C-N 121.103 -0.998 . . . . 0.0 108.322 179.266 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -44.4 -24.95 0.21 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.349 -0.844 . . . . 0.0 109.032 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.464 ' HD2' ' OD2' ' A' ' 48' ' ' ASP . 68.7 mttt -110.8 104.44 13.07 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.454 -0.779 . . . . 0.0 109.14 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.573 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -72.19 -23.34 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.194 -0.941 . . . . 0.0 108.552 179.857 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 24.2 p -77.87 4.0 13.02 Favored 'General case' 0 C--N 1.3 -1.549 0 C-N-CA 119.827 -0.749 . . . . 0.0 109.294 179.21 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.464 ' OD2' ' HD2' ' A' ' 45' ' ' LYS . 1.8 m-20 -102.42 -33.78 9.41 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.151 -0.968 . . . . 0.0 108.824 179.598 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.626 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 23.5 m-85 -92.88 -33.05 14.37 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.449 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.532 HD12 ' CG2' ' A' ' 13' ' ' VAL . 0.2 OUTLIER -102.23 138.19 39.49 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.973 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.535 ' O ' ' CB ' ' A' ' 13' ' ' VAL . 0.0 OUTLIER -142.32 142.35 32.5 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.48 -0.763 . . . . 0.0 109.41 -179.788 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' MET . . . . . 0.471 ' HA ' HG13 ' A' ' 13' ' ' VAL . 0.1 OUTLIER -59.6 131.49 51.09 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.353 -0.842 . . . . 0.0 110.666 -179.394 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 90.45 -16.75 56.99 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.945 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . 0.412 ' CD ' ' HB2' ' A' ' 51' ' ' GLN . 6.7 mt-30 -70.46 169.4 14.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.173 -1.192 . . . . 0.0 109.886 -179.642 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . 0.467 ' OE1' ' HE3' ' A' ' 12' ' ' LYS . 3.2 mt-10 -139.7 132.87 29.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.193 -0.942 . . . . 0.0 108.556 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.1 m -141.05 136.83 16.34 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 120.916 -1.115 . . . . 0.0 110.402 -179.4 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.429 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.3 Cg_endo -80.2 144.4 16.48 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 C-N-CA 122.524 2.149 . . . . 0.0 109.065 178.785 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.495 ' O ' ' CG1' ' A' ' 8' ' ' VAL . 1.5 m -144.13 -174.8 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 120.918 -1.114 . . . . 0.0 110.062 -179.612 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 4.1 mttt -121.9 135.14 54.87 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.516 -0.74 . . . . 0.0 109.357 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.538 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 58.9 t -64.55 100.08 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.275 -0.891 . . . . 0.0 109.002 179.734 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.616 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 2.8 tp -75.17 -15.23 60.58 Favored 'General case' 0 C--N 1.308 -1.239 0 O-C-N 121.216 -0.928 . . . . 0.0 109.723 -179.542 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.616 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 8.4 mt-10 105.88 -178.95 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.258 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -179.333 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.431 HG13 ' HA2' ' A' ' 67' ' ' GLY . 0.4 OUTLIER -111.01 169.85 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.043 -1.036 . . . . 0.0 109.671 -179.539 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.442 ' OD2' ' HB2' ' A' ' 68' ' ' ARG . 11.1 p30 -87.67 -167.86 2.03 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.218 -0.927 . . . . 0.0 109.565 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -68.68 -10.71 57.91 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -0.864 . . . . 0.0 109.793 -179.834 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 29.3 mt-30 -103.49 -95.44 0.31 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.201 -0.937 . . . . 0.0 109.549 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.431 ' HA2' HG13 ' A' ' 63' ' ' VAL . . . -169.05 49.51 0.22 Allowed Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.732 -1.347 . . . . 0.0 109.732 -179.999 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.442 ' HB2' ' OD2' ' A' ' 64' ' ' ASP . 0.5 OUTLIER -107.7 94.43 5.08 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.172 -1.193 . . . . 0.0 109.3 179.842 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.488 ' CD1' ' HB3' ' A' ' 29' ' ' LYS . 2.9 mt -42.87 108.22 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.359 -0.838 . . . . 0.0 109.634 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.5 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 0.0 OUTLIER -91.08 95.91 10.33 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.285 -0.884 . . . . 0.0 109.817 179.995 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.448 ' CD1' ' HA3' ' A' ' 31' ' ' GLY . 20.6 mt -93.35 153.54 18.48 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.206 -0.934 . . . . 0.0 108.916 179.577 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.413 ' OG ' HD12 ' A' ' 61' ' ' LEU . 0.4 OUTLIER -121.28 101.46 7.65 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.15 -0.969 . . . . 0.0 110.08 -179.622 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.526 ' CG2' ' O ' ' A' ' 38' ' ' ILE . 0.1 OUTLIER -45.28 137.96 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.2 -0.937 . . . . 0.0 108.96 179.838 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.02 151.39 1.29 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.404 -0.81 . . . . 0.0 109.871 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 57.19 40.11 28.33 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -0.892 . . . . 0.0 109.604 179.762 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.44 ' HB3' ' O ' ' A' ' 73' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 118.019 -0.991 . . . . 0.0 109.453 179.824 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.269 0.557 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.3 pt-20 -81.79 -165.8 1.06 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.159 -0.963 . . . . 0.0 109.542 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.592 ' N ' ' CD1' ' A' ' 3' ' ' ILE . 0.1 OUTLIER -144.86 -179.16 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 O-C-N 121.288 -0.883 . . . . 0.0 109.518 -179.618 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -146.32 -174.37 4.43 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.433 -0.792 . . . . 0.0 109.349 179.858 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.489 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 4.6 t -76.04 162.86 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.175 -0.953 . . . . 0.0 109.135 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.489 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 77.43 -1.63 65.13 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 -179.369 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.503 ' CD ' HG21 ' A' ' 3' ' ' ILE . 3.3 ttm105 -105.31 164.33 11.93 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.171 -1.193 . . . . 0.0 109.724 -179.705 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.418 HG12 ' O ' ' A' ' 58' ' ' VAL . 89.9 t -89.93 131.79 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.26 -0.9 . . . . 0.0 108.933 179.512 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.443 ' CZ ' ' HB ' ' A' ' 3' ' ' ILE . 4.0 m-85 -107.78 179.33 4.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.183 -0.948 . . . . 0.0 110.031 -179.501 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -121.19 101.19 7.49 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 178.012 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.79 115.95 4.35 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 119.85 -1.167 . . . . 0.0 111.099 -177.865 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.509 ' O ' HG12 ' A' ' 23' ' ' VAL . 5.7 mtmt -88.66 152.04 22.07 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 107.208 -1.404 . . . . 0.0 107.208 178.075 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.498 ' HB ' ' O ' ' A' ' 51' ' ' GLN . 34.9 t -87.34 110.76 20.97 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 O-C-N 120.751 -1.218 . . . . 0.0 109.142 -179.07 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.529 ' O ' ' CG ' ' A' ' 15' ' ' ARG . 0.5 OUTLIER -120.7 5.2 10.54 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.442 -0.786 . . . . 0.0 109.807 -179.227 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.529 ' CG ' ' O ' ' A' ' 14' ' ' THR . 3.5 mpp_? -176.15 152.5 1.16 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.047 -1.033 . . . . 0.0 110.225 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.507 HD12 HG22 ' A' ' 16' ' ' ILE . 35.0 mt -142.19 159.01 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 179.209 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.624 HG21 ' N ' ' A' ' 20' ' ' GLY . 0.7 OUTLIER -137.19 153.65 29.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 120.82 -1.175 . . . . 0.0 109.872 -179.243 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -59.13 -40.06 84.29 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.873 -1.142 . . . . 0.0 109.12 179.248 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.623 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 20.1 p90 -91.66 27.71 1.96 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.431 -0.793 . . . . 0.0 110.148 -179.739 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.624 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 151.82 -148.64 19.87 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 119.033 -1.556 . . . . 0.0 110.899 -179.559 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.503 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -155.32 148.46 24.71 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.241 -1.153 . . . . 0.0 108.846 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.652 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 11.6 m-30 -107.92 160.9 15.41 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.58 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.515 HG11 ' N ' ' A' ' 24' ' ' ALA . 20.4 t -149.39 162.25 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.129 -0.982 . . . . 0.0 109.49 -179.522 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.525 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -133.73 145.44 49.86 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.122 -0.986 . . . . 0.0 109.811 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.515 ' O ' ' N ' ' A' ' 27' ' ' GLY . 3.2 pt -120.24 153.46 23.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 O-C-N 121.065 -1.022 . . . . 0.0 109.273 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.458 ' C ' ' O ' ' A' ' 25' ' ' ILE . . . 38.81 -94.49 0.01 OUTLIER Glycine 0 N--CA 1.494 2.563 0 N-CA-C 109.919 -1.272 . . . . 0.0 109.919 179.469 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.515 ' N ' ' O ' ' A' ' 25' ' ' ILE . . . -172.63 -33.48 0.03 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.859 -1.297 . . . . 0.0 109.859 179.816 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -84.3 -9.41 81.97 Favored Glycine 0 N--CA 1.491 2.329 0 O-C-N 121.162 -1.199 . . . . 0.0 110.214 -179.69 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.461 ' O ' HG13 ' A' ' 25' ' ' ILE . 2.5 mmmt -138.68 157.13 46.69 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.007 -1.29 . . . . 0.0 109.776 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.525 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -132.56 151.44 51.93 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.155 -0.966 . . . . 0.0 110.43 -179.861 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.533 ' CA ' HD13 ' A' ' 71' ' ' LEU . . . -104.72 -175.64 24.81 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 179.309 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.652 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -149.43 120.59 7.78 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.846 -1.385 . . . . 0.0 110.724 179.753 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.528 HG22 ' CD1' ' A' ' 50' ' ' LEU . 88.3 t -93.67 60.1 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 177.85 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.42 ' C ' ' O ' ' A' ' 33' ' ' VAL . 5.6 t-80 -47.6 158.42 0.19 Allowed 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.779 -1.201 . . . . 0.0 108.383 -179.533 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.539 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.8 tp -47.76 -52.94 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.081 -1.012 . . . . 0.0 110.07 -179.276 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.439 ' C ' ' HG2' ' A' ' 37' ' ' GLN . 0.0 OUTLIER -81.48 39.41 0.53 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.091 -1.005 . . . . 0.0 110.375 -179.631 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.454 ' C ' HD13 ' A' ' 38' ' ' ILE . 11.9 mm100 -144.83 50.41 1.26 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.926 -1.109 . . . . 0.0 109.641 -179.882 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.648 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.6 mp -120.08 -99.79 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 120.765 -1.209 . . . . 0.0 110.675 -179.484 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.511 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . -111.72 -151.69 0.49 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.211 -0.931 . . . . 0.0 110.269 -178.622 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -62.13 -65.15 0.73 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.559 -0.713 . . . . 0.0 109.918 -179.628 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.48 ' HD2' ' OH ' ' A' ' 49' ' ' TYR . 4.6 ptpt -60.96 173.36 0.79 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.121 -0.987 . . . . 0.0 109.318 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 6.0 mmm180 -78.7 -2.06 37.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.295 -0.878 . . . . 0.0 110.138 -179.156 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.613 ' CG2' ' CZ ' ' A' ' 49' ' ' TYR . 24.4 t 54.76 76.09 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 120.998 -1.064 . . . . 0.0 108.475 -179.527 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -46.97 -22.06 0.28 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.328 -0.858 . . . . 0.0 109.718 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.541 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.5 OUTLIER -128.28 117.78 22.09 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.113 -0.992 . . . . 0.0 109.858 -179.805 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.538 HG22 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -77.65 -25.81 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.199 -0.938 . . . . 0.0 108.701 179.485 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 63.5 p -77.1 3.73 11.85 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.383 -0.823 . . . . 0.0 109.307 179.237 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.404 ' OD2' ' CB ' ' A' ' 45' ' ' LYS . 99.1 m-20 -101.86 -24.36 14.04 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.482 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.648 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 22.1 m-85 -100.29 -25.87 14.1 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.733 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.528 ' CD1' HG22 ' A' ' 33' ' ' VAL . 0.2 OUTLIER -111.25 142.74 43.06 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.909 . . . . 0.0 109.391 179.465 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.498 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.2 OUTLIER -141.72 133.41 27.07 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.537 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 9.9 mtm -54.78 97.49 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.137 -0.977 . . . . 0.0 110.077 -179.487 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.9 -36.0 2.51 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 119.847 -1.168 . . . . 0.0 110.304 179.341 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 5.2 mm-40 -57.5 162.47 2.89 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.066 -1.256 . . . . 0.0 109.695 -179.677 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . 0.404 ' HG3' ' HA ' ' A' ' 12' ' ' LYS . 0.7 OUTLIER -137.55 125.93 23.34 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.412 -0.805 . . . . 0.0 109.184 179.819 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.0 m -130.25 139.26 35.09 Favored Pre-proline 0 N--CA 1.488 1.451 0 O-C-N 121.063 -1.023 . . . . 0.0 109.606 -179.837 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.453 ' O ' ' HB2' ' A' ' 74' ' ' LYS . 35.5 Cg_endo -78.44 134.13 12.33 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.503 2.135 . . . . 0.0 110.352 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.47 ' CG2' ' HB3' ' A' ' 71' ' ' LEU . 0.9 OUTLIER -127.41 179.17 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.152 -0.968 . . . . 0.0 109.782 -179.922 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.427 ' O ' ' N ' ' A' ' 61' ' ' LEU . 0.0 OUTLIER -117.01 122.19 43.51 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.639 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.44 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 91.2 t -53.25 94.95 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.189 -0.944 . . . . 0.0 109.528 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.604 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 13.4 tp -67.68 -14.97 63.39 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.279 -0.888 . . . . 0.0 109.221 179.793 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.604 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 0.6 OUTLIER 96.17 -171.29 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.005 0 CA-C-O 121.244 0.545 . . . . 0.0 109.614 -179.916 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.442 HG23 ' HA ' ' A' ' 69' ' ' ILE . 2.1 t -133.41 175.69 10.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.308 -0.87 . . . . 0.0 109.759 -179.418 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 3.1 p-10 -108.15 -164.46 0.96 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.307 -0.87 . . . . 0.0 109.358 179.962 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 11.5 mmm180 -79.21 7.37 7.75 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.036 -1.04 . . . . 0.0 109.822 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -99.32 -46.59 5.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.172 -0.955 . . . . 0.0 109.387 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 120.78 23.44 2.78 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.426 ' O ' HG11 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -91.07 99.49 12.51 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.327 -1.102 . . . . 0.0 109.334 -179.949 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.456 HD11 ' O ' ' A' ' 30' ' ' GLU . 38.2 mt -46.17 121.19 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.18 -0.95 . . . . 0.0 109.412 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.499 ' CB ' ' O ' ' A' ' 62' ' ' GLU . 0.1 OUTLIER -108.14 103.69 12.95 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.188 -0.945 . . . . 0.0 109.57 -179.944 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.533 HD13 ' CA ' ' A' ' 31' ' ' GLY . 81.4 mt -105.33 155.24 19.28 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.16 -0.963 . . . . 0.0 108.842 179.686 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.41 ' O ' ' C ' ' A' ' 73' ' ' ILE . 0.3 OUTLIER -121.32 97.21 5.41 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.115 -0.99 . . . . 0.0 110.362 -179.204 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.456 HG23 ' O ' ' A' ' 38' ' ' ILE . 0.2 OUTLIER -42.67 123.02 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.317 -0.864 . . . . 0.0 109.099 179.605 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.453 ' HB2' ' O ' ' A' ' 57' ' ' PRO . 0.8 OUTLIER -67.61 167.51 12.9 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.208 -0.933 . . . . 0.0 109.768 -179.651 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.406 ' O ' ' C ' ' A' ' 76' ' ' ALA . 6.2 mt-10 -64.09 -15.51 59.77 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.434 -0.791 . . . . 0.0 109.402 179.82 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.406 ' C ' ' O ' ' A' ' 75' ' ' GLU . . . . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 118.019 -0.991 . . . . 0.0 109.67 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.516 ' O ' ' CB ' ' A' ' 3' ' ' ILE . 3.3 mt-10 -103.64 -170.84 1.84 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.247 -0.908 . . . . 0.0 109.573 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.516 ' CB ' ' O ' ' A' ' 2' ' ' GLU . 0.3 OUTLIER 75.09 134.2 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 119.228 -0.989 . . . . 0.0 108.893 -179.444 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -123.53 157.48 33.5 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.171 -0.956 . . . . 0.0 110.085 -179.628 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.551 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 19.0 t -64.08 167.98 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.469 -0.769 . . . . 0.0 109.15 179.764 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.551 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 74.67 2.77 65.15 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 -179.276 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 1.1 ttm180 -88.96 -176.83 5.31 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.27 -1.135 . . . . 0.0 109.211 179.92 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.481 ' HA ' ' O ' ' A' ' 58' ' ' VAL . 55.3 t -102.5 119.54 50.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.148 -0.97 . . . . 0.0 108.945 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.646 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 3.0 m-85 -104.75 129.72 52.94 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.085 -1.009 . . . . 0.0 109.956 -179.561 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.5 m -74.49 98.08 3.25 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 178.398 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -77.73 120.45 5.51 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 -178.396 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.516 ' O ' ' CG1' ' A' ' 23' ' ' VAL . 0.0 OUTLIER -92.47 150.51 20.74 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.71 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.54 ' CG1' HD11 ' A' ' 50' ' ' LEU . 20.7 t -89.49 106.12 16.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 120.908 -1.12 . . . . 0.0 108.991 -179.905 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.553 ' CG2' ' HB1' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -120.59 3.06 10.71 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.234 -0.916 . . . . 0.0 109.67 -179.506 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.514 ' CG ' ' O ' ' A' ' 14' ' ' THR . 5.0 mpp_? -173.31 153.48 2.43 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.174 -0.954 . . . . 0.0 109.821 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.442 HG21 ' N ' ' A' ' 17' ' ' VAL . 14.7 mt -140.84 159.76 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.562 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.651 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -139.67 155.55 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 120.822 -1.174 . . . . 0.0 110.285 -179.746 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -59.06 -44.48 91.84 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.967 -1.083 . . . . 0.0 109.803 179.449 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.651 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 8.2 p90 -90.42 24.62 2.53 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.107 -0.996 . . . . 0.0 110.377 -179.389 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.629 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 158.4 -152.28 23.41 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 118.977 -1.582 . . . . 0.0 111.044 -179.583 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.499 ' CB ' ' HB ' ' A' ' 33' ' ' VAL . . . -151.36 146.9 26.32 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.214 -1.168 . . . . 0.0 108.906 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.63 ' CE1' HD12 ' A' ' 32' ' ' LEU . 10.3 m-30 -106.73 157.93 17.35 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.259 -0.901 . . . . 0.0 108.992 179.754 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.647 HG11 ' N ' ' A' ' 24' ' ' ALA . 42.3 t -150.58 154.66 8.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 120.945 -1.097 . . . . 0.0 109.674 -178.834 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.647 ' N ' HG11 ' A' ' 23' ' ' VAL . . . -121.87 138.21 54.48 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.89 -1.131 . . . . 0.0 109.319 179.662 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.466 HG13 ' O ' ' A' ' 29' ' ' LYS . 2.5 pt -114.5 -172.4 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.166 -0.958 . . . . 0.0 109.239 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -91.35 178.4 41.53 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 179.625 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 87.48 -16.84 47.37 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 104.38 12.38 29.07 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.619 -1.393 . . . . 0.0 109.619 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.485 ' HB3' ' CD1' ' A' ' 69' ' ' ILE . 4.7 mttm -115.97 159.93 20.94 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.235 -1.156 . . . . 0.0 109.069 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.505 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 0.4 OUTLIER -119.28 141.13 49.24 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.063 -1.023 . . . . 0.0 110.067 -179.757 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.53 ' HA3' ' CD1' ' A' ' 71' ' ' LEU . . . -91.93 -177.7 42.21 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.03 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.63 HD12 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -149.93 120.14 7.29 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 120.796 -1.414 . . . . 0.0 110.842 179.687 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.499 ' HB ' ' CB ' ' A' ' 21' ' ' ALA . 93.4 t -92.84 60.1 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 177.714 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.461 ' HB2' HD21 ' A' ' 32' ' ' LEU . 3.0 t-80 -48.76 156.51 0.47 Allowed 'General case' 0 N--CA 1.486 1.346 0 O-C-N 120.895 -1.128 . . . . 0.0 108.681 -179.375 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.537 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.7 tp -48.45 -48.92 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.296 -0.878 . . . . 0.0 110.623 -179.385 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.463 ' O ' ' HG2' ' A' ' 37' ' ' GLN . 0.5 OUTLIER -81.25 40.93 0.58 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.145 -0.972 . . . . 0.0 110.693 -179.396 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.463 ' HG2' ' O ' ' A' ' 36' ' ' SER . 12.0 mt-30 -150.95 51.73 0.86 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.713 -1.242 . . . . 0.0 110.047 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.651 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.7 mp -123.04 -97.91 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.886 -1.134 . . . . 0.0 110.094 -179.889 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.579 ' O ' ' CB ' ' A' ' 40' ' ' ASP . . . -103.3 59.33 0.76 Allowed 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.432 -0.792 . . . . 0.0 108.999 -179.493 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.579 ' CB ' ' O ' ' A' ' 39' ' ' ALA . 9.8 t0 83.61 -43.05 0.09 Allowed 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -178.96 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.525 ' CB ' ' O ' ' A' ' 40' ' ' ASP . 0.2 OUTLIER 162.49 -20.05 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.364 -0.835 . . . . 0.0 110.044 179.825 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.454 ' O ' ' OH ' ' A' ' 49' ' ' TYR . 0.0 OUTLIER -73.63 80.62 1.51 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.185 -0.947 . . . . 0.0 110.764 -179.171 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.601 ' HA ' ' CE1' ' A' ' 49' ' ' TYR . 50.1 t -140.32 82.14 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.106 -0.996 . . . . 0.0 109.169 178.839 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 43' ' ' VAL . 29.3 tt0 -41.83 -29.53 0.21 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.371 -0.83 . . . . 0.0 109.982 -179.61 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.483 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 1.1 mmtp -150.45 141.8 23.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.077 -1.015 . . . . 0.0 109.792 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.541 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -74.12 -25.82 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 O-C-N 121.202 -0.936 . . . . 0.0 108.664 179.413 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.8 p -78.38 3.18 16.38 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.745 -0.782 . . . . 0.0 109.108 179.372 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.421 ' OD2' ' HB2' ' A' ' 45' ' ' LYS . 4.7 m-20 -101.82 -29.4 11.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.171 -0.956 . . . . 0.0 108.749 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.651 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 20.4 m-85 -98.29 -27.5 14.1 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.571 -0.705 . . . . 0.0 109.129 179.765 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.54 HD11 ' CG1' ' A' ' 13' ' ' VAL . 0.2 OUTLIER -104.9 141.03 37.26 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.603 -0.686 . . . . 0.0 109.35 -179.73 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.537 ' HB3' ' CG ' ' A' ' 54' ' ' GLN . 43.6 tt0 -136.46 132.34 35.24 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.488 -0.757 . . . . 0.0 109.641 -179.712 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' MET . . . . . 0.481 ' HA ' HG13 ' A' ' 13' ' ' VAL . 4.7 mtt -65.26 112.11 3.31 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.354 -0.841 . . . . 0.0 109.605 179.975 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 113.71 -23.07 13.78 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . 0.537 ' CG ' ' HB3' ' A' ' 51' ' ' GLN . 57.0 mm-40 -79.37 167.5 20.78 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.251 -1.147 . . . . 0.0 109.583 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . 0.5 ' N ' ' OE1' ' A' ' 55' ' ' GLU . 1.3 mp0 -133.36 147.59 51.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.312 -0.867 . . . . 0.0 109.177 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 19.1 m -144.74 141.21 17.27 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.156 -0.965 . . . . 0.0 109.771 -179.859 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.54 126.39 7.45 Favored 'Trans proline' 0 C--N 1.312 -1.391 0 C-N-CA 122.575 2.183 . . . . 0.0 110.238 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.481 ' O ' ' HA ' ' A' ' 8' ' ' VAL . 1.0 OUTLIER -132.31 -170.98 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.191 -0.943 . . . . 0.0 109.516 179.843 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.514 ' O ' ' N ' ' A' ' 61' ' ' LEU . 29.6 mtpt -134.43 127.01 30.68 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.414 -0.804 . . . . 0.0 109.459 179.801 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.646 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 26.2 t -53.42 89.9 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.281 -0.887 . . . . 0.0 109.018 179.688 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.595 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 16.2 tp -58.65 -19.6 40.6 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.241 -0.912 . . . . 0.0 109.605 -179.694 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.595 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 2.6 pt-20 95.54 -163.05 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.134 0 CA-C-O 121.428 0.632 . . . . 0.0 109.869 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.563 ' N ' ' CG ' ' A' ' 62' ' ' GLU . 55.3 t -142.42 147.6 20.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.561 -0.712 . . . . 0.0 109.453 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -128.15 -151.31 0.47 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.178 -0.952 . . . . 0.0 109.263 179.837 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 22.5 mtp180 -51.54 -57.23 9.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.166 -0.959 . . . . 0.0 108.976 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 6.6 mt-30 -118.99 124.85 47.99 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.289 -0.882 . . . . 0.0 108.941 179.46 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.467 ' O ' ' CG1' ' A' ' 63' ' ' VAL . . . 143.61 105.27 0.51 Allowed Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 -179.753 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.437 ' O ' ' C ' ' A' ' 69' ' ' ILE . 61.1 mtt-85 -88.79 120.98 30.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.338 -1.095 . . . . 0.0 109.206 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.485 ' CD1' ' HB3' ' A' ' 29' ' ' LYS . 58.1 mt 42.82 84.36 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.296 -0.878 . . . . 0.0 109.352 -179.863 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.487 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 0.3 OUTLIER -89.92 111.34 22.37 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.901 -1.125 . . . . 0.0 108.981 179.893 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.53 ' CD1' ' HA3' ' A' ' 31' ' ' GLY . 18.8 mt -100.24 149.94 23.05 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.148 -0.97 . . . . 0.0 109.549 -179.797 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.443 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.3 OUTLIER -114.67 106.7 14.54 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.375 -0.828 . . . . 0.0 109.565 -179.742 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -65.84 135.24 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.261 -0.899 . . . . 0.0 109.229 -179.996 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.4 -149.54 0.05 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.315 -0.866 . . . . 0.0 109.228 179.715 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -64.45 -44.2 91.88 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.154 -0.966 . . . . 0.0 109.497 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.515 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.483 -179.87 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.605 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.45 ' C ' ' CD1' ' A' ' 3' ' ' ILE . 0.5 OUTLIER 63.66 -175.76 0.16 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.244 -0.91 . . . . 0.0 109.396 -179.892 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.587 ' CG2' ' CZ ' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -134.62 123.8 42.85 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 O-C-N 121.12 -0.988 . . . . 0.0 110.238 -179.038 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -98.55 144.61 27.68 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.521 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.527 ' CG2' ' HA ' ' A' ' 62' ' ' GLU . 7.1 t -75.71 158.1 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.111 -0.993 . . . . 0.0 109.654 -179.667 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.417 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 76.62 2.15 74.27 Favored Glycine 0 N--CA 1.487 2.096 0 N-CA-C 109.16 -1.576 . . . . 0.0 109.16 -179.537 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 3.8 ttt-85 -97.75 179.95 4.65 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.292 -1.122 . . . . 0.0 109.67 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.524 HG11 ' N ' ' A' ' 9' ' ' TYR . 71.6 t -119.36 143.68 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.275 -0.89 . . . . 0.0 109.019 179.821 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.587 ' CZ ' ' CG2' ' A' ' 3' ' ' ILE . 11.5 m-85 -136.53 129.51 31.06 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.059 -1.026 . . . . 0.0 110.77 -179.521 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.454 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 0.4 OUTLIER -97.58 112.05 24.07 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.149 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -113.48 151.97 18.16 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.134 -1.508 . . . . 0.0 110.59 -178.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.525 ' HG2' ' CG ' ' A' ' 55' ' ' GLU . 3.4 mtmm -89.63 162.32 15.68 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.876 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.5 HG13 ' HA ' ' A' ' 52' ' ' MET . 60.3 t -88.16 97.56 6.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 120.994 -1.066 . . . . 0.0 108.203 179.651 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.511 HG22 ' CB ' ' A' ' 24' ' ' ALA . 1.6 p -103.43 -4.64 23.8 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.475 -0.765 . . . . 0.0 110.426 -178.642 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.526 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -163.37 153.8 15.96 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.913 -1.117 . . . . 0.0 110.584 -179.699 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.449 HG22 HD11 ' A' ' 16' ' ' ILE . 19.8 mt -143.21 155.41 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 178.931 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.645 HG21 ' N ' ' A' ' 20' ' ' GLY . 0.6 OUTLIER -135.54 154.96 35.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.837 -1.164 . . . . 0.0 110.055 -178.934 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 12.0 t0 -60.5 -40.44 91.41 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.687 -1.258 . . . . 0.0 109.323 179.43 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.643 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 15.5 p90 -90.2 23.14 2.98 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.356 -0.84 . . . . 0.0 110.289 -179.743 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.645 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 156.23 -149.42 20.35 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 119.294 -1.432 . . . . 0.0 110.975 -179.654 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.536 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -153.54 146.85 24.79 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.042 -1.27 . . . . 0.0 108.99 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.647 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 11.2 m-30 -109.35 155.89 20.67 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.395 -0.816 . . . . 0.0 109.175 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.591 ' CG2' ' CG2' ' A' ' 33' ' ' VAL . 7.0 t -144.23 168.23 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 120.93 -1.106 . . . . 0.0 109.145 179.795 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.566 ' N ' ' CG1' ' A' ' 23' ' ' VAL . . . -138.05 150.92 47.36 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.06 -1.025 . . . . 0.0 110.743 -179.328 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.459 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.8 pt -122.0 111.04 29.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.182 -0.949 . . . . 0.0 108.951 179.315 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.85 -86.08 1.27 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -179.43 -38.99 0.07 OUTLIER Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.463 ' O ' ' OE2' ' A' ' 30' ' ' GLU . . . -80.23 -45.79 7.94 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.474 ' HB3' HD12 ' A' ' 69' ' ' ILE . 0.0 OUTLIER -99.53 150.37 22.28 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.186 -1.185 . . . . 0.0 109.124 -179.997 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.534 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 5.2 mp0 -131.78 155.04 48.44 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 120.84 -1.162 . . . . 0.0 111.081 -179.468 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.464 ' HA3' HD11 ' A' ' 71' ' ' LEU . . . -105.72 -174.0 23.82 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 108.352 -1.899 . . . . 0.0 108.352 179.141 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.647 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.51 122.89 8.42 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.716 -1.461 . . . . 0.0 111.054 179.674 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.591 ' CG2' ' CG2' ' A' ' 23' ' ' VAL . 14.9 t -99.62 64.73 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 177.333 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.452 ' HB3' ' HG3' ' A' ' 37' ' ' GLN . 3.6 t-80 -49.58 162.23 0.17 Allowed 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.835 -1.165 . . . . 0.0 108.746 -179.474 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.557 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.3 OUTLIER -52.79 -52.05 31.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.214 -0.929 . . . . 0.0 110.329 -179.269 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.445 ' C ' ' HG2' ' A' ' 37' ' ' GLN . 11.5 m -81.42 32.46 0.35 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 120.994 -1.066 . . . . 0.0 110.764 -179.351 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.555 ' NE2' ' NH2' ' A' ' 70' ' ' ARG . 0.3 OUTLIER -138.24 48.24 1.97 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.695 -1.253 . . . . 0.0 109.978 -179.955 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.64 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.5 mp -119.39 -99.39 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 120.956 -1.09 . . . . 0.0 110.019 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.538 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . -97.68 -141.25 0.3 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.317 -0.864 . . . . 0.0 109.09 -179.266 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.487 ' O ' ' HB2' ' A' ' 41' ' ' LYS . 0.2 OUTLIER -44.39 -57.21 3.67 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.054 -1.028 . . . . 0.0 108.994 179.791 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.487 ' HB2' ' O ' ' A' ' 40' ' ' ASP . 0.4 OUTLIER 173.32 -30.34 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.5 -0.75 . . . . 0.0 109.148 -179.994 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.438 ' O ' ' C ' ' A' ' 43' ' ' VAL . 11.5 mtm180 -48.03 -95.59 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.368 -0.833 . . . . 0.0 110.034 -179.524 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.615 ' HA ' ' CE1' ' A' ' 49' ' ' TYR . 90.0 t 41.78 49.16 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.334 -0.854 . . . . 0.0 109.06 -179.055 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.412 ' C ' ' O ' ' A' ' 43' ' ' VAL . 11.1 mt-10 -41.31 -30.66 0.19 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.556 -0.715 . . . . 0.0 109.506 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.479 ' O ' HG11 ' A' ' 43' ' ' VAL . 14.1 mttt -122.21 130.05 52.83 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.35 -0.844 . . . . 0.0 109.066 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.518 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -78.62 -24.31 13.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.19 -0.944 . . . . 0.0 108.932 -179.976 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 3.2 p -76.78 4.38 9.81 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.328 -0.858 . . . . 0.0 109.48 179.388 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.476 ' N ' ' OD1' ' A' ' 48' ' ' ASP . 2.0 m-20 -99.55 -37.43 9.17 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.156 -0.965 . . . . 0.0 108.727 179.515 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.64 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 18.0 m-85 -90.19 -32.69 16.5 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.683 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.509 ' CD1' HG22 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -99.21 140.38 33.45 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.532 -0.73 . . . . 0.0 109.223 179.938 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.457 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 45.6 mt-30 -136.35 112.56 9.8 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.463 -0.773 . . . . 0.0 109.253 -179.821 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' MET . . . . . 0.5 ' HA ' HG13 ' A' ' 13' ' ' VAL . 0.7 OUTLIER -52.49 94.59 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.277 -0.889 . . . . 0.0 110.176 -179.769 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 143.37 -38.88 1.35 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.771 -1.204 . . . . 0.0 110.428 179.508 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 22.4 mt-30 -77.36 169.17 18.8 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.128 -1.219 . . . . 0.0 109.782 -179.42 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . 0.525 ' CG ' ' HG2' ' A' ' 12' ' ' LYS . 3.6 mt-10 -122.81 125.32 45.22 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.297 -0.877 . . . . 0.0 109.217 179.739 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.419 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 22.9 m -117.49 142.64 30.73 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.187 -0.946 . . . . 0.0 109.97 -179.68 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.454 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.3 Cg_endo -80.28 153.66 21.43 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 122.753 2.302 . . . . 0.0 110.105 179.669 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.535 ' CG2' HD23 ' A' ' 71' ' ' LEU . 0.9 OUTLIER -150.47 -170.27 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.169 -0.957 . . . . 0.0 109.63 179.8 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.51 ' O ' ' N ' ' A' ' 61' ' ' LEU . 7.7 mtpt -140.75 124.44 17.03 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.398 -0.814 . . . . 0.0 109.663 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.448 HG13 ' HA ' ' A' ' 5' ' ' VAL . 43.0 t -52.6 89.57 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.415 -0.803 . . . . 0.0 108.991 179.365 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.556 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 0.5 OUTLIER -63.62 -31.1 72.17 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.403 -0.811 . . . . 0.0 109.444 -179.596 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.556 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 2.1 mt-10 158.91 -167.7 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.828 0 CA-C-O 121.59 0.71 . . . . 0.0 110.194 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.469 HG21 ' O ' ' A' ' 62' ' ' GLU . 32.1 t -145.83 135.66 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 179.567 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.467 ' OD2' ' HB2' ' A' ' 68' ' ' ARG . 0.5 OUTLIER -84.96 -174.59 5.35 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.151 -0.968 . . . . 0.0 109.879 -179.782 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -73.61 -10.39 59.66 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.321 -0.862 . . . . 0.0 109.872 -179.678 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 82.2 mm-40 -89.68 12.89 15.6 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.183 -0.948 . . . . 0.0 109.586 -179.725 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 61.22 29.86 72.36 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.467 ' HB2' ' OD2' ' A' ' 64' ' ' ASP . 1.2 mmp_? -89.7 140.08 29.93 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.199 -1.177 . . . . 0.0 108.966 179.67 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.474 HD12 ' HB3' ' A' ' 29' ' ' LYS . 22.4 mt -82.49 107.72 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.243 -0.911 . . . . 0.0 109.85 -179.506 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.555 ' NH2' ' NE2' ' A' ' 37' ' ' GLN . 26.0 tpt85 -89.63 91.11 8.53 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.205 -0.934 . . . . 0.0 108.946 179.488 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.535 HD23 ' CG2' ' A' ' 58' ' ' VAL . 52.8 mt -89.96 161.08 16.06 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.252 -0.905 . . . . 0.0 110.112 -179.323 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.54 ' OG ' ' CD1' ' A' ' 61' ' ' LEU . 0.3 OUTLIER -124.36 116.58 22.82 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.481 -0.762 . . . . 0.0 110.028 -179.725 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.523 HD12 ' CG1' ' A' ' 33' ' ' VAL . 1.3 mp -46.43 134.97 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.079 -1.013 . . . . 0.0 108.511 179.368 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -74.67 -26.79 60.09 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.157 -0.964 . . . . 0.0 109.976 -179.334 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.413 ' CG ' ' O ' ' A' ' 75' ' ' GLU . 28.8 tt0 -81.72 7.95 11.22 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 121.281 -0.887 . . . . 0.0 109.406 179.613 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.515 ' N ' HG23 ' A' ' 73' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.476 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.386 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.342 0.591 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.422 ' O ' ' C ' ' A' ' 3' ' ' ILE . 20.5 mp0 -114.31 82.56 1.73 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.202 -0.937 . . . . 0.0 109.638 -179.809 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.551 ' CD1' ' OH ' ' A' ' 9' ' ' TYR . 0.2 OUTLIER -42.03 143.78 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.232 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.84 168.47 19.01 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.999 -1.063 . . . . 0.0 110.218 -179.312 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.559 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 16.7 t -77.36 168.14 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.284 -0.885 . . . . 0.0 109.299 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.559 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 80.23 6.63 89.12 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 108.854 -1.698 . . . . 0.0 108.854 -179.195 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.521 ' HG3' ' N ' ' A' ' 8' ' ' VAL . 4.5 tpt180 -102.6 156.16 17.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.389 -1.065 . . . . 0.0 109.424 -179.591 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.521 ' N ' ' HG3' ' A' ' 7' ' ' ARG . 75.8 t -88.8 119.67 36.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.138 -0.976 . . . . 0.0 108.813 179.729 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.578 ' CD1' HG22 ' A' ' 60' ' ' VAL . 4.4 m-30 -105.22 129.47 53.59 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.113 -0.992 . . . . 0.0 110.066 -178.947 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.6 m -77.0 102.39 6.42 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 178.628 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -80.21 116.2 4.21 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.933 -1.127 . . . . 0.0 110.373 -178.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.542 ' O ' HG12 ' A' ' 23' ' ' VAL . 9.1 mttt -89.16 149.97 22.9 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.655 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.546 ' CG2' ' CD2' ' A' ' 50' ' ' LEU . 85.8 t -86.83 106.69 16.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 120.956 -1.09 . . . . 0.0 109.059 -179.292 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.547 ' CG2' ' HB1' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -113.99 -25.43 8.57 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.529 -0.732 . . . . 0.0 109.21 -179.492 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.513 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 5.6 mtp180 -143.86 152.23 40.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.262 -0.899 . . . . 0.0 109.967 179.762 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.7 mt -139.85 154.42 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.249 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.645 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -134.83 154.3 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 120.782 -1.199 . . . . 0.0 110.313 -178.835 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -59.28 -42.81 92.12 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.796 -1.19 . . . . 0.0 109.539 179.298 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.645 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 9.9 p90 -90.73 27.28 1.81 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.17 -0.956 . . . . 0.0 110.065 -179.766 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.636 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 154.85 -153.01 24.49 Favored Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.012 -1.566 . . . . 0.0 111.141 -179.488 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.509 ' CB ' HG13 ' A' ' 46' ' ' VAL . . . -150.02 143.81 25.41 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.057 -1.26 . . . . 0.0 109.075 -179.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.626 ' CE1' HD12 ' A' ' 32' ' ' LEU . 9.5 m-30 -104.27 160.79 14.59 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.174 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.545 ' CG2' HG22 ' A' ' 33' ' ' VAL . 24.9 t -151.09 159.42 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.841 -1.162 . . . . 0.0 110.514 -178.613 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.547 ' HB1' ' CG2' ' A' ' 14' ' ' THR . . . -138.14 143.04 40.14 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.24 -0.912 . . . . 0.0 109.142 179.618 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.537 ' CG1' ' O ' ' A' ' 29' ' ' LYS . 11.9 pt -100.47 -34.77 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 120.825 -1.172 . . . . 0.0 109.001 179.742 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.424 ' N ' HG13 ' A' ' 25' ' ' ILE . . . 95.78 159.91 32.81 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.89 -13.04 65.57 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 125.55 46.43 0.23 Allowed Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.81 -1.316 . . . . 0.0 109.81 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.537 ' O ' ' CG1' ' A' ' 25' ' ' ILE . 0.0 OUTLIER -178.71 149.99 0.49 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.031 -1.276 . . . . 0.0 110.088 179.709 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.484 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 1.4 pm0 -136.04 156.6 48.49 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.059 -1.026 . . . . 0.0 110.194 -179.505 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.486 ' HA3' ' CD1' ' A' ' 71' ' ' LEU . . . -112.4 176.7 18.03 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 108.798 -1.721 . . . . 0.0 108.798 179.496 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.626 HD12 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -140.98 119.45 12.29 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.986 -1.302 . . . . 0.0 110.074 179.285 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.598 ' CG1' ' CD1' ' A' ' 50' ' ' LEU . 47.0 t -94.02 62.3 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.099 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . . . . . . . . . 3.4 t-80 -48.56 156.18 0.47 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.857 -1.152 . . . . 0.0 108.712 -179.53 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.536 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 3.2 tp -45.52 -53.96 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.365 -0.834 . . . . 0.0 110.899 -179.117 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.432 ' O ' ' HG2' ' A' ' 37' ' ' GLN . 5.3 t -81.27 41.4 0.6 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.049 -1.032 . . . . 0.0 110.633 -179.254 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.467 ' C ' ' CD1' ' A' ' 38' ' ' ILE . 43.5 mt-30 -150.8 61.45 0.93 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.782 -1.199 . . . . 0.0 110.598 -179.843 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.589 HG23 ' CD2' ' A' ' 49' ' ' TYR . 1.9 mp -129.37 -95.56 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 120.849 -1.157 . . . . 0.0 109.684 179.372 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.539 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . -122.51 -161.25 0.93 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.555 -0.715 . . . . 0.0 109.752 -179.251 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -60.02 -61.49 2.57 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.363 -0.836 . . . . 0.0 109.414 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.12 153.16 0.48 Allowed 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.226 -0.921 . . . . 0.0 109.24 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -67.71 -5.27 15.21 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.299 -0.876 . . . . 0.0 109.885 -179.635 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.626 HG21 ' CZ ' ' A' ' 49' ' ' TYR . 75.7 t 48.78 51.63 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 120.996 -1.065 . . . . 0.0 109.016 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . 0.453 ' C ' ' O ' ' A' ' 43' ' ' VAL . 0.3 OUTLIER -40.71 -32.24 0.2 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.631 -0.668 . . . . 0.0 109.621 -179.99 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.467 ' HD2' ' OD2' ' A' ' 48' ' ' ASP . 2.7 mtmp? -111.69 118.23 35.08 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.417 -0.802 . . . . 0.0 109.514 -179.87 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.51 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -74.93 -26.59 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 179.509 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 7.9 p -78.93 5.36 11.76 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.36 -0.838 . . . . 0.0 109.176 179.215 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.467 ' OD2' ' HD2' ' A' ' 45' ' ' LYS . 3.2 m-20 -98.43 -37.24 9.68 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 179.383 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.626 ' CZ ' HG21 ' A' ' 43' ' ' VAL . 15.9 m-85 -90.28 -34.01 15.91 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.626 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.598 ' CD1' ' CG1' ' A' ' 33' ' ' VAL . 0.0 OUTLIER -110.66 148.11 32.92 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.354 -0.841 . . . . 0.0 110.395 179.886 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.464 ' O ' ' CG1' ' A' ' 13' ' ' VAL . 2.3 tt0 -150.62 147.03 26.91 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.57 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 8.2 mtp -65.84 88.05 0.1 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.098 -1.001 . . . . 0.0 109.743 -179.593 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 145.19 -20.81 1.92 Allowed Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.725 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 19.7 mm-40 -80.86 168.86 18.28 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.309 -1.112 . . . . 0.0 110.008 -179.733 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -144.04 116.77 8.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.387 -0.821 . . . . 0.0 109.097 179.684 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.5 m -114.41 142.31 27.92 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.13 -0.981 . . . . 0.0 109.359 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -78.93 142.39 17.45 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.351 2.034 . . . . 0.0 110.322 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.426 HG21 ' O ' ' A' ' 9' ' ' TYR . 0.8 OUTLIER -138.1 174.96 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.333 -0.855 . . . . 0.0 109.32 -179.886 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.522 ' O ' ' N ' ' A' ' 61' ' ' LEU . 0.1 OUTLIER -126.64 111.16 14.0 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.284 -0.885 . . . . 0.0 109.381 179.511 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.578 HG22 ' CD1' ' A' ' 9' ' ' TYR . 80.4 t -52.38 88.81 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.524 -0.735 . . . . 0.0 109.077 179.707 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.524 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 9.9 tp -67.19 -26.23 66.52 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.425 -0.797 . . . . 0.0 109.96 -179.387 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.524 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 2.6 mt-10 160.88 148.89 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.252 -0.905 . . . . 0.0 110.11 179.663 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.487 ' O ' ' O ' ' A' ' 64' ' ' ASP . 44.3 t -150.3 -106.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.416 -0.803 . . . . 0.0 109.226 179.377 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.487 ' O ' ' O ' ' A' ' 63' ' ' VAL . 0.3 OUTLIER 41.82 -169.2 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.85 0 O-C-N 120.939 -1.101 . . . . 0.0 110.639 179.469 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 1.4 ptm180 -51.46 -50.35 59.97 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.277 -0.889 . . . . 0.0 109.544 -179.793 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 -90.28 67.67 6.82 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.312 -0.868 . . . . 0.0 109.123 179.794 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.481 ' O ' HG11 ' A' ' 63' ' ' VAL . . . 164.95 101.79 0.16 Allowed Glycine 0 N--CA 1.487 2.05 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.715 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 53.6 mtt180 -89.45 84.03 6.39 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.34 -1.094 . . . . 0.0 109.601 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.551 ' CG2' ' O ' ' A' ' 69' ' ' ILE . 16.3 mm 51.32 65.46 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.327 -0.858 . . . . 0.0 110.073 179.541 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.74 78.91 6.84 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.95 -1.094 . . . . 0.0 108.714 179.164 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.486 ' CD1' ' HA3' ' A' ' 31' ' ' GLY . 22.5 mt -89.36 145.55 25.28 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.263 -0.898 . . . . 0.0 109.216 -179.731 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.49 99.07 8.61 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.448 -0.782 . . . . 0.0 110.498 -178.927 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.471 ' O ' ' C ' ' A' ' 74' ' ' LYS . 15.5 mm -51.69 137.95 9.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.316 -0.865 . . . . 0.0 109.295 179.697 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.471 ' C ' ' O ' ' A' ' 73' ' ' ILE . 0.2 OUTLIER -37.41 147.16 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.587 -0.696 . . . . 0.0 110.102 -179.835 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 13.5 tt0 55.33 28.25 11.1 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.191 -0.943 . . . . 0.0 109.274 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.506 0 CA-C-O 118.024 -0.989 . . . . 0.0 109.544 -179.814 . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.625 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 178.15 -168.36 0.07 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.239 -0.913 . . . . 0.0 109.621 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.538 ' CG2' ' OH ' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -128.16 -163.28 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 121.321 -0.862 . . . . 0.0 109.272 -179.769 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.486 ' O ' ' HG3' ' A' ' 7' ' ' ARG . 0.8 OUTLIER -143.77 152.22 40.96 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.393 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.526 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 8.7 t -80.48 163.86 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.077 -1.014 . . . . 0.0 109.551 -179.795 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.526 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 95.45 4.17 60.97 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.486 ' HG3' ' O ' ' A' ' 4' ' ' GLU . 0.0 OUTLIER -111.64 171.25 7.6 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.159 -1.201 . . . . 0.0 109.823 -179.541 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.523 ' CG1' ' O ' ' A' ' 58' ' ' VAL . 75.9 t -97.28 141.48 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.289 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.629 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 11.0 m-85 -120.87 127.7 52.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.036 -1.04 . . . . 0.0 110.502 -179.287 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' THR . . . . . 0.462 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 5.6 m -97.04 109.22 22.02 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 178.501 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -110.77 150.1 17.74 Favored Glycine 0 N--CA 1.487 2.095 0 C-N-CA 119.472 -1.347 . . . . 0.0 110.495 -178.837 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.468 ' O ' HG11 ' A' ' 23' ' ' VAL . 0.8 OUTLIER -89.81 163.02 15.21 Favored 'General case' 0 C--N 1.304 -1.394 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 179.08 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.544 HG23 ' CD2' ' A' ' 50' ' ' LEU . 41.6 t -89.0 103.27 13.8 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 O-C-N 121.096 -1.002 . . . . 0.0 108.754 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.534 ' CG2' ' CB ' ' A' ' 24' ' ' ALA . 0.5 OUTLIER -106.6 -12.46 15.57 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.282 -0.886 . . . . 0.0 109.779 -179.198 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.484 ' HD2' ' O ' ' A' ' 14' ' ' THR . 0.5 OUTLIER -159.26 153.9 24.42 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.054 -1.029 . . . . 0.0 110.41 -179.662 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.451 HG22 HD11 ' A' ' 16' ' ' ILE . 11.1 mt -139.69 157.65 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 179.255 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.664 HG21 ' N ' ' A' ' 20' ' ' GLY . 0.8 OUTLIER -137.75 153.7 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 120.697 -1.252 . . . . 0.0 110.128 -178.947 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.69 -40.66 93.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.594 -1.316 . . . . 0.0 109.232 179.186 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.647 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 16.3 p90 -90.04 24.17 2.55 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.273 -0.892 . . . . 0.0 110.19 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.664 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 155.82 -153.5 24.8 Favored Glycine 0 N--CA 1.494 2.506 0 C-N-CA 119.091 -1.528 . . . . 0.0 111.272 -179.405 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.497 ' HB2' ' HB ' ' A' ' 33' ' ' VAL . . . -149.78 145.35 26.58 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.116 -1.226 . . . . 0.0 108.931 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.632 ' CE1' HD12 ' A' ' 32' ' ' LEU . 10.2 m-30 -107.78 145.25 33.81 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.337 -0.852 . . . . 0.0 109.232 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.539 ' CG2' ' CG2' ' A' ' 33' ' ' VAL . 48.9 t -133.33 167.52 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.134 -0.979 . . . . 0.0 109.597 -179.681 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.545 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -136.64 135.29 38.17 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.884 -1.135 . . . . 0.0 110.78 -179.42 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.496 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.1 pt -113.25 93.83 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 120.94 -1.1 . . . . 0.0 108.863 178.961 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -47.82 121.27 6.77 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.816 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 100.6 71.62 0.96 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.775 -1.33 . . . . 0.0 109.775 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . 0.464 ' O ' ' CB ' ' A' ' 29' ' ' LYS . . . 136.87 -56.33 0.69 Allowed Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 179.695 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.496 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER 167.87 -155.41 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.123 -1.222 . . . . 0.0 109.406 -179.757 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.545 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 4.6 pt-20 -111.08 150.48 29.31 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.771 -1.206 . . . . 0.0 109.988 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.427 ' O ' ' O ' ' A' ' 23' ' ' VAL . . . -97.95 -175.4 33.47 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 108.03 -2.028 . . . . 0.0 108.03 178.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.632 HD12 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -151.13 121.04 7.09 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 120.89 -1.359 . . . . 0.0 111.39 179.645 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.539 ' CG2' ' CG2' ' A' ' 23' ' ' VAL . 71.8 t -94.67 61.81 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 177.286 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.517 ' O ' ' CD1' ' A' ' 38' ' ' ILE . 3.1 t-80 -49.54 152.83 1.27 Allowed 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.89 -1.131 . . . . 0.0 108.814 -179.165 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.526 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.4 OUTLIER -46.96 -49.01 7.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.372 -0.83 . . . . 0.0 109.982 -179.591 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.436 ' C ' ' HG2' ' A' ' 37' ' ' GLN . 0.3 OUTLIER -81.6 40.42 0.58 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.21 -0.931 . . . . 0.0 110.327 -179.819 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.458 ' OE1' ' HA ' ' A' ' 37' ' ' GLN . 14.7 mm-40 -147.88 31.9 0.86 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.849 -1.157 . . . . 0.0 109.388 -179.878 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.634 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.6 mp -111.22 -98.74 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 O-C-N 121.13 -0.981 . . . . 0.0 109.992 -179.581 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.515 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . -104.6 179.24 4.33 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.323 -0.861 . . . . 0.0 109.38 -179.706 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.425 ' C ' ' O ' ' A' ' 39' ' ' ALA . 8.9 t0 -42.41 -55.19 3.51 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.444 -0.785 . . . . 0.0 109.367 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.464 ' HD2' ' OH ' ' A' ' 49' ' ' TYR . 3.1 ptpt -66.42 169.18 7.79 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.219 -0.925 . . . . 0.0 109.257 179.792 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.487 ' O ' ' HB ' ' A' ' 43' ' ' VAL . 1.1 mmt85 -79.67 -3.11 45.83 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.247 -0.908 . . . . 0.0 109.971 -179.558 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.61 ' CG1' ' CD1' ' A' ' 49' ' ' TYR . 24.1 t 63.27 82.28 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 O-C-N 121.151 -0.968 . . . . 0.0 109.553 179.803 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -49.02 -22.61 0.92 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.442 -0.786 . . . . 0.0 109.426 179.619 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.539 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 1.3 mmpt? -130.11 113.05 14.03 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.315 -0.866 . . . . 0.0 109.945 -179.58 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.516 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -76.64 -26.05 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.233 -0.917 . . . . 0.0 108.839 179.563 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 52.9 p -76.56 3.74 10.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.838 . . . . 0.0 109.35 179.396 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.464 ' OD2' ' CB ' ' A' ' 45' ' ' LYS . 98.5 m-20 -103.88 -30.26 10.46 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.143 -0.973 . . . . 0.0 108.515 179.716 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.634 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 16.3 m-85 -91.24 -31.58 16.09 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 179.501 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.544 ' CD2' HG23 ' A' ' 13' ' ' VAL . 1.3 mt -108.23 155.22 20.71 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.278 -0.889 . . . . 0.0 109.418 179.446 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.487 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 5.9 tp60 -141.53 138.43 32.72 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.321 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 9.4 mtt -63.3 112.82 2.87 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.144 -0.973 . . . . 0.0 109.908 -179.497 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 108.3 -22.66 26.53 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . 0.47 ' CG ' ' HB3' ' A' ' 51' ' ' GLN . 35.3 mt-30 -68.94 162.6 26.34 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.173 -1.193 . . . . 0.0 109.89 -179.757 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . 0.423 ' C ' HG11 ' A' ' 56' ' ' VAL . 1.1 mt-10 -114.32 141.82 47.11 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.359 -0.838 . . . . 0.0 109.033 179.6 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . 0.423 HG11 ' C ' ' A' ' 55' ' ' GLU . 31.7 m -144.13 131.04 10.31 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 120.948 -1.095 . . . . 0.0 110.25 -179.823 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.462 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.6 Cg_endo -80.65 154.14 20.51 Favored 'Trans proline' 0 C--N 1.316 -1.176 0 C-N-CA 122.65 2.233 . . . . 0.0 109.765 179.405 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.523 ' O ' ' CG1' ' A' ' 8' ' ' VAL . 0.9 OUTLIER -150.89 -169.73 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.035 -1.041 . . . . 0.0 109.625 179.733 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.492 ' CE ' HG21 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -135.68 138.53 42.89 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.469 -0.769 . . . . 0.0 109.205 179.557 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.629 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 5.1 t -73.16 83.3 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.334 -0.854 . . . . 0.0 108.853 179.758 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.534 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 4.6 tp -58.96 -28.56 66.41 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.427 -0.796 . . . . 0.0 109.767 -179.565 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.534 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 0.0 OUTLIER 163.16 138.45 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.221 -0.924 . . . . 0.0 110.34 179.602 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.482 HG11 ' O ' ' A' ' 67' ' ' GLY . 42.2 t -150.21 -106.34 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.444 -0.785 . . . . 0.0 109.275 179.247 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.431 ' CG ' ' O ' ' A' ' 63' ' ' VAL . 2.6 p30 41.05 -161.86 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.917 -1.114 . . . . 0.0 110.345 179.601 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . 0.401 ' N ' ' OD1' ' A' ' 64' ' ' ASP . 3.2 ttm105 -45.35 -66.08 0.45 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.423 -0.798 . . . . 0.0 109.804 -179.729 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 10.6 mt-30 -89.31 89.36 7.87 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.191 -0.943 . . . . 0.0 109.031 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . 0.482 ' O ' HG11 ' A' ' 63' ' ' VAL . . . 163.98 102.8 0.17 Allowed Glycine 0 N--CA 1.485 1.919 0 N-CA-C 108.841 -1.703 . . . . 0.0 108.841 -179.584 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 10.3 mtt180 -88.15 72.35 9.13 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.347 -1.09 . . . . 0.0 109.15 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.527 ' CG2' ' O ' ' A' ' 69' ' ' ILE . 35.0 mt 53.24 68.97 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.524 -0.735 . . . . 0.0 109.636 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.467 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 3.4 mmm180 -89.77 78.25 6.93 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.14 -0.975 . . . . 0.0 108.692 179.437 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.446 ' HG ' HG21 ' A' ' 69' ' ' ILE . 19.4 mt -89.12 155.16 19.61 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.277 -0.889 . . . . 0.0 109.28 -179.65 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.16 117.55 20.96 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.509 -0.744 . . . . 0.0 110.001 -179.145 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.455 ' O ' ' HB1' ' A' ' 76' ' ' ALA . 0.0 OUTLIER -56.07 133.05 20.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.223 -0.923 . . . . 0.0 109.037 179.883 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -43.31 -32.6 0.83 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.467 -0.771 . . . . 0.0 110.05 -179.302 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.46 ' O ' ' HA ' ' A' ' 39' ' ' ALA . 2.7 mt-10 -89.98 41.29 1.04 Allowed 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 179.707 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.455 ' HB1' ' O ' ' A' ' 73' ' ' ILE . . . . . . . . 0 N--CA 1.488 1.462 0 CA-C-O 118.034 -0.984 . . . . 0.0 109.363 -179.774 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' A' ' 3' ' ' ILE . 18.3 tt0 -59.19 -17.95 32.12 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.199 -0.938 . . . . 0.0 109.395 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.522 HG21 ' OH ' ' A' ' 9' ' ' TYR . 0.3 OUTLIER 59.37 150.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.758 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . 0.523 ' O ' ' HG3' ' A' ' 7' ' ' ARG . 3.2 tt0 -150.39 -170.19 3.59 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.038 -1.039 . . . . 0.0 109.426 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.47 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 2.3 t -81.8 161.85 3.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.116 -0.99 . . . . 0.0 109.296 179.68 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.47 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 90.23 13.24 60.53 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 179.404 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.523 ' HG3' ' O ' ' A' ' 4' ' ' GLU . 0.0 OUTLIER -124.07 -174.74 3.07 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.102 -1.234 . . . . 0.0 109.669 -179.838 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 23.9 t -89.62 135.19 26.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.425 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 178.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.673 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 4.0 m-85 -122.64 136.79 54.98 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.037 -1.04 . . . . 0.0 110.195 -178.848 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 7.0 m -90.34 102.66 15.39 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 178.125 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.441 ' HA3' HG13 ' A' ' 23' ' ' VAL . . . -79.54 128.39 8.51 Favored Glycine 0 N--CA 1.488 2.114 0 C-N-CA 119.843 -1.17 . . . . 0.0 110.794 -178.197 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.537 ' O ' HG12 ' A' ' 23' ' ' VAL . 6.1 mttt -89.08 147.61 24.14 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 178.29 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.472 HG13 ' HA ' ' A' ' 52' ' ' MET . 17.1 t -86.42 104.2 13.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 O-C-N 120.384 -1.447 . . . . 0.0 108.708 -179.289 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.532 ' O ' ' CD ' ' A' ' 15' ' ' ARG . 1.5 p -111.29 -9.15 14.3 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.697 -0.627 . . . . 0.0 109.858 -178.888 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.532 ' CD ' ' O ' ' A' ' 14' ' ' THR . 1.1 mpp_? -166.76 157.82 12.41 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.026 -1.046 . . . . 0.0 110.256 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.412 ' HA ' ' HA ' ' A' ' 21' ' ' ALA . 14.7 mt -144.1 153.66 15.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.057 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.666 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.9 OUTLIER -133.67 155.46 40.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.835 -1.165 . . . . 0.0 109.884 -179.413 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -59.34 -41.74 89.89 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.753 -1.217 . . . . 0.0 109.345 179.444 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.666 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 12.8 p90 -91.33 26.56 2.2 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.346 -0.846 . . . . 0.0 110.296 -179.609 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.622 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 156.25 -152.99 24.37 Favored Glycine 0 N--CA 1.493 2.456 0 C-N-CA 119.108 -1.52 . . . . 0.0 111.174 -179.669 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.508 ' CB ' ' HB ' ' A' ' 33' ' ' VAL . . . -152.24 144.54 23.99 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.259 -1.142 . . . . 0.0 109.017 -179.657 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.623 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 9.6 m-30 -105.28 152.72 22.55 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.171 -0.956 . . . . 0.0 109.244 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.537 HG12 ' O ' ' A' ' 12' ' ' LYS . 35.5 t -145.35 162.95 12.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.266 -0.896 . . . . 0.0 109.385 -179.476 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.528 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -135.18 130.72 35.79 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.852 -1.155 . . . . 0.0 110.089 -179.066 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.497 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.0 OUTLIER -114.88 85.81 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 120.938 -1.101 . . . . 0.0 109.157 179.504 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 25' ' ' ILE . . . -43.15 151.78 0.36 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 -179.818 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 80.03 49.81 5.81 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 153.36 -74.66 0.24 Allowed Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.826 -1.309 . . . . 0.0 109.826 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.497 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.1 OUTLIER -171.8 -160.69 0.17 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.141 -1.211 . . . . 0.0 109.421 -179.674 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.528 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 2.8 mt-10 -105.91 148.46 27.59 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 120.725 -1.234 . . . . 0.0 109.628 179.772 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 23' ' ' VAL . . . -98.97 -179.36 31.71 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 108.452 -1.859 . . . . 0.0 108.452 179.342 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.623 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.64 117.37 5.82 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 120.814 -1.404 . . . . 0.0 110.652 179.577 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.525 ' CG2' HG23 ' A' ' 23' ' ' VAL . 30.1 t -91.23 61.06 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 177.51 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.492 ' HB2' HD21 ' A' ' 32' ' ' LEU . 3.7 t-80 -50.73 156.28 0.98 Allowed 'General case' 0 C--N 1.304 -1.394 0 O-C-N 120.964 -1.085 . . . . 0.0 108.624 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.537 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.9 OUTLIER -48.87 -47.35 16.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.171 -0.956 . . . . 0.0 109.789 -179.954 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.478 ' O ' ' HG2' ' A' ' 37' ' ' GLN . 37.4 t -81.42 40.2 0.56 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.158 -0.964 . . . . 0.0 110.647 -179.498 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.488 ' HG3' ' HB3' ' A' ' 34' ' ' HIS . 35.9 mt-30 -150.51 43.35 0.84 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.851 -1.155 . . . . 0.0 110.032 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.648 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.6 mp -120.68 -98.97 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.086 -1.008 . . . . 0.0 109.521 179.719 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.529 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . -112.79 153.0 28.49 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.244 -0.91 . . . . 0.0 109.636 -179.725 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 39' ' ' ALA . 4.4 t70 -44.21 -45.14 8.28 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.298 -0.876 . . . . 0.0 109.189 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.442 ' O ' ' C ' ' A' ' 42' ' ' ARG . 0.3 OUTLIER -68.01 122.45 18.25 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.286 -0.884 . . . . 0.0 109.225 179.766 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.442 ' C ' ' O ' ' A' ' 41' ' ' LYS . 0.7 OUTLIER -41.26 126.24 2.68 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.427 -0.795 . . . . 0.0 109.759 -179.844 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.613 HG23 ' CG ' ' A' ' 49' ' ' TYR . 17.7 t -88.11 85.81 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.567 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -44.91 -21.33 0.05 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.544 -0.722 . . . . 0.0 110.316 -179.686 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.539 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 5.7 mttt -139.1 117.5 12.01 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.013 -1.054 . . . . 0.0 110.191 -179.433 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.494 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -72.52 -27.61 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.38 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 81.9 p -75.97 1.26 15.79 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.798 -0.761 . . . . 0.0 109.15 179.439 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.456 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 2.1 m-20 -97.71 -35.35 10.59 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.291 -0.881 . . . . 0.0 109.041 179.696 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.648 ' CD2' ' CG2' ' A' ' 38' ' ' ILE . 7.0 m-85 -91.46 -27.38 18.31 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.404 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.475 HD22 ' CG2' ' A' ' 33' ' ' VAL . 0.2 OUTLIER -104.46 140.31 38.13 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 179.598 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.476 ' HB3' ' HB2' ' A' ' 54' ' ' GLN . 4.1 tp-100 -132.41 124.46 28.69 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.198 -0.939 . . . . 0.0 109.788 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' MET . . . . . 0.472 ' HA ' HG13 ' A' ' 13' ' ' VAL . 23.6 ptp -58.42 130.07 45.01 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.381 -0.824 . . . . 0.0 109.869 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 93.86 -31.17 6.75 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 179.598 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . 0.476 ' HB2' ' HB3' ' A' ' 51' ' ' GLN . 56.8 mt-30 -77.97 -172.94 2.91 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.129 -1.218 . . . . 0.0 109.817 -179.62 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -143.56 157.06 44.72 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.441 -0.787 . . . . 0.0 108.943 179.704 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -140.0 140.91 25.29 Favored Pre-proline 0 C--N 1.303 -1.423 0 O-C-N 121.143 -0.973 . . . . 0.0 109.581 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.453 ' O ' ' HB3' ' A' ' 74' ' ' LYS . 36.3 Cg_endo -79.24 130.38 9.17 Favored 'Trans proline' 0 C--N 1.311 -1.403 0 C-N-CA 122.438 2.092 . . . . 0.0 109.9 179.551 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.459 HG21 ' O ' ' A' ' 9' ' ' TYR . 1.1 m -143.18 -170.02 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.087 -1.008 . . . . 0.0 109.99 -179.631 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.406 ' O ' ' N ' ' A' ' 61' ' ' LEU . 0.5 OUTLIER -135.08 126.81 29.12 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.672 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.673 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 36.2 t -51.74 97.36 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.278 -0.889 . . . . 0.0 109.306 -179.757 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.553 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 18.1 tp -67.36 -16.39 64.22 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.148 -0.97 . . . . 0.0 108.98 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.553 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 5.2 mt-10 91.62 -168.49 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.002 0 CA-C-O 121.582 0.706 . . . . 0.0 110.114 179.687 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.512 HG12 ' N ' ' A' ' 68' ' ' ARG . 58.2 t -137.55 159.73 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.484 -0.76 . . . . 0.0 109.477 -179.519 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 9.0 p-10 -90.28 -161.28 0.78 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.348 -0.845 . . . . 0.0 109.295 179.762 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.79 41.01 0.63 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.214 -0.929 . . . . 0.0 110.058 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 5.1 tt0 -129.21 -51.02 1.2 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.938 -1.101 . . . . 0.0 109.555 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 125.92 26.94 1.19 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.512 ' N ' HG12 ' A' ' 63' ' ' VAL . 7.9 ptp180 -101.91 120.11 39.87 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.204 -1.174 . . . . 0.0 109.266 179.725 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.492 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 1.5 mt -66.11 118.68 9.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.327 -0.858 . . . . 0.0 109.961 -179.636 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.496 ' HB3' ' HB3' ' A' ' 61' ' ' LEU . 6.9 tpt180 -105.2 115.39 30.19 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.17 -0.956 . . . . 0.0 109.419 179.657 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.486 ' CD2' ' N ' ' A' ' 71' ' ' LEU . 3.4 mm? -106.37 147.35 29.34 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.217 -0.927 . . . . 0.0 109.654 -179.704 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.407 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.4 OUTLIER -112.14 106.26 14.83 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.393 -0.817 . . . . 0.0 109.704 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.483 HD12 ' CG1' ' A' ' 33' ' ' VAL . 0.9 OUTLIER -52.02 144.19 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.108 -0.995 . . . . 0.0 109.303 -179.871 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.46 ' CE ' ' HB1' ' A' ' 76' ' ' ALA . 1.0 OUTLIER -51.64 -176.7 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.371 -0.831 . . . . 0.0 109.843 -179.692 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 27.7 mm-40 -43.64 -41.61 4.78 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.412 -0.805 . . . . 0.0 109.449 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.472 ' O ' ' HA ' ' A' ' 39' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.51 0 CA-C-O 117.997 -1.001 . . . . 0.0 109.381 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.476 ' O ' ' CB ' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.502 0 CA-C-O 121.293 0.568 . . . . 0.0 109.494 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLU . . . . . 0.476 ' CB ' ' O ' ' A' ' 1' ' ' ALA . 2.3 mm-40 165.0 -36.42 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.31 -0.868 . . . . 0.0 109.35 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' ILE . . . . . 0.629 ' N ' ' CD1' ' A' ' 3' ' ' ILE . 0.1 OUTLIER -156.42 154.64 6.05 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.959 0 C-N-CA 119.731 -0.788 . . . . 0.0 109.249 -179.681 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.88 170.58 9.65 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.204 -0.935 . . . . 0.0 109.485 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.51 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 3.4 t -62.64 163.47 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.375 -0.828 . . . . 0.0 109.413 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . 0.51 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 88.28 4.29 77.67 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.604 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ARG . . . . . 0.476 ' HD3' HG23 ' A' ' 3' ' ' ILE . 5.6 ttt-85 -112.88 176.51 4.99 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.153 -1.204 . . . . 0.0 109.835 -179.733 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' VAL . . . . . 0.402 HG11 ' O ' ' A' ' 58' ' ' VAL . 71.3 t -104.83 129.81 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.352 -0.843 . . . . 0.0 109.306 179.79 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' TYR . . . . . 0.488 ' OH ' ' HB ' ' A' ' 3' ' ' ILE . 3.1 m-85 -106.27 -174.67 2.59 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.147 -0.97 . . . . 0.0 109.836 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 11.4 m -147.28 110.79 4.92 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.419 ' CA ' ' O ' ' A' ' 24' ' ' ALA . . . -121.26 143.24 15.96 Favored Glycine 0 N--CA 1.488 2.122 0 C-N-CA 118.868 -1.634 . . . . 0.0 110.908 -178.194 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' LYS . . . . . 0.486 ' O ' HG11 ' A' ' 23' ' ' VAL . 8.8 mttp -90.43 165.58 13.75 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.802 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' VAL . . . . . 0.507 ' CG1' HD11 ' A' ' 50' ' ' LEU . 39.1 t -88.27 102.89 13.16 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.744 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.487 179.426 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' THR . . . . . 0.539 ' CG2' ' CB ' ' A' ' 24' ' ' ALA . 0.1 OUTLIER -101.75 -7.98 22.11 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.292 -0.88 . . . . 0.0 109.494 -179.351 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' ARG . . . . . 0.504 ' CG ' ' C ' ' A' ' 14' ' ' THR . 0.0 OUTLIER -167.64 147.24 5.02 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.151 -0.968 . . . . 0.0 109.613 -179.599 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' ILE . . . . . 0.405 ' C ' HG11 ' A' ' 17' ' ' VAL . 62.1 mt -131.13 163.34 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' VAL . . . . . 0.655 ' CG2' ' CD1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -138.82 154.38 26.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 120.726 -1.234 . . . . 0.0 110.425 -179.559 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -59.23 -43.16 92.34 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.843 -1.161 . . . . 0.0 109.812 179.531 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' PHE . . . . . 0.655 ' CD1' ' CG2' ' A' ' 17' ' ' VAL . 6.4 p90 -92.12 25.6 2.81 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.249 -0.907 . . . . 0.0 110.266 -179.384 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' GLY . . . . . 0.643 ' N ' HG21 ' A' ' 17' ' ' VAL . . . 157.66 -154.79 25.84 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 119.033 -1.556 . . . . 0.0 110.98 -179.71 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' ALA . . . . . 0.493 ' HB1' HG13 ' A' ' 46' ' ' VAL . . . -149.61 145.97 27.05 Favored 'General case' 0 N--CA 1.486 1.345 0 O-C-N 121.089 -1.242 . . . . 0.0 108.995 -179.759 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' PHE . . . . . 0.643 ' CD1' ' CD1' ' A' ' 32' ' ' LEU . 10.8 m-30 -106.87 158.2 17.19 Favored 'General case' 0 C--N 1.298 -1.672 0 O-C-N 121.316 -0.865 . . . . 0.0 108.738 179.481 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' VAL . . . . . 0.578 ' CG2' ' CG2' ' A' ' 33' ' ' VAL . 37.6 t -148.34 166.34 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.069 -1.02 . . . . 0.0 109.755 -179.507 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' ALA . . . . . 0.542 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -137.91 144.65 41.4 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.287 -0.883 . . . . 0.0 109.539 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ILE . . . . . 0.535 ' CG1' ' O ' ' A' ' 29' ' ' LYS . 5.5 pt -104.28 -20.72 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 120.625 -1.297 . . . . 0.0 108.562 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' A' ' 25' ' ' ILE . . . 59.73 142.07 0.01 OUTLIER Glycine 0 N--CA 1.489 2.193 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 179.34 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 82.59 15.21 74.1 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.934 -1.266 . . . . 0.0 109.934 179.592 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 178.9 -52.74 0.09 OUTLIER Glycine 0 N--CA 1.491 2.313 0 C-N-CA 119.625 -1.274 . . . . 0.0 110.18 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' LYS . . . . . 0.535 ' O ' ' CG1' ' A' ' 25' ' ' ILE . 0.4 OUTLIER -173.9 -161.78 0.13 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.069 -1.254 . . . . 0.0 110.06 -179.519 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' GLU . . . . . 0.542 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 12.6 mp0 -123.39 153.24 40.65 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.836 -1.165 . . . . 0.0 110.109 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' GLY . . . . . 0.464 ' O ' ' O ' ' A' ' 23' ' ' VAL . . . -103.67 -175.48 25.92 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 108.8 -1.72 . . . . 0.0 108.8 179.521 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' LEU . . . . . 0.643 ' CD1' ' CD1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.57 119.82 6.81 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.97 -1.312 . . . . 0.0 110.552 179.624 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . 0.578 ' CG2' ' CG2' ' A' ' 23' ' ' VAL . 25.2 t -96.84 63.21 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 177.736 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' HIS . . . . . 0.532 ' O ' ' CD1' ' A' ' 38' ' ' ILE . 7.7 t-80 -48.64 162.57 0.1 Allowed 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.741 -1.224 . . . . 0.0 108.359 -179.627 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.558 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.4 OUTLIER -55.5 -45.79 78.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.012 -1.055 . . . . 0.0 110.53 -179.49 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' SER . . . . . 0.466 ' C ' ' HG2' ' A' ' 37' ' ' GLN . 0.9 OUTLIER -80.05 23.77 0.45 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.153 -0.967 . . . . 0.0 110.795 -179.338 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' GLN . . . . . 0.533 ' O ' ' CD1' ' A' ' 73' ' ' ILE . 3.4 mm100 -138.74 64.18 1.49 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.883 -1.136 . . . . 0.0 109.293 179.546 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ILE . . . . . 0.633 ' CG2' ' CD2' ' A' ' 49' ' ' TYR . 1.8 mp -129.35 -94.59 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.042 -1.036 . . . . 0.0 109.704 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' ALA . . . . . 0.546 ' N ' ' CG2' ' A' ' 38' ' ' ILE . . . -114.98 -168.4 1.38 Allowed 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.455 -0.778 . . . . 0.0 109.852 -179.346 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -65.8 -58.06 6.51 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.4 -0.813 . . . . 0.0 109.417 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' LYS . . . . . 0.446 ' HA ' ' HE2' ' A' ' 41' ' ' LYS . 0.1 OUTLIER -65.41 125.97 26.79 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.359 -0.838 . . . . 0.0 109.227 179.939 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' ARG . . . . . 0.438 ' C ' ' O ' ' A' ' 41' ' ' LYS . 4.8 mtt180 -44.22 133.8 5.2 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.259 -0.901 . . . . 0.0 108.97 179.793 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' VAL . . . . . 0.647 ' CG1' ' CD1' ' A' ' 49' ' ' TYR . 44.3 t -97.3 82.39 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 121.2 -0.937 . . . . 0.0 109.06 -179.809 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -53.98 -19.02 4.06 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.365 -0.834 . . . . 0.0 109.114 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' LYS . . . . . 0.543 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.2 OUTLIER -121.68 108.19 13.25 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.436 -0.79 . . . . 0.0 109.748 -179.569 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' VAL . . . . . 0.519 HG12 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -76.3 -24.76 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.331 -0.856 . . . . 0.0 109.179 179.972 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.2 p -78.28 5.95 9.28 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.364 -0.835 . . . . 0.0 109.541 179.873 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' ASP . . . . . 0.434 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 10.2 m-20 -104.35 -37.59 7.17 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.136 -0.977 . . . . 0.0 108.716 179.548 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' TYR . . . . . 0.647 ' CD1' ' CG1' ' A' ' 43' ' ' VAL . 11.7 m-85 -89.84 -38.01 14.05 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.532 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' LEU . . . . . 0.507 HD11 ' CG1' ' A' ' 13' ' ' VAL . 0.2 OUTLIER -96.45 136.02 37.52 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.435 -0.791 . . . . 0.0 109.301 -179.931 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' GLN . . . . . 0.503 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.9 OUTLIER -129.72 132.57 46.66 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.659 -0.651 . . . . 0.0 109.372 -179.517 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 11.5 mtt -57.31 113.52 1.79 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.313 -0.867 . . . . 0.0 109.661 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 106.14 -34.09 6.0 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.636 -1.385 . . . . 0.0 109.636 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 6.9 mt-30 -54.4 143.02 24.94 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.32 -1.106 . . . . 0.0 110.025 -179.722 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -104.15 129.39 51.88 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.313 -0.867 . . . . 0.0 108.898 179.368 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.2 m -132.78 134.48 24.65 Favored Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 120.99 -1.069 . . . . 0.0 110.085 -179.617 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' PRO . . . . . 0.474 ' O ' ' HB2' ' A' ' 74' ' ' LYS . 37.0 Cg_endo -81.72 143.51 13.38 Favored 'Trans proline' 0 C--N 1.314 -1.283 0 C-N-CA 122.705 2.27 . . . . 0.0 110.015 179.341 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' VAL . . . . . 0.466 ' HA ' ' O ' ' A' ' 72' ' ' SER . 0.9 OUTLIER -135.31 -177.87 2.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.062 -1.024 . . . . 0.0 109.322 179.676 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . 0.546 ' O ' ' N ' ' A' ' 61' ' ' LEU . 0.0 OUTLIER -131.72 110.78 11.13 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.277 -0.889 . . . . 0.0 109.212 179.737 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' VAL . . . . . 0.49 HG13 ' CG2' ' A' ' 5' ' ' VAL . 25.1 t -49.67 90.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.374 -0.829 . . . . 0.0 109.112 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.546 ' N ' ' O ' ' A' ' 59' ' ' LYS . 4.5 tp -82.28 -22.17 35.86 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.383 -0.823 . . . . 0.0 109.735 -179.31 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' GLU . . . . . 0.469 ' O ' ' HB3' ' A' ' 70' ' ' ARG . 1.9 tp10 179.91 113.58 0.05 OUTLIER 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.237 -0.915 . . . . 0.0 109.842 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 50.9 t -146.61 -59.9 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.114 -0.991 . . . . 0.0 109.628 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 65' ' ' ARG . 38.6 p-10 -58.52 -15.5 11.47 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.256 -0.903 . . . . 0.0 109.575 -179.804 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' ARG . . . . . 0.512 ' N ' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -63.79 -67.95 0.39 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.1 -1.0 . . . . 0.0 109.352 -179.986 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 3.9 mm100 -122.57 -39.49 2.54 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.263 -0.898 . . . . 0.0 109.23 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 115.21 31.0 2.13 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 179.787 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' ARG . . . . . 0.479 ' O ' ' C ' ' A' ' 69' ' ' ILE . 3.2 mtt180 -95.01 35.67 1.26 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.059 -1.26 . . . . 0.0 109.179 179.837 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.479 ' C ' ' O ' ' A' ' 68' ' ' ARG . 19.9 mt 31.65 76.97 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 CA-C-O 121.183 0.516 . . . . 0.0 110.844 179.742 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.469 ' HB3' ' O ' ' A' ' 62' ' ' GLU . 0.0 OUTLIER -101.32 72.12 1.41 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.118 -0.989 . . . . 0.0 108.971 179.433 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' LEU . . . . . 0.416 ' HB3' ' CG2' ' A' ' 58' ' ' VAL . 23.4 mt -89.62 146.71 24.36 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.325 -0.859 . . . . 0.0 109.477 -179.703 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' SER . . . . . 0.494 ' CB ' ' HB2' ' A' ' 59' ' ' LYS . 0.3 OUTLIER -100.66 110.63 22.77 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.336 -0.852 . . . . 0.0 109.546 179.931 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . 0.533 ' CD1' ' O ' ' A' ' 37' ' ' GLN . 1.9 mp -62.68 127.11 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.496 -0.752 . . . . 0.0 109.733 -179.738 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' LYS . . . . . 0.522 ' O ' ' CG ' ' A' ' 75' ' ' GLU . 0.0 OUTLIER -62.67 -160.12 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.301 -0.874 . . . . 0.0 109.29 179.666 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' GLU . . . . . 0.522 ' CG ' ' O ' ' A' ' 74' ' ' LYS . 22.9 pt-20 40.71 32.55 0.16 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.47 -0.769 . . . . 0.0 109.448 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ALA . . . . . 0.45 ' HB1' ' O ' ' A' ' 73' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 117.996 -1.002 . . . . 0.0 109.406 -179.831 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.48 HG13 ' O ' ' A' ' 58' ' ' VAL . 40.6 t . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.622 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 15.2 m-85 -136.17 129.19 31.32 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.967 -1.083 . . . . 0.0 110.386 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.5 m -76.91 102.06 6.21 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 178.264 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -83.14 113.81 3.74 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 119.813 -1.184 . . . . 0.0 110.73 -178.262 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.574 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -89.31 153.87 20.54 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 178.697 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.991 HG22 HD13 ' A' ' 50' ' ' LEU . 77.1 t -87.43 116.11 29.12 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 O-C-N 120.759 -1.213 . . . . 0.0 109.116 -179.572 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 14' ' ' THR . . . . . 1.135 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.2 OUTLIER -126.72 7.24 6.8 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.386 -0.821 . . . . 0.0 109.473 -179.396 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.539 ' HB3' ' HB2' ' A' ' 22' ' ' PHE . 1.9 mtp180 -178.26 149.52 0.53 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.304 -0.872 . . . . 0.0 109.575 179.692 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.405 HG22 ' N ' ' A' ' 17' ' ' VAL . 33.6 mt -140.9 157.16 22.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.487 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 1.018 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -135.78 152.93 31.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.858 -1.151 . . . . 0.0 110.057 -179.395 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -58.62 -41.44 85.93 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.721 -1.237 . . . . 0.0 109.035 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 1.018 ' CE1' HG21 ' A' ' 17' ' ' VAL . 17.3 p90 -90.41 28.68 1.41 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.363 -0.836 . . . . 0.0 110.33 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.594 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 151.72 -152.29 24.07 Favored Glycine 0 N--CA 1.491 2.326 0 C-N-CA 119.073 -1.537 . . . . 0.0 111.018 -179.607 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.801 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -151.75 147.11 26.29 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.125 -1.221 . . . . 0.0 108.938 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.972 ' CE1' HD11 ' A' ' 32' ' ' LEU . 8.8 m-30 -106.93 158.66 16.85 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 179.642 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.933 ' CG2' HG23 ' A' ' 33' ' ' VAL . 31.8 t -147.61 161.92 7.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.035 -1.041 . . . . 0.0 109.858 -179.154 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 1.135 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -139.74 150.34 44.68 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.103 -0.998 . . . . 0.0 109.436 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.678 HD11 ' HB2' ' A' ' 29' ' ' LYS . 4.5 pt . . . . . 0 N--CA 1.494 1.726 0 O-C-N 120.823 -1.173 . . . . 0.0 109.706 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.678 ' HB2' HD11 ' A' ' 25' ' ' ILE . 14.7 mtpt . . . . . 0 N--CA 1.489 1.476 0 CA-C-O 121.445 0.64 . . . . 0.0 109.389 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.56 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 1.1 mt-10 -130.34 158.8 38.83 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.061 -1.024 . . . . 0.0 110.356 -179.678 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.627 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -108.68 -173.73 21.48 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 179.328 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.972 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.26 123.21 8.76 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.853 -1.381 . . . . 0.0 110.682 179.751 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.933 HG23 ' CG2' ' A' ' 23' ' ' VAL . 60.8 t -97.67 62.16 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 177.662 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.496 ' HB3' ' HG3' ' A' ' 37' ' ' GLN . 3.3 t-80 -48.39 159.49 0.21 Allowed 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.692 -1.255 . . . . 0.0 108.147 -179.623 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.594 ' O ' HD13 ' A' ' 38' ' ' ILE . 3.1 tp -48.58 -50.35 12.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.587 0 O-C-N 121.099 -1.001 . . . . 0.0 110.09 -179.121 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.536 ' N ' HG23 ' A' ' 35' ' ' ILE . 5.3 m -81.57 41.22 0.62 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.182 -0.949 . . . . 0.0 110.424 -179.656 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.905 ' C ' HD12 ' A' ' 38' ' ' ILE . 40.3 mt-30 -150.69 53.0 0.88 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.847 -1.158 . . . . 0.0 110.245 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.944 HG21 HG21 ' A' ' 43' ' ' VAL . 1.6 mp -119.09 -98.92 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.928 -1.107 . . . . 0.0 109.936 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.765 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.302 -1.469 0 O-C-N 121.315 -0.866 . . . . 0.0 109.641 -179.424 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.152 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 80.4 t . . . . . 0 N--CA 1.487 1.401 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.425 ' C ' ' O ' ' A' ' 43' ' ' VAL . 0.0 OUTLIER -43.73 -26.66 0.26 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.38 -0.825 . . . . 0.0 108.896 179.849 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.455 ' HB3' ' CG ' ' A' ' 48' ' ' ASP . 0.1 OUTLIER -109.83 114.33 27.8 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.495 -0.753 . . . . 0.0 108.988 179.479 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.594 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -78.16 -24.14 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.141 -0.975 . . . . 0.0 108.62 179.747 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 3.7 p -76.22 1.61 15.45 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.44 -0.787 . . . . 0.0 109.344 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.455 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 14.4 m-20 -96.05 -40.35 9.29 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.111 -0.993 . . . . 0.0 108.926 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 1.152 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 9.5 m-85 -89.56 -28.77 19.36 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.487 -0.758 . . . . 0.0 109.019 179.715 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.991 HD13 HG22 ' A' ' 13' ' ' VAL . 0.1 OUTLIER -102.75 134.74 45.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.504 -0.748 . . . . 0.0 109.537 -179.842 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.517 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 1.9 tt0 -140.39 143.03 35.45 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.59 -0.694 . . . . 0.0 109.314 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 39.1 mtm -67.54 93.77 0.38 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.179 -0.951 . . . . 0.0 109.441 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.69 -18.91 4.81 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' GLN . . . . . 0.466 ' O ' HG23 ' A' ' 13' ' ' VAL . 11.6 mm-40 -79.7 124.86 28.96 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.328 -1.101 . . . . 0.0 109.637 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -106.27 117.78 34.94 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.257 -0.902 . . . . 0.0 109.109 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.455 HG21 HD11 ' A' ' 73' ' ' ILE . 33.8 m -118.98 151.76 50.85 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.134 -0.979 . . . . 0.0 109.836 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 56' ' ' VAL . 36.0 Cg_endo -78.87 142.57 17.72 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.695 2.264 . . . . 0.0 110.509 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.788 HG21 ' HB3' ' A' ' 71' ' ' LEU . 0.9 OUTLIER -141.67 -177.22 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.211 -0.931 . . . . 0.0 109.354 179.622 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.476 ' HG2' HG22 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -134.03 128.73 34.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.283 -0.886 . . . . 0.0 109.475 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.622 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 62.0 t . . . . . 0 N--CA 1.491 1.597 0 O-C-N 121.266 -0.896 . . . . 0.0 109.037 179.504 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.788 ' HB3' HG21 ' A' ' 58' ' ' VAL . 15.1 mt . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -118.21 106.64 13.03 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.341 -0.849 . . . . 0.0 109.871 -179.618 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.477 HG22 ' O ' ' A' ' 38' ' ' ILE . 0.1 OUTLIER -58.77 139.12 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.269 -0.894 . . . . 0.0 109.001 179.865 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 2.4 mmtm . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.26 -0.9 . . . . 0.0 109.281 179.803 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.624 HG13 ' O ' ' A' ' 58' ' ' VAL . 48.1 t . . . . . 0 N--CA 1.489 1.486 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.506 ' CE1' HG21 ' A' ' 60' ' ' VAL . 3.0 m-85 -110.31 179.92 3.95 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.156 -0.965 . . . . 0.0 109.392 179.775 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.473 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 3.5 m -136.65 107.58 6.68 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 178.94 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.507 ' HA2' ' O ' ' A' ' 24' ' ' ALA . . . -109.82 141.6 16.2 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.065 -1.541 . . . . 0.0 110.331 -178.743 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.455 ' O ' HG13 ' A' ' 23' ' ' VAL . 27.4 mtpt -89.15 163.73 15.32 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 178.939 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.968 HG22 HD23 ' A' ' 50' ' ' LEU . 95.3 t -87.43 102.02 11.94 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.725 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.2 p -106.12 -11.67 16.02 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.478 -0.764 . . . . 0.0 110.186 -178.62 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.562 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -161.2 156.33 24.07 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.954 -1.091 . . . . 0.0 110.455 -179.781 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.462 ' HA ' ' HA ' ' A' ' 21' ' ' ALA . 24.1 mt -147.61 142.77 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.161 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 1.086 HG21 ' CE1' ' A' ' 19' ' ' PHE . 1.5 m -120.79 157.82 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.898 -1.126 . . . . 0.0 110.186 -178.771 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.2 -39.41 86.46 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.807 -1.183 . . . . 0.0 109.459 179.097 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 1.086 ' CE1' HG21 ' A' ' 17' ' ' VAL . 10.1 p90 -95.16 27.06 3.4 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.14 -0.975 . . . . 0.0 110.222 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.597 ' N ' HG22 ' A' ' 17' ' ' VAL . . . 158.29 -157.43 28.31 Favored Glycine 0 N--CA 1.49 2.244 0 C-N-CA 118.936 -1.602 . . . . 0.0 110.802 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.778 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -149.23 145.4 27.1 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.215 -1.168 . . . . 0.0 109.154 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.965 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.3 m-30 -106.5 158.4 16.94 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.467 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.798 ' CG2' HG23 ' A' ' 33' ' ' VAL . 32.3 t -148.87 164.95 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.067 -1.02 . . . . 0.0 109.533 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.725 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -133.76 152.93 52.01 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.032 -1.043 . . . . 0.0 109.998 -179.478 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.667 HD11 ' HB3' ' A' ' 29' ' ' LYS . 2.0 pt . . . . . 0 N--CA 1.494 1.74 0 O-C-N 120.666 -1.271 . . . . 0.0 109.429 179.362 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.667 ' HB3' HD11 ' A' ' 25' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.464 0 CA-C-O 121.716 0.77 . . . . 0.0 109.8 . . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.59 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 13.8 mt-10 -134.6 154.08 51.66 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.925 -1.109 . . . . 0.0 110.222 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.67 ' CA ' HD12 ' A' ' 71' ' ' LEU . . . -101.06 -175.99 29.12 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 108.478 -1.849 . . . . 0.0 108.478 179.307 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.965 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.17 119.31 6.76 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.979 -1.306 . . . . 0.0 110.73 179.429 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 1.021 HG21 HD11 ' A' ' 50' ' ' LEU . 41.3 t -95.93 62.21 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 177.907 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.519 ' O ' ' CD1' ' A' ' 38' ' ' ILE . 3.9 t-160 -49.37 160.12 0.27 Allowed 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.898 -1.127 . . . . 0.0 108.46 -179.49 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.593 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.9 tp -52.2 -49.58 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.236 -0.915 . . . . 0.0 110.286 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.557 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.4 OUTLIER -81.28 41.34 0.6 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.16 -0.963 . . . . 0.0 110.582 -179.331 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.732 ' C ' HD12 ' A' ' 38' ' ' ILE . 30.7 mt-30 -150.65 33.38 0.62 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.766 -1.209 . . . . 0.0 110.42 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.759 ' HB ' HG21 ' A' ' 43' ' ' VAL . 1.5 mp -108.72 -96.29 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.815 -1.178 . . . . 0.0 110.157 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.667 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.3 -1.55 0 O-C-N 121.361 -0.837 . . . . 0.0 110.326 -178.922 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.041 HG13 ' CD1' ' A' ' 49' ' ' TYR . 5.5 t . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 121.15 0.5 . . . . 0.0 110.245 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.406 ' C ' ' O ' ' A' ' 43' ' ' VAL . 2.3 mp0 -47.85 -26.01 1.5 Allowed 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 178.973 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.456 ' HB2' ' CG ' ' A' ' 48' ' ' ASP . 0.1 OUTLIER -127.86 124.65 38.04 Favored 'General case' 0 N--CA 1.487 1.375 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.453 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.568 HG21 ' O ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -70.23 -25.74 28.02 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.355 -0.841 . . . . 0.0 109.119 -179.507 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 3.4 p -75.43 5.28 5.98 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.431 -0.793 . . . . 0.0 109.878 179.598 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.456 ' CG ' ' HB2' ' A' ' 45' ' ' LYS . 12.5 m-20 -101.14 -34.7 9.59 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.008 -1.057 . . . . 0.0 108.677 179.534 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 1.041 ' CD1' HG13 ' A' ' 43' ' ' VAL . 6.3 m-85 -89.51 -34.07 16.53 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.524 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 1.021 HD11 HG21 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -102.57 154.4 19.16 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.173 -1.011 . . . . 0.0 110.366 179.783 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.465 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.6 OUTLIER -142.95 133.83 25.47 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.487 -0.758 . . . . 0.0 109.13 179.982 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 3.9 mtt -63.99 100.44 0.31 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.258 -0.901 . . . . 0.0 109.847 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 129.97 -24.84 4.47 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' GLN . . . . . 0.409 ' HA ' ' OE1' ' A' ' 54' ' ' GLN . 13.2 mm100 -78.87 158.48 28.1 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.232 -1.158 . . . . 0.0 109.786 -179.785 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -110.61 111.66 23.04 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.328 -0.857 . . . . 0.0 109.026 179.576 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.626 ' O ' HG23 ' A' ' 56' ' ' VAL . 6.8 m -103.24 121.99 46.84 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.184 -0.947 . . . . 0.0 110.108 -179.424 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.473 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.5 Cg_endo -80.84 146.71 16.61 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 C-N-CA 122.559 2.173 . . . . 0.0 110.077 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.838 HG21 ' HB3' ' A' ' 71' ' ' LEU . 1.0 OUTLIER -140.01 -168.77 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.06 -1.025 . . . . 0.0 109.655 -179.994 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.593 ' N ' HG23 ' A' ' 58' ' ' VAL . 14.9 mtpt -131.23 119.61 22.06 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.401 -0.812 . . . . 0.0 109.493 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.608 ' HA ' HD23 ' A' ' 71' ' ' LEU . 95.9 t . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.838 ' HB3' HG21 ' A' ' 58' ' ' VAL . 96.5 mt . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 121.459 0.647 . . . . 0.0 110.043 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -117.16 113.55 22.41 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.508 -0.745 . . . . 0.0 109.571 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.423 HG13 HG13 ' A' ' 33' ' ' VAL . 0.6 OUTLIER -47.56 122.81 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.349 -0.844 . . . . 0.0 109.264 179.927 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.467 ' HB3' ' O ' ' A' ' 57' ' ' PRO . 4.2 ttpp . . . . . 0 N--CA 1.488 1.451 0 O-C-N 121.19 -0.944 . . . . 0.0 108.939 179.431 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.567 HG13 ' O ' ' A' ' 58' ' ' VAL . 54.9 t . . . . . 0 N--CA 1.489 1.48 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.561 ' CE1' ' CG2' ' A' ' 60' ' ' VAL . 2.9 m-85 -106.52 -179.4 3.93 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.119 -0.988 . . . . 0.0 110.071 -178.731 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.8 m -129.04 105.52 8.25 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 178.181 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.434 ' HA2' ' O ' ' A' ' 24' ' ' ALA . . . -108.16 132.21 11.0 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 119.318 -1.42 . . . . 0.0 111.254 -177.747 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.474 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.3 OUTLIER -91.39 158.83 16.3 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 178.348 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.859 ' CG2' HD22 ' A' ' 50' ' ' LEU . 61.2 t -87.82 97.02 6.2 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 O-C-N 120.858 -1.151 . . . . 0.0 109.045 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.786 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -101.37 -5.78 24.93 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.527 -0.733 . . . . 0.0 109.817 -179.255 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.56 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -164.95 153.71 12.37 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.122 -0.986 . . . . 0.0 110.113 -179.693 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.681 HG21 HG22 ' A' ' 47' ' ' THR . 7.7 mt -141.58 152.92 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 178.842 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 1.013 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -132.33 151.27 34.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.903 -1.123 . . . . 0.0 109.907 -179.011 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -58.41 -38.78 78.09 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.735 -1.228 . . . . 0.0 108.835 179.203 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 1.013 ' CE1' HG21 ' A' ' 17' ' ' VAL . 23.3 p90 -92.57 30.13 1.59 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.504 -0.748 . . . . 0.0 109.943 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.595 ' C ' HG22 ' A' ' 17' ' ' VAL . . . 149.54 -150.99 23.16 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 119.114 -1.517 . . . . 0.0 111.219 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.819 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -152.58 144.9 23.98 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.094 -1.239 . . . . 0.0 109.158 -179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.965 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.3 m-30 -106.29 142.38 36.07 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.306 -0.872 . . . . 0.0 108.881 179.566 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.878 ' CG2' HG23 ' A' ' 33' ' ' VAL . 40.8 t -132.91 163.02 39.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 120.902 -1.124 . . . . 0.0 109.643 -179.444 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.786 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -130.15 153.24 48.73 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.103 -0.998 . . . . 0.0 109.65 -179.608 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.657 HD11 ' HB3' ' A' ' 29' ' ' LYS . 1.8 pt . . . . . 0 N--CA 1.492 1.645 0 O-C-N 120.984 -1.072 . . . . 0.0 109.417 179.825 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.657 ' HB3' HD11 ' A' ' 25' ' ' ILE . 16.5 mmtt . . . . . 0 N--CA 1.488 1.464 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.512 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 1.2 mt-10 -136.81 150.75 48.51 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.973 -1.079 . . . . 0.0 110.102 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.496 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -102.33 -177.19 27.54 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 108.137 -1.985 . . . . 0.0 108.137 179.03 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.965 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -149.53 116.76 6.05 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.694 -1.474 . . . . 0.0 110.431 179.119 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.878 HG23 ' CG2' ' A' ' 23' ' ' VAL . 93.3 t -90.85 59.93 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 178.049 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.518 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.6 t-80 -48.73 157.28 0.39 Allowed 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.57 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.8 tp -47.19 -47.76 9.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.089 -1.007 . . . . 0.0 110.119 -179.207 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.472 ' N ' HG23 ' A' ' 35' ' ' ILE . 56.7 p -81.18 39.41 0.51 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.064 -1.023 . . . . 0.0 110.791 -179.463 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.98 ' C ' HD12 ' A' ' 38' ' ' ILE . 12.4 mt-30 -150.52 53.42 0.89 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.646 -1.283 . . . . 0.0 110.664 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.98 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.7 mp -126.25 -96.31 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.952 -1.093 . . . . 0.0 109.529 179.24 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.787 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.302 -1.469 0 O-C-N 121.411 -0.806 . . . . 0.0 109.195 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.106 HG13 ' CD1' ' A' ' 49' ' ' TYR . 54.6 t . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 108.976 -0.749 . . . . 0.0 108.976 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.433 ' C ' ' O ' ' A' ' 43' ' ' VAL . 16.8 mt-10 -40.99 -28.05 0.07 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.558 -0.714 . . . . 0.0 110.314 -179.399 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.492 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.1 OUTLIER -142.63 138.51 30.76 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.961 -1.087 . . . . 0.0 110.206 -179.697 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.551 HG21 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -80.61 -26.47 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.356 -0.84 . . . . 0.0 108.845 179.514 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.681 HG22 HG21 ' A' ' 16' ' ' ILE . 47.3 p -78.47 5.12 11.45 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.317 -0.864 . . . . 0.0 109.023 179.056 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.466 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 4.1 m-20 -104.48 -30.76 9.83 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.328 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 1.106 ' CD1' HG13 ' A' ' 43' ' ' VAL . 17.8 m-85 -90.25 -33.98 15.94 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.595 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.859 HD22 ' CG2' ' A' ' 13' ' ' VAL . 3.5 mt -108.1 151.78 25.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.194 -0.941 . . . . 0.0 110.005 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.521 ' CB ' ' HG3' ' A' ' 54' ' ' GLN . 0.1 OUTLIER -136.93 138.52 40.72 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 179.033 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 23.4 mtt -62.6 91.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.003 -1.06 . . . . 0.0 109.839 -179.523 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 137.52 -22.59 3.17 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 119.732 -1.223 . . . . 0.0 110.388 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' GLN . . . . . 0.521 ' HG3' ' CB ' ' A' ' 51' ' ' GLN . 6.5 mm-40 -77.28 145.29 37.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.055 -1.262 . . . . 0.0 110.074 -179.377 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -113.19 127.26 56.13 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.475 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.438 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 15.9 m -132.45 142.37 44.66 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.02 -1.05 . . . . 0.0 110.032 -179.524 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.454 ' O ' ' HB2' ' A' ' 74' ' ' LYS . 36.9 Cg_endo -80.27 129.42 7.66 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.665 2.244 . . . . 0.0 110.335 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.865 HG21 ' HB3' ' A' ' 71' ' ' LEU . 0.8 OUTLIER -120.6 -170.5 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.19 -0.944 . . . . 0.0 109.317 179.753 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.631 ' N ' HG23 ' A' ' 58' ' ' VAL . 0.1 OUTLIER -132.12 141.83 49.28 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.257 -0.902 . . . . 0.0 109.319 179.883 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.561 ' CG2' ' CE1' ' A' ' 9' ' ' TYR . 26.5 t . . . . . 0 N--CA 1.492 1.645 0 O-C-N 121.449 -0.782 . . . . 0.0 109.139 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.865 ' HB3' HG21 ' A' ' 58' ' ' VAL . 17.5 mt . . . . . 0 N--CA 1.489 1.51 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.442 ' C ' ' HB ' ' A' ' 58' ' ' VAL . 0.6 OUTLIER -134.11 117.14 16.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.105 -0.997 . . . . 0.0 110.302 -179.262 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.431 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.1 OUTLIER -44.07 131.89 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.299 -0.876 . . . . 0.0 108.962 179.691 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.454 ' HB2' ' O ' ' A' ' 57' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.602 0 O-C-N 121.215 -0.928 . . . . 0.0 110.137 -179.374 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.945 HG13 ' O ' ' A' ' 58' ' ' VAL . 93.5 t . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.482 ' CE1' HG23 ' A' ' 60' ' ' VAL . 9.2 m-85 -118.69 -168.19 1.5 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.302 -0.874 . . . . 0.0 109.758 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.534 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 34.3 m -166.21 127.81 1.83 Allowed 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.443 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.5 ' HA3' ' O ' ' A' ' 24' ' ' ALA . . . -149.53 -177.84 23.97 Favored Glycine 0 N--CA 1.489 2.202 0 C-N-CA 118.44 -1.838 . . . . 0.0 111.266 -178.636 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.543 ' O ' HG13 ' A' ' 23' ' ' VAL . 15.6 mtpt -104.45 168.27 9.2 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.808 -0.819 . . . . 0.0 108.929 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.926 HG22 HD13 ' A' ' 50' ' ' LEU . 72.4 t -87.98 101.37 11.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 O-C-N 121.156 -0.965 . . . . 0.0 108.423 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.665 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.1 p -111.11 11.12 21.96 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.275 -0.89 . . . . 0.0 110.286 -178.814 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.555 ' HB3' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -175.29 147.01 0.86 Allowed 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.956 -1.09 . . . . 0.0 110.255 179.75 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.4 HG21 HG22 ' A' ' 47' ' ' THR . 17.2 mt -139.28 151.71 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.068 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 1.054 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -129.61 154.05 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.765 -1.209 . . . . 0.0 110.088 -179.089 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -59.13 -41.7 88.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.866 -1.147 . . . . 0.0 109.327 179.173 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 1.054 ' CE1' HG21 ' A' ' 17' ' ' VAL . 14.0 p90 -91.3 27.14 2.0 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.313 -0.867 . . . . 0.0 110.22 -179.716 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.606 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 155.22 -153.58 24.88 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.898 -1.62 . . . . 0.0 111.063 -179.365 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.792 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -150.33 144.71 25.69 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.063 -1.257 . . . . 0.0 109.007 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.959 ' CE1' HD11 ' A' ' 32' ' ' LEU . 11.1 m-30 -108.41 162.11 14.41 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.401 -0.812 . . . . 0.0 109.214 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.571 ' CG2' HG23 ' A' ' 33' ' ' VAL . 3.5 t -150.63 166.81 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.166 -0.958 . . . . 0.0 109.433 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.665 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -132.79 145.24 50.83 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.209 -0.932 . . . . 0.0 108.856 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.985 HD11 ' HB2' ' A' ' 29' ' ' LYS . 7.7 pt . . . . . 0 N--CA 1.496 1.84 0 O-C-N 120.547 -1.346 . . . . 0.0 109.653 -179.829 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.985 ' HB2' HD11 ' A' ' 25' ' ' ILE . 5.8 mmtm . . . . . 0 N--CA 1.49 1.529 0 CA-C-O 121.774 0.797 . . . . 0.0 109.68 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.553 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 7.3 pt-20 -128.01 157.47 40.55 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 120.867 -1.146 . . . . 0.0 110.474 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.812 ' CA ' HD12 ' A' ' 71' ' ' LEU . . . -105.83 -175.79 23.83 Favored Glycine 0 N--CA 1.487 2.042 0 N-CA-C 108.337 -1.905 . . . . 0.0 108.337 179.298 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.959 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.79 121.29 7.4 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 120.746 -1.444 . . . . 0.0 111.542 -179.794 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.792 ' HB ' ' HB3' ' A' ' 21' ' ' ALA . 26.0 t -95.86 62.9 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 176.922 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.475 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.7 t-160 -48.08 155.02 0.5 Allowed 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.885 -1.135 . . . . 0.0 108.883 -179.274 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.576 HG23 ' H ' ' A' ' 36' ' ' SER . 3.0 tp -45.84 -52.09 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.218 -0.926 . . . . 0.0 110.315 -179.431 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.576 ' H ' HG23 ' A' ' 35' ' ' ILE . 0.0 OUTLIER -81.52 42.96 0.71 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.294 -0.879 . . . . 0.0 110.524 -179.33 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.972 ' C ' HD12 ' A' ' 38' ' ' ILE . 68.3 mt-30 -150.83 53.38 0.87 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.859 -1.151 . . . . 0.0 110.036 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.972 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.7 mp -124.53 -96.01 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.926 -1.109 . . . . 0.0 110.376 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.797 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.3 -1.554 0 O-C-N 121.492 -0.755 . . . . 0.0 109.674 -178.845 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.031 HG13 ' CD1' ' A' ' 49' ' ' TYR . 60.2 t . . . . . 0 N--CA 1.486 1.36 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.433 ' C ' ' O ' ' A' ' 43' ' ' VAL . 3.6 mm-40 -45.06 -25.05 0.29 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.224 -0.922 . . . . 0.0 108.744 179.633 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.429 ' N ' ' C ' ' A' ' 43' ' ' VAL . 25.0 mmtp -119.66 122.7 42.09 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.537 -0.727 . . . . 0.0 109.157 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.606 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -78.98 -24.54 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.271 -0.893 . . . . 0.0 108.842 179.812 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.4 HG22 HG21 ' A' ' 16' ' ' ILE . 72.5 p -75.9 4.4 8.25 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.449 -0.782 . . . . 0.0 109.723 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -102.75 -38.16 7.57 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.135 -0.978 . . . . 0.0 109.183 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 1.031 ' CD1' HG13 ' A' ' 43' ' ' VAL . 9.9 m-85 -89.43 -33.55 16.78 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.349 -0.844 . . . . 0.0 109.104 179.669 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.926 HD13 HG22 ' A' ' 13' ' ' VAL . 0.1 OUTLIER -98.86 135.54 40.15 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.412 -0.805 . . . . 0.0 109.443 -179.793 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.479 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.0 OUTLIER -138.89 122.5 17.41 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.556 -0.715 . . . . 0.0 109.6 -179.84 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 52' ' ' MET . . . . . 0.504 ' CG ' ' O ' ' A' ' 52' ' ' MET . 5.1 ptm -48.6 105.79 0.09 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.317 -0.864 . . . . 0.0 109.947 -179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 133.92 -43.55 1.26 Allowed Glycine 0 N--CA 1.492 2.398 0 C-N-CA 119.832 -1.175 . . . . 0.0 110.471 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' GLN . . . . . 0.424 ' O ' HG23 ' A' ' 13' ' ' VAL . 15.8 mt-30 -69.32 146.15 52.43 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.01 -1.288 . . . . 0.0 110.107 -179.399 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.51 ' HA ' ' HA ' ' A' ' 12' ' ' LYS . 0.4 OUTLIER -122.53 140.08 53.18 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.355 -0.841 . . . . 0.0 109.115 179.526 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.416 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 24.8 m -146.73 155.95 48.37 Favored Pre-proline 0 N--CA 1.487 1.424 0 O-C-N 121.164 -0.96 . . . . 0.0 110.052 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.534 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 37.2 Cg_endo -83.37 146.9 12.51 Favored 'Trans proline' 0 C--N 1.314 -1.261 0 C-N-CA 123.161 2.574 . . . . 0.0 110.428 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.945 ' O ' HG13 ' A' ' 8' ' ' VAL . 1.0 OUTLIER -141.29 -168.61 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.186 -0.946 . . . . 0.0 109.287 179.368 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.702 ' CG ' HG22 ' A' ' 8' ' ' VAL . 17.2 mtmt -134.3 134.14 41.54 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.385 -0.822 . . . . 0.0 109.779 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.486 ' O ' HG12 ' A' ' 60' ' ' VAL . 47.6 t . . . . . 0 N--CA 1.493 1.721 0 O-C-N 121.392 -0.818 . . . . 0.0 109.197 179.632 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.812 HD12 ' CA ' ' A' ' 31' ' ' GLY . 13.6 mt . . . . . 0 N--CA 1.487 1.376 0 CA-C-O 121.469 0.652 . . . . 0.0 109.607 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.423 ' O ' ' C ' ' A' ' 73' ' ' ILE . 0.3 OUTLIER -133.43 107.65 8.19 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.442 -0.786 . . . . 0.0 109.724 -179.636 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.423 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.0 OUTLIER -44.92 140.31 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.249 -0.907 . . . . 0.0 108.77 179.713 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.416 ' HD3' ' HB2' ' A' ' 57' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.634 0 O-C-N 121.15 -0.969 . . . . 0.0 109.424 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.537 ' HA ' ' HA ' ' A' ' 59' ' ' LYS . 68.1 t . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.626 ' CD1' HG23 ' A' ' 60' ' ' VAL . 14.0 m-85 -143.94 128.42 17.99 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.023 -1.048 . . . . 0.0 110.355 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -91.06 115.62 28.16 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 178.15 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -113.6 141.3 16.87 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 119.119 -1.515 . . . . 0.0 110.626 -178.362 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.516 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.8 OUTLIER -89.56 162.07 15.86 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 178.724 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.741 HG22 HD13 ' A' ' 50' ' ' LEU . 58.2 t -87.86 105.39 15.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 120.986 -1.072 . . . . 0.0 108.368 179.616 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.918 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -111.7 -0.8 15.89 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.262 -0.899 . . . . 0.0 110.218 -178.859 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.527 ' CD ' ' O ' ' A' ' 14' ' ' THR . 0.3 OUTLIER -168.05 152.42 6.34 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.902 -1.123 . . . . 0.0 110.314 179.97 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.441 ' HA ' ' HA ' ' A' ' 21' ' ' ALA . 56.6 mt -145.37 150.03 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 179.058 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 1.095 HG21 ' CE1' ' A' ' 19' ' ' PHE . 1.2 m -126.93 156.33 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 120.932 -1.105 . . . . 0.0 109.813 -179.076 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -60.37 -37.89 82.18 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.784 -1.197 . . . . 0.0 109.455 179.208 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 1.095 ' CE1' HG21 ' A' ' 17' ' ' VAL . 13.9 p90 -94.56 26.43 3.47 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.244 -0.91 . . . . 0.0 110.379 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.593 ' HA2' ' N ' ' A' ' 35' ' ' ILE . . . 155.54 -154.08 25.25 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.481 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.726 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -152.27 146.23 25.25 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.043 -1.269 . . . . 0.0 109.439 -179.558 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.957 ' CE1' HD11 ' A' ' 32' ' ' LEU . 12.4 m-30 -108.04 158.54 17.31 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.354 -0.842 . . . . 0.0 109.145 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.788 ' CG2' HG23 ' A' ' 33' ' ' VAL . 7.7 t -145.85 163.75 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.166 -0.959 . . . . 0.0 109.151 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.918 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -137.1 146.55 45.25 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.017 -1.052 . . . . 0.0 110.119 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.522 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.1 pt . . . . . 0 N--CA 1.494 1.735 0 O-C-N 120.779 -1.201 . . . . 0.0 108.667 178.985 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.522 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.512 0 CA-C-O 121.548 0.69 . . . . 0.0 109.514 . . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.573 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 3.5 pt-20 -134.68 153.4 52.01 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 120.847 -1.158 . . . . 0.0 110.224 -179.855 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -102.57 -173.51 27.0 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 108.504 -1.839 . . . . 0.0 108.504 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.957 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.31 119.02 6.55 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.993 -1.298 . . . . 0.0 110.692 179.514 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.83 HG12 HD11 ' A' ' 38' ' ' ILE . 8.4 t -96.59 63.56 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 177.588 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.551 ' HB3' ' CG ' ' A' ' 37' ' ' GLN . 4.4 t-80 -47.7 166.08 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.308 0 O-C-N 120.879 -1.138 . . . . 0.0 108.279 -179.594 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.662 ' HA ' HG13 ' A' ' 46' ' ' VAL . 0.2 OUTLIER -55.19 -55.33 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.136 -0.977 . . . . 0.0 110.296 -179.256 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.626 ' H ' HG23 ' A' ' 35' ' ' ILE . 92.6 p -82.31 42.57 0.75 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.018 -1.051 . . . . 0.0 110.334 -179.734 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.95 ' O ' HD13 ' A' ' 73' ' ' ILE . 20.8 mm-40 -145.27 44.46 1.32 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.938 -1.101 . . . . 0.0 109.598 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.925 HG21 ' CD2' ' A' ' 49' ' ' TYR . 1.8 mp -119.33 -91.66 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.253 -0.904 . . . . 0.0 108.978 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.825 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.298 -1.654 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.023 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 39.6 t . . . . . 0 N--CA 1.482 1.132 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 25.5 tp10 -46.49 -22.5 0.27 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.151 -0.968 . . . . 0.0 109.244 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.539 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 28.9 mttp -119.68 109.12 15.27 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.386 -0.821 . . . . 0.0 109.246 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.662 HG13 ' HA ' ' A' ' 35' ' ' ILE . 0.0 OUTLIER -77.52 -22.87 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.232 -0.918 . . . . 0.0 108.781 179.842 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 18.6 p -76.99 2.57 14.48 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.449 -0.782 . . . . 0.0 109.216 179.251 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.404 ' OD2' ' HD2' ' A' ' 45' ' ' LYS . 1.7 m-20 -101.42 -33.68 9.89 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.1 -1.0 . . . . 0.0 109.264 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 1.023 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 6.6 m-85 -94.98 -30.78 13.94 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.575 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.741 HD13 HG22 ' A' ' 13' ' ' VAL . 0.2 OUTLIER -105.61 140.73 38.24 Favored 'General case' 0 N--CA 1.488 1.454 0 CA-C-O 121.536 0.684 . . . . 0.0 109.35 -179.731 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.511 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 2.0 tm0? -148.61 124.38 10.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.462 -0.774 . . . . 0.0 109.301 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 56.8 mtp -48.8 112.65 0.64 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.288 -0.883 . . . . 0.0 109.924 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 113.11 -44.85 1.42 Allowed Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' GLN . . . . . 0.539 ' O ' HG23 ' A' ' 13' ' ' VAL . 15.5 mm100 -56.92 102.96 0.09 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.147 -1.208 . . . . 0.0 109.586 -179.727 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -65.18 137.14 57.43 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.188 -0.945 . . . . 0.0 109.125 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.7 m -135.48 132.13 19.7 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.229 -0.919 . . . . 0.0 109.841 -179.767 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.414 ' HG2' ' HG3' ' A' ' 74' ' ' LYS . 36.4 Cg_endo -79.96 142.63 15.72 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.461 2.107 . . . . 0.0 110.129 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.892 ' CG2' HD12 ' A' ' 71' ' ' LEU . 0.9 OUTLIER -141.43 -173.74 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.232 -0.917 . . . . 0.0 109.246 179.665 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.571 ' N ' HG23 ' A' ' 58' ' ' VAL . 9.0 mtmm -142.35 111.26 6.33 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.295 -0.878 . . . . 0.0 110.248 -179.71 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.626 HG23 ' CD1' ' A' ' 9' ' ' TYR . 61.5 t . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.857 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.892 HD12 ' CG2' ' A' ' 58' ' ' VAL . 0.3 OUTLIER . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 . . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.427 ' HB2' ' O ' ' A' ' 59' ' ' LYS . 0.6 OUTLIER -109.85 111.71 23.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.197 -0.94 . . . . 0.0 110.219 -179.231 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.95 HD13 ' O ' ' A' ' 37' ' ' GLN . 1.2 mp -56.96 128.21 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.181 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.441 ' C ' ' O ' ' A' ' 73' ' ' ILE . 0.6 OUTLIER . . . . . 0 N--CA 1.494 1.751 0 O-C-N 121.357 -0.84 . . . . 0.0 110.351 -179.136 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.8 t . . . . . 0 N--CA 1.489 1.491 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.673 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 4.6 m-85 -122.28 133.21 54.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.043 -1.035 . . . . 0.0 109.998 -179.598 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.3 m -83.87 103.29 13.02 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.546 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.31 119.82 5.11 Favored Glycine 0 N--CA 1.487 2.056 0 C-N-CA 119.884 -1.151 . . . . 0.0 110.737 -178.495 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.604 ' O ' HG13 ' A' ' 23' ' ' VAL . 2.0 mtmt -89.29 148.46 23.55 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 178.77 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.646 HG22 ' CD2' ' A' ' 50' ' ' LEU . 3.8 t -86.85 117.6 31.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 O-C-N 120.597 -1.314 . . . . 0.0 108.656 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.952 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.5 p -128.16 -3.41 5.67 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.419 -0.801 . . . . 0.0 109.933 -178.596 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.535 ' HG3' ' HB3' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -173.77 150.57 1.71 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.128 -0.982 . . . . 0.0 109.872 179.396 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.502 HG22 ' N ' ' A' ' 17' ' ' VAL . 18.0 mt -136.31 161.49 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.374 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 1.055 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -139.97 153.34 22.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 120.59 -1.319 . . . . 0.0 110.623 -179.009 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -59.22 -41.19 88.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.766 -1.209 . . . . 0.0 109.376 179.093 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 1.055 ' CE1' HG21 ' A' ' 17' ' ' VAL . 14.3 p90 -90.99 28.42 1.58 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.356 -0.84 . . . . 0.0 110.096 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.797 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 149.7 -149.28 21.2 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.08 -1.533 . . . . 0.0 110.834 -179.717 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 1.047 ' HB1' HD12 ' A' ' 50' ' ' LEU . . . -153.64 147.79 25.73 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 120.967 -1.313 . . . . 0.0 109.263 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.972 ' CE1' HD11 ' A' ' 32' ' ' LEU . 11.9 m-30 -106.7 158.35 17.03 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.4 -0.813 . . . . 0.0 109.083 179.641 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.757 ' CG2' HG23 ' A' ' 33' ' ' VAL . 15.6 t -150.12 162.11 4.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.291 -0.881 . . . . 0.0 109.185 -179.464 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.952 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -133.57 136.5 44.97 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.147 -0.97 . . . . 0.0 109.494 -179.631 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.49 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.7 pt . . . . . 0 N--CA 1.492 1.671 0 O-C-N 120.917 -1.115 . . . . 0.0 109.47 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.49 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 121.423 0.63 . . . . 0.0 109.501 . . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.56 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -120.49 149.83 41.78 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.804 -1.185 . . . . 0.0 110.46 -179.57 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.725 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -102.69 -178.1 26.99 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.198 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.972 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -148.56 119.79 7.8 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.863 -1.375 . . . . 0.0 110.67 179.744 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.778 ' HB ' ' HB3' ' A' ' 21' ' ' ALA . 59.4 t -94.4 62.26 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 177.776 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.457 ' HB2' HD23 ' A' ' 32' ' ' LEU . 4.0 t-80 -50.16 159.39 0.45 Allowed 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.888 -1.132 . . . . 0.0 108.637 -179.53 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.582 HG23 ' H ' ' A' ' 36' ' ' SER . 1.6 tp -48.53 -52.94 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.169 -0.957 . . . . 0.0 110.342 -179.614 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.582 ' H ' HG23 ' A' ' 35' ' ' ILE . 1.9 t -81.84 44.85 0.86 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.12 -0.987 . . . . 0.0 110.536 -179.448 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.778 ' C ' HD12 ' A' ' 38' ' ' ILE . 46.8 mt-30 -150.36 37.03 0.67 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.783 -1.198 . . . . 0.0 109.88 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.887 HG21 ' CD2' ' A' ' 49' ' ' TYR . 1.8 mp -114.77 -96.69 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.932 -1.105 . . . . 0.0 110.285 -179.58 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.772 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.301 -1.512 0 O-C-N 121.447 -0.783 . . . . 0.0 109.43 -179.17 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.113 HG13 ' CD1' ' A' ' 49' ' ' TYR . 59.1 t . . . . . 0 N--CA 1.494 1.728 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.446 ' C ' ' O ' ' A' ' 43' ' ' VAL . 20.9 tp10 -38.57 -29.27 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.569 -0.707 . . . . 0.0 110.538 -179.264 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.487 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 3.5 mttm -133.03 132.37 41.75 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.915 -1.115 . . . . 0.0 109.978 -179.552 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.797 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -79.65 -25.74 12.35 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 179.18 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 10.5 p -77.2 4.45 10.44 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.653 -0.654 . . . . 0.0 109.355 179.325 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.487 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 2.8 m-20 -106.53 -30.16 9.22 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.147 -0.97 . . . . 0.0 108.621 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 1.113 ' CD1' HG13 ' A' ' 43' ' ' VAL . 19.0 m-85 -92.14 -30.91 15.71 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.576 -0.703 . . . . 0.0 109.264 179.764 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 1.047 HD12 ' HB1' ' A' ' 21' ' ' ALA . 0.6 OUTLIER -106.08 143.48 34.15 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.633 179.857 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.515 ' O ' ' CB ' ' A' ' 13' ' ' VAL . 4.1 tt0 -130.69 129.69 42.92 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.273 -0.892 . . . . 0.0 108.999 179.455 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 10.2 mtt -63.57 118.33 8.04 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.142 -0.973 . . . . 0.0 109.674 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 105.12 -23.05 31.66 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' GLN . . . . . 0.499 ' CG ' ' HB3' ' A' ' 51' ' ' GLN . 12.8 mt-30 -73.31 -172.61 1.17 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.23 -1.159 . . . . 0.0 109.647 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.463 ' HG2' ' HA ' ' A' ' 12' ' ' LYS . 5.6 mt-10 -156.76 128.75 7.29 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.214 -0.929 . . . . 0.0 109.518 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.411 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 14.6 m -128.5 145.63 56.71 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.223 -0.923 . . . . 0.0 109.721 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 56' ' ' VAL . 36.3 Cg_endo -79.79 139.93 14.28 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.644 2.229 . . . . 0.0 110.155 179.718 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.818 ' CG2' HD22 ' A' ' 71' ' ' LEU . 1.0 OUTLIER -142.49 -177.96 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.162 -0.961 . . . . 0.0 109.777 -179.844 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.418 ' N ' HG23 ' A' ' 58' ' ' VAL . 5.3 mttm -127.0 116.52 20.88 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.443 -0.786 . . . . 0.0 109.465 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.673 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 13.6 t . . . . . 0 C--N 1.302 -1.459 0 O-C-N 121.166 -0.959 . . . . 0.0 109.353 179.704 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.818 HD22 ' CG2' ' A' ' 58' ' ' VAL . 12.0 mt . . . . . 0 N--CA 1.486 1.361 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.25 90.01 3.17 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.199 -0.938 . . . . 0.0 110.071 -179.333 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -50.27 133.23 10.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.328 -0.858 . . . . 0.0 108.983 179.752 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 4.1 tttp . . . . . 0 N--CA 1.492 1.661 0 O-C-N 121.232 -0.918 . . . . 0.0 109.33 -179.932 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.6 t . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.637 ' CE1' ' CG2' ' A' ' 60' ' ' VAL . 10.3 m-85 -119.53 -177.24 3.33 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.142 -0.974 . . . . 0.0 109.975 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.58 111.86 6.29 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 178.885 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -125.09 153.34 17.94 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.009 -1.567 . . . . 0.0 110.809 -178.224 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.495 ' O ' HG13 ' A' ' 23' ' ' VAL . 16.1 mttm -95.93 166.07 11.96 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 178.938 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.081 HG22 HD13 ' A' ' 50' ' ' LEU . 79.3 t -88.46 105.23 15.45 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 121.062 -1.023 . . . . 0.0 108.323 179.404 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.53 ' O ' ' CD ' ' A' ' 15' ' ' ARG . 1.7 p -117.57 6.27 12.48 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.269 -0.895 . . . . 0.0 110.077 -179.014 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.53 ' CD ' ' O ' ' A' ' 14' ' ' THR . 0.0 OUTLIER -169.69 149.25 3.8 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.08 -1.013 . . . . 0.0 109.935 179.867 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.494 HG22 ' N ' ' A' ' 17' ' ' VAL . 19.5 mt -141.99 163.49 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 179.479 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 1.045 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -143.48 153.41 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.8 -1.188 . . . . 0.0 110.205 -179.43 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -58.21 -42.7 86.8 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.784 -1.198 . . . . 0.0 109.324 179.276 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 1.045 ' CE1' HG21 ' A' ' 17' ' ' VAL . 12.1 p90 -90.61 29.42 1.31 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.217 -0.927 . . . . 0.0 110.351 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.56 ' HA2' ' N ' ' A' ' 35' ' ' ILE . . . 150.47 -152.08 24.01 Favored Glycine 0 N--CA 1.494 2.54 0 C-N-CA 119.102 -1.523 . . . . 0.0 110.936 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.711 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -152.78 148.81 27.66 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.992 -1.299 . . . . 0.0 108.979 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.959 ' CE1' HD11 ' A' ' 32' ' ' LEU . 11.1 m-30 -107.81 163.81 12.79 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.345 -0.847 . . . . 0.0 108.753 179.571 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.938 ' CG2' HG23 ' A' ' 33' ' ' VAL . 22.7 t -149.5 165.49 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.093 -1.004 . . . . 0.0 109.204 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.591 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -132.42 141.44 48.86 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.057 -1.027 . . . . 0.0 110.592 -179.108 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.518 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.1 pt . . . . . 0 N--CA 1.491 1.585 0 O-C-N 121.079 -1.013 . . . . 0.0 108.81 179.083 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.518 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.3 OUTLIER . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 121.4 0.619 . . . . 0.0 109.625 . . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.591 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 1.4 pp20? -133.14 149.42 52.08 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 120.924 -1.11 . . . . 0.0 110.328 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.618 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -98.08 -172.68 32.79 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 108.251 -1.939 . . . . 0.0 108.251 179.194 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.959 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.65 119.76 6.74 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 120.842 -1.387 . . . . 0.0 111.047 179.737 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.938 HG23 ' CG2' ' A' ' 23' ' ' VAL . 49.3 t -95.47 61.3 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.32 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.507 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.6 t-80 -49.11 160.82 0.18 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.846 -1.159 . . . . 0.0 108.331 -179.373 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.56 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.6 tp -52.96 -41.29 40.11 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 121.029 -1.045 . . . . 0.0 109.986 -179.731 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.485 ' O ' ' HG2' ' A' ' 37' ' ' GLN . 49.9 m -81.59 30.29 0.36 Allowed 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.086 -1.009 . . . . 0.0 110.922 -179.425 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.968 ' C ' HD12 ' A' ' 38' ' ' ILE . 29.5 mt-30 -149.22 65.32 1.02 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.653 -1.28 . . . . 0.0 110.174 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.989 HG12 HG11 ' A' ' 43' ' ' VAL . 1.6 mp -123.54 -99.37 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 120.87 -1.144 . . . . 0.0 109.843 179.489 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.781 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.302 -1.476 0 O-C-N 121.16 -0.962 . . . . 0.0 109.33 -179.544 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.066 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 72.4 t . . . . . 0 N--CA 1.494 1.739 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 29.4 mp0 -45.01 -31.0 1.15 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.344 -0.847 . . . . 0.0 109.397 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.504 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 0.3 OUTLIER -112.17 114.78 27.79 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.202 -0.936 . . . . 0.0 109.386 179.873 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.555 HG21 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -73.18 -22.66 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.746 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 3.0 p -77.31 4.41 10.76 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.535 -0.728 . . . . 0.0 109.387 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.504 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 2.4 m-20 -103.93 -29.89 10.66 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.156 -0.965 . . . . 0.0 108.75 179.566 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 1.066 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 32.3 m-85 -96.49 -30.11 13.52 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.616 -0.678 . . . . 0.0 109.337 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 1.081 HD13 HG22 ' A' ' 13' ' ' VAL . 0.1 OUTLIER -104.07 133.98 48.1 Favored 'General case' 0 N--CA 1.489 1.497 0 CA-C-O 121.816 0.817 . . . . 0.0 109.774 -179.695 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.497 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.0 OUTLIER -136.21 123.49 21.85 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.912 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 52' ' ' MET . . . . . 0.426 ' HA ' ' O ' ' A' ' 13' ' ' VAL . 3.1 mtt -52.44 110.01 0.45 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.18 -0.95 . . . . 0.0 110.772 -179.189 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 122.54 -9.87 9.25 Favored Glycine 0 N--CA 1.496 2.648 0 C-N-CA 119.894 -1.146 . . . . 0.0 110.606 178.868 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -80.96 175.66 10.5 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.146 -1.208 . . . . 0.0 110.174 -179.601 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -142.72 117.72 10.01 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.564 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.3 m -135.95 145.42 52.54 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 120.993 -1.067 . . . . 0.0 110.635 -179.207 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.487 ' HG2' ' CD ' ' A' ' 74' ' ' LYS . 37.2 Cg_endo -82.98 155.64 15.07 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 C-N-CA 122.873 2.382 . . . . 0.0 109.486 178.806 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.995 HG21 ' HB3' ' A' ' 71' ' ' LEU . 1.2 m -150.48 -173.74 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.823 -1.173 . . . . 0.0 110.206 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.437 ' N ' HG23 ' A' ' 58' ' ' VAL . 0.3 OUTLIER -123.18 129.2 51.09 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 179.628 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.637 ' CG2' ' CE1' ' A' ' 9' ' ' TYR . 89.0 t . . . . . 0 N--CA 1.49 1.534 0 O-C-N 121.27 -0.894 . . . . 0.0 110.071 -179.375 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.995 ' HB3' HG21 ' A' ' 58' ' ' VAL . 12.6 mt . . . . . 0 N--CA 1.488 1.434 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.478 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.4 OUTLIER -115.79 109.61 17.9 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.301 -0.875 . . . . 0.0 109.781 -179.572 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.603 HG22 ' O ' ' A' ' 38' ' ' ILE . 0.1 OUTLIER -42.4 126.32 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.364 -0.835 . . . . 0.0 108.925 179.918 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.487 ' CD ' ' HG2' ' A' ' 57' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.444 0 O-C-N 121.167 -0.958 . . . . 0.0 109.46 -179.66 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.513 HG13 ' O ' ' A' ' 58' ' ' VAL . 72.9 t . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.594 ' CE1' ' CG2' ' A' ' 60' ' ' VAL . 14.7 m-85 -133.96 -171.56 2.77 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.033 -1.042 . . . . 0.0 110.225 -179.62 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.453 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 24.8 m -159.29 120.45 3.26 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 179.243 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.524 ' CA ' ' O ' ' A' ' 24' ' ' ALA . . . -131.92 164.59 23.66 Favored Glycine 0 N--CA 1.49 2.27 0 C-N-CA 118.759 -1.686 . . . . 0.0 111.077 -178.323 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.564 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.3 OUTLIER -101.76 168.37 9.49 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.385 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.569 HG23 ' O ' ' A' ' 54' ' ' GLN . 96.0 t -88.01 99.34 8.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.656 0 O-C-N 120.719 -1.238 . . . . 0.0 108.475 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.778 HG21 ' CB ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -105.24 -3.1 23.27 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.351 -0.843 . . . . 0.0 110.191 -178.8 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.57 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 1.8 mpp_? -165.82 155.44 12.28 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.946 -1.096 . . . . 0.0 110.19 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.519 HG21 HG22 ' A' ' 47' ' ' THR . 21.3 mt -144.43 157.89 15.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 179.575 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 1.039 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -140.09 155.85 24.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 120.664 -1.273 . . . . 0.0 110.196 -178.995 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -60.69 -41.21 94.68 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.63 -1.294 . . . . 0.0 109.456 179.472 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 1.039 ' CE1' HG21 ' A' ' 17' ' ' VAL . 12.4 p90 -89.73 24.61 2.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.186 -0.947 . . . . 0.0 110.039 -179.774 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.805 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 154.76 -149.07 20.27 Favored Glycine 0 N--CA 1.493 2.445 0 C-N-CA 119.166 -1.492 . . . . 0.0 110.958 -179.682 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.842 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -154.94 148.05 24.79 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.217 -1.166 . . . . 0.0 108.465 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.961 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.9 m-30 -108.75 160.88 15.61 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 179.693 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.564 HG13 ' O ' ' A' ' 12' ' ' LYS . 3.2 t -150.82 165.33 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.08 -1.012 . . . . 0.0 109.335 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.778 ' CB ' HG21 ' A' ' 14' ' ' THR . . . -127.08 150.46 49.46 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.066 -1.021 . . . . 0.0 109.864 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.512 HG13 ' O ' ' A' ' 29' ' ' LYS . 0.8 OUTLIER . . . . . 0 N--CA 1.493 1.704 0 O-C-N 121.102 -0.999 . . . . 0.0 109.397 179.646 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.512 ' O ' HG13 ' A' ' 25' ' ' ILE . 20.8 mmmt . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 121.632 0.73 . . . . 0.0 109.319 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.541 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -129.7 151.95 49.73 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 120.887 -1.133 . . . . 0.0 110.448 -179.305 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.959 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -99.17 -174.53 31.57 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 179.191 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.961 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.23 121.81 8.0 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.764 -1.433 . . . . 0.0 111.46 179.946 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.957 HG13 ' CD1' ' A' ' 73' ' ' ILE . 52.7 t -94.44 62.37 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 177.274 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.494 ' CB ' ' OE1' ' A' ' 37' ' ' GLN . 3.3 t-80 -50.43 155.13 1.1 Allowed 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.862 -1.149 . . . . 0.0 108.804 -179.37 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.563 HG23 ' N ' ' A' ' 36' ' ' SER . 4.1 tp -46.64 -49.92 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.361 -0.837 . . . . 0.0 110.765 -179.528 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.563 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.0 OUTLIER -81.5 41.84 0.65 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.952 -1.093 . . . . 0.0 110.524 -179.434 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.995 ' C ' HD12 ' A' ' 38' ' ' ILE . 17.2 mt-30 -150.38 51.44 0.89 Allowed 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.875 -1.141 . . . . 0.0 110.016 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.995 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.7 mp -127.27 -96.5 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 120.935 -1.103 . . . . 0.0 110.312 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.794 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.496 0 O-C-N 121.563 -0.711 . . . . 0.0 109.899 -179.01 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.123 HG13 ' CD1' ' A' ' 49' ' ' TYR . 54.1 t . . . . . 0 N--CA 1.492 1.652 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 71.7 tt0 -45.26 -26.36 0.49 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.434 -0.791 . . . . 0.0 110.13 -179.295 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -131.54 131.64 43.53 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.067 -1.021 . . . . 0.0 109.991 -179.6 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.805 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -80.04 -26.2 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.992 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.519 HG22 HG21 ' A' ' 16' ' ' ILE . 7.3 p -80.36 6.58 11.72 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 178.926 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -105.3 -25.01 12.59 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 179.23 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 1.123 ' CD1' HG13 ' A' ' 43' ' ' VAL . 26.0 m-85 -97.57 -33.61 11.28 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 179.74 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.9 HD11 HG21 ' A' ' 33' ' ' VAL . 0.7 OUTLIER -104.38 143.08 33.48 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.198 -0.939 . . . . 0.0 109.449 179.292 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.503 ' HB3' ' HG3' ' A' ' 54' ' ' GLN . 1.3 tm0? -133.86 134.94 43.34 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 7.0 mtt -54.99 102.54 0.07 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.142 -0.973 . . . . 0.0 109.733 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 126.84 -38.09 2.25 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 119.784 -1.198 . . . . 0.0 110.186 179.542 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' GLN . . . . . 0.569 ' O ' HG23 ' A' ' 13' ' ' VAL . 19.3 mm-40 -59.58 128.95 39.58 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.24 -1.153 . . . . 0.0 110.056 -179.579 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.489 ' HA ' ' HA ' ' A' ' 12' ' ' LYS . 61.8 mt-10 -108.89 131.96 54.5 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.34 -0.85 . . . . 0.0 108.9 179.375 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 17.1 m -137.34 153.44 74.71 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.086 -1.009 . . . . 0.0 110.177 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.9 Cg_endo -79.69 155.89 24.2 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.937 2.425 . . . . 0.0 110.09 179.57 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.803 HG21 ' HB3' ' A' ' 71' ' ' LEU . 1.0 OUTLIER -147.94 -174.73 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.047 -1.033 . . . . 0.0 109.469 179.927 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.513 ' N ' HG23 ' A' ' 58' ' ' VAL . 1.7 mttp -136.38 119.97 17.12 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.452 -0.78 . . . . 0.0 109.384 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.594 ' CG2' ' CE1' ' A' ' 9' ' ' TYR . 60.8 t . . . . . 0 N--CA 1.492 1.654 0 O-C-N 121.303 -0.873 . . . . 0.0 109.281 179.824 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.959 HD12 ' HA3' ' A' ' 31' ' ' GLY . 23.5 mt . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 121.357 0.599 . . . . 0.0 109.6 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.491 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.5 OUTLIER -100.38 123.5 44.68 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.39 -0.819 . . . . 0.0 109.737 -179.594 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.957 ' CD1' HG13 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -63.3 123.65 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.418 -0.801 . . . . 0.0 109.226 179.988 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.428 ' HD3' ' HB2' ' A' ' 57' ' ' PRO . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.925 . . . . 0.0 109.397 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.464 ' HA ' ' O ' ' A' ' 58' ' ' VAL . 78.8 t . . . . . 0 N--CA 1.489 1.482 0 CA-C-O 121.309 0.576 . . . . 0.0 109.801 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.464 ' CE1' ' CG2' ' A' ' 60' ' ' VAL . 5.1 m-85 -92.18 -168.74 2.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.325 -0.859 . . . . 0.0 109.148 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.545 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 21.3 m -151.48 115.85 5.07 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 178.69 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.536 ' CA ' ' O ' ' A' ' 24' ' ' ALA . . . -129.16 152.8 19.57 Favored Glycine 0 N--CA 1.487 2.035 0 C-N-CA 119.148 -1.501 . . . . 0.0 110.844 -178.57 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.49 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -93.61 167.7 11.5 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.006 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.745 HG13 HD23 ' A' ' 50' ' ' LEU . 58.4 t -88.35 106.28 16.43 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.754 0 C-N-CA 119.164 -1.014 . . . . 0.0 108.34 179.736 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.832 HG21 ' CB ' ' A' ' 24' ' ' ALA . 0.5 OUTLIER -111.07 -3.28 15.55 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.341 -0.85 . . . . 0.0 110.226 -178.577 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.548 ' CD ' ' OG1' ' A' ' 14' ' ' THR . 0.0 OUTLIER -173.45 150.73 1.86 Allowed 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.98 -1.075 . . . . 0.0 110.007 179.479 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.465 HG21 HG22 ' A' ' 47' ' ' THR . 13.1 mt -136.73 161.38 36.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.525 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 1.032 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.9 OUTLIER -138.65 153.89 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 120.653 -1.28 . . . . 0.0 110.225 -179.63 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -58.59 -43.69 89.61 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.771 -1.205 . . . . 0.0 109.495 179.196 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 1.032 ' CE1' HG21 ' A' ' 17' ' ' VAL . 11.6 p90 -89.98 27.9 1.49 Allowed 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.22 -0.925 . . . . 0.0 110.251 -179.54 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.677 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 153.67 -153.68 25.0 Favored Glycine 0 N--CA 1.492 2.375 0 C-N-CA 118.914 -1.613 . . . . 0.0 111.249 -179.731 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.761 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -151.75 147.69 26.99 Favored 'General case' 0 C--N 1.305 -1.349 0 O-C-N 121.109 -1.23 . . . . 0.0 109.056 -179.737 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.972 ' CE1' HD11 ' A' ' 32' ' ' LEU . 12.2 m-30 -108.25 160.12 16.09 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.694 ' CG2' HG23 ' A' ' 33' ' ' VAL . 24.0 t -150.41 166.58 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.06 -1.025 . . . . 0.0 109.666 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.832 ' CB ' HG21 ' A' ' 14' ' ' THR . . . -130.99 144.99 51.89 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.183 -0.948 . . . . 0.0 109.714 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.553 HD13 HD11 ' A' ' 71' ' ' LEU . 2.2 pt . . . . . 0 N--CA 1.494 1.731 0 O-C-N 120.906 -1.121 . . . . 0.0 109.399 179.835 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.488 ' O ' HG13 ' A' ' 25' ' ' ILE . 56.2 mmtt . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.546 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 10.7 pt-20 -124.47 152.75 42.97 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 120.918 -1.114 . . . . 0.0 110.975 -179.35 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.87 ' CA ' HD12 ' A' ' 71' ' ' LEU . . . -100.72 -176.54 29.62 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 108.359 -1.896 . . . . 0.0 108.359 179.165 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.972 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.26 120.88 7.48 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.863 -1.375 . . . . 0.0 110.913 179.645 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.954 HG11 ' CD1' ' A' ' 50' ' ' LEU . 61.8 t -96.19 63.11 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 177.712 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.44 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.1 t-80 -50.45 156.62 0.84 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.837 -1.165 . . . . 0.0 108.623 -179.48 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.561 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.2 OUTLIER -46.65 -48.97 6.85 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.113 -0.992 . . . . 0.0 109.575 -179.793 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.537 ' N ' HG23 ' A' ' 35' ' ' ILE . 4.9 p -81.59 40.39 0.58 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.287 -0.883 . . . . 0.0 110.389 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.56 ' C ' HD12 ' A' ' 38' ' ' ILE . 71.4 mt-30 -148.93 30.63 0.79 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.714 -1.241 . . . . 0.0 110.069 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.824 HG21 ' CD2' ' A' ' 49' ' ' TYR . 1.8 mp -104.65 -96.32 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.016 -1.053 . . . . 0.0 109.602 179.68 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.792 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.3 -1.585 0 O-C-N 121.463 -0.773 . . . . 0.0 109.502 -179.588 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.064 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 87.4 t . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.434 ' C ' ' O ' ' A' ' 43' ' ' VAL . 0.4 OUTLIER -45.33 -27.22 0.63 Allowed 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 179.568 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.446 ' HB3' ' CG ' ' A' ' 48' ' ' ASP . 0.0 OUTLIER -115.44 113.44 23.72 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 179.239 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.677 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -73.67 -25.35 20.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 -179.981 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.465 HG22 HG21 ' A' ' 16' ' ' ILE . 61.1 p -77.68 5.72 8.73 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.471 -0.768 . . . . 0.0 109.414 179.279 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.446 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 13.3 m-20 -101.29 -32.7 10.37 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 179.292 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 1.064 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 19.5 m-85 -90.43 -36.23 14.69 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 179.502 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.954 ' CD1' HG11 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -101.61 158.01 16.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.292 -0.88 . . . . 0.0 110.527 179.789 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.423 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 16.8 tp60 -149.35 127.6 12.11 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.503 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 5.6 mtt -59.69 111.82 1.58 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.124 -0.985 . . . . 0.0 110.19 -179.463 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 120.8 -25.43 7.19 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 119.874 -1.155 . . . . 0.0 110.383 179.301 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 9.6 mt-30 -74.95 177.09 6.57 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.082 -1.246 . . . . 0.0 110.323 -179.434 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.418 ' HA ' ' HA ' ' A' ' 12' ' ' LYS . 0.1 OUTLIER -139.13 126.53 21.59 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.76 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.2 m -138.01 144.98 45.97 Favored Pre-proline 0 N--CA 1.489 1.505 0 O-C-N 120.947 -1.096 . . . . 0.0 110.5 -179.293 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.545 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 37.1 Cg_endo -81.81 153.11 17.2 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 122.951 2.434 . . . . 0.0 110.117 179.418 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.806 HG21 ' HB3' ' A' ' 71' ' ' LEU . 0.8 OUTLIER -144.39 -168.86 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.1 -1.0 . . . . 0.0 109.344 179.457 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.651 ' N ' HG23 ' A' ' 58' ' ' VAL . 5.6 mttt -133.87 136.85 44.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.33 -0.856 . . . . 0.0 109.298 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.521 ' HA ' HD23 ' A' ' 71' ' ' LEU . 86.2 t . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.35 -0.844 . . . . 0.0 109.025 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.87 HD12 ' CA ' ' A' ' 31' ' ' GLY . 20.8 mt . . . . . 0 N--CA 1.489 1.516 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.445 ' O ' ' C ' ' A' ' 73' ' ' ILE . 2.1 m -125.73 117.01 22.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.289 -0.882 . . . . 0.0 109.744 -179.69 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.445 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.1 OUTLIER -44.22 136.91 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.274 -0.891 . . . . 0.0 108.785 179.68 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.444 ' CD ' ' HE3' ' A' ' 59' ' ' LYS . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.475 0 O-C-N 121.191 -0.943 . . . . 0.0 109.532 -179.714 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.686 HG22 ' HG2' ' A' ' 59' ' ' LYS . 40.8 t . . . . . 0 N--CA 1.491 1.583 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.507 ' CE1' HG23 ' A' ' 60' ' ' VAL . 13.3 m-85 -116.64 -174.25 2.53 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.173 -0.954 . . . . 0.0 110.239 -179.825 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.468 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 5.5 m -155.89 111.77 3.05 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 179.258 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.434 ' CA ' ' O ' ' A' ' 24' ' ' ALA . . . -126.58 153.66 18.85 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 118.906 -1.616 . . . . 0.0 111.04 -178.095 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.5 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -89.71 164.12 14.82 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 179.128 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.705 ' CG2' HD22 ' A' ' 50' ' ' LEU . 99.4 t -88.08 95.96 5.56 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 O-C-N 120.753 -1.217 . . . . 0.0 108.336 179.703 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.743 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.1 p -96.53 -1.9 46.17 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.5 -0.75 . . . . 0.0 109.865 -178.945 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.544 ' CD ' ' OG1' ' A' ' 14' ' ' THR . 0.0 OUTLIER -173.37 143.21 1.06 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.174 -0.954 . . . . 0.0 109.687 179.982 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.792 HG21 HG22 ' A' ' 47' ' ' THR . 8.8 mt -131.56 159.16 43.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 179.323 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 1.005 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -135.44 153.83 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 120.634 -1.291 . . . . 0.0 110.42 -178.474 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -61.3 -39.69 91.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.569 -1.332 . . . . 0.0 109.376 179.416 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 1.005 ' CE1' HG21 ' A' ' 17' ' ' VAL . 15.5 p90 -90.86 23.42 3.15 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.364 -0.835 . . . . 0.0 110.107 -179.736 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.601 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 155.16 -152.28 23.81 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 119.214 -1.47 . . . . 0.0 110.822 -179.402 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.826 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -151.42 145.01 24.94 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 120.759 -1.436 . . . . 0.0 109.31 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.961 ' CE1' HD11 ' A' ' 32' ' ' LEU . 12.4 m-30 -107.18 156.78 18.46 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.559 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.5 HG13 ' O ' ' A' ' 12' ' ' LYS . 7.2 t -150.44 162.13 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.045 -1.035 . . . . 0.0 109.793 -179.533 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.743 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -128.17 144.49 51.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.283 -0.886 . . . . 0.0 109.06 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.602 HD11 ' HB3' ' A' ' 29' ' ' LYS . 1.8 pt . . . . . 0 N--CA 1.494 1.745 0 O-C-N 120.775 -1.203 . . . . 0.0 109.915 -179.794 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.602 ' HB3' HD11 ' A' ' 25' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.428 0 CA-C-O 121.653 0.739 . . . . 0.0 109.683 . . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.542 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 0.3 OUTLIER -128.44 149.11 50.71 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.937 -1.102 . . . . 0.0 110.092 -179.661 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -98.7 -178.3 32.3 Favored Glycine 0 N--CA 1.486 2.02 0 N-CA-C 108.216 -1.954 . . . . 0.0 108.216 179.106 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.961 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -148.87 116.53 6.24 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 120.827 -1.396 . . . . 0.0 110.541 179.604 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 1.07 HG21 HD11 ' A' ' 50' ' ' LEU . 91.9 t -89.95 59.35 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 177.75 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.509 ' HB2' HD23 ' A' ' 32' ' ' LEU . 4.5 t-80 -47.28 156.19 0.27 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 120.739 -1.225 . . . . 0.0 108.551 -179.463 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.569 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.2 OUTLIER -49.81 -47.25 22.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.163 -0.96 . . . . 0.0 109.49 -179.713 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.509 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.3 OUTLIER -81.22 39.79 0.53 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.413 -0.804 . . . . 0.0 110.399 -179.925 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.791 ' C ' HD12 ' A' ' 38' ' ' ILE . 47.1 mm-40 -147.98 34.15 0.83 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.934 -1.104 . . . . 0.0 109.27 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.809 HG21 ' CD2' ' A' ' 49' ' ' TYR . 1.6 mp -112.48 -97.11 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.248 -0.908 . . . . 0.0 109.916 -179.613 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.773 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.301 -1.524 0 O-C-N 121.311 -0.868 . . . . 0.0 109.825 -179.402 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.001 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 2.5 t . . . . . 0 N--CA 1.481 1.075 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.451 ' C ' ' O ' ' A' ' 43' ' ' VAL . 3.2 mp0 -40.32 -25.06 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.639 -0.663 . . . . 0.0 109.923 -179.59 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.538 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.8 OUTLIER -151.28 121.56 7.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.146 -0.971 . . . . 0.0 110.021 -179.813 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.601 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -71.71 -26.92 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 178.959 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.792 HG22 HG21 ' A' ' 16' ' ' ILE . 58.6 p -79.14 6.02 10.64 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.892 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.48 ' OD2' ' HB2' ' A' ' 45' ' ' LYS . 26.6 m-20 -106.25 -26.9 11.34 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 179.204 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 1.001 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 12.9 m-85 -92.54 -34.83 13.9 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.247 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 1.07 HD11 HG21 ' A' ' 33' ' ' VAL . 4.6 mt -109.57 152.9 24.9 Favored 'General case' 0 N--CA 1.492 1.635 0 C-N-CA 119.473 -0.891 . . . . 0.0 109.752 179.637 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.482 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.9 OUTLIER -128.19 138.68 52.58 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.39 -0.819 . . . . 0.0 108.982 179.437 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 22.6 mtp -63.17 114.19 3.61 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.217 -0.927 . . . . 0.0 109.716 -179.719 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 109.38 -23.85 21.72 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.519 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' GLN . . . . . 0.462 ' HG3' ' HB3' ' A' ' 51' ' ' GLN . 1.5 mt-30 -74.5 147.78 41.57 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.098 -1.236 . . . . 0.0 109.791 -179.718 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.475 ' HA ' ' HA ' ' A' ' 12' ' ' LYS . 0.3 OUTLIER -107.06 146.95 30.57 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.329 -0.857 . . . . 0.0 109.37 179.889 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.456 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 18.8 m -150.6 140.03 13.52 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.079 -1.013 . . . . 0.0 109.944 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 37.2 Cg_endo -82.96 151.85 14.33 Favored 'Trans proline' 0 C--N 1.315 -1.21 0 C-N-CA 122.786 2.324 . . . . 0.0 110.137 179.311 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.85 ' CG2' HD12 ' A' ' 71' ' ' LEU . 0.9 OUTLIER -147.72 -171.22 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.167 -0.958 . . . . 0.0 109.299 179.511 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.686 ' HG2' HG22 ' A' ' 8' ' ' VAL . 10.8 mttt -138.59 121.7 16.84 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.079 -1.013 . . . . 0.0 109.955 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.706 ' HA ' HD13 ' A' ' 71' ' ' LEU . 35.2 t . . . . . 0 N--CA 1.492 1.662 0 O-C-N 121.294 -0.879 . . . . 0.0 108.944 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.85 HD12 ' CG2' ' A' ' 58' ' ' VAL . 2.4 mm? . . . . . 0 N--CA 1.489 1.503 0 CA-C-O 121.546 0.689 . . . . 0.0 109.935 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -119.33 112.71 19.78 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.522 -0.736 . . . . 0.0 109.366 -179.87 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.57 HD12 HG13 ' A' ' 33' ' ' VAL . 0.1 OUTLIER -55.63 136.08 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.271 -0.893 . . . . 0.0 109.336 -179.67 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.442 ' C ' ' O ' ' A' ' 73' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.727 0 O-C-N 121.351 -0.843 . . . . 0.0 109.814 -179.481 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 24.1 t . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.588 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 4.2 m-85 -110.87 130.69 55.51 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.124 -0.985 . . . . 0.0 110.012 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 11.0 m -80.45 100.49 8.53 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.335 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.47 126.0 7.25 Favored Glycine 0 N--CA 1.487 2.072 0 C-N-CA 119.87 -1.157 . . . . 0.0 110.487 -178.539 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.586 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -89.75 148.12 23.44 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.794 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.856 HG13 ' CD1' ' A' ' 50' ' ' LEU . 22.8 t -87.85 112.21 23.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 120.568 -1.332 . . . . 0.0 108.97 -179.648 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.989 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -122.8 -6.09 8.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.437 -0.789 . . . . 0.0 110.216 -178.916 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.462 ' HD2' ' O ' ' A' ' 14' ' ' THR . 0.9 OUTLIER -164.68 153.66 12.93 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.916 -1.115 . . . . 0.0 110.06 -179.949 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.443 HG22 ' N ' ' A' ' 17' ' ' VAL . 12.2 mt -141.08 161.57 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 179.438 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 1.025 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -140.15 153.44 22.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 120.881 -1.137 . . . . 0.0 109.982 -179.58 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -58.45 -41.78 85.9 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.778 -1.202 . . . . 0.0 109.145 179.405 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 1.025 ' CE1' HG21 ' A' ' 17' ' ' VAL . 15.5 p90 -90.3 29.31 1.27 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.381 -0.825 . . . . 0.0 110.077 -179.743 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.543 ' HA2' ' N ' ' A' ' 35' ' ' ILE . . . 149.81 -148.86 20.57 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 118.964 -1.589 . . . . 0.0 110.976 -179.766 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.752 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -154.94 148.83 25.66 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.233 -1.157 . . . . 0.0 108.917 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.977 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.5 m-30 -106.94 162.46 13.81 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.339 -0.851 . . . . 0.0 108.954 179.682 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.942 ' CG2' HG23 ' A' ' 33' ' ' VAL . 22.5 t -149.03 160.87 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.08 -1.013 . . . . 0.0 109.64 -179.64 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.989 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -133.8 135.92 44.14 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.306 -0.871 . . . . 0.0 109.55 -179.843 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.792 HD13 HD11 ' A' ' 71' ' ' LEU . 1.2 pt . . . . . 0 N--CA 1.493 1.683 0 O-C-N 120.818 -1.176 . . . . 0.0 109.509 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.483 ' O ' HG13 ' A' ' 25' ' ' ILE . 4.4 mtmt . . . . . 0 N--CA 1.488 1.442 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.556 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 6.4 mt-10 -127.48 150.87 49.47 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.741 -1.224 . . . . 0.0 111.004 -179.151 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.76 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -102.33 -172.96 27.25 Favored Glycine 0 N--CA 1.488 2.104 0 N-CA-C 108.22 -1.952 . . . . 0.0 108.22 178.967 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.977 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.14 121.8 8.05 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.737 -1.449 . . . . 0.0 110.951 179.743 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 1.004 HG12 HD11 ' A' ' 38' ' ' ILE . 61.1 t -95.3 61.36 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 177.523 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.472 ' HB2' HD23 ' A' ' 32' ' ' LEU . 2.6 t-80 -48.88 158.13 0.35 Allowed 'General case' 0 C--N 1.304 -1.37 0 O-C-N 120.893 -1.13 . . . . 0.0 108.653 -179.462 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.543 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.9 tp -46.66 -51.01 5.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.188 -0.945 . . . . 0.0 109.864 -179.464 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.533 ' N ' HG23 ' A' ' 35' ' ' ILE . 42.6 p -81.99 44.51 0.85 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.302 -0.874 . . . . 0.0 110.372 -179.639 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.929 ' C ' HD12 ' A' ' 38' ' ' ILE . 51.0 mm-40 -144.29 33.61 1.2 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.903 -1.123 . . . . 0.0 110.214 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 1.004 HD11 HG12 ' A' ' 33' ' ' VAL . 1.6 mp -120.29 -98.49 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.833 -1.167 . . . . 0.0 110.214 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.771 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.302 -1.476 0 O-C-N 121.459 -0.776 . . . . 0.0 109.45 -179.206 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.119 HG13 ' CD1' ' A' ' 49' ' ' TYR . 58.7 t . . . . . 0 N--CA 1.487 1.387 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 43' ' ' VAL . 14.0 mt-10 -45.78 -24.27 0.36 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.354 -0.841 . . . . 0.0 108.988 179.488 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.456 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 4.7 mmtp -134.97 123.71 23.76 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.327 -0.858 . . . . 0.0 109.4 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.54 HG11 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -73.68 -23.47 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 O-C-N 121.131 -0.981 . . . . 0.0 108.643 179.647 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 8.3 p -75.4 1.39 14.03 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.482 -0.761 . . . . 0.0 109.389 179.198 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.456 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 0.9 OUTLIER -102.17 -35.59 8.84 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.149 -0.969 . . . . 0.0 109.245 -179.999 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 1.119 ' CD1' HG13 ' A' ' 43' ' ' VAL . 3.9 m-85 -90.83 -28.72 18.0 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.35 -0.844 . . . . 0.0 108.972 179.791 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.856 ' CD1' HG13 ' A' ' 13' ' ' VAL . 0.2 OUTLIER -109.72 140.9 43.06 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.495 -0.753 . . . . 0.0 109.565 -179.575 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.728 ' C ' HG11 ' A' ' 13' ' ' VAL . 2.3 mp0 -150.62 131.93 14.57 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.398 -0.814 . . . . 0.0 109.476 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -61.84 107.61 0.87 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.273 -0.892 . . . . 0.0 109.955 -179.929 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 132.33 -31.97 2.91 Favored Glycine 0 N--CA 1.491 2.321 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.306 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -80.3 162.28 24.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.033 -1.275 . . . . 0.0 109.818 -179.668 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -125.28 138.66 54.09 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.518 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.434 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 17.2 m -140.58 143.92 34.44 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.017 -1.052 . . . . 0.0 110.008 -179.461 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 56' ' ' VAL . 36.3 Cg_endo -79.05 145.93 19.85 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.59 2.193 . . . . 0.0 110.241 179.704 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.69 ' CG2' HD22 ' A' ' 71' ' ' LEU . 1.0 OUTLIER -148.21 -174.84 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.196 -0.94 . . . . 0.0 109.901 -179.878 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.458 ' N ' HG23 ' A' ' 58' ' ' VAL . 3.0 mtpt -123.51 135.66 54.15 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.52 -0.737 . . . . 0.0 109.239 179.606 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.588 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 96.1 t . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.33 -0.856 . . . . 0.0 109.229 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.792 HD11 HD13 ' A' ' 25' ' ' ILE . 31.3 mt . . . . . 0 N--CA 1.487 1.423 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.467 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.4 OUTLIER -123.24 108.08 12.41 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.273 -0.892 . . . . 0.0 110.049 -179.259 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.469 ' HA ' HG12 ' A' ' 58' ' ' VAL . 0.0 OUTLIER -48.61 140.83 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.227 -0.921 . . . . 0.0 108.911 179.886 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 11.3 mmtt . . . . . 0 N--CA 1.491 1.611 0 O-C-N 121.318 -0.864 . . . . 0.0 109.744 -179.684 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.545 HG22 ' HG2' ' A' ' 59' ' ' LYS . 41.3 t . . . . . 0 N--CA 1.492 1.633 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.87 ' CD2' HD13 ' A' ' 25' ' ' ILE . 2.8 m-30 -114.75 135.12 54.52 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.154 -0.966 . . . . 0.0 110.158 -179.335 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -73.82 100.74 3.54 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 177.448 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -82.26 122.73 5.82 Favored Glycine 0 N--CA 1.488 2.119 0 C-N-CA 120.009 -1.091 . . . . 0.0 111.368 -177.302 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.518 ' O ' HG13 ' A' ' 23' ' ' VAL . 2.4 mttt -96.07 143.24 27.39 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 177.988 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.014 HG13 HD23 ' A' ' 50' ' ' LEU . 24.9 t -88.1 107.66 17.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 120.802 -1.186 . . . . 0.0 108.934 -179.648 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.886 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -116.93 -7.95 11.34 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.454 -0.778 . . . . 0.0 109.813 -179.07 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.485 ' HB3' ' HB2' ' A' ' 22' ' ' PHE . 0.9 OUTLIER -161.48 148.22 14.45 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.054 -1.029 . . . . 0.0 110.158 -179.899 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.616 HG21 HG22 ' A' ' 47' ' ' THR . 11.8 mt -137.05 157.38 35.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 179.005 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 1.045 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -136.3 153.4 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 120.749 -1.22 . . . . 0.0 110.034 -179.192 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -59.07 -41.94 89.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.69 -1.257 . . . . 0.0 109.331 179.228 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 1.045 ' CE1' HG21 ' A' ' 17' ' ' VAL . 12.9 p90 -91.16 27.24 1.93 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.3 -0.875 . . . . 0.0 110.361 -179.525 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.553 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 154.4 -154.9 25.83 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 118.895 -1.621 . . . . 0.0 110.829 -179.505 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.759 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -148.45 143.97 27.1 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.042 -1.27 . . . . 0.0 108.853 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.97 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.0 m-30 -105.94 154.77 20.11 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.254 -0.904 . . . . 0.0 108.825 179.748 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.81 ' CG2' HG23 ' A' ' 33' ' ' VAL . 35.2 t -144.04 161.81 15.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.066 -1.021 . . . . 0.0 109.783 -179.273 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.886 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -137.2 148.81 46.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.157 -0.964 . . . . 0.0 109.515 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.87 HD13 ' CD2' ' A' ' 9' ' ' TYR . 2.7 pt . . . . . 0 N--CA 1.492 1.673 0 O-C-N 121.006 -1.059 . . . . 0.0 109.044 179.642 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.496 ' O ' HG13 ' A' ' 25' ' ' ILE . 1.7 mtpp . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.533 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 17.3 mt-10 -134.99 153.46 52.08 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.998 -1.063 . . . . 0.0 110.334 -179.786 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.663 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -107.3 -175.78 22.64 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 179.43 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.97 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.49 119.29 6.6 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.875 -1.368 . . . . 0.0 110.736 179.72 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 1.093 HG21 HD11 ' A' ' 50' ' ' LEU . 96.3 t -93.84 61.14 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.543 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 177.71 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.474 ' HB2' HD23 ' A' ' 32' ' ' LEU . 6.6 t-80 -47.7 156.45 0.31 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.906 -1.122 . . . . 0.0 108.417 -179.571 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.589 ' O ' HD13 ' A' ' 38' ' ' ILE . 3.1 tp -49.62 -43.37 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.154 -0.966 . . . . 0.0 110.321 -179.536 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.438 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.4 OUTLIER -81.25 34.29 0.36 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.182 -0.949 . . . . 0.0 110.94 -179.34 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.921 ' C ' HD12 ' A' ' 38' ' ' ILE . 71.4 mt-30 -150.81 58.4 0.92 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.709 -1.244 . . . . 0.0 110.14 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.981 HG21 HG21 ' A' ' 43' ' ' VAL . 1.7 mp -122.08 -97.86 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 120.984 -1.073 . . . . 0.0 109.569 179.746 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.749 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.298 -0.876 . . . . 0.0 109.382 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.167 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 66.9 t . . . . . 0 N--CA 1.488 1.443 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.424 ' O ' ' HG3' ' A' ' 44' ' ' GLU . 13.8 tp10 -45.38 -26.59 0.56 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.162 -0.961 . . . . 0.0 108.467 179.662 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.48 ' HB3' ' CG ' ' A' ' 48' ' ' ASP . 4.2 mptt -108.0 105.63 15.5 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.28 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.553 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -75.22 -25.52 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.399 -0.813 . . . . 0.0 109.09 -179.681 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.616 HG22 HG21 ' A' ' 16' ' ' ILE . 62.7 p -77.55 6.22 7.55 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.413 -0.805 . . . . 0.0 109.464 179.181 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.48 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 58.9 m-20 -101.7 -32.32 10.37 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.426 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 1.167 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 15.9 m-85 -92.45 -34.85 13.95 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.494 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 1.093 HD11 HG21 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -100.0 156.62 17.06 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.322 -0.861 . . . . 0.0 110.571 -179.854 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.503 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 61.8 mt-30 -146.85 126.57 13.42 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' MET . . . . . 0.525 ' CG ' ' O ' ' A' ' 52' ' ' MET . 3.2 ptp -60.81 98.59 0.07 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.15 -0.969 . . . . 0.0 109.94 -179.654 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 132.21 -25.44 3.86 Favored Glycine 0 N--CA 1.493 2.45 0 C-N-CA 119.719 -1.229 . . . . 0.0 110.368 179.467 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 89.0 mm-40 -79.19 150.49 31.65 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.105 -1.232 . . . . 0.0 110.402 -179.358 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -116.9 113.71 22.84 Favored 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.088 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.405 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 17.7 m -115.24 150.23 44.06 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.107 -0.996 . . . . 0.0 110.121 -179.205 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 56' ' ' VAL . 36.2 Cg_endo -78.5 126.91 7.79 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.675 2.25 . . . . 0.0 110.24 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.963 ' CG2' HD22 ' A' ' 71' ' ' LEU . 1.3 m -131.9 -172.74 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.148 -0.97 . . . . 0.0 109.722 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.545 ' HG2' HG22 ' A' ' 8' ' ' VAL . 9.8 mtmt -133.12 116.87 16.82 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.6 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.69 ' HA ' HD23 ' A' ' 71' ' ' LEU . 52.6 t . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.344 -0.848 . . . . 0.0 109.217 -179.744 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.963 HD22 ' CG2' ' A' ' 58' ' ' VAL . 11.1 mt . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.249 0.547 . . . . 0.0 109.633 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 59' ' ' LYS . 0.6 OUTLIER -115.95 93.68 4.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.301 -0.874 . . . . 0.0 109.838 -179.85 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.467 ' O ' ' O ' ' A' ' 74' ' ' LYS . 0.1 OUTLIER -48.8 141.14 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.202 -0.936 . . . . 0.0 109.251 179.762 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.467 ' O ' ' O ' ' A' ' 73' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.686 0 O-C-N 121.311 -0.868 . . . . 0.0 109.673 -179.789 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.891 HG13 ' O ' ' A' ' 58' ' ' VAL . 97.3 t . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.638 ' O ' HG22 ' A' ' 58' ' ' VAL . 6.4 m-85 -119.41 126.65 51.88 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.858 -1.151 . . . . 0.0 110.525 -179.673 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.449 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 0.2 OUTLIER -95.31 127.34 41.28 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 178.352 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -127.62 150.14 18.15 Favored Glycine 0 N--CA 1.486 2.025 0 C-N-CA 118.834 -1.651 . . . . 0.0 110.953 -178.723 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.509 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.1 OUTLIER -89.8 163.21 15.14 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 178.624 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.945 HG22 HD13 ' A' ' 50' ' ' LEU . 69.8 t -88.42 107.9 18.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 O-C-N 121.006 -1.059 . . . . 0.0 108.445 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.635 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.3 p -118.51 -0.52 11.38 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.544 -0.862 . . . . 0.0 110.167 -178.889 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.511 ' HB3' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -167.96 148.04 4.95 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.987 -1.071 . . . . 0.0 109.985 179.739 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.436 HG22 ' N ' ' A' ' 17' ' ' VAL . 30.6 mt -140.31 157.38 24.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.232 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 1.014 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -135.38 152.98 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.918 -1.114 . . . . 0.0 109.751 -179.321 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -60.41 -39.08 86.08 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.631 -1.293 . . . . 0.0 109.218 179.458 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 1.014 ' CE1' HG21 ' A' ' 17' ' ' VAL . 18.4 p90 -91.86 24.92 2.96 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.497 -0.752 . . . . 0.0 110.073 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.618 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 156.07 -152.78 24.19 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.881 -179.188 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.75 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -151.91 145.65 25.05 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.853 -1.38 . . . . 0.0 108.843 179.636 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.959 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.3 m-30 -107.26 160.37 15.65 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.35 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.824 ' CG2' HG23 ' A' ' 33' ' ' VAL . 14.3 t -149.99 167.67 2.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.009 -1.057 . . . . 0.0 109.536 -179.228 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.635 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -131.62 147.43 52.52 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.137 -0.977 . . . . 0.0 109.278 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.52 HG13 ' O ' ' A' ' 29' ' ' LYS . 0.5 OUTLIER . . . . . 0 N--CA 1.493 1.716 0 O-C-N 120.561 -1.337 . . . . 0.0 109.808 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.52 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.373 0.606 . . . . 0.0 109.807 . . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.582 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 7.2 mt-10 -120.18 153.05 36.81 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 120.814 -1.179 . . . . 0.0 110.811 -179.393 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.975 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -99.1 -172.8 31.39 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 108.555 -1.818 . . . . 0.0 108.555 179.061 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.959 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.83 120.19 6.85 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.824 -1.397 . . . . 0.0 111.082 179.6 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.824 HG23 ' CG2' ' A' ' 23' ' ' VAL . 48.6 t -95.15 61.79 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 177.276 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.486 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.1 t-160 -48.77 157.1 0.41 Allowed 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.785 -1.197 . . . . 0.0 108.908 -179.131 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.764 ' O ' HD13 ' A' ' 38' ' ' ILE . 0.4 OUTLIER -49.62 -47.09 21.3 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.297 -0.877 . . . . 0.0 110.237 -179.58 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.516 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.6 OUTLIER -80.48 33.33 0.3 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.251 -0.906 . . . . 0.0 110.972 -179.133 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.894 ' C ' HD12 ' A' ' 38' ' ' ILE . 44.7 mm-40 -148.26 57.99 1.08 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.823 -1.173 . . . . 0.0 109.735 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.98 ' CG2' HG21 ' A' ' 43' ' ' VAL . 1.5 mp -116.84 -99.56 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 120.942 -1.099 . . . . 0.0 110.075 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.765 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.304 -1.408 0 O-C-N 121.272 -0.892 . . . . 0.0 109.649 -179.341 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.127 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 72.1 t . . . . . 0 N--CA 1.485 1.324 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -44.4 -24.95 0.21 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.349 -0.844 . . . . 0.0 109.032 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.49 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 68.7 mttt -110.8 104.44 13.07 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.454 -0.779 . . . . 0.0 109.14 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.618 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -72.19 -23.34 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.194 -0.941 . . . . 0.0 108.552 179.857 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 24.2 p -77.87 4.0 13.02 Favored 'General case' 0 C--N 1.3 -1.549 0 C-N-CA 119.827 -0.749 . . . . 0.0 109.294 179.21 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.49 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 1.8 m-20 -102.42 -33.78 9.41 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.151 -0.968 . . . . 0.0 108.824 179.598 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 1.127 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 23.5 m-85 -92.88 -33.05 14.37 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.449 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.945 HD13 HG22 ' A' ' 13' ' ' VAL . 0.2 OUTLIER -102.23 138.19 39.49 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.973 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.593 ' C ' HG11 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -142.32 142.35 32.5 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.48 -0.763 . . . . 0.0 109.41 -179.788 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -59.6 131.49 51.09 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.353 -0.842 . . . . 0.0 110.666 -179.394 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 90.45 -16.75 56.99 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.945 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' GLN . . . . . 0.425 ' CD ' ' HB2' ' A' ' 51' ' ' GLN . 19.0 mt-30 -70.46 169.4 14.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.173 -1.192 . . . . 0.0 109.886 -179.642 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.489 ' OE1' ' HE3' ' A' ' 12' ' ' LYS . 3.2 mt-10 -139.7 132.87 29.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.193 -0.942 . . . . 0.0 108.556 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.1 m -141.05 136.83 16.34 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 120.916 -1.115 . . . . 0.0 110.402 -179.4 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.449 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.3 Cg_endo -80.2 144.4 16.48 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 C-N-CA 122.524 2.149 . . . . 0.0 109.065 178.785 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.891 ' O ' HG13 ' A' ' 8' ' ' VAL . 1.5 m -144.13 -174.8 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 120.918 -1.114 . . . . 0.0 110.062 -179.612 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 4.1 mttt -121.9 135.14 54.87 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.516 -0.74 . . . . 0.0 109.357 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.538 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 58.9 t . . . . . 0 N--CA 1.49 1.526 0 O-C-N 121.275 -0.891 . . . . 0.0 109.002 179.734 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.975 HD12 ' HA3' ' A' ' 31' ' ' GLY . 20.6 mt . . . . . 0 N--CA 1.488 1.463 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.415 ' C ' ' HB ' ' A' ' 58' ' ' VAL . 0.4 OUTLIER -121.28 101.46 7.65 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.15 -0.969 . . . . 0.0 110.08 -179.622 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.624 HG22 ' O ' ' A' ' 38' ' ' ILE . 0.1 OUTLIER -45.28 137.96 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.2 -0.937 . . . . 0.0 108.96 179.838 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.589 0 O-C-N 121.404 -0.81 . . . . 0.0 109.871 -179.75 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.582 HG13 ' O ' ' A' ' 58' ' ' VAL . 89.9 t . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.44 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 4.0 m-85 -107.78 179.33 4.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.183 -0.948 . . . . 0.0 110.031 -179.501 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -121.19 101.19 7.49 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 178.012 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.79 115.95 4.35 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 119.85 -1.167 . . . . 0.0 111.099 -177.865 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.562 ' O ' HG13 ' A' ' 23' ' ' VAL . 5.7 mtmt -88.66 152.04 22.07 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 107.208 -1.404 . . . . 0.0 107.208 178.075 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.665 HG13 HD13 ' A' ' 50' ' ' LEU . 34.9 t -87.34 110.76 20.97 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 O-C-N 120.751 -1.218 . . . . 0.0 109.142 -179.07 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.973 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.5 OUTLIER -120.7 5.2 10.54 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.442 -0.786 . . . . 0.0 109.807 -179.227 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.529 ' CG ' ' O ' ' A' ' 14' ' ' THR . 3.5 mpp_? -176.15 152.5 1.16 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.047 -1.033 . . . . 0.0 110.225 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.59 HG21 HG22 ' A' ' 47' ' ' THR . 35.0 mt -142.19 159.01 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 179.209 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 1.033 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -137.19 153.65 29.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 120.82 -1.175 . . . . 0.0 109.872 -179.243 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -59.13 -40.06 84.29 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.873 -1.142 . . . . 0.0 109.12 179.248 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 1.033 ' CE1' HG21 ' A' ' 17' ' ' VAL . 20.1 p90 -91.66 27.71 1.96 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.431 -0.793 . . . . 0.0 110.148 -179.739 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.592 ' C ' HG22 ' A' ' 17' ' ' VAL . . . 151.82 -148.64 19.87 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 119.033 -1.556 . . . . 0.0 110.899 -179.559 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.75 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -155.32 148.46 24.71 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.241 -1.153 . . . . 0.0 108.846 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.947 ' CE1' HD11 ' A' ' 32' ' ' LEU . 11.6 m-30 -107.92 160.9 15.41 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.58 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.795 ' CG2' HG23 ' A' ' 33' ' ' VAL . 20.4 t -149.39 162.25 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.129 -0.982 . . . . 0.0 109.49 -179.522 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.973 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -133.73 145.44 49.86 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.122 -0.986 . . . . 0.0 109.811 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.488 HG13 ' O ' ' A' ' 29' ' ' LYS . 3.2 pt . . . . . 0 N--CA 1.493 1.675 0 O-C-N 121.065 -1.022 . . . . 0.0 109.273 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.488 ' O ' HG13 ' A' ' 25' ' ' ILE . 2.5 mmmt . . . . . 0 N--CA 1.492 1.636 0 CA-C-O 121.213 0.53 . . . . 0.0 109.776 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.539 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -132.56 151.44 51.93 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.155 -0.966 . . . . 0.0 110.43 -179.861 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.831 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -104.72 -175.64 24.81 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 179.309 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.947 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -149.43 120.59 7.78 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.846 -1.385 . . . . 0.0 110.724 179.753 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.795 HG23 ' CG2' ' A' ' 23' ' ' VAL . 88.3 t -93.67 60.1 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 177.85 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.482 ' HB2' HD23 ' A' ' 32' ' ' LEU . 5.6 t-80 -47.6 158.42 0.19 Allowed 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.779 -1.201 . . . . 0.0 108.383 -179.533 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.676 ' O ' HD13 ' A' ' 38' ' ' ILE . 2.8 tp -47.76 -52.94 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.081 -1.012 . . . . 0.0 110.07 -179.276 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.578 ' H ' HG23 ' A' ' 35' ' ' ILE . 0.0 OUTLIER -81.48 39.41 0.53 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.091 -1.005 . . . . 0.0 110.375 -179.631 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.924 ' C ' HD12 ' A' ' 38' ' ' ILE . 45.2 mm-40 -144.83 50.41 1.26 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.926 -1.109 . . . . 0.0 109.641 -179.882 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.924 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.6 mp -120.08 -99.79 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 120.765 -1.209 . . . . 0.0 110.675 -179.484 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.788 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 N--CA 1.488 1.438 0 O-C-N 121.211 -0.931 . . . . 0.0 110.269 -178.622 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.136 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 24.4 t . . . . . 0 N--CA 1.485 1.308 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -46.97 -22.06 0.28 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.328 -0.858 . . . . 0.0 109.718 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.541 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.5 OUTLIER -128.28 117.78 22.09 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.113 -0.992 . . . . 0.0 109.858 -179.805 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.549 HG21 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -77.65 -25.81 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.199 -0.938 . . . . 0.0 108.701 179.485 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.59 HG22 HG21 ' A' ' 16' ' ' ILE . 63.5 p -77.1 3.73 11.85 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.383 -0.823 . . . . 0.0 109.307 179.237 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.404 ' OD2' ' CB ' ' A' ' 45' ' ' LYS . 99.1 m-20 -101.86 -24.36 14.04 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.482 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 1.136 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 22.1 m-85 -100.29 -25.87 14.1 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.733 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.669 HD12 ' HB1' ' A' ' 21' ' ' ALA . 0.2 OUTLIER -111.25 142.74 43.06 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.909 . . . . 0.0 109.391 179.465 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.508 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.2 OUTLIER -141.72 133.41 27.07 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.537 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 9.9 mtm -54.78 97.49 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.137 -0.977 . . . . 0.0 110.077 -179.487 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.9 -36.0 2.51 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 119.847 -1.168 . . . . 0.0 110.304 179.341 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 5.2 mm-40 -57.5 162.47 2.89 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.066 -1.256 . . . . 0.0 109.695 -179.677 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.434 ' HG3' ' HA ' ' A' ' 12' ' ' LYS . 0.7 OUTLIER -137.55 125.93 23.34 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.412 -0.805 . . . . 0.0 109.184 179.819 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.406 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 16.0 m -130.25 139.26 35.09 Favored Pre-proline 0 N--CA 1.488 1.451 0 O-C-N 121.063 -1.023 . . . . 0.0 109.606 -179.837 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.471 ' O ' ' HB2' ' A' ' 74' ' ' LYS . 35.5 Cg_endo -78.44 134.13 12.33 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.503 2.135 . . . . 0.0 110.352 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.792 HG21 ' HB3' ' A' ' 71' ' ' LEU . 0.9 OUTLIER -127.41 179.17 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.152 -0.968 . . . . 0.0 109.782 -179.922 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.521 ' HG3' HG22 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -117.01 122.19 43.51 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.639 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.649 ' HA ' HD23 ' A' ' 71' ' ' LEU . 91.2 t . . . . . 0 N--CA 1.49 1.552 0 O-C-N 121.189 -0.944 . . . . 0.0 109.528 -179.88 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.831 HD12 ' HA3' ' A' ' 31' ' ' GLY . 81.4 mt . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.41 ' O ' ' C ' ' A' ' 73' ' ' ILE . 0.3 OUTLIER -121.32 97.21 5.41 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.115 -0.99 . . . . 0.0 110.362 -179.204 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.455 ' CG2' ' O ' ' A' ' 38' ' ' ILE . 0.2 OUTLIER -42.67 123.02 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.317 -0.864 . . . . 0.0 109.099 179.605 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 57' ' ' PRO . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.614 0 O-C-N 121.208 -0.933 . . . . 0.0 109.768 -179.651 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.623 HG13 ' O ' ' A' ' 58' ' ' VAL . 55.3 t . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.646 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 3.0 m-85 -104.75 129.72 52.94 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.085 -1.009 . . . . 0.0 109.956 -179.561 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.5 m -74.49 98.08 3.25 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 178.398 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -77.73 120.45 5.51 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 -178.396 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.993 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -92.47 150.51 20.74 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.71 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.605 HG11 ' C ' ' A' ' 51' ' ' GLN . 20.7 t -89.49 106.12 16.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 120.908 -1.12 . . . . 0.0 108.991 -179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 14' ' ' THR . . . . . 1.036 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -120.59 3.06 10.71 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.234 -0.916 . . . . 0.0 109.67 -179.506 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.517 ' HB3' ' HB2' ' A' ' 22' ' ' PHE . 5.0 mpp_? -173.31 153.48 2.43 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.174 -0.954 . . . . 0.0 109.821 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.425 HG22 ' N ' ' A' ' 17' ' ' VAL . 14.7 mt -140.84 159.76 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.562 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 1.06 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -139.67 155.55 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 120.822 -1.174 . . . . 0.0 110.285 -179.746 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -59.06 -44.48 91.84 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.967 -1.083 . . . . 0.0 109.803 179.449 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 1.06 ' CE1' HG21 ' A' ' 17' ' ' VAL . 8.2 p90 -90.42 24.62 2.53 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.107 -0.996 . . . . 0.0 110.377 -179.389 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.786 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 158.4 -152.28 23.41 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 118.977 -1.582 . . . . 0.0 111.044 -179.583 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.819 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -151.36 146.9 26.32 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.214 -1.168 . . . . 0.0 108.906 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.979 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.3 m-30 -106.73 157.93 17.35 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.259 -0.901 . . . . 0.0 108.992 179.754 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.993 HG13 ' O ' ' A' ' 12' ' ' LYS . 42.3 t -150.58 154.66 8.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 120.945 -1.097 . . . . 0.0 109.674 -178.834 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 1.036 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -121.87 138.21 54.48 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.89 -1.131 . . . . 0.0 109.319 179.662 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.563 HD12 ' CD2' ' A' ' 9' ' ' TYR . 2.5 pt . . . . . 0 N--CA 1.494 1.733 0 O-C-N 121.166 -0.958 . . . . 0.0 109.239 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.495 ' O ' HG13 ' A' ' 25' ' ' ILE . 4.7 mttm . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.52 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 0.4 OUTLIER -119.28 141.13 49.24 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.063 -1.023 . . . . 0.0 110.067 -179.757 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.9 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -91.93 -177.7 42.21 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.03 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.979 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -149.93 120.14 7.29 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 120.796 -1.414 . . . . 0.0 110.842 179.687 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.828 HG23 HG21 ' A' ' 23' ' ' VAL . 93.4 t -92.84 60.1 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 177.714 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.49 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.0 t-80 -48.76 156.51 0.47 Allowed 'General case' 0 N--CA 1.486 1.346 0 O-C-N 120.895 -1.128 . . . . 0.0 108.681 -179.375 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.553 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.7 tp -48.45 -48.92 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.296 -0.878 . . . . 0.0 110.623 -179.385 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.54 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.5 OUTLIER -81.25 40.93 0.58 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.145 -0.972 . . . . 0.0 110.693 -179.396 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.946 ' C ' HD12 ' A' ' 38' ' ' ILE . 44.3 mt-30 -150.95 51.73 0.86 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.713 -1.242 . . . . 0.0 110.047 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.946 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.7 mp -123.04 -97.91 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.886 -1.134 . . . . 0.0 110.094 -179.889 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.799 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.302 -1.499 0 O-C-N 121.432 -0.792 . . . . 0.0 108.999 -179.493 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.945 HG13 ' CD1' ' A' ' 49' ' ' TYR . 50.1 t . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 43' ' ' VAL . 29.3 tt0 -41.83 -29.53 0.21 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.371 -0.83 . . . . 0.0 109.982 -179.61 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.483 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 1.1 mmtp -150.45 141.8 23.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.077 -1.015 . . . . 0.0 109.792 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.786 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -74.12 -25.82 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 O-C-N 121.202 -0.936 . . . . 0.0 108.664 179.413 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.8 p -78.38 3.18 16.38 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.745 -0.782 . . . . 0.0 109.108 179.372 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.443 ' OD2' ' HB2' ' A' ' 45' ' ' LYS . 4.7 m-20 -101.82 -29.4 11.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.171 -0.956 . . . . 0.0 108.749 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.945 ' CD1' HG13 ' A' ' 43' ' ' VAL . 20.4 m-85 -98.29 -27.5 14.1 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.571 -0.705 . . . . 0.0 109.129 179.765 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.648 HD21 HG21 ' A' ' 33' ' ' VAL . 0.2 OUTLIER -104.9 141.03 37.26 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.603 -0.686 . . . . 0.0 109.35 -179.73 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.605 ' C ' HG11 ' A' ' 13' ' ' VAL . 43.6 tt0 -136.46 132.34 35.24 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.488 -0.757 . . . . 0.0 109.641 -179.712 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 4.7 mtt -65.26 112.11 3.31 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.354 -0.841 . . . . 0.0 109.605 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 113.71 -23.07 13.78 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' GLN . . . . . 0.545 ' CG ' ' HB3' ' A' ' 51' ' ' GLN . 57.0 mm-40 -79.37 167.5 20.78 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.251 -1.147 . . . . 0.0 109.583 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.5 ' N ' ' OE1' ' A' ' 55' ' ' GLU . 1.3 mp0 -133.36 147.59 51.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.312 -0.867 . . . . 0.0 109.177 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.476 HG21 HD11 ' A' ' 73' ' ' ILE . 19.1 m -144.74 141.21 17.27 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.156 -0.965 . . . . 0.0 109.771 -179.859 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.54 126.39 7.45 Favored 'Trans proline' 0 C--N 1.312 -1.391 0 C-N-CA 122.575 2.183 . . . . 0.0 110.238 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.623 ' O ' HG13 ' A' ' 8' ' ' VAL . 1.0 OUTLIER -132.31 -170.98 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.191 -0.943 . . . . 0.0 109.516 179.843 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.535 ' N ' HG23 ' A' ' 58' ' ' VAL . 29.6 mtpt -134.43 127.01 30.68 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.414 -0.804 . . . . 0.0 109.459 179.801 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.646 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 26.2 t . . . . . 0 N--CA 1.489 1.504 0 O-C-N 121.281 -0.887 . . . . 0.0 109.018 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.9 HD12 ' HA3' ' A' ' 31' ' ' GLY . 18.8 mt . . . . . 0 N--CA 1.487 1.42 0 CA-C-O 121.358 0.599 . . . . 0.0 109.549 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.458 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.3 OUTLIER -114.67 106.7 14.54 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.375 -0.828 . . . . 0.0 109.565 -179.742 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.476 HD11 HG21 ' A' ' 56' ' ' VAL . 0.1 OUTLIER -65.84 135.24 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.261 -0.899 . . . . 0.0 109.229 -179.996 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.471 0 O-C-N 121.315 -0.866 . . . . 0.0 109.228 179.715 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.739 HG22 ' HG3' ' A' ' 59' ' ' LYS . 71.6 t . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.525 ' O ' HG22 ' A' ' 58' ' ' VAL . 11.5 m-85 -136.53 129.51 31.06 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.059 -1.026 . . . . 0.0 110.77 -179.521 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.504 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 0.4 OUTLIER -97.58 112.05 24.07 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.149 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -113.48 151.97 18.16 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.134 -1.508 . . . . 0.0 110.59 -178.575 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.524 ' HG2' ' CG ' ' A' ' 55' ' ' GLU . 3.4 mtmm -89.63 162.32 15.68 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.876 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.56 HG22 HD13 ' A' ' 50' ' ' LEU . 60.3 t -88.16 97.56 6.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 120.994 -1.066 . . . . 0.0 108.203 179.651 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.718 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.6 p -103.43 -4.64 23.8 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.475 -0.765 . . . . 0.0 110.426 -178.642 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.551 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -163.37 153.8 15.96 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.913 -1.117 . . . . 0.0 110.584 -179.699 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.402 ' HA ' ' HA ' ' A' ' 21' ' ' ALA . 19.8 mt -143.21 155.41 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 178.931 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 1.027 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -135.54 154.96 35.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.837 -1.164 . . . . 0.0 110.055 -178.934 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 12.0 t0 -60.5 -40.44 91.41 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.687 -1.258 . . . . 0.0 109.323 179.43 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 1.027 ' CE1' HG21 ' A' ' 17' ' ' VAL . 15.5 p90 -90.2 23.14 2.98 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.356 -0.84 . . . . 0.0 110.289 -179.743 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.595 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 156.23 -149.42 20.35 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 119.294 -1.432 . . . . 0.0 110.975 -179.654 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.708 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -153.54 146.85 24.79 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.042 -1.27 . . . . 0.0 108.99 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.966 ' CE1' HD11 ' A' ' 32' ' ' LEU . 11.2 m-30 -109.35 155.89 20.67 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.395 -0.816 . . . . 0.0 109.175 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.768 ' CG2' HG23 ' A' ' 33' ' ' VAL . 7.0 t -144.23 168.23 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 120.93 -1.106 . . . . 0.0 109.145 179.795 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.718 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -138.05 150.92 47.36 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.06 -1.025 . . . . 0.0 110.743 -179.328 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.484 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.8 pt . . . . . 0 N--CA 1.492 1.661 0 O-C-N 121.182 -0.949 . . . . 0.0 108.951 179.315 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.484 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 . . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.544 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 5.2 mp0 -131.78 155.04 48.44 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 120.84 -1.162 . . . . 0.0 111.081 -179.468 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.789 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -105.72 -174.0 23.82 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 108.352 -1.899 . . . . 0.0 108.352 179.141 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.966 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.51 122.89 8.42 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.716 -1.461 . . . . 0.0 111.054 179.674 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.768 HG23 ' CG2' ' A' ' 23' ' ' VAL . 14.9 t -99.62 64.73 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 177.333 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.499 ' HB3' ' HG3' ' A' ' 37' ' ' GLN . 3.6 t-80 -49.58 162.23 0.17 Allowed 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.835 -1.165 . . . . 0.0 108.746 -179.474 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.609 ' O ' HD13 ' A' ' 38' ' ' ILE . 0.3 OUTLIER -52.79 -52.05 31.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.214 -0.929 . . . . 0.0 110.329 -179.269 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.561 ' N ' HG23 ' A' ' 35' ' ' ILE . 11.5 m -81.42 32.46 0.35 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 120.994 -1.066 . . . . 0.0 110.764 -179.351 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.894 ' C ' HD12 ' A' ' 38' ' ' ILE . 18.4 mm-40 -138.24 48.24 1.97 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.695 -1.253 . . . . 0.0 109.978 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.894 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.5 mp -119.39 -99.39 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 120.956 -1.09 . . . . 0.0 110.019 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.806 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.302 -1.476 0 O-C-N 121.317 -0.864 . . . . 0.0 109.09 -179.266 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 0.965 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 90.0 t . . . . . 0 N--CA 1.493 1.723 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.412 ' C ' ' O ' ' A' ' 43' ' ' VAL . 11.1 mt-10 -41.31 -30.66 0.19 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.556 -0.715 . . . . 0.0 109.506 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.462 ' HB2' ' CG ' ' A' ' 48' ' ' ASP . 14.1 mttt -122.21 130.05 52.83 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.35 -0.844 . . . . 0.0 109.066 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.595 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -78.62 -24.31 13.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.19 -0.944 . . . . 0.0 108.932 -179.976 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 3.2 p -76.78 4.38 9.81 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.328 -0.858 . . . . 0.0 109.48 179.388 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.476 ' N ' ' OD1' ' A' ' 48' ' ' ASP . 2.0 m-20 -99.55 -37.43 9.17 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.156 -0.965 . . . . 0.0 108.727 179.515 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 0.965 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 18.0 m-85 -90.19 -32.69 16.5 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.683 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.667 HD11 HG21 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -99.21 140.38 33.45 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.532 -0.73 . . . . 0.0 109.223 179.938 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.493 ' H ' HG21 ' A' ' 13' ' ' VAL . 45.6 mt-30 -136.35 112.56 9.8 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.463 -0.773 . . . . 0.0 109.253 -179.821 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' MET . . . . . 0.451 ' O ' ' CE ' ' A' ' 52' ' ' MET . 0.7 OUTLIER -52.49 94.59 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.277 -0.889 . . . . 0.0 110.176 -179.769 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 143.37 -38.88 1.35 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.771 -1.204 . . . . 0.0 110.428 179.508 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 22.4 mt-30 -77.36 169.17 18.8 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.128 -1.219 . . . . 0.0 109.782 -179.42 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' GLU . . . . . 0.524 ' CG ' ' HG2' ' A' ' 12' ' ' LYS . 3.6 mt-10 -122.81 125.32 45.22 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.297 -0.877 . . . . 0.0 109.217 179.739 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.442 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 22.9 m -117.49 142.64 30.73 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.187 -0.946 . . . . 0.0 109.97 -179.68 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.504 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.3 Cg_endo -80.28 153.66 21.43 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 122.753 2.302 . . . . 0.0 110.105 179.669 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.819 ' CG2' HD22 ' A' ' 71' ' ' LEU . 0.9 OUTLIER -150.47 -170.27 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.169 -0.957 . . . . 0.0 109.63 179.8 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.739 ' HG3' HG22 ' A' ' 8' ' ' VAL . 7.7 mtpt -140.75 124.44 17.03 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.398 -0.814 . . . . 0.0 109.663 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.572 ' HA ' HD23 ' A' ' 71' ' ' LEU . 43.0 t . . . . . 0 N--CA 1.491 1.579 0 O-C-N 121.415 -0.803 . . . . 0.0 108.991 179.365 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.819 HD22 ' CG2' ' A' ' 58' ' ' VAL . 52.8 mt . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 121.532 0.682 . . . . 0.0 110.112 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 73' ' ' ILE . 0.3 OUTLIER -124.36 116.58 22.82 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.481 -0.762 . . . . 0.0 110.028 -179.725 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.745 HD13 ' O ' ' A' ' 37' ' ' GLN . 1.3 mp -46.43 134.97 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.079 -1.013 . . . . 0.0 108.511 179.368 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.649 0 O-C-N 121.157 -0.964 . . . . 0.0 109.976 -179.334 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.75 HG22 ' HG3' ' A' ' 59' ' ' LYS . 75.8 t . . . . . 0 N--CA 1.493 1.693 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.468 ' HD2' HD13 ' A' ' 25' ' ' ILE . 4.4 m-30 -105.22 129.47 53.59 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.113 -0.992 . . . . 0.0 110.066 -178.947 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.6 m -77.0 102.39 6.42 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 178.628 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -80.21 116.2 4.21 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.933 -1.127 . . . . 0.0 110.373 -178.995 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.632 ' O ' HG13 ' A' ' 23' ' ' VAL . 9.1 mttt -89.16 149.97 22.9 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.655 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 1.029 HG22 ' CD2' ' A' ' 50' ' ' LEU . 85.8 t -86.83 106.69 16.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 120.956 -1.09 . . . . 0.0 109.059 -179.292 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' THR . . . . . 1.04 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -113.99 -25.43 8.57 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.529 -0.732 . . . . 0.0 109.21 -179.492 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.537 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 5.6 mtp180 -143.86 152.23 40.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.262 -0.899 . . . . 0.0 109.967 179.762 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.7 mt -139.85 154.42 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.249 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 1.061 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -134.83 154.3 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 120.782 -1.199 . . . . 0.0 110.313 -178.835 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -59.28 -42.81 92.12 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.796 -1.19 . . . . 0.0 109.539 179.298 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 1.061 ' CE1' HG21 ' A' ' 17' ' ' VAL . 9.9 p90 -90.73 27.28 1.81 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.17 -0.956 . . . . 0.0 110.065 -179.766 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.91 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 154.85 -153.01 24.49 Favored Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.012 -1.566 . . . . 0.0 111.141 -179.488 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.825 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -150.02 143.81 25.41 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.057 -1.26 . . . . 0.0 109.075 -179.87 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.98 ' CE1' HD11 ' A' ' 32' ' ' LEU . 9.5 m-30 -104.27 160.79 14.59 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.174 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.859 ' CG2' HG23 ' A' ' 33' ' ' VAL . 24.9 t -151.09 159.42 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.841 -1.162 . . . . 0.0 110.514 -178.613 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 1.04 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -138.14 143.04 40.14 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.24 -0.912 . . . . 0.0 109.142 179.618 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.927 HD11 ' CB ' ' A' ' 29' ' ' LYS . 11.9 pt . . . . . 0 N--CA 1.494 1.728 0 O-C-N 120.825 -1.172 . . . . 0.0 109.001 179.742 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.927 ' CB ' HD11 ' A' ' 25' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.895 0.855 . . . . 0.0 110.088 . . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.501 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 1.4 pm0 -136.04 156.6 48.49 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.059 -1.026 . . . . 0.0 110.194 -179.505 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.792 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -112.4 176.7 18.03 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 108.798 -1.721 . . . . 0.0 108.798 179.496 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.98 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -140.98 119.45 12.29 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.986 -1.302 . . . . 0.0 110.074 179.285 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.988 HG21 HD11 ' A' ' 50' ' ' LEU . 47.0 t -94.02 62.3 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.099 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.452 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.4 t-80 -48.56 156.18 0.47 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.857 -1.152 . . . . 0.0 108.712 -179.53 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.618 HG23 ' H ' ' A' ' 36' ' ' SER . 3.2 tp -45.52 -53.96 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.365 -0.834 . . . . 0.0 110.899 -179.117 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.618 ' H ' HG23 ' A' ' 35' ' ' ILE . 5.3 t -81.27 41.4 0.6 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.049 -1.032 . . . . 0.0 110.633 -179.254 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.995 ' C ' HD12 ' A' ' 38' ' ' ILE . 43.5 mt-30 -150.8 61.45 0.93 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.782 -1.199 . . . . 0.0 110.598 -179.843 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.995 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.9 mp -129.37 -95.56 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 120.849 -1.157 . . . . 0.0 109.684 179.372 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.794 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.3 -1.552 0 O-C-N 121.555 -0.715 . . . . 0.0 109.752 -179.251 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.074 HG13 ' CD1' ' A' ' 49' ' ' TYR . 75.7 t . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' GLU . . . . . 0.453 ' C ' ' O ' ' A' ' 43' ' ' VAL . 0.3 OUTLIER -40.71 -32.24 0.2 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.631 -0.668 . . . . 0.0 109.621 -179.99 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.475 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 2.7 mtmp? -111.69 118.23 35.08 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.417 -0.802 . . . . 0.0 109.514 -179.87 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.91 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -74.93 -26.59 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 179.509 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 7.9 p -78.93 5.36 11.76 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.36 -0.838 . . . . 0.0 109.176 179.215 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.475 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 3.2 m-20 -98.43 -37.24 9.68 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 179.383 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 1.074 ' CD1' HG13 ' A' ' 43' ' ' VAL . 15.9 m-85 -90.28 -34.01 15.91 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.626 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 1.029 ' CD2' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -110.66 148.11 32.92 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.354 -0.841 . . . . 0.0 110.395 179.886 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.621 ' C ' HG11 ' A' ' 13' ' ' VAL . 2.3 tt0 -150.62 147.03 26.91 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.57 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 8.2 mtp -65.84 88.05 0.1 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.098 -1.001 . . . . 0.0 109.743 -179.593 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 145.19 -20.81 1.92 Allowed Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.725 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' GLN . . . . . 0.406 ' HG2' ' HB3' ' A' ' 51' ' ' GLN . 12.5 mm100 -80.86 168.86 18.28 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.309 -1.112 . . . . 0.0 110.008 -179.733 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -144.04 116.77 8.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.387 -0.821 . . . . 0.0 109.097 179.684 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.5 m -114.41 142.31 27.92 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.13 -0.981 . . . . 0.0 109.359 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -78.93 142.39 17.45 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.351 2.034 . . . . 0.0 110.322 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.627 HG21 HD13 ' A' ' 71' ' ' LEU . 0.8 OUTLIER -138.1 174.96 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.333 -0.855 . . . . 0.0 109.32 -179.886 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.75 ' HG3' HG22 ' A' ' 8' ' ' VAL . 0.1 OUTLIER -126.64 111.16 14.0 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.284 -0.885 . . . . 0.0 109.381 179.511 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.487 ' HA ' HD23 ' A' ' 71' ' ' LEU . 80.4 t . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.524 -0.735 . . . . 0.0 109.077 179.707 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.792 HD12 ' HA3' ' A' ' 31' ' ' GLY . 22.5 mt . . . . . 0 N--CA 1.488 1.445 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.49 99.07 8.61 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.448 -0.782 . . . . 0.0 110.498 -178.927 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.485 HG13 ' O ' ' A' ' 37' ' ' GLN . 15.5 mm -51.69 137.95 9.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.316 -0.865 . . . . 0.0 109.295 179.697 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.471 ' C ' ' O ' ' A' ' 73' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.497 1.897 0 O-C-N 121.587 -0.696 . . . . 0.0 110.102 -179.835 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.968 HG13 ' O ' ' A' ' 58' ' ' VAL . 75.9 t . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.629 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 11.0 m-85 -120.87 127.7 52.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.036 -1.04 . . . . 0.0 110.502 -179.287 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' THR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 5.6 m -97.04 109.22 22.02 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 178.501 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -110.77 150.1 17.74 Favored Glycine 0 N--CA 1.487 2.095 0 C-N-CA 119.472 -1.347 . . . . 0.0 110.495 -178.837 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.446 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.8 OUTLIER -89.81 163.02 15.21 Favored 'General case' 0 C--N 1.304 -1.394 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 179.08 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.828 ' CG2' HD22 ' A' ' 50' ' ' LEU . 41.6 t -89.0 103.27 13.8 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 O-C-N 121.096 -1.002 . . . . 0.0 108.754 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.747 HG21 ' CB ' ' A' ' 24' ' ' ALA . 0.5 OUTLIER -106.6 -12.46 15.57 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.282 -0.886 . . . . 0.0 109.779 -179.198 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.496 ' HD2' ' O ' ' A' ' 14' ' ' THR . 0.5 OUTLIER -159.26 153.9 24.42 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.054 -1.029 . . . . 0.0 110.41 -179.662 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.473 HG21 HG22 ' A' ' 47' ' ' THR . 11.1 mt -139.69 157.65 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 179.255 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 1.026 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -137.75 153.7 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 120.697 -1.252 . . . . 0.0 110.128 -178.947 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.69 -40.66 93.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.594 -1.316 . . . . 0.0 109.232 179.186 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 1.026 ' CE1' HG21 ' A' ' 17' ' ' VAL . 16.3 p90 -90.04 24.17 2.55 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.273 -0.892 . . . . 0.0 110.19 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.796 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 155.82 -153.5 24.8 Favored Glycine 0 N--CA 1.494 2.506 0 C-N-CA 119.091 -1.528 . . . . 0.0 111.272 -179.405 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.955 ' HB1' HD12 ' A' ' 50' ' ' LEU . . . -149.78 145.35 26.58 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.116 -1.226 . . . . 0.0 108.931 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.973 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.2 m-30 -107.78 145.25 33.81 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.337 -0.852 . . . . 0.0 109.232 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.901 ' CG2' HG23 ' A' ' 33' ' ' VAL . 48.9 t -133.33 167.52 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.134 -0.979 . . . . 0.0 109.597 -179.681 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.747 ' CB ' HG21 ' A' ' 14' ' ' THR . . . -136.64 135.29 38.17 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.884 -1.135 . . . . 0.0 110.78 -179.42 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.528 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.1 pt . . . . . 0 N--CA 1.494 1.75 0 O-C-N 120.94 -1.1 . . . . 0.0 108.863 178.961 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.528 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 . . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.574 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 4.6 pt-20 -111.08 150.48 29.31 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.771 -1.206 . . . . 0.0 109.988 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.682 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -97.95 -175.4 33.47 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 108.03 -2.028 . . . . 0.0 108.03 178.985 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.973 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -151.13 121.04 7.09 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 120.89 -1.359 . . . . 0.0 111.39 179.645 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.901 HG23 ' CG2' ' A' ' 23' ' ' VAL . 71.8 t -94.67 61.81 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 177.286 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.517 ' O ' ' CD1' ' A' ' 38' ' ' ILE . 3.1 t-80 -49.54 152.83 1.27 Allowed 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.89 -1.131 . . . . 0.0 108.814 -179.165 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.578 ' O ' HD13 ' A' ' 38' ' ' ILE . 0.4 OUTLIER -46.96 -49.01 7.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.372 -0.83 . . . . 0.0 109.982 -179.591 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.516 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.3 OUTLIER -81.6 40.42 0.58 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.21 -0.931 . . . . 0.0 110.327 -179.819 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.775 ' C ' HD12 ' A' ' 38' ' ' ILE . 14.7 mm-40 -147.88 31.9 0.86 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.849 -1.157 . . . . 0.0 109.388 -179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.844 HG21 ' CD2' ' A' ' 49' ' ' TYR . 1.6 mp -111.22 -98.74 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 O-C-N 121.13 -0.981 . . . . 0.0 109.992 -179.581 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.776 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.511 0 O-C-N 121.323 -0.861 . . . . 0.0 109.38 -179.706 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.047 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 24.1 t . . . . . 0 N--CA 1.486 1.375 0 CA-C-O 121.426 0.631 . . . . 0.0 109.553 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -49.02 -22.61 0.92 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.442 -0.786 . . . . 0.0 109.426 179.619 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.539 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 1.3 mmpt? -130.11 113.05 14.03 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.315 -0.866 . . . . 0.0 109.945 -179.58 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.796 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -76.64 -26.05 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.233 -0.917 . . . . 0.0 108.839 179.563 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.473 HG22 HG21 ' A' ' 16' ' ' ILE . 52.9 p -76.56 3.74 10.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.838 . . . . 0.0 109.35 179.396 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.464 ' OD2' ' CB ' ' A' ' 45' ' ' LYS . 98.5 m-20 -103.88 -30.26 10.46 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.143 -0.973 . . . . 0.0 108.515 179.716 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 1.047 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 16.3 m-85 -91.24 -31.58 16.09 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 179.501 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.955 HD12 ' HB1' ' A' ' 21' ' ' ALA . 1.3 mt -108.23 155.22 20.71 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.278 -0.889 . . . . 0.0 109.418 179.446 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.497 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 5.9 tp60 -141.53 138.43 32.72 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.321 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 9.4 mtt -63.3 112.82 2.87 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.144 -0.973 . . . . 0.0 109.908 -179.497 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 108.3 -22.66 26.53 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' GLN . . . . . 0.492 ' CG ' ' HB3' ' A' ' 51' ' ' GLN . 35.3 mt-30 -68.94 162.6 26.34 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.173 -1.193 . . . . 0.0 109.89 -179.757 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -114.32 141.82 47.11 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.359 -0.838 . . . . 0.0 109.033 179.6 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.445 ' O ' HG23 ' A' ' 56' ' ' VAL . 31.7 m -144.13 131.04 10.31 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 120.948 -1.095 . . . . 0.0 110.25 -179.823 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.494 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.6 Cg_endo -80.65 154.14 20.51 Favored 'Trans proline' 0 C--N 1.316 -1.176 0 C-N-CA 122.65 2.233 . . . . 0.0 109.765 179.405 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.968 ' O ' HG13 ' A' ' 8' ' ' VAL . 0.9 OUTLIER -150.89 -169.73 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.035 -1.041 . . . . 0.0 109.625 179.733 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.625 ' N ' HG23 ' A' ' 58' ' ' VAL . 0.0 OUTLIER -135.68 138.53 42.89 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.469 -0.769 . . . . 0.0 109.205 179.557 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.629 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 5.1 t . . . . . 0 N--CA 1.49 1.551 0 O-C-N 121.334 -0.854 . . . . 0.0 108.853 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.682 HD12 ' HA3' ' A' ' 31' ' ' GLY . 19.4 mt . . . . . 0 N--CA 1.489 1.525 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.16 117.55 20.96 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.509 -0.744 . . . . 0.0 110.001 -179.145 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.429 ' HB ' ' O ' ' A' ' 37' ' ' GLN . 0.0 OUTLIER -56.07 133.05 20.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.223 -0.923 . . . . 0.0 109.037 179.883 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.707 0 O-C-N 121.467 -0.771 . . . . 0.0 110.05 -179.302 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.458 HG13 ' O ' ' A' ' 58' ' ' VAL . 23.9 t . . . . . 0 N--CA 1.487 1.425 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.673 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 4.0 m-85 -122.64 136.79 54.98 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.037 -1.04 . . . . 0.0 110.195 -178.848 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 7.0 m -90.34 102.66 15.39 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 178.125 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.472 ' HA3' HG11 ' A' ' 23' ' ' VAL . . . -79.54 128.39 8.51 Favored Glycine 0 N--CA 1.488 2.114 0 C-N-CA 119.843 -1.17 . . . . 0.0 110.794 -178.197 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.58 ' O ' HG13 ' A' ' 23' ' ' VAL . 6.1 mttt -89.08 147.61 24.14 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 178.29 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.729 HG13 HD12 ' A' ' 50' ' ' LEU . 17.1 t -86.42 104.2 13.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 O-C-N 120.384 -1.447 . . . . 0.0 108.708 -179.289 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.914 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.5 p -111.29 -9.15 14.3 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.697 -0.627 . . . . 0.0 109.858 -178.888 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.551 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 1.1 mpp_? -166.76 157.82 12.41 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.026 -1.046 . . . . 0.0 110.256 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.556 HG21 HG22 ' A' ' 47' ' ' THR . 14.7 mt -144.1 153.66 15.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.057 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 1.061 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.9 OUTLIER -133.67 155.46 40.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.835 -1.165 . . . . 0.0 109.884 -179.413 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -59.34 -41.74 89.89 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.753 -1.217 . . . . 0.0 109.345 179.444 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 1.061 ' CE1' HG21 ' A' ' 17' ' ' VAL . 12.8 p90 -91.33 26.56 2.2 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.346 -0.846 . . . . 0.0 110.296 -179.609 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.772 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 156.25 -152.99 24.37 Favored Glycine 0 N--CA 1.493 2.456 0 C-N-CA 119.108 -1.52 . . . . 0.0 111.174 -179.669 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.912 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -152.24 144.54 23.99 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.259 -1.142 . . . . 0.0 109.017 -179.657 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.972 ' CE1' HD11 ' A' ' 32' ' ' LEU . 9.6 m-30 -105.28 152.72 22.55 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.171 -0.956 . . . . 0.0 109.244 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.801 ' CG2' HG23 ' A' ' 33' ' ' VAL . 35.5 t -145.35 162.95 12.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.266 -0.896 . . . . 0.0 109.385 -179.476 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.914 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -135.18 130.72 35.79 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.852 -1.155 . . . . 0.0 110.089 -179.066 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.526 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.673 0 O-C-N 120.938 -1.101 . . . . 0.0 109.157 179.504 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.526 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.433 0.635 . . . . 0.0 109.421 . . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.553 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 2.8 mt-10 -105.91 148.46 27.59 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 120.725 -1.234 . . . . 0.0 109.628 179.772 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 23' ' ' VAL . . . -98.97 -179.36 31.71 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 108.452 -1.859 . . . . 0.0 108.452 179.342 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.972 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.64 117.37 5.82 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 120.814 -1.404 . . . . 0.0 110.652 179.577 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.912 ' HB ' ' HB3' ' A' ' 21' ' ' ALA . 30.1 t -91.23 61.06 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 177.51 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.568 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.7 t-80 -50.73 156.28 0.98 Allowed 'General case' 0 C--N 1.304 -1.394 0 O-C-N 120.964 -1.085 . . . . 0.0 108.624 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.556 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.9 OUTLIER -48.87 -47.35 16.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.171 -0.956 . . . . 0.0 109.789 -179.954 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.541 ' N ' HG23 ' A' ' 35' ' ' ILE . 37.4 t -81.42 40.2 0.56 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.158 -0.964 . . . . 0.0 110.647 -179.498 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.932 ' C ' HD12 ' A' ' 38' ' ' ILE . 35.9 mt-30 -150.51 43.35 0.84 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.851 -1.155 . . . . 0.0 110.032 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 0.932 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.6 mp -120.68 -98.97 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.086 -1.008 . . . . 0.0 109.521 179.719 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.765 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.301 -1.534 0 O-C-N 121.244 -0.91 . . . . 0.0 109.636 -179.725 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.024 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 17.7 t . . . . . 0 N--CA 1.484 1.263 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -44.91 -21.33 0.05 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.544 -0.722 . . . . 0.0 110.316 -179.686 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.539 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 5.7 mttt -139.1 117.5 12.01 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.013 -1.054 . . . . 0.0 110.191 -179.433 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.772 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -72.52 -27.61 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.38 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 47' ' ' THR . . . . . 0.556 HG22 HG21 ' A' ' 16' ' ' ILE . 81.9 p -75.97 1.26 15.79 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.798 -0.761 . . . . 0.0 109.15 179.439 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.469 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 2.1 m-20 -97.71 -35.35 10.59 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.291 -0.881 . . . . 0.0 109.041 179.696 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 1.024 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 7.0 m-85 -91.46 -27.38 18.31 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.404 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.874 HD21 HG21 ' A' ' 33' ' ' VAL . 0.2 OUTLIER -104.46 140.31 38.13 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 179.598 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.563 ' O ' HG21 ' A' ' 13' ' ' VAL . 4.1 tp-100 -132.41 124.46 28.69 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.198 -0.939 . . . . 0.0 109.788 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' MET . . . . . 0.474 ' O ' ' HG3' ' A' ' 52' ' ' MET . 23.6 ptp -58.42 130.07 45.01 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.381 -0.824 . . . . 0.0 109.869 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 93.86 -31.17 6.75 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 179.598 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' GLN . . . . . 0.485 ' HB2' ' HB3' ' A' ' 51' ' ' GLN . 56.8 mt-30 -77.97 -172.94 2.91 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.129 -1.218 . . . . 0.0 109.817 -179.62 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -143.56 157.06 44.72 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.441 -0.787 . . . . 0.0 108.943 179.704 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -140.0 140.91 25.29 Favored Pre-proline 0 C--N 1.303 -1.423 0 O-C-N 121.143 -0.973 . . . . 0.0 109.581 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.444 ' O ' ' HB3' ' A' ' 74' ' ' LYS . 36.3 Cg_endo -79.24 130.38 9.17 Favored 'Trans proline' 0 C--N 1.311 -1.403 0 C-N-CA 122.438 2.092 . . . . 0.0 109.9 179.551 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.911 HG21 HD12 ' A' ' 71' ' ' LEU . 1.1 m -143.18 -170.02 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.087 -1.008 . . . . 0.0 109.99 -179.631 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.537 ' N ' HG23 ' A' ' 58' ' ' VAL . 0.5 OUTLIER -135.08 126.81 29.12 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.672 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.673 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 36.2 t . . . . . 0 N--CA 1.488 1.473 0 O-C-N 121.278 -0.889 . . . . 0.0 109.306 -179.757 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.911 HD12 HG21 ' A' ' 58' ' ' VAL . 3.4 mm? . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.24 0.543 . . . . 0.0 109.654 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.421 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.4 OUTLIER -112.14 106.26 14.83 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.393 -0.817 . . . . 0.0 109.704 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.472 HD11 HG22 ' A' ' 33' ' ' VAL . 0.9 OUTLIER -52.02 144.19 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.108 -0.995 . . . . 0.0 109.303 -179.871 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.444 ' HB3' ' O ' ' A' ' 57' ' ' PRO . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.371 -0.831 . . . . 0.0 109.843 -179.692 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 8' ' ' VAL . . . . . 0.795 HG22 ' HG3' ' A' ' 59' ' ' LYS . 71.3 t . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' TYR . . . . . 0.496 ' CE1' HG21 ' A' ' 60' ' ' VAL . 3.1 m-85 -106.27 -174.67 2.59 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.147 -0.97 . . . . 0.0 109.836 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 11.4 m -147.28 110.79 4.92 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.935 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.43 ' HA2' ' HA ' ' A' ' 25' ' ' ILE . . . -121.26 143.24 15.96 Favored Glycine 0 N--CA 1.488 2.122 0 C-N-CA 118.868 -1.634 . . . . 0.0 110.908 -178.194 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 12' ' ' LYS . . . . . 0.45 ' O ' HG13 ' A' ' 23' ' ' VAL . 8.8 mttp -90.43 165.58 13.75 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.802 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' VAL . . . . . 0.834 HG22 HD13 ' A' ' 50' ' ' LEU . 39.1 t -88.27 102.89 13.16 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.744 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.487 179.426 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.774 HG21 ' CB ' ' A' ' 24' ' ' ALA . 0.1 OUTLIER -101.75 -7.98 22.11 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.292 -0.88 . . . . 0.0 109.494 -179.351 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 15' ' ' ARG . . . . . 0.504 ' CG ' ' C ' ' A' ' 14' ' ' THR . 0.0 OUTLIER -167.64 147.24 5.02 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.151 -0.968 . . . . 0.0 109.613 -179.599 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 16' ' ' ILE . . . . . 0.532 HG22 ' N ' ' A' ' 17' ' ' VAL . 62.1 mt -131.13 163.34 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.982 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' VAL . . . . . 1.059 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -138.82 154.38 26.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 120.726 -1.234 . . . . 0.0 110.425 -179.559 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -59.23 -43.16 92.34 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.843 -1.161 . . . . 0.0 109.812 179.531 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 19' ' ' PHE . . . . . 1.059 ' CE1' HG21 ' A' ' 17' ' ' VAL . 6.4 p90 -92.12 25.6 2.81 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.249 -0.907 . . . . 0.0 110.266 -179.384 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' GLY . . . . . 0.864 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 157.66 -154.79 25.84 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 119.033 -1.556 . . . . 0.0 110.98 -179.71 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 21' ' ' ALA . . . . . 0.772 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -149.61 145.97 27.05 Favored 'General case' 0 N--CA 1.486 1.345 0 O-C-N 121.089 -1.242 . . . . 0.0 108.995 -179.759 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' PHE . . . . . 0.967 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.8 m-30 -106.87 158.2 17.19 Favored 'General case' 0 C--N 1.298 -1.672 0 O-C-N 121.316 -0.865 . . . . 0.0 108.738 179.481 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 23' ' ' VAL . . . . . 0.908 ' CG2' HG23 ' A' ' 33' ' ' VAL . 37.6 t -148.34 166.34 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.069 -1.02 . . . . 0.0 109.755 -179.507 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' ALA . . . . . 0.774 ' CB ' HG21 ' A' ' 14' ' ' THR . . . -137.91 144.65 41.4 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.287 -0.883 . . . . 0.0 109.539 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ILE . . . . . 0.535 ' CG1' ' O ' ' A' ' 29' ' ' LYS . 5.5 pt . . . . . 0 N--CA 1.494 1.771 0 O-C-N 120.625 -1.297 . . . . 0.0 108.562 179.253 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' LYS . . . . . 0.535 ' O ' ' CG1' ' A' ' 25' ' ' ILE . 0.4 OUTLIER . . . . . 0 N--CA 1.492 1.674 0 CA-C-O 121.684 0.754 . . . . 0.0 110.06 . . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 30' ' ' GLU . . . . . 0.568 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 12.6 mp0 -123.39 153.24 40.65 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.836 -1.165 . . . . 0.0 110.109 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' GLY . . . . . 0.56 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -103.67 -175.48 25.92 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 108.8 -1.72 . . . . 0.0 108.8 179.521 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 32' ' ' LEU . . . . . 0.967 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.57 119.82 6.81 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.97 -1.312 . . . . 0.0 110.552 179.624 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 33' ' ' VAL . . . . . 0.908 HG23 ' CG2' ' A' ' 23' ' ' VAL . 25.2 t -96.84 63.21 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 177.736 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' HIS . . . . . 0.532 ' O ' ' CD1' ' A' ' 38' ' ' ILE . 7.7 t-80 -48.64 162.57 0.1 Allowed 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.741 -1.224 . . . . 0.0 108.359 -179.627 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.636 ' O ' HD13 ' A' ' 38' ' ' ILE . 0.4 OUTLIER -55.5 -45.79 78.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.012 -1.055 . . . . 0.0 110.53 -179.49 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 36' ' ' SER . . . . . 0.489 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.9 OUTLIER -80.05 23.77 0.45 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.153 -0.967 . . . . 0.0 110.795 -179.338 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 37' ' ' GLN . . . . . 0.992 ' C ' HD12 ' A' ' 38' ' ' ILE . 3.4 mm100 -138.74 64.18 1.49 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.883 -1.136 . . . . 0.0 109.293 179.546 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ILE . . . . . 1.069 HG21 HG21 ' A' ' 43' ' ' VAL . 1.8 mp -129.35 -94.59 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.042 -1.036 . . . . 0.0 109.704 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' ALA . . . . . 0.803 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.3 -1.544 0 O-C-N 121.455 -0.778 . . . . 0.0 109.852 -179.346 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' VAL . . . . . 1.069 HG21 HG21 ' A' ' 38' ' ' ILE . 44.3 t . . . . . 0 N--CA 1.482 1.154 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -53.98 -19.02 4.06 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.365 -0.834 . . . . 0.0 109.114 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 45' ' ' LYS . . . . . 0.543 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.2 OUTLIER -121.68 108.19 13.25 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.436 -0.79 . . . . 0.0 109.748 -179.569 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 46' ' ' VAL . . . . . 0.864 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -76.3 -24.76 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.331 -0.856 . . . . 0.0 109.179 179.972 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.2 p -78.28 5.95 9.28 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.364 -0.835 . . . . 0.0 109.541 179.873 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 48' ' ' ASP . . . . . 0.457 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 10.2 m-20 -104.35 -37.59 7.17 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.136 -0.977 . . . . 0.0 108.716 179.548 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' TYR . . . . . 1.028 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 11.7 m-85 -89.84 -38.01 14.05 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.532 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' LEU . . . . . 0.834 HD13 HG22 ' A' ' 13' ' ' VAL . 0.2 OUTLIER -96.45 136.02 37.52 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.435 -0.791 . . . . 0.0 109.301 -179.931 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 51' ' ' GLN . . . . . 0.52 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 2.8 mm-40 -129.72 132.57 46.66 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.659 -0.651 . . . . 0.0 109.372 -179.517 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 11.5 mtt -57.31 113.52 1.79 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.313 -0.867 . . . . 0.0 109.661 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 106.14 -34.09 6.0 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.636 -1.385 . . . . 0.0 109.636 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' GLN . . . . . 0.472 ' O ' HG23 ' A' ' 13' ' ' VAL . 6.9 mt-30 -54.4 143.02 24.94 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.32 -1.106 . . . . 0.0 110.025 -179.722 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -104.15 129.39 51.88 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.313 -0.867 . . . . 0.0 108.898 179.368 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.405 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 33.2 m -132.78 134.48 24.65 Favored Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 120.99 -1.069 . . . . 0.0 110.085 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' PRO . . . . . 0.471 ' O ' ' HB2' ' A' ' 74' ' ' LYS . 37.0 Cg_endo -81.72 143.51 13.38 Favored 'Trans proline' 0 C--N 1.314 -1.283 0 C-N-CA 122.705 2.27 . . . . 0.0 110.015 179.341 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' VAL . . . . . 0.737 HG21 HD13 ' A' ' 71' ' ' LEU . 0.9 OUTLIER -135.31 -177.87 2.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.062 -1.024 . . . . 0.0 109.322 179.676 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 59' ' ' LYS . . . . . 0.795 ' HG3' HG22 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -131.72 110.78 11.13 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.277 -0.889 . . . . 0.0 109.212 179.737 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 60' ' ' VAL . . . . . 0.496 HG21 ' CE1' ' A' ' 9' ' ' TYR . 25.1 t . . . . . 0 N--CA 1.492 1.647 0 O-C-N 121.374 -0.829 . . . . 0.0 109.112 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 71' ' ' LEU . . . . . 0.737 HD13 HG21 ' A' ' 58' ' ' VAL . 23.4 mt . . . . . 0 N--CA 1.489 1.48 0 CA-C-O 121.352 0.596 . . . . 0.0 109.477 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 72' ' ' SER . . . . . 0.508 ' CB ' ' HB2' ' A' ' 59' ' ' LYS . 0.3 OUTLIER -100.66 110.63 22.77 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.336 -0.852 . . . . 0.0 109.546 179.931 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 73' ' ' ILE . . . . . 0.602 HD13 ' O ' ' A' ' 37' ' ' GLN . 1.9 mp -62.68 127.11 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.496 -0.752 . . . . 0.0 109.733 -179.738 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 74' ' ' LYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 57' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.602 0 O-C-N 121.301 -0.874 . . . . 0.0 109.29 179.666 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.493 ' O ' ' HG2' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.493 ' HG2' ' O ' ' A' ' 1' ' ' ALA . 1.3 pt-20 41.05 -166.51 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.659 -0.651 . . . . 0.0 109.837 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.573 HG21 ' OH ' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -141.34 -167.44 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.145 -0.972 . . . . 0.0 109.588 -179.301 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -121.73 141.55 51.07 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.425 -0.797 . . . . 0.0 109.053 179.376 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.783 HG22 HG11 ' A' ' 60' ' ' VAL . 2.6 t -80.14 161.66 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.179 -0.951 . . . . 0.0 109.74 -179.655 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.49 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 95.97 -7.02 67.17 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 1.1 ttm180 -98.44 168.14 10.39 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.3 -1.118 . . . . 0.0 109.646 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.48 HG13 ' O ' ' A' ' 58' ' ' VAL . 40.6 t -89.87 150.83 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.371 -0.831 . . . . 0.0 108.899 179.758 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.622 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 15.2 m-85 -136.17 129.19 31.32 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.967 -1.083 . . . . 0.0 110.386 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.5 m -76.91 102.06 6.21 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 178.264 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -83.14 113.81 3.74 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 119.813 -1.184 . . . . 0.0 110.73 -178.262 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.574 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -89.31 153.87 20.54 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 178.697 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.991 HG22 HD13 ' A' ' 50' ' ' LEU . 77.1 t -87.43 116.11 29.12 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 O-C-N 120.759 -1.213 . . . . 0.0 109.116 -179.572 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' THR . . . . . 1.135 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.2 OUTLIER -126.72 7.24 6.8 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.386 -0.821 . . . . 0.0 109.473 -179.396 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.539 ' HB3' ' HB2' ' A' ' 22' ' ' PHE . 1.9 mtp180 -178.26 149.52 0.53 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.304 -0.872 . . . . 0.0 109.575 179.692 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.405 HG22 ' N ' ' A' ' 17' ' ' VAL . 33.6 mt -140.9 157.16 22.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.487 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 1.018 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -135.78 152.93 31.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.858 -1.151 . . . . 0.0 110.057 -179.395 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -58.62 -41.44 85.93 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.721 -1.237 . . . . 0.0 109.035 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.018 ' CE1' HG21 ' A' ' 17' ' ' VAL . 17.3 p90 -90.41 28.68 1.41 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.363 -0.836 . . . . 0.0 110.33 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.594 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 151.72 -152.29 24.07 Favored Glycine 0 N--CA 1.491 2.326 0 C-N-CA 119.073 -1.537 . . . . 0.0 111.018 -179.607 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.801 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -151.75 147.11 26.29 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.125 -1.221 . . . . 0.0 108.938 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.972 ' CE1' HD11 ' A' ' 32' ' ' LEU . 8.8 m-30 -106.93 158.66 16.85 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 179.642 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.933 ' CG2' HG23 ' A' ' 33' ' ' VAL . 31.8 t -147.61 161.92 7.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.035 -1.041 . . . . 0.0 109.858 -179.154 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 1.135 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -139.74 150.34 44.68 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.103 -0.998 . . . . 0.0 109.436 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.678 HD11 ' HB2' ' A' ' 29' ' ' LYS . 4.5 pt -112.53 -0.98 9.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 120.823 -1.173 . . . . 0.0 109.706 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 69.31 146.98 0.23 Allowed Glycine 0 N--CA 1.49 2.233 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 106.36 -3.59 37.43 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 110.73 1.95 28.89 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.678 ' HB2' HD11 ' A' ' 25' ' ' ILE . 14.7 mtpt -129.42 143.55 50.89 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.194 -1.18 . . . . 0.0 109.389 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.577 ' H ' HD13 ' A' ' 69' ' ' ILE . 1.1 mt-10 -130.34 158.8 38.83 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.061 -1.024 . . . . 0.0 110.356 -179.678 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.627 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -108.68 -173.73 21.48 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 179.328 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.972 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.26 123.21 8.76 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.853 -1.381 . . . . 0.0 110.682 179.751 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.933 HG23 ' CG2' ' A' ' 23' ' ' VAL . 60.8 t -97.67 62.16 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 177.662 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.496 ' HB3' ' HG3' ' A' ' 37' ' ' GLN . 3.3 t-80 -48.39 159.49 0.21 Allowed 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.692 -1.255 . . . . 0.0 108.147 -179.623 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.594 ' O ' HD13 ' A' ' 38' ' ' ILE . 3.1 tp -48.58 -50.35 12.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.587 0 O-C-N 121.099 -1.001 . . . . 0.0 110.09 -179.121 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.536 ' N ' HG23 ' A' ' 35' ' ' ILE . 5.3 m -81.57 41.22 0.62 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.182 -0.949 . . . . 0.0 110.424 -179.656 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.905 ' C ' HD12 ' A' ' 38' ' ' ILE . 40.3 mt-30 -150.69 53.0 0.88 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.847 -1.158 . . . . 0.0 110.245 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.944 HG21 HG21 ' A' ' 43' ' ' VAL . 1.6 mp -119.09 -98.92 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.928 -1.107 . . . . 0.0 109.936 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.765 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -126.42 162.28 25.94 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.315 -0.866 . . . . 0.0 109.641 -179.424 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -47.3 -33.1 5.29 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.225 -0.922 . . . . 0.0 109.09 179.594 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -66.74 141.88 57.58 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.277 -0.889 . . . . 0.0 109.39 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 80.0 mtp180 -61.07 114.64 3.22 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.22 -0.925 . . . . 0.0 109.531 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.152 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 80.4 t -101.99 55.0 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.263 -0.898 . . . . 0.0 108.861 179.591 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.425 ' C ' ' O ' ' A' ' 43' ' ' VAL . 0.0 OUTLIER -43.73 -26.66 0.26 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.38 -0.825 . . . . 0.0 108.896 179.849 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.455 ' HB3' ' CG ' ' A' ' 48' ' ' ASP . 0.1 OUTLIER -109.83 114.33 27.8 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.495 -0.753 . . . . 0.0 108.988 179.479 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.594 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -78.16 -24.14 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.141 -0.975 . . . . 0.0 108.62 179.747 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 3.7 p -76.22 1.61 15.45 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.44 -0.787 . . . . 0.0 109.344 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.455 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 14.4 m-20 -96.05 -40.35 9.29 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.111 -0.993 . . . . 0.0 108.926 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 1.152 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 9.5 m-85 -89.56 -28.77 19.36 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.487 -0.758 . . . . 0.0 109.019 179.715 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.991 HD13 HG22 ' A' ' 13' ' ' VAL . 0.1 OUTLIER -102.75 134.74 45.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.504 -0.748 . . . . 0.0 109.537 -179.842 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.517 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 1.9 tt0 -140.39 143.03 35.45 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.59 -0.694 . . . . 0.0 109.314 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 39.1 mtm -67.54 93.77 0.38 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.179 -0.951 . . . . 0.0 109.441 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.69 -18.91 4.81 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLN . . . . . 0.466 ' O ' HG23 ' A' ' 13' ' ' VAL . 11.6 mm-40 -79.7 124.86 28.96 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.328 -1.101 . . . . 0.0 109.637 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -106.27 117.78 34.94 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.257 -0.902 . . . . 0.0 109.109 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.455 HG21 HD11 ' A' ' 73' ' ' ILE . 33.8 m -118.98 151.76 50.85 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.134 -0.979 . . . . 0.0 109.836 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 56' ' ' VAL . 36.0 Cg_endo -78.87 142.57 17.72 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.695 2.264 . . . . 0.0 110.509 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.788 HG21 ' HB3' ' A' ' 71' ' ' LEU . 0.9 OUTLIER -141.67 -177.22 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.211 -0.931 . . . . 0.0 109.354 179.622 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.488 ' O ' ' N ' ' A' ' 61' ' ' LEU . 0.0 OUTLIER -134.03 128.73 34.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.283 -0.886 . . . . 0.0 109.475 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.783 HG11 HG22 ' A' ' 5' ' ' VAL . 62.0 t -55.21 89.53 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.266 -0.896 . . . . 0.0 109.037 179.504 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.591 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 10.3 tp -57.05 -34.8 68.59 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.35 -0.843 . . . . 0.0 108.879 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.591 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 0.1 OUTLIER 151.58 177.95 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.059 0 CA-C-O 121.332 0.587 . . . . 0.0 109.537 179.586 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.784 HG22 ' HA ' ' A' ' 69' ' ' ILE . 60.3 t -143.17 106.27 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.365 -0.834 . . . . 0.0 109.387 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.8 p30 -63.16 -172.07 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.255 -0.903 . . . . 0.0 109.784 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 16.9 mtm180 -75.52 -1.12 22.79 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.367 -0.833 . . . . 0.0 109.587 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -91.05 8.75 33.87 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.131 -0.981 . . . . 0.0 109.509 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 56.18 28.11 53.59 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.416 ' O ' ' C ' ' A' ' 69' ' ' ILE . 35.0 mmm-85 -90.82 84.41 5.82 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.285 -1.127 . . . . 0.0 109.351 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.784 ' HA ' HG22 ' A' ' 63' ' ' VAL . 4.3 mt -42.83 105.34 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.325 -0.859 . . . . 0.0 109.788 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.428 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 0.7 OUTLIER -90.99 94.5 9.67 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.249 -0.907 . . . . 0.0 109.359 179.754 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.788 ' HB3' HG21 ' A' ' 58' ' ' VAL . 15.1 mt -89.82 151.51 21.74 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.176 -0.953 . . . . 0.0 109.23 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.578 ' OG ' HD13 ' A' ' 61' ' ' LEU . 0.6 OUTLIER -118.21 106.64 13.03 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.341 -0.849 . . . . 0.0 109.871 -179.618 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.477 HG22 ' O ' ' A' ' 38' ' ' ILE . 0.1 OUTLIER -58.77 139.12 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.269 -0.894 . . . . 0.0 109.001 179.865 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 2.4 mmtm -74.28 -94.9 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.26 -0.9 . . . . 0.0 109.281 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -156.82 45.35 0.4 Allowed 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.29 -0.881 . . . . 0.0 109.45 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 118.029 -0.986 . . . . 0.0 109.476 -179.97 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.295 0.569 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.471 ' O ' ' CB ' ' A' ' 3' ' ' ILE . 0.1 OUTLIER -141.39 172.73 12.27 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 109.645 -179.949 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.637 HD13 ' HD2' ' A' ' 7' ' ' ARG . 0.3 OUTLIER 170.38 129.24 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 O-C-N 121.444 -0.785 . . . . 0.0 109.323 -179.46 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -142.3 -160.1 1.05 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.369 -0.832 . . . . 0.0 109.297 179.908 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.57 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 3.2 t -71.77 167.62 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.177 -0.952 . . . . 0.0 109.087 179.833 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.57 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 77.42 2.11 78.49 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.67 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.637 ' HD2' HD13 ' A' ' 3' ' ' ILE . 0.4 OUTLIER -102.08 169.85 8.48 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.269 -1.136 . . . . 0.0 109.291 179.901 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.624 HG13 ' O ' ' A' ' 58' ' ' VAL . 48.1 t -101.29 134.55 41.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.198 -0.939 . . . . 0.0 109.385 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.506 ' CE1' HG21 ' A' ' 60' ' ' VAL . 3.0 m-85 -110.31 179.92 3.95 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.156 -0.965 . . . . 0.0 109.392 179.775 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.473 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 3.5 m -136.65 107.58 6.68 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 178.94 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.507 ' HA2' ' O ' ' A' ' 24' ' ' ALA . . . -109.82 141.6 16.2 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.065 -1.541 . . . . 0.0 110.331 -178.743 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.455 ' O ' HG13 ' A' ' 23' ' ' VAL . 27.4 mtpt -89.15 163.73 15.32 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 178.939 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.968 HG22 HD23 ' A' ' 50' ' ' LEU . 95.3 t -87.43 102.02 11.94 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.725 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.2 p -106.12 -11.67 16.02 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.478 -0.764 . . . . 0.0 110.186 -178.62 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.562 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -161.2 156.33 24.07 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.954 -1.091 . . . . 0.0 110.455 -179.781 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.462 ' HA ' ' HA ' ' A' ' 21' ' ' ALA . 24.1 mt -147.61 142.77 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.161 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 1.086 HG21 ' CE1' ' A' ' 19' ' ' PHE . 1.5 m -120.79 157.82 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.898 -1.126 . . . . 0.0 110.186 -178.771 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.2 -39.41 86.46 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.807 -1.183 . . . . 0.0 109.459 179.097 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.086 ' CE1' HG21 ' A' ' 17' ' ' VAL . 10.1 p90 -95.16 27.06 3.4 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.14 -0.975 . . . . 0.0 110.222 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.597 ' N ' HG22 ' A' ' 17' ' ' VAL . . . 158.29 -157.43 28.31 Favored Glycine 0 N--CA 1.49 2.244 0 C-N-CA 118.936 -1.602 . . . . 0.0 110.802 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.778 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -149.23 145.4 27.1 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.215 -1.168 . . . . 0.0 109.154 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.965 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.3 m-30 -106.5 158.4 16.94 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.467 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.798 ' CG2' HG23 ' A' ' 33' ' ' VAL . 32.3 t -148.87 164.95 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.067 -1.02 . . . . 0.0 109.533 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.725 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -133.76 152.93 52.01 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.032 -1.043 . . . . 0.0 109.998 -179.478 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.667 HD11 ' HB3' ' A' ' 29' ' ' LYS . 2.0 pt -118.0 -99.78 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 120.666 -1.271 . . . . 0.0 109.429 179.362 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -63.83 -127.59 0.01 OUTLIER Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -117.97 -38.11 0.84 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -99.89 1.81 56.71 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.667 ' HB3' HD11 ' A' ' 25' ' ' ILE . 0.0 OUTLIER -127.53 143.23 51.21 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.184 -1.186 . . . . 0.0 109.8 179.949 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.59 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 13.8 mt-10 -134.6 154.08 51.66 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.925 -1.109 . . . . 0.0 110.222 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.67 ' CA ' HD12 ' A' ' 71' ' ' LEU . . . -101.06 -175.99 29.12 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 108.478 -1.849 . . . . 0.0 108.478 179.307 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.965 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.17 119.31 6.76 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.979 -1.306 . . . . 0.0 110.73 179.429 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 1.021 HG21 HD11 ' A' ' 50' ' ' LEU . 41.3 t -95.93 62.21 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 177.907 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.519 ' O ' ' CD1' ' A' ' 38' ' ' ILE . 3.9 t-160 -49.37 160.12 0.27 Allowed 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.898 -1.127 . . . . 0.0 108.46 -179.49 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.593 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.9 tp -52.2 -49.58 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.236 -0.915 . . . . 0.0 110.286 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.557 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.4 OUTLIER -81.28 41.34 0.6 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.16 -0.963 . . . . 0.0 110.582 -179.331 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.732 ' C ' HD12 ' A' ' 38' ' ' ILE . 30.7 mt-30 -150.65 33.38 0.62 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.766 -1.209 . . . . 0.0 110.42 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.759 ' HB ' HG21 ' A' ' 43' ' ' VAL . 1.5 mp -108.72 -96.29 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.815 -1.178 . . . . 0.0 110.157 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.667 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -92.76 47.05 1.26 Allowed 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.361 -0.837 . . . . 0.0 110.326 -178.922 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.568 ' CB ' ' O ' ' A' ' 39' ' ' ALA . 6.5 t70 83.01 -45.65 0.13 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.596 -0.69 . . . . 0.0 110.495 179.125 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.479 ' O ' ' O ' ' A' ' 42' ' ' ARG . 0.0 OUTLIER -166.61 -33.41 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.88 -1.137 . . . . 0.0 110.043 -179.707 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.514 ' C ' HG23 ' A' ' 43' ' ' VAL . 9.2 mtp180 -56.66 -159.37 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.168 -0.958 . . . . 0.0 109.652 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.041 HG13 ' CD1' ' A' ' 49' ' ' TYR . 5.5 t 80.05 55.28 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.605 -0.684 . . . . 0.0 110.245 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.406 ' C ' ' O ' ' A' ' 43' ' ' VAL . 2.3 mp0 -47.85 -26.01 1.5 Allowed 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 178.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.456 ' HB2' ' CG ' ' A' ' 48' ' ' ASP . 0.1 OUTLIER -127.86 124.65 38.04 Favored 'General case' 0 N--CA 1.487 1.375 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.453 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.568 HG21 ' O ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -70.23 -25.74 28.02 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.355 -0.841 . . . . 0.0 109.119 -179.507 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 3.4 p -75.43 5.28 5.98 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.431 -0.793 . . . . 0.0 109.878 179.598 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.456 ' CG ' ' HB2' ' A' ' 45' ' ' LYS . 12.5 m-20 -101.14 -34.7 9.59 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.008 -1.057 . . . . 0.0 108.677 179.534 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 1.041 ' CD1' HG13 ' A' ' 43' ' ' VAL . 6.3 m-85 -89.51 -34.07 16.53 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.524 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 1.021 HD11 HG21 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -102.57 154.4 19.16 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.173 -1.011 . . . . 0.0 110.366 179.783 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.465 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.6 OUTLIER -142.95 133.83 25.47 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.487 -0.758 . . . . 0.0 109.13 179.982 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 3.9 mtt -63.99 100.44 0.31 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.258 -0.901 . . . . 0.0 109.847 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 129.97 -24.84 4.47 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' GLN . . . . . 0.409 ' HA ' ' OE1' ' A' ' 54' ' ' GLN . 13.2 mm100 -78.87 158.48 28.1 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.232 -1.158 . . . . 0.0 109.786 -179.785 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -110.61 111.66 23.04 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.328 -0.857 . . . . 0.0 109.026 179.576 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.626 ' O ' HG23 ' A' ' 56' ' ' VAL . 6.8 m -103.24 121.99 46.84 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.184 -0.947 . . . . 0.0 110.108 -179.424 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.991 ' HG2' ' HB3' ' A' ' 76' ' ' ALA . 36.5 Cg_endo -80.84 146.71 16.61 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 C-N-CA 122.559 2.173 . . . . 0.0 110.077 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.838 HG21 ' HB3' ' A' ' 71' ' ' LEU . 1.0 OUTLIER -140.01 -168.77 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.06 -1.025 . . . . 0.0 109.655 -179.994 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.593 ' N ' HG23 ' A' ' 58' ' ' VAL . 14.9 mtpt -131.23 119.61 22.06 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.401 -0.812 . . . . 0.0 109.493 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.608 ' HA ' HD23 ' A' ' 71' ' ' LEU . 95.9 t -54.37 89.19 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.418 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.514 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 9.5 tp -68.72 -24.54 64.48 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.339 -0.85 . . . . 0.0 110.034 -179.249 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.514 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 0.5 OUTLIER 166.15 133.88 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.001 -1.062 . . . . 0.0 110.854 179.79 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.447 ' O ' ' HA3' ' A' ' 67' ' ' GLY . 36.9 t -150.98 -96.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 178.804 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.444 ' O ' ' O ' ' A' ' 63' ' ' VAL . 5.2 p-10 40.73 -162.45 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.069 -1.019 . . . . 0.0 110.234 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 33.1 mmt180 -51.03 -62.81 1.39 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.336 -0.852 . . . . 0.0 109.027 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' GLN . . . . . 0.409 ' HG3' ' OD2' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -89.89 90.37 8.15 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.279 -0.888 . . . . 0.0 108.842 179.443 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.447 ' HA3' ' O ' ' A' ' 63' ' ' VAL . . . 167.78 100.76 0.14 Allowed Glycine 0 N--CA 1.486 1.978 0 N-CA-C 108.592 -1.803 . . . . 0.0 108.592 -179.413 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 68.8 mtp180 -88.95 79.51 7.29 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.523 -0.986 . . . . 0.0 109.726 -179.307 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.803 HG22 ' O ' ' A' ' 69' ' ' ILE . 12.7 mm 50.05 71.64 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.466 -0.771 . . . . 0.0 110.216 179.526 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.492 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 0.0 OUTLIER -97.62 76.37 2.51 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.961 -1.087 . . . . 0.0 108.07 178.755 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.838 ' HB3' HG21 ' A' ' 58' ' ' VAL . 96.5 mt -88.96 153.41 21.05 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.329 -0.857 . . . . 0.0 110.043 -178.765 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -117.16 113.55 22.41 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.508 -0.745 . . . . 0.0 109.571 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.423 HG13 HG13 ' A' ' 33' ' ' VAL . 0.6 OUTLIER -47.56 122.81 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.349 -0.844 . . . . 0.0 109.264 179.927 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.467 ' HB3' ' O ' ' A' ' 57' ' ' PRO . 4.2 ttpp -79.29 -16.57 56.19 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.19 -0.944 . . . . 0.0 108.939 179.431 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 67.52 42.4 2.13 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -179.572 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.991 ' HB3' ' HG2' ' A' ' 57' ' ' PRO . . . . . . . . 0 N--CA 1.488 1.457 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.453 -179.705 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.302 0.572 . . . . 0.0 109.473 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.507 ' O ' ' CB ' ' A' ' 3' ' ' ILE . 64.3 mt-10 47.69 -125.32 1.72 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.199 -0.938 . . . . 0.0 109.404 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.592 HD12 ' OH ' ' A' ' 9' ' ' TYR . 0.3 OUTLIER 75.09 146.01 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 120.674 -1.267 . . . . 0.0 108.879 -179.652 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -142.02 176.81 8.66 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.095 -1.003 . . . . 0.0 109.959 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.881 HG22 HG11 ' A' ' 60' ' ' VAL . 2.7 t -79.97 169.52 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.363 -0.836 . . . . 0.0 109.146 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.577 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 73.98 16.91 79.34 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.333 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.426 ' CD ' ' N ' ' A' ' 8' ' ' VAL . 0.1 OUTLIER -116.12 152.69 33.16 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.564 -0.963 . . . . 0.0 109.061 -179.61 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.567 HG13 ' O ' ' A' ' 58' ' ' VAL . 54.9 t -88.65 129.95 38.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 179.357 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.592 ' OH ' HD12 ' A' ' 3' ' ' ILE . 2.9 m-85 -106.52 -179.4 3.93 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.119 -0.988 . . . . 0.0 110.071 -178.731 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.8 m -129.04 105.52 8.25 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 178.181 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.434 ' HA2' ' O ' ' A' ' 24' ' ' ALA . . . -108.16 132.21 11.0 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 119.318 -1.42 . . . . 0.0 111.254 -177.747 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.474 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.3 OUTLIER -91.39 158.83 16.3 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 178.348 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.859 ' CG2' HD22 ' A' ' 50' ' ' LEU . 61.2 t -87.82 97.02 6.2 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 O-C-N 120.858 -1.151 . . . . 0.0 109.045 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.786 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -101.37 -5.78 24.93 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.527 -0.733 . . . . 0.0 109.817 -179.255 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.56 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -164.95 153.71 12.37 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.122 -0.986 . . . . 0.0 110.113 -179.693 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.681 HG21 HG22 ' A' ' 47' ' ' THR . 7.7 mt -141.58 152.92 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 178.842 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 1.013 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -132.33 151.27 34.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.903 -1.123 . . . . 0.0 109.907 -179.011 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -58.41 -38.78 78.09 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.735 -1.228 . . . . 0.0 108.835 179.203 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.013 ' CE1' HG21 ' A' ' 17' ' ' VAL . 23.3 p90 -92.57 30.13 1.59 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.504 -0.748 . . . . 0.0 109.943 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.595 ' C ' HG22 ' A' ' 17' ' ' VAL . . . 149.54 -150.99 23.16 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 119.114 -1.517 . . . . 0.0 111.219 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.819 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -152.58 144.9 23.98 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.094 -1.239 . . . . 0.0 109.158 -179.877 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.965 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.3 m-30 -106.29 142.38 36.07 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.306 -0.872 . . . . 0.0 108.881 179.566 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.878 ' CG2' HG23 ' A' ' 33' ' ' VAL . 40.8 t -132.91 163.02 39.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 120.902 -1.124 . . . . 0.0 109.643 -179.444 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.786 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -130.15 153.24 48.73 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.103 -0.998 . . . . 0.0 109.65 -179.608 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.657 HD11 ' HB3' ' A' ' 29' ' ' LYS . 1.8 pt -120.15 -105.25 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 120.984 -1.072 . . . . 0.0 109.417 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -83.62 161.28 38.49 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -52.55 107.47 0.52 Allowed Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 116.36 -50.48 0.78 Allowed Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.657 ' HB3' HD11 ' A' ' 25' ' ' ILE . 16.5 mmtt -87.03 142.53 27.87 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.222 -1.164 . . . . 0.0 109.261 179.85 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.512 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 1.2 mt-10 -136.81 150.75 48.51 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.973 -1.079 . . . . 0.0 110.102 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.496 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -102.33 -177.19 27.54 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 108.137 -1.985 . . . . 0.0 108.137 179.03 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.965 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -149.53 116.76 6.05 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.694 -1.474 . . . . 0.0 110.431 179.119 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.878 HG23 ' CG2' ' A' ' 23' ' ' VAL . 93.3 t -90.85 59.93 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 178.049 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.518 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.6 t-80 -48.73 157.28 0.39 Allowed 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.57 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.8 tp -47.19 -47.76 9.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.089 -1.007 . . . . 0.0 110.119 -179.207 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.472 ' N ' HG23 ' A' ' 35' ' ' ILE . 56.7 p -81.18 39.41 0.51 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.064 -1.023 . . . . 0.0 110.791 -179.463 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.98 ' C ' HD12 ' A' ' 38' ' ' ILE . 12.4 mt-30 -150.52 53.42 0.89 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.646 -1.283 . . . . 0.0 110.664 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.98 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.7 mp -126.25 -96.31 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.952 -1.093 . . . . 0.0 109.529 179.24 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.787 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -97.31 54.67 1.22 Allowed 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.411 -0.806 . . . . 0.0 109.195 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.537 ' CB ' ' O ' ' A' ' 39' ' ' ALA . 11.1 t0 83.13 -42.57 0.1 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.793 -0.567 . . . . 0.0 109.663 -179.631 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.508 ' HB2' ' O ' ' A' ' 40' ' ' ASP . 0.0 OUTLIER 166.54 -21.61 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.198 -0.939 . . . . 0.0 109.938 -179.945 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.11 76.87 3.66 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.096 -1.002 . . . . 0.0 110.419 -179.14 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.106 HG13 ' CD1' ' A' ' 49' ' ' TYR . 54.6 t -142.45 74.75 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 108.976 178.91 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.433 ' C ' ' O ' ' A' ' 43' ' ' VAL . 16.8 mt-10 -40.99 -28.05 0.07 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.558 -0.714 . . . . 0.0 110.314 -179.399 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.492 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.1 OUTLIER -142.63 138.51 30.76 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.961 -1.087 . . . . 0.0 110.206 -179.697 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.551 HG21 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -80.61 -26.47 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.356 -0.84 . . . . 0.0 108.845 179.514 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.681 HG22 HG21 ' A' ' 16' ' ' ILE . 47.3 p -78.47 5.12 11.45 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.317 -0.864 . . . . 0.0 109.023 179.056 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.466 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 4.1 m-20 -104.48 -30.76 9.83 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.328 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 1.106 ' CD1' HG13 ' A' ' 43' ' ' VAL . 17.8 m-85 -90.25 -33.98 15.94 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.595 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.859 HD22 ' CG2' ' A' ' 13' ' ' VAL . 3.5 mt -108.1 151.78 25.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.194 -0.941 . . . . 0.0 110.005 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.521 ' CB ' ' HG3' ' A' ' 54' ' ' GLN . 0.1 OUTLIER -136.93 138.52 40.72 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 179.033 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 23.4 mtt -62.6 91.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.003 -1.06 . . . . 0.0 109.839 -179.523 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 137.52 -22.59 3.17 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 119.732 -1.223 . . . . 0.0 110.388 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' GLN . . . . . 0.521 ' HG3' ' CB ' ' A' ' 51' ' ' GLN . 6.5 mm-40 -77.28 145.29 37.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.055 -1.262 . . . . 0.0 110.074 -179.377 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -113.19 127.26 56.13 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.475 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.438 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 15.9 m -132.45 142.37 44.66 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.02 -1.05 . . . . 0.0 110.032 -179.524 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.454 ' O ' ' HB2' ' A' ' 74' ' ' LYS . 36.9 Cg_endo -80.27 129.42 7.66 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.665 2.244 . . . . 0.0 110.335 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.865 HG21 ' HB3' ' A' ' 71' ' ' LEU . 0.8 OUTLIER -120.6 -170.5 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.19 -0.944 . . . . 0.0 109.317 179.753 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.631 ' N ' HG23 ' A' ' 58' ' ' VAL . 0.1 OUTLIER -132.12 141.83 49.28 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.257 -0.902 . . . . 0.0 109.319 179.883 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.881 HG11 HG22 ' A' ' 5' ' ' VAL . 26.5 t -68.76 87.82 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.449 -0.782 . . . . 0.0 109.139 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.686 HD12 ' OG ' ' A' ' 72' ' ' SER . 0.5 OUTLIER -56.51 -29.45 61.86 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.345 -0.847 . . . . 0.0 109.388 -179.888 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.547 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 1.0 OUTLIER 160.96 164.36 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.359 -0.838 . . . . 0.0 110.279 179.644 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.474 ' HA ' ' O ' ' A' ' 66' ' ' GLN . 50.5 t -150.13 -48.98 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.491 -0.756 . . . . 0.0 109.359 179.595 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 63' ' ' VAL . 0.5 OUTLIER -44.36 -61.26 1.58 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.199 -0.938 . . . . 0.0 109.483 179.993 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.38 -52.87 63.75 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.088 -1.008 . . . . 0.0 108.689 179.506 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' GLN . . . . . 0.474 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 0.0 OUTLIER -108.49 107.39 17.89 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 179.272 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -74.6 3.47 41.96 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 -179.335 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.48 ' O ' ' O ' ' A' ' 69' ' ' ILE . 0.0 OUTLIER -89.6 41.74 1.06 Allowed 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.953 -1.322 . . . . 0.0 109.352 179.885 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.57 HG22 ' HG ' ' A' ' 71' ' ' LEU . 63.2 mt 39.35 94.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.827 -0.545 . . . . 0.0 110.121 179.491 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.463 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 8.9 mmm180 -89.74 79.55 6.72 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.007 -1.058 . . . . 0.0 109.854 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.865 ' HB3' HG21 ' A' ' 58' ' ' VAL . 17.5 mt -91.11 147.38 23.11 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.217 -0.927 . . . . 0.0 108.78 179.435 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.686 ' OG ' HD12 ' A' ' 61' ' ' LEU . 0.6 OUTLIER -134.11 117.14 16.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.105 -0.997 . . . . 0.0 110.302 -179.262 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.431 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.1 OUTLIER -44.07 131.89 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.299 -0.876 . . . . 0.0 108.962 179.691 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.454 ' HB2' ' O ' ' A' ' 57' ' ' PRO . 0.0 OUTLIER -71.82 177.3 4.3 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.215 -0.928 . . . . 0.0 110.137 -179.374 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -49.85 -43.83 49.18 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.465 -0.772 . . . . 0.0 109.574 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 117.94 -1.029 . . . . 0.0 109.372 -179.867 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 29.9 mp0 -142.2 -166.84 2.33 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.363 -0.836 . . . . 0.0 109.001 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.546 HG21 ' CE2' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -123.4 -169.71 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.014 -1.054 . . . . 0.0 109.361 179.971 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -149.47 134.19 17.77 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.379 -0.826 . . . . 0.0 109.212 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.651 HG22 HG11 ' A' ' 60' ' ' VAL . 4.2 t -60.87 162.94 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.256 -0.902 . . . . 0.0 109.465 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.495 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 80.87 2.34 90.18 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.23 -1.548 . . . . 0.0 109.23 -179.593 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.531 ' HG2' ' N ' ' A' ' 8' ' ' VAL . 28.2 ttt85 -102.01 160.34 14.59 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.292 -1.122 . . . . 0.0 109.609 -179.778 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.945 HG13 ' O ' ' A' ' 58' ' ' VAL . 93.5 t -96.9 142.95 13.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.243 -0.911 . . . . 0.0 109.369 179.763 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.546 ' CE2' HG21 ' A' ' 3' ' ' ILE . 9.2 m-85 -118.69 -168.19 1.5 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.302 -0.874 . . . . 0.0 109.758 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.534 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 34.3 m -166.21 127.81 1.83 Allowed 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.443 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.5 ' HA3' ' O ' ' A' ' 24' ' ' ALA . . . -149.53 -177.84 23.97 Favored Glycine 0 N--CA 1.489 2.202 0 C-N-CA 118.44 -1.838 . . . . 0.0 111.266 -178.636 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.543 ' O ' HG13 ' A' ' 23' ' ' VAL . 15.6 mtpt -104.45 168.27 9.2 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.808 -0.819 . . . . 0.0 108.929 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.926 HG22 HD13 ' A' ' 50' ' ' LEU . 72.4 t -87.98 101.37 11.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 O-C-N 121.156 -0.965 . . . . 0.0 108.423 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.665 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.1 p -111.11 11.12 21.96 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.275 -0.89 . . . . 0.0 110.286 -178.814 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.555 ' HB3' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -175.29 147.01 0.86 Allowed 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.956 -1.09 . . . . 0.0 110.255 179.75 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.4 HG21 HG22 ' A' ' 47' ' ' THR . 17.2 mt -139.28 151.71 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.068 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 1.054 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -129.61 154.05 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.765 -1.209 . . . . 0.0 110.088 -179.089 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -59.13 -41.7 88.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.866 -1.147 . . . . 0.0 109.327 179.173 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.054 ' CE1' HG21 ' A' ' 17' ' ' VAL . 14.0 p90 -91.3 27.14 2.0 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.313 -0.867 . . . . 0.0 110.22 -179.716 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.606 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 155.22 -153.58 24.88 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.898 -1.62 . . . . 0.0 111.063 -179.365 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.792 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -150.33 144.71 25.69 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.063 -1.257 . . . . 0.0 109.007 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.959 ' CE1' HD11 ' A' ' 32' ' ' LEU . 11.1 m-30 -108.41 162.11 14.41 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.401 -0.812 . . . . 0.0 109.214 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.571 ' CG2' HG23 ' A' ' 33' ' ' VAL . 3.5 t -150.63 166.81 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.166 -0.958 . . . . 0.0 109.433 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.665 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -132.79 145.24 50.83 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.209 -0.932 . . . . 0.0 108.856 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.985 HD11 ' HB2' ' A' ' 29' ' ' LYS . 7.7 pt -98.83 -20.47 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 120.547 -1.346 . . . . 0.0 109.653 -179.829 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.11 -8.42 57.67 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -89.54 34.18 4.11 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.427 ' C ' ' HG2' ' A' ' 29' ' ' LYS . . . 87.79 -1.23 85.21 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.634 -1.387 . . . . 0.0 109.634 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.985 ' HB2' HD11 ' A' ' 25' ' ' ILE . 5.8 mmtm -140.68 174.55 10.41 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.193 -1.181 . . . . 0.0 109.68 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.553 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 7.3 pt-20 -128.01 157.47 40.55 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 120.867 -1.146 . . . . 0.0 110.474 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.812 ' CA ' HD12 ' A' ' 71' ' ' LEU . . . -105.83 -175.79 23.83 Favored Glycine 0 N--CA 1.487 2.042 0 N-CA-C 108.337 -1.905 . . . . 0.0 108.337 179.298 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.959 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.79 121.29 7.4 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 120.746 -1.444 . . . . 0.0 111.542 -179.794 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.792 ' HB ' ' HB3' ' A' ' 21' ' ' ALA . 26.0 t -95.86 62.9 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 176.922 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.475 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.7 t-160 -48.08 155.02 0.5 Allowed 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.885 -1.135 . . . . 0.0 108.883 -179.274 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.576 HG23 ' H ' ' A' ' 36' ' ' SER . 3.0 tp -45.84 -52.09 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.218 -0.926 . . . . 0.0 110.315 -179.431 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.576 ' H ' HG23 ' A' ' 35' ' ' ILE . 0.0 OUTLIER -81.52 42.96 0.71 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.294 -0.879 . . . . 0.0 110.524 -179.33 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.972 ' C ' HD12 ' A' ' 38' ' ' ILE . 68.3 mt-30 -150.83 53.38 0.87 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.859 -1.151 . . . . 0.0 110.036 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.972 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.7 mp -124.53 -96.01 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.926 -1.109 . . . . 0.0 110.376 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.797 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -95.09 -39.9 9.9 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.492 -0.755 . . . . 0.0 109.674 -178.845 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.497 ' O ' ' HB2' ' A' ' 41' ' ' LYS . 9.9 p-10 174.74 -40.66 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.418 -0.801 . . . . 0.0 109.475 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.497 ' HB2' ' O ' ' A' ' 40' ' ' ASP . 0.2 OUTLIER 172.23 -18.39 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.288 -0.883 . . . . 0.0 110.793 -179.763 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.43 6.93 4.01 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.821 -1.174 . . . . 0.0 110.51 -179.3 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.031 HG13 ' CD1' ' A' ' 49' ' ' TYR . 60.2 t -86.76 52.55 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 O-C-N 120.925 -1.109 . . . . 0.0 109.242 179.659 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.433 ' C ' ' O ' ' A' ' 43' ' ' VAL . 3.6 mm-40 -45.06 -25.05 0.29 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.224 -0.922 . . . . 0.0 108.744 179.633 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.429 ' N ' ' C ' ' A' ' 43' ' ' VAL . 25.0 mmtp -119.66 122.7 42.09 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.537 -0.727 . . . . 0.0 109.157 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.606 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -78.98 -24.54 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.271 -0.893 . . . . 0.0 108.842 179.812 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.4 HG22 HG21 ' A' ' 16' ' ' ILE . 72.5 p -75.9 4.4 8.25 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.449 -0.782 . . . . 0.0 109.723 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -102.75 -38.16 7.57 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.135 -0.978 . . . . 0.0 109.183 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 1.031 ' CD1' HG13 ' A' ' 43' ' ' VAL . 9.9 m-85 -89.43 -33.55 16.78 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.349 -0.844 . . . . 0.0 109.104 179.669 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.926 HD13 HG22 ' A' ' 13' ' ' VAL . 0.1 OUTLIER -98.86 135.54 40.15 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.412 -0.805 . . . . 0.0 109.443 -179.793 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.479 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.0 OUTLIER -138.89 122.5 17.41 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.556 -0.715 . . . . 0.0 109.6 -179.84 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 52' ' ' MET . . . . . 0.504 ' CG ' ' O ' ' A' ' 52' ' ' MET . 5.1 ptm -48.6 105.79 0.09 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.317 -0.864 . . . . 0.0 109.947 -179.925 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 133.92 -43.55 1.26 Allowed Glycine 0 N--CA 1.492 2.398 0 C-N-CA 119.832 -1.175 . . . . 0.0 110.471 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' GLN . . . . . 0.424 ' O ' HG23 ' A' ' 13' ' ' VAL . 15.8 mt-30 -69.32 146.15 52.43 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.01 -1.288 . . . . 0.0 110.107 -179.399 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.51 ' HA ' ' HA ' ' A' ' 12' ' ' LYS . 0.4 OUTLIER -122.53 140.08 53.18 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.355 -0.841 . . . . 0.0 109.115 179.526 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.416 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 24.8 m -146.73 155.95 48.37 Favored Pre-proline 0 N--CA 1.487 1.424 0 O-C-N 121.164 -0.96 . . . . 0.0 110.052 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.534 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 37.2 Cg_endo -83.37 146.9 12.51 Favored 'Trans proline' 0 C--N 1.314 -1.261 0 C-N-CA 123.161 2.574 . . . . 0.0 110.428 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.945 ' O ' HG13 ' A' ' 8' ' ' VAL . 1.0 OUTLIER -141.29 -168.61 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.186 -0.946 . . . . 0.0 109.287 179.368 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.702 ' CG ' HG22 ' A' ' 8' ' ' VAL . 17.2 mtmt -134.3 134.14 41.54 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.385 -0.822 . . . . 0.0 109.779 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.651 HG11 HG22 ' A' ' 5' ' ' VAL . 47.6 t -63.49 87.43 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.392 -0.818 . . . . 0.0 109.197 179.632 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.575 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 4.9 tp -53.56 -37.78 63.24 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.644 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.575 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 2.7 pt-20 153.4 167.66 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.064 0 CA-C-O 121.765 0.793 . . . . 0.0 110.14 179.374 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.537 HG13 ' O ' ' A' ' 67' ' ' GLY . 49.1 t -151.52 130.29 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 O-C-N 121.494 -0.753 . . . . 0.0 109.37 179.155 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.424 ' O ' ' C ' ' A' ' 65' ' ' ARG . 14.6 p-10 -154.09 -177.38 6.38 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.236 -0.915 . . . . 0.0 109.382 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ARG . . . . . 0.424 ' C ' ' O ' ' A' ' 64' ' ' ASP . 9.3 ptm180 -44.13 -44.26 7.53 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.186 -0.946 . . . . 0.0 108.973 179.837 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -105.35 57.13 0.68 Allowed 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 179.15 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.537 ' O ' HG13 ' A' ' 63' ' ' VAL . . . -175.08 92.41 0.09 OUTLIER Glycine 0 N--CA 1.489 2.202 0 N-CA-C 108.989 -1.645 . . . . 0.0 108.989 -179.662 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 4.3 mtt180 -88.54 100.08 12.8 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.25 -1.147 . . . . 0.0 108.989 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.535 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 61.2 mt 52.42 78.42 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.474 -0.766 . . . . 0.0 109.511 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.463 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 26.2 mmm180 -89.72 87.68 7.09 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.841 -1.162 . . . . 0.0 108.62 179.517 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.812 HD12 ' CA ' ' A' ' 31' ' ' GLY . 13.6 mt -89.16 163.64 15.35 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.324 -0.86 . . . . 0.0 109.607 -179.305 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.5 ' OG ' HD13 ' A' ' 61' ' ' LEU . 0.3 OUTLIER -133.43 107.65 8.19 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.442 -0.786 . . . . 0.0 109.724 -179.636 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.423 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.0 OUTLIER -44.92 140.31 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.249 -0.907 . . . . 0.0 108.77 179.713 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.416 ' HD3' ' HB2' ' A' ' 57' ' ' PRO . 0.0 OUTLIER -50.58 170.6 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.15 -0.969 . . . . 0.0 109.424 179.973 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 46.51 61.85 2.58 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.149 -0.969 . . . . 0.0 109.048 -179.802 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.419 -179.646 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.518 0 CA-C-O 121.254 0.549 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.683 ' C ' HD13 ' A' ' 3' ' ' ILE . 2.5 mp0 -95.7 -169.32 1.93 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.272 -0.893 . . . . 0.0 109.605 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.683 HD13 ' C ' ' A' ' 2' ' ' GLU . 0.0 OUTLIER -124.11 115.5 45.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 C-N-CA 119.472 -0.891 . . . . 0.0 110.21 -179.092 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -117.8 147.95 42.54 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 179.582 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.465 HG22 ' HA ' ' A' ' 62' ' ' GLU . 14.8 t -69.54 159.77 5.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 O-C-N 120.991 -1.068 . . . . 0.0 109.577 -179.745 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.451 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 71.06 7.32 62.36 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 108.998 -1.641 . . . . 0.0 108.998 -179.38 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.77 178.6 5.86 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.284 -1.127 . . . . 0.0 109.67 -179.818 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.537 ' HA ' ' HA ' ' A' ' 59' ' ' LYS . 68.1 t -114.97 144.84 21.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.305 -0.872 . . . . 0.0 109.448 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.626 ' CD1' HG23 ' A' ' 60' ' ' VAL . 14.0 m-85 -143.94 128.42 17.99 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.023 -1.048 . . . . 0.0 110.355 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -91.06 115.62 28.16 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 178.15 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -113.6 141.3 16.87 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 119.119 -1.515 . . . . 0.0 110.626 -178.362 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.516 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.8 OUTLIER -89.56 162.07 15.86 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 178.724 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.741 HG22 HD13 ' A' ' 50' ' ' LEU . 58.2 t -87.86 105.39 15.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 120.986 -1.072 . . . . 0.0 108.368 179.616 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.918 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -111.7 -0.8 15.89 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.262 -0.899 . . . . 0.0 110.218 -178.859 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.527 ' CD ' ' O ' ' A' ' 14' ' ' THR . 0.3 OUTLIER -168.05 152.42 6.34 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.902 -1.123 . . . . 0.0 110.314 179.97 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.441 ' HA ' ' HA ' ' A' ' 21' ' ' ALA . 56.6 mt -145.37 150.03 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 179.058 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 1.095 HG21 ' CE1' ' A' ' 19' ' ' PHE . 1.2 m -126.93 156.33 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 120.932 -1.105 . . . . 0.0 109.813 -179.076 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -60.37 -37.89 82.18 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.784 -1.197 . . . . 0.0 109.455 179.208 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.095 ' CE1' HG21 ' A' ' 17' ' ' VAL . 13.9 p90 -94.56 26.43 3.47 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.244 -0.91 . . . . 0.0 110.379 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.593 ' HA2' ' N ' ' A' ' 35' ' ' ILE . . . 155.54 -154.08 25.25 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.481 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.726 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -152.27 146.23 25.25 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.043 -1.269 . . . . 0.0 109.439 -179.558 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.957 ' CE1' HD11 ' A' ' 32' ' ' LEU . 12.4 m-30 -108.04 158.54 17.31 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.354 -0.842 . . . . 0.0 109.145 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.788 ' CG2' HG23 ' A' ' 33' ' ' VAL . 7.7 t -145.85 163.75 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.166 -0.959 . . . . 0.0 109.151 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.918 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -137.1 146.55 45.25 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.017 -1.052 . . . . 0.0 110.119 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.522 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.1 pt -106.77 22.22 3.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 120.779 -1.201 . . . . 0.0 108.667 178.985 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 147.66 -143.27 11.01 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -111.75 9.24 27.85 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -118.96 -67.78 0.31 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.522 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER -97.66 151.11 20.44 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.234 -1.157 . . . . 0.0 109.514 -179.97 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.573 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 3.5 pt-20 -134.68 153.4 52.01 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 120.847 -1.158 . . . . 0.0 110.224 -179.855 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -102.57 -173.51 27.0 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 108.504 -1.839 . . . . 0.0 108.504 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.957 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.31 119.02 6.55 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.993 -1.298 . . . . 0.0 110.692 179.514 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.83 HG12 HD11 ' A' ' 38' ' ' ILE . 8.4 t -96.59 63.56 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 177.588 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.551 ' HB3' ' CG ' ' A' ' 37' ' ' GLN . 4.4 t-80 -47.7 166.08 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.308 0 O-C-N 120.879 -1.138 . . . . 0.0 108.279 -179.594 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.662 ' HA ' HG13 ' A' ' 46' ' ' VAL . 0.2 OUTLIER -55.19 -55.33 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.136 -0.977 . . . . 0.0 110.296 -179.256 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.626 ' H ' HG23 ' A' ' 35' ' ' ILE . 92.6 p -82.31 42.57 0.75 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.018 -1.051 . . . . 0.0 110.334 -179.734 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.95 ' O ' HD13 ' A' ' 73' ' ' ILE . 20.8 mm-40 -145.27 44.46 1.32 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.938 -1.101 . . . . 0.0 109.598 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.925 HG21 ' CD2' ' A' ' 49' ' ' TYR . 1.8 mp -119.33 -91.66 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.253 -0.904 . . . . 0.0 108.978 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.825 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -118.93 157.79 27.0 Favored 'General case' 0 C--N 1.298 -1.654 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 39' ' ' ALA . 0.2 OUTLIER -43.06 -49.97 6.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.315 -0.866 . . . . 0.0 109.568 -179.674 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.41 ' O ' ' C ' ' A' ' 42' ' ' ARG . 0.0 OUTLIER -58.52 120.66 9.23 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.161 -0.962 . . . . 0.0 109.141 179.806 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.41 ' C ' ' O ' ' A' ' 41' ' ' LYS . 0.0 OUTLIER -44.35 123.97 3.8 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.316 -0.865 . . . . 0.0 109.601 -179.901 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.023 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 39.6 t -94.23 70.72 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 179.314 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 25.5 tp10 -46.49 -22.5 0.27 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.151 -0.968 . . . . 0.0 109.244 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.539 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 28.9 mttp -119.68 109.12 15.27 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.386 -0.821 . . . . 0.0 109.246 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.662 HG13 ' HA ' ' A' ' 35' ' ' ILE . 0.0 OUTLIER -77.52 -22.87 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.232 -0.918 . . . . 0.0 108.781 179.842 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 18.6 p -76.99 2.57 14.48 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.449 -0.782 . . . . 0.0 109.216 179.251 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.404 ' OD2' ' HD2' ' A' ' 45' ' ' LYS . 1.7 m-20 -101.42 -33.68 9.89 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.1 -1.0 . . . . 0.0 109.264 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 1.023 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 6.6 m-85 -94.98 -30.78 13.94 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.575 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.741 HD13 HG22 ' A' ' 13' ' ' VAL . 0.2 OUTLIER -105.61 140.73 38.24 Favored 'General case' 0 N--CA 1.488 1.454 0 CA-C-O 121.536 0.684 . . . . 0.0 109.35 -179.731 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.511 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 2.0 tm0? -148.61 124.38 10.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.462 -0.774 . . . . 0.0 109.301 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 56.8 mtp -48.8 112.65 0.64 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.288 -0.883 . . . . 0.0 109.924 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 113.11 -44.85 1.42 Allowed Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' GLN . . . . . 0.539 ' O ' HG23 ' A' ' 13' ' ' VAL . 15.5 mm100 -56.92 102.96 0.09 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.147 -1.208 . . . . 0.0 109.586 -179.727 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -65.18 137.14 57.43 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.188 -0.945 . . . . 0.0 109.125 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.7 m -135.48 132.13 19.7 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.229 -0.919 . . . . 0.0 109.841 -179.767 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.414 ' HG2' ' HG3' ' A' ' 74' ' ' LYS . 36.4 Cg_endo -79.96 142.63 15.72 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.461 2.107 . . . . 0.0 110.129 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.892 ' CG2' HD12 ' A' ' 71' ' ' LEU . 0.9 OUTLIER -141.43 -173.74 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.232 -0.917 . . . . 0.0 109.246 179.665 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.571 ' N ' HG23 ' A' ' 58' ' ' VAL . 9.0 mtmm -142.35 111.26 6.33 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.295 -0.878 . . . . 0.0 110.248 -179.71 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.626 HG23 ' CD1' ' A' ' 9' ' ' TYR . 61.5 t -45.57 94.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.857 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.579 HD13 ' OG ' ' A' ' 72' ' ' SER . 4.6 tp -75.89 -26.84 57.39 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.331 -0.855 . . . . 0.0 109.866 -178.991 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.523 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 8.9 pt-20 162.73 -171.88 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.378 -0.827 . . . . 0.0 110.427 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.505 ' O ' ' N ' ' A' ' 67' ' ' GLY . 49.0 t -143.49 -42.68 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 179.644 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.447 ' O ' ' C ' ' A' ' 65' ' ' ARG . 0.3 OUTLIER -45.46 -45.94 13.34 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.405 -0.81 . . . . 0.0 109.926 -179.948 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ARG . . . . . 0.447 ' C ' ' O ' ' A' ' 64' ' ' ASP . 11.2 ttm180 -41.71 -70.84 0.09 Allowed 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.293 -0.879 . . . . 0.0 109.677 -179.772 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -97.25 -52.23 3.9 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.228 -0.92 . . . . 0.0 109.248 179.864 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.505 ' N ' ' O ' ' A' ' 63' ' ' VAL . . . 110.88 -17.99 26.96 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.144 -1.583 . . . . 0.0 109.144 -179.81 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.473 ' O ' ' HB ' ' A' ' 69' ' ' ILE . 0.0 OUTLIER -98.31 51.87 1.02 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.398 -1.06 . . . . 0.0 108.895 179.514 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.556 HG23 ' CD2' ' A' ' 71' ' ' LEU . 4.0 mt 62.13 109.28 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 121.493 -0.755 . . . . 0.0 109.392 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.5 ' CB ' ' O ' ' A' ' 62' ' ' GLU . 0.0 OUTLIER -106.09 92.62 4.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.458 -0.776 . . . . 0.0 109.376 179.947 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.892 HD12 ' CG2' ' A' ' 58' ' ' VAL . 0.3 OUTLIER -94.74 154.53 17.25 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.324 -0.86 . . . . 0.0 109.366 -179.94 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.579 ' OG ' HD13 ' A' ' 61' ' ' LEU . 0.6 OUTLIER -109.85 111.71 23.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.197 -0.94 . . . . 0.0 110.219 -179.231 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.95 HD13 ' O ' ' A' ' 37' ' ' GLN . 1.2 mp -56.96 128.21 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.181 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.441 ' C ' ' O ' ' A' ' 73' ' ' ILE . 0.6 OUTLIER -39.44 -59.33 1.1 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.357 -0.84 . . . . 0.0 110.351 -179.136 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -48.27 -45.67 34.93 Favored 'General case' 0 C--N 1.292 -1.898 0 O-C-N 121.498 -0.752 . . . . 0.0 109.439 -179.84 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.437 ' HB3' ' O ' ' A' ' 73' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 118.055 -0.974 . . . . 0.0 109.622 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.459 ' O ' ' O ' ' A' ' 3' ' ' ILE . 8.6 mt-10 54.43 40.9 32.14 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.246 -0.909 . . . . 0.0 109.381 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.498 HD13 ' CD ' ' A' ' 7' ' ' ARG . 0.3 OUTLIER 62.26 127.14 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.233 -0.917 . . . . 0.0 108.806 179.768 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.455 ' O ' ' HG3' ' A' ' 7' ' ' ARG . 1.6 pt-20 -129.17 -150.96 0.46 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.272 -0.892 . . . . 0.0 109.922 -179.408 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 1.076 HG22 HG11 ' A' ' 60' ' ' VAL . 2.2 t -80.36 163.55 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.351 -0.843 . . . . 0.0 109.714 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.504 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 90.08 13.97 59.77 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.498 ' CD ' HD13 ' A' ' 3' ' ' ILE . 0.1 OUTLIER -133.79 -173.87 3.36 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.086 -1.243 . . . . 0.0 109.643 -179.333 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.8 t -90.05 134.13 29.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.192 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.673 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 4.6 m-85 -122.28 133.21 54.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.043 -1.035 . . . . 0.0 109.998 -179.598 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.3 m -83.87 103.29 13.02 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.546 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.31 119.82 5.11 Favored Glycine 0 N--CA 1.487 2.056 0 C-N-CA 119.884 -1.151 . . . . 0.0 110.737 -178.495 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.604 ' O ' HG13 ' A' ' 23' ' ' VAL . 2.0 mtmt -89.29 148.46 23.55 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 178.77 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.646 HG22 ' CD2' ' A' ' 50' ' ' LEU . 3.8 t -86.85 117.6 31.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 O-C-N 120.597 -1.314 . . . . 0.0 108.656 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.952 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.5 p -128.16 -3.41 5.67 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.419 -0.801 . . . . 0.0 109.933 -178.596 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.535 ' HG3' ' HB3' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -173.77 150.57 1.71 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.128 -0.982 . . . . 0.0 109.872 179.396 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.502 HG22 ' N ' ' A' ' 17' ' ' VAL . 18.0 mt -136.31 161.49 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.374 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 1.055 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -139.97 153.34 22.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 120.59 -1.319 . . . . 0.0 110.623 -179.009 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -59.22 -41.19 88.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.766 -1.209 . . . . 0.0 109.376 179.093 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.055 ' CE1' HG21 ' A' ' 17' ' ' VAL . 14.3 p90 -90.99 28.42 1.58 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.356 -0.84 . . . . 0.0 110.096 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.797 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 149.7 -149.28 21.2 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.08 -1.533 . . . . 0.0 110.834 -179.717 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 1.047 ' HB1' HD12 ' A' ' 50' ' ' LEU . . . -153.64 147.79 25.73 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 120.967 -1.313 . . . . 0.0 109.263 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.972 ' CE1' HD11 ' A' ' 32' ' ' LEU . 11.9 m-30 -106.7 158.35 17.03 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.4 -0.813 . . . . 0.0 109.083 179.641 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.757 ' CG2' HG23 ' A' ' 33' ' ' VAL . 15.6 t -150.12 162.11 4.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.291 -0.881 . . . . 0.0 109.185 -179.464 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.952 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -133.57 136.5 44.97 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.147 -0.97 . . . . 0.0 109.494 -179.631 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.49 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.7 pt -110.87 51.81 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 120.917 -1.115 . . . . 0.0 109.47 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 120.71 -166.85 13.84 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -104.06 20.21 41.37 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -126.16 -36.79 0.52 Allowed Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.49 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.6 OUTLIER -134.21 146.04 49.75 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.157 -1.201 . . . . 0.0 109.501 -179.787 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.72 ' O ' HD13 ' A' ' 69' ' ' ILE . 1.0 OUTLIER -120.49 149.83 41.78 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.804 -1.185 . . . . 0.0 110.46 -179.57 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.725 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -102.69 -178.1 26.99 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.198 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.972 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -148.56 119.79 7.8 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.863 -1.375 . . . . 0.0 110.67 179.744 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.778 ' HB ' ' HB3' ' A' ' 21' ' ' ALA . 59.4 t -94.4 62.26 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 177.776 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.457 ' HB2' HD23 ' A' ' 32' ' ' LEU . 4.0 t-80 -50.16 159.39 0.45 Allowed 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.888 -1.132 . . . . 0.0 108.637 -179.53 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.582 HG23 ' H ' ' A' ' 36' ' ' SER . 1.6 tp -48.53 -52.94 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.169 -0.957 . . . . 0.0 110.342 -179.614 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.582 ' H ' HG23 ' A' ' 35' ' ' ILE . 1.9 t -81.84 44.85 0.86 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.12 -0.987 . . . . 0.0 110.536 -179.448 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.778 ' C ' HD12 ' A' ' 38' ' ' ILE . 46.8 mt-30 -150.36 37.03 0.67 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.783 -1.198 . . . . 0.0 109.88 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.887 HG21 ' CD2' ' A' ' 49' ' ' TYR . 1.8 mp -114.77 -96.69 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.932 -1.105 . . . . 0.0 110.285 -179.58 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.772 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -97.46 51.75 1.09 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.447 -0.783 . . . . 0.0 109.43 -179.17 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.541 ' CB ' ' O ' ' A' ' 39' ' ' ALA . 5.0 m-20 82.28 -41.88 0.13 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.782 -0.574 . . . . 0.0 110.106 179.843 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.442 ' CB ' ' O ' ' A' ' 40' ' ' ASP . 0.0 OUTLIER 171.05 -22.95 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.883 -1.136 . . . . 0.0 110.767 -179.691 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.6 mtm180 -79.49 77.98 6.03 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.878 -1.139 . . . . 0.0 110.974 -178.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.113 HG13 ' CD1' ' A' ' 49' ' ' TYR . 59.1 t -144.32 63.73 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.313 -0.867 . . . . 0.0 108.756 178.68 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.446 ' C ' ' O ' ' A' ' 43' ' ' VAL . 20.9 tp10 -38.57 -29.27 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.569 -0.707 . . . . 0.0 110.538 -179.264 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.487 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 3.5 mttm -133.03 132.37 41.75 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.915 -1.115 . . . . 0.0 109.978 -179.552 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.797 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -79.65 -25.74 12.35 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 179.18 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 10.5 p -77.2 4.45 10.44 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.653 -0.654 . . . . 0.0 109.355 179.325 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.487 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 2.8 m-20 -106.53 -30.16 9.22 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.147 -0.97 . . . . 0.0 108.621 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 1.113 ' CD1' HG13 ' A' ' 43' ' ' VAL . 19.0 m-85 -92.14 -30.91 15.71 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.576 -0.703 . . . . 0.0 109.264 179.764 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 1.047 HD12 ' HB1' ' A' ' 21' ' ' ALA . 0.6 OUTLIER -106.08 143.48 34.15 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.633 179.857 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.515 ' O ' ' CB ' ' A' ' 13' ' ' VAL . 4.1 tt0 -130.69 129.69 42.92 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.273 -0.892 . . . . 0.0 108.999 179.455 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 10.2 mtt -63.57 118.33 8.04 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.142 -0.973 . . . . 0.0 109.674 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 105.12 -23.05 31.66 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' GLN . . . . . 0.499 ' CG ' ' HB3' ' A' ' 51' ' ' GLN . 12.8 mt-30 -73.31 -172.61 1.17 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.23 -1.159 . . . . 0.0 109.647 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.463 ' HG2' ' HA ' ' A' ' 12' ' ' LYS . 5.6 mt-10 -156.76 128.75 7.29 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.214 -0.929 . . . . 0.0 109.518 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.411 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 14.6 m -128.5 145.63 56.71 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.223 -0.923 . . . . 0.0 109.721 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 56' ' ' VAL . 36.3 Cg_endo -79.79 139.93 14.28 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.644 2.229 . . . . 0.0 110.155 179.718 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.818 ' CG2' HD22 ' A' ' 71' ' ' LEU . 1.0 OUTLIER -142.49 -177.96 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.162 -0.961 . . . . 0.0 109.777 -179.844 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.418 ' N ' HG23 ' A' ' 58' ' ' VAL . 5.3 mttm -127.0 116.52 20.88 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.443 -0.786 . . . . 0.0 109.465 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 1.076 HG11 HG22 ' A' ' 5' ' ' VAL . 13.6 t -51.31 99.34 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.166 -0.959 . . . . 0.0 109.353 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.611 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 9.8 tp -75.74 -16.01 60.2 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.327 -0.858 . . . . 0.0 109.573 -179.666 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.611 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 2.3 tt0 92.71 -175.83 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.663 HG13 ' O ' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -122.24 -167.19 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.993 -1.067 . . . . 0.0 109.852 -179.457 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.629 ' H ' HG12 ' A' ' 63' ' ' VAL . 9.6 p-10 -135.33 -139.83 0.17 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.376 -0.827 . . . . 0.0 109.64 -179.635 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 3.0 tpm_? -67.43 -29.34 68.8 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.146 -0.971 . . . . 0.0 109.901 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' GLN . . . . . 0.46 ' HB3' ' HG2' ' A' ' 68' ' ' ARG . 2.8 tt0 -89.64 -174.12 4.2 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.003 -1.06 . . . . 0.0 109.434 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -109.86 45.69 1.28 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.663 ' O ' HG13 ' A' ' 63' ' ' VAL . 9.6 mmm180 -105.03 91.51 3.83 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.149 -1.206 . . . . 0.0 109.448 179.816 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.72 HD13 ' O ' ' A' ' 30' ' ' GLU . 2.4 mt -47.37 120.0 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.129 -0.982 . . . . 0.0 109.362 179.928 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.493 ' NH1' ' HB2' ' A' ' 68' ' ' ARG . 7.1 mmt-85 -94.5 100.57 12.53 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.208 -0.933 . . . . 0.0 109.718 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.818 HD22 ' CG2' ' A' ' 58' ' ' VAL . 12.0 mt -90.7 146.36 24.07 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 121.264 -0.897 . . . . 0.0 108.725 179.612 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.25 90.01 3.17 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.199 -0.938 . . . . 0.0 110.071 -179.333 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -50.27 133.23 10.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.328 -0.858 . . . . 0.0 108.983 179.752 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.411 ' O ' ' C ' ' A' ' 75' ' ' GLU . 4.1 tttp -73.98 167.51 21.35 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.232 -0.918 . . . . 0.0 109.33 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.411 ' C ' ' O ' ' A' ' 74' ' ' LYS . 5.1 mt-10 -45.06 -40.11 6.39 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.198 -0.939 . . . . 0.0 109.385 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 117.927 -1.035 . . . . 0.0 109.514 179.993 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 121.254 0.549 . . . . 0.0 109.539 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER 51.86 -171.64 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.207 -0.933 . . . . 0.0 109.465 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.643 HG21 ' OH ' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -130.72 -161.63 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 O-C-N 121.346 -0.846 . . . . 0.0 109.26 -179.499 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -134.9 135.65 41.74 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.312 -0.868 . . . . 0.0 109.013 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.418 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 4.0 t -67.24 157.45 6.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.194 -0.941 . . . . 0.0 109.35 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.418 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 85.24 -5.74 82.06 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 109.001 -1.64 . . . . 0.0 109.001 -179.391 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 5.4 ttm180 -85.04 159.41 20.22 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.21 -1.171 . . . . 0.0 109.519 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.6 t -92.08 138.69 19.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.154 -0.966 . . . . 0.0 109.465 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.643 ' OH ' HG21 ' A' ' 3' ' ' ILE . 10.3 m-85 -119.53 -177.24 3.33 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.142 -0.974 . . . . 0.0 109.975 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.58 111.86 6.29 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 178.885 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -125.09 153.34 17.94 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.009 -1.567 . . . . 0.0 110.809 -178.224 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.495 ' O ' HG13 ' A' ' 23' ' ' VAL . 16.1 mttm -95.93 166.07 11.96 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 178.938 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.081 HG22 HD13 ' A' ' 50' ' ' LEU . 79.3 t -88.46 105.23 15.45 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 121.062 -1.023 . . . . 0.0 108.323 179.404 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.53 ' O ' ' CD ' ' A' ' 15' ' ' ARG . 1.7 p -117.57 6.27 12.48 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.269 -0.895 . . . . 0.0 110.077 -179.014 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.53 ' CD ' ' O ' ' A' ' 14' ' ' THR . 0.0 OUTLIER -169.69 149.25 3.8 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.08 -1.013 . . . . 0.0 109.935 179.867 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.494 HG22 ' N ' ' A' ' 17' ' ' VAL . 19.5 mt -141.99 163.49 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 179.479 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 1.045 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -143.48 153.41 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.8 -1.188 . . . . 0.0 110.205 -179.43 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -58.21 -42.7 86.8 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.784 -1.198 . . . . 0.0 109.324 179.276 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.045 ' CE1' HG21 ' A' ' 17' ' ' VAL . 12.1 p90 -90.61 29.42 1.31 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.217 -0.927 . . . . 0.0 110.351 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.56 ' HA2' ' N ' ' A' ' 35' ' ' ILE . . . 150.47 -152.08 24.01 Favored Glycine 0 N--CA 1.494 2.54 0 C-N-CA 119.102 -1.523 . . . . 0.0 110.936 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.711 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -152.78 148.81 27.66 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.992 -1.299 . . . . 0.0 108.979 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.959 ' CE1' HD11 ' A' ' 32' ' ' LEU . 11.1 m-30 -107.81 163.81 12.79 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.345 -0.847 . . . . 0.0 108.753 179.571 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.938 ' CG2' HG23 ' A' ' 33' ' ' VAL . 22.7 t -149.5 165.49 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.093 -1.004 . . . . 0.0 109.204 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.591 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -132.42 141.44 48.86 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.057 -1.027 . . . . 0.0 110.592 -179.108 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.518 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.1 pt -110.91 -93.0 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.079 -1.013 . . . . 0.0 108.81 179.083 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -70.38 -163.34 4.5 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.321 -1.511 . . . . 0.0 109.321 179.547 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.42 -23.98 48.85 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.848 -1.301 . . . . 0.0 109.848 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -115.03 -13.91 8.85 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 -179.741 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.518 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.3 OUTLIER -104.95 142.7 34.3 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.121 -1.223 . . . . 0.0 109.625 -179.973 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.743 ' O ' HG21 ' A' ' 69' ' ' ILE . 1.4 pp20? -133.14 149.42 52.08 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 120.924 -1.11 . . . . 0.0 110.328 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.618 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -98.08 -172.68 32.79 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 108.251 -1.939 . . . . 0.0 108.251 179.194 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.959 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.65 119.76 6.74 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 120.842 -1.387 . . . . 0.0 111.047 179.737 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.938 HG23 ' CG2' ' A' ' 23' ' ' VAL . 49.3 t -95.47 61.3 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.32 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.507 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.6 t-80 -49.11 160.82 0.18 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.846 -1.159 . . . . 0.0 108.331 -179.373 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.56 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.6 tp -52.96 -41.29 40.11 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 121.029 -1.045 . . . . 0.0 109.986 -179.731 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.485 ' O ' ' HG2' ' A' ' 37' ' ' GLN . 49.9 m -81.59 30.29 0.36 Allowed 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.086 -1.009 . . . . 0.0 110.922 -179.425 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.968 ' C ' HD12 ' A' ' 38' ' ' ILE . 29.5 mt-30 -149.22 65.32 1.02 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.653 -1.28 . . . . 0.0 110.174 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.989 HG12 HG11 ' A' ' 43' ' ' VAL . 1.6 mp -123.54 -99.37 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 120.87 -1.144 . . . . 0.0 109.843 179.489 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.781 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -111.92 -142.49 0.38 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.16 -0.962 . . . . 0.0 109.33 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.475 ' O ' ' CB ' ' A' ' 41' ' ' LYS . 2.2 t70 -43.65 -51.88 6.76 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.128 -0.982 . . . . 0.0 109.721 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.475 ' CB ' ' O ' ' A' ' 40' ' ' ASP . 0.8 OUTLIER 165.7 -22.62 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.248 -0.907 . . . . 0.0 109.985 -179.703 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -77.18 77.24 3.72 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.127 -0.983 . . . . 0.0 110.676 -179.119 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.066 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 72.4 t -137.51 49.74 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.117 -0.989 . . . . 0.0 108.874 178.673 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 29.4 mp0 -45.01 -31.0 1.15 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.344 -0.847 . . . . 0.0 109.397 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.504 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 0.3 OUTLIER -112.17 114.78 27.79 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.202 -0.936 . . . . 0.0 109.386 179.873 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.555 HG21 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -73.18 -22.66 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.746 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 3.0 p -77.31 4.41 10.76 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.535 -0.728 . . . . 0.0 109.387 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.504 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 2.4 m-20 -103.93 -29.89 10.66 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.156 -0.965 . . . . 0.0 108.75 179.566 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 1.066 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 32.3 m-85 -96.49 -30.11 13.52 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.616 -0.678 . . . . 0.0 109.337 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 1.081 HD13 HG22 ' A' ' 13' ' ' VAL . 0.1 OUTLIER -104.07 133.98 48.1 Favored 'General case' 0 N--CA 1.489 1.497 0 CA-C-O 121.816 0.817 . . . . 0.0 109.774 -179.695 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.497 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.0 OUTLIER -136.21 123.49 21.85 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.912 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 52' ' ' MET . . . . . 0.426 ' HA ' ' O ' ' A' ' 13' ' ' VAL . 3.1 mtt -52.44 110.01 0.45 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.18 -0.95 . . . . 0.0 110.772 -179.189 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 122.54 -9.87 9.25 Favored Glycine 0 N--CA 1.496 2.648 0 C-N-CA 119.894 -1.146 . . . . 0.0 110.606 178.868 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -80.96 175.66 10.5 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.146 -1.208 . . . . 0.0 110.174 -179.601 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -142.72 117.72 10.01 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.564 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.3 m -135.95 145.42 52.54 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 120.993 -1.067 . . . . 0.0 110.635 -179.207 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.487 ' HG2' ' CD ' ' A' ' 74' ' ' LYS . 37.2 Cg_endo -82.98 155.64 15.07 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 C-N-CA 122.873 2.382 . . . . 0.0 109.486 178.806 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.995 HG21 ' HB3' ' A' ' 71' ' ' LEU . 1.2 m -150.48 -173.74 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.823 -1.173 . . . . 0.0 110.206 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.437 ' N ' HG23 ' A' ' 58' ' ' VAL . 0.3 OUTLIER -123.18 129.2 51.09 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 179.628 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.637 ' CG2' ' CE1' ' A' ' 9' ' ' TYR . 89.0 t -59.38 91.55 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.27 -0.894 . . . . 0.0 110.071 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.938 HD23 ' HG2' ' A' ' 70' ' ' ARG . 14.2 tp -60.17 -18.31 47.04 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.245 -0.909 . . . . 0.0 109.228 179.593 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.599 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 1.6 pt-20 97.89 -161.79 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.149 0 CA-C-O 121.676 0.75 . . . . 0.0 109.901 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.883 HG13 ' O ' ' A' ' 67' ' ' GLY . 41.4 t -140.68 119.24 10.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 65' ' ' ARG . 20.8 p-10 -97.17 -158.07 0.64 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.222 -0.924 . . . . 0.0 109.255 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ARG . . . . . 0.425 ' C ' ' O ' ' A' ' 64' ' ' ASP . 4.5 mtp85 -44.3 -75.4 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.249 -0.907 . . . . 0.0 108.876 179.727 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 4.2 pt20 -103.26 123.94 47.69 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.245 -0.909 . . . . 0.0 108.799 179.087 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.883 ' O ' HG13 ' A' ' 63' ' ' VAL . . . 151.07 104.66 0.29 Allowed Glycine 0 N--CA 1.487 2.069 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 -179.58 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.5 ptm180 -88.42 125.42 34.72 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.399 -1.059 . . . . 0.0 109.279 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.743 HG21 ' O ' ' A' ' 30' ' ' GLU . 21.7 mt 45.15 86.43 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.392 -0.817 . . . . 0.0 109.182 -179.639 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.938 ' HG2' HD23 ' A' ' 61' ' ' LEU . 4.0 tpt180 -89.51 88.21 7.35 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.028 -1.045 . . . . 0.0 109.554 -179.8 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.995 ' HB3' HG21 ' A' ' 58' ' ' VAL . 12.6 mt -89.87 140.74 29.31 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.137 -0.977 . . . . 0.0 109.057 179.69 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.478 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.4 OUTLIER -115.79 109.61 17.9 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.301 -0.875 . . . . 0.0 109.781 -179.572 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.603 HG22 ' O ' ' A' ' 38' ' ' ILE . 0.1 OUTLIER -42.4 126.32 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.364 -0.835 . . . . 0.0 108.925 179.918 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.704 ' HD2' ' HB2' ' A' ' 76' ' ' ALA . 0.0 OUTLIER -61.94 -158.32 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.167 -0.958 . . . . 0.0 109.46 -179.66 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 4.2 tp10 -101.72 47.41 0.9 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.343 -0.848 . . . . 0.0 109.615 -179.762 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.704 ' HB2' ' HD2' ' A' ' 74' ' ' LYS . . . . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 118.078 -0.963 . . . . 0.0 109.358 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.41 ' O ' ' HB2' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.532 ' C ' HD13 ' A' ' 3' ' ' ILE . 2.9 mm-40 67.34 -176.13 0.2 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.162 -0.961 . . . . 0.0 109.537 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.608 HG21 ' OH ' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -130.37 -161.08 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 O-C-N 121.297 -0.877 . . . . 0.0 109.578 -179.564 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -127.64 116.63 20.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.36 -0.837 . . . . 0.0 109.01 179.8 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.53 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 20.1 t -52.06 164.56 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.177 -0.952 . . . . 0.0 109.67 -179.706 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.53 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 85.29 -4.89 84.89 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -179.486 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 60.2 ttt-85 -95.51 157.77 15.75 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.262 -1.14 . . . . 0.0 109.724 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.513 HG13 ' O ' ' A' ' 58' ' ' VAL . 72.9 t -90.45 153.93 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.306 -0.871 . . . . 0.0 109.368 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.608 ' OH ' HG21 ' A' ' 3' ' ' ILE . 14.7 m-85 -133.96 -171.56 2.77 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.033 -1.042 . . . . 0.0 110.225 -179.62 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.453 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 24.8 m -159.29 120.45 3.26 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 179.243 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.524 ' CA ' ' O ' ' A' ' 24' ' ' ALA . . . -131.92 164.59 23.66 Favored Glycine 0 N--CA 1.49 2.27 0 C-N-CA 118.759 -1.686 . . . . 0.0 111.077 -178.323 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.564 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.3 OUTLIER -101.76 168.37 9.49 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.385 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.569 HG23 ' O ' ' A' ' 54' ' ' GLN . 96.0 t -88.01 99.34 8.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.656 0 O-C-N 120.719 -1.238 . . . . 0.0 108.475 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.778 HG21 ' CB ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -105.24 -3.1 23.27 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.351 -0.843 . . . . 0.0 110.191 -178.8 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.57 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 1.8 mpp_? -165.82 155.44 12.28 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.946 -1.096 . . . . 0.0 110.19 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.519 HG21 HG22 ' A' ' 47' ' ' THR . 21.3 mt -144.43 157.89 15.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 179.575 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 1.039 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -140.09 155.85 24.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 120.664 -1.273 . . . . 0.0 110.196 -178.995 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -60.69 -41.21 94.68 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.63 -1.294 . . . . 0.0 109.456 179.472 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.039 ' CE1' HG21 ' A' ' 17' ' ' VAL . 12.4 p90 -89.73 24.61 2.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.186 -0.947 . . . . 0.0 110.039 -179.774 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.805 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 154.76 -149.07 20.27 Favored Glycine 0 N--CA 1.493 2.445 0 C-N-CA 119.166 -1.492 . . . . 0.0 110.958 -179.682 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.842 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -154.94 148.05 24.79 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.217 -1.166 . . . . 0.0 108.465 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.961 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.9 m-30 -108.75 160.88 15.61 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 179.693 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.564 HG13 ' O ' ' A' ' 12' ' ' LYS . 3.2 t -150.82 165.33 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.08 -1.012 . . . . 0.0 109.335 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.778 ' CB ' HG21 ' A' ' 14' ' ' THR . . . -127.08 150.46 49.46 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.066 -1.021 . . . . 0.0 109.864 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.512 HG13 ' O ' ' A' ' 29' ' ' LYS . 0.8 OUTLIER -113.32 24.13 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.102 -0.999 . . . . 0.0 109.397 179.646 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 128.83 -165.65 21.57 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -92.26 89.47 1.4 Allowed Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 158.34 -58.96 0.34 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.512 ' O ' HG13 ' A' ' 25' ' ' ILE . 20.8 mmmt -119.7 153.7 35.21 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.362 -1.081 . . . . 0.0 109.319 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.572 ' O ' HD13 ' A' ' 69' ' ' ILE . 0.0 OUTLIER -129.7 151.95 49.73 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 120.887 -1.133 . . . . 0.0 110.448 -179.305 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.959 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -99.17 -174.53 31.57 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 179.191 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.961 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.23 121.81 8.0 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.764 -1.433 . . . . 0.0 111.46 179.946 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.957 HG13 ' CD1' ' A' ' 73' ' ' ILE . 52.7 t -94.44 62.37 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 177.274 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.494 ' CB ' ' OE1' ' A' ' 37' ' ' GLN . 3.3 t-80 -50.43 155.13 1.1 Allowed 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.862 -1.149 . . . . 0.0 108.804 -179.37 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.563 HG23 ' N ' ' A' ' 36' ' ' SER . 4.1 tp -46.64 -49.92 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.361 -0.837 . . . . 0.0 110.765 -179.528 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.563 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.0 OUTLIER -81.5 41.84 0.65 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.952 -1.093 . . . . 0.0 110.524 -179.434 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.995 ' C ' HD12 ' A' ' 38' ' ' ILE . 17.2 mt-30 -150.38 51.44 0.89 Allowed 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.875 -1.141 . . . . 0.0 110.016 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.995 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.7 mp -127.27 -96.5 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 120.935 -1.103 . . . . 0.0 110.312 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.794 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -100.11 53.12 0.9 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.563 -0.711 . . . . 0.0 109.899 -179.01 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.561 ' CB ' ' O ' ' A' ' 39' ' ' ALA . 11.7 t0 82.54 -44.92 0.15 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.787 -0.571 . . . . 0.0 109.967 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.431 ' HB2' ' O ' ' A' ' 40' ' ' ASP . 0.1 OUTLIER 172.97 -25.59 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.035 -1.041 . . . . 0.0 110.572 -179.62 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.423 ' O ' ' OH ' ' A' ' 49' ' ' TYR . 0.1 OUTLIER -76.43 78.58 3.15 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.136 -0.977 . . . . 0.0 110.846 -178.763 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.123 HG13 ' CD1' ' A' ' 49' ' ' TYR . 54.1 t -144.61 67.03 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 178.512 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 71.7 tt0 -45.26 -26.36 0.49 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.434 -0.791 . . . . 0.0 110.13 -179.295 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -131.54 131.64 43.53 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.067 -1.021 . . . . 0.0 109.991 -179.6 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.805 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -80.04 -26.2 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.992 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.519 HG22 HG21 ' A' ' 16' ' ' ILE . 7.3 p -80.36 6.58 11.72 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 178.926 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -105.3 -25.01 12.59 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 179.23 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 1.123 ' CD1' HG13 ' A' ' 43' ' ' VAL . 26.0 m-85 -97.57 -33.61 11.28 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 179.74 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.9 HD11 HG21 ' A' ' 33' ' ' VAL . 0.7 OUTLIER -104.38 143.08 33.48 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.198 -0.939 . . . . 0.0 109.449 179.292 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.503 ' HB3' ' HG3' ' A' ' 54' ' ' GLN . 1.3 tm0? -133.86 134.94 43.34 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 7.0 mtt -54.99 102.54 0.07 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.142 -0.973 . . . . 0.0 109.733 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 126.84 -38.09 2.25 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 119.784 -1.198 . . . . 0.0 110.186 179.542 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' GLN . . . . . 0.569 ' O ' HG23 ' A' ' 13' ' ' VAL . 19.3 mm-40 -59.58 128.95 39.58 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.24 -1.153 . . . . 0.0 110.056 -179.579 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.489 ' HA ' ' HA ' ' A' ' 12' ' ' LYS . 61.8 mt-10 -108.89 131.96 54.5 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.34 -0.85 . . . . 0.0 108.9 179.375 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 17.1 m -137.34 153.44 74.71 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.086 -1.009 . . . . 0.0 110.177 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.9 Cg_endo -79.69 155.89 24.2 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.937 2.425 . . . . 0.0 110.09 179.57 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.803 HG21 ' HB3' ' A' ' 71' ' ' LEU . 1.0 OUTLIER -147.94 -174.73 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.047 -1.033 . . . . 0.0 109.469 179.927 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.513 ' N ' HG23 ' A' ' 58' ' ' VAL . 1.7 mttp -136.38 119.97 17.12 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.452 -0.78 . . . . 0.0 109.384 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.594 ' CG2' ' CE1' ' A' ' 9' ' ' TYR . 60.8 t -48.39 95.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.303 -0.873 . . . . 0.0 109.281 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.662 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 11.7 tp -74.46 -27.31 60.53 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.38 -0.825 . . . . 0.0 109.351 -179.655 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.662 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 8.2 tp10 136.42 158.28 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.342 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.714 HG22 ' HA ' ' A' ' 69' ' ' ILE . 6.3 t -88.66 129.5 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.034 -1.041 . . . . 0.0 109.089 179.84 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 48.8 p-10 -69.38 -176.09 0.91 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.303 -0.873 . . . . 0.0 109.978 -179.579 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -73.73 -4.41 34.35 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.406 -0.809 . . . . 0.0 109.717 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' GLN . . . . . 0.451 ' O ' ' HG3' ' A' ' 66' ' ' GLN . 1.0 OUTLIER -90.17 9.02 30.03 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.175 -0.953 . . . . 0.0 109.4 -179.957 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 70.2 6.7 58.14 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.534 ' O ' HG13 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -92.15 152.08 20.07 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.171 -1.193 . . . . 0.0 109.315 179.897 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.714 ' HA ' HG22 ' A' ' 63' ' ' VAL . 0.8 OUTLIER -83.25 121.13 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.227 -0.92 . . . . 0.0 109.881 -179.56 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.448 ' CB ' ' O ' ' A' ' 62' ' ' GLU . 2.4 tpt180 -89.77 97.39 11.16 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.24 -0.913 . . . . 0.0 109.039 179.593 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.959 HD12 ' HA3' ' A' ' 31' ' ' GLY . 23.5 mt -89.59 143.48 26.78 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 121.304 -0.873 . . . . 0.0 109.6 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.491 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.5 OUTLIER -100.38 123.5 44.68 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.39 -0.819 . . . . 0.0 109.737 -179.594 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.957 ' CD1' HG13 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -63.3 123.65 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.418 -0.801 . . . . 0.0 109.226 179.988 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.428 ' HD3' ' HB2' ' A' ' 57' ' ' PRO . 0.1 OUTLIER -67.14 178.82 1.33 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.925 . . . . 0.0 109.397 179.859 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -87.72 42.48 1.05 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.362 -0.836 . . . . 0.0 109.616 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.526 0 CA-C-O 118.044 -0.979 . . . . 0.0 109.512 179.879 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.468 ' O ' ' O ' ' A' ' 3' ' ' ILE . 3.1 tt0 -92.09 80.46 5.1 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.298 -0.876 . . . . 0.0 109.739 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.479 HG23 ' N ' ' A' ' 4' ' ' GLU . 0.4 OUTLIER -45.17 169.77 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.196 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.479 ' N ' HG23 ' A' ' 3' ' ' ILE . 0.6 OUTLIER -123.73 140.36 53.06 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.006 -1.059 . . . . 0.0 109.604 -179.87 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.548 HG12 ' N ' ' A' ' 6' ' ' GLY . 24.1 t -67.4 165.42 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.232 -0.917 . . . . 0.0 109.332 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.548 ' N ' HG12 ' A' ' 5' ' ' VAL . . . 75.6 1.61 66.6 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 108.886 -1.686 . . . . 0.0 108.886 -179.295 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.472 ' HD3' HD11 ' A' ' 3' ' ' ILE . 2.4 ttt180 -81.86 170.15 16.0 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.277 -1.131 . . . . 0.0 109.429 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.464 ' HA ' ' O ' ' A' ' 58' ' ' VAL . 78.8 t -108.54 115.85 50.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.185 -0.947 . . . . 0.0 109.801 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.464 ' CE1' ' CG2' ' A' ' 60' ' ' VAL . 5.1 m-85 -92.18 -168.74 2.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.325 -0.859 . . . . 0.0 109.148 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.545 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 21.3 m -151.48 115.85 5.07 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 178.69 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.536 ' CA ' ' O ' ' A' ' 24' ' ' ALA . . . -129.16 152.8 19.57 Favored Glycine 0 N--CA 1.487 2.035 0 C-N-CA 119.148 -1.501 . . . . 0.0 110.844 -178.57 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.49 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -93.61 167.7 11.5 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.006 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.745 HG13 HD23 ' A' ' 50' ' ' LEU . 58.4 t -88.35 106.28 16.43 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.754 0 C-N-CA 119.164 -1.014 . . . . 0.0 108.34 179.736 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.832 HG21 ' CB ' ' A' ' 24' ' ' ALA . 0.5 OUTLIER -111.07 -3.28 15.55 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.341 -0.85 . . . . 0.0 110.226 -178.577 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.548 ' CD ' ' OG1' ' A' ' 14' ' ' THR . 0.0 OUTLIER -173.45 150.73 1.86 Allowed 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.98 -1.075 . . . . 0.0 110.007 179.479 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.465 HG21 HG22 ' A' ' 47' ' ' THR . 13.1 mt -136.73 161.38 36.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.525 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 1.032 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.9 OUTLIER -138.65 153.89 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 120.653 -1.28 . . . . 0.0 110.225 -179.63 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -58.59 -43.69 89.61 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.771 -1.205 . . . . 0.0 109.495 179.196 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.032 ' CE1' HG21 ' A' ' 17' ' ' VAL . 11.6 p90 -89.98 27.9 1.49 Allowed 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.22 -0.925 . . . . 0.0 110.251 -179.54 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.677 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 153.67 -153.68 25.0 Favored Glycine 0 N--CA 1.492 2.375 0 C-N-CA 118.914 -1.613 . . . . 0.0 111.249 -179.731 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.761 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -151.75 147.69 26.99 Favored 'General case' 0 C--N 1.305 -1.349 0 O-C-N 121.109 -1.23 . . . . 0.0 109.056 -179.737 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.972 ' CE1' HD11 ' A' ' 32' ' ' LEU . 12.2 m-30 -108.25 160.12 16.09 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.694 ' CG2' HG23 ' A' ' 33' ' ' VAL . 24.0 t -150.41 166.58 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.06 -1.025 . . . . 0.0 109.666 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.832 ' CB ' HG21 ' A' ' 14' ' ' THR . . . -130.99 144.99 51.89 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.183 -0.948 . . . . 0.0 109.714 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.553 HD13 HD11 ' A' ' 71' ' ' LEU . 2.2 pt -116.18 45.31 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.906 -1.121 . . . . 0.0 109.399 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 125.58 -162.36 19.84 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.731 -1.348 . . . . 0.0 109.731 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -107.19 48.49 0.95 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -160.02 -46.88 0.02 OUTLIER Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.488 ' O ' HG13 ' A' ' 25' ' ' ILE . 56.2 mmtt -121.21 149.29 43.06 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.406 -1.055 . . . . 0.0 108.833 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.546 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 10.7 pt-20 -124.47 152.75 42.97 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 120.918 -1.114 . . . . 0.0 110.975 -179.35 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.87 ' CA ' HD12 ' A' ' 71' ' ' LEU . . . -100.72 -176.54 29.62 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 108.359 -1.896 . . . . 0.0 108.359 179.165 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.972 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.26 120.88 7.48 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.863 -1.375 . . . . 0.0 110.913 179.645 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.954 HG11 ' CD1' ' A' ' 50' ' ' LEU . 61.8 t -96.19 63.11 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 177.712 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.44 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.1 t-80 -50.45 156.62 0.84 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.837 -1.165 . . . . 0.0 108.623 -179.48 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.561 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.2 OUTLIER -46.65 -48.97 6.85 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.113 -0.992 . . . . 0.0 109.575 -179.793 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.537 ' N ' HG23 ' A' ' 35' ' ' ILE . 4.9 p -81.59 40.39 0.58 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.287 -0.883 . . . . 0.0 110.389 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.56 ' C ' HD12 ' A' ' 38' ' ' ILE . 71.4 mt-30 -148.93 30.63 0.79 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.714 -1.241 . . . . 0.0 110.069 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.824 HG21 ' CD2' ' A' ' 49' ' ' TYR . 1.8 mp -104.65 -96.32 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.016 -1.053 . . . . 0.0 109.602 179.68 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.792 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -109.23 -150.71 0.46 Allowed 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.463 -0.773 . . . . 0.0 109.502 -179.588 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.496 ' O ' ' HB2' ' A' ' 41' ' ' LYS . 8.7 m-20 -46.35 -56.68 5.49 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.31 -0.869 . . . . 0.0 109.891 -179.796 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.496 ' HB2' ' O ' ' A' ' 40' ' ' ASP . 22.4 tttt 170.65 -7.53 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.298 -0.876 . . . . 0.0 111.046 -179.716 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 2.2 mtm105 -80.73 41.31 0.56 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.742 -1.224 . . . . 0.0 110.583 -179.449 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.064 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 87.4 t -106.09 47.5 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 120.749 -1.219 . . . . 0.0 109.466 179.494 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.434 ' C ' ' O ' ' A' ' 43' ' ' VAL . 0.4 OUTLIER -45.33 -27.22 0.63 Allowed 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 179.568 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.446 ' HB3' ' CG ' ' A' ' 48' ' ' ASP . 0.0 OUTLIER -115.44 113.44 23.72 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 179.239 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.677 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -73.67 -25.35 20.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 -179.981 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.465 HG22 HG21 ' A' ' 16' ' ' ILE . 61.1 p -77.68 5.72 8.73 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.471 -0.768 . . . . 0.0 109.414 179.279 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.446 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 13.3 m-20 -101.29 -32.7 10.37 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 179.292 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 1.064 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 19.5 m-85 -90.43 -36.23 14.69 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 179.502 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.954 ' CD1' HG11 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -101.61 158.01 16.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.292 -0.88 . . . . 0.0 110.527 179.789 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.423 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 16.8 tp60 -149.35 127.6 12.11 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.503 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 5.6 mtt -59.69 111.82 1.58 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.124 -0.985 . . . . 0.0 110.19 -179.463 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 120.8 -25.43 7.19 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 119.874 -1.155 . . . . 0.0 110.383 179.301 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 9.6 mt-30 -74.95 177.09 6.57 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.082 -1.246 . . . . 0.0 110.323 -179.434 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.418 ' HA ' ' HA ' ' A' ' 12' ' ' LYS . 0.1 OUTLIER -139.13 126.53 21.59 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.76 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.2 m -138.01 144.98 45.97 Favored Pre-proline 0 N--CA 1.489 1.505 0 O-C-N 120.947 -1.096 . . . . 0.0 110.5 -179.293 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.545 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 37.1 Cg_endo -81.81 153.11 17.2 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 122.951 2.434 . . . . 0.0 110.117 179.418 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.806 HG21 ' HB3' ' A' ' 71' ' ' LEU . 0.8 OUTLIER -144.39 -168.86 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.1 -1.0 . . . . 0.0 109.344 179.457 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.651 ' N ' HG23 ' A' ' 58' ' ' VAL . 5.6 mttt -133.87 136.85 44.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.33 -0.856 . . . . 0.0 109.298 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.521 ' HA ' HD23 ' A' ' 71' ' ' LEU . 86.2 t -65.39 86.87 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.35 -0.844 . . . . 0.0 109.025 179.675 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.504 ' O ' ' HB2' ' A' ' 62' ' ' GLU . 4.6 tp -56.32 -33.3 65.46 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.449 -0.782 . . . . 0.0 109.401 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.504 ' HB2' ' O ' ' A' ' 61' ' ' LEU . 0.8 OUTLIER 167.62 157.76 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.468 -0.77 . . . . 0.0 110.118 -179.952 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.494 ' HA ' ' O ' ' A' ' 66' ' ' GLN . 46.6 t -150.15 -52.44 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.473 -0.767 . . . . 0.0 109.21 179.162 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.425 ' C ' ' O ' ' A' ' 63' ' ' VAL . 0.5 OUTLIER -44.47 -50.81 9.22 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.301 -0.875 . . . . 0.0 109.324 -179.937 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ARG . . . . . 0.523 ' CB ' ' OE1' ' A' ' 66' ' ' GLN . 0.1 OUTLIER -68.01 -37.32 81.29 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.239 -0.913 . . . . 0.0 108.913 179.597 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 66' ' ' GLN . . . . . 0.523 ' OE1' ' CB ' ' A' ' 65' ' ' ARG . 2.0 pm0 -128.37 112.76 14.76 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.479 -0.763 . . . . 0.0 109.08 179.598 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -74.39 5.32 28.95 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 -179.498 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.471 ' O ' ' O ' ' A' ' 69' ' ' ILE . 7.9 mtt180 -89.79 39.17 0.94 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.746 -1.444 . . . . 0.0 109.496 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.525 HG21 ' O ' ' A' ' 30' ' ' GLU . 61.9 mt 36.87 95.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 CA-C-O 121.181 0.515 . . . . 0.0 110.437 179.445 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.467 ' HG2' HD23 ' A' ' 61' ' ' LEU . 10.0 tpt180 -89.88 81.5 6.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.16 -0.963 . . . . 0.0 109.625 179.777 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.87 HD12 ' CA ' ' A' ' 31' ' ' GLY . 20.8 mt -92.23 143.75 26.1 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.214 -0.929 . . . . 0.0 109.276 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.445 ' O ' ' C ' ' A' ' 73' ' ' ILE . 2.1 m -125.73 117.01 22.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.289 -0.882 . . . . 0.0 109.744 -179.69 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.445 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.1 OUTLIER -44.22 136.91 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.274 -0.891 . . . . 0.0 108.785 179.68 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.444 ' CD ' ' HE3' ' A' ' 59' ' ' LYS . 0.1 OUTLIER -48.12 170.99 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.191 -0.943 . . . . 0.0 109.532 -179.714 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER 46.7 44.03 13.43 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.248 -0.908 . . . . 0.0 109.466 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 118.011 -0.995 . . . . 0.0 109.41 179.823 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.44 ' O ' ' O ' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' A' ' 1' ' ' ALA . 4.6 mt-10 49.15 -178.13 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.207 -0.933 . . . . 0.0 109.72 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.521 HG21 ' OH ' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -127.48 -164.52 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 121.399 -0.813 . . . . 0.0 109.66 -179.511 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -126.25 119.13 26.64 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.496 -0.753 . . . . 0.0 109.201 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.666 HG22 HG11 ' A' ' 60' ' ' VAL . 3.0 t -56.4 157.13 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.27 -0.894 . . . . 0.0 109.402 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 83.73 -1.31 88.92 Favored Glycine 0 N--CA 1.488 2.123 0 N-CA-C 109.137 -1.585 . . . . 0.0 109.137 -179.387 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 8.0 ttt85 -89.25 156.05 19.0 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.217 -1.166 . . . . 0.0 109.915 -179.802 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.686 HG22 ' HG2' ' A' ' 59' ' ' LYS . 40.8 t -93.39 134.95 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.439 -0.788 . . . . 0.0 109.265 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.521 ' OH ' HG21 ' A' ' 3' ' ' ILE . 13.3 m-85 -116.64 -174.25 2.53 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.173 -0.954 . . . . 0.0 110.239 -179.825 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.468 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 5.5 m -155.89 111.77 3.05 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 179.258 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.434 ' CA ' ' O ' ' A' ' 24' ' ' ALA . . . -126.58 153.66 18.85 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 118.906 -1.616 . . . . 0.0 111.04 -178.095 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.5 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -89.71 164.12 14.82 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 179.128 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.705 ' CG2' HD22 ' A' ' 50' ' ' LEU . 99.4 t -88.08 95.96 5.56 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 O-C-N 120.753 -1.217 . . . . 0.0 108.336 179.703 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.743 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.1 p -96.53 -1.9 46.17 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.5 -0.75 . . . . 0.0 109.865 -178.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.544 ' CD ' ' OG1' ' A' ' 14' ' ' THR . 0.0 OUTLIER -173.37 143.21 1.06 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.174 -0.954 . . . . 0.0 109.687 179.982 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.792 HG21 HG22 ' A' ' 47' ' ' THR . 8.8 mt -131.56 159.16 43.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 179.323 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 1.005 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -135.44 153.83 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 120.634 -1.291 . . . . 0.0 110.42 -178.474 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -61.3 -39.69 91.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.569 -1.332 . . . . 0.0 109.376 179.416 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.005 ' CE1' HG21 ' A' ' 17' ' ' VAL . 15.5 p90 -90.86 23.42 3.15 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.364 -0.835 . . . . 0.0 110.107 -179.736 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.601 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 155.16 -152.28 23.81 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 119.214 -1.47 . . . . 0.0 110.822 -179.402 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.826 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -151.42 145.01 24.94 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 120.759 -1.436 . . . . 0.0 109.31 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.961 ' CE1' HD11 ' A' ' 32' ' ' LEU . 12.4 m-30 -107.18 156.78 18.46 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.559 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.5 HG13 ' O ' ' A' ' 12' ' ' LYS . 7.2 t -150.44 162.13 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.045 -1.035 . . . . 0.0 109.793 -179.533 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.743 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -128.17 144.49 51.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.283 -0.886 . . . . 0.0 109.06 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.602 HD11 ' HB3' ' A' ' 29' ' ' LYS . 1.8 pt -103.4 2.94 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 120.775 -1.203 . . . . 0.0 109.915 -179.794 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 118.1 175.15 16.69 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.711 -1.233 . . . . 0.0 110.248 179.386 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -55.71 93.55 0.02 OUTLIER Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.408 ' O ' ' HG2' ' A' ' 29' ' ' LYS . . . 165.52 -42.02 0.28 Allowed Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.602 ' HB3' HD11 ' A' ' 25' ' ' ILE . 0.0 OUTLIER -173.31 171.9 3.92 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.328 -1.101 . . . . 0.0 109.683 179.631 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.657 ' O ' HD13 ' A' ' 69' ' ' ILE . 0.3 OUTLIER -128.44 149.11 50.71 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.937 -1.102 . . . . 0.0 110.092 -179.661 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -98.7 -178.3 32.3 Favored Glycine 0 N--CA 1.486 2.02 0 N-CA-C 108.216 -1.954 . . . . 0.0 108.216 179.106 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.961 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -148.87 116.53 6.24 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 120.827 -1.396 . . . . 0.0 110.541 179.604 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 1.07 HG21 HD11 ' A' ' 50' ' ' LEU . 91.9 t -89.95 59.35 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 177.75 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.509 ' HB2' HD23 ' A' ' 32' ' ' LEU . 4.5 t-80 -47.28 156.19 0.27 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 120.739 -1.225 . . . . 0.0 108.551 -179.463 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.569 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.2 OUTLIER -49.81 -47.25 22.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.163 -0.96 . . . . 0.0 109.49 -179.713 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.509 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.3 OUTLIER -81.22 39.79 0.53 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.413 -0.804 . . . . 0.0 110.399 -179.925 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.791 ' C ' HD12 ' A' ' 38' ' ' ILE . 47.1 mm-40 -147.98 34.15 0.83 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.934 -1.104 . . . . 0.0 109.27 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.809 HG21 ' CD2' ' A' ' 49' ' ' TYR . 1.6 mp -112.48 -97.11 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.248 -0.908 . . . . 0.0 109.916 -179.613 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.773 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -100.42 16.31 24.95 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.311 -0.868 . . . . 0.0 109.825 -179.402 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.572 ' CB ' ' O ' ' A' ' 39' ' ' ALA . 7.5 t70 83.85 -57.43 0.13 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.751 -0.593 . . . . 0.0 109.7 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 18.9 mttm -59.78 -179.58 0.1 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.203 -0.936 . . . . 0.0 109.194 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.411 ' O ' ' N ' ' A' ' 44' ' ' GLU . 3.3 mmt180 -79.88 92.26 5.48 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.3 -0.875 . . . . 0.0 109.503 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.001 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 2.5 t -58.55 95.31 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 179.326 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.451 ' C ' ' O ' ' A' ' 43' ' ' VAL . 3.2 mp0 -40.32 -25.06 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.639 -0.663 . . . . 0.0 109.923 -179.59 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.538 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.8 OUTLIER -151.28 121.56 7.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.146 -0.971 . . . . 0.0 110.021 -179.813 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.601 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -71.71 -26.92 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 178.959 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.792 HG22 HG21 ' A' ' 16' ' ' ILE . 58.6 p -79.14 6.02 10.64 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.892 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.48 ' OD2' ' HB2' ' A' ' 45' ' ' LYS . 26.6 m-20 -106.25 -26.9 11.34 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 179.204 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 1.001 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 12.9 m-85 -92.54 -34.83 13.9 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.247 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 1.07 HD11 HG21 ' A' ' 33' ' ' VAL . 4.6 mt -109.57 152.9 24.9 Favored 'General case' 0 N--CA 1.492 1.635 0 C-N-CA 119.473 -0.891 . . . . 0.0 109.752 179.637 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.482 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.9 OUTLIER -128.19 138.68 52.58 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.39 -0.819 . . . . 0.0 108.982 179.437 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 22.6 mtp -63.17 114.19 3.61 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.217 -0.927 . . . . 0.0 109.716 -179.719 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 109.38 -23.85 21.72 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.519 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' GLN . . . . . 0.462 ' HG3' ' HB3' ' A' ' 51' ' ' GLN . 1.5 mt-30 -74.5 147.78 41.57 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.098 -1.236 . . . . 0.0 109.791 -179.718 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.475 ' HA ' ' HA ' ' A' ' 12' ' ' LYS . 0.3 OUTLIER -107.06 146.95 30.57 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.329 -0.857 . . . . 0.0 109.37 179.889 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.456 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 18.8 m -150.6 140.03 13.52 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.079 -1.013 . . . . 0.0 109.944 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 37.2 Cg_endo -82.96 151.85 14.33 Favored 'Trans proline' 0 C--N 1.315 -1.21 0 C-N-CA 122.786 2.324 . . . . 0.0 110.137 179.311 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.85 ' CG2' HD12 ' A' ' 71' ' ' LEU . 0.9 OUTLIER -147.72 -171.22 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.167 -0.958 . . . . 0.0 109.299 179.511 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.686 ' HG2' HG22 ' A' ' 8' ' ' VAL . 10.8 mttt -138.59 121.7 16.84 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.079 -1.013 . . . . 0.0 109.955 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.706 ' HA ' HD13 ' A' ' 71' ' ' LEU . 35.2 t -51.04 91.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.294 -0.879 . . . . 0.0 108.944 179.251 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.704 HD13 ' OG ' ' A' ' 72' ' ' SER . 6.5 tp -66.42 -26.76 67.38 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.506 -0.746 . . . . 0.0 109.646 -179.616 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.537 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 21.2 tt0 162.54 153.06 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.326 -0.859 . . . . 0.0 110.164 179.828 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.493 ' HA ' ' O ' ' A' ' 67' ' ' GLY . 74.7 t -151.2 -87.77 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.289 -0.882 . . . . 0.0 109.26 179.133 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.483 ' O ' ' O ' ' A' ' 63' ' ' VAL . 2.1 p-10 41.58 -167.7 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.36 -0.838 . . . . 0.0 110.155 179.648 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 1.2 ttt-85 -64.65 -29.17 70.17 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.12 -0.987 . . . . 0.0 108.969 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -104.86 74.06 1.11 Allowed 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.391 -0.818 . . . . 0.0 108.955 179.542 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' A' ' 63' ' ' VAL . . . 157.28 103.47 0.2 Allowed Glycine 0 N--CA 1.487 2.045 0 N-CA-C 109.114 -1.594 . . . . 0.0 109.114 -179.557 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.433 ' O ' ' CG ' ' A' ' 68' ' ' ARG . 0.0 OUTLIER -89.01 96.63 10.81 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.333 -1.098 . . . . 0.0 109.295 -179.818 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.72 HG22 ' O ' ' A' ' 69' ' ' ILE . 42.4 mt 45.37 64.92 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.463 -0.773 . . . . 0.0 110.189 179.722 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.471 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 0.0 OUTLIER -90.01 83.89 6.13 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.025 -1.047 . . . . 0.0 108.905 179.342 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.85 HD12 ' CG2' ' A' ' 58' ' ' VAL . 2.4 mm? -89.18 164.05 15.16 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.267 -0.896 . . . . 0.0 109.935 -179.314 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.704 ' OG ' HD13 ' A' ' 61' ' ' LEU . 0.4 OUTLIER -119.33 112.71 19.78 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.522 -0.736 . . . . 0.0 109.366 -179.87 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.57 HD12 HG13 ' A' ' 33' ' ' VAL . 0.1 OUTLIER -55.63 136.08 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.271 -0.893 . . . . 0.0 109.336 -179.67 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.442 ' C ' ' O ' ' A' ' 73' ' ' ILE . 0.0 OUTLIER -41.48 -39.14 1.44 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.351 -0.843 . . . . 0.0 109.814 -179.481 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.549 ' H ' HG23 ' A' ' 73' ' ' ILE . 1.2 tt0 -90.72 45.85 1.29 Allowed 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 179.627 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.494 0 CA-C-O 118.032 -0.985 . . . . 0.0 109.412 -179.65 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 121.287 0.565 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -93.75 -159.55 0.7 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.184 -0.947 . . . . 0.0 109.315 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.866 ' H ' HD12 ' A' ' 3' ' ' ILE . 0.1 OUTLIER -144.86 -164.73 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 O-C-N 121.199 -0.938 . . . . 0.0 109.319 -179.655 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -149.1 152.2 35.75 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.308 -0.87 . . . . 0.0 109.475 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.602 HG22 HG11 ' A' ' 60' ' ' VAL . 6.5 t -61.16 168.4 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.205 -0.934 . . . . 0.0 109.042 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.567 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 70.74 10.33 67.29 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 108.935 -1.666 . . . . 0.0 108.935 -179.466 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -109.92 176.14 5.18 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.365 -1.079 . . . . 0.0 109.421 -179.888 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 24.1 t -91.37 123.58 43.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.199 -0.938 . . . . 0.0 109.011 179.621 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.706 ' OH ' HD13 ' A' ' 3' ' ' ILE . 4.2 m-85 -110.87 130.69 55.51 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.124 -0.985 . . . . 0.0 110.012 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 11.0 m -80.45 100.49 8.53 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.335 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.47 126.0 7.25 Favored Glycine 0 N--CA 1.487 2.072 0 C-N-CA 119.87 -1.157 . . . . 0.0 110.487 -178.539 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.586 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -89.75 148.12 23.44 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.794 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.856 HG13 ' CD1' ' A' ' 50' ' ' LEU . 22.8 t -87.85 112.21 23.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 120.568 -1.332 . . . . 0.0 108.97 -179.648 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.989 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -122.8 -6.09 8.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.437 -0.789 . . . . 0.0 110.216 -178.916 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.462 ' HD2' ' O ' ' A' ' 14' ' ' THR . 0.9 OUTLIER -164.68 153.66 12.93 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.916 -1.115 . . . . 0.0 110.06 -179.949 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.443 HG22 ' N ' ' A' ' 17' ' ' VAL . 12.2 mt -141.08 161.57 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 179.438 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 1.025 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -140.15 153.44 22.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 120.881 -1.137 . . . . 0.0 109.982 -179.58 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -58.45 -41.78 85.9 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.778 -1.202 . . . . 0.0 109.145 179.405 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.025 ' CE1' HG21 ' A' ' 17' ' ' VAL . 15.5 p90 -90.3 29.31 1.27 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.381 -0.825 . . . . 0.0 110.077 -179.743 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.543 ' HA2' ' N ' ' A' ' 35' ' ' ILE . . . 149.81 -148.86 20.57 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 118.964 -1.589 . . . . 0.0 110.976 -179.766 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.752 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -154.94 148.83 25.66 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.233 -1.157 . . . . 0.0 108.917 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.977 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.5 m-30 -106.94 162.46 13.81 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.339 -0.851 . . . . 0.0 108.954 179.682 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.942 ' CG2' HG23 ' A' ' 33' ' ' VAL . 22.5 t -149.03 160.87 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.08 -1.013 . . . . 0.0 109.64 -179.64 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.989 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -133.8 135.92 44.14 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.306 -0.871 . . . . 0.0 109.55 -179.843 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.792 HD13 HD11 ' A' ' 71' ' ' LEU . 1.2 pt -108.81 -97.28 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 120.818 -1.176 . . . . 0.0 109.509 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 27' ' ' GLY . . . 159.56 -58.05 0.32 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.656 ' HA3' HD11 ' A' ' 3' ' ' ILE . . . -43.93 -34.55 3.03 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.541 -1.423 . . . . 0.0 109.541 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.447 ' O ' ' CG ' ' A' ' 29' ' ' LYS . . . -122.58 -69.85 0.25 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.483 ' O ' HG13 ' A' ' 25' ' ' ILE . 4.4 mtmt -164.15 -107.7 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.232 -1.158 . . . . 0.0 109.674 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.556 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 6.4 mt-10 -127.48 150.87 49.47 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.741 -1.224 . . . . 0.0 111.004 -179.151 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.76 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -102.33 -172.96 27.25 Favored Glycine 0 N--CA 1.488 2.104 0 N-CA-C 108.22 -1.952 . . . . 0.0 108.22 178.967 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.977 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.14 121.8 8.05 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.737 -1.449 . . . . 0.0 110.951 179.743 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 1.004 HG12 HD11 ' A' ' 38' ' ' ILE . 61.1 t -95.3 61.36 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 177.523 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.472 ' HB2' HD23 ' A' ' 32' ' ' LEU . 2.6 t-80 -48.88 158.13 0.35 Allowed 'General case' 0 C--N 1.304 -1.37 0 O-C-N 120.893 -1.13 . . . . 0.0 108.653 -179.462 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.543 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.9 tp -46.66 -51.01 5.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.188 -0.945 . . . . 0.0 109.864 -179.464 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.533 ' N ' HG23 ' A' ' 35' ' ' ILE . 42.6 p -81.99 44.51 0.85 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.302 -0.874 . . . . 0.0 110.372 -179.639 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.929 ' C ' HD12 ' A' ' 38' ' ' ILE . 51.0 mm-40 -144.29 33.61 1.2 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.903 -1.123 . . . . 0.0 110.214 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 1.004 HD11 HG12 ' A' ' 33' ' ' VAL . 1.6 mp -120.29 -98.49 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.833 -1.167 . . . . 0.0 110.214 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.771 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -98.05 41.12 1.14 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.459 -0.776 . . . . 0.0 109.45 -179.206 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.567 ' CB ' ' O ' ' A' ' 39' ' ' ALA . 16.7 t70 82.96 -62.92 0.12 Allowed 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 -179.499 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -168.79 -0.13 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.066 -1.021 . . . . 0.0 111.774 -179.492 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -81.45 20.41 0.88 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.518 -1.364 . . . . 0.0 110.357 -179.806 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.119 HG13 ' CD1' ' A' ' 49' ' ' TYR . 58.7 t -102.41 67.43 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 O-C-N 120.889 -1.132 . . . . 0.0 109.41 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 43' ' ' VAL . 14.0 mt-10 -45.78 -24.27 0.36 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.354 -0.841 . . . . 0.0 108.988 179.488 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.456 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 4.7 mmtp -134.97 123.71 23.76 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.327 -0.858 . . . . 0.0 109.4 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.54 HG11 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -73.68 -23.47 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 O-C-N 121.131 -0.981 . . . . 0.0 108.643 179.647 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 8.3 p -75.4 1.39 14.03 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.482 -0.761 . . . . 0.0 109.389 179.198 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.456 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 0.9 OUTLIER -102.17 -35.59 8.84 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.149 -0.969 . . . . 0.0 109.245 -179.999 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 1.119 ' CD1' HG13 ' A' ' 43' ' ' VAL . 3.9 m-85 -90.83 -28.72 18.0 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.35 -0.844 . . . . 0.0 108.972 179.791 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.856 ' CD1' HG13 ' A' ' 13' ' ' VAL . 0.2 OUTLIER -109.72 140.9 43.06 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.495 -0.753 . . . . 0.0 109.565 -179.575 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.728 ' C ' HG11 ' A' ' 13' ' ' VAL . 2.3 mp0 -150.62 131.93 14.57 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.398 -0.814 . . . . 0.0 109.476 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -61.84 107.61 0.87 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.273 -0.892 . . . . 0.0 109.955 -179.929 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 132.33 -31.97 2.91 Favored Glycine 0 N--CA 1.491 2.321 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.306 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -80.3 162.28 24.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.033 -1.275 . . . . 0.0 109.818 -179.668 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -125.28 138.66 54.09 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.518 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.434 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 17.2 m -140.58 143.92 34.44 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.017 -1.052 . . . . 0.0 110.008 -179.461 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 56' ' ' VAL . 36.3 Cg_endo -79.05 145.93 19.85 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.59 2.193 . . . . 0.0 110.241 179.704 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.69 ' CG2' HD22 ' A' ' 71' ' ' LEU . 1.0 OUTLIER -148.21 -174.84 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.196 -0.94 . . . . 0.0 109.901 -179.878 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.458 ' N ' HG23 ' A' ' 58' ' ' VAL . 3.0 mtpt -123.51 135.66 54.15 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.52 -0.737 . . . . 0.0 109.239 179.606 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.602 HG11 HG22 ' A' ' 5' ' ' VAL . 96.1 t -67.1 91.72 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.33 -0.856 . . . . 0.0 109.229 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.576 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 5.9 tp -65.11 -16.96 64.05 Favored 'General case' 0 C--N 1.305 -1.358 0 O-C-N 121.315 -0.866 . . . . 0.0 109.773 -179.552 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.576 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 20.6 mt-10 96.47 -176.83 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.239 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 -179.782 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.501 HG22 ' HA ' ' A' ' 69' ' ' ILE . 82.8 t -114.58 129.85 69.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.178 -0.951 . . . . 0.0 109.741 -179.606 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -119.75 -30.0 4.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.27 -0.894 . . . . 0.0 109.603 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.09 -79.59 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.209 -0.932 . . . . 0.0 109.436 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 1.1 tt0 -151.15 -45.82 0.12 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.106 -0.996 . . . . 0.0 109.105 179.786 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -162.43 24.95 0.22 Allowed Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.449 ' O ' ' CG ' ' A' ' 68' ' ' ARG . 0.1 OUTLIER -99.05 105.67 17.82 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.291 -1.123 . . . . 0.0 109.367 -179.907 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.775 HD13 HD11 ' A' ' 25' ' ' ILE . 82.2 mt -47.64 120.53 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.203 -0.936 . . . . 0.0 109.606 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.548 ' CB ' ' O ' ' A' ' 62' ' ' GLU . 1.2 tpt180 -93.74 91.76 7.16 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.157 -0.964 . . . . 0.0 108.955 179.403 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.792 HD11 HD13 ' A' ' 25' ' ' ILE . 31.3 mt -89.51 150.19 22.56 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.34 -0.85 . . . . 0.0 109.024 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.467 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.4 OUTLIER -123.24 108.08 12.41 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.273 -0.892 . . . . 0.0 110.049 -179.259 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.469 ' HA ' HG12 ' A' ' 58' ' ' VAL . 0.0 OUTLIER -48.61 140.83 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.227 -0.921 . . . . 0.0 108.911 179.886 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 11.3 mmtt -47.19 151.53 0.68 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.318 -0.864 . . . . 0.0 109.744 -179.684 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 46.4 73.44 0.18 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.321 -0.862 . . . . 0.0 109.521 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.629 ' HB2' ' O ' ' A' ' 38' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.506 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.47 ' O ' ' O ' ' A' ' 3' ' ' ILE . 91.5 mt-10 -121.81 -22.4 5.79 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.19 -0.943 . . . . 0.0 109.839 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.527 HG23 ' N ' ' A' ' 4' ' ' GLU . 0.4 OUTLIER 53.52 170.96 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.298 -1.65 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 -179.821 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.527 ' N ' HG23 ' A' ' 3' ' ' ILE . 1.3 mt-10 -150.52 162.99 39.54 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.984 -1.072 . . . . 0.0 110.042 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.661 HG22 HG11 ' A' ' 60' ' ' VAL . 2.5 t -70.05 161.96 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.348 -0.845 . . . . 0.0 109.204 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.459 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 86.54 9.99 74.34 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 -179.585 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.404 ' HD3' ' CD1' ' A' ' 3' ' ' ILE . 1.7 ttt180 -107.53 178.18 4.61 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.29 -1.124 . . . . 0.0 109.437 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.545 HG22 ' HG2' ' A' ' 59' ' ' LYS . 41.3 t -90.0 127.65 42.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.199 -0.938 . . . . 0.0 108.82 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.87 ' CD2' HD13 ' A' ' 25' ' ' ILE . 2.8 m-30 -114.75 135.12 54.52 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.154 -0.966 . . . . 0.0 110.158 -179.335 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -73.82 100.74 3.54 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 177.448 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -82.26 122.73 5.82 Favored Glycine 0 N--CA 1.488 2.119 0 C-N-CA 120.009 -1.091 . . . . 0.0 111.368 -177.302 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.518 ' O ' HG13 ' A' ' 23' ' ' VAL . 2.4 mttt -96.07 143.24 27.39 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 177.988 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.014 HG13 HD23 ' A' ' 50' ' ' LEU . 24.9 t -88.1 107.66 17.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 120.802 -1.186 . . . . 0.0 108.934 -179.648 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.886 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -116.93 -7.95 11.34 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.454 -0.778 . . . . 0.0 109.813 -179.07 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.485 ' HB3' ' HB2' ' A' ' 22' ' ' PHE . 0.9 OUTLIER -161.48 148.22 14.45 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.054 -1.029 . . . . 0.0 110.158 -179.899 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.616 HG21 HG22 ' A' ' 47' ' ' THR . 11.8 mt -137.05 157.38 35.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 179.005 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 1.045 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -136.3 153.4 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 120.749 -1.22 . . . . 0.0 110.034 -179.192 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -59.07 -41.94 89.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.69 -1.257 . . . . 0.0 109.331 179.228 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.045 ' CE1' HG21 ' A' ' 17' ' ' VAL . 12.9 p90 -91.16 27.24 1.93 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.3 -0.875 . . . . 0.0 110.361 -179.525 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.553 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 154.4 -154.9 25.83 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 118.895 -1.621 . . . . 0.0 110.829 -179.505 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.759 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -148.45 143.97 27.1 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.042 -1.27 . . . . 0.0 108.853 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.97 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.0 m-30 -105.94 154.77 20.11 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.254 -0.904 . . . . 0.0 108.825 179.748 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.81 ' CG2' HG23 ' A' ' 33' ' ' VAL . 35.2 t -144.04 161.81 15.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.066 -1.021 . . . . 0.0 109.783 -179.273 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.886 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -137.2 148.81 46.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.157 -0.964 . . . . 0.0 109.515 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.87 HD13 ' CD2' ' A' ' 9' ' ' TYR . 2.7 pt -126.47 161.59 32.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.006 -1.059 . . . . 0.0 109.044 179.642 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -79.37 143.79 26.34 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 124.04 2.14 8.59 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 87.5 29.23 22.33 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.496 ' O ' HG13 ' A' ' 25' ' ' ILE . 1.7 mtpp -142.08 163.22 33.47 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.344 -1.092 . . . . 0.0 109.313 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.533 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 17.3 mt-10 -134.99 153.46 52.08 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.998 -1.063 . . . . 0.0 110.334 -179.786 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.663 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -107.3 -175.78 22.64 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 179.43 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.97 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.49 119.29 6.6 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.875 -1.368 . . . . 0.0 110.736 179.72 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 1.093 HG21 HD11 ' A' ' 50' ' ' LEU . 96.3 t -93.84 61.14 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.543 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 177.71 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.474 ' HB2' HD23 ' A' ' 32' ' ' LEU . 6.6 t-80 -47.7 156.45 0.31 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.906 -1.122 . . . . 0.0 108.417 -179.571 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.589 ' O ' HD13 ' A' ' 38' ' ' ILE . 3.1 tp -49.62 -43.37 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.154 -0.966 . . . . 0.0 110.321 -179.536 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.438 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.4 OUTLIER -81.25 34.29 0.36 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.182 -0.949 . . . . 0.0 110.94 -179.34 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.921 ' C ' HD12 ' A' ' 38' ' ' ILE . 71.4 mt-30 -150.81 58.4 0.92 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.709 -1.244 . . . . 0.0 110.14 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.981 HG21 HG21 ' A' ' 43' ' ' VAL . 1.7 mp -122.08 -97.86 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 120.984 -1.073 . . . . 0.0 109.569 179.746 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.749 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -123.67 172.37 8.86 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.298 -0.876 . . . . 0.0 109.382 -179.809 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -51.62 -53.16 41.43 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.244 -0.91 . . . . 0.0 109.373 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -55.43 150.52 11.61 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.323 -0.861 . . . . 0.0 109.517 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 5.4 mmt180 -65.79 128.9 37.84 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.3 -0.875 . . . . 0.0 109.487 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.167 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 66.9 t -108.65 55.75 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.287 -0.883 . . . . 0.0 109.046 179.641 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.424 ' O ' ' HG3' ' A' ' 44' ' ' GLU . 13.8 tp10 -45.38 -26.59 0.56 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.162 -0.961 . . . . 0.0 108.467 179.662 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.48 ' HB3' ' CG ' ' A' ' 48' ' ' ASP . 4.2 mptt -108.0 105.63 15.5 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.28 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.553 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -75.22 -25.52 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.399 -0.813 . . . . 0.0 109.09 -179.681 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.616 HG22 HG21 ' A' ' 16' ' ' ILE . 62.7 p -77.55 6.22 7.55 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.413 -0.805 . . . . 0.0 109.464 179.181 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.48 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 58.9 m-20 -101.7 -32.32 10.37 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.426 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 1.167 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 15.9 m-85 -92.45 -34.85 13.95 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.494 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 1.093 HD11 HG21 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -100.0 156.62 17.06 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.322 -0.861 . . . . 0.0 110.571 -179.854 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.503 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 61.8 mt-30 -146.85 126.57 13.42 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' MET . . . . . 0.525 ' CG ' ' O ' ' A' ' 52' ' ' MET . 3.2 ptp -60.81 98.59 0.07 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.15 -0.969 . . . . 0.0 109.94 -179.654 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 132.21 -25.44 3.86 Favored Glycine 0 N--CA 1.493 2.45 0 C-N-CA 119.719 -1.229 . . . . 0.0 110.368 179.467 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 89.0 mm-40 -79.19 150.49 31.65 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.105 -1.232 . . . . 0.0 110.402 -179.358 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -116.9 113.71 22.84 Favored 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.088 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.405 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 17.7 m -115.24 150.23 44.06 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.107 -0.996 . . . . 0.0 110.121 -179.205 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 56' ' ' VAL . 36.2 Cg_endo -78.5 126.91 7.79 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.675 2.25 . . . . 0.0 110.24 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.963 ' CG2' HD22 ' A' ' 71' ' ' LEU . 1.3 m -131.9 -172.74 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.148 -0.97 . . . . 0.0 109.722 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.545 ' HG2' HG22 ' A' ' 8' ' ' VAL . 9.8 mtmt -133.12 116.87 16.82 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.6 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.69 ' HA ' HD23 ' A' ' 71' ' ' LEU . 52.6 t -49.94 91.39 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.344 -0.848 . . . . 0.0 109.217 -179.744 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.592 ' O ' ' CG ' ' A' ' 62' ' ' GLU . 15.8 tp -64.93 -20.81 66.66 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.425 -0.797 . . . . 0.0 109.985 -179.379 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.592 ' CG ' ' O ' ' A' ' 61' ' ' LEU . 0.2 OUTLIER 89.35 -171.08 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.014 0 CA-C-O 121.219 0.533 . . . . 0.0 109.594 -179.73 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.793 HG22 ' O ' ' A' ' 68' ' ' ARG . 69.7 t -126.74 95.9 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.297 -0.877 . . . . 0.0 109.824 -179.759 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.425 ' C ' ' O ' ' A' ' 63' ' ' VAL . 0.0 OUTLIER -44.34 -73.15 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.236 -0.915 . . . . 0.0 108.886 179.498 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ARG . . . . . 0.598 ' O ' HG12 ' A' ' 63' ' ' VAL . 8.2 ptm180 -76.47 -141.55 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.094 -1.004 . . . . 0.0 108.925 179.276 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' GLN . . . . . 0.519 ' N ' ' HG3' ' A' ' 65' ' ' ARG . 2.7 mt-30 -123.48 102.23 7.77 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.943 -1.098 . . . . 0.0 109.419 179.767 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.678 ' H ' HG11 ' A' ' 63' ' ' VAL . . . -154.02 -100.02 0.18 Allowed Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.793 ' O ' HG22 ' A' ' 63' ' ' VAL . 0.1 OUTLIER -132.9 152.5 51.87 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.161 -1.199 . . . . 0.0 109.516 -179.893 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.6 ' HA ' HG23 ' A' ' 63' ' ' VAL . 1.3 mp -50.53 121.76 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.414 -0.804 . . . . 0.0 110.002 -179.529 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.442 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 7.4 mmt85 -90.38 116.31 28.23 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.2 -0.938 . . . . 0.0 109.106 179.408 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.963 HD22 ' CG2' ' A' ' 58' ' ' VAL . 11.1 mt -89.65 152.55 21.31 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.129 -0.982 . . . . 0.0 109.633 -179.754 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 59' ' ' LYS . 0.6 OUTLIER -115.95 93.68 4.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.301 -0.874 . . . . 0.0 109.838 -179.85 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.467 ' O ' ' O ' ' A' ' 74' ' ' LYS . 0.1 OUTLIER -48.8 141.14 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.202 -0.936 . . . . 0.0 109.251 179.762 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.467 ' O ' ' O ' ' A' ' 73' ' ' ILE . 0.1 OUTLIER -42.9 167.24 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.311 -0.868 . . . . 0.0 109.673 -179.789 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.464 ' CA ' ' OE1' ' A' ' 75' ' ' GLU . 0.1 OUTLIER 57.68 29.52 17.43 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.161 -0.962 . . . . 0.0 109.097 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.996 -1.002 . . . . 0.0 109.55 179.975 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.586 0 N-CA-C 109.419 -0.585 . . . . 0.0 109.419 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.652 ' C ' HD13 ' A' ' 3' ' ' ILE . 2.4 tt0 60.21 -153.36 0.38 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.15 -0.969 . . . . 0.0 109.408 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.652 HD13 ' C ' ' A' ' 2' ' ' GLU . 0.0 OUTLIER -133.39 -161.73 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.171 -0.956 . . . . 0.0 109.611 -179.436 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.473 ' O ' ' HG3' ' A' ' 7' ' ' ARG . 1.3 tp10 -104.95 131.09 52.9 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.433 -0.792 . . . . 0.0 108.887 179.364 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.773 HG22 ' CG1' ' A' ' 60' ' ' VAL . 12.5 t -79.6 165.68 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.224 -0.923 . . . . 0.0 109.809 -179.532 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.546 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 96.37 -0.55 61.79 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 -179.753 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.599 ' O ' HG23 ' A' ' 60' ' ' VAL . 0.0 OUTLIER -110.33 164.13 12.97 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.147 -1.208 . . . . 0.0 109.593 -179.546 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.891 HG13 ' O ' ' A' ' 58' ' ' VAL . 97.3 t -90.18 135.52 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.345 -0.847 . . . . 0.0 108.756 179.388 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.638 ' O ' HG22 ' A' ' 58' ' ' VAL . 6.4 m-85 -119.41 126.65 51.88 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.858 -1.151 . . . . 0.0 110.525 -179.673 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.449 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 0.2 OUTLIER -95.31 127.34 41.28 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 178.352 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -127.62 150.14 18.15 Favored Glycine 0 N--CA 1.486 2.025 0 C-N-CA 118.834 -1.651 . . . . 0.0 110.953 -178.723 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.509 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.1 OUTLIER -89.8 163.21 15.14 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 178.624 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.945 HG22 HD13 ' A' ' 50' ' ' LEU . 69.8 t -88.42 107.9 18.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 O-C-N 121.006 -1.059 . . . . 0.0 108.445 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.635 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.3 p -118.51 -0.52 11.38 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.544 -0.862 . . . . 0.0 110.167 -178.889 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.511 ' HB3' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -167.96 148.04 4.95 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.987 -1.071 . . . . 0.0 109.985 179.739 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.436 HG22 ' N ' ' A' ' 17' ' ' VAL . 30.6 mt -140.31 157.38 24.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.232 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 1.014 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -135.38 152.98 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.918 -1.114 . . . . 0.0 109.751 -179.321 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -60.41 -39.08 86.08 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.631 -1.293 . . . . 0.0 109.218 179.458 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.014 ' CE1' HG21 ' A' ' 17' ' ' VAL . 18.4 p90 -91.86 24.92 2.96 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.497 -0.752 . . . . 0.0 110.073 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.618 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 156.07 -152.78 24.19 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.881 -179.188 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.75 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -151.91 145.65 25.05 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.853 -1.38 . . . . 0.0 108.843 179.636 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.959 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.3 m-30 -107.26 160.37 15.65 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.35 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.824 ' CG2' HG23 ' A' ' 33' ' ' VAL . 14.3 t -149.99 167.67 2.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.009 -1.057 . . . . 0.0 109.536 -179.228 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.635 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -131.62 147.43 52.52 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.137 -0.977 . . . . 0.0 109.278 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.52 HG13 ' O ' ' A' ' 29' ' ' LYS . 0.5 OUTLIER -109.54 -14.35 10.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 120.561 -1.337 . . . . 0.0 109.808 -179.995 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 25' ' ' ILE . . . 59.31 128.07 0.01 OUTLIER Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.37 2.02 58.61 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.493 ' O ' HD11 ' A' ' 25' ' ' ILE . . . -156.79 33.36 0.57 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.52 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER 74.71 -156.11 0.05 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.456 -1.026 . . . . 0.0 109.807 179.857 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.582 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 7.2 mt-10 -120.18 153.05 36.81 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 120.814 -1.179 . . . . 0.0 110.811 -179.393 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.975 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -99.1 -172.8 31.39 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 108.555 -1.818 . . . . 0.0 108.555 179.061 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.959 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.83 120.19 6.85 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.824 -1.397 . . . . 0.0 111.082 179.6 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.824 HG23 ' CG2' ' A' ' 23' ' ' VAL . 48.6 t -95.15 61.79 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 177.276 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.486 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.1 t-160 -48.77 157.1 0.41 Allowed 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.785 -1.197 . . . . 0.0 108.908 -179.131 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.764 ' O ' HD13 ' A' ' 38' ' ' ILE . 0.4 OUTLIER -49.62 -47.09 21.3 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.297 -0.877 . . . . 0.0 110.237 -179.58 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.516 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.6 OUTLIER -80.48 33.33 0.3 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.251 -0.906 . . . . 0.0 110.972 -179.133 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.894 ' C ' HD12 ' A' ' 38' ' ' ILE . 44.7 mm-40 -148.26 57.99 1.08 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.823 -1.173 . . . . 0.0 109.735 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.98 ' CG2' HG21 ' A' ' 43' ' ' VAL . 1.5 mp -116.84 -99.56 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 120.942 -1.099 . . . . 0.0 110.075 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.765 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -117.37 43.55 2.31 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.272 -0.892 . . . . 0.0 109.649 -179.341 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.45 ' O ' ' OD1' ' A' ' 40' ' ' ASP . 2.1 p30 42.62 27.57 0.1 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.39 -0.819 . . . . 0.0 109.074 -179.55 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.437 ' N ' ' O ' ' A' ' 39' ' ' ALA . 1.8 ttmt -124.35 -178.68 4.18 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 3.8 mtp180 -77.35 77.5 3.88 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.205 -0.934 . . . . 0.0 109.639 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.127 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 72.1 t -87.73 49.58 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 O-C-N 121.103 -0.998 . . . . 0.0 108.322 179.266 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -44.4 -24.95 0.21 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.349 -0.844 . . . . 0.0 109.032 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.49 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 68.7 mttt -110.8 104.44 13.07 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.454 -0.779 . . . . 0.0 109.14 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.618 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -72.19 -23.34 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.194 -0.941 . . . . 0.0 108.552 179.857 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 24.2 p -77.87 4.0 13.02 Favored 'General case' 0 C--N 1.3 -1.549 0 C-N-CA 119.827 -0.749 . . . . 0.0 109.294 179.21 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.49 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 1.8 m-20 -102.42 -33.78 9.41 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.151 -0.968 . . . . 0.0 108.824 179.598 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 1.127 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 23.5 m-85 -92.88 -33.05 14.37 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.449 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.945 HD13 HG22 ' A' ' 13' ' ' VAL . 0.2 OUTLIER -102.23 138.19 39.49 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.973 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.593 ' C ' HG11 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -142.32 142.35 32.5 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.48 -0.763 . . . . 0.0 109.41 -179.788 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -59.6 131.49 51.09 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.353 -0.842 . . . . 0.0 110.666 -179.394 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 90.45 -16.75 56.99 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.945 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' GLN . . . . . 0.425 ' CD ' ' HB2' ' A' ' 51' ' ' GLN . 19.0 mt-30 -70.46 169.4 14.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.173 -1.192 . . . . 0.0 109.886 -179.642 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.489 ' OE1' ' HE3' ' A' ' 12' ' ' LYS . 3.2 mt-10 -139.7 132.87 29.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.193 -0.942 . . . . 0.0 108.556 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.1 m -141.05 136.83 16.34 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 120.916 -1.115 . . . . 0.0 110.402 -179.4 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.449 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.3 Cg_endo -80.2 144.4 16.48 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 C-N-CA 122.524 2.149 . . . . 0.0 109.065 178.785 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.891 ' O ' HG13 ' A' ' 8' ' ' VAL . 1.5 m -144.13 -174.8 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 120.918 -1.114 . . . . 0.0 110.062 -179.612 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 4.1 mttt -121.9 135.14 54.87 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.516 -0.74 . . . . 0.0 109.357 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.773 ' CG1' HG22 ' A' ' 5' ' ' VAL . 58.9 t -64.55 100.08 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.275 -0.891 . . . . 0.0 109.002 179.734 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.616 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 2.8 tp -75.17 -15.23 60.58 Favored 'General case' 0 C--N 1.308 -1.239 0 O-C-N 121.216 -0.928 . . . . 0.0 109.723 -179.542 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.616 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 8.4 mt-10 105.88 -178.95 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.258 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -179.333 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -111.01 169.85 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.043 -1.036 . . . . 0.0 109.671 -179.539 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.436 ' OD2' ' HB2' ' A' ' 68' ' ' ARG . 11.1 p30 -87.67 -167.86 2.03 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.218 -0.927 . . . . 0.0 109.565 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -68.68 -10.71 57.91 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -0.864 . . . . 0.0 109.793 -179.834 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 29.3 mt-30 -103.49 -95.44 0.31 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.201 -0.937 . . . . 0.0 109.549 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -169.05 49.51 0.22 Allowed Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.732 -1.347 . . . . 0.0 109.732 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.436 ' HB2' ' OD2' ' A' ' 64' ' ' ASP . 0.5 OUTLIER -107.7 94.43 5.08 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.172 -1.193 . . . . 0.0 109.3 179.842 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.51 ' CD1' ' HB3' ' A' ' 29' ' ' LYS . 2.9 mt -42.87 108.22 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.359 -0.838 . . . . 0.0 109.634 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.522 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 0.0 OUTLIER -91.08 95.91 10.33 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.285 -0.884 . . . . 0.0 109.817 179.995 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.975 HD12 ' HA3' ' A' ' 31' ' ' GLY . 20.6 mt -93.35 153.54 18.48 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.206 -0.934 . . . . 0.0 108.916 179.577 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.485 ' OG ' HD13 ' A' ' 61' ' ' LEU . 0.4 OUTLIER -121.28 101.46 7.65 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.15 -0.969 . . . . 0.0 110.08 -179.622 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.624 HG22 ' O ' ' A' ' 38' ' ' ILE . 0.1 OUTLIER -45.28 137.96 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.2 -0.937 . . . . 0.0 108.96 179.838 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.02 151.39 1.29 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.404 -0.81 . . . . 0.0 109.871 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.408 ' O ' ' HA ' ' A' ' 39' ' ' ALA . 0.3 OUTLIER 57.19 40.11 28.33 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -0.892 . . . . 0.0 109.604 179.762 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.474 ' HB2' ' O ' ' A' ' 73' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 118.019 -0.991 . . . . 0.0 109.453 179.824 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.269 0.557 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.3 pt-20 -81.79 -165.8 1.06 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.159 -0.963 . . . . 0.0 109.542 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.888 ' H ' HD12 ' A' ' 3' ' ' ILE . 0.1 OUTLIER -144.86 -179.16 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 O-C-N 121.288 -0.883 . . . . 0.0 109.518 -179.618 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -146.32 -174.37 4.43 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.433 -0.792 . . . . 0.0 109.349 179.858 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.553 ' HA ' HG11 ' A' ' 60' ' ' VAL . 4.6 t -76.04 162.86 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.175 -0.953 . . . . 0.0 109.135 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.489 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 77.43 -1.63 65.13 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 -179.369 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.68 ' CD ' HG22 ' A' ' 3' ' ' ILE . 3.3 ttm105 -105.31 164.33 11.93 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.171 -1.193 . . . . 0.0 109.724 -179.705 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.582 HG13 ' O ' ' A' ' 58' ' ' VAL . 89.9 t -89.93 131.79 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.26 -0.9 . . . . 0.0 108.933 179.512 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.653 ' OH ' HD13 ' A' ' 3' ' ' ILE . 4.0 m-85 -107.78 179.33 4.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.183 -0.948 . . . . 0.0 110.031 -179.501 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -121.19 101.19 7.49 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 178.012 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.79 115.95 4.35 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 119.85 -1.167 . . . . 0.0 111.099 -177.865 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.562 ' O ' HG13 ' A' ' 23' ' ' VAL . 5.7 mtmt -88.66 152.04 22.07 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 107.208 -1.404 . . . . 0.0 107.208 178.075 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.665 HG13 HD13 ' A' ' 50' ' ' LEU . 34.9 t -87.34 110.76 20.97 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 O-C-N 120.751 -1.218 . . . . 0.0 109.142 -179.07 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.973 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.5 OUTLIER -120.7 5.2 10.54 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.442 -0.786 . . . . 0.0 109.807 -179.227 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.529 ' CG ' ' O ' ' A' ' 14' ' ' THR . 3.5 mpp_? -176.15 152.5 1.16 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.047 -1.033 . . . . 0.0 110.225 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.59 HG21 HG22 ' A' ' 47' ' ' THR . 35.0 mt -142.19 159.01 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 179.209 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 1.033 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -137.19 153.65 29.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 120.82 -1.175 . . . . 0.0 109.872 -179.243 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -59.13 -40.06 84.29 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.873 -1.142 . . . . 0.0 109.12 179.248 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.033 ' CE1' HG21 ' A' ' 17' ' ' VAL . 20.1 p90 -91.66 27.71 1.96 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.431 -0.793 . . . . 0.0 110.148 -179.739 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.592 ' C ' HG22 ' A' ' 17' ' ' VAL . . . 151.82 -148.64 19.87 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 119.033 -1.556 . . . . 0.0 110.899 -179.559 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.75 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -155.32 148.46 24.71 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.241 -1.153 . . . . 0.0 108.846 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.947 ' CE1' HD11 ' A' ' 32' ' ' LEU . 11.6 m-30 -107.92 160.9 15.41 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.58 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.795 ' CG2' HG23 ' A' ' 33' ' ' VAL . 20.4 t -149.39 162.25 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.129 -0.982 . . . . 0.0 109.49 -179.522 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.973 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -133.73 145.44 49.86 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.122 -0.986 . . . . 0.0 109.811 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.515 ' O ' ' N ' ' A' ' 27' ' ' GLY . 3.2 pt -120.24 153.46 23.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 O-C-N 121.065 -1.022 . . . . 0.0 109.273 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.458 ' C ' ' O ' ' A' ' 25' ' ' ILE . . . 38.81 -94.49 0.01 OUTLIER Glycine 0 N--CA 1.494 2.563 0 N-CA-C 109.919 -1.272 . . . . 0.0 109.919 179.469 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.515 ' N ' ' O ' ' A' ' 25' ' ' ILE . . . -172.63 -33.48 0.03 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.859 -1.297 . . . . 0.0 109.859 179.816 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -84.3 -9.41 81.97 Favored Glycine 0 N--CA 1.491 2.329 0 O-C-N 121.162 -1.199 . . . . 0.0 110.214 -179.69 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.562 ' HD2' HD11 ' A' ' 69' ' ' ILE . 2.5 mmmt -138.68 157.13 46.69 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.007 -1.29 . . . . 0.0 109.776 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.539 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -132.56 151.44 51.93 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.155 -0.966 . . . . 0.0 110.43 -179.861 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.831 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -104.72 -175.64 24.81 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 179.309 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.947 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -149.43 120.59 7.78 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.846 -1.385 . . . . 0.0 110.724 179.753 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.795 HG23 ' CG2' ' A' ' 23' ' ' VAL . 88.3 t -93.67 60.1 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 177.85 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.482 ' HB2' HD23 ' A' ' 32' ' ' LEU . 5.6 t-80 -47.6 158.42 0.19 Allowed 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.779 -1.201 . . . . 0.0 108.383 -179.533 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.676 ' O ' HD13 ' A' ' 38' ' ' ILE . 2.8 tp -47.76 -52.94 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.081 -1.012 . . . . 0.0 110.07 -179.276 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.578 ' H ' HG23 ' A' ' 35' ' ' ILE . 0.0 OUTLIER -81.48 39.41 0.53 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.091 -1.005 . . . . 0.0 110.375 -179.631 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.924 ' C ' HD12 ' A' ' 38' ' ' ILE . 45.2 mm-40 -144.83 50.41 1.26 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.926 -1.109 . . . . 0.0 109.641 -179.882 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.924 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.6 mp -120.08 -99.79 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 120.765 -1.209 . . . . 0.0 110.675 -179.484 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.788 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -111.72 -151.69 0.49 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.211 -0.931 . . . . 0.0 110.269 -178.622 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -62.13 -65.15 0.73 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.559 -0.713 . . . . 0.0 109.918 -179.628 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.474 ' HD2' ' OH ' ' A' ' 49' ' ' TYR . 4.6 ptpt -60.96 173.36 0.79 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.121 -0.987 . . . . 0.0 109.318 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 6.0 mmm180 -78.7 -2.06 37.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.295 -0.878 . . . . 0.0 110.138 -179.156 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.136 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 24.4 t 54.76 76.09 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 120.998 -1.064 . . . . 0.0 108.475 -179.527 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -46.97 -22.06 0.28 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.328 -0.858 . . . . 0.0 109.718 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.541 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.5 OUTLIER -128.28 117.78 22.09 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.113 -0.992 . . . . 0.0 109.858 -179.805 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.549 HG21 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -77.65 -25.81 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.199 -0.938 . . . . 0.0 108.701 179.485 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.59 HG22 HG21 ' A' ' 16' ' ' ILE . 63.5 p -77.1 3.73 11.85 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.383 -0.823 . . . . 0.0 109.307 179.237 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.404 ' OD2' ' CB ' ' A' ' 45' ' ' LYS . 99.1 m-20 -101.86 -24.36 14.04 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.482 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 1.136 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 22.1 m-85 -100.29 -25.87 14.1 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.733 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.669 HD12 ' HB1' ' A' ' 21' ' ' ALA . 0.2 OUTLIER -111.25 142.74 43.06 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.909 . . . . 0.0 109.391 179.465 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.508 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.2 OUTLIER -141.72 133.41 27.07 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.537 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 9.9 mtm -54.78 97.49 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.137 -0.977 . . . . 0.0 110.077 -179.487 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.9 -36.0 2.51 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 119.847 -1.168 . . . . 0.0 110.304 179.341 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 5.2 mm-40 -57.5 162.47 2.89 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.066 -1.256 . . . . 0.0 109.695 -179.677 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.434 ' HG3' ' HA ' ' A' ' 12' ' ' LYS . 0.7 OUTLIER -137.55 125.93 23.34 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.412 -0.805 . . . . 0.0 109.184 179.819 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.406 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 16.0 m -130.25 139.26 35.09 Favored Pre-proline 0 N--CA 1.488 1.451 0 O-C-N 121.063 -1.023 . . . . 0.0 109.606 -179.837 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.471 ' O ' ' HB2' ' A' ' 74' ' ' LYS . 35.5 Cg_endo -78.44 134.13 12.33 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.503 2.135 . . . . 0.0 110.352 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.792 HG21 ' HB3' ' A' ' 71' ' ' LEU . 0.9 OUTLIER -127.41 179.17 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.152 -0.968 . . . . 0.0 109.782 -179.922 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.521 ' HG3' HG22 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -117.01 122.19 43.51 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.639 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.649 ' HA ' HD23 ' A' ' 71' ' ' LEU . 91.2 t -53.25 94.95 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.189 -0.944 . . . . 0.0 109.528 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.604 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 13.4 tp -67.68 -14.97 63.39 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.279 -0.888 . . . . 0.0 109.221 179.793 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.604 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 0.6 OUTLIER 96.17 -171.29 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.005 0 CA-C-O 121.244 0.545 . . . . 0.0 109.614 -179.916 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.738 HG13 ' O ' ' A' ' 68' ' ' ARG . 2.1 t -133.41 175.69 10.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.308 -0.87 . . . . 0.0 109.759 -179.418 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.587 ' H ' HG12 ' A' ' 63' ' ' VAL . 3.1 p-10 -108.15 -164.46 0.96 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.307 -0.87 . . . . 0.0 109.358 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 11.5 mmm180 -79.21 7.37 7.75 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.036 -1.04 . . . . 0.0 109.822 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -99.32 -46.59 5.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.172 -0.955 . . . . 0.0 109.387 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 120.78 23.44 2.78 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.738 ' O ' HG13 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -91.07 99.49 12.51 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.327 -1.102 . . . . 0.0 109.334 -179.949 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.562 HD11 ' HD2' ' A' ' 29' ' ' LYS . 38.2 mt -46.17 121.19 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.18 -0.95 . . . . 0.0 109.412 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.572 ' HG2' HD23 ' A' ' 61' ' ' LEU . 0.1 OUTLIER -108.14 103.69 12.95 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.188 -0.945 . . . . 0.0 109.57 -179.944 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.831 HD12 ' HA3' ' A' ' 31' ' ' GLY . 81.4 mt -105.33 155.24 19.28 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.16 -0.963 . . . . 0.0 108.842 179.686 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.41 ' O ' ' C ' ' A' ' 73' ' ' ILE . 0.3 OUTLIER -121.32 97.21 5.41 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.115 -0.99 . . . . 0.0 110.362 -179.204 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.455 ' CG2' ' O ' ' A' ' 38' ' ' ILE . 0.2 OUTLIER -42.67 123.02 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.317 -0.864 . . . . 0.0 109.099 179.605 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 57' ' ' PRO . 0.8 OUTLIER -67.61 167.51 12.9 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.208 -0.933 . . . . 0.0 109.768 -179.651 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.406 ' O ' ' C ' ' A' ' 76' ' ' ALA . 6.2 mt-10 -64.09 -15.51 59.77 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.434 -0.791 . . . . 0.0 109.402 179.82 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.406 ' C ' ' O ' ' A' ' 75' ' ' GLU . . . . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 118.019 -0.991 . . . . 0.0 109.67 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.516 ' O ' ' CB ' ' A' ' 3' ' ' ILE . 3.3 mt-10 -103.64 -170.84 1.84 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.247 -0.908 . . . . 0.0 109.573 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.561 HG21 ' OH ' ' A' ' 9' ' ' TYR . 0.3 OUTLIER 75.09 134.2 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 119.228 -0.989 . . . . 0.0 108.893 -179.444 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.4 ' O ' ' HB2' ' A' ' 7' ' ' ARG . 0.6 OUTLIER -123.53 157.48 33.5 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.171 -0.956 . . . . 0.0 110.085 -179.628 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.566 HG12 ' N ' ' A' ' 6' ' ' GLY . 19.0 t -64.08 167.98 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.469 -0.769 . . . . 0.0 109.15 179.764 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.566 ' N ' HG12 ' A' ' 5' ' ' VAL . . . 74.67 2.77 65.15 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 -179.276 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.4 ' HB2' ' O ' ' A' ' 4' ' ' GLU . 1.1 ttm180 -88.96 -176.83 5.31 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.27 -1.135 . . . . 0.0 109.211 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.623 HG13 ' O ' ' A' ' 58' ' ' VAL . 55.3 t -102.5 119.54 50.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.148 -0.97 . . . . 0.0 108.945 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.646 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 3.0 m-85 -104.75 129.72 52.94 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.085 -1.009 . . . . 0.0 109.956 -179.561 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.5 m -74.49 98.08 3.25 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 178.398 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -77.73 120.45 5.51 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 -178.396 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.993 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -92.47 150.51 20.74 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.71 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.605 HG11 ' C ' ' A' ' 51' ' ' GLN . 20.7 t -89.49 106.12 16.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 120.908 -1.12 . . . . 0.0 108.991 -179.905 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 14' ' ' THR . . . . . 1.036 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -120.59 3.06 10.71 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.234 -0.916 . . . . 0.0 109.67 -179.506 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.517 ' HB3' ' HB2' ' A' ' 22' ' ' PHE . 5.0 mpp_? -173.31 153.48 2.43 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.174 -0.954 . . . . 0.0 109.821 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.425 HG22 ' N ' ' A' ' 17' ' ' VAL . 14.7 mt -140.84 159.76 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.562 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 1.06 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -139.67 155.55 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 120.822 -1.174 . . . . 0.0 110.285 -179.746 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -59.06 -44.48 91.84 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.967 -1.083 . . . . 0.0 109.803 179.449 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.06 ' CE1' HG21 ' A' ' 17' ' ' VAL . 8.2 p90 -90.42 24.62 2.53 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.107 -0.996 . . . . 0.0 110.377 -179.389 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.786 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 158.4 -152.28 23.41 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 118.977 -1.582 . . . . 0.0 111.044 -179.583 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.819 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -151.36 146.9 26.32 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.214 -1.168 . . . . 0.0 108.906 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.979 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.3 m-30 -106.73 157.93 17.35 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.259 -0.901 . . . . 0.0 108.992 179.754 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.993 HG13 ' O ' ' A' ' 12' ' ' LYS . 42.3 t -150.58 154.66 8.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 120.945 -1.097 . . . . 0.0 109.674 -178.834 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 1.036 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -121.87 138.21 54.48 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.89 -1.131 . . . . 0.0 109.319 179.662 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.563 HD12 ' CD2' ' A' ' 9' ' ' TYR . 2.5 pt -114.5 -172.4 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.166 -0.958 . . . . 0.0 109.239 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -91.35 178.4 41.53 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 179.625 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 87.48 -16.84 47.37 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 104.38 12.38 29.07 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.619 -1.393 . . . . 0.0 109.619 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.495 ' O ' HG13 ' A' ' 25' ' ' ILE . 4.7 mttm -115.97 159.93 20.94 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.235 -1.156 . . . . 0.0 109.069 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.52 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 0.4 OUTLIER -119.28 141.13 49.24 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.063 -1.023 . . . . 0.0 110.067 -179.757 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.9 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -91.93 -177.7 42.21 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.03 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.979 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -149.93 120.14 7.29 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 120.796 -1.414 . . . . 0.0 110.842 179.687 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.828 HG23 HG21 ' A' ' 23' ' ' VAL . 93.4 t -92.84 60.1 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 177.714 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.49 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.0 t-80 -48.76 156.51 0.47 Allowed 'General case' 0 N--CA 1.486 1.346 0 O-C-N 120.895 -1.128 . . . . 0.0 108.681 -179.375 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.553 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.7 tp -48.45 -48.92 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.296 -0.878 . . . . 0.0 110.623 -179.385 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.54 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.5 OUTLIER -81.25 40.93 0.58 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.145 -0.972 . . . . 0.0 110.693 -179.396 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.946 ' C ' HD12 ' A' ' 38' ' ' ILE . 12.0 mt-30 -150.95 51.73 0.86 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.713 -1.242 . . . . 0.0 110.047 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.946 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.7 mp -123.04 -97.91 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.886 -1.134 . . . . 0.0 110.094 -179.889 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.799 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -103.3 59.33 0.76 Allowed 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.432 -0.792 . . . . 0.0 108.999 -179.493 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.579 ' CB ' ' O ' ' A' ' 39' ' ' ALA . 9.8 t0 83.61 -43.05 0.09 Allowed 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -178.96 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.525 ' CB ' ' O ' ' A' ' 40' ' ' ASP . 0.2 OUTLIER 162.49 -20.05 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.364 -0.835 . . . . 0.0 110.044 179.825 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.63 80.62 1.51 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.185 -0.947 . . . . 0.0 110.764 -179.171 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.945 HG13 ' CD1' ' A' ' 49' ' ' TYR . 50.1 t -140.32 82.14 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.106 -0.996 . . . . 0.0 109.169 178.839 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 43' ' ' VAL . 29.3 tt0 -41.83 -29.53 0.21 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.371 -0.83 . . . . 0.0 109.982 -179.61 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.483 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 1.1 mmtp -150.45 141.8 23.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.077 -1.015 . . . . 0.0 109.792 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.786 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -74.12 -25.82 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 O-C-N 121.202 -0.936 . . . . 0.0 108.664 179.413 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.8 p -78.38 3.18 16.38 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.745 -0.782 . . . . 0.0 109.108 179.372 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.443 ' OD2' ' HB2' ' A' ' 45' ' ' LYS . 4.7 m-20 -101.82 -29.4 11.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.171 -0.956 . . . . 0.0 108.749 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.945 ' CD1' HG13 ' A' ' 43' ' ' VAL . 20.4 m-85 -98.29 -27.5 14.1 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.571 -0.705 . . . . 0.0 109.129 179.765 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.648 HD21 HG21 ' A' ' 33' ' ' VAL . 0.2 OUTLIER -104.9 141.03 37.26 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.603 -0.686 . . . . 0.0 109.35 -179.73 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.605 ' C ' HG11 ' A' ' 13' ' ' VAL . 43.6 tt0 -136.46 132.34 35.24 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.488 -0.757 . . . . 0.0 109.641 -179.712 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 4.7 mtt -65.26 112.11 3.31 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.354 -0.841 . . . . 0.0 109.605 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 113.71 -23.07 13.78 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' GLN . . . . . 0.545 ' CG ' ' HB3' ' A' ' 51' ' ' GLN . 57.0 mm-40 -79.37 167.5 20.78 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.251 -1.147 . . . . 0.0 109.583 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.5 ' N ' ' OE1' ' A' ' 55' ' ' GLU . 1.3 mp0 -133.36 147.59 51.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.312 -0.867 . . . . 0.0 109.177 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.476 HG21 HD11 ' A' ' 73' ' ' ILE . 19.1 m -144.74 141.21 17.27 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.156 -0.965 . . . . 0.0 109.771 -179.859 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.54 126.39 7.45 Favored 'Trans proline' 0 C--N 1.312 -1.391 0 C-N-CA 122.575 2.183 . . . . 0.0 110.238 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.623 ' O ' HG13 ' A' ' 8' ' ' VAL . 1.0 OUTLIER -132.31 -170.98 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.191 -0.943 . . . . 0.0 109.516 179.843 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.535 ' N ' HG23 ' A' ' 58' ' ' VAL . 29.6 mtpt -134.43 127.01 30.68 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.414 -0.804 . . . . 0.0 109.459 179.801 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.646 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 26.2 t -53.42 89.9 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.281 -0.887 . . . . 0.0 109.018 179.688 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.595 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 16.2 tp -58.65 -19.6 40.6 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.241 -0.912 . . . . 0.0 109.605 -179.694 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.595 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 2.6 pt-20 95.54 -163.05 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.134 0 CA-C-O 121.428 0.632 . . . . 0.0 109.869 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.906 HG13 ' O ' ' A' ' 67' ' ' GLY . 55.3 t -142.42 147.6 20.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.561 -0.712 . . . . 0.0 109.453 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -128.15 -151.31 0.47 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.178 -0.952 . . . . 0.0 109.263 179.837 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 22.5 mtp180 -51.54 -57.23 9.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.166 -0.959 . . . . 0.0 108.976 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 6.6 mt-30 -118.99 124.85 47.99 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.289 -0.882 . . . . 0.0 108.941 179.46 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.906 ' O ' HG13 ' A' ' 63' ' ' VAL . . . 143.61 105.27 0.51 Allowed Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 -179.753 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.437 ' O ' ' C ' ' A' ' 69' ' ' ILE . 61.1 mtt-85 -88.79 120.98 30.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.338 -1.095 . . . . 0.0 109.206 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.493 ' CD1' ' HB3' ' A' ' 29' ' ' LYS . 58.1 mt 42.82 84.36 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.296 -0.878 . . . . 0.0 109.352 -179.863 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.495 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 0.3 OUTLIER -89.92 111.34 22.37 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.901 -1.125 . . . . 0.0 108.981 179.893 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.9 HD12 ' HA3' ' A' ' 31' ' ' GLY . 18.8 mt -100.24 149.94 23.05 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.148 -0.97 . . . . 0.0 109.549 -179.797 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.458 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.3 OUTLIER -114.67 106.7 14.54 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.375 -0.828 . . . . 0.0 109.565 -179.742 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.476 HD11 HG21 ' A' ' 56' ' ' VAL . 0.1 OUTLIER -65.84 135.24 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.261 -0.899 . . . . 0.0 109.229 -179.996 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.4 -149.54 0.05 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.315 -0.866 . . . . 0.0 109.228 179.715 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -64.45 -44.2 91.88 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.154 -0.966 . . . . 0.0 109.497 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.515 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.483 -179.87 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.605 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.904 ' C ' HD13 ' A' ' 3' ' ' ILE . 0.5 OUTLIER 63.66 -175.76 0.16 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.244 -0.91 . . . . 0.0 109.396 -179.892 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.904 HD13 ' C ' ' A' ' 2' ' ' GLU . 0.0 OUTLIER -134.62 123.8 42.85 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 O-C-N 121.12 -0.988 . . . . 0.0 110.238 -179.038 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -98.55 144.61 27.68 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.521 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.669 HG22 ' HA ' ' A' ' 62' ' ' GLU . 7.1 t -75.71 158.1 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.111 -0.993 . . . . 0.0 109.654 -179.667 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.417 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 76.62 2.15 74.27 Favored Glycine 0 N--CA 1.487 2.096 0 N-CA-C 109.16 -1.576 . . . . 0.0 109.16 -179.537 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 3.8 ttt-85 -97.75 179.95 4.65 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.292 -1.122 . . . . 0.0 109.67 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.739 HG22 ' HG3' ' A' ' 59' ' ' LYS . 71.6 t -119.36 143.68 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.275 -0.89 . . . . 0.0 109.019 179.821 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.587 ' CZ ' ' CG2' ' A' ' 3' ' ' ILE . 11.5 m-85 -136.53 129.51 31.06 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.059 -1.026 . . . . 0.0 110.77 -179.521 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.504 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 0.4 OUTLIER -97.58 112.05 24.07 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.149 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -113.48 151.97 18.16 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.134 -1.508 . . . . 0.0 110.59 -178.575 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.524 ' HG2' ' CG ' ' A' ' 55' ' ' GLU . 3.4 mtmm -89.63 162.32 15.68 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.876 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.56 HG22 HD13 ' A' ' 50' ' ' LEU . 60.3 t -88.16 97.56 6.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 120.994 -1.066 . . . . 0.0 108.203 179.651 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.718 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.6 p -103.43 -4.64 23.8 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.475 -0.765 . . . . 0.0 110.426 -178.642 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.551 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -163.37 153.8 15.96 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.913 -1.117 . . . . 0.0 110.584 -179.699 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.402 ' HA ' ' HA ' ' A' ' 21' ' ' ALA . 19.8 mt -143.21 155.41 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 178.931 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 1.027 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -135.54 154.96 35.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.837 -1.164 . . . . 0.0 110.055 -178.934 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 12.0 t0 -60.5 -40.44 91.41 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.687 -1.258 . . . . 0.0 109.323 179.43 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.027 ' CE1' HG21 ' A' ' 17' ' ' VAL . 15.5 p90 -90.2 23.14 2.98 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.356 -0.84 . . . . 0.0 110.289 -179.743 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.595 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 156.23 -149.42 20.35 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 119.294 -1.432 . . . . 0.0 110.975 -179.654 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.708 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -153.54 146.85 24.79 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.042 -1.27 . . . . 0.0 108.99 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.966 ' CE1' HD11 ' A' ' 32' ' ' LEU . 11.2 m-30 -109.35 155.89 20.67 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.395 -0.816 . . . . 0.0 109.175 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.768 ' CG2' HG23 ' A' ' 33' ' ' VAL . 7.0 t -144.23 168.23 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 120.93 -1.106 . . . . 0.0 109.145 179.795 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.718 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -138.05 150.92 47.36 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.06 -1.025 . . . . 0.0 110.743 -179.328 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.484 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.8 pt -122.0 111.04 29.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.182 -0.949 . . . . 0.0 108.951 179.315 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.85 -86.08 1.27 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -179.43 -38.99 0.07 OUTLIER Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.463 ' O ' ' OE2' ' A' ' 30' ' ' GLU . . . -80.23 -45.79 7.94 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.832 ' HG2' HD11 ' A' ' 3' ' ' ILE . 0.0 OUTLIER -99.53 150.37 22.28 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.186 -1.185 . . . . 0.0 109.124 -179.997 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.544 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 5.2 mp0 -131.78 155.04 48.44 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 120.84 -1.162 . . . . 0.0 111.081 -179.468 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.789 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -105.72 -174.0 23.82 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 108.352 -1.899 . . . . 0.0 108.352 179.141 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.966 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.51 122.89 8.42 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.716 -1.461 . . . . 0.0 111.054 179.674 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.768 HG23 ' CG2' ' A' ' 23' ' ' VAL . 14.9 t -99.62 64.73 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 177.333 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.499 ' HB3' ' HG3' ' A' ' 37' ' ' GLN . 3.6 t-80 -49.58 162.23 0.17 Allowed 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.835 -1.165 . . . . 0.0 108.746 -179.474 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.609 ' O ' HD13 ' A' ' 38' ' ' ILE . 0.3 OUTLIER -52.79 -52.05 31.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.214 -0.929 . . . . 0.0 110.329 -179.269 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.561 ' N ' HG23 ' A' ' 35' ' ' ILE . 11.5 m -81.42 32.46 0.35 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 120.994 -1.066 . . . . 0.0 110.764 -179.351 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.894 ' C ' HD12 ' A' ' 38' ' ' ILE . 18.4 mm-40 -138.24 48.24 1.97 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.695 -1.253 . . . . 0.0 109.978 -179.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.894 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.5 mp -119.39 -99.39 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 120.956 -1.09 . . . . 0.0 110.019 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.806 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -97.68 -141.25 0.3 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.317 -0.864 . . . . 0.0 109.09 -179.266 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.491 ' O ' ' HB2' ' A' ' 41' ' ' LYS . 0.2 OUTLIER -44.39 -57.21 3.67 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.054 -1.028 . . . . 0.0 108.994 179.791 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.491 ' HB2' ' O ' ' A' ' 40' ' ' ASP . 0.4 OUTLIER 173.32 -30.34 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.5 -0.75 . . . . 0.0 109.148 -179.994 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.438 ' O ' ' C ' ' A' ' 43' ' ' VAL . 11.5 mtm180 -48.03 -95.59 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.368 -0.833 . . . . 0.0 110.034 -179.524 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 0.965 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 90.0 t 41.78 49.16 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.334 -0.854 . . . . 0.0 109.06 -179.055 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.412 ' C ' ' O ' ' A' ' 43' ' ' VAL . 11.1 mt-10 -41.31 -30.66 0.19 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.556 -0.715 . . . . 0.0 109.506 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.462 ' HB2' ' CG ' ' A' ' 48' ' ' ASP . 14.1 mttt -122.21 130.05 52.83 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.35 -0.844 . . . . 0.0 109.066 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.595 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -78.62 -24.31 13.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.19 -0.944 . . . . 0.0 108.932 -179.976 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 3.2 p -76.78 4.38 9.81 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.328 -0.858 . . . . 0.0 109.48 179.388 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.476 ' N ' ' OD1' ' A' ' 48' ' ' ASP . 2.0 m-20 -99.55 -37.43 9.17 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.156 -0.965 . . . . 0.0 108.727 179.515 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 0.965 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 18.0 m-85 -90.19 -32.69 16.5 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.683 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.667 HD11 HG21 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -99.21 140.38 33.45 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.532 -0.73 . . . . 0.0 109.223 179.938 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.493 ' H ' HG21 ' A' ' 13' ' ' VAL . 45.6 mt-30 -136.35 112.56 9.8 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.463 -0.773 . . . . 0.0 109.253 -179.821 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' MET . . . . . 0.451 ' O ' ' CE ' ' A' ' 52' ' ' MET . 0.7 OUTLIER -52.49 94.59 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.277 -0.889 . . . . 0.0 110.176 -179.769 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 143.37 -38.88 1.35 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.771 -1.204 . . . . 0.0 110.428 179.508 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 22.4 mt-30 -77.36 169.17 18.8 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.128 -1.219 . . . . 0.0 109.782 -179.42 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' GLU . . . . . 0.524 ' CG ' ' HG2' ' A' ' 12' ' ' LYS . 3.6 mt-10 -122.81 125.32 45.22 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.297 -0.877 . . . . 0.0 109.217 179.739 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.442 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 22.9 m -117.49 142.64 30.73 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.187 -0.946 . . . . 0.0 109.97 -179.68 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.504 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.3 Cg_endo -80.28 153.66 21.43 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 122.753 2.302 . . . . 0.0 110.105 179.669 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.819 ' CG2' HD22 ' A' ' 71' ' ' LEU . 0.9 OUTLIER -150.47 -170.27 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.169 -0.957 . . . . 0.0 109.63 179.8 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.739 ' HG3' HG22 ' A' ' 8' ' ' VAL . 7.7 mtpt -140.75 124.44 17.03 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.398 -0.814 . . . . 0.0 109.663 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.572 ' HA ' HD23 ' A' ' 71' ' ' LEU . 43.0 t -52.6 89.57 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.415 -0.803 . . . . 0.0 108.991 179.365 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.789 HD12 ' OG ' ' A' ' 72' ' ' SER . 0.5 OUTLIER -63.62 -31.1 72.17 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.403 -0.811 . . . . 0.0 109.444 -179.596 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.669 ' HA ' HG22 ' A' ' 5' ' ' VAL . 2.1 mt-10 158.91 -167.7 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.828 0 CA-C-O 121.59 0.71 . . . . 0.0 110.194 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 32.1 t -145.83 135.66 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 179.567 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.47 ' OD2' ' HB2' ' A' ' 68' ' ' ARG . 0.5 OUTLIER -84.96 -174.59 5.35 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.151 -0.968 . . . . 0.0 109.879 -179.782 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -73.61 -10.39 59.66 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.321 -0.862 . . . . 0.0 109.872 -179.678 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 82.2 mm-40 -89.68 12.89 15.6 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.183 -0.948 . . . . 0.0 109.586 -179.725 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 61.22 29.86 72.36 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.47 ' HB2' ' OD2' ' A' ' 64' ' ' ASP . 1.2 mmp_? -89.7 140.08 29.93 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.199 -1.177 . . . . 0.0 108.966 179.67 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.632 HG22 ' HG ' ' A' ' 71' ' ' LEU . 22.4 mt -82.49 107.72 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.243 -0.911 . . . . 0.0 109.85 -179.506 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.476 ' HB3' ' O ' ' A' ' 62' ' ' GLU . 26.0 tpt85 -89.63 91.11 8.53 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.205 -0.934 . . . . 0.0 108.946 179.488 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.819 HD22 ' CG2' ' A' ' 58' ' ' VAL . 52.8 mt -89.96 161.08 16.06 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.252 -0.905 . . . . 0.0 110.112 -179.323 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.789 ' OG ' HD12 ' A' ' 61' ' ' LEU . 0.3 OUTLIER -124.36 116.58 22.82 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.481 -0.762 . . . . 0.0 110.028 -179.725 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.745 HD13 ' O ' ' A' ' 37' ' ' GLN . 1.3 mp -46.43 134.97 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.079 -1.013 . . . . 0.0 108.511 179.368 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -74.67 -26.79 60.09 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.157 -0.964 . . . . 0.0 109.976 -179.334 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.413 ' CG ' ' O ' ' A' ' 75' ' ' GLU . 28.8 tt0 -81.72 7.95 11.22 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 121.281 -0.887 . . . . 0.0 109.406 179.613 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.518 ' N ' HG22 ' A' ' 73' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.476 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.386 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.342 0.591 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.422 ' O ' ' C ' ' A' ' 3' ' ' ILE . 20.5 mp0 -114.31 82.56 1.73 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.202 -0.937 . . . . 0.0 109.638 -179.809 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.921 HD12 ' OH ' ' A' ' 9' ' ' TYR . 0.2 OUTLIER -42.03 143.78 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.232 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.84 168.47 19.01 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.999 -1.063 . . . . 0.0 110.218 -179.312 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.559 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 16.7 t -77.36 168.14 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.284 -0.885 . . . . 0.0 109.299 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.559 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 80.23 6.63 89.12 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 108.854 -1.698 . . . . 0.0 108.854 -179.195 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.509 ' HG3' ' N ' ' A' ' 8' ' ' VAL . 4.5 tpt180 -102.6 156.16 17.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.389 -1.065 . . . . 0.0 109.424 -179.591 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.75 HG22 ' HG3' ' A' ' 59' ' ' LYS . 75.8 t -88.8 119.67 36.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.138 -0.976 . . . . 0.0 108.813 179.729 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.921 ' OH ' HD12 ' A' ' 3' ' ' ILE . 4.4 m-30 -105.22 129.47 53.59 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.113 -0.992 . . . . 0.0 110.066 -178.947 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.6 m -77.0 102.39 6.42 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 178.628 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -80.21 116.2 4.21 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.933 -1.127 . . . . 0.0 110.373 -178.995 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.632 ' O ' HG13 ' A' ' 23' ' ' VAL . 9.1 mttt -89.16 149.97 22.9 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.655 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 1.029 HG22 ' CD2' ' A' ' 50' ' ' LEU . 85.8 t -86.83 106.69 16.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 120.956 -1.09 . . . . 0.0 109.059 -179.292 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' THR . . . . . 1.04 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -113.99 -25.43 8.57 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.529 -0.732 . . . . 0.0 109.21 -179.492 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.537 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 5.6 mtp180 -143.86 152.23 40.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.262 -0.899 . . . . 0.0 109.967 179.762 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.7 mt -139.85 154.42 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.249 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 1.061 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -134.83 154.3 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 120.782 -1.199 . . . . 0.0 110.313 -178.835 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -59.28 -42.81 92.12 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.796 -1.19 . . . . 0.0 109.539 179.298 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.061 ' CE1' HG21 ' A' ' 17' ' ' VAL . 9.9 p90 -90.73 27.28 1.81 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.17 -0.956 . . . . 0.0 110.065 -179.766 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.91 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 154.85 -153.01 24.49 Favored Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.012 -1.566 . . . . 0.0 111.141 -179.488 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.825 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -150.02 143.81 25.41 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.057 -1.26 . . . . 0.0 109.075 -179.87 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.98 ' CE1' HD11 ' A' ' 32' ' ' LEU . 9.5 m-30 -104.27 160.79 14.59 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.174 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.859 ' CG2' HG23 ' A' ' 33' ' ' VAL . 24.9 t -151.09 159.42 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.841 -1.162 . . . . 0.0 110.514 -178.613 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 1.04 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -138.14 143.04 40.14 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.24 -0.912 . . . . 0.0 109.142 179.618 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.927 HD11 ' CB ' ' A' ' 29' ' ' LYS . 11.9 pt -100.47 -34.77 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 120.825 -1.172 . . . . 0.0 109.001 179.742 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.43 ' N ' HG13 ' A' ' 25' ' ' ILE . . . 95.78 159.91 32.81 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.89 -13.04 65.57 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 125.55 46.43 0.23 Allowed Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.81 -1.316 . . . . 0.0 109.81 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.927 ' CB ' HD11 ' A' ' 25' ' ' ILE . 0.0 OUTLIER -178.71 149.99 0.49 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.031 -1.276 . . . . 0.0 110.088 179.709 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.617 ' O ' HD12 ' A' ' 69' ' ' ILE . 1.4 pm0 -136.04 156.6 48.49 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.059 -1.026 . . . . 0.0 110.194 -179.505 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.792 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -112.4 176.7 18.03 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 108.798 -1.721 . . . . 0.0 108.798 179.496 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.98 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -140.98 119.45 12.29 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.986 -1.302 . . . . 0.0 110.074 179.285 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.988 HG21 HD11 ' A' ' 50' ' ' LEU . 47.0 t -94.02 62.3 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.099 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.452 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.4 t-80 -48.56 156.18 0.47 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.857 -1.152 . . . . 0.0 108.712 -179.53 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.618 HG23 ' H ' ' A' ' 36' ' ' SER . 3.2 tp -45.52 -53.96 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.365 -0.834 . . . . 0.0 110.899 -179.117 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.618 ' H ' HG23 ' A' ' 35' ' ' ILE . 5.3 t -81.27 41.4 0.6 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.049 -1.032 . . . . 0.0 110.633 -179.254 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.995 ' C ' HD12 ' A' ' 38' ' ' ILE . 43.5 mt-30 -150.8 61.45 0.93 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.782 -1.199 . . . . 0.0 110.598 -179.843 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.995 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.9 mp -129.37 -95.56 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 120.849 -1.157 . . . . 0.0 109.684 179.372 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.794 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -122.51 -161.25 0.93 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.555 -0.715 . . . . 0.0 109.752 -179.251 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -60.02 -61.49 2.57 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.363 -0.836 . . . . 0.0 109.414 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.12 153.16 0.48 Allowed 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.226 -0.921 . . . . 0.0 109.24 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -67.71 -5.27 15.21 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.299 -0.876 . . . . 0.0 109.885 -179.635 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.074 HG13 ' CD1' ' A' ' 49' ' ' TYR . 75.7 t 48.78 51.63 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 120.996 -1.065 . . . . 0.0 109.016 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLU . . . . . 0.453 ' C ' ' O ' ' A' ' 43' ' ' VAL . 0.3 OUTLIER -40.71 -32.24 0.2 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.631 -0.668 . . . . 0.0 109.621 -179.99 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.475 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 2.7 mtmp? -111.69 118.23 35.08 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.417 -0.802 . . . . 0.0 109.514 -179.87 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.91 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -74.93 -26.59 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 179.509 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 7.9 p -78.93 5.36 11.76 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.36 -0.838 . . . . 0.0 109.176 179.215 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.475 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 3.2 m-20 -98.43 -37.24 9.68 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 179.383 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 1.074 ' CD1' HG13 ' A' ' 43' ' ' VAL . 15.9 m-85 -90.28 -34.01 15.91 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.626 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 1.029 ' CD2' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -110.66 148.11 32.92 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.354 -0.841 . . . . 0.0 110.395 179.886 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.621 ' C ' HG11 ' A' ' 13' ' ' VAL . 2.3 tt0 -150.62 147.03 26.91 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.57 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 8.2 mtp -65.84 88.05 0.1 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.098 -1.001 . . . . 0.0 109.743 -179.593 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 145.19 -20.81 1.92 Allowed Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.725 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' GLN . . . . . 0.406 ' HG2' ' HB3' ' A' ' 51' ' ' GLN . 12.5 mm100 -80.86 168.86 18.28 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.309 -1.112 . . . . 0.0 110.008 -179.733 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -144.04 116.77 8.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.387 -0.821 . . . . 0.0 109.097 179.684 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.5 m -114.41 142.31 27.92 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.13 -0.981 . . . . 0.0 109.359 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -78.93 142.39 17.45 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.351 2.034 . . . . 0.0 110.322 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.627 HG21 HD13 ' A' ' 71' ' ' LEU . 0.8 OUTLIER -138.1 174.96 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.333 -0.855 . . . . 0.0 109.32 -179.886 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.75 ' HG3' HG22 ' A' ' 8' ' ' VAL . 0.1 OUTLIER -126.64 111.16 14.0 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.284 -0.885 . . . . 0.0 109.381 179.511 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.487 ' HA ' HD23 ' A' ' 71' ' ' LEU . 80.4 t -52.38 88.81 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.524 -0.735 . . . . 0.0 109.077 179.707 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.524 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 9.9 tp -67.19 -26.23 66.52 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.425 -0.797 . . . . 0.0 109.96 -179.387 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.524 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 2.6 mt-10 160.88 148.89 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.252 -0.905 . . . . 0.0 110.11 179.663 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.687 HG13 ' H ' ' A' ' 69' ' ' ILE . 44.3 t -150.3 -106.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.416 -0.803 . . . . 0.0 109.226 179.377 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.487 ' O ' ' O ' ' A' ' 63' ' ' VAL . 0.3 OUTLIER 41.82 -169.2 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.85 0 O-C-N 120.939 -1.101 . . . . 0.0 110.639 179.469 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 1.4 ptm180 -51.46 -50.35 59.97 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.277 -0.889 . . . . 0.0 109.544 -179.793 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 -90.28 67.67 6.82 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.312 -0.868 . . . . 0.0 109.123 179.794 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 63' ' ' VAL . . . 164.95 101.79 0.16 Allowed Glycine 0 N--CA 1.487 2.05 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.715 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 53.6 mtt180 -89.45 84.03 6.39 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.34 -1.094 . . . . 0.0 109.601 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.816 HG22 ' O ' ' A' ' 69' ' ' ILE . 16.3 mm 51.32 65.46 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.327 -0.858 . . . . 0.0 110.073 179.541 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.74 78.91 6.84 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.95 -1.094 . . . . 0.0 108.714 179.164 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.792 HD12 ' HA3' ' A' ' 31' ' ' GLY . 22.5 mt -89.36 145.55 25.28 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.263 -0.898 . . . . 0.0 109.216 -179.731 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.49 99.07 8.61 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.448 -0.782 . . . . 0.0 110.498 -178.927 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.736 ' O ' ' HB2' ' A' ' 76' ' ' ALA . 15.5 mm -51.69 137.95 9.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.316 -0.865 . . . . 0.0 109.295 179.697 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.471 ' C ' ' O ' ' A' ' 73' ' ' ILE . 0.2 OUTLIER -37.41 147.16 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.587 -0.696 . . . . 0.0 110.102 -179.835 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 13.5 tt0 55.33 28.25 11.1 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.191 -0.943 . . . . 0.0 109.274 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.736 ' HB2' ' O ' ' A' ' 73' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.506 0 CA-C-O 118.024 -0.989 . . . . 0.0 109.544 -179.814 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.625 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 178.15 -168.36 0.07 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.239 -0.913 . . . . 0.0 109.621 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.637 HG21 ' OH ' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -128.16 -163.28 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 121.321 -0.862 . . . . 0.0 109.272 -179.769 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.501 ' O ' ' HG3' ' A' ' 7' ' ' ARG . 0.8 OUTLIER -143.77 152.22 40.96 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.393 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.526 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 8.7 t -80.48 163.86 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.077 -1.014 . . . . 0.0 109.551 -179.795 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.526 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 95.45 4.17 60.97 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.501 ' HG3' ' O ' ' A' ' 4' ' ' GLU . 0.0 OUTLIER -111.64 171.25 7.6 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.159 -1.201 . . . . 0.0 109.823 -179.541 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.968 HG13 ' O ' ' A' ' 58' ' ' VAL . 75.9 t -97.28 141.48 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.289 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.637 ' OH ' HG21 ' A' ' 3' ' ' ILE . 11.0 m-85 -120.87 127.7 52.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.036 -1.04 . . . . 0.0 110.502 -179.287 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' THR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 5.6 m -97.04 109.22 22.02 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 178.501 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -110.77 150.1 17.74 Favored Glycine 0 N--CA 1.487 2.095 0 C-N-CA 119.472 -1.347 . . . . 0.0 110.495 -178.837 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.446 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.8 OUTLIER -89.81 163.02 15.21 Favored 'General case' 0 C--N 1.304 -1.394 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 179.08 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.828 ' CG2' HD22 ' A' ' 50' ' ' LEU . 41.6 t -89.0 103.27 13.8 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 O-C-N 121.096 -1.002 . . . . 0.0 108.754 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.747 HG21 ' CB ' ' A' ' 24' ' ' ALA . 0.5 OUTLIER -106.6 -12.46 15.57 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.282 -0.886 . . . . 0.0 109.779 -179.198 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.496 ' HD2' ' O ' ' A' ' 14' ' ' THR . 0.5 OUTLIER -159.26 153.9 24.42 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.054 -1.029 . . . . 0.0 110.41 -179.662 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.473 HG21 HG22 ' A' ' 47' ' ' THR . 11.1 mt -139.69 157.65 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 179.255 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 1.026 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -137.75 153.7 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 120.697 -1.252 . . . . 0.0 110.128 -178.947 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.69 -40.66 93.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.594 -1.316 . . . . 0.0 109.232 179.186 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.026 ' CE1' HG21 ' A' ' 17' ' ' VAL . 16.3 p90 -90.04 24.17 2.55 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.273 -0.892 . . . . 0.0 110.19 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.796 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 155.82 -153.5 24.8 Favored Glycine 0 N--CA 1.494 2.506 0 C-N-CA 119.091 -1.528 . . . . 0.0 111.272 -179.405 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.955 ' HB1' HD12 ' A' ' 50' ' ' LEU . . . -149.78 145.35 26.58 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.116 -1.226 . . . . 0.0 108.931 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.973 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.2 m-30 -107.78 145.25 33.81 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.337 -0.852 . . . . 0.0 109.232 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.901 ' CG2' HG23 ' A' ' 33' ' ' VAL . 48.9 t -133.33 167.52 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.134 -0.979 . . . . 0.0 109.597 -179.681 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.747 ' CB ' HG21 ' A' ' 14' ' ' THR . . . -136.64 135.29 38.17 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.884 -1.135 . . . . 0.0 110.78 -179.42 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.528 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.1 pt -113.25 93.83 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 120.94 -1.1 . . . . 0.0 108.863 178.961 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -47.82 121.27 6.77 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.816 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 100.6 71.62 0.96 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.775 -1.33 . . . . 0.0 109.775 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' GLY . . . . . 0.464 ' O ' ' CB ' ' A' ' 29' ' ' LYS . . . 136.87 -56.33 0.69 Allowed Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 179.695 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.528 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER 167.87 -155.41 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.123 -1.222 . . . . 0.0 109.406 -179.757 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 1.048 ' O ' HD13 ' A' ' 69' ' ' ILE . 4.6 pt-20 -111.08 150.48 29.31 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.771 -1.206 . . . . 0.0 109.988 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.682 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -97.95 -175.4 33.47 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 108.03 -2.028 . . . . 0.0 108.03 178.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.973 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -151.13 121.04 7.09 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 120.89 -1.359 . . . . 0.0 111.39 179.645 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.901 HG23 ' CG2' ' A' ' 23' ' ' VAL . 71.8 t -94.67 61.81 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 177.286 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.517 ' O ' ' CD1' ' A' ' 38' ' ' ILE . 3.1 t-80 -49.54 152.83 1.27 Allowed 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.89 -1.131 . . . . 0.0 108.814 -179.165 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.578 ' O ' HD13 ' A' ' 38' ' ' ILE . 0.4 OUTLIER -46.96 -49.01 7.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.372 -0.83 . . . . 0.0 109.982 -179.591 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.516 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.3 OUTLIER -81.6 40.42 0.58 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.21 -0.931 . . . . 0.0 110.327 -179.819 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.775 ' C ' HD12 ' A' ' 38' ' ' ILE . 14.7 mm-40 -147.88 31.9 0.86 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.849 -1.157 . . . . 0.0 109.388 -179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.844 HG21 ' CD2' ' A' ' 49' ' ' TYR . 1.6 mp -111.22 -98.74 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 O-C-N 121.13 -0.981 . . . . 0.0 109.992 -179.581 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.776 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -104.6 179.24 4.33 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.323 -0.861 . . . . 0.0 109.38 -179.706 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.425 ' C ' ' O ' ' A' ' 39' ' ' ALA . 8.9 t0 -42.41 -55.19 3.51 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.444 -0.785 . . . . 0.0 109.367 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.491 ' HD2' ' OH ' ' A' ' 49' ' ' TYR . 3.1 ptpt -66.42 169.18 7.79 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.219 -0.925 . . . . 0.0 109.257 179.792 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.497 ' O ' ' HB ' ' A' ' 43' ' ' VAL . 1.1 mmt85 -79.67 -3.11 45.83 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.247 -0.908 . . . . 0.0 109.971 -179.558 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.047 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 24.1 t 63.27 82.28 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 O-C-N 121.151 -0.968 . . . . 0.0 109.553 179.803 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -49.02 -22.61 0.92 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.442 -0.786 . . . . 0.0 109.426 179.619 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.539 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 1.3 mmpt? -130.11 113.05 14.03 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.315 -0.866 . . . . 0.0 109.945 -179.58 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.796 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -76.64 -26.05 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.233 -0.917 . . . . 0.0 108.839 179.563 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.473 HG22 HG21 ' A' ' 16' ' ' ILE . 52.9 p -76.56 3.74 10.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.838 . . . . 0.0 109.35 179.396 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.464 ' OD2' ' CB ' ' A' ' 45' ' ' LYS . 98.5 m-20 -103.88 -30.26 10.46 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.143 -0.973 . . . . 0.0 108.515 179.716 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 1.047 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 16.3 m-85 -91.24 -31.58 16.09 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 179.501 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.955 HD12 ' HB1' ' A' ' 21' ' ' ALA . 1.3 mt -108.23 155.22 20.71 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.278 -0.889 . . . . 0.0 109.418 179.446 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.497 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 5.9 tp60 -141.53 138.43 32.72 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.321 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 9.4 mtt -63.3 112.82 2.87 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.144 -0.973 . . . . 0.0 109.908 -179.497 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 108.3 -22.66 26.53 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' GLN . . . . . 0.492 ' CG ' ' HB3' ' A' ' 51' ' ' GLN . 35.3 mt-30 -68.94 162.6 26.34 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.173 -1.193 . . . . 0.0 109.89 -179.757 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -114.32 141.82 47.11 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.359 -0.838 . . . . 0.0 109.033 179.6 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.445 ' O ' HG23 ' A' ' 56' ' ' VAL . 31.7 m -144.13 131.04 10.31 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 120.948 -1.095 . . . . 0.0 110.25 -179.823 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.494 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.6 Cg_endo -80.65 154.14 20.51 Favored 'Trans proline' 0 C--N 1.316 -1.176 0 C-N-CA 122.65 2.233 . . . . 0.0 109.765 179.405 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.968 ' O ' HG13 ' A' ' 8' ' ' VAL . 0.9 OUTLIER -150.89 -169.73 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.035 -1.041 . . . . 0.0 109.625 179.733 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.625 ' N ' HG23 ' A' ' 58' ' ' VAL . 0.0 OUTLIER -135.68 138.53 42.89 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.469 -0.769 . . . . 0.0 109.205 179.557 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.629 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 5.1 t -73.16 83.3 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.334 -0.854 . . . . 0.0 108.853 179.758 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.534 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 4.6 tp -58.96 -28.56 66.41 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.427 -0.796 . . . . 0.0 109.767 -179.565 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.534 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 0.0 OUTLIER 163.16 138.45 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.221 -0.924 . . . . 0.0 110.34 179.602 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.49 HG13 ' H ' ' A' ' 69' ' ' ILE . 42.2 t -150.21 -106.34 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.444 -0.785 . . . . 0.0 109.275 179.247 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.435 ' N ' HG12 ' A' ' 63' ' ' VAL . 2.6 p30 41.05 -161.86 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.917 -1.114 . . . . 0.0 110.345 179.601 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ARG . . . . . 0.401 ' N ' ' OD1' ' A' ' 64' ' ' ASP . 3.2 ttm105 -45.35 -66.08 0.45 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.423 -0.798 . . . . 0.0 109.804 -179.729 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 10.6 mt-30 -89.31 89.36 7.87 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.191 -0.943 . . . . 0.0 109.031 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 67' ' ' GLY . . . . . 0.457 ' HA3' ' HA ' ' A' ' 63' ' ' VAL . . . 163.98 102.8 0.17 Allowed Glycine 0 N--CA 1.485 1.919 0 N-CA-C 108.841 -1.703 . . . . 0.0 108.841 -179.584 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 10.3 mtt180 -88.15 72.35 9.13 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.347 -1.09 . . . . 0.0 109.15 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 1.048 HD13 ' O ' ' A' ' 30' ' ' GLU . 35.0 mt 53.24 68.97 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.524 -0.735 . . . . 0.0 109.636 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.454 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 3.4 mmm180 -89.77 78.25 6.93 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.14 -0.975 . . . . 0.0 108.692 179.437 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.682 HD12 ' HA3' ' A' ' 31' ' ' GLY . 19.4 mt -89.12 155.16 19.61 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.277 -0.889 . . . . 0.0 109.28 -179.65 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.16 117.55 20.96 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.509 -0.744 . . . . 0.0 110.001 -179.145 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.634 HG23 ' H ' ' A' ' 75' ' ' GLU . 0.0 OUTLIER -56.07 133.05 20.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.223 -0.923 . . . . 0.0 109.037 179.883 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -43.31 -32.6 0.83 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.467 -0.771 . . . . 0.0 110.05 -179.302 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.634 ' H ' HG23 ' A' ' 73' ' ' ILE . 2.7 mt-10 -89.98 41.29 1.04 Allowed 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 179.707 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.462 0 CA-C-O 118.034 -0.984 . . . . 0.0 109.363 -179.774 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' A' ' 3' ' ' ILE . 18.3 tt0 -59.19 -17.95 32.12 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.199 -0.938 . . . . 0.0 109.395 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.597 HG23 ' OH ' ' A' ' 9' ' ' TYR . 0.3 OUTLIER 59.37 150.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.758 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 4' ' ' GLU . . . . . 0.545 ' O ' ' HG3' ' A' ' 7' ' ' ARG . 3.2 tt0 -150.39 -170.19 3.59 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.038 -1.039 . . . . 0.0 109.426 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.984 HG22 HG11 ' A' ' 60' ' ' VAL . 2.3 t -81.8 161.85 3.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.116 -0.99 . . . . 0.0 109.296 179.68 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.47 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 90.23 13.24 60.53 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 179.404 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.545 ' HG3' ' O ' ' A' ' 4' ' ' GLU . 0.0 OUTLIER -124.07 -174.74 3.07 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.102 -1.234 . . . . 0.0 109.669 -179.838 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.458 HG13 ' O ' ' A' ' 58' ' ' VAL . 23.9 t -89.62 135.19 26.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.425 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 178.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.673 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 4.0 m-85 -122.64 136.79 54.98 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.037 -1.04 . . . . 0.0 110.195 -178.848 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 7.0 m -90.34 102.66 15.39 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 178.125 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.472 ' HA3' HG11 ' A' ' 23' ' ' VAL . . . -79.54 128.39 8.51 Favored Glycine 0 N--CA 1.488 2.114 0 C-N-CA 119.843 -1.17 . . . . 0.0 110.794 -178.197 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.58 ' O ' HG13 ' A' ' 23' ' ' VAL . 6.1 mttt -89.08 147.61 24.14 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 178.29 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.729 HG13 HD12 ' A' ' 50' ' ' LEU . 17.1 t -86.42 104.2 13.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 O-C-N 120.384 -1.447 . . . . 0.0 108.708 -179.289 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.914 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.5 p -111.29 -9.15 14.3 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.697 -0.627 . . . . 0.0 109.858 -178.888 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.551 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 1.1 mpp_? -166.76 157.82 12.41 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.026 -1.046 . . . . 0.0 110.256 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.556 HG21 HG22 ' A' ' 47' ' ' THR . 14.7 mt -144.1 153.66 15.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.057 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 1.061 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.9 OUTLIER -133.67 155.46 40.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.835 -1.165 . . . . 0.0 109.884 -179.413 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -59.34 -41.74 89.89 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.753 -1.217 . . . . 0.0 109.345 179.444 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.061 ' CE1' HG21 ' A' ' 17' ' ' VAL . 12.8 p90 -91.33 26.56 2.2 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.346 -0.846 . . . . 0.0 110.296 -179.609 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.772 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 156.25 -152.99 24.37 Favored Glycine 0 N--CA 1.493 2.456 0 C-N-CA 119.108 -1.52 . . . . 0.0 111.174 -179.669 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.912 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -152.24 144.54 23.99 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.259 -1.142 . . . . 0.0 109.017 -179.657 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.972 ' CE1' HD11 ' A' ' 32' ' ' LEU . 9.6 m-30 -105.28 152.72 22.55 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.171 -0.956 . . . . 0.0 109.244 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.801 ' CG2' HG23 ' A' ' 33' ' ' VAL . 35.5 t -145.35 162.95 12.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.266 -0.896 . . . . 0.0 109.385 -179.476 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.914 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -135.18 130.72 35.79 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.852 -1.155 . . . . 0.0 110.089 -179.066 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.526 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.0 OUTLIER -114.88 85.81 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 120.938 -1.101 . . . . 0.0 109.157 179.504 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 25' ' ' ILE . . . -43.15 151.78 0.36 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 -179.818 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 80.03 49.81 5.81 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 153.36 -74.66 0.24 Allowed Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.826 -1.309 . . . . 0.0 109.826 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.585 ' HD2' HD11 ' A' ' 69' ' ' ILE . 0.1 OUTLIER -171.8 -160.69 0.17 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.141 -1.211 . . . . 0.0 109.421 -179.674 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.753 ' O ' HD13 ' A' ' 69' ' ' ILE . 2.8 mt-10 -105.91 148.46 27.59 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 120.725 -1.234 . . . . 0.0 109.628 179.772 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 23' ' ' VAL . . . -98.97 -179.36 31.71 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 108.452 -1.859 . . . . 0.0 108.452 179.342 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.972 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.64 117.37 5.82 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 120.814 -1.404 . . . . 0.0 110.652 179.577 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.912 ' HB ' ' HB3' ' A' ' 21' ' ' ALA . 30.1 t -91.23 61.06 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 177.51 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.568 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.7 t-80 -50.73 156.28 0.98 Allowed 'General case' 0 C--N 1.304 -1.394 0 O-C-N 120.964 -1.085 . . . . 0.0 108.624 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.556 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.9 OUTLIER -48.87 -47.35 16.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.171 -0.956 . . . . 0.0 109.789 -179.954 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.541 ' N ' HG23 ' A' ' 35' ' ' ILE . 37.4 t -81.42 40.2 0.56 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.158 -0.964 . . . . 0.0 110.647 -179.498 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.932 ' C ' HD12 ' A' ' 38' ' ' ILE . 35.9 mt-30 -150.51 43.35 0.84 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.851 -1.155 . . . . 0.0 110.032 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 0.932 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.6 mp -120.68 -98.97 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.086 -1.008 . . . . 0.0 109.521 179.719 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.765 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -112.79 153.0 28.49 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.244 -0.91 . . . . 0.0 109.636 -179.725 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 39' ' ' ALA . 4.4 t70 -44.21 -45.14 8.28 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.298 -0.876 . . . . 0.0 109.189 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.442 ' O ' ' C ' ' A' ' 42' ' ' ARG . 0.3 OUTLIER -68.01 122.45 18.25 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.286 -0.884 . . . . 0.0 109.225 179.766 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.442 ' C ' ' O ' ' A' ' 41' ' ' LYS . 0.7 OUTLIER -41.26 126.24 2.68 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.427 -0.795 . . . . 0.0 109.759 -179.844 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.024 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 17.7 t -88.11 85.81 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.567 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -44.91 -21.33 0.05 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.544 -0.722 . . . . 0.0 110.316 -179.686 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.539 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 5.7 mttt -139.1 117.5 12.01 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.013 -1.054 . . . . 0.0 110.191 -179.433 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.772 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -72.52 -27.61 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.38 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 47' ' ' THR . . . . . 0.556 HG22 HG21 ' A' ' 16' ' ' ILE . 81.9 p -75.97 1.26 15.79 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.798 -0.761 . . . . 0.0 109.15 179.439 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.469 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 2.1 m-20 -97.71 -35.35 10.59 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.291 -0.881 . . . . 0.0 109.041 179.696 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 1.024 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 7.0 m-85 -91.46 -27.38 18.31 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.404 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.874 HD21 HG21 ' A' ' 33' ' ' VAL . 0.2 OUTLIER -104.46 140.31 38.13 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 179.598 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.563 ' O ' HG21 ' A' ' 13' ' ' VAL . 4.1 tp-100 -132.41 124.46 28.69 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.198 -0.939 . . . . 0.0 109.788 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' MET . . . . . 0.474 ' O ' ' HG3' ' A' ' 52' ' ' MET . 23.6 ptp -58.42 130.07 45.01 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.381 -0.824 . . . . 0.0 109.869 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 93.86 -31.17 6.75 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 179.598 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' GLN . . . . . 0.485 ' HB2' ' HB3' ' A' ' 51' ' ' GLN . 56.8 mt-30 -77.97 -172.94 2.91 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.129 -1.218 . . . . 0.0 109.817 -179.62 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -143.56 157.06 44.72 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.441 -0.787 . . . . 0.0 108.943 179.704 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -140.0 140.91 25.29 Favored Pre-proline 0 C--N 1.303 -1.423 0 O-C-N 121.143 -0.973 . . . . 0.0 109.581 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.444 ' O ' ' HB3' ' A' ' 74' ' ' LYS . 36.3 Cg_endo -79.24 130.38 9.17 Favored 'Trans proline' 0 C--N 1.311 -1.403 0 C-N-CA 122.438 2.092 . . . . 0.0 109.9 179.551 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.911 HG21 HD12 ' A' ' 71' ' ' LEU . 1.1 m -143.18 -170.02 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.087 -1.008 . . . . 0.0 109.99 -179.631 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.537 ' N ' HG23 ' A' ' 58' ' ' VAL . 0.5 OUTLIER -135.08 126.81 29.12 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.672 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.984 HG11 HG22 ' A' ' 5' ' ' VAL . 36.2 t -51.74 97.36 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.278 -0.889 . . . . 0.0 109.306 -179.757 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.94 HD23 ' HG2' ' A' ' 70' ' ' ARG . 18.1 tp -67.36 -16.39 64.22 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.148 -0.97 . . . . 0.0 108.98 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.553 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 5.2 mt-10 91.62 -168.49 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.002 0 CA-C-O 121.582 0.706 . . . . 0.0 110.114 179.687 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.714 HG22 ' O ' ' A' ' 68' ' ' ARG . 58.2 t -137.55 159.73 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.484 -0.76 . . . . 0.0 109.477 -179.519 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.487 ' N ' HG12 ' A' ' 63' ' ' VAL . 9.0 p-10 -90.28 -161.28 0.78 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.348 -0.845 . . . . 0.0 109.295 179.762 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.79 41.01 0.63 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.214 -0.929 . . . . 0.0 110.058 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 5.1 tt0 -129.21 -51.02 1.2 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.938 -1.101 . . . . 0.0 109.555 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 125.92 26.94 1.19 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.714 ' O ' HG22 ' A' ' 63' ' ' VAL . 7.9 ptp180 -101.91 120.11 39.87 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.204 -1.174 . . . . 0.0 109.266 179.725 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.753 HD13 ' O ' ' A' ' 30' ' ' GLU . 1.5 mt -66.11 118.68 9.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.327 -0.858 . . . . 0.0 109.961 -179.636 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.94 ' HG2' HD23 ' A' ' 61' ' ' LEU . 6.9 tpt180 -105.2 115.39 30.19 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.17 -0.956 . . . . 0.0 109.419 179.657 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.911 HD12 HG21 ' A' ' 58' ' ' VAL . 3.4 mm? -106.37 147.35 29.34 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.217 -0.927 . . . . 0.0 109.654 -179.704 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.502 ' OG ' HD13 ' A' ' 61' ' ' LEU . 0.4 OUTLIER -112.14 106.26 14.83 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.393 -0.817 . . . . 0.0 109.704 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.472 HD11 HG22 ' A' ' 33' ' ' VAL . 0.9 OUTLIER -52.02 144.19 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.108 -0.995 . . . . 0.0 109.303 -179.871 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.444 ' HB3' ' O ' ' A' ' 57' ' ' PRO . 1.0 OUTLIER -51.64 -176.7 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.371 -0.831 . . . . 0.0 109.843 -179.692 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 27.7 mm-40 -43.64 -41.61 4.78 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.412 -0.805 . . . . 0.0 109.449 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ALA . . . . . 0.473 ' O ' ' HA ' ' A' ' 39' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.51 0 CA-C-O 117.997 -1.001 . . . . 0.0 109.381 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.476 ' O ' ' CB ' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.502 0 CA-C-O 121.293 0.568 . . . . 0.0 109.494 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLU . . . . . 0.476 ' CB ' ' O ' ' A' ' 1' ' ' ALA . 2.3 mm-40 165.0 -36.42 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.31 -0.868 . . . . 0.0 109.35 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 3' ' ' ILE . . . . . 0.831 HD13 ' OH ' ' A' ' 9' ' ' TYR . 0.1 OUTLIER -156.42 154.64 6.05 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.959 0 C-N-CA 119.731 -0.788 . . . . 0.0 109.249 -179.681 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.88 170.58 9.65 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.204 -0.935 . . . . 0.0 109.485 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.749 HG22 HG12 ' A' ' 60' ' ' VAL . 3.4 t -62.64 163.47 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.375 -0.828 . . . . 0.0 109.413 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 6' ' ' GLY . . . . . 0.51 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 88.28 4.29 77.67 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.604 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ARG . . . . . 0.468 ' HD3' HG22 ' A' ' 3' ' ' ILE . 5.6 ttt-85 -112.88 176.51 4.99 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.153 -1.204 . . . . 0.0 109.835 -179.733 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 8' ' ' VAL . . . . . 0.795 HG22 ' HG3' ' A' ' 59' ' ' LYS . 71.3 t -104.83 129.81 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.352 -0.843 . . . . 0.0 109.306 179.79 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 9' ' ' TYR . . . . . 0.831 ' OH ' HD13 ' A' ' 3' ' ' ILE . 3.1 m-85 -106.27 -174.67 2.59 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.147 -0.97 . . . . 0.0 109.836 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 11.4 m -147.28 110.79 4.92 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.935 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.43 ' HA2' ' HA ' ' A' ' 25' ' ' ILE . . . -121.26 143.24 15.96 Favored Glycine 0 N--CA 1.488 2.122 0 C-N-CA 118.868 -1.634 . . . . 0.0 110.908 -178.194 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 12' ' ' LYS . . . . . 0.45 ' O ' HG13 ' A' ' 23' ' ' VAL . 8.8 mttp -90.43 165.58 13.75 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.802 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' VAL . . . . . 0.834 HG22 HD13 ' A' ' 50' ' ' LEU . 39.1 t -88.27 102.89 13.16 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.744 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.487 179.426 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.774 HG21 ' CB ' ' A' ' 24' ' ' ALA . 0.1 OUTLIER -101.75 -7.98 22.11 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.292 -0.88 . . . . 0.0 109.494 -179.351 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 15' ' ' ARG . . . . . 0.504 ' CG ' ' C ' ' A' ' 14' ' ' THR . 0.0 OUTLIER -167.64 147.24 5.02 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.151 -0.968 . . . . 0.0 109.613 -179.599 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 16' ' ' ILE . . . . . 0.532 HG22 ' N ' ' A' ' 17' ' ' VAL . 62.1 mt -131.13 163.34 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' VAL . . . . . 1.059 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -138.82 154.38 26.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 120.726 -1.234 . . . . 0.0 110.425 -179.559 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -59.23 -43.16 92.34 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.843 -1.161 . . . . 0.0 109.812 179.531 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 19' ' ' PHE . . . . . 1.059 ' CE1' HG21 ' A' ' 17' ' ' VAL . 6.4 p90 -92.12 25.6 2.81 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.249 -0.907 . . . . 0.0 110.266 -179.384 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' GLY . . . . . 0.864 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 157.66 -154.79 25.84 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 119.033 -1.556 . . . . 0.0 110.98 -179.71 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 21' ' ' ALA . . . . . 0.772 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -149.61 145.97 27.05 Favored 'General case' 0 N--CA 1.486 1.345 0 O-C-N 121.089 -1.242 . . . . 0.0 108.995 -179.759 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' PHE . . . . . 0.967 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.8 m-30 -106.87 158.2 17.19 Favored 'General case' 0 C--N 1.298 -1.672 0 O-C-N 121.316 -0.865 . . . . 0.0 108.738 179.481 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 23' ' ' VAL . . . . . 0.908 ' CG2' HG23 ' A' ' 33' ' ' VAL . 37.6 t -148.34 166.34 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.069 -1.02 . . . . 0.0 109.755 -179.507 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' ALA . . . . . 0.774 ' CB ' HG21 ' A' ' 14' ' ' THR . . . -137.91 144.65 41.4 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.287 -0.883 . . . . 0.0 109.539 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ILE . . . . . 0.535 ' CG1' ' O ' ' A' ' 29' ' ' LYS . 5.5 pt -104.28 -20.72 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 120.625 -1.297 . . . . 0.0 108.562 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 26' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' A' ' 25' ' ' ILE . . . 59.73 142.07 0.01 OUTLIER Glycine 0 N--CA 1.489 2.193 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 179.34 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 82.59 15.21 74.1 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.934 -1.266 . . . . 0.0 109.934 179.592 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 178.9 -52.74 0.09 OUTLIER Glycine 0 N--CA 1.491 2.313 0 C-N-CA 119.625 -1.274 . . . . 0.0 110.18 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' LYS . . . . . 0.535 ' O ' ' CG1' ' A' ' 25' ' ' ILE . 0.4 OUTLIER -173.9 -161.78 0.13 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.069 -1.254 . . . . 0.0 110.06 -179.519 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 30' ' ' GLU . . . . . 0.568 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 12.6 mp0 -123.39 153.24 40.65 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.836 -1.165 . . . . 0.0 110.109 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' GLY . . . . . 0.56 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -103.67 -175.48 25.92 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 108.8 -1.72 . . . . 0.0 108.8 179.521 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 32' ' ' LEU . . . . . 0.967 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.57 119.82 6.81 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.97 -1.312 . . . . 0.0 110.552 179.624 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 33' ' ' VAL . . . . . 0.908 HG23 ' CG2' ' A' ' 23' ' ' VAL . 25.2 t -96.84 63.21 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 177.736 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' HIS . . . . . 0.532 ' O ' ' CD1' ' A' ' 38' ' ' ILE . 7.7 t-80 -48.64 162.57 0.1 Allowed 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.741 -1.224 . . . . 0.0 108.359 -179.627 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.636 ' O ' HD13 ' A' ' 38' ' ' ILE . 0.4 OUTLIER -55.5 -45.79 78.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.012 -1.055 . . . . 0.0 110.53 -179.49 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 36' ' ' SER . . . . . 0.489 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.9 OUTLIER -80.05 23.77 0.45 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.153 -0.967 . . . . 0.0 110.795 -179.338 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 37' ' ' GLN . . . . . 0.992 ' C ' HD12 ' A' ' 38' ' ' ILE . 3.4 mm100 -138.74 64.18 1.49 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.883 -1.136 . . . . 0.0 109.293 179.546 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ILE . . . . . 1.069 HG21 HG21 ' A' ' 43' ' ' VAL . 1.8 mp -129.35 -94.59 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.042 -1.036 . . . . 0.0 109.704 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' ALA . . . . . 0.803 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -114.98 -168.4 1.38 Allowed 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.455 -0.778 . . . . 0.0 109.852 -179.346 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -65.8 -58.06 6.51 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.4 -0.813 . . . . 0.0 109.417 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 41' ' ' LYS . . . . . 0.452 ' HA ' ' HE2' ' A' ' 41' ' ' LYS . 0.1 OUTLIER -65.41 125.97 26.79 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.359 -0.838 . . . . 0.0 109.227 179.939 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 42' ' ' ARG . . . . . 0.438 ' C ' ' O ' ' A' ' 41' ' ' LYS . 4.8 mtt180 -44.22 133.8 5.2 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.259 -0.901 . . . . 0.0 108.97 179.793 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 43' ' ' VAL . . . . . 1.069 HG21 HG21 ' A' ' 38' ' ' ILE . 44.3 t -97.3 82.39 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 121.2 -0.937 . . . . 0.0 109.06 -179.809 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -53.98 -19.02 4.06 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.365 -0.834 . . . . 0.0 109.114 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 45' ' ' LYS . . . . . 0.543 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.2 OUTLIER -121.68 108.19 13.25 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.436 -0.79 . . . . 0.0 109.748 -179.569 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 46' ' ' VAL . . . . . 0.864 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -76.3 -24.76 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.331 -0.856 . . . . 0.0 109.179 179.972 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.2 p -78.28 5.95 9.28 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.364 -0.835 . . . . 0.0 109.541 179.873 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 48' ' ' ASP . . . . . 0.457 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 10.2 m-20 -104.35 -37.59 7.17 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.136 -0.977 . . . . 0.0 108.716 179.548 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' TYR . . . . . 1.028 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 11.7 m-85 -89.84 -38.01 14.05 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.532 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' LEU . . . . . 0.834 HD13 HG22 ' A' ' 13' ' ' VAL . 0.2 OUTLIER -96.45 136.02 37.52 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.435 -0.791 . . . . 0.0 109.301 -179.931 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 51' ' ' GLN . . . . . 0.52 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 2.8 mm-40 -129.72 132.57 46.66 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.659 -0.651 . . . . 0.0 109.372 -179.517 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 11.5 mtt -57.31 113.52 1.79 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.313 -0.867 . . . . 0.0 109.661 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 106.14 -34.09 6.0 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.636 -1.385 . . . . 0.0 109.636 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' GLN . . . . . 0.472 ' O ' HG23 ' A' ' 13' ' ' VAL . 6.9 mt-30 -54.4 143.02 24.94 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.32 -1.106 . . . . 0.0 110.025 -179.722 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -104.15 129.39 51.88 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.313 -0.867 . . . . 0.0 108.898 179.368 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.405 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 33.2 m -132.78 134.48 24.65 Favored Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 120.99 -1.069 . . . . 0.0 110.085 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' PRO . . . . . 0.471 ' O ' ' HB2' ' A' ' 74' ' ' LYS . 37.0 Cg_endo -81.72 143.51 13.38 Favored 'Trans proline' 0 C--N 1.314 -1.283 0 C-N-CA 122.705 2.27 . . . . 0.0 110.015 179.341 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' VAL . . . . . 0.737 HG21 HD13 ' A' ' 71' ' ' LEU . 0.9 OUTLIER -135.31 -177.87 2.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.062 -1.024 . . . . 0.0 109.322 179.676 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 59' ' ' LYS . . . . . 0.795 ' HG3' HG22 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -131.72 110.78 11.13 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.277 -0.889 . . . . 0.0 109.212 179.737 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 60' ' ' VAL . . . . . 0.749 HG12 HG22 ' A' ' 5' ' ' VAL . 25.1 t -49.67 90.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.374 -0.829 . . . . 0.0 109.112 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.546 ' N ' ' O ' ' A' ' 59' ' ' LYS . 4.5 tp -82.28 -22.17 35.86 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.383 -0.823 . . . . 0.0 109.735 -179.31 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' GLU . . . . . 0.496 ' O ' ' HB3' ' A' ' 70' ' ' ARG . 1.9 tp10 179.91 113.58 0.05 OUTLIER 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.237 -0.915 . . . . 0.0 109.842 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 50.9 t -146.61 -59.9 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.114 -0.991 . . . . 0.0 109.628 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 65' ' ' ARG . 38.6 p-10 -58.52 -15.5 11.47 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.256 -0.903 . . . . 0.0 109.575 -179.804 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 65' ' ' ARG . . . . . 0.512 ' N ' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -63.79 -67.95 0.39 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.1 -1.0 . . . . 0.0 109.352 -179.986 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 3.9 mm100 -122.57 -39.49 2.54 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.263 -0.898 . . . . 0.0 109.23 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 115.21 31.0 2.13 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 179.787 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 68' ' ' ARG . . . . . 0.479 ' O ' ' C ' ' A' ' 69' ' ' ILE . 3.2 mtt180 -95.01 35.67 1.26 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.059 -1.26 . . . . 0.0 109.179 179.837 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.607 HG22 ' O ' ' A' ' 69' ' ' ILE . 19.9 mt 31.65 76.97 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 CA-C-O 121.183 0.516 . . . . 0.0 110.844 179.742 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.496 ' HB3' ' O ' ' A' ' 62' ' ' GLU . 0.0 OUTLIER -101.32 72.12 1.41 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.118 -0.989 . . . . 0.0 108.971 179.433 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 71' ' ' LEU . . . . . 0.737 HD13 HG21 ' A' ' 58' ' ' VAL . 23.4 mt -89.62 146.71 24.36 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.325 -0.859 . . . . 0.0 109.477 -179.703 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' SER . . . . . 0.508 ' CB ' ' HB2' ' A' ' 59' ' ' LYS . 0.3 OUTLIER -100.66 110.63 22.77 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.336 -0.852 . . . . 0.0 109.546 179.931 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.602 HD13 ' O ' ' A' ' 37' ' ' GLN . 1.9 mp -62.68 127.11 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.496 -0.752 . . . . 0.0 109.733 -179.738 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 74' ' ' LYS . . . . . 0.522 ' O ' ' CG ' ' A' ' 75' ' ' GLU . 0.0 OUTLIER -62.67 -160.12 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.301 -0.874 . . . . 0.0 109.29 179.666 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 75' ' ' GLU . . . . . 0.522 ' CG ' ' O ' ' A' ' 74' ' ' LYS . 22.9 pt-20 40.71 32.55 0.16 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.47 -0.769 . . . . 0.0 109.448 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 117.996 -1.002 . . . . 0.0 109.406 -179.831 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.48 HG13 ' O ' ' A' ' 58' ' ' VAL . 40.6 t . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.622 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 15.2 m-85 -136.17 129.19 31.32 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.967 -1.083 . . . . 0.0 110.386 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.5 m -76.91 102.06 6.21 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 178.264 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -83.14 113.81 3.74 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 119.813 -1.184 . . . . 0.0 110.73 -178.262 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.574 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -89.31 153.87 20.54 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 178.697 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.991 HG22 HD13 ' A' ' 50' ' ' LEU . 77.1 t -87.43 116.11 29.12 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 O-C-N 120.759 -1.213 . . . . 0.0 109.116 -179.572 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 1.135 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.2 OUTLIER -126.72 7.24 6.8 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.386 -0.821 . . . . 0.0 109.473 -179.396 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.539 ' HB3' ' HB2' ' A' ' 22' ' ' PHE . 1.9 mtp180 -178.26 149.52 0.53 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.304 -0.872 . . . . 0.0 109.575 179.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.405 HG22 ' N ' ' A' ' 17' ' ' VAL . 33.6 mt -140.9 157.16 22.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.487 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 1.018 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -135.78 152.93 31.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.858 -1.151 . . . . 0.0 110.057 -179.395 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -58.62 -41.44 85.93 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.721 -1.237 . . . . 0.0 109.035 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 1.018 ' CE1' HG21 ' A' ' 17' ' ' VAL . 17.3 p90 -90.41 28.68 1.41 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.363 -0.836 . . . . 0.0 110.33 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.594 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 151.72 -152.29 24.07 Favored Glycine 0 N--CA 1.491 2.326 0 C-N-CA 119.073 -1.537 . . . . 0.0 111.018 -179.607 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.801 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -151.75 147.11 26.29 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.125 -1.221 . . . . 0.0 108.938 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.972 ' CE1' HD11 ' A' ' 32' ' ' LEU . 8.8 m-30 -106.93 158.66 16.85 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 179.642 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.933 ' CG2' HG23 ' A' ' 33' ' ' VAL . 31.8 t -147.61 161.92 7.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.035 -1.041 . . . . 0.0 109.858 -179.154 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 1.135 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -139.74 150.34 44.68 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.103 -0.998 . . . . 0.0 109.436 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.678 HD11 ' HB2' ' A' ' 29' ' ' LYS . 4.5 pt . . . . . 0 N--CA 1.494 1.726 0 O-C-N 120.823 -1.173 . . . . 0.0 109.706 179.87 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.678 ' HB2' HD11 ' A' ' 25' ' ' ILE . 14.7 mtpt . . . . . 0 N--CA 1.489 1.476 0 CA-C-O 121.445 0.64 . . . . 0.0 109.389 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.56 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 1.1 mt-10 -130.34 158.8 38.83 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.061 -1.024 . . . . 0.0 110.356 -179.678 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.627 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -108.68 -173.73 21.48 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 179.328 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.972 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.26 123.21 8.76 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.853 -1.381 . . . . 0.0 110.682 179.751 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.933 HG23 ' CG2' ' A' ' 23' ' ' VAL . 60.8 t -97.67 62.16 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 177.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.496 ' HB3' ' HG3' ' A' ' 37' ' ' GLN . 3.3 t-80 -48.39 159.49 0.21 Allowed 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.692 -1.255 . . . . 0.0 108.147 -179.623 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.594 ' O ' HD13 ' A' ' 38' ' ' ILE . 3.1 tp -48.58 -50.35 12.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.587 0 O-C-N 121.099 -1.001 . . . . 0.0 110.09 -179.121 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.536 ' N ' HG23 ' A' ' 35' ' ' ILE . 5.3 m -81.57 41.22 0.62 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.182 -0.949 . . . . 0.0 110.424 -179.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.905 ' C ' HD12 ' A' ' 38' ' ' ILE . 40.3 mt-30 -150.69 53.0 0.88 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.847 -1.158 . . . . 0.0 110.245 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.944 HG21 HG21 ' A' ' 43' ' ' VAL . 1.6 mp -119.09 -98.92 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.928 -1.107 . . . . 0.0 109.936 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.765 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.302 -1.469 0 O-C-N 121.315 -0.866 . . . . 0.0 109.641 -179.424 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.152 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 80.4 t . . . . . 0 N--CA 1.487 1.401 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.425 ' C ' ' O ' ' A' ' 43' ' ' VAL . 0.0 OUTLIER -43.73 -26.66 0.26 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.38 -0.825 . . . . 0.0 108.896 179.849 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.455 ' HB3' ' CG ' ' A' ' 48' ' ' ASP . 0.1 OUTLIER -109.83 114.33 27.8 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.495 -0.753 . . . . 0.0 108.988 179.479 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.594 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -78.16 -24.14 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.141 -0.975 . . . . 0.0 108.62 179.747 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 3.7 p -76.22 1.61 15.45 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.44 -0.787 . . . . 0.0 109.344 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.455 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 14.4 m-20 -96.05 -40.35 9.29 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.111 -0.993 . . . . 0.0 108.926 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 1.152 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 9.5 m-85 -89.56 -28.77 19.36 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.487 -0.758 . . . . 0.0 109.019 179.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.991 HD13 HG22 ' A' ' 13' ' ' VAL . 0.1 OUTLIER -102.75 134.74 45.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.504 -0.748 . . . . 0.0 109.537 -179.842 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.517 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 1.9 tt0 -140.39 143.03 35.45 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.59 -0.694 . . . . 0.0 109.314 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 39.1 mtm -67.54 93.77 0.38 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.179 -0.951 . . . . 0.0 109.441 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.69 -18.91 4.81 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' GLN . . . . . 0.466 ' O ' HG23 ' A' ' 13' ' ' VAL . 11.6 mm-40 -79.7 124.86 28.96 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.328 -1.101 . . . . 0.0 109.637 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -106.27 117.78 34.94 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.257 -0.902 . . . . 0.0 109.109 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.455 HG21 HD11 ' A' ' 73' ' ' ILE . 33.8 m -118.98 151.76 50.85 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.134 -0.979 . . . . 0.0 109.836 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 56' ' ' VAL . 36.0 Cg_endo -78.87 142.57 17.72 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.695 2.264 . . . . 0.0 110.509 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.788 HG21 ' HB3' ' A' ' 71' ' ' LEU . 0.9 OUTLIER -141.67 -177.22 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.211 -0.931 . . . . 0.0 109.354 179.622 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.476 ' HG2' HG22 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -134.03 128.73 34.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.283 -0.886 . . . . 0.0 109.475 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.622 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 62.0 t . . . . . 0 N--CA 1.491 1.597 0 O-C-N 121.266 -0.896 . . . . 0.0 109.037 179.504 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.788 ' HB3' HG21 ' A' ' 58' ' ' VAL . 15.1 mt . . . . . 0 N--CA 1.489 1.493 0 N-CA-C 109.23 -0.655 . . . . 0.0 109.23 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -118.21 106.64 13.03 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.341 -0.849 . . . . 0.0 109.871 -179.618 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.477 HG22 ' O ' ' A' ' 38' ' ' ILE . 0.1 OUTLIER -58.77 139.12 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.269 -0.894 . . . . 0.0 109.001 179.865 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 2.4 mmtm . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.26 -0.9 . . . . 0.0 109.281 179.803 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.624 HG13 ' O ' ' A' ' 58' ' ' VAL . 48.1 t . . . . . 0 N--CA 1.489 1.486 0 N-CA-C 109.385 -0.598 . . . . 0.0 109.385 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.506 ' CE1' HG21 ' A' ' 60' ' ' VAL . 3.0 m-85 -110.31 179.92 3.95 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.156 -0.965 . . . . 0.0 109.392 179.775 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.473 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 3.5 m -136.65 107.58 6.68 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 178.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.507 ' HA2' ' O ' ' A' ' 24' ' ' ALA . . . -109.82 141.6 16.2 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.065 -1.541 . . . . 0.0 110.331 -178.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.455 ' O ' HG13 ' A' ' 23' ' ' VAL . 27.4 mtpt -89.15 163.73 15.32 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 178.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.968 HG22 HD23 ' A' ' 50' ' ' LEU . 95.3 t -87.43 102.02 11.94 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.725 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.2 p -106.12 -11.67 16.02 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.478 -0.764 . . . . 0.0 110.186 -178.62 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.562 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -161.2 156.33 24.07 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.954 -1.091 . . . . 0.0 110.455 -179.781 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.462 ' HA ' ' HA ' ' A' ' 21' ' ' ALA . 24.1 mt -147.61 142.77 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.161 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 1.086 HG21 ' CE1' ' A' ' 19' ' ' PHE . 1.5 m -120.79 157.82 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.898 -1.126 . . . . 0.0 110.186 -178.771 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.2 -39.41 86.46 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.807 -1.183 . . . . 0.0 109.459 179.097 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 1.086 ' CE1' HG21 ' A' ' 17' ' ' VAL . 10.1 p90 -95.16 27.06 3.4 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.14 -0.975 . . . . 0.0 110.222 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.597 ' N ' HG22 ' A' ' 17' ' ' VAL . . . 158.29 -157.43 28.31 Favored Glycine 0 N--CA 1.49 2.244 0 C-N-CA 118.936 -1.602 . . . . 0.0 110.802 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.778 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -149.23 145.4 27.1 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.215 -1.168 . . . . 0.0 109.154 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.965 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.3 m-30 -106.5 158.4 16.94 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.467 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.798 ' CG2' HG23 ' A' ' 33' ' ' VAL . 32.3 t -148.87 164.95 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.067 -1.02 . . . . 0.0 109.533 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.725 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -133.76 152.93 52.01 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.032 -1.043 . . . . 0.0 109.998 -179.478 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.667 HD11 ' HB3' ' A' ' 29' ' ' LYS . 2.0 pt . . . . . 0 N--CA 1.494 1.74 0 O-C-N 120.666 -1.271 . . . . 0.0 109.429 179.362 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.667 ' HB3' HD11 ' A' ' 25' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.464 0 CA-C-O 121.716 0.77 . . . . 0.0 109.8 . . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.59 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 13.8 mt-10 -134.6 154.08 51.66 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.925 -1.109 . . . . 0.0 110.222 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.67 ' CA ' HD12 ' A' ' 71' ' ' LEU . . . -101.06 -175.99 29.12 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 108.478 -1.849 . . . . 0.0 108.478 179.307 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.965 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.17 119.31 6.76 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.979 -1.306 . . . . 0.0 110.73 179.429 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 1.021 HG21 HD11 ' A' ' 50' ' ' LEU . 41.3 t -95.93 62.21 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 177.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.519 ' O ' ' CD1' ' A' ' 38' ' ' ILE . 3.9 t-160 -49.37 160.12 0.27 Allowed 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.898 -1.127 . . . . 0.0 108.46 -179.49 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.593 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.9 tp -52.2 -49.58 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.236 -0.915 . . . . 0.0 110.286 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.557 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.4 OUTLIER -81.28 41.34 0.6 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.16 -0.963 . . . . 0.0 110.582 -179.331 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.732 ' C ' HD12 ' A' ' 38' ' ' ILE . 30.7 mt-30 -150.65 33.38 0.62 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.766 -1.209 . . . . 0.0 110.42 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.759 ' HB ' HG21 ' A' ' 43' ' ' VAL . 1.5 mp -108.72 -96.29 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.815 -1.178 . . . . 0.0 110.157 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.667 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.3 -1.55 0 O-C-N 121.361 -0.837 . . . . 0.0 110.326 -178.922 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.041 HG13 ' CD1' ' A' ' 49' ' ' TYR . 5.5 t . . . . . 0 N--CA 1.491 1.621 0 CA-C-O 121.15 0.5 . . . . 0.0 110.245 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.406 ' C ' ' O ' ' A' ' 43' ' ' VAL . 2.3 mp0 -47.85 -26.01 1.5 Allowed 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 178.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.456 ' HB2' ' CG ' ' A' ' 48' ' ' ASP . 0.1 OUTLIER -127.86 124.65 38.04 Favored 'General case' 0 N--CA 1.487 1.375 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.453 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.568 HG21 ' O ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -70.23 -25.74 28.02 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.355 -0.841 . . . . 0.0 109.119 -179.507 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 3.4 p -75.43 5.28 5.98 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.431 -0.793 . . . . 0.0 109.878 179.598 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.456 ' CG ' ' HB2' ' A' ' 45' ' ' LYS . 12.5 m-20 -101.14 -34.7 9.59 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.008 -1.057 . . . . 0.0 108.677 179.534 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 1.041 ' CD1' HG13 ' A' ' 43' ' ' VAL . 6.3 m-85 -89.51 -34.07 16.53 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.524 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 1.021 HD11 HG21 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -102.57 154.4 19.16 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.173 -1.011 . . . . 0.0 110.366 179.783 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.465 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.6 OUTLIER -142.95 133.83 25.47 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.487 -0.758 . . . . 0.0 109.13 179.982 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 3.9 mtt -63.99 100.44 0.31 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.258 -0.901 . . . . 0.0 109.847 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 129.97 -24.84 4.47 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' GLN . . . . . 0.409 ' HA ' ' OE1' ' A' ' 54' ' ' GLN . 13.2 mm100 -78.87 158.48 28.1 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.232 -1.158 . . . . 0.0 109.786 -179.785 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -110.61 111.66 23.04 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.328 -0.857 . . . . 0.0 109.026 179.576 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.626 ' O ' HG23 ' A' ' 56' ' ' VAL . 6.8 m -103.24 121.99 46.84 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.184 -0.947 . . . . 0.0 110.108 -179.424 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.473 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.5 Cg_endo -80.84 146.71 16.61 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 C-N-CA 122.559 2.173 . . . . 0.0 110.077 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.838 HG21 ' HB3' ' A' ' 71' ' ' LEU . 1.0 OUTLIER -140.01 -168.77 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.06 -1.025 . . . . 0.0 109.655 -179.994 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.593 ' N ' HG23 ' A' ' 58' ' ' VAL . 14.9 mtpt -131.23 119.61 22.06 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.401 -0.812 . . . . 0.0 109.493 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.608 ' HA ' HD23 ' A' ' 71' ' ' LEU . 95.9 t . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.418 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.838 ' HB3' HG21 ' A' ' 58' ' ' VAL . 96.5 mt . . . . . 0 N--CA 1.491 1.578 0 CA-C-O 121.459 0.647 . . . . 0.0 110.043 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -117.16 113.55 22.41 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.508 -0.745 . . . . 0.0 109.571 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.423 HG13 HG13 ' A' ' 33' ' ' VAL . 0.6 OUTLIER -47.56 122.81 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.349 -0.844 . . . . 0.0 109.264 179.927 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.467 ' HB3' ' O ' ' A' ' 57' ' ' PRO . 4.2 ttpp . . . . . 0 N--CA 1.488 1.451 0 O-C-N 121.19 -0.944 . . . . 0.0 108.939 179.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.567 HG13 ' O ' ' A' ' 58' ' ' VAL . 54.9 t . . . . . 0 N--CA 1.489 1.48 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.561 ' CE1' ' CG2' ' A' ' 60' ' ' VAL . 2.9 m-85 -106.52 -179.4 3.93 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.119 -0.988 . . . . 0.0 110.071 -178.731 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.8 m -129.04 105.52 8.25 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 178.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.434 ' HA2' ' O ' ' A' ' 24' ' ' ALA . . . -108.16 132.21 11.0 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 119.318 -1.42 . . . . 0.0 111.254 -177.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.474 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.3 OUTLIER -91.39 158.83 16.3 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 178.348 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.859 ' CG2' HD22 ' A' ' 50' ' ' LEU . 61.2 t -87.82 97.02 6.2 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 O-C-N 120.858 -1.151 . . . . 0.0 109.045 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.786 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -101.37 -5.78 24.93 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.527 -0.733 . . . . 0.0 109.817 -179.255 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.56 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -164.95 153.71 12.37 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.122 -0.986 . . . . 0.0 110.113 -179.693 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.681 HG21 HG22 ' A' ' 47' ' ' THR . 7.7 mt -141.58 152.92 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 178.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 1.013 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -132.33 151.27 34.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.903 -1.123 . . . . 0.0 109.907 -179.011 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -58.41 -38.78 78.09 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.735 -1.228 . . . . 0.0 108.835 179.203 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 1.013 ' CE1' HG21 ' A' ' 17' ' ' VAL . 23.3 p90 -92.57 30.13 1.59 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.504 -0.748 . . . . 0.0 109.943 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.595 ' C ' HG22 ' A' ' 17' ' ' VAL . . . 149.54 -150.99 23.16 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 119.114 -1.517 . . . . 0.0 111.219 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.819 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -152.58 144.9 23.98 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.094 -1.239 . . . . 0.0 109.158 -179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.965 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.3 m-30 -106.29 142.38 36.07 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.306 -0.872 . . . . 0.0 108.881 179.566 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.878 ' CG2' HG23 ' A' ' 33' ' ' VAL . 40.8 t -132.91 163.02 39.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 120.902 -1.124 . . . . 0.0 109.643 -179.444 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.786 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -130.15 153.24 48.73 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.103 -0.998 . . . . 0.0 109.65 -179.608 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.657 HD11 ' HB3' ' A' ' 29' ' ' LYS . 1.8 pt . . . . . 0 N--CA 1.492 1.645 0 O-C-N 120.984 -1.072 . . . . 0.0 109.417 179.825 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.657 ' HB3' HD11 ' A' ' 25' ' ' ILE . 16.5 mmtt . . . . . 0 N--CA 1.488 1.464 0 N-CA-C 109.261 -0.644 . . . . 0.0 109.261 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.512 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 1.2 mt-10 -136.81 150.75 48.51 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.973 -1.079 . . . . 0.0 110.102 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.496 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -102.33 -177.19 27.54 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 108.137 -1.985 . . . . 0.0 108.137 179.03 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.965 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -149.53 116.76 6.05 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.694 -1.474 . . . . 0.0 110.431 179.119 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.878 HG23 ' CG2' ' A' ' 23' ' ' VAL . 93.3 t -90.85 59.93 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 178.049 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.518 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.6 t-80 -48.73 157.28 0.39 Allowed 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.57 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.8 tp -47.19 -47.76 9.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.089 -1.007 . . . . 0.0 110.119 -179.207 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.472 ' N ' HG23 ' A' ' 35' ' ' ILE . 56.7 p -81.18 39.41 0.51 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.064 -1.023 . . . . 0.0 110.791 -179.463 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.98 ' C ' HD12 ' A' ' 38' ' ' ILE . 12.4 mt-30 -150.52 53.42 0.89 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.646 -1.283 . . . . 0.0 110.664 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.98 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.7 mp -126.25 -96.31 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.952 -1.093 . . . . 0.0 109.529 179.24 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.787 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.302 -1.469 0 O-C-N 121.411 -0.806 . . . . 0.0 109.195 -179.897 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.106 HG13 ' CD1' ' A' ' 49' ' ' TYR . 54.6 t . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 108.976 -0.749 . . . . 0.0 108.976 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.433 ' C ' ' O ' ' A' ' 43' ' ' VAL . 16.8 mt-10 -40.99 -28.05 0.07 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.558 -0.714 . . . . 0.0 110.314 -179.399 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.492 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.1 OUTLIER -142.63 138.51 30.76 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.961 -1.087 . . . . 0.0 110.206 -179.697 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.551 HG21 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -80.61 -26.47 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.356 -0.84 . . . . 0.0 108.845 179.514 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.681 HG22 HG21 ' A' ' 16' ' ' ILE . 47.3 p -78.47 5.12 11.45 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.317 -0.864 . . . . 0.0 109.023 179.056 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.466 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 4.1 m-20 -104.48 -30.76 9.83 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.328 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 1.106 ' CD1' HG13 ' A' ' 43' ' ' VAL . 17.8 m-85 -90.25 -33.98 15.94 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.859 HD22 ' CG2' ' A' ' 13' ' ' VAL . 3.5 mt -108.1 151.78 25.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.194 -0.941 . . . . 0.0 110.005 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.521 ' CB ' ' HG3' ' A' ' 54' ' ' GLN . 0.1 OUTLIER -136.93 138.52 40.72 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 179.033 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 23.4 mtt -62.6 91.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.003 -1.06 . . . . 0.0 109.839 -179.523 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 137.52 -22.59 3.17 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 119.732 -1.223 . . . . 0.0 110.388 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' GLN . . . . . 0.521 ' HG3' ' CB ' ' A' ' 51' ' ' GLN . 6.5 mm-40 -77.28 145.29 37.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.055 -1.262 . . . . 0.0 110.074 -179.377 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -113.19 127.26 56.13 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.475 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.438 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 15.9 m -132.45 142.37 44.66 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.02 -1.05 . . . . 0.0 110.032 -179.524 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.454 ' O ' ' HB2' ' A' ' 74' ' ' LYS . 36.9 Cg_endo -80.27 129.42 7.66 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.665 2.244 . . . . 0.0 110.335 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.865 HG21 ' HB3' ' A' ' 71' ' ' LEU . 0.8 OUTLIER -120.6 -170.5 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.19 -0.944 . . . . 0.0 109.317 179.753 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.631 ' N ' HG23 ' A' ' 58' ' ' VAL . 0.1 OUTLIER -132.12 141.83 49.28 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.257 -0.902 . . . . 0.0 109.319 179.883 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.561 ' CG2' ' CE1' ' A' ' 9' ' ' TYR . 26.5 t . . . . . 0 N--CA 1.492 1.645 0 O-C-N 121.449 -0.782 . . . . 0.0 109.139 179.884 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.865 ' HB3' HG21 ' A' ' 58' ' ' VAL . 17.5 mt . . . . . 0 N--CA 1.489 1.51 0 N-CA-C 108.78 -0.822 . . . . 0.0 108.78 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.442 ' C ' ' HB ' ' A' ' 58' ' ' VAL . 0.6 OUTLIER -134.11 117.14 16.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.105 -0.997 . . . . 0.0 110.302 -179.262 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.431 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.1 OUTLIER -44.07 131.89 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.299 -0.876 . . . . 0.0 108.962 179.691 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.454 ' HB2' ' O ' ' A' ' 57' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.602 0 O-C-N 121.215 -0.928 . . . . 0.0 110.137 -179.374 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.945 HG13 ' O ' ' A' ' 58' ' ' VAL . 93.5 t . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.369 -0.604 . . . . 0.0 109.369 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.482 ' CE1' HG23 ' A' ' 60' ' ' VAL . 9.2 m-85 -118.69 -168.19 1.5 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.302 -0.874 . . . . 0.0 109.758 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.534 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 34.3 m -166.21 127.81 1.83 Allowed 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.443 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.5 ' HA3' ' O ' ' A' ' 24' ' ' ALA . . . -149.53 -177.84 23.97 Favored Glycine 0 N--CA 1.489 2.202 0 C-N-CA 118.44 -1.838 . . . . 0.0 111.266 -178.636 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.543 ' O ' HG13 ' A' ' 23' ' ' VAL . 15.6 mtpt -104.45 168.27 9.2 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.808 -0.819 . . . . 0.0 108.929 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.926 HG22 HD13 ' A' ' 50' ' ' LEU . 72.4 t -87.98 101.37 11.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 O-C-N 121.156 -0.965 . . . . 0.0 108.423 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.665 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.1 p -111.11 11.12 21.96 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.275 -0.89 . . . . 0.0 110.286 -178.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.555 ' HB3' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -175.29 147.01 0.86 Allowed 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.956 -1.09 . . . . 0.0 110.255 179.75 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.4 HG21 HG22 ' A' ' 47' ' ' THR . 17.2 mt -139.28 151.71 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.068 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 1.054 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -129.61 154.05 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.765 -1.209 . . . . 0.0 110.088 -179.089 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -59.13 -41.7 88.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.866 -1.147 . . . . 0.0 109.327 179.173 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 1.054 ' CE1' HG21 ' A' ' 17' ' ' VAL . 14.0 p90 -91.3 27.14 2.0 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.313 -0.867 . . . . 0.0 110.22 -179.716 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.606 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 155.22 -153.58 24.88 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.898 -1.62 . . . . 0.0 111.063 -179.365 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.792 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -150.33 144.71 25.69 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.063 -1.257 . . . . 0.0 109.007 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.959 ' CE1' HD11 ' A' ' 32' ' ' LEU . 11.1 m-30 -108.41 162.11 14.41 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.401 -0.812 . . . . 0.0 109.214 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.571 ' CG2' HG23 ' A' ' 33' ' ' VAL . 3.5 t -150.63 166.81 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.166 -0.958 . . . . 0.0 109.433 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.665 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -132.79 145.24 50.83 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.209 -0.932 . . . . 0.0 108.856 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.985 HD11 ' HB2' ' A' ' 29' ' ' LYS . 7.7 pt . . . . . 0 N--CA 1.496 1.84 0 O-C-N 120.547 -1.346 . . . . 0.0 109.653 -179.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.985 ' HB2' HD11 ' A' ' 25' ' ' ILE . 5.8 mmtm . . . . . 0 N--CA 1.49 1.529 0 CA-C-O 121.774 0.797 . . . . 0.0 109.68 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.553 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 7.3 pt-20 -128.01 157.47 40.55 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 120.867 -1.146 . . . . 0.0 110.474 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.812 ' CA ' HD12 ' A' ' 71' ' ' LEU . . . -105.83 -175.79 23.83 Favored Glycine 0 N--CA 1.487 2.042 0 N-CA-C 108.337 -1.905 . . . . 0.0 108.337 179.298 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.959 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.79 121.29 7.4 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 120.746 -1.444 . . . . 0.0 111.542 -179.794 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.792 ' HB ' ' HB3' ' A' ' 21' ' ' ALA . 26.0 t -95.86 62.9 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 176.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.475 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.7 t-160 -48.08 155.02 0.5 Allowed 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.885 -1.135 . . . . 0.0 108.883 -179.274 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.576 HG23 ' H ' ' A' ' 36' ' ' SER . 3.0 tp -45.84 -52.09 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.218 -0.926 . . . . 0.0 110.315 -179.431 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.576 ' H ' HG23 ' A' ' 35' ' ' ILE . 0.0 OUTLIER -81.52 42.96 0.71 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.294 -0.879 . . . . 0.0 110.524 -179.33 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.972 ' C ' HD12 ' A' ' 38' ' ' ILE . 68.3 mt-30 -150.83 53.38 0.87 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.859 -1.151 . . . . 0.0 110.036 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.972 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.7 mp -124.53 -96.01 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.926 -1.109 . . . . 0.0 110.376 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.797 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.3 -1.554 0 O-C-N 121.492 -0.755 . . . . 0.0 109.674 -178.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.031 HG13 ' CD1' ' A' ' 49' ' ' TYR . 60.2 t . . . . . 0 N--CA 1.486 1.36 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.433 ' C ' ' O ' ' A' ' 43' ' ' VAL . 3.6 mm-40 -45.06 -25.05 0.29 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.224 -0.922 . . . . 0.0 108.744 179.633 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.429 ' N ' ' C ' ' A' ' 43' ' ' VAL . 25.0 mmtp -119.66 122.7 42.09 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.537 -0.727 . . . . 0.0 109.157 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.606 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -78.98 -24.54 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.271 -0.893 . . . . 0.0 108.842 179.812 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.4 HG22 HG21 ' A' ' 16' ' ' ILE . 72.5 p -75.9 4.4 8.25 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.449 -0.782 . . . . 0.0 109.723 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -102.75 -38.16 7.57 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.135 -0.978 . . . . 0.0 109.183 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 1.031 ' CD1' HG13 ' A' ' 43' ' ' VAL . 9.9 m-85 -89.43 -33.55 16.78 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.349 -0.844 . . . . 0.0 109.104 179.669 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.926 HD13 HG22 ' A' ' 13' ' ' VAL . 0.1 OUTLIER -98.86 135.54 40.15 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.412 -0.805 . . . . 0.0 109.443 -179.793 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.479 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.0 OUTLIER -138.89 122.5 17.41 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.556 -0.715 . . . . 0.0 109.6 -179.84 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . 0.504 ' CG ' ' O ' ' A' ' 52' ' ' MET . 5.1 ptm -48.6 105.79 0.09 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.317 -0.864 . . . . 0.0 109.947 -179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 133.92 -43.55 1.26 Allowed Glycine 0 N--CA 1.492 2.398 0 C-N-CA 119.832 -1.175 . . . . 0.0 110.471 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' GLN . . . . . 0.424 ' O ' HG23 ' A' ' 13' ' ' VAL . 15.8 mt-30 -69.32 146.15 52.43 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.01 -1.288 . . . . 0.0 110.107 -179.399 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.51 ' HA ' ' HA ' ' A' ' 12' ' ' LYS . 0.4 OUTLIER -122.53 140.08 53.18 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.355 -0.841 . . . . 0.0 109.115 179.526 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.416 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 24.8 m -146.73 155.95 48.37 Favored Pre-proline 0 N--CA 1.487 1.424 0 O-C-N 121.164 -0.96 . . . . 0.0 110.052 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.534 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 37.2 Cg_endo -83.37 146.9 12.51 Favored 'Trans proline' 0 C--N 1.314 -1.261 0 C-N-CA 123.161 2.574 . . . . 0.0 110.428 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.945 ' O ' HG13 ' A' ' 8' ' ' VAL . 1.0 OUTLIER -141.29 -168.61 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.186 -0.946 . . . . 0.0 109.287 179.368 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.702 ' CG ' HG22 ' A' ' 8' ' ' VAL . 17.2 mtmt -134.3 134.14 41.54 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.385 -0.822 . . . . 0.0 109.779 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.486 ' O ' HG12 ' A' ' 60' ' ' VAL . 47.6 t . . . . . 0 N--CA 1.493 1.721 0 O-C-N 121.392 -0.818 . . . . 0.0 109.197 179.632 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.812 HD12 ' CA ' ' A' ' 31' ' ' GLY . 13.6 mt . . . . . 0 N--CA 1.487 1.376 0 CA-C-O 121.469 0.652 . . . . 0.0 109.607 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.423 ' O ' ' C ' ' A' ' 73' ' ' ILE . 0.3 OUTLIER -133.43 107.65 8.19 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.442 -0.786 . . . . 0.0 109.724 -179.636 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.423 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.0 OUTLIER -44.92 140.31 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.249 -0.907 . . . . 0.0 108.77 179.713 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.416 ' HD3' ' HB2' ' A' ' 57' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.634 0 O-C-N 121.15 -0.969 . . . . 0.0 109.424 179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.537 ' HA ' ' HA ' ' A' ' 59' ' ' LYS . 68.1 t . . . . . 0 N--CA 1.49 1.569 0 N-CA-C 109.448 -0.575 . . . . 0.0 109.448 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.626 ' CD1' HG23 ' A' ' 60' ' ' VAL . 14.0 m-85 -143.94 128.42 17.99 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.023 -1.048 . . . . 0.0 110.355 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -91.06 115.62 28.16 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 178.15 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -113.6 141.3 16.87 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 119.119 -1.515 . . . . 0.0 110.626 -178.362 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.516 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.8 OUTLIER -89.56 162.07 15.86 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 178.724 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.741 HG22 HD13 ' A' ' 50' ' ' LEU . 58.2 t -87.86 105.39 15.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 120.986 -1.072 . . . . 0.0 108.368 179.616 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.918 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -111.7 -0.8 15.89 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.262 -0.899 . . . . 0.0 110.218 -178.859 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.527 ' CD ' ' O ' ' A' ' 14' ' ' THR . 0.3 OUTLIER -168.05 152.42 6.34 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.902 -1.123 . . . . 0.0 110.314 179.97 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.441 ' HA ' ' HA ' ' A' ' 21' ' ' ALA . 56.6 mt -145.37 150.03 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 179.058 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 1.095 HG21 ' CE1' ' A' ' 19' ' ' PHE . 1.2 m -126.93 156.33 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 120.932 -1.105 . . . . 0.0 109.813 -179.076 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -60.37 -37.89 82.18 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.784 -1.197 . . . . 0.0 109.455 179.208 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 1.095 ' CE1' HG21 ' A' ' 17' ' ' VAL . 13.9 p90 -94.56 26.43 3.47 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.244 -0.91 . . . . 0.0 110.379 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.593 ' HA2' ' N ' ' A' ' 35' ' ' ILE . . . 155.54 -154.08 25.25 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.481 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.726 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -152.27 146.23 25.25 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.043 -1.269 . . . . 0.0 109.439 -179.558 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.957 ' CE1' HD11 ' A' ' 32' ' ' LEU . 12.4 m-30 -108.04 158.54 17.31 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.354 -0.842 . . . . 0.0 109.145 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.788 ' CG2' HG23 ' A' ' 33' ' ' VAL . 7.7 t -145.85 163.75 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.166 -0.959 . . . . 0.0 109.151 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.918 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -137.1 146.55 45.25 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.017 -1.052 . . . . 0.0 110.119 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.522 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.1 pt . . . . . 0 N--CA 1.494 1.735 0 O-C-N 120.779 -1.201 . . . . 0.0 108.667 178.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.522 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.489 1.512 0 CA-C-O 121.548 0.69 . . . . 0.0 109.514 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.573 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 3.5 pt-20 -134.68 153.4 52.01 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 120.847 -1.158 . . . . 0.0 110.224 -179.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -102.57 -173.51 27.0 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 108.504 -1.839 . . . . 0.0 108.504 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.957 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.31 119.02 6.55 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.993 -1.298 . . . . 0.0 110.692 179.514 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.83 HG12 HD11 ' A' ' 38' ' ' ILE . 8.4 t -96.59 63.56 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 177.588 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.551 ' HB3' ' CG ' ' A' ' 37' ' ' GLN . 4.4 t-80 -47.7 166.08 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.308 0 O-C-N 120.879 -1.138 . . . . 0.0 108.279 -179.594 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.662 ' HA ' HG13 ' A' ' 46' ' ' VAL . 0.2 OUTLIER -55.19 -55.33 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.136 -0.977 . . . . 0.0 110.296 -179.256 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.626 ' H ' HG23 ' A' ' 35' ' ' ILE . 92.6 p -82.31 42.57 0.75 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.018 -1.051 . . . . 0.0 110.334 -179.734 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.95 ' O ' HD13 ' A' ' 73' ' ' ILE . 20.8 mm-40 -145.27 44.46 1.32 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.938 -1.101 . . . . 0.0 109.598 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.925 HG21 ' CD2' ' A' ' 49' ' ' TYR . 1.8 mp -119.33 -91.66 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.253 -0.904 . . . . 0.0 108.978 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.825 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.298 -1.654 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 -179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.023 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 39.6 t . . . . . 0 N--CA 1.482 1.132 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 25.5 tp10 -46.49 -22.5 0.27 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.151 -0.968 . . . . 0.0 109.244 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.539 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 28.9 mttp -119.68 109.12 15.27 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.386 -0.821 . . . . 0.0 109.246 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.662 HG13 ' HA ' ' A' ' 35' ' ' ILE . 0.0 OUTLIER -77.52 -22.87 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.232 -0.918 . . . . 0.0 108.781 179.842 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 18.6 p -76.99 2.57 14.48 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.449 -0.782 . . . . 0.0 109.216 179.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.404 ' OD2' ' HD2' ' A' ' 45' ' ' LYS . 1.7 m-20 -101.42 -33.68 9.89 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.1 -1.0 . . . . 0.0 109.264 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 1.023 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 6.6 m-85 -94.98 -30.78 13.94 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.575 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.741 HD13 HG22 ' A' ' 13' ' ' VAL . 0.2 OUTLIER -105.61 140.73 38.24 Favored 'General case' 0 N--CA 1.488 1.454 0 CA-C-O 121.536 0.684 . . . . 0.0 109.35 -179.731 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.511 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 2.0 tm0? -148.61 124.38 10.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.462 -0.774 . . . . 0.0 109.301 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 56.8 mtp -48.8 112.65 0.64 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.288 -0.883 . . . . 0.0 109.924 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 113.11 -44.85 1.42 Allowed Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' GLN . . . . . 0.539 ' O ' HG23 ' A' ' 13' ' ' VAL . 15.5 mm100 -56.92 102.96 0.09 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.147 -1.208 . . . . 0.0 109.586 -179.727 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -65.18 137.14 57.43 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.188 -0.945 . . . . 0.0 109.125 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.7 m -135.48 132.13 19.7 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.229 -0.919 . . . . 0.0 109.841 -179.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.414 ' HG2' ' HG3' ' A' ' 74' ' ' LYS . 36.4 Cg_endo -79.96 142.63 15.72 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.461 2.107 . . . . 0.0 110.129 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.892 ' CG2' HD12 ' A' ' 71' ' ' LEU . 0.9 OUTLIER -141.43 -173.74 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.232 -0.917 . . . . 0.0 109.246 179.665 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.571 ' N ' HG23 ' A' ' 58' ' ' VAL . 9.0 mtmm -142.35 111.26 6.33 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.295 -0.878 . . . . 0.0 110.248 -179.71 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.626 HG23 ' CD1' ' A' ' 9' ' ' TYR . 61.5 t . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.857 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.892 HD12 ' CG2' ' A' ' 58' ' ' VAL . 0.3 OUTLIER . . . . . 0 N--CA 1.489 1.517 0 N-CA-C 109.366 -0.605 . . . . 0.0 109.366 . . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.427 ' HB2' ' O ' ' A' ' 59' ' ' LYS . 0.6 OUTLIER -109.85 111.71 23.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.197 -0.94 . . . . 0.0 110.219 -179.231 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.95 HD13 ' O ' ' A' ' 37' ' ' GLN . 1.2 mp -56.96 128.21 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.181 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.441 ' C ' ' O ' ' A' ' 73' ' ' ILE . 0.6 OUTLIER . . . . . 0 N--CA 1.494 1.751 0 O-C-N 121.357 -0.84 . . . . 0.0 110.351 -179.136 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.8 t . . . . . 0 N--CA 1.489 1.491 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.673 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 4.6 m-85 -122.28 133.21 54.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.043 -1.035 . . . . 0.0 109.998 -179.598 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.3 m -83.87 103.29 13.02 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.546 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.31 119.82 5.11 Favored Glycine 0 N--CA 1.487 2.056 0 C-N-CA 119.884 -1.151 . . . . 0.0 110.737 -178.495 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.604 ' O ' HG13 ' A' ' 23' ' ' VAL . 2.0 mtmt -89.29 148.46 23.55 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 178.77 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.646 HG22 ' CD2' ' A' ' 50' ' ' LEU . 3.8 t -86.85 117.6 31.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 O-C-N 120.597 -1.314 . . . . 0.0 108.656 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.952 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.5 p -128.16 -3.41 5.67 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.419 -0.801 . . . . 0.0 109.933 -178.596 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.535 ' HG3' ' HB3' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -173.77 150.57 1.71 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.128 -0.982 . . . . 0.0 109.872 179.396 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.502 HG22 ' N ' ' A' ' 17' ' ' VAL . 18.0 mt -136.31 161.49 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.374 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 1.055 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -139.97 153.34 22.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 120.59 -1.319 . . . . 0.0 110.623 -179.009 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -59.22 -41.19 88.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.766 -1.209 . . . . 0.0 109.376 179.093 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 1.055 ' CE1' HG21 ' A' ' 17' ' ' VAL . 14.3 p90 -90.99 28.42 1.58 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.356 -0.84 . . . . 0.0 110.096 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.797 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 149.7 -149.28 21.2 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.08 -1.533 . . . . 0.0 110.834 -179.717 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 1.047 ' HB1' HD12 ' A' ' 50' ' ' LEU . . . -153.64 147.79 25.73 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 120.967 -1.313 . . . . 0.0 109.263 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.972 ' CE1' HD11 ' A' ' 32' ' ' LEU . 11.9 m-30 -106.7 158.35 17.03 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.4 -0.813 . . . . 0.0 109.083 179.641 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.757 ' CG2' HG23 ' A' ' 33' ' ' VAL . 15.6 t -150.12 162.11 4.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.291 -0.881 . . . . 0.0 109.185 -179.464 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.952 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -133.57 136.5 44.97 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.147 -0.97 . . . . 0.0 109.494 -179.631 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.49 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.7 pt . . . . . 0 N--CA 1.492 1.671 0 O-C-N 120.917 -1.115 . . . . 0.0 109.47 179.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.49 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.6 OUTLIER . . . . . 0 N--CA 1.49 1.538 0 CA-C-O 121.423 0.63 . . . . 0.0 109.501 . . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.56 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -120.49 149.83 41.78 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.804 -1.185 . . . . 0.0 110.46 -179.57 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.725 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -102.69 -178.1 26.99 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.198 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.972 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -148.56 119.79 7.8 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.863 -1.375 . . . . 0.0 110.67 179.744 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.778 ' HB ' ' HB3' ' A' ' 21' ' ' ALA . 59.4 t -94.4 62.26 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 177.776 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.457 ' HB2' HD23 ' A' ' 32' ' ' LEU . 4.0 t-80 -50.16 159.39 0.45 Allowed 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.888 -1.132 . . . . 0.0 108.637 -179.53 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.582 HG23 ' H ' ' A' ' 36' ' ' SER . 1.6 tp -48.53 -52.94 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.169 -0.957 . . . . 0.0 110.342 -179.614 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.582 ' H ' HG23 ' A' ' 35' ' ' ILE . 1.9 t -81.84 44.85 0.86 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.12 -0.987 . . . . 0.0 110.536 -179.448 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.778 ' C ' HD12 ' A' ' 38' ' ' ILE . 46.8 mt-30 -150.36 37.03 0.67 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.783 -1.198 . . . . 0.0 109.88 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.887 HG21 ' CD2' ' A' ' 49' ' ' TYR . 1.8 mp -114.77 -96.69 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.932 -1.105 . . . . 0.0 110.285 -179.58 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.772 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.301 -1.512 0 O-C-N 121.447 -0.783 . . . . 0.0 109.43 -179.17 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.113 HG13 ' CD1' ' A' ' 49' ' ' TYR . 59.1 t . . . . . 0 N--CA 1.494 1.728 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.446 ' C ' ' O ' ' A' ' 43' ' ' VAL . 20.9 tp10 -38.57 -29.27 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.569 -0.707 . . . . 0.0 110.538 -179.264 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.487 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 3.5 mttm -133.03 132.37 41.75 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.915 -1.115 . . . . 0.0 109.978 -179.552 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.797 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -79.65 -25.74 12.35 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 179.18 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 10.5 p -77.2 4.45 10.44 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.653 -0.654 . . . . 0.0 109.355 179.325 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.487 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 2.8 m-20 -106.53 -30.16 9.22 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.147 -0.97 . . . . 0.0 108.621 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 1.113 ' CD1' HG13 ' A' ' 43' ' ' VAL . 19.0 m-85 -92.14 -30.91 15.71 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.576 -0.703 . . . . 0.0 109.264 179.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 1.047 HD12 ' HB1' ' A' ' 21' ' ' ALA . 0.6 OUTLIER -106.08 143.48 34.15 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.633 179.857 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.515 ' O ' ' CB ' ' A' ' 13' ' ' VAL . 4.1 tt0 -130.69 129.69 42.92 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.273 -0.892 . . . . 0.0 108.999 179.455 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 10.2 mtt -63.57 118.33 8.04 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.142 -0.973 . . . . 0.0 109.674 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 105.12 -23.05 31.66 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' GLN . . . . . 0.499 ' CG ' ' HB3' ' A' ' 51' ' ' GLN . 4.9 mt-30 -73.31 -172.61 1.17 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.23 -1.159 . . . . 0.0 109.647 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.463 ' HG2' ' HA ' ' A' ' 12' ' ' LYS . 5.6 mt-10 -156.76 128.75 7.29 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.214 -0.929 . . . . 0.0 109.518 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.411 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 14.6 m -128.5 145.63 56.71 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.223 -0.923 . . . . 0.0 109.721 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 56' ' ' VAL . 36.3 Cg_endo -79.79 139.93 14.28 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.644 2.229 . . . . 0.0 110.155 179.718 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.818 ' CG2' HD22 ' A' ' 71' ' ' LEU . 1.0 OUTLIER -142.49 -177.96 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.162 -0.961 . . . . 0.0 109.777 -179.844 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.418 ' N ' HG23 ' A' ' 58' ' ' VAL . 5.3 mttm -127.0 116.52 20.88 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.443 -0.786 . . . . 0.0 109.465 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.673 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 13.6 t . . . . . 0 C--N 1.302 -1.459 0 O-C-N 121.166 -0.959 . . . . 0.0 109.353 179.704 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.818 HD22 ' CG2' ' A' ' 58' ' ' VAL . 12.0 mt . . . . . 0 N--CA 1.486 1.361 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.25 90.01 3.17 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.199 -0.938 . . . . 0.0 110.071 -179.333 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -50.27 133.23 10.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.328 -0.858 . . . . 0.0 108.983 179.752 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 4.1 tttp . . . . . 0 N--CA 1.492 1.661 0 O-C-N 121.232 -0.918 . . . . 0.0 109.33 -179.932 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.6 t . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.465 -0.569 . . . . 0.0 109.465 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.637 ' CE1' ' CG2' ' A' ' 60' ' ' VAL . 10.3 m-85 -119.53 -177.24 3.33 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.142 -0.974 . . . . 0.0 109.975 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.58 111.86 6.29 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 178.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -125.09 153.34 17.94 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.009 -1.567 . . . . 0.0 110.809 -178.224 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.495 ' O ' HG13 ' A' ' 23' ' ' VAL . 16.1 mttm -95.93 166.07 11.96 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 178.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.081 HG22 HD13 ' A' ' 50' ' ' LEU . 79.3 t -88.46 105.23 15.45 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 121.062 -1.023 . . . . 0.0 108.323 179.404 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.53 ' O ' ' CD ' ' A' ' 15' ' ' ARG . 1.7 p -117.57 6.27 12.48 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.269 -0.895 . . . . 0.0 110.077 -179.014 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.53 ' CD ' ' O ' ' A' ' 14' ' ' THR . 0.0 OUTLIER -169.69 149.25 3.8 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.08 -1.013 . . . . 0.0 109.935 179.867 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.494 HG22 ' N ' ' A' ' 17' ' ' VAL . 19.5 mt -141.99 163.49 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 179.479 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 1.045 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -143.48 153.41 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.8 -1.188 . . . . 0.0 110.205 -179.43 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -58.21 -42.7 86.8 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.784 -1.198 . . . . 0.0 109.324 179.276 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 1.045 ' CE1' HG21 ' A' ' 17' ' ' VAL . 12.1 p90 -90.61 29.42 1.31 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.217 -0.927 . . . . 0.0 110.351 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.56 ' HA2' ' N ' ' A' ' 35' ' ' ILE . . . 150.47 -152.08 24.01 Favored Glycine 0 N--CA 1.494 2.54 0 C-N-CA 119.102 -1.523 . . . . 0.0 110.936 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.711 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -152.78 148.81 27.66 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.992 -1.299 . . . . 0.0 108.979 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.959 ' CE1' HD11 ' A' ' 32' ' ' LEU . 11.1 m-30 -107.81 163.81 12.79 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.345 -0.847 . . . . 0.0 108.753 179.571 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.938 ' CG2' HG23 ' A' ' 33' ' ' VAL . 22.7 t -149.5 165.49 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.093 -1.004 . . . . 0.0 109.204 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.591 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -132.42 141.44 48.86 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.057 -1.027 . . . . 0.0 110.592 -179.108 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.518 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.1 pt . . . . . 0 N--CA 1.491 1.585 0 O-C-N 121.079 -1.013 . . . . 0.0 108.81 179.083 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.518 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.3 OUTLIER . . . . . 0 N--CA 1.491 1.584 0 CA-C-O 121.4 0.619 . . . . 0.0 109.625 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.591 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 1.4 pp20? -133.14 149.42 52.08 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 120.924 -1.11 . . . . 0.0 110.328 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.618 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -98.08 -172.68 32.79 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 108.251 -1.939 . . . . 0.0 108.251 179.194 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.959 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.65 119.76 6.74 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 120.842 -1.387 . . . . 0.0 111.047 179.737 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.938 HG23 ' CG2' ' A' ' 23' ' ' VAL . 49.3 t -95.47 61.3 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.32 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.507 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.6 t-80 -49.11 160.82 0.18 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.846 -1.159 . . . . 0.0 108.331 -179.373 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.56 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.6 tp -52.96 -41.29 40.11 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 121.029 -1.045 . . . . 0.0 109.986 -179.731 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.485 ' O ' ' HG2' ' A' ' 37' ' ' GLN . 49.9 m -81.59 30.29 0.36 Allowed 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.086 -1.009 . . . . 0.0 110.922 -179.425 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.968 ' C ' HD12 ' A' ' 38' ' ' ILE . 6.3 mt-30 -149.22 65.32 1.02 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.653 -1.28 . . . . 0.0 110.174 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.989 HG12 HG11 ' A' ' 43' ' ' VAL . 1.6 mp -123.54 -99.37 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 120.87 -1.144 . . . . 0.0 109.843 179.489 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.781 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.302 -1.476 0 O-C-N 121.16 -0.962 . . . . 0.0 109.33 -179.544 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.066 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 72.4 t . . . . . 0 N--CA 1.494 1.739 0 N-CA-C 108.874 -0.787 . . . . 0.0 108.874 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 29.4 mp0 -45.01 -31.0 1.15 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.344 -0.847 . . . . 0.0 109.397 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.504 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 0.3 OUTLIER -112.17 114.78 27.79 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.202 -0.936 . . . . 0.0 109.386 179.873 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.555 HG21 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -73.18 -22.66 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.746 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 3.0 p -77.31 4.41 10.76 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.535 -0.728 . . . . 0.0 109.387 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.504 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 2.4 m-20 -103.93 -29.89 10.66 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.156 -0.965 . . . . 0.0 108.75 179.566 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 1.066 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 32.3 m-85 -96.49 -30.11 13.52 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.616 -0.678 . . . . 0.0 109.337 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 1.081 HD13 HG22 ' A' ' 13' ' ' VAL . 0.1 OUTLIER -104.07 133.98 48.1 Favored 'General case' 0 N--CA 1.489 1.497 0 CA-C-O 121.816 0.817 . . . . 0.0 109.774 -179.695 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.497 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.0 OUTLIER -136.21 123.49 21.85 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.912 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . 0.426 ' HA ' ' O ' ' A' ' 13' ' ' VAL . 3.1 mtt -52.44 110.01 0.45 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.18 -0.95 . . . . 0.0 110.772 -179.189 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 122.54 -9.87 9.25 Favored Glycine 0 N--CA 1.496 2.648 0 C-N-CA 119.894 -1.146 . . . . 0.0 110.606 178.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -80.96 175.66 10.5 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.146 -1.208 . . . . 0.0 110.174 -179.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -142.72 117.72 10.01 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.3 m -135.95 145.42 52.54 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 120.993 -1.067 . . . . 0.0 110.635 -179.207 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.487 ' HG2' ' CD ' ' A' ' 74' ' ' LYS . 37.2 Cg_endo -82.98 155.64 15.07 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 C-N-CA 122.873 2.382 . . . . 0.0 109.486 178.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.995 HG21 ' HB3' ' A' ' 71' ' ' LEU . 1.2 m -150.48 -173.74 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.823 -1.173 . . . . 0.0 110.206 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.437 ' N ' HG23 ' A' ' 58' ' ' VAL . 0.3 OUTLIER -123.18 129.2 51.09 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 179.628 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.637 ' CG2' ' CE1' ' A' ' 9' ' ' TYR . 89.0 t . . . . . 0 N--CA 1.49 1.534 0 O-C-N 121.27 -0.894 . . . . 0.0 110.071 -179.375 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.995 ' HB3' HG21 ' A' ' 58' ' ' VAL . 12.6 mt . . . . . 0 N--CA 1.488 1.434 0 N-CA-C 109.057 -0.72 . . . . 0.0 109.057 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.478 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.4 OUTLIER -115.79 109.61 17.9 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.301 -0.875 . . . . 0.0 109.781 -179.572 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.603 HG22 ' O ' ' A' ' 38' ' ' ILE . 0.1 OUTLIER -42.4 126.32 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.364 -0.835 . . . . 0.0 108.925 179.918 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.487 ' CD ' ' HG2' ' A' ' 57' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.444 0 O-C-N 121.167 -0.958 . . . . 0.0 109.46 -179.66 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.513 HG13 ' O ' ' A' ' 58' ' ' VAL . 72.9 t . . . . . 0 N--CA 1.491 1.603 0 N-CA-C 109.368 -0.605 . . . . 0.0 109.368 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.594 ' CE1' ' CG2' ' A' ' 60' ' ' VAL . 14.7 m-85 -133.96 -171.56 2.77 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.033 -1.042 . . . . 0.0 110.225 -179.62 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.453 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 24.8 m -159.29 120.45 3.26 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 179.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.524 ' CA ' ' O ' ' A' ' 24' ' ' ALA . . . -131.92 164.59 23.66 Favored Glycine 0 N--CA 1.49 2.27 0 C-N-CA 118.759 -1.686 . . . . 0.0 111.077 -178.323 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.564 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.3 OUTLIER -101.76 168.37 9.49 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.385 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.569 HG23 ' O ' ' A' ' 54' ' ' GLN . 96.0 t -88.01 99.34 8.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.656 0 O-C-N 120.719 -1.238 . . . . 0.0 108.475 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.778 HG21 ' CB ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -105.24 -3.1 23.27 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.351 -0.843 . . . . 0.0 110.191 -178.8 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.57 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 1.8 mpp_? -165.82 155.44 12.28 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.946 -1.096 . . . . 0.0 110.19 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.519 HG21 HG22 ' A' ' 47' ' ' THR . 21.3 mt -144.43 157.89 15.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 179.575 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 1.039 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -140.09 155.85 24.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 120.664 -1.273 . . . . 0.0 110.196 -178.995 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -60.69 -41.21 94.68 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.63 -1.294 . . . . 0.0 109.456 179.472 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 1.039 ' CE1' HG21 ' A' ' 17' ' ' VAL . 12.4 p90 -89.73 24.61 2.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.186 -0.947 . . . . 0.0 110.039 -179.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.805 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 154.76 -149.07 20.27 Favored Glycine 0 N--CA 1.493 2.445 0 C-N-CA 119.166 -1.492 . . . . 0.0 110.958 -179.682 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.842 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -154.94 148.05 24.79 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.217 -1.166 . . . . 0.0 108.465 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.961 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.9 m-30 -108.75 160.88 15.61 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 179.693 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.564 HG13 ' O ' ' A' ' 12' ' ' LYS . 3.2 t -150.82 165.33 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.08 -1.012 . . . . 0.0 109.335 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.778 ' CB ' HG21 ' A' ' 14' ' ' THR . . . -127.08 150.46 49.46 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.066 -1.021 . . . . 0.0 109.864 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.512 HG13 ' O ' ' A' ' 29' ' ' LYS . 0.8 OUTLIER . . . . . 0 N--CA 1.493 1.704 0 O-C-N 121.102 -0.999 . . . . 0.0 109.397 179.646 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.512 ' O ' HG13 ' A' ' 25' ' ' ILE . 20.8 mmmt . . . . . 0 N--CA 1.49 1.547 0 CA-C-O 121.632 0.73 . . . . 0.0 109.319 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.541 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -129.7 151.95 49.73 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 120.887 -1.133 . . . . 0.0 110.448 -179.305 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.959 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -99.17 -174.53 31.57 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 179.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.961 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.23 121.81 8.0 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.764 -1.433 . . . . 0.0 111.46 179.946 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.957 HG13 ' CD1' ' A' ' 73' ' ' ILE . 52.7 t -94.44 62.37 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 177.274 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.494 ' CB ' ' OE1' ' A' ' 37' ' ' GLN . 3.3 t-80 -50.43 155.13 1.1 Allowed 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.862 -1.149 . . . . 0.0 108.804 -179.37 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.563 HG23 ' N ' ' A' ' 36' ' ' SER . 4.1 tp -46.64 -49.92 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.361 -0.837 . . . . 0.0 110.765 -179.528 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.563 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.0 OUTLIER -81.5 41.84 0.65 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.952 -1.093 . . . . 0.0 110.524 -179.434 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.995 ' C ' HD12 ' A' ' 38' ' ' ILE . 17.2 mt-30 -150.38 51.44 0.89 Allowed 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.875 -1.141 . . . . 0.0 110.016 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.995 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.7 mp -127.27 -96.5 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 120.935 -1.103 . . . . 0.0 110.312 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.794 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.496 0 O-C-N 121.563 -0.711 . . . . 0.0 109.899 -179.01 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.123 HG13 ' CD1' ' A' ' 49' ' ' TYR . 54.1 t . . . . . 0 N--CA 1.492 1.652 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 71.7 tt0 -45.26 -26.36 0.49 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.434 -0.791 . . . . 0.0 110.13 -179.295 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -131.54 131.64 43.53 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.067 -1.021 . . . . 0.0 109.991 -179.6 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.805 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -80.04 -26.2 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.992 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.519 HG22 HG21 ' A' ' 16' ' ' ILE . 7.3 p -80.36 6.58 11.72 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 178.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -105.3 -25.01 12.59 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 179.23 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 1.123 ' CD1' HG13 ' A' ' 43' ' ' VAL . 26.0 m-85 -97.57 -33.61 11.28 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 179.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.9 HD11 HG21 ' A' ' 33' ' ' VAL . 0.7 OUTLIER -104.38 143.08 33.48 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.198 -0.939 . . . . 0.0 109.449 179.292 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.503 ' HB3' ' HG3' ' A' ' 54' ' ' GLN . 1.3 tm0? -133.86 134.94 43.34 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 7.0 mtt -54.99 102.54 0.07 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.142 -0.973 . . . . 0.0 109.733 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 126.84 -38.09 2.25 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 119.784 -1.198 . . . . 0.0 110.186 179.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' GLN . . . . . 0.569 ' O ' HG23 ' A' ' 13' ' ' VAL . 19.3 mm-40 -59.58 128.95 39.58 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.24 -1.153 . . . . 0.0 110.056 -179.579 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.489 ' HA ' ' HA ' ' A' ' 12' ' ' LYS . 61.8 mt-10 -108.89 131.96 54.5 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.34 -0.85 . . . . 0.0 108.9 179.375 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 17.1 m -137.34 153.44 74.71 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.086 -1.009 . . . . 0.0 110.177 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.9 Cg_endo -79.69 155.89 24.2 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.937 2.425 . . . . 0.0 110.09 179.57 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.803 HG21 ' HB3' ' A' ' 71' ' ' LEU . 1.0 OUTLIER -147.94 -174.73 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.047 -1.033 . . . . 0.0 109.469 179.927 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.513 ' N ' HG23 ' A' ' 58' ' ' VAL . 1.7 mttp -136.38 119.97 17.12 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.452 -0.78 . . . . 0.0 109.384 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.594 ' CG2' ' CE1' ' A' ' 9' ' ' TYR . 60.8 t . . . . . 0 N--CA 1.492 1.654 0 O-C-N 121.303 -0.873 . . . . 0.0 109.281 179.824 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.959 HD12 ' HA3' ' A' ' 31' ' ' GLY . 23.5 mt . . . . . 0 N--CA 1.487 1.383 0 CA-C-O 121.357 0.599 . . . . 0.0 109.6 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.491 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.5 OUTLIER -100.38 123.5 44.68 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.39 -0.819 . . . . 0.0 109.737 -179.594 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.957 ' CD1' HG13 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -63.3 123.65 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.418 -0.801 . . . . 0.0 109.226 179.988 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.428 ' HD3' ' HB2' ' A' ' 57' ' ' PRO . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.925 . . . . 0.0 109.397 179.859 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.464 ' HA ' ' O ' ' A' ' 58' ' ' VAL . 78.8 t . . . . . 0 N--CA 1.489 1.482 0 CA-C-O 121.309 0.576 . . . . 0.0 109.801 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.464 ' CE1' ' CG2' ' A' ' 60' ' ' VAL . 5.1 m-85 -92.18 -168.74 2.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.325 -0.859 . . . . 0.0 109.148 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.545 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 21.3 m -151.48 115.85 5.07 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 178.69 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.536 ' CA ' ' O ' ' A' ' 24' ' ' ALA . . . -129.16 152.8 19.57 Favored Glycine 0 N--CA 1.487 2.035 0 C-N-CA 119.148 -1.501 . . . . 0.0 110.844 -178.57 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.49 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -93.61 167.7 11.5 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.006 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.745 HG13 HD23 ' A' ' 50' ' ' LEU . 58.4 t -88.35 106.28 16.43 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.754 0 C-N-CA 119.164 -1.014 . . . . 0.0 108.34 179.736 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.832 HG21 ' CB ' ' A' ' 24' ' ' ALA . 0.5 OUTLIER -111.07 -3.28 15.55 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.341 -0.85 . . . . 0.0 110.226 -178.577 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.548 ' CD ' ' OG1' ' A' ' 14' ' ' THR . 0.0 OUTLIER -173.45 150.73 1.86 Allowed 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.98 -1.075 . . . . 0.0 110.007 179.479 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.465 HG21 HG22 ' A' ' 47' ' ' THR . 13.1 mt -136.73 161.38 36.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.525 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 1.032 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.9 OUTLIER -138.65 153.89 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 120.653 -1.28 . . . . 0.0 110.225 -179.63 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -58.59 -43.69 89.61 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.771 -1.205 . . . . 0.0 109.495 179.196 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 1.032 ' CE1' HG21 ' A' ' 17' ' ' VAL . 11.6 p90 -89.98 27.9 1.49 Allowed 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.22 -0.925 . . . . 0.0 110.251 -179.54 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.677 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 153.67 -153.68 25.0 Favored Glycine 0 N--CA 1.492 2.375 0 C-N-CA 118.914 -1.613 . . . . 0.0 111.249 -179.731 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.761 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -151.75 147.69 26.99 Favored 'General case' 0 C--N 1.305 -1.349 0 O-C-N 121.109 -1.23 . . . . 0.0 109.056 -179.737 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.972 ' CE1' HD11 ' A' ' 32' ' ' LEU . 12.2 m-30 -108.25 160.12 16.09 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.694 ' CG2' HG23 ' A' ' 33' ' ' VAL . 24.0 t -150.41 166.58 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.06 -1.025 . . . . 0.0 109.666 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.832 ' CB ' HG21 ' A' ' 14' ' ' THR . . . -130.99 144.99 51.89 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.183 -0.948 . . . . 0.0 109.714 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.553 HD13 HD11 ' A' ' 71' ' ' LEU . 2.2 pt . . . . . 0 N--CA 1.494 1.731 0 O-C-N 120.906 -1.121 . . . . 0.0 109.399 179.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.488 ' O ' HG13 ' A' ' 25' ' ' ILE . 56.2 mmtt . . . . . 0 N--CA 1.488 1.471 0 N-CA-C 108.833 -0.803 . . . . 0.0 108.833 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.546 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 10.7 pt-20 -124.47 152.75 42.97 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 120.918 -1.114 . . . . 0.0 110.975 -179.35 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.87 ' CA ' HD12 ' A' ' 71' ' ' LEU . . . -100.72 -176.54 29.62 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 108.359 -1.896 . . . . 0.0 108.359 179.165 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.972 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.26 120.88 7.48 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.863 -1.375 . . . . 0.0 110.913 179.645 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.954 HG11 ' CD1' ' A' ' 50' ' ' LEU . 61.8 t -96.19 63.11 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 177.712 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.44 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.1 t-80 -50.45 156.62 0.84 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.837 -1.165 . . . . 0.0 108.623 -179.48 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.561 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.2 OUTLIER -46.65 -48.97 6.85 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.113 -0.992 . . . . 0.0 109.575 -179.793 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.537 ' N ' HG23 ' A' ' 35' ' ' ILE . 4.9 p -81.59 40.39 0.58 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.287 -0.883 . . . . 0.0 110.389 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.56 ' C ' HD12 ' A' ' 38' ' ' ILE . 71.4 mt-30 -148.93 30.63 0.79 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.714 -1.241 . . . . 0.0 110.069 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.824 HG21 ' CD2' ' A' ' 49' ' ' TYR . 1.8 mp -104.65 -96.32 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.016 -1.053 . . . . 0.0 109.602 179.68 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.792 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.3 -1.585 0 O-C-N 121.463 -0.773 . . . . 0.0 109.502 -179.588 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.064 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 87.4 t . . . . . 0 N--CA 1.49 1.571 0 N-CA-C 109.466 -0.568 . . . . 0.0 109.466 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.434 ' C ' ' O ' ' A' ' 43' ' ' VAL . 0.4 OUTLIER -45.33 -27.22 0.63 Allowed 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 179.568 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.446 ' HB3' ' CG ' ' A' ' 48' ' ' ASP . 0.0 OUTLIER -115.44 113.44 23.72 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 179.239 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.677 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -73.67 -25.35 20.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 -179.981 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.465 HG22 HG21 ' A' ' 16' ' ' ILE . 61.1 p -77.68 5.72 8.73 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.471 -0.768 . . . . 0.0 109.414 179.279 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.446 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 13.3 m-20 -101.29 -32.7 10.37 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 179.292 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 1.064 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 19.5 m-85 -90.43 -36.23 14.69 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 179.502 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.954 ' CD1' HG11 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -101.61 158.01 16.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.292 -0.88 . . . . 0.0 110.527 179.789 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.423 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 16.8 tp60 -149.35 127.6 12.11 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.503 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 5.6 mtt -59.69 111.82 1.58 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.124 -0.985 . . . . 0.0 110.19 -179.463 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 120.8 -25.43 7.19 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 119.874 -1.155 . . . . 0.0 110.383 179.301 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 9.6 mt-30 -74.95 177.09 6.57 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.082 -1.246 . . . . 0.0 110.323 -179.434 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.418 ' HA ' ' HA ' ' A' ' 12' ' ' LYS . 0.1 OUTLIER -139.13 126.53 21.59 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.76 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.2 m -138.01 144.98 45.97 Favored Pre-proline 0 N--CA 1.489 1.505 0 O-C-N 120.947 -1.096 . . . . 0.0 110.5 -179.293 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.545 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 37.1 Cg_endo -81.81 153.11 17.2 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 122.951 2.434 . . . . 0.0 110.117 179.418 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.806 HG21 ' HB3' ' A' ' 71' ' ' LEU . 0.8 OUTLIER -144.39 -168.86 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.1 -1.0 . . . . 0.0 109.344 179.457 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.651 ' N ' HG23 ' A' ' 58' ' ' VAL . 5.6 mttt -133.87 136.85 44.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.33 -0.856 . . . . 0.0 109.298 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.521 ' HA ' HD23 ' A' ' 71' ' ' LEU . 86.2 t . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.35 -0.844 . . . . 0.0 109.025 179.675 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.87 HD12 ' CA ' ' A' ' 31' ' ' GLY . 20.8 mt . . . . . 0 N--CA 1.489 1.516 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.445 ' O ' ' C ' ' A' ' 73' ' ' ILE . 2.1 m -125.73 117.01 22.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.289 -0.882 . . . . 0.0 109.744 -179.69 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.445 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.1 OUTLIER -44.22 136.91 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.274 -0.891 . . . . 0.0 108.785 179.68 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.444 ' CD ' ' HE3' ' A' ' 59' ' ' LYS . 0.1 OUTLIER . . . . . 0 N--CA 1.488 1.475 0 O-C-N 121.191 -0.943 . . . . 0.0 109.532 -179.714 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.686 HG22 ' HG2' ' A' ' 59' ' ' LYS . 40.8 t . . . . . 0 N--CA 1.491 1.583 0 N-CA-C 109.265 -0.643 . . . . 0.0 109.265 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.507 ' CE1' HG23 ' A' ' 60' ' ' VAL . 13.3 m-85 -116.64 -174.25 2.53 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.173 -0.954 . . . . 0.0 110.239 -179.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.468 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 5.5 m -155.89 111.77 3.05 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 179.258 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.434 ' CA ' ' O ' ' A' ' 24' ' ' ALA . . . -126.58 153.66 18.85 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 118.906 -1.616 . . . . 0.0 111.04 -178.095 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.5 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -89.71 164.12 14.82 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 179.128 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.705 ' CG2' HD22 ' A' ' 50' ' ' LEU . 99.4 t -88.08 95.96 5.56 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 O-C-N 120.753 -1.217 . . . . 0.0 108.336 179.703 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.743 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.1 p -96.53 -1.9 46.17 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.5 -0.75 . . . . 0.0 109.865 -178.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.544 ' CD ' ' OG1' ' A' ' 14' ' ' THR . 0.0 OUTLIER -173.37 143.21 1.06 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.174 -0.954 . . . . 0.0 109.687 179.982 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.792 HG21 HG22 ' A' ' 47' ' ' THR . 8.8 mt -131.56 159.16 43.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 179.323 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 1.005 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -135.44 153.83 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 120.634 -1.291 . . . . 0.0 110.42 -178.474 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -61.3 -39.69 91.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.569 -1.332 . . . . 0.0 109.376 179.416 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 1.005 ' CE1' HG21 ' A' ' 17' ' ' VAL . 15.5 p90 -90.86 23.42 3.15 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.364 -0.835 . . . . 0.0 110.107 -179.736 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.601 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 155.16 -152.28 23.81 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 119.214 -1.47 . . . . 0.0 110.822 -179.402 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.826 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -151.42 145.01 24.94 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 120.759 -1.436 . . . . 0.0 109.31 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.961 ' CE1' HD11 ' A' ' 32' ' ' LEU . 12.4 m-30 -107.18 156.78 18.46 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.5 HG13 ' O ' ' A' ' 12' ' ' LYS . 7.2 t -150.44 162.13 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.045 -1.035 . . . . 0.0 109.793 -179.533 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.743 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -128.17 144.49 51.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.283 -0.886 . . . . 0.0 109.06 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.602 HD11 ' HB3' ' A' ' 29' ' ' LYS . 1.8 pt . . . . . 0 N--CA 1.494 1.745 0 O-C-N 120.775 -1.203 . . . . 0.0 109.915 -179.794 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.602 ' HB3' HD11 ' A' ' 25' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.428 0 CA-C-O 121.653 0.739 . . . . 0.0 109.683 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.542 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 0.3 OUTLIER -128.44 149.11 50.71 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.937 -1.102 . . . . 0.0 110.092 -179.661 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -98.7 -178.3 32.3 Favored Glycine 0 N--CA 1.486 2.02 0 N-CA-C 108.216 -1.954 . . . . 0.0 108.216 179.106 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.961 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -148.87 116.53 6.24 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 120.827 -1.396 . . . . 0.0 110.541 179.604 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 1.07 HG21 HD11 ' A' ' 50' ' ' LEU . 91.9 t -89.95 59.35 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 177.75 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.509 ' HB2' HD23 ' A' ' 32' ' ' LEU . 4.5 t-80 -47.28 156.19 0.27 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 120.739 -1.225 . . . . 0.0 108.551 -179.463 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.569 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.2 OUTLIER -49.81 -47.25 22.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.163 -0.96 . . . . 0.0 109.49 -179.713 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.509 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.3 OUTLIER -81.22 39.79 0.53 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.413 -0.804 . . . . 0.0 110.399 -179.925 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.791 ' C ' HD12 ' A' ' 38' ' ' ILE . 47.1 mm-40 -147.98 34.15 0.83 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.934 -1.104 . . . . 0.0 109.27 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.809 HG21 ' CD2' ' A' ' 49' ' ' TYR . 1.6 mp -112.48 -97.11 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.248 -0.908 . . . . 0.0 109.916 -179.613 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.773 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.301 -1.524 0 O-C-N 121.311 -0.868 . . . . 0.0 109.825 -179.402 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.001 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 2.5 t . . . . . 0 N--CA 1.481 1.075 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.451 ' C ' ' O ' ' A' ' 43' ' ' VAL . 3.2 mp0 -40.32 -25.06 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.639 -0.663 . . . . 0.0 109.923 -179.59 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.538 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.8 OUTLIER -151.28 121.56 7.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.146 -0.971 . . . . 0.0 110.021 -179.813 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.601 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -71.71 -26.92 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 178.959 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.792 HG22 HG21 ' A' ' 16' ' ' ILE . 58.6 p -79.14 6.02 10.64 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.48 ' OD2' ' HB2' ' A' ' 45' ' ' LYS . 26.6 m-20 -106.25 -26.9 11.34 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 179.204 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 1.001 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 12.9 m-85 -92.54 -34.83 13.9 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.247 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 1.07 HD11 HG21 ' A' ' 33' ' ' VAL . 4.6 mt -109.57 152.9 24.9 Favored 'General case' 0 N--CA 1.492 1.635 0 C-N-CA 119.473 -0.891 . . . . 0.0 109.752 179.637 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.482 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.9 OUTLIER -128.19 138.68 52.58 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.39 -0.819 . . . . 0.0 108.982 179.437 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 22.6 mtp -63.17 114.19 3.61 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.217 -0.927 . . . . 0.0 109.716 -179.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 109.38 -23.85 21.72 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' GLN . . . . . 0.462 ' HG3' ' HB3' ' A' ' 51' ' ' GLN . 1.5 mt-30 -74.5 147.78 41.57 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.098 -1.236 . . . . 0.0 109.791 -179.718 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.475 ' HA ' ' HA ' ' A' ' 12' ' ' LYS . 0.3 OUTLIER -107.06 146.95 30.57 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.329 -0.857 . . . . 0.0 109.37 179.889 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.456 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 18.8 m -150.6 140.03 13.52 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.079 -1.013 . . . . 0.0 109.944 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 37.2 Cg_endo -82.96 151.85 14.33 Favored 'Trans proline' 0 C--N 1.315 -1.21 0 C-N-CA 122.786 2.324 . . . . 0.0 110.137 179.311 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.85 ' CG2' HD12 ' A' ' 71' ' ' LEU . 0.9 OUTLIER -147.72 -171.22 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.167 -0.958 . . . . 0.0 109.299 179.511 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.686 ' HG2' HG22 ' A' ' 8' ' ' VAL . 10.8 mttt -138.59 121.7 16.84 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.079 -1.013 . . . . 0.0 109.955 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.706 ' HA ' HD13 ' A' ' 71' ' ' LEU . 35.2 t . . . . . 0 N--CA 1.492 1.662 0 O-C-N 121.294 -0.879 . . . . 0.0 108.944 179.251 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.85 HD12 ' CG2' ' A' ' 58' ' ' VAL . 2.4 mm? . . . . . 0 N--CA 1.489 1.503 0 CA-C-O 121.546 0.689 . . . . 0.0 109.935 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -119.33 112.71 19.78 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.522 -0.736 . . . . 0.0 109.366 -179.87 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.57 HD12 HG13 ' A' ' 33' ' ' VAL . 0.1 OUTLIER -55.63 136.08 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.271 -0.893 . . . . 0.0 109.336 -179.67 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.442 ' C ' ' O ' ' A' ' 73' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.494 1.727 0 O-C-N 121.351 -0.843 . . . . 0.0 109.814 -179.481 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 24.1 t . . . . . 0 N--CA 1.49 1.572 0 N-CA-C 109.011 -0.737 . . . . 0.0 109.011 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.588 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 4.2 m-85 -110.87 130.69 55.51 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.124 -0.985 . . . . 0.0 110.012 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 11.0 m -80.45 100.49 8.53 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.335 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.47 126.0 7.25 Favored Glycine 0 N--CA 1.487 2.072 0 C-N-CA 119.87 -1.157 . . . . 0.0 110.487 -178.539 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.586 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -89.75 148.12 23.44 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.794 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.856 HG13 ' CD1' ' A' ' 50' ' ' LEU . 22.8 t -87.85 112.21 23.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 120.568 -1.332 . . . . 0.0 108.97 -179.648 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.989 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -122.8 -6.09 8.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.437 -0.789 . . . . 0.0 110.216 -178.916 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.462 ' HD2' ' O ' ' A' ' 14' ' ' THR . 0.9 OUTLIER -164.68 153.66 12.93 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.916 -1.115 . . . . 0.0 110.06 -179.949 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.443 HG22 ' N ' ' A' ' 17' ' ' VAL . 12.2 mt -141.08 161.57 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 179.438 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 1.025 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -140.15 153.44 22.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 120.881 -1.137 . . . . 0.0 109.982 -179.58 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -58.45 -41.78 85.9 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.778 -1.202 . . . . 0.0 109.145 179.405 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 1.025 ' CE1' HG21 ' A' ' 17' ' ' VAL . 15.5 p90 -90.3 29.31 1.27 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.381 -0.825 . . . . 0.0 110.077 -179.743 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.543 ' HA2' ' N ' ' A' ' 35' ' ' ILE . . . 149.81 -148.86 20.57 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 118.964 -1.589 . . . . 0.0 110.976 -179.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.752 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -154.94 148.83 25.66 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.233 -1.157 . . . . 0.0 108.917 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.977 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.5 m-30 -106.94 162.46 13.81 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.339 -0.851 . . . . 0.0 108.954 179.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.942 ' CG2' HG23 ' A' ' 33' ' ' VAL . 22.5 t -149.03 160.87 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.08 -1.013 . . . . 0.0 109.64 -179.64 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.989 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -133.8 135.92 44.14 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.306 -0.871 . . . . 0.0 109.55 -179.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.792 HD13 HD11 ' A' ' 71' ' ' LEU . 1.2 pt . . . . . 0 N--CA 1.493 1.683 0 O-C-N 120.818 -1.176 . . . . 0.0 109.509 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.483 ' O ' HG13 ' A' ' 25' ' ' ILE . 4.4 mtmt . . . . . 0 N--CA 1.488 1.442 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.556 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 6.4 mt-10 -127.48 150.87 49.47 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.741 -1.224 . . . . 0.0 111.004 -179.151 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.76 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -102.33 -172.96 27.25 Favored Glycine 0 N--CA 1.488 2.104 0 N-CA-C 108.22 -1.952 . . . . 0.0 108.22 178.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.977 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.14 121.8 8.05 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.737 -1.449 . . . . 0.0 110.951 179.743 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 1.004 HG12 HD11 ' A' ' 38' ' ' ILE . 61.1 t -95.3 61.36 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 177.523 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.472 ' HB2' HD23 ' A' ' 32' ' ' LEU . 2.6 t-80 -48.88 158.13 0.35 Allowed 'General case' 0 C--N 1.304 -1.37 0 O-C-N 120.893 -1.13 . . . . 0.0 108.653 -179.462 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.543 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.9 tp -46.66 -51.01 5.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.188 -0.945 . . . . 0.0 109.864 -179.464 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.533 ' N ' HG23 ' A' ' 35' ' ' ILE . 42.6 p -81.99 44.51 0.85 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.302 -0.874 . . . . 0.0 110.372 -179.639 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.929 ' C ' HD12 ' A' ' 38' ' ' ILE . 3.6 mm100 -144.29 33.61 1.2 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.903 -1.123 . . . . 0.0 110.214 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 1.004 HD11 HG12 ' A' ' 33' ' ' VAL . 1.6 mp -120.29 -98.49 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.833 -1.167 . . . . 0.0 110.214 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.771 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.302 -1.476 0 O-C-N 121.459 -0.776 . . . . 0.0 109.45 -179.206 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.119 HG13 ' CD1' ' A' ' 49' ' ' TYR . 58.7 t . . . . . 0 N--CA 1.487 1.387 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 43' ' ' VAL . 14.0 mt-10 -45.78 -24.27 0.36 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.354 -0.841 . . . . 0.0 108.988 179.488 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.456 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 4.7 mmtp -134.97 123.71 23.76 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.327 -0.858 . . . . 0.0 109.4 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.54 HG11 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -73.68 -23.47 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 O-C-N 121.131 -0.981 . . . . 0.0 108.643 179.647 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 8.3 p -75.4 1.39 14.03 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.482 -0.761 . . . . 0.0 109.389 179.198 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.456 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 0.9 OUTLIER -102.17 -35.59 8.84 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.149 -0.969 . . . . 0.0 109.245 -179.999 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 1.119 ' CD1' HG13 ' A' ' 43' ' ' VAL . 3.9 m-85 -90.83 -28.72 18.0 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.35 -0.844 . . . . 0.0 108.972 179.791 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.856 ' CD1' HG13 ' A' ' 13' ' ' VAL . 0.2 OUTLIER -109.72 140.9 43.06 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.495 -0.753 . . . . 0.0 109.565 -179.575 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.728 ' C ' HG11 ' A' ' 13' ' ' VAL . 2.3 mp0 -150.62 131.93 14.57 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.398 -0.814 . . . . 0.0 109.476 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -61.84 107.61 0.87 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.273 -0.892 . . . . 0.0 109.955 -179.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 132.33 -31.97 2.91 Favored Glycine 0 N--CA 1.491 2.321 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.306 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -80.3 162.28 24.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.033 -1.275 . . . . 0.0 109.818 -179.668 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -125.28 138.66 54.09 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.518 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.434 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 17.2 m -140.58 143.92 34.44 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.017 -1.052 . . . . 0.0 110.008 -179.461 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 56' ' ' VAL . 36.3 Cg_endo -79.05 145.93 19.85 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.59 2.193 . . . . 0.0 110.241 179.704 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.69 ' CG2' HD22 ' A' ' 71' ' ' LEU . 1.0 OUTLIER -148.21 -174.84 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.196 -0.94 . . . . 0.0 109.901 -179.878 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.458 ' N ' HG23 ' A' ' 58' ' ' VAL . 3.0 mtpt -123.51 135.66 54.15 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.52 -0.737 . . . . 0.0 109.239 179.606 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.588 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 96.1 t . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.33 -0.856 . . . . 0.0 109.229 179.95 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.792 HD11 HD13 ' A' ' 25' ' ' ILE . 31.3 mt . . . . . 0 N--CA 1.487 1.423 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.467 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.4 OUTLIER -123.24 108.08 12.41 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.273 -0.892 . . . . 0.0 110.049 -179.259 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.469 ' HA ' HG12 ' A' ' 58' ' ' VAL . 0.0 OUTLIER -48.61 140.83 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.227 -0.921 . . . . 0.0 108.911 179.886 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 11.3 mmtt . . . . . 0 N--CA 1.491 1.611 0 O-C-N 121.318 -0.864 . . . . 0.0 109.744 -179.684 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.545 HG22 ' HG2' ' A' ' 59' ' ' LYS . 41.3 t . . . . . 0 N--CA 1.492 1.633 0 N-CA-C 108.82 -0.807 . . . . 0.0 108.82 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.87 ' CD2' HD13 ' A' ' 25' ' ' ILE . 2.8 m-30 -114.75 135.12 54.52 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.154 -0.966 . . . . 0.0 110.158 -179.335 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -73.82 100.74 3.54 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 177.448 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -82.26 122.73 5.82 Favored Glycine 0 N--CA 1.488 2.119 0 C-N-CA 120.009 -1.091 . . . . 0.0 111.368 -177.302 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.518 ' O ' HG13 ' A' ' 23' ' ' VAL . 2.4 mttt -96.07 143.24 27.39 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 177.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.014 HG13 HD23 ' A' ' 50' ' ' LEU . 24.9 t -88.1 107.66 17.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 120.802 -1.186 . . . . 0.0 108.934 -179.648 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.886 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -116.93 -7.95 11.34 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.454 -0.778 . . . . 0.0 109.813 -179.07 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.485 ' HB3' ' HB2' ' A' ' 22' ' ' PHE . 0.9 OUTLIER -161.48 148.22 14.45 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.054 -1.029 . . . . 0.0 110.158 -179.899 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.616 HG21 HG22 ' A' ' 47' ' ' THR . 11.8 mt -137.05 157.38 35.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 179.005 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 1.045 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -136.3 153.4 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 120.749 -1.22 . . . . 0.0 110.034 -179.192 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -59.07 -41.94 89.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.69 -1.257 . . . . 0.0 109.331 179.228 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 1.045 ' CE1' HG21 ' A' ' 17' ' ' VAL . 12.9 p90 -91.16 27.24 1.93 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.3 -0.875 . . . . 0.0 110.361 -179.525 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.553 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 154.4 -154.9 25.83 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 118.895 -1.621 . . . . 0.0 110.829 -179.505 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.759 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -148.45 143.97 27.1 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.042 -1.27 . . . . 0.0 108.853 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.97 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.0 m-30 -105.94 154.77 20.11 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.254 -0.904 . . . . 0.0 108.825 179.748 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.81 ' CG2' HG23 ' A' ' 33' ' ' VAL . 35.2 t -144.04 161.81 15.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.066 -1.021 . . . . 0.0 109.783 -179.273 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.886 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -137.2 148.81 46.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.157 -0.964 . . . . 0.0 109.515 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.87 HD13 ' CD2' ' A' ' 9' ' ' TYR . 2.7 pt . . . . . 0 N--CA 1.492 1.673 0 O-C-N 121.006 -1.059 . . . . 0.0 109.044 179.642 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.496 ' O ' HG13 ' A' ' 25' ' ' ILE . 1.7 mtpp . . . . . 0 N--CA 1.491 1.581 0 N-CA-C 109.313 -0.625 . . . . 0.0 109.313 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.533 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 17.3 mt-10 -134.99 153.46 52.08 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.998 -1.063 . . . . 0.0 110.334 -179.786 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.663 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -107.3 -175.78 22.64 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 179.43 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.97 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.49 119.29 6.6 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.875 -1.368 . . . . 0.0 110.736 179.72 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 1.093 HG21 HD11 ' A' ' 50' ' ' LEU . 96.3 t -93.84 61.14 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.543 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 177.71 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.474 ' HB2' HD23 ' A' ' 32' ' ' LEU . 6.6 t-80 -47.7 156.45 0.31 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.906 -1.122 . . . . 0.0 108.417 -179.571 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.589 ' O ' HD13 ' A' ' 38' ' ' ILE . 3.1 tp -49.62 -43.37 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.154 -0.966 . . . . 0.0 110.321 -179.536 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.438 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.4 OUTLIER -81.25 34.29 0.36 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.182 -0.949 . . . . 0.0 110.94 -179.34 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.921 ' C ' HD12 ' A' ' 38' ' ' ILE . 71.4 mt-30 -150.81 58.4 0.92 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.709 -1.244 . . . . 0.0 110.14 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.981 HG21 HG21 ' A' ' 43' ' ' VAL . 1.7 mp -122.08 -97.86 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 120.984 -1.073 . . . . 0.0 109.569 179.746 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.749 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.298 -0.876 . . . . 0.0 109.382 -179.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.167 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 66.9 t . . . . . 0 N--CA 1.488 1.443 0 N-CA-C 109.046 -0.724 . . . . 0.0 109.046 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.424 ' O ' ' HG3' ' A' ' 44' ' ' GLU . 13.8 tp10 -45.38 -26.59 0.56 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.162 -0.961 . . . . 0.0 108.467 179.662 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.48 ' HB3' ' CG ' ' A' ' 48' ' ' ASP . 4.2 mptt -108.0 105.63 15.5 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.28 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.553 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -75.22 -25.52 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.399 -0.813 . . . . 0.0 109.09 -179.681 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.616 HG22 HG21 ' A' ' 16' ' ' ILE . 62.7 p -77.55 6.22 7.55 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.413 -0.805 . . . . 0.0 109.464 179.181 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.48 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 58.9 m-20 -101.7 -32.32 10.37 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.426 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 1.167 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 15.9 m-85 -92.45 -34.85 13.95 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.494 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 1.093 HD11 HG21 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -100.0 156.62 17.06 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.322 -0.861 . . . . 0.0 110.571 -179.854 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.503 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 61.8 mt-30 -146.85 126.57 13.42 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . 0.525 ' CG ' ' O ' ' A' ' 52' ' ' MET . 3.2 ptp -60.81 98.59 0.07 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.15 -0.969 . . . . 0.0 109.94 -179.654 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 132.21 -25.44 3.86 Favored Glycine 0 N--CA 1.493 2.45 0 C-N-CA 119.719 -1.229 . . . . 0.0 110.368 179.467 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 89.0 mm-40 -79.19 150.49 31.65 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.105 -1.232 . . . . 0.0 110.402 -179.358 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -116.9 113.71 22.84 Favored 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.088 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.405 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 17.7 m -115.24 150.23 44.06 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.107 -0.996 . . . . 0.0 110.121 -179.205 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 56' ' ' VAL . 36.2 Cg_endo -78.5 126.91 7.79 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.675 2.25 . . . . 0.0 110.24 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.963 ' CG2' HD22 ' A' ' 71' ' ' LEU . 1.3 m -131.9 -172.74 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.148 -0.97 . . . . 0.0 109.722 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.545 ' HG2' HG22 ' A' ' 8' ' ' VAL . 9.8 mtmt -133.12 116.87 16.82 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.6 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.69 ' HA ' HD23 ' A' ' 71' ' ' LEU . 52.6 t . . . . . 0 N--CA 1.49 1.541 0 O-C-N 121.344 -0.848 . . . . 0.0 109.217 -179.744 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.963 HD22 ' CG2' ' A' ' 58' ' ' VAL . 11.1 mt . . . . . 0 N--CA 1.491 1.594 0 CA-C-O 121.249 0.547 . . . . 0.0 109.633 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 59' ' ' LYS . 0.6 OUTLIER -115.95 93.68 4.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.301 -0.874 . . . . 0.0 109.838 -179.85 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.467 ' O ' ' O ' ' A' ' 74' ' ' LYS . 0.1 OUTLIER -48.8 141.14 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.202 -0.936 . . . . 0.0 109.251 179.762 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.467 ' O ' ' O ' ' A' ' 73' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.493 1.686 0 O-C-N 121.311 -0.868 . . . . 0.0 109.673 -179.789 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.891 HG13 ' O ' ' A' ' 58' ' ' VAL . 97.3 t . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 108.756 -0.831 . . . . 0.0 108.756 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.638 ' O ' HG22 ' A' ' 58' ' ' VAL . 6.4 m-85 -119.41 126.65 51.88 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.858 -1.151 . . . . 0.0 110.525 -179.673 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.449 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 0.2 OUTLIER -95.31 127.34 41.28 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 178.352 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -127.62 150.14 18.15 Favored Glycine 0 N--CA 1.486 2.025 0 C-N-CA 118.834 -1.651 . . . . 0.0 110.953 -178.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.509 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.1 OUTLIER -89.8 163.21 15.14 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 178.624 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.945 HG22 HD13 ' A' ' 50' ' ' LEU . 69.8 t -88.42 107.9 18.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 O-C-N 121.006 -1.059 . . . . 0.0 108.445 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.635 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.3 p -118.51 -0.52 11.38 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.544 -0.862 . . . . 0.0 110.167 -178.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.511 ' HB3' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -167.96 148.04 4.95 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.987 -1.071 . . . . 0.0 109.985 179.739 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.436 HG22 ' N ' ' A' ' 17' ' ' VAL . 30.6 mt -140.31 157.38 24.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.232 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 1.014 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -135.38 152.98 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.918 -1.114 . . . . 0.0 109.751 -179.321 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -60.41 -39.08 86.08 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.631 -1.293 . . . . 0.0 109.218 179.458 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 1.014 ' CE1' HG21 ' A' ' 17' ' ' VAL . 18.4 p90 -91.86 24.92 2.96 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.497 -0.752 . . . . 0.0 110.073 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.618 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 156.07 -152.78 24.19 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.881 -179.188 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.75 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -151.91 145.65 25.05 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.853 -1.38 . . . . 0.0 108.843 179.636 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.959 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.3 m-30 -107.26 160.37 15.65 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.35 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.824 ' CG2' HG23 ' A' ' 33' ' ' VAL . 14.3 t -149.99 167.67 2.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.009 -1.057 . . . . 0.0 109.536 -179.228 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.635 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -131.62 147.43 52.52 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.137 -0.977 . . . . 0.0 109.278 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.52 HG13 ' O ' ' A' ' 29' ' ' LYS . 0.5 OUTLIER . . . . . 0 N--CA 1.493 1.716 0 O-C-N 120.561 -1.337 . . . . 0.0 109.808 -179.995 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.52 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.373 0.606 . . . . 0.0 109.807 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.582 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 7.2 mt-10 -120.18 153.05 36.81 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 120.814 -1.179 . . . . 0.0 110.811 -179.393 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.975 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -99.1 -172.8 31.39 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 108.555 -1.818 . . . . 0.0 108.555 179.061 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.959 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.83 120.19 6.85 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.824 -1.397 . . . . 0.0 111.082 179.6 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.824 HG23 ' CG2' ' A' ' 23' ' ' VAL . 48.6 t -95.15 61.79 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 177.276 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.486 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.1 t-160 -48.77 157.1 0.41 Allowed 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.785 -1.197 . . . . 0.0 108.908 -179.131 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.764 ' O ' HD13 ' A' ' 38' ' ' ILE . 0.4 OUTLIER -49.62 -47.09 21.3 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.297 -0.877 . . . . 0.0 110.237 -179.58 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.516 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.6 OUTLIER -80.48 33.33 0.3 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.251 -0.906 . . . . 0.0 110.972 -179.133 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.894 ' C ' HD12 ' A' ' 38' ' ' ILE . 44.7 mm-40 -148.26 57.99 1.08 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.823 -1.173 . . . . 0.0 109.735 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.98 ' CG2' HG21 ' A' ' 43' ' ' VAL . 1.5 mp -116.84 -99.56 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 120.942 -1.099 . . . . 0.0 110.075 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.765 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.304 -1.408 0 O-C-N 121.272 -0.892 . . . . 0.0 109.649 -179.341 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.127 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 72.1 t . . . . . 0 N--CA 1.485 1.324 0 N-CA-C 108.322 -0.992 . . . . 0.0 108.322 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -44.4 -24.95 0.21 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.349 -0.844 . . . . 0.0 109.032 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.49 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 68.7 mttt -110.8 104.44 13.07 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.454 -0.779 . . . . 0.0 109.14 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.618 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -72.19 -23.34 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.194 -0.941 . . . . 0.0 108.552 179.857 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 24.2 p -77.87 4.0 13.02 Favored 'General case' 0 C--N 1.3 -1.549 0 C-N-CA 119.827 -0.749 . . . . 0.0 109.294 179.21 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.49 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 1.8 m-20 -102.42 -33.78 9.41 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.151 -0.968 . . . . 0.0 108.824 179.598 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 1.127 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 23.5 m-85 -92.88 -33.05 14.37 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.449 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.945 HD13 HG22 ' A' ' 13' ' ' VAL . 0.2 OUTLIER -102.23 138.19 39.49 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.973 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.593 ' C ' HG11 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -142.32 142.35 32.5 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.48 -0.763 . . . . 0.0 109.41 -179.788 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -59.6 131.49 51.09 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.353 -0.842 . . . . 0.0 110.666 -179.394 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 90.45 -16.75 56.99 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' GLN . . . . . 0.425 ' CD ' ' HB2' ' A' ' 51' ' ' GLN . 6.7 mt-30 -70.46 169.4 14.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.173 -1.192 . . . . 0.0 109.886 -179.642 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.489 ' OE1' ' HE3' ' A' ' 12' ' ' LYS . 3.2 mt-10 -139.7 132.87 29.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.193 -0.942 . . . . 0.0 108.556 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.1 m -141.05 136.83 16.34 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 120.916 -1.115 . . . . 0.0 110.402 -179.4 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.449 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.3 Cg_endo -80.2 144.4 16.48 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 C-N-CA 122.524 2.149 . . . . 0.0 109.065 178.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.891 ' O ' HG13 ' A' ' 8' ' ' VAL . 1.5 m -144.13 -174.8 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 120.918 -1.114 . . . . 0.0 110.062 -179.612 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 4.1 mttt -121.9 135.14 54.87 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.516 -0.74 . . . . 0.0 109.357 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.538 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 58.9 t . . . . . 0 N--CA 1.49 1.526 0 O-C-N 121.275 -0.891 . . . . 0.0 109.002 179.734 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.975 HD12 ' HA3' ' A' ' 31' ' ' GLY . 20.6 mt . . . . . 0 N--CA 1.488 1.463 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.415 ' C ' ' HB ' ' A' ' 58' ' ' VAL . 0.4 OUTLIER -121.28 101.46 7.65 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.15 -0.969 . . . . 0.0 110.08 -179.622 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.624 HG22 ' O ' ' A' ' 38' ' ' ILE . 0.1 OUTLIER -45.28 137.96 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.2 -0.937 . . . . 0.0 108.96 179.838 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.589 0 O-C-N 121.404 -0.81 . . . . 0.0 109.871 -179.75 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.582 HG13 ' O ' ' A' ' 58' ' ' VAL . 89.9 t . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 108.933 -0.765 . . . . 0.0 108.933 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.44 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 4.0 m-85 -107.78 179.33 4.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.183 -0.948 . . . . 0.0 110.031 -179.501 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -121.19 101.19 7.49 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 178.012 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.79 115.95 4.35 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 119.85 -1.167 . . . . 0.0 111.099 -177.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.562 ' O ' HG13 ' A' ' 23' ' ' VAL . 5.7 mtmt -88.66 152.04 22.07 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 107.208 -1.404 . . . . 0.0 107.208 178.075 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.665 HG13 HD13 ' A' ' 50' ' ' LEU . 34.9 t -87.34 110.76 20.97 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 O-C-N 120.751 -1.218 . . . . 0.0 109.142 -179.07 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.973 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.5 OUTLIER -120.7 5.2 10.54 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.442 -0.786 . . . . 0.0 109.807 -179.227 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.529 ' CG ' ' O ' ' A' ' 14' ' ' THR . 3.5 mpp_? -176.15 152.5 1.16 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.047 -1.033 . . . . 0.0 110.225 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.59 HG21 HG22 ' A' ' 47' ' ' THR . 35.0 mt -142.19 159.01 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 179.209 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 1.033 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -137.19 153.65 29.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 120.82 -1.175 . . . . 0.0 109.872 -179.243 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -59.13 -40.06 84.29 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.873 -1.142 . . . . 0.0 109.12 179.248 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 1.033 ' CE1' HG21 ' A' ' 17' ' ' VAL . 20.1 p90 -91.66 27.71 1.96 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.431 -0.793 . . . . 0.0 110.148 -179.739 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.592 ' C ' HG22 ' A' ' 17' ' ' VAL . . . 151.82 -148.64 19.87 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 119.033 -1.556 . . . . 0.0 110.899 -179.559 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.75 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -155.32 148.46 24.71 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.241 -1.153 . . . . 0.0 108.846 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.947 ' CE1' HD11 ' A' ' 32' ' ' LEU . 11.6 m-30 -107.92 160.9 15.41 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.58 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.795 ' CG2' HG23 ' A' ' 33' ' ' VAL . 20.4 t -149.39 162.25 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.129 -0.982 . . . . 0.0 109.49 -179.522 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.973 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -133.73 145.44 49.86 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.122 -0.986 . . . . 0.0 109.811 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.488 HG13 ' O ' ' A' ' 29' ' ' LYS . 3.2 pt . . . . . 0 N--CA 1.493 1.675 0 O-C-N 121.065 -1.022 . . . . 0.0 109.273 -179.872 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.488 ' O ' HG13 ' A' ' 25' ' ' ILE . 2.5 mmmt . . . . . 0 N--CA 1.492 1.636 0 CA-C-O 121.213 0.53 . . . . 0.0 109.776 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.539 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -132.56 151.44 51.93 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.155 -0.966 . . . . 0.0 110.43 -179.861 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.831 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -104.72 -175.64 24.81 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 179.309 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.947 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -149.43 120.59 7.78 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.846 -1.385 . . . . 0.0 110.724 179.753 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.795 HG23 ' CG2' ' A' ' 23' ' ' VAL . 88.3 t -93.67 60.1 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 177.85 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.482 ' HB2' HD23 ' A' ' 32' ' ' LEU . 5.6 t-80 -47.6 158.42 0.19 Allowed 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.779 -1.201 . . . . 0.0 108.383 -179.533 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.676 ' O ' HD13 ' A' ' 38' ' ' ILE . 2.8 tp -47.76 -52.94 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.081 -1.012 . . . . 0.0 110.07 -179.276 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.578 ' H ' HG23 ' A' ' 35' ' ' ILE . 0.0 OUTLIER -81.48 39.41 0.53 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.091 -1.005 . . . . 0.0 110.375 -179.631 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.924 ' C ' HD12 ' A' ' 38' ' ' ILE . 11.9 mm100 -144.83 50.41 1.26 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.926 -1.109 . . . . 0.0 109.641 -179.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.924 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.6 mp -120.08 -99.79 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 120.765 -1.209 . . . . 0.0 110.675 -179.484 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.788 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 N--CA 1.488 1.438 0 O-C-N 121.211 -0.931 . . . . 0.0 110.269 -178.622 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.136 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 24.4 t . . . . . 0 N--CA 1.485 1.308 0 N-CA-C 108.475 -0.935 . . . . 0.0 108.475 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -46.97 -22.06 0.28 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.328 -0.858 . . . . 0.0 109.718 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.541 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.5 OUTLIER -128.28 117.78 22.09 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.113 -0.992 . . . . 0.0 109.858 -179.805 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.549 HG21 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -77.65 -25.81 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.199 -0.938 . . . . 0.0 108.701 179.485 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.59 HG22 HG21 ' A' ' 16' ' ' ILE . 63.5 p -77.1 3.73 11.85 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.383 -0.823 . . . . 0.0 109.307 179.237 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.404 ' OD2' ' CB ' ' A' ' 45' ' ' LYS . 99.1 m-20 -101.86 -24.36 14.04 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.482 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 1.136 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 22.1 m-85 -100.29 -25.87 14.1 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.733 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.669 HD12 ' HB1' ' A' ' 21' ' ' ALA . 0.2 OUTLIER -111.25 142.74 43.06 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.909 . . . . 0.0 109.391 179.465 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.508 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.2 OUTLIER -141.72 133.41 27.07 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.537 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 9.9 mtm -54.78 97.49 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.137 -0.977 . . . . 0.0 110.077 -179.487 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.9 -36.0 2.51 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 119.847 -1.168 . . . . 0.0 110.304 179.341 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 5.2 mm-40 -57.5 162.47 2.89 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.066 -1.256 . . . . 0.0 109.695 -179.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.434 ' HG3' ' HA ' ' A' ' 12' ' ' LYS . 0.7 OUTLIER -137.55 125.93 23.34 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.412 -0.805 . . . . 0.0 109.184 179.819 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.406 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 16.0 m -130.25 139.26 35.09 Favored Pre-proline 0 N--CA 1.488 1.451 0 O-C-N 121.063 -1.023 . . . . 0.0 109.606 -179.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.471 ' O ' ' HB2' ' A' ' 74' ' ' LYS . 35.5 Cg_endo -78.44 134.13 12.33 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.503 2.135 . . . . 0.0 110.352 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.792 HG21 ' HB3' ' A' ' 71' ' ' LEU . 0.9 OUTLIER -127.41 179.17 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.152 -0.968 . . . . 0.0 109.782 -179.922 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.521 ' HG3' HG22 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -117.01 122.19 43.51 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.639 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.649 ' HA ' HD23 ' A' ' 71' ' ' LEU . 91.2 t . . . . . 0 N--CA 1.49 1.552 0 O-C-N 121.189 -0.944 . . . . 0.0 109.528 -179.88 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.831 HD12 ' HA3' ' A' ' 31' ' ' GLY . 81.4 mt . . . . . 0 N--CA 1.489 1.497 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.41 ' O ' ' C ' ' A' ' 73' ' ' ILE . 0.3 OUTLIER -121.32 97.21 5.41 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.115 -0.99 . . . . 0.0 110.362 -179.204 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.455 ' CG2' ' O ' ' A' ' 38' ' ' ILE . 0.2 OUTLIER -42.67 123.02 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.317 -0.864 . . . . 0.0 109.099 179.605 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 57' ' ' PRO . 0.8 OUTLIER . . . . . 0 N--CA 1.491 1.614 0 O-C-N 121.208 -0.933 . . . . 0.0 109.768 -179.651 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.623 HG13 ' O ' ' A' ' 58' ' ' VAL . 55.3 t . . . . . 0 N--CA 1.49 1.557 0 N-CA-C 108.945 -0.761 . . . . 0.0 108.945 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.646 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 3.0 m-85 -104.75 129.72 52.94 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.085 -1.009 . . . . 0.0 109.956 -179.561 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.5 m -74.49 98.08 3.25 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 178.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -77.73 120.45 5.51 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 -178.396 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.993 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -92.47 150.51 20.74 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.71 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.605 HG11 ' C ' ' A' ' 51' ' ' GLN . 20.7 t -89.49 106.12 16.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 120.908 -1.12 . . . . 0.0 108.991 -179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 1.036 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -120.59 3.06 10.71 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.234 -0.916 . . . . 0.0 109.67 -179.506 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.517 ' HB3' ' HB2' ' A' ' 22' ' ' PHE . 5.0 mpp_? -173.31 153.48 2.43 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.174 -0.954 . . . . 0.0 109.821 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.425 HG22 ' N ' ' A' ' 17' ' ' VAL . 14.7 mt -140.84 159.76 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.562 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 1.06 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -139.67 155.55 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 120.822 -1.174 . . . . 0.0 110.285 -179.746 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -59.06 -44.48 91.84 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.967 -1.083 . . . . 0.0 109.803 179.449 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 1.06 ' CE1' HG21 ' A' ' 17' ' ' VAL . 8.2 p90 -90.42 24.62 2.53 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.107 -0.996 . . . . 0.0 110.377 -179.389 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.786 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 158.4 -152.28 23.41 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 118.977 -1.582 . . . . 0.0 111.044 -179.583 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.819 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -151.36 146.9 26.32 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.214 -1.168 . . . . 0.0 108.906 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.979 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.3 m-30 -106.73 157.93 17.35 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.259 -0.901 . . . . 0.0 108.992 179.754 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.993 HG13 ' O ' ' A' ' 12' ' ' LYS . 42.3 t -150.58 154.66 8.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 120.945 -1.097 . . . . 0.0 109.674 -178.834 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 1.036 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -121.87 138.21 54.48 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.89 -1.131 . . . . 0.0 109.319 179.662 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.563 HD12 ' CD2' ' A' ' 9' ' ' TYR . 2.5 pt . . . . . 0 N--CA 1.494 1.733 0 O-C-N 121.166 -0.958 . . . . 0.0 109.239 -179.997 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.495 ' O ' HG13 ' A' ' 25' ' ' ILE . 4.7 mttm . . . . . 0 N--CA 1.49 1.534 0 N-CA-C 109.069 -0.715 . . . . 0.0 109.069 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.52 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 0.4 OUTLIER -119.28 141.13 49.24 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.063 -1.023 . . . . 0.0 110.067 -179.757 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.9 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -91.93 -177.7 42.21 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.03 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.979 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -149.93 120.14 7.29 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 120.796 -1.414 . . . . 0.0 110.842 179.687 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.828 HG23 HG21 ' A' ' 23' ' ' VAL . 93.4 t -92.84 60.1 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 177.714 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.49 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.0 t-80 -48.76 156.51 0.47 Allowed 'General case' 0 N--CA 1.486 1.346 0 O-C-N 120.895 -1.128 . . . . 0.0 108.681 -179.375 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.553 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.7 tp -48.45 -48.92 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.296 -0.878 . . . . 0.0 110.623 -179.385 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.54 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.5 OUTLIER -81.25 40.93 0.58 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.145 -0.972 . . . . 0.0 110.693 -179.396 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.946 ' C ' HD12 ' A' ' 38' ' ' ILE . 12.0 mt-30 -150.95 51.73 0.86 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.713 -1.242 . . . . 0.0 110.047 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.946 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.7 mp -123.04 -97.91 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.886 -1.134 . . . . 0.0 110.094 -179.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.799 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.302 -1.499 0 O-C-N 121.432 -0.792 . . . . 0.0 108.999 -179.493 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.945 HG13 ' CD1' ' A' ' 49' ' ' TYR . 50.1 t . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 43' ' ' VAL . 29.3 tt0 -41.83 -29.53 0.21 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.371 -0.83 . . . . 0.0 109.982 -179.61 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.483 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 1.1 mmtp -150.45 141.8 23.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.077 -1.015 . . . . 0.0 109.792 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.786 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -74.12 -25.82 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 O-C-N 121.202 -0.936 . . . . 0.0 108.664 179.413 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.8 p -78.38 3.18 16.38 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.745 -0.782 . . . . 0.0 109.108 179.372 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.443 ' OD2' ' HB2' ' A' ' 45' ' ' LYS . 4.7 m-20 -101.82 -29.4 11.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.171 -0.956 . . . . 0.0 108.749 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.945 ' CD1' HG13 ' A' ' 43' ' ' VAL . 20.4 m-85 -98.29 -27.5 14.1 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.571 -0.705 . . . . 0.0 109.129 179.765 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.648 HD21 HG21 ' A' ' 33' ' ' VAL . 0.2 OUTLIER -104.9 141.03 37.26 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.603 -0.686 . . . . 0.0 109.35 -179.73 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.605 ' C ' HG11 ' A' ' 13' ' ' VAL . 43.6 tt0 -136.46 132.34 35.24 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.488 -0.757 . . . . 0.0 109.641 -179.712 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 4.7 mtt -65.26 112.11 3.31 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.354 -0.841 . . . . 0.0 109.605 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 113.71 -23.07 13.78 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' GLN . . . . . 0.545 ' CG ' ' HB3' ' A' ' 51' ' ' GLN . 57.0 mm-40 -79.37 167.5 20.78 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.251 -1.147 . . . . 0.0 109.583 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.5 ' N ' ' OE1' ' A' ' 55' ' ' GLU . 1.3 mp0 -133.36 147.59 51.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.312 -0.867 . . . . 0.0 109.177 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.476 HG21 HD11 ' A' ' 73' ' ' ILE . 19.1 m -144.74 141.21 17.27 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.156 -0.965 . . . . 0.0 109.771 -179.859 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.54 126.39 7.45 Favored 'Trans proline' 0 C--N 1.312 -1.391 0 C-N-CA 122.575 2.183 . . . . 0.0 110.238 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.623 ' O ' HG13 ' A' ' 8' ' ' VAL . 1.0 OUTLIER -132.31 -170.98 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.191 -0.943 . . . . 0.0 109.516 179.843 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.535 ' N ' HG23 ' A' ' 58' ' ' VAL . 29.6 mtpt -134.43 127.01 30.68 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.414 -0.804 . . . . 0.0 109.459 179.801 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.646 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 26.2 t . . . . . 0 N--CA 1.489 1.504 0 O-C-N 121.281 -0.887 . . . . 0.0 109.018 179.688 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.9 HD12 ' HA3' ' A' ' 31' ' ' GLY . 18.8 mt . . . . . 0 N--CA 1.487 1.42 0 CA-C-O 121.358 0.599 . . . . 0.0 109.549 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.458 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.3 OUTLIER -114.67 106.7 14.54 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.375 -0.828 . . . . 0.0 109.565 -179.742 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.476 HD11 HG21 ' A' ' 56' ' ' VAL . 0.1 OUTLIER -65.84 135.24 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.261 -0.899 . . . . 0.0 109.229 -179.996 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.488 1.471 0 O-C-N 121.315 -0.866 . . . . 0.0 109.228 179.715 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.739 HG22 ' HG3' ' A' ' 59' ' ' LYS . 71.6 t . . . . . 0 N--CA 1.491 1.591 0 N-CA-C 109.019 -0.734 . . . . 0.0 109.019 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.525 ' O ' HG22 ' A' ' 58' ' ' VAL . 11.5 m-85 -136.53 129.51 31.06 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.059 -1.026 . . . . 0.0 110.77 -179.521 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.504 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 0.4 OUTLIER -97.58 112.05 24.07 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.149 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -113.48 151.97 18.16 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.134 -1.508 . . . . 0.0 110.59 -178.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.524 ' HG2' ' CG ' ' A' ' 55' ' ' GLU . 3.4 mtmm -89.63 162.32 15.68 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.876 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.56 HG22 HD13 ' A' ' 50' ' ' LEU . 60.3 t -88.16 97.56 6.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 120.994 -1.066 . . . . 0.0 108.203 179.651 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.718 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.6 p -103.43 -4.64 23.8 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.475 -0.765 . . . . 0.0 110.426 -178.642 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.551 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -163.37 153.8 15.96 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.913 -1.117 . . . . 0.0 110.584 -179.699 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.402 ' HA ' ' HA ' ' A' ' 21' ' ' ALA . 19.8 mt -143.21 155.41 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 178.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 1.027 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -135.54 154.96 35.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.837 -1.164 . . . . 0.0 110.055 -178.934 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 12.0 t0 -60.5 -40.44 91.41 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.687 -1.258 . . . . 0.0 109.323 179.43 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 1.027 ' CE1' HG21 ' A' ' 17' ' ' VAL . 15.5 p90 -90.2 23.14 2.98 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.356 -0.84 . . . . 0.0 110.289 -179.743 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.595 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 156.23 -149.42 20.35 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 119.294 -1.432 . . . . 0.0 110.975 -179.654 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.708 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -153.54 146.85 24.79 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.042 -1.27 . . . . 0.0 108.99 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.966 ' CE1' HD11 ' A' ' 32' ' ' LEU . 11.2 m-30 -109.35 155.89 20.67 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.395 -0.816 . . . . 0.0 109.175 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.768 ' CG2' HG23 ' A' ' 33' ' ' VAL . 7.0 t -144.23 168.23 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 120.93 -1.106 . . . . 0.0 109.145 179.795 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.718 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -138.05 150.92 47.36 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.06 -1.025 . . . . 0.0 110.743 -179.328 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.484 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.8 pt . . . . . 0 N--CA 1.492 1.661 0 O-C-N 121.182 -0.949 . . . . 0.0 108.951 179.315 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.484 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 . . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.544 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 5.2 mp0 -131.78 155.04 48.44 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 120.84 -1.162 . . . . 0.0 111.081 -179.468 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.789 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -105.72 -174.0 23.82 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 108.352 -1.899 . . . . 0.0 108.352 179.141 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.966 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.51 122.89 8.42 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.716 -1.461 . . . . 0.0 111.054 179.674 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.768 HG23 ' CG2' ' A' ' 23' ' ' VAL . 14.9 t -99.62 64.73 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 177.333 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.499 ' HB3' ' HG3' ' A' ' 37' ' ' GLN . 3.6 t-80 -49.58 162.23 0.17 Allowed 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.835 -1.165 . . . . 0.0 108.746 -179.474 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.609 ' O ' HD13 ' A' ' 38' ' ' ILE . 0.3 OUTLIER -52.79 -52.05 31.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.214 -0.929 . . . . 0.0 110.329 -179.269 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.561 ' N ' HG23 ' A' ' 35' ' ' ILE . 11.5 m -81.42 32.46 0.35 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 120.994 -1.066 . . . . 0.0 110.764 -179.351 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.894 ' C ' HD12 ' A' ' 38' ' ' ILE . 0.3 OUTLIER -138.24 48.24 1.97 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.695 -1.253 . . . . 0.0 109.978 -179.955 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.894 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.5 mp -119.39 -99.39 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 120.956 -1.09 . . . . 0.0 110.019 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.806 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.302 -1.476 0 O-C-N 121.317 -0.864 . . . . 0.0 109.09 -179.266 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 0.965 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 90.0 t . . . . . 0 N--CA 1.493 1.723 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.412 ' C ' ' O ' ' A' ' 43' ' ' VAL . 11.1 mt-10 -41.31 -30.66 0.19 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.556 -0.715 . . . . 0.0 109.506 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.462 ' HB2' ' CG ' ' A' ' 48' ' ' ASP . 14.1 mttt -122.21 130.05 52.83 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.35 -0.844 . . . . 0.0 109.066 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.595 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -78.62 -24.31 13.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.19 -0.944 . . . . 0.0 108.932 -179.976 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 3.2 p -76.78 4.38 9.81 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.328 -0.858 . . . . 0.0 109.48 179.388 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.476 ' N ' ' OD1' ' A' ' 48' ' ' ASP . 2.0 m-20 -99.55 -37.43 9.17 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.156 -0.965 . . . . 0.0 108.727 179.515 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 0.965 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 18.0 m-85 -90.19 -32.69 16.5 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.683 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.667 HD11 HG21 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -99.21 140.38 33.45 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.532 -0.73 . . . . 0.0 109.223 179.938 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.493 ' H ' HG21 ' A' ' 13' ' ' VAL . 45.6 mt-30 -136.35 112.56 9.8 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.463 -0.773 . . . . 0.0 109.253 -179.821 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . 0.451 ' O ' ' CE ' ' A' ' 52' ' ' MET . 0.7 OUTLIER -52.49 94.59 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.277 -0.889 . . . . 0.0 110.176 -179.769 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 143.37 -38.88 1.35 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.771 -1.204 . . . . 0.0 110.428 179.508 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 22.4 mt-30 -77.36 169.17 18.8 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.128 -1.219 . . . . 0.0 109.782 -179.42 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . 0.524 ' CG ' ' HG2' ' A' ' 12' ' ' LYS . 3.6 mt-10 -122.81 125.32 45.22 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.297 -0.877 . . . . 0.0 109.217 179.739 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.442 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 22.9 m -117.49 142.64 30.73 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.187 -0.946 . . . . 0.0 109.97 -179.68 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.504 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.3 Cg_endo -80.28 153.66 21.43 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 122.753 2.302 . . . . 0.0 110.105 179.669 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.819 ' CG2' HD22 ' A' ' 71' ' ' LEU . 0.9 OUTLIER -150.47 -170.27 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.169 -0.957 . . . . 0.0 109.63 179.8 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.739 ' HG3' HG22 ' A' ' 8' ' ' VAL . 7.7 mtpt -140.75 124.44 17.03 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.398 -0.814 . . . . 0.0 109.663 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.572 ' HA ' HD23 ' A' ' 71' ' ' LEU . 43.0 t . . . . . 0 N--CA 1.491 1.579 0 O-C-N 121.415 -0.803 . . . . 0.0 108.991 179.365 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.819 HD22 ' CG2' ' A' ' 58' ' ' VAL . 52.8 mt . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 121.532 0.682 . . . . 0.0 110.112 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.404 ' O ' ' C ' ' A' ' 73' ' ' ILE . 0.3 OUTLIER -124.36 116.58 22.82 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.481 -0.762 . . . . 0.0 110.028 -179.725 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.745 HD13 ' O ' ' A' ' 37' ' ' GLN . 1.3 mp -46.43 134.97 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.079 -1.013 . . . . 0.0 108.511 179.368 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.492 1.649 0 O-C-N 121.157 -0.964 . . . . 0.0 109.976 -179.334 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.75 HG22 ' HG3' ' A' ' 59' ' ' LYS . 75.8 t . . . . . 0 N--CA 1.493 1.693 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.468 ' HD2' HD13 ' A' ' 25' ' ' ILE . 4.4 m-30 -105.22 129.47 53.59 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.113 -0.992 . . . . 0.0 110.066 -178.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.6 m -77.0 102.39 6.42 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 178.628 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -80.21 116.2 4.21 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.933 -1.127 . . . . 0.0 110.373 -178.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.632 ' O ' HG13 ' A' ' 23' ' ' VAL . 9.1 mttt -89.16 149.97 22.9 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.655 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 1.029 HG22 ' CD2' ' A' ' 50' ' ' LEU . 85.8 t -86.83 106.69 16.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 120.956 -1.09 . . . . 0.0 109.059 -179.292 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 1.04 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -113.99 -25.43 8.57 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.529 -0.732 . . . . 0.0 109.21 -179.492 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.537 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 5.6 mtp180 -143.86 152.23 40.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.262 -0.899 . . . . 0.0 109.967 179.762 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.7 mt -139.85 154.42 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.249 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 1.061 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -134.83 154.3 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 120.782 -1.199 . . . . 0.0 110.313 -178.835 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -59.28 -42.81 92.12 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.796 -1.19 . . . . 0.0 109.539 179.298 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 1.061 ' CE1' HG21 ' A' ' 17' ' ' VAL . 9.9 p90 -90.73 27.28 1.81 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.17 -0.956 . . . . 0.0 110.065 -179.766 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.91 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 154.85 -153.01 24.49 Favored Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.012 -1.566 . . . . 0.0 111.141 -179.488 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.825 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -150.02 143.81 25.41 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.057 -1.26 . . . . 0.0 109.075 -179.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.98 ' CE1' HD11 ' A' ' 32' ' ' LEU . 9.5 m-30 -104.27 160.79 14.59 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.174 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.859 ' CG2' HG23 ' A' ' 33' ' ' VAL . 24.9 t -151.09 159.42 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.841 -1.162 . . . . 0.0 110.514 -178.613 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 1.04 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -138.14 143.04 40.14 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.24 -0.912 . . . . 0.0 109.142 179.618 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.927 HD11 ' CB ' ' A' ' 29' ' ' LYS . 11.9 pt . . . . . 0 N--CA 1.494 1.728 0 O-C-N 120.825 -1.172 . . . . 0.0 109.001 179.742 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.927 ' CB ' HD11 ' A' ' 25' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.607 0 CA-C-O 121.895 0.855 . . . . 0.0 110.088 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.501 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 1.4 pm0 -136.04 156.6 48.49 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.059 -1.026 . . . . 0.0 110.194 -179.505 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.792 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -112.4 176.7 18.03 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 108.798 -1.721 . . . . 0.0 108.798 179.496 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.98 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -140.98 119.45 12.29 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.986 -1.302 . . . . 0.0 110.074 179.285 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.988 HG21 HD11 ' A' ' 50' ' ' LEU . 47.0 t -94.02 62.3 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.099 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.452 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.4 t-80 -48.56 156.18 0.47 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.857 -1.152 . . . . 0.0 108.712 -179.53 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.618 HG23 ' H ' ' A' ' 36' ' ' SER . 3.2 tp -45.52 -53.96 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.365 -0.834 . . . . 0.0 110.899 -179.117 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.618 ' H ' HG23 ' A' ' 35' ' ' ILE . 5.3 t -81.27 41.4 0.6 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.049 -1.032 . . . . 0.0 110.633 -179.254 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.995 ' C ' HD12 ' A' ' 38' ' ' ILE . 43.5 mt-30 -150.8 61.45 0.93 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.782 -1.199 . . . . 0.0 110.598 -179.843 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.995 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.9 mp -129.37 -95.56 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 120.849 -1.157 . . . . 0.0 109.684 179.372 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.794 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.3 -1.552 0 O-C-N 121.555 -0.715 . . . . 0.0 109.752 -179.251 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.074 HG13 ' CD1' ' A' ' 49' ' ' TYR . 75.7 t . . . . . 0 N--CA 1.489 1.505 0 N-CA-C 109.016 -0.735 . . . . 0.0 109.016 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . 0.453 ' C ' ' O ' ' A' ' 43' ' ' VAL . 0.3 OUTLIER -40.71 -32.24 0.2 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.631 -0.668 . . . . 0.0 109.621 -179.99 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.475 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 2.7 mtmp? -111.69 118.23 35.08 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.417 -0.802 . . . . 0.0 109.514 -179.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.91 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -74.93 -26.59 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 179.509 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 7.9 p -78.93 5.36 11.76 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.36 -0.838 . . . . 0.0 109.176 179.215 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.475 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 3.2 m-20 -98.43 -37.24 9.68 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 179.383 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 1.074 ' CD1' HG13 ' A' ' 43' ' ' VAL . 15.9 m-85 -90.28 -34.01 15.91 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.626 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 1.029 ' CD2' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -110.66 148.11 32.92 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.354 -0.841 . . . . 0.0 110.395 179.886 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.621 ' C ' HG11 ' A' ' 13' ' ' VAL . 2.3 tt0 -150.62 147.03 26.91 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.57 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 8.2 mtp -65.84 88.05 0.1 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.098 -1.001 . . . . 0.0 109.743 -179.593 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 145.19 -20.81 1.92 Allowed Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.725 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' GLN . . . . . 0.406 ' HG2' ' HB3' ' A' ' 51' ' ' GLN . 19.7 mm-40 -80.86 168.86 18.28 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.309 -1.112 . . . . 0.0 110.008 -179.733 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -144.04 116.77 8.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.387 -0.821 . . . . 0.0 109.097 179.684 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.5 m -114.41 142.31 27.92 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.13 -0.981 . . . . 0.0 109.359 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -78.93 142.39 17.45 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.351 2.034 . . . . 0.0 110.322 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.627 HG21 HD13 ' A' ' 71' ' ' LEU . 0.8 OUTLIER -138.1 174.96 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.333 -0.855 . . . . 0.0 109.32 -179.886 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.75 ' HG3' HG22 ' A' ' 8' ' ' VAL . 0.1 OUTLIER -126.64 111.16 14.0 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.284 -0.885 . . . . 0.0 109.381 179.511 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.487 ' HA ' HD23 ' A' ' 71' ' ' LEU . 80.4 t . . . . . 0 N--CA 1.491 1.617 0 O-C-N 121.524 -0.735 . . . . 0.0 109.077 179.707 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.792 HD12 ' HA3' ' A' ' 31' ' ' GLY . 22.5 mt . . . . . 0 N--CA 1.488 1.445 0 N-CA-C 109.216 -0.661 . . . . 0.0 109.216 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.49 99.07 8.61 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.448 -0.782 . . . . 0.0 110.498 -178.927 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.485 HG13 ' O ' ' A' ' 37' ' ' GLN . 15.5 mm -51.69 137.95 9.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.316 -0.865 . . . . 0.0 109.295 179.697 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.471 ' C ' ' O ' ' A' ' 73' ' ' ILE . 0.2 OUTLIER . . . . . 0 N--CA 1.497 1.897 0 O-C-N 121.587 -0.696 . . . . 0.0 110.102 -179.835 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.968 HG13 ' O ' ' A' ' 58' ' ' VAL . 75.9 t . . . . . 0 N--CA 1.49 1.554 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.629 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 11.0 m-85 -120.87 127.7 52.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.036 -1.04 . . . . 0.0 110.502 -179.287 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 5.6 m -97.04 109.22 22.02 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 178.501 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -110.77 150.1 17.74 Favored Glycine 0 N--CA 1.487 2.095 0 C-N-CA 119.472 -1.347 . . . . 0.0 110.495 -178.837 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.446 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.8 OUTLIER -89.81 163.02 15.21 Favored 'General case' 0 C--N 1.304 -1.394 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 179.08 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.828 ' CG2' HD22 ' A' ' 50' ' ' LEU . 41.6 t -89.0 103.27 13.8 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 O-C-N 121.096 -1.002 . . . . 0.0 108.754 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.747 HG21 ' CB ' ' A' ' 24' ' ' ALA . 0.5 OUTLIER -106.6 -12.46 15.57 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.282 -0.886 . . . . 0.0 109.779 -179.198 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.496 ' HD2' ' O ' ' A' ' 14' ' ' THR . 0.5 OUTLIER -159.26 153.9 24.42 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.054 -1.029 . . . . 0.0 110.41 -179.662 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.473 HG21 HG22 ' A' ' 47' ' ' THR . 11.1 mt -139.69 157.65 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 179.255 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 1.026 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -137.75 153.7 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 120.697 -1.252 . . . . 0.0 110.128 -178.947 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.69 -40.66 93.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.594 -1.316 . . . . 0.0 109.232 179.186 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 1.026 ' CE1' HG21 ' A' ' 17' ' ' VAL . 16.3 p90 -90.04 24.17 2.55 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.273 -0.892 . . . . 0.0 110.19 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.796 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 155.82 -153.5 24.8 Favored Glycine 0 N--CA 1.494 2.506 0 C-N-CA 119.091 -1.528 . . . . 0.0 111.272 -179.405 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.955 ' HB1' HD12 ' A' ' 50' ' ' LEU . . . -149.78 145.35 26.58 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.116 -1.226 . . . . 0.0 108.931 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.973 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.2 m-30 -107.78 145.25 33.81 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.337 -0.852 . . . . 0.0 109.232 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.901 ' CG2' HG23 ' A' ' 33' ' ' VAL . 48.9 t -133.33 167.52 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.134 -0.979 . . . . 0.0 109.597 -179.681 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.747 ' CB ' HG21 ' A' ' 14' ' ' THR . . . -136.64 135.29 38.17 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.884 -1.135 . . . . 0.0 110.78 -179.42 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.528 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.1 pt . . . . . 0 N--CA 1.494 1.75 0 O-C-N 120.94 -1.1 . . . . 0.0 108.863 178.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.528 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.555 0 N-CA-C 109.406 -0.59 . . . . 0.0 109.406 . . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.574 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 4.6 pt-20 -111.08 150.48 29.31 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.771 -1.206 . . . . 0.0 109.988 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.682 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -97.95 -175.4 33.47 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 108.03 -2.028 . . . . 0.0 108.03 178.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.973 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -151.13 121.04 7.09 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 120.89 -1.359 . . . . 0.0 111.39 179.645 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.901 HG23 ' CG2' ' A' ' 23' ' ' VAL . 71.8 t -94.67 61.81 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 177.286 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.517 ' O ' ' CD1' ' A' ' 38' ' ' ILE . 3.1 t-80 -49.54 152.83 1.27 Allowed 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.89 -1.131 . . . . 0.0 108.814 -179.165 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.578 ' O ' HD13 ' A' ' 38' ' ' ILE . 0.4 OUTLIER -46.96 -49.01 7.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.372 -0.83 . . . . 0.0 109.982 -179.591 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.516 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.3 OUTLIER -81.6 40.42 0.58 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.21 -0.931 . . . . 0.0 110.327 -179.819 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.775 ' C ' HD12 ' A' ' 38' ' ' ILE . 14.7 mm-40 -147.88 31.9 0.86 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.849 -1.157 . . . . 0.0 109.388 -179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.844 HG21 ' CD2' ' A' ' 49' ' ' TYR . 1.6 mp -111.22 -98.74 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 O-C-N 121.13 -0.981 . . . . 0.0 109.992 -179.581 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.776 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.511 0 O-C-N 121.323 -0.861 . . . . 0.0 109.38 -179.706 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.047 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 24.1 t . . . . . 0 N--CA 1.486 1.375 0 CA-C-O 121.426 0.631 . . . . 0.0 109.553 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -49.02 -22.61 0.92 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.442 -0.786 . . . . 0.0 109.426 179.619 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.539 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 1.3 mmpt? -130.11 113.05 14.03 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.315 -0.866 . . . . 0.0 109.945 -179.58 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.796 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -76.64 -26.05 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.233 -0.917 . . . . 0.0 108.839 179.563 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.473 HG22 HG21 ' A' ' 16' ' ' ILE . 52.9 p -76.56 3.74 10.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.838 . . . . 0.0 109.35 179.396 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.464 ' OD2' ' CB ' ' A' ' 45' ' ' LYS . 98.5 m-20 -103.88 -30.26 10.46 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.143 -0.973 . . . . 0.0 108.515 179.716 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 1.047 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 16.3 m-85 -91.24 -31.58 16.09 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 179.501 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.955 HD12 ' HB1' ' A' ' 21' ' ' ALA . 1.3 mt -108.23 155.22 20.71 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.278 -0.889 . . . . 0.0 109.418 179.446 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.497 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 5.9 tp60 -141.53 138.43 32.72 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.321 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 9.4 mtt -63.3 112.82 2.87 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.144 -0.973 . . . . 0.0 109.908 -179.497 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 108.3 -22.66 26.53 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' GLN . . . . . 0.492 ' CG ' ' HB3' ' A' ' 51' ' ' GLN . 35.3 mt-30 -68.94 162.6 26.34 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.173 -1.193 . . . . 0.0 109.89 -179.757 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -114.32 141.82 47.11 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.359 -0.838 . . . . 0.0 109.033 179.6 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.445 ' O ' HG23 ' A' ' 56' ' ' VAL . 31.7 m -144.13 131.04 10.31 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 120.948 -1.095 . . . . 0.0 110.25 -179.823 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.494 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.6 Cg_endo -80.65 154.14 20.51 Favored 'Trans proline' 0 C--N 1.316 -1.176 0 C-N-CA 122.65 2.233 . . . . 0.0 109.765 179.405 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.968 ' O ' HG13 ' A' ' 8' ' ' VAL . 0.9 OUTLIER -150.89 -169.73 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.035 -1.041 . . . . 0.0 109.625 179.733 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.625 ' N ' HG23 ' A' ' 58' ' ' VAL . 0.0 OUTLIER -135.68 138.53 42.89 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.469 -0.769 . . . . 0.0 109.205 179.557 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.629 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 5.1 t . . . . . 0 N--CA 1.49 1.551 0 O-C-N 121.334 -0.854 . . . . 0.0 108.853 179.758 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.682 HD12 ' HA3' ' A' ' 31' ' ' GLY . 19.4 mt . . . . . 0 N--CA 1.489 1.525 0 N-CA-C 109.28 -0.637 . . . . 0.0 109.28 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.16 117.55 20.96 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.509 -0.744 . . . . 0.0 110.001 -179.145 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.429 ' HB ' ' O ' ' A' ' 37' ' ' GLN . 0.0 OUTLIER -56.07 133.05 20.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.223 -0.923 . . . . 0.0 109.037 179.883 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.493 1.707 0 O-C-N 121.467 -0.771 . . . . 0.0 110.05 -179.302 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.458 HG13 ' O ' ' A' ' 58' ' ' VAL . 23.9 t . . . . . 0 N--CA 1.487 1.425 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.673 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 4.0 m-85 -122.64 136.79 54.98 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.037 -1.04 . . . . 0.0 110.195 -178.848 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 7.0 m -90.34 102.66 15.39 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 178.125 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.472 ' HA3' HG11 ' A' ' 23' ' ' VAL . . . -79.54 128.39 8.51 Favored Glycine 0 N--CA 1.488 2.114 0 C-N-CA 119.843 -1.17 . . . . 0.0 110.794 -178.197 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.58 ' O ' HG13 ' A' ' 23' ' ' VAL . 6.1 mttt -89.08 147.61 24.14 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 178.29 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.729 HG13 HD12 ' A' ' 50' ' ' LEU . 17.1 t -86.42 104.2 13.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 O-C-N 120.384 -1.447 . . . . 0.0 108.708 -179.289 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.914 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.5 p -111.29 -9.15 14.3 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.697 -0.627 . . . . 0.0 109.858 -178.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.551 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 1.1 mpp_? -166.76 157.82 12.41 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.026 -1.046 . . . . 0.0 110.256 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.556 HG21 HG22 ' A' ' 47' ' ' THR . 14.7 mt -144.1 153.66 15.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.057 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 1.061 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.9 OUTLIER -133.67 155.46 40.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.835 -1.165 . . . . 0.0 109.884 -179.413 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -59.34 -41.74 89.89 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.753 -1.217 . . . . 0.0 109.345 179.444 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 1.061 ' CE1' HG21 ' A' ' 17' ' ' VAL . 12.8 p90 -91.33 26.56 2.2 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.346 -0.846 . . . . 0.0 110.296 -179.609 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.772 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 156.25 -152.99 24.37 Favored Glycine 0 N--CA 1.493 2.456 0 C-N-CA 119.108 -1.52 . . . . 0.0 111.174 -179.669 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.912 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -152.24 144.54 23.99 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.259 -1.142 . . . . 0.0 109.017 -179.657 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.972 ' CE1' HD11 ' A' ' 32' ' ' LEU . 9.6 m-30 -105.28 152.72 22.55 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.171 -0.956 . . . . 0.0 109.244 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.801 ' CG2' HG23 ' A' ' 33' ' ' VAL . 35.5 t -145.35 162.95 12.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.266 -0.896 . . . . 0.0 109.385 -179.476 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.914 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -135.18 130.72 35.79 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.852 -1.155 . . . . 0.0 110.089 -179.066 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.526 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.0 OUTLIER . . . . . 0 N--CA 1.492 1.673 0 O-C-N 120.938 -1.101 . . . . 0.0 109.157 179.504 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.526 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.1 OUTLIER . . . . . 0 N--CA 1.491 1.599 0 CA-C-O 121.433 0.635 . . . . 0.0 109.421 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.553 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 2.8 mt-10 -105.91 148.46 27.59 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 120.725 -1.234 . . . . 0.0 109.628 179.772 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 23' ' ' VAL . . . -98.97 -179.36 31.71 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 108.452 -1.859 . . . . 0.0 108.452 179.342 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.972 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.64 117.37 5.82 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 120.814 -1.404 . . . . 0.0 110.652 179.577 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.912 ' HB ' ' HB3' ' A' ' 21' ' ' ALA . 30.1 t -91.23 61.06 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 177.51 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.568 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.7 t-80 -50.73 156.28 0.98 Allowed 'General case' 0 C--N 1.304 -1.394 0 O-C-N 120.964 -1.085 . . . . 0.0 108.624 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.556 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.9 OUTLIER -48.87 -47.35 16.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.171 -0.956 . . . . 0.0 109.789 -179.954 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.541 ' N ' HG23 ' A' ' 35' ' ' ILE . 37.4 t -81.42 40.2 0.56 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.158 -0.964 . . . . 0.0 110.647 -179.498 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.932 ' C ' HD12 ' A' ' 38' ' ' ILE . 35.9 mt-30 -150.51 43.35 0.84 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.851 -1.155 . . . . 0.0 110.032 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 0.932 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.6 mp -120.68 -98.97 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.086 -1.008 . . . . 0.0 109.521 179.719 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.765 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.301 -1.534 0 O-C-N 121.244 -0.91 . . . . 0.0 109.636 -179.725 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.024 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 17.7 t . . . . . 0 N--CA 1.484 1.263 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -44.91 -21.33 0.05 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.544 -0.722 . . . . 0.0 110.316 -179.686 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.539 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 5.7 mttt -139.1 117.5 12.01 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.013 -1.054 . . . . 0.0 110.191 -179.433 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.772 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -72.52 -27.61 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.38 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . 0.556 HG22 HG21 ' A' ' 16' ' ' ILE . 81.9 p -75.97 1.26 15.79 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.798 -0.761 . . . . 0.0 109.15 179.439 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.469 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 2.1 m-20 -97.71 -35.35 10.59 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.291 -0.881 . . . . 0.0 109.041 179.696 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 1.024 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 7.0 m-85 -91.46 -27.38 18.31 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.404 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.874 HD21 HG21 ' A' ' 33' ' ' VAL . 0.2 OUTLIER -104.46 140.31 38.13 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 179.598 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.563 ' O ' HG21 ' A' ' 13' ' ' VAL . 4.1 tp-100 -132.41 124.46 28.69 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.198 -0.939 . . . . 0.0 109.788 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . 0.474 ' O ' ' HG3' ' A' ' 52' ' ' MET . 23.6 ptp -58.42 130.07 45.01 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.381 -0.824 . . . . 0.0 109.869 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 93.86 -31.17 6.75 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 179.598 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' GLN . . . . . 0.485 ' HB2' ' HB3' ' A' ' 51' ' ' GLN . 56.8 mt-30 -77.97 -172.94 2.91 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.129 -1.218 . . . . 0.0 109.817 -179.62 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -143.56 157.06 44.72 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.441 -0.787 . . . . 0.0 108.943 179.704 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -140.0 140.91 25.29 Favored Pre-proline 0 C--N 1.303 -1.423 0 O-C-N 121.143 -0.973 . . . . 0.0 109.581 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.444 ' O ' ' HB3' ' A' ' 74' ' ' LYS . 36.3 Cg_endo -79.24 130.38 9.17 Favored 'Trans proline' 0 C--N 1.311 -1.403 0 C-N-CA 122.438 2.092 . . . . 0.0 109.9 179.551 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.911 HG21 HD12 ' A' ' 71' ' ' LEU . 1.1 m -143.18 -170.02 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.087 -1.008 . . . . 0.0 109.99 -179.631 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.537 ' N ' HG23 ' A' ' 58' ' ' VAL . 0.5 OUTLIER -135.08 126.81 29.12 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.672 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.673 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 36.2 t . . . . . 0 N--CA 1.488 1.473 0 O-C-N 121.278 -0.889 . . . . 0.0 109.306 -179.757 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.911 HD12 HG21 ' A' ' 58' ' ' VAL . 3.4 mm? . . . . . 0 N--CA 1.491 1.577 0 CA-C-O 121.24 0.543 . . . . 0.0 109.654 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.421 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.4 OUTLIER -112.14 106.26 14.83 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.393 -0.817 . . . . 0.0 109.704 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.472 HD11 HG22 ' A' ' 33' ' ' VAL . 0.9 OUTLIER -52.02 144.19 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.108 -0.995 . . . . 0.0 109.303 -179.871 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.444 ' HB3' ' O ' ' A' ' 57' ' ' PRO . 1.0 OUTLIER . . . . . 0 N--CA 1.491 1.615 0 O-C-N 121.371 -0.831 . . . . 0.0 109.843 -179.692 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' VAL . . . . . 0.795 HG22 ' HG3' ' A' ' 59' ' ' LYS . 71.3 t . . . . . 0 N--CA 1.491 1.593 0 N-CA-C 109.306 -0.627 . . . . 0.0 109.306 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' TYR . . . . . 0.496 ' CE1' HG21 ' A' ' 60' ' ' VAL . 3.1 m-85 -106.27 -174.67 2.59 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.147 -0.97 . . . . 0.0 109.836 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 11.4 m -147.28 110.79 4.92 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.43 ' HA2' ' HA ' ' A' ' 25' ' ' ILE . . . -121.26 143.24 15.96 Favored Glycine 0 N--CA 1.488 2.122 0 C-N-CA 118.868 -1.634 . . . . 0.0 110.908 -178.194 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' LYS . . . . . 0.45 ' O ' HG13 ' A' ' 23' ' ' VAL . 8.8 mttp -90.43 165.58 13.75 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' VAL . . . . . 0.834 HG22 HD13 ' A' ' 50' ' ' LEU . 39.1 t -88.27 102.89 13.16 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.744 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.487 179.426 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.774 HG21 ' CB ' ' A' ' 24' ' ' ALA . 0.1 OUTLIER -101.75 -7.98 22.11 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.292 -0.88 . . . . 0.0 109.494 -179.351 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' ARG . . . . . 0.504 ' CG ' ' C ' ' A' ' 14' ' ' THR . 0.0 OUTLIER -167.64 147.24 5.02 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.151 -0.968 . . . . 0.0 109.613 -179.599 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' ILE . . . . . 0.532 HG22 ' N ' ' A' ' 17' ' ' VAL . 62.1 mt -131.13 163.34 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' VAL . . . . . 1.059 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -138.82 154.38 26.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 120.726 -1.234 . . . . 0.0 110.425 -179.559 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -59.23 -43.16 92.34 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.843 -1.161 . . . . 0.0 109.812 179.531 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' PHE . . . . . 1.059 ' CE1' HG21 ' A' ' 17' ' ' VAL . 6.4 p90 -92.12 25.6 2.81 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.249 -0.907 . . . . 0.0 110.266 -179.384 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' GLY . . . . . 0.864 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 157.66 -154.79 25.84 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 119.033 -1.556 . . . . 0.0 110.98 -179.71 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' ALA . . . . . 0.772 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -149.61 145.97 27.05 Favored 'General case' 0 N--CA 1.486 1.345 0 O-C-N 121.089 -1.242 . . . . 0.0 108.995 -179.759 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' PHE . . . . . 0.967 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.8 m-30 -106.87 158.2 17.19 Favored 'General case' 0 C--N 1.298 -1.672 0 O-C-N 121.316 -0.865 . . . . 0.0 108.738 179.481 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' VAL . . . . . 0.908 ' CG2' HG23 ' A' ' 33' ' ' VAL . 37.6 t -148.34 166.34 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.069 -1.02 . . . . 0.0 109.755 -179.507 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' ALA . . . . . 0.774 ' CB ' HG21 ' A' ' 14' ' ' THR . . . -137.91 144.65 41.4 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.287 -0.883 . . . . 0.0 109.539 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ILE . . . . . 0.535 ' CG1' ' O ' ' A' ' 29' ' ' LYS . 5.5 pt . . . . . 0 N--CA 1.494 1.771 0 O-C-N 120.625 -1.297 . . . . 0.0 108.562 179.253 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' LYS . . . . . 0.535 ' O ' ' CG1' ' A' ' 25' ' ' ILE . 0.4 OUTLIER . . . . . 0 N--CA 1.492 1.674 0 CA-C-O 121.684 0.754 . . . . 0.0 110.06 . . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' GLU . . . . . 0.568 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 12.6 mp0 -123.39 153.24 40.65 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.836 -1.165 . . . . 0.0 110.109 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' GLY . . . . . 0.56 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -103.67 -175.48 25.92 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 108.8 -1.72 . . . . 0.0 108.8 179.521 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' LEU . . . . . 0.967 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.57 119.82 6.81 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.97 -1.312 . . . . 0.0 110.552 179.624 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . 0.908 HG23 ' CG2' ' A' ' 23' ' ' VAL . 25.2 t -96.84 63.21 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 177.736 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' HIS . . . . . 0.532 ' O ' ' CD1' ' A' ' 38' ' ' ILE . 7.7 t-80 -48.64 162.57 0.1 Allowed 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.741 -1.224 . . . . 0.0 108.359 -179.627 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.636 ' O ' HD13 ' A' ' 38' ' ' ILE . 0.4 OUTLIER -55.5 -45.79 78.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.012 -1.055 . . . . 0.0 110.53 -179.49 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' SER . . . . . 0.489 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.9 OUTLIER -80.05 23.77 0.45 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.153 -0.967 . . . . 0.0 110.795 -179.338 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' GLN . . . . . 0.992 ' C ' HD12 ' A' ' 38' ' ' ILE . 3.4 mm100 -138.74 64.18 1.49 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.883 -1.136 . . . . 0.0 109.293 179.546 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ILE . . . . . 1.069 HG21 HG21 ' A' ' 43' ' ' VAL . 1.8 mp -129.35 -94.59 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.042 -1.036 . . . . 0.0 109.704 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' ALA . . . . . 0.803 ' N ' HG22 ' A' ' 38' ' ' ILE . . . . . . . . 0 C--N 1.3 -1.544 0 O-C-N 121.455 -0.778 . . . . 0.0 109.852 -179.346 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' VAL . . . . . 1.069 HG21 HG21 ' A' ' 38' ' ' ILE . 44.3 t . . . . . 0 N--CA 1.482 1.154 0 N-CA-C 109.06 -0.719 . . . . 0.0 109.06 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -53.98 -19.02 4.06 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.365 -0.834 . . . . 0.0 109.114 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' LYS . . . . . 0.543 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.2 OUTLIER -121.68 108.19 13.25 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.436 -0.79 . . . . 0.0 109.748 -179.569 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' VAL . . . . . 0.864 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -76.3 -24.76 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.331 -0.856 . . . . 0.0 109.179 179.972 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.2 p -78.28 5.95 9.28 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.364 -0.835 . . . . 0.0 109.541 179.873 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' ASP . . . . . 0.457 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 10.2 m-20 -104.35 -37.59 7.17 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.136 -0.977 . . . . 0.0 108.716 179.548 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' TYR . . . . . 1.028 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 11.7 m-85 -89.84 -38.01 14.05 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.532 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' LEU . . . . . 0.834 HD13 HG22 ' A' ' 13' ' ' VAL . 0.2 OUTLIER -96.45 136.02 37.52 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.435 -0.791 . . . . 0.0 109.301 -179.931 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' GLN . . . . . 0.52 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.9 OUTLIER -129.72 132.57 46.66 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.659 -0.651 . . . . 0.0 109.372 -179.517 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 11.5 mtt -57.31 113.52 1.79 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.313 -0.867 . . . . 0.0 109.661 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 106.14 -34.09 6.0 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.636 -1.385 . . . . 0.0 109.636 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' GLN . . . . . 0.472 ' O ' HG23 ' A' ' 13' ' ' VAL . 6.9 mt-30 -54.4 143.02 24.94 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.32 -1.106 . . . . 0.0 110.025 -179.722 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -104.15 129.39 51.88 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.313 -0.867 . . . . 0.0 108.898 179.368 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.405 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 33.2 m -132.78 134.48 24.65 Favored Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 120.99 -1.069 . . . . 0.0 110.085 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' PRO . . . . . 0.471 ' O ' ' HB2' ' A' ' 74' ' ' LYS . 37.0 Cg_endo -81.72 143.51 13.38 Favored 'Trans proline' 0 C--N 1.314 -1.283 0 C-N-CA 122.705 2.27 . . . . 0.0 110.015 179.341 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' VAL . . . . . 0.737 HG21 HD13 ' A' ' 71' ' ' LEU . 0.9 OUTLIER -135.31 -177.87 2.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.062 -1.024 . . . . 0.0 109.322 179.676 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . 0.795 ' HG3' HG22 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -131.72 110.78 11.13 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.277 -0.889 . . . . 0.0 109.212 179.737 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' VAL . . . . . 0.496 HG21 ' CE1' ' A' ' 9' ' ' TYR . 25.1 t . . . . . 0 N--CA 1.492 1.647 0 O-C-N 121.374 -0.829 . . . . 0.0 109.112 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' LEU . . . . . 0.737 HD13 HG21 ' A' ' 58' ' ' VAL . 23.4 mt . . . . . 0 N--CA 1.489 1.48 0 CA-C-O 121.352 0.596 . . . . 0.0 109.477 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' SER . . . . . 0.508 ' CB ' ' HB2' ' A' ' 59' ' ' LYS . 0.3 OUTLIER -100.66 110.63 22.77 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.336 -0.852 . . . . 0.0 109.546 179.931 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' ILE . . . . . 0.602 HD13 ' O ' ' A' ' 37' ' ' GLN . 1.9 mp -62.68 127.11 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.496 -0.752 . . . . 0.0 109.733 -179.738 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' LYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 57' ' ' PRO . 0.0 OUTLIER . . . . . 0 N--CA 1.491 1.602 0 O-C-N 121.301 -0.874 . . . . 0.0 109.29 179.666 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.493 ' O ' ' HG2' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.544 0 N-CA-C 109.505 -0.554 . . . . 0.0 109.505 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.493 ' HG2' ' O ' ' A' ' 1' ' ' ALA . 1.3 pt-20 41.05 -166.51 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.75 0 O-C-N 121.659 -0.651 . . . . 0.0 109.837 -179.85 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.573 HG21 ' OH ' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -141.34 -167.44 0.36 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.145 -0.972 . . . . 0.0 109.588 -179.301 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 35.3 tt0 -121.73 141.55 51.07 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.425 -0.797 . . . . 0.0 109.053 179.376 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.783 HG22 HG11 ' A' ' 60' ' ' VAL . 2.6 t -80.14 161.66 3.92 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.179 -0.951 . . . . 0.0 109.74 -179.655 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.49 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 95.97 -7.02 67.17 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.43 -1.468 . . . . 0.0 109.43 -179.913 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 1.1 ttm180 -98.44 168.14 10.39 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.3 -1.118 . . . . 0.0 109.646 -179.827 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.48 HG13 ' O ' ' A' ' 58' ' ' VAL . 40.6 t -89.87 150.83 3.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.371 -0.831 . . . . 0.0 108.899 179.758 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.622 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 15.2 m-85 -136.17 129.19 31.32 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 120.967 -1.083 . . . . 0.0 110.386 -179.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 5.5 m -76.91 102.06 6.21 Favored 'General case' 0 C--N 1.302 -1.473 0 N-CA-C 107.523 -1.288 . . . . 0.0 107.523 178.264 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -83.14 113.81 3.74 Favored Glycine 0 N--CA 1.488 2.153 0 C-N-CA 119.813 -1.184 . . . . 0.0 110.73 -178.262 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.574 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -89.31 153.87 20.54 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 108.002 -1.11 . . . . 0.0 108.002 178.697 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.991 HG22 HD13 ' A' ' 50' ' ' LEU . 77.1 t -87.43 116.11 29.12 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 O-C-N 120.759 -1.213 . . . . 0.0 109.116 -179.572 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 1.135 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.2 OUTLIER -126.72 7.24 6.8 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.386 -0.821 . . . . 0.0 109.473 -179.396 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.539 ' HB3' ' HB2' ' A' ' 22' ' ' PHE . 1.9 mtp180 -178.26 149.52 0.53 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.304 -0.872 . . . . 0.0 109.575 179.692 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.405 HG22 ' N ' ' A' ' 17' ' ' VAL . 33.6 mt -140.9 157.16 22.96 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.785 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 179.487 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 1.018 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -135.78 152.93 31.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.858 -1.151 . . . . 0.0 110.057 -179.395 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 1.8 t70 -58.62 -41.44 85.93 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 120.721 -1.237 . . . . 0.0 109.035 179.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.018 ' CE1' HG21 ' A' ' 17' ' ' VAL . 17.3 p90 -90.41 28.68 1.41 Allowed 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.363 -0.836 . . . . 0.0 110.33 -179.821 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.594 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 151.72 -152.29 24.07 Favored Glycine 0 N--CA 1.491 2.326 0 C-N-CA 119.073 -1.537 . . . . 0.0 111.018 -179.607 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.801 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -151.75 147.11 26.29 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.125 -1.221 . . . . 0.0 108.938 -179.979 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.972 ' CE1' HD11 ' A' ' 32' ' ' LEU . 8.8 m-30 -106.93 158.66 16.85 Favored 'General case' 0 C--N 1.3 -1.584 0 N-CA-C 108.672 -0.862 . . . . 0.0 108.672 179.642 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.933 ' CG2' HG23 ' A' ' 33' ' ' VAL . 31.8 t -147.61 161.92 7.45 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.035 -1.041 . . . . 0.0 109.858 -179.154 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 1.135 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -139.74 150.34 44.68 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.103 -0.998 . . . . 0.0 109.436 179.924 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.678 HD11 ' HB2' ' A' ' 29' ' ' LYS . 4.5 pt -112.53 -0.98 9.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 O-C-N 120.823 -1.173 . . . . 0.0 109.706 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 69.31 146.98 0.23 Allowed Glycine 0 N--CA 1.49 2.233 0 N-CA-C 109.65 -1.38 . . . . 0.0 109.65 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 106.36 -3.59 37.43 Favored Glycine 0 N--CA 1.491 2.324 0 N-CA-C 109.715 -1.354 . . . . 0.0 109.715 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 110.73 1.95 28.89 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.585 -1.406 . . . . 0.0 109.585 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.678 ' HB2' HD11 ' A' ' 25' ' ' ILE . 14.7 mtpt -129.42 143.55 50.89 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.194 -1.18 . . . . 0.0 109.389 -179.891 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.577 ' H ' HD13 ' A' ' 69' ' ' ILE . 1.1 mt-10 -130.34 158.8 38.83 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.061 -1.024 . . . . 0.0 110.356 -179.678 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.627 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -108.68 -173.73 21.48 Favored Glycine 0 N--CA 1.489 2.199 0 N-CA-C 108.761 -1.736 . . . . 0.0 108.761 179.328 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.972 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.26 123.21 8.76 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 120.853 -1.381 . . . . 0.0 110.682 179.751 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.933 HG23 ' CG2' ' A' ' 23' ' ' VAL . 60.8 t -97.67 62.16 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 177.662 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.496 ' HB3' ' HG3' ' A' ' 37' ' ' GLN . 3.3 t-80 -48.39 159.49 0.21 Allowed 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.692 -1.255 . . . . 0.0 108.147 -179.623 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.594 ' O ' HD13 ' A' ' 38' ' ' ILE . 3.1 tp -48.58 -50.35 12.84 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.587 0 O-C-N 121.099 -1.001 . . . . 0.0 110.09 -179.121 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.536 ' N ' HG23 ' A' ' 35' ' ' ILE . 5.3 m -81.57 41.22 0.62 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.182 -0.949 . . . . 0.0 110.424 -179.656 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.905 ' C ' HD12 ' A' ' 38' ' ' ILE . 40.3 mt-30 -150.69 53.0 0.88 Allowed 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.847 -1.158 . . . . 0.0 110.245 -179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.944 HG21 HG21 ' A' ' 43' ' ' VAL . 1.6 mp -119.09 -98.92 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.928 -1.107 . . . . 0.0 109.936 179.772 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.765 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -126.42 162.28 25.94 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.315 -0.866 . . . . 0.0 109.641 -179.424 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -47.3 -33.1 5.29 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.225 -0.922 . . . . 0.0 109.09 179.594 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.4 OUTLIER -66.74 141.88 57.58 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.277 -0.889 . . . . 0.0 109.39 179.917 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 80.0 mtp180 -61.07 114.64 3.22 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.22 -0.925 . . . . 0.0 109.531 -179.957 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.152 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 80.4 t -101.99 55.0 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.263 -0.898 . . . . 0.0 108.861 179.591 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.425 ' C ' ' O ' ' A' ' 43' ' ' VAL . 0.0 OUTLIER -43.73 -26.66 0.26 Allowed 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.38 -0.825 . . . . 0.0 108.896 179.849 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.455 ' HB3' ' CG ' ' A' ' 48' ' ' ASP . 0.1 OUTLIER -109.83 114.33 27.8 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.495 -0.753 . . . . 0.0 108.988 179.479 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.594 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -78.16 -24.14 13.8 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 O-C-N 121.141 -0.975 . . . . 0.0 108.62 179.747 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 3.7 p -76.22 1.61 15.45 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.44 -0.787 . . . . 0.0 109.344 179.334 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.455 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 14.4 m-20 -96.05 -40.35 9.29 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.111 -0.993 . . . . 0.0 108.926 179.682 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 1.152 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 9.5 m-85 -89.56 -28.77 19.36 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.487 -0.758 . . . . 0.0 109.019 179.715 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.991 HD13 HG22 ' A' ' 13' ' ' VAL . 0.1 OUTLIER -102.75 134.74 45.64 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.504 -0.748 . . . . 0.0 109.537 -179.842 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.517 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 1.9 tt0 -140.39 143.03 35.45 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.59 -0.694 . . . . 0.0 109.314 179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 39.1 mtm -67.54 93.77 0.38 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.179 -0.951 . . . . 0.0 109.441 179.864 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 131.69 -18.91 4.81 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.442 -1.463 . . . . 0.0 109.442 -179.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . 0.466 ' O ' HG23 ' A' ' 13' ' ' VAL . 11.6 mm-40 -79.7 124.86 28.96 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.328 -1.101 . . . . 0.0 109.637 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 3.5 mt-10 -106.27 117.78 34.94 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.257 -0.902 . . . . 0.0 109.109 179.854 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.455 HG21 HD11 ' A' ' 73' ' ' ILE . 33.8 m -118.98 151.76 50.85 Favored Pre-proline 0 N--CA 1.492 1.642 0 O-C-N 121.134 -0.979 . . . . 0.0 109.836 -179.766 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.415 ' HD3' ' HA ' ' A' ' 56' ' ' VAL . 36.0 Cg_endo -78.87 142.57 17.72 Favored 'Trans proline' 0 C--N 1.309 -1.514 0 C-N-CA 122.695 2.264 . . . . 0.0 110.509 179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.788 HG21 ' HB3' ' A' ' 71' ' ' LEU . 0.9 OUTLIER -141.67 -177.22 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.211 -0.931 . . . . 0.0 109.354 179.622 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.488 ' O ' ' N ' ' A' ' 61' ' ' LEU . 0.0 OUTLIER -134.03 128.73 34.92 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.283 -0.886 . . . . 0.0 109.475 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.783 HG11 HG22 ' A' ' 5' ' ' VAL . 62.0 t -55.21 89.53 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.266 -0.896 . . . . 0.0 109.037 179.504 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.591 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 10.3 tp -57.05 -34.8 68.59 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.35 -0.843 . . . . 0.0 108.879 -179.98 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.591 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 0.1 OUTLIER 151.58 177.95 0.0 OUTLIER 'General case' 0 N--CA 1.5 2.059 0 CA-C-O 121.332 0.587 . . . . 0.0 109.537 179.586 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.784 HG22 ' HA ' ' A' ' 69' ' ' ILE . 60.3 t -143.17 106.27 1.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.365 -0.834 . . . . 0.0 109.387 179.568 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 30.8 p30 -63.16 -172.07 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.255 -0.903 . . . . 0.0 109.784 -179.796 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 16.9 mtm180 -75.52 -1.12 22.79 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.367 -0.833 . . . . 0.0 109.587 179.985 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -91.05 8.75 33.87 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.131 -0.981 . . . . 0.0 109.509 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 56.18 28.11 53.59 Favored Glycine 0 N--CA 1.491 2.316 0 N-CA-C 109.661 -1.376 . . . . 0.0 109.661 179.895 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.416 ' O ' ' C ' ' A' ' 69' ' ' ILE . 35.0 mmm-85 -90.82 84.41 5.82 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.285 -1.127 . . . . 0.0 109.351 179.841 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.784 ' HA ' HG22 ' A' ' 63' ' ' VAL . 4.3 mt -42.83 105.34 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.325 -0.859 . . . . 0.0 109.788 -179.873 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.428 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 0.7 OUTLIER -90.99 94.5 9.67 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.249 -0.907 . . . . 0.0 109.359 179.754 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.788 ' HB3' HG21 ' A' ' 58' ' ' VAL . 15.1 mt -89.82 151.51 21.74 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.176 -0.953 . . . . 0.0 109.23 179.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.578 ' OG ' HD13 ' A' ' 61' ' ' LEU . 0.6 OUTLIER -118.21 106.64 13.03 Favored 'General case' 0 N--CA 1.488 1.449 0 O-C-N 121.341 -0.849 . . . . 0.0 109.871 -179.618 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.477 HG22 ' O ' ' A' ' 38' ' ' ILE . 0.1 OUTLIER -58.77 139.12 18.91 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.269 -0.894 . . . . 0.0 109.001 179.865 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 2.4 mmtm -74.28 -94.9 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.26 -0.9 . . . . 0.0 109.281 179.803 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 28.5 mt-10 -156.82 45.35 0.4 Allowed 'General case' 0 C--N 1.3 -1.574 0 O-C-N 121.29 -0.881 . . . . 0.0 109.45 179.821 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 118.029 -0.986 . . . . 0.0 109.476 -179.97 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 121.295 0.569 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.471 ' O ' ' CB ' ' A' ' 3' ' ' ILE . 0.1 OUTLIER -141.39 172.73 12.27 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.188 -0.945 . . . . 0.0 109.645 -179.949 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.637 HD13 ' HD2' ' A' ' 7' ' ' ARG . 0.3 OUTLIER 170.38 129.24 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 O-C-N 121.444 -0.785 . . . . 0.0 109.323 -179.46 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -142.3 -160.1 1.05 Allowed 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.369 -0.832 . . . . 0.0 109.297 179.908 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.57 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 3.2 t -71.77 167.62 2.06 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.177 -0.952 . . . . 0.0 109.087 179.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.57 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 77.42 2.11 78.49 Favored Glycine 0 N--CA 1.489 2.168 0 N-CA-C 109.235 -1.546 . . . . 0.0 109.235 -179.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.637 ' HD2' HD13 ' A' ' 3' ' ' ILE . 0.4 OUTLIER -102.08 169.85 8.48 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.269 -1.136 . . . . 0.0 109.291 179.901 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.624 HG13 ' O ' ' A' ' 58' ' ' VAL . 48.1 t -101.29 134.55 41.17 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.198 -0.939 . . . . 0.0 109.385 179.96 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.506 ' CE1' HG21 ' A' ' 60' ' ' VAL . 3.0 m-85 -110.31 179.92 3.95 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.156 -0.965 . . . . 0.0 109.392 179.775 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.473 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 3.5 m -136.65 107.58 6.68 Favored 'General case' 0 C--N 1.3 -1.572 0 N-CA-C 107.85 -1.167 . . . . 0.0 107.85 178.94 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.507 ' HA2' ' O ' ' A' ' 24' ' ' ALA . . . -109.82 141.6 16.2 Favored Glycine 0 N--CA 1.486 2.013 0 C-N-CA 119.065 -1.541 . . . . 0.0 110.331 -178.743 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.455 ' O ' HG13 ' A' ' 23' ' ' VAL . 27.4 mtpt -89.15 163.73 15.32 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 107.892 -1.151 . . . . 0.0 107.892 178.939 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.968 HG22 HD23 ' A' ' 50' ' ' LEU . 95.3 t -87.43 102.02 11.94 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 179.6 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.725 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.2 p -106.12 -11.67 16.02 Favored 'General case' 0 C--N 1.301 -1.543 0 O-C-N 121.478 -0.764 . . . . 0.0 110.186 -178.62 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.562 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -161.2 156.33 24.07 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 120.954 -1.091 . . . . 0.0 110.455 -179.781 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.462 ' HA ' ' HA ' ' A' ' 21' ' ' ALA . 24.1 mt -147.61 142.77 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.724 0 N-CA-C 108.014 -1.106 . . . . 0.0 108.014 179.161 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 1.086 HG21 ' CE1' ' A' ' 19' ' ' PHE . 1.5 m -120.79 157.82 23.55 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 120.898 -1.126 . . . . 0.0 110.186 -178.771 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.2 -39.41 86.46 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 120.807 -1.183 . . . . 0.0 109.459 179.097 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.086 ' CE1' HG21 ' A' ' 17' ' ' VAL . 10.1 p90 -95.16 27.06 3.4 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.14 -0.975 . . . . 0.0 110.222 -179.919 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.597 ' N ' HG22 ' A' ' 17' ' ' VAL . . . 158.29 -157.43 28.31 Favored Glycine 0 N--CA 1.49 2.244 0 C-N-CA 118.936 -1.602 . . . . 0.0 110.802 -179.917 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.778 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -149.23 145.4 27.1 Favored 'General case' 0 C--N 1.303 -1.435 0 O-C-N 121.215 -1.168 . . . . 0.0 109.154 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.965 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.3 m-30 -106.5 158.4 16.94 Favored 'General case' 0 C--N 1.297 -1.68 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 179.467 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.798 ' CG2' HG23 ' A' ' 33' ' ' VAL . 32.3 t -148.87 164.95 4.26 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.067 -1.02 . . . . 0.0 109.533 -179.548 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.725 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -133.76 152.93 52.01 Favored 'General case' 0 N--CA 1.493 1.678 0 O-C-N 121.032 -1.043 . . . . 0.0 109.998 -179.478 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.667 HD11 ' HB3' ' A' ' 29' ' ' LYS . 2.0 pt -118.0 -99.78 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.494 1.74 0 O-C-N 120.666 -1.271 . . . . 0.0 109.429 179.362 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -63.83 -127.59 0.01 OUTLIER Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.58 -1.408 . . . . 0.0 109.58 180.0 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -117.97 -38.11 0.84 Allowed Glycine 0 N--CA 1.491 2.306 0 N-CA-C 109.372 -1.491 . . . . 0.0 109.372 179.902 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -99.89 1.81 56.71 Favored Glycine 0 N--CA 1.49 2.257 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.667 ' HB3' HD11 ' A' ' 25' ' ' ILE . 0.0 OUTLIER -127.53 143.23 51.21 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.184 -1.186 . . . . 0.0 109.8 179.949 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.59 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 13.8 mt-10 -134.6 154.08 51.66 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 120.925 -1.109 . . . . 0.0 110.222 -179.894 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.67 ' CA ' HD12 ' A' ' 71' ' ' LEU . . . -101.06 -175.99 29.12 Favored Glycine 0 N--CA 1.489 2.214 0 N-CA-C 108.478 -1.849 . . . . 0.0 108.478 179.307 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.965 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.17 119.31 6.76 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 120.979 -1.306 . . . . 0.0 110.73 179.429 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 1.021 HG21 HD11 ' A' ' 50' ' ' LEU . 41.3 t -95.93 62.21 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.573 0 N-CA-C 107.952 -1.129 . . . . 0.0 107.952 177.907 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.519 ' O ' ' CD1' ' A' ' 38' ' ' ILE . 3.9 t-160 -49.37 160.12 0.27 Allowed 'General case' 0 C--N 1.303 -1.44 0 O-C-N 120.898 -1.127 . . . . 0.0 108.46 -179.49 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.593 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.9 tp -52.2 -49.58 40.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.236 -0.915 . . . . 0.0 110.286 -179.284 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.557 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.4 OUTLIER -81.28 41.34 0.6 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.16 -0.963 . . . . 0.0 110.582 -179.331 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.732 ' C ' HD12 ' A' ' 38' ' ' ILE . 30.7 mt-30 -150.65 33.38 0.62 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.766 -1.209 . . . . 0.0 110.42 179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.759 ' HB ' HG21 ' A' ' 43' ' ' VAL . 1.5 mp -108.72 -96.29 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.648 0 O-C-N 120.815 -1.178 . . . . 0.0 110.157 179.897 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.667 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -92.76 47.05 1.26 Allowed 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.361 -0.837 . . . . 0.0 110.326 -178.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.568 ' CB ' ' O ' ' A' ' 39' ' ' ALA . 6.5 t70 83.01 -45.65 0.13 Allowed 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.596 -0.69 . . . . 0.0 110.495 179.125 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.479 ' O ' ' O ' ' A' ' 42' ' ' ARG . 0.0 OUTLIER -166.61 -33.41 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.703 0 O-C-N 120.88 -1.137 . . . . 0.0 110.043 -179.707 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.514 ' C ' HG23 ' A' ' 43' ' ' VAL . 9.2 mtp180 -56.66 -159.37 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.168 -0.958 . . . . 0.0 109.652 -179.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.041 HG13 ' CD1' ' A' ' 49' ' ' TYR . 5.5 t 80.05 55.28 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 121.605 -0.684 . . . . 0.0 110.245 179.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.406 ' C ' ' O ' ' A' ' 43' ' ' VAL . 2.3 mp0 -47.85 -26.01 1.5 Allowed 'General case' 0 N--CA 1.487 1.405 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 178.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.456 ' HB2' ' CG ' ' A' ' 48' ' ' ASP . 0.1 OUTLIER -127.86 124.65 38.04 Favored 'General case' 0 N--CA 1.487 1.375 0 N-CA-C 108.699 -0.852 . . . . 0.0 108.699 179.453 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.568 HG21 ' O ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -70.23 -25.74 28.02 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.078 0 O-C-N 121.355 -0.841 . . . . 0.0 109.119 -179.507 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 3.4 p -75.43 5.28 5.98 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.431 -0.793 . . . . 0.0 109.878 179.598 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.456 ' CG ' ' HB2' ' A' ' 45' ' ' LYS . 12.5 m-20 -101.14 -34.7 9.59 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.008 -1.057 . . . . 0.0 108.677 179.534 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 1.041 ' CD1' HG13 ' A' ' 43' ' ' VAL . 6.3 m-85 -89.51 -34.07 16.53 Favored 'General case' 0 C--N 1.302 -1.461 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.524 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 1.021 HD11 HG21 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -102.57 154.4 19.16 Favored 'General case' 0 N--CA 1.489 1.518 0 C-N-CA 119.173 -1.011 . . . . 0.0 110.366 179.783 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.465 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.6 OUTLIER -142.95 133.83 25.47 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.487 -0.758 . . . . 0.0 109.13 179.982 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 3.9 mtt -63.99 100.44 0.31 Allowed 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.258 -0.901 . . . . 0.0 109.847 -179.771 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 129.97 -24.84 4.47 Favored Glycine 0 N--CA 1.492 2.369 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 179.688 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . 0.409 ' HA ' ' OE1' ' A' ' 54' ' ' GLN . 13.2 mm100 -78.87 158.48 28.1 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.232 -1.158 . . . . 0.0 109.786 -179.785 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 22.8 mt-10 -110.61 111.66 23.04 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.328 -0.857 . . . . 0.0 109.026 179.576 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.626 ' O ' HG23 ' A' ' 56' ' ' VAL . 6.8 m -103.24 121.99 46.84 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.184 -0.947 . . . . 0.0 110.108 -179.424 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.991 ' HG2' ' HB3' ' A' ' 76' ' ' ALA . 36.5 Cg_endo -80.84 146.71 16.61 Favored 'Trans proline' 0 C--N 1.313 -1.321 0 C-N-CA 122.559 2.173 . . . . 0.0 110.077 179.253 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.838 HG21 ' HB3' ' A' ' 71' ' ' LEU . 1.0 OUTLIER -140.01 -168.77 0.45 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.06 -1.025 . . . . 0.0 109.655 -179.994 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.593 ' N ' HG23 ' A' ' 58' ' ' VAL . 14.9 mtpt -131.23 119.61 22.06 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.401 -0.812 . . . . 0.0 109.493 179.815 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.608 ' HA ' HD23 ' A' ' 71' ' ' LEU . 95.9 t -54.37 89.19 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 N-CA-C 108.783 -0.821 . . . . 0.0 108.783 179.418 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.514 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 9.5 tp -68.72 -24.54 64.48 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.339 -0.85 . . . . 0.0 110.034 -179.249 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.514 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 0.5 OUTLIER 166.15 133.88 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.708 0 O-C-N 121.001 -1.062 . . . . 0.0 110.854 179.79 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.447 ' O ' ' HA3' ' A' ' 67' ' ' GLY . 36.9 t -150.98 -96.09 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 178.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.444 ' O ' ' O ' ' A' ' 63' ' ' VAL . 5.2 p-10 40.73 -162.45 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.069 -1.019 . . . . 0.0 110.234 179.328 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 33.1 mmt180 -51.03 -62.81 1.39 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.336 -0.852 . . . . 0.0 109.027 179.738 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . 0.409 ' HG3' ' OD2' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -89.89 90.37 8.15 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.279 -0.888 . . . . 0.0 108.842 179.443 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.447 ' HA3' ' O ' ' A' ' 63' ' ' VAL . . . 167.78 100.76 0.14 Allowed Glycine 0 N--CA 1.486 1.978 0 N-CA-C 108.592 -1.803 . . . . 0.0 108.592 -179.413 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 68.8 mtp180 -88.95 79.51 7.29 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.523 -0.986 . . . . 0.0 109.726 -179.307 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.803 HG22 ' O ' ' A' ' 69' ' ' ILE . 12.7 mm 50.05 71.64 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.466 -0.771 . . . . 0.0 110.216 179.526 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.492 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 0.0 OUTLIER -97.62 76.37 2.51 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 120.961 -1.087 . . . . 0.0 108.07 178.755 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.838 ' HB3' HG21 ' A' ' 58' ' ' VAL . 96.5 mt -88.96 153.41 21.05 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.329 -0.857 . . . . 0.0 110.043 -178.765 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -117.16 113.55 22.41 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.508 -0.745 . . . . 0.0 109.571 179.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.423 HG13 HG13 ' A' ' 33' ' ' VAL . 0.6 OUTLIER -47.56 122.81 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.349 -0.844 . . . . 0.0 109.264 179.927 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.467 ' HB3' ' O ' ' A' ' 57' ' ' PRO . 4.2 ttpp -79.29 -16.57 56.19 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.19 -0.944 . . . . 0.0 108.939 179.431 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 67.52 42.4 2.13 Favored 'General case' 0 C--N 1.3 -1.587 0 N-CA-C 108.705 -0.85 . . . . 0.0 108.705 -179.572 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.991 ' HB3' ' HG2' ' A' ' 57' ' ' PRO . . . . . . . . 0 N--CA 1.488 1.457 0 CA-C-O 118.023 -0.989 . . . . 0.0 109.453 -179.705 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.55 0 CA-C-O 121.302 0.572 . . . . 0.0 109.473 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.507 ' O ' ' CB ' ' A' ' 3' ' ' ILE . 64.3 mt-10 47.69 -125.32 1.72 Allowed 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.199 -0.938 . . . . 0.0 109.404 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.592 HD12 ' OH ' ' A' ' 9' ' ' TYR . 0.3 OUTLIER 75.09 146.01 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 120.674 -1.267 . . . . 0.0 108.879 -179.652 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 3.6 pt-20 -142.02 176.81 8.66 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.095 -1.003 . . . . 0.0 109.959 -179.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.881 HG22 HG11 ' A' ' 60' ' ' VAL . 2.7 t -79.97 169.52 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.363 -0.836 . . . . 0.0 109.146 179.996 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.577 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 73.98 16.91 79.34 Favored Glycine 0 N--CA 1.489 2.173 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 -179.333 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.426 ' CD ' ' N ' ' A' ' 8' ' ' VAL . 0.1 OUTLIER -116.12 152.69 33.16 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.564 -0.963 . . . . 0.0 109.061 -179.61 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.567 HG13 ' O ' ' A' ' 58' ' ' VAL . 54.9 t -88.65 129.95 38.92 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.48 0 N-CA-C 108.325 -0.991 . . . . 0.0 108.325 179.357 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.592 ' OH ' HD12 ' A' ' 3' ' ' ILE . 2.9 m-85 -106.52 -179.4 3.93 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.119 -0.988 . . . . 0.0 110.071 -178.731 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 2.8 m -129.04 105.52 8.25 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 106.868 -1.53 . . . . 0.0 106.868 178.181 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.434 ' HA2' ' O ' ' A' ' 24' ' ' ALA . . . -108.16 132.21 11.0 Favored Glycine 0 N--CA 1.487 2.042 0 C-N-CA 119.318 -1.42 . . . . 0.0 111.254 -177.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.474 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.3 OUTLIER -91.39 158.83 16.3 Favored 'General case' 0 C--N 1.304 -1.393 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 178.348 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.859 ' CG2' HD22 ' A' ' 50' ' ' LEU . 61.2 t -87.82 97.02 6.2 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.7 0 O-C-N 120.858 -1.151 . . . . 0.0 109.045 -179.844 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.786 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -101.37 -5.78 24.93 Favored 'General case' 0 C--N 1.303 -1.432 0 O-C-N 121.527 -0.733 . . . . 0.0 109.817 -179.255 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.56 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -164.95 153.71 12.37 Favored 'General case' 0 N--CA 1.494 1.745 0 O-C-N 121.122 -0.986 . . . . 0.0 110.113 -179.693 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.681 HG21 HG22 ' A' ' 47' ' ' THR . 7.7 mt -141.58 152.92 19.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 N-CA-C 108.094 -1.076 . . . . 0.0 108.094 178.842 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 1.013 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -132.33 151.27 34.53 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.903 -1.123 . . . . 0.0 109.907 -179.011 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.3 OUTLIER -58.41 -38.78 78.09 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 120.735 -1.228 . . . . 0.0 108.835 179.203 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.013 ' CE1' HG21 ' A' ' 17' ' ' VAL . 23.3 p90 -92.57 30.13 1.59 Allowed 'General case' 0 N--CA 1.493 1.68 0 O-C-N 121.504 -0.748 . . . . 0.0 109.943 -179.881 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.595 ' C ' HG22 ' A' ' 17' ' ' VAL . . . 149.54 -150.99 23.16 Favored Glycine 0 N--CA 1.493 2.478 0 C-N-CA 119.114 -1.517 . . . . 0.0 111.219 -179.709 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.819 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -152.58 144.9 23.98 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.094 -1.239 . . . . 0.0 109.158 -179.877 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.965 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.3 m-30 -106.29 142.38 36.07 Favored 'General case' 0 C--N 1.298 -1.641 0 O-C-N 121.306 -0.872 . . . . 0.0 108.881 179.566 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.878 ' CG2' HG23 ' A' ' 33' ' ' VAL . 40.8 t -132.91 163.02 39.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 120.902 -1.124 . . . . 0.0 109.643 -179.444 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.786 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -130.15 153.24 48.73 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.103 -0.998 . . . . 0.0 109.65 -179.608 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.657 HD11 ' HB3' ' A' ' 29' ' ' LYS . 1.8 pt -120.15 -105.25 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 120.984 -1.072 . . . . 0.0 109.417 179.825 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -83.62 161.28 38.49 Favored Glycine 0 N--CA 1.491 2.332 0 N-CA-C 109.479 -1.448 . . . . 0.0 109.479 179.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -52.55 107.47 0.52 Allowed Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.504 -1.438 . . . . 0.0 109.504 -179.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 116.36 -50.48 0.78 Allowed Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 -179.948 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.657 ' HB3' HD11 ' A' ' 25' ' ' ILE . 16.5 mmtt -87.03 142.53 27.87 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.222 -1.164 . . . . 0.0 109.261 179.85 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.512 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 1.2 mt-10 -136.81 150.75 48.51 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.973 -1.079 . . . . 0.0 110.102 -179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.496 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -102.33 -177.19 27.54 Favored Glycine 0 N--CA 1.486 2.018 0 N-CA-C 108.137 -1.985 . . . . 0.0 108.137 179.03 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.965 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -149.53 116.76 6.05 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 120.694 -1.474 . . . . 0.0 110.431 179.119 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.878 HG23 ' CG2' ' A' ' 23' ' ' VAL . 93.3 t -90.85 59.93 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.298 -1.647 0 N-CA-C 107.699 -1.223 . . . . 0.0 107.699 178.049 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.518 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.6 t-80 -48.73 157.28 0.39 Allowed 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 -179.73 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.57 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.8 tp -47.19 -47.76 9.08 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.089 -1.007 . . . . 0.0 110.119 -179.207 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.472 ' N ' HG23 ' A' ' 35' ' ' ILE . 56.7 p -81.18 39.41 0.51 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.064 -1.023 . . . . 0.0 110.791 -179.463 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.98 ' C ' HD12 ' A' ' 38' ' ' ILE . 12.4 mt-30 -150.52 53.42 0.89 Allowed 'General case' 0 N--CA 1.495 1.801 0 O-C-N 120.646 -1.283 . . . . 0.0 110.664 179.805 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.98 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.7 mp -126.25 -96.31 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 120.952 -1.093 . . . . 0.0 109.529 179.24 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.787 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -97.31 54.67 1.22 Allowed 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.411 -0.806 . . . . 0.0 109.195 -179.897 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.537 ' CB ' ' O ' ' A' ' 39' ' ' ALA . 11.1 t0 83.13 -42.57 0.1 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.793 -0.567 . . . . 0.0 109.663 -179.631 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.508 ' HB2' ' O ' ' A' ' 40' ' ' ASP . 0.0 OUTLIER 166.54 -21.61 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.198 -0.939 . . . . 0.0 109.938 -179.945 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.11 76.87 3.66 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.096 -1.002 . . . . 0.0 110.419 -179.14 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.106 HG13 ' CD1' ' A' ' 49' ' ' TYR . 54.6 t -142.45 74.75 0.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.212 -0.93 . . . . 0.0 108.976 178.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.433 ' C ' ' O ' ' A' ' 43' ' ' VAL . 16.8 mt-10 -40.99 -28.05 0.07 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.558 -0.714 . . . . 0.0 110.314 -179.399 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.492 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.1 OUTLIER -142.63 138.51 30.76 Favored 'General case' 0 N--CA 1.492 1.658 0 O-C-N 120.961 -1.087 . . . . 0.0 110.206 -179.697 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.551 HG21 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -80.61 -26.47 11.28 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.861 0 O-C-N 121.356 -0.84 . . . . 0.0 108.845 179.514 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.681 HG22 HG21 ' A' ' 16' ' ' ILE . 47.3 p -78.47 5.12 11.45 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.317 -0.864 . . . . 0.0 109.023 179.056 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.466 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 4.1 m-20 -104.48 -30.76 9.83 Favored 'General case' 0 N--CA 1.491 1.577 0 N-CA-C 108.139 -1.06 . . . . 0.0 108.139 179.328 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 1.106 ' CD1' HG13 ' A' ' 43' ' ' VAL . 17.8 m-85 -90.25 -33.98 15.94 Favored 'General case' 0 C--N 1.302 -1.484 0 N-CA-C 109.004 -0.739 . . . . 0.0 109.004 179.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.859 HD22 ' CG2' ' A' ' 13' ' ' VAL . 3.5 mt -108.1 151.78 25.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.194 -0.941 . . . . 0.0 110.005 179.507 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.521 ' CB ' ' HG3' ' A' ' 54' ' ' GLN . 0.1 OUTLIER -136.93 138.52 40.72 Favored 'General case' 0 N--CA 1.49 1.545 0 N-CA-C 108.476 -0.935 . . . . 0.0 108.476 179.033 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 23.4 mtt -62.6 91.38 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.003 -1.06 . . . . 0.0 109.839 -179.523 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 137.52 -22.59 3.17 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 119.732 -1.223 . . . . 0.0 110.388 179.487 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . 0.521 ' HG3' ' CB ' ' A' ' 51' ' ' GLN . 6.5 mm-40 -77.28 145.29 37.56 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.055 -1.262 . . . . 0.0 110.074 -179.377 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.2 mp0 -113.19 127.26 56.13 Favored 'General case' 0 N--CA 1.49 1.532 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.475 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.438 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 15.9 m -132.45 142.37 44.66 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.02 -1.05 . . . . 0.0 110.032 -179.524 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.454 ' O ' ' HB2' ' A' ' 74' ' ' LYS . 36.9 Cg_endo -80.27 129.42 7.66 Favored 'Trans proline' 0 C--N 1.312 -1.349 0 C-N-CA 122.665 2.244 . . . . 0.0 110.335 179.989 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.865 HG21 ' HB3' ' A' ' 71' ' ' LEU . 0.8 OUTLIER -120.6 -170.5 0.57 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.19 -0.944 . . . . 0.0 109.317 179.753 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.631 ' N ' HG23 ' A' ' 58' ' ' VAL . 0.1 OUTLIER -132.12 141.83 49.28 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.257 -0.902 . . . . 0.0 109.319 179.883 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.881 HG11 HG22 ' A' ' 5' ' ' VAL . 26.5 t -68.76 87.82 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.645 0 O-C-N 121.449 -0.782 . . . . 0.0 109.139 179.884 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.686 HD12 ' OG ' ' A' ' 72' ' ' SER . 0.5 OUTLIER -56.51 -29.45 61.86 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.345 -0.847 . . . . 0.0 109.388 -179.888 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.547 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 1.0 OUTLIER 160.96 164.36 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.749 0 O-C-N 121.359 -0.838 . . . . 0.0 110.279 179.644 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.474 ' HA ' ' O ' ' A' ' 66' ' ' GLN . 50.5 t -150.13 -48.98 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 O-C-N 121.491 -0.756 . . . . 0.0 109.359 179.595 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.417 ' C ' ' O ' ' A' ' 63' ' ' VAL . 0.5 OUTLIER -44.36 -61.26 1.58 Allowed 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.199 -0.938 . . . . 0.0 109.483 179.993 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -59.38 -52.87 63.75 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.088 -1.008 . . . . 0.0 108.689 179.506 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . 0.474 ' O ' ' HA ' ' A' ' 63' ' ' VAL . 0.0 OUTLIER -108.49 107.39 17.89 Favored 'General case' 0 N--CA 1.487 1.381 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 179.272 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -74.6 3.47 41.96 Favored Glycine 0 N--CA 1.491 2.321 0 N-CA-C 110.31 -1.116 . . . . 0.0 110.31 -179.335 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.48 ' O ' ' O ' ' A' ' 69' ' ' ILE . 0.0 OUTLIER -89.6 41.74 1.06 Allowed 'General case' 0 N--CA 1.488 1.444 0 O-C-N 120.953 -1.322 . . . . 0.0 109.352 179.885 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.57 HG22 ' HG ' ' A' ' 71' ' ' LEU . 63.2 mt 39.35 94.74 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.827 -0.545 . . . . 0.0 110.121 179.491 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.463 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 8.9 mmm180 -89.74 79.55 6.72 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.007 -1.058 . . . . 0.0 109.854 -179.917 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.865 ' HB3' HG21 ' A' ' 58' ' ' VAL . 17.5 mt -91.11 147.38 23.11 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.217 -0.927 . . . . 0.0 108.78 179.435 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.686 ' OG ' HD12 ' A' ' 61' ' ' LEU . 0.6 OUTLIER -134.11 117.14 16.25 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.105 -0.997 . . . . 0.0 110.302 -179.262 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.431 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.1 OUTLIER -44.07 131.89 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.299 -0.876 . . . . 0.0 108.962 179.691 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.454 ' HB2' ' O ' ' A' ' 57' ' ' PRO . 0.0 OUTLIER -71.82 177.3 4.3 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.215 -0.928 . . . . 0.0 110.137 -179.374 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 7.4 tp10 -49.85 -43.83 49.18 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.465 -0.772 . . . . 0.0 109.574 179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 117.94 -1.029 . . . . 0.0 109.372 -179.867 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.546 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 29.9 mp0 -142.2 -166.84 2.33 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.363 -0.836 . . . . 0.0 109.001 179.893 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.546 HG21 ' CE2' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -123.4 -169.71 0.58 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.014 -1.054 . . . . 0.0 109.361 179.971 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -149.47 134.19 17.77 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.379 -0.826 . . . . 0.0 109.212 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.651 HG22 HG11 ' A' ' 60' ' ' VAL . 4.2 t -60.87 162.94 1.19 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.256 -0.902 . . . . 0.0 109.465 -179.712 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.495 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 80.87 2.34 90.18 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 109.23 -1.548 . . . . 0.0 109.23 -179.593 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.531 ' HG2' ' N ' ' A' ' 8' ' ' VAL . 28.2 ttt85 -102.01 160.34 14.59 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.292 -1.122 . . . . 0.0 109.609 -179.778 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.945 HG13 ' O ' ' A' ' 58' ' ' VAL . 93.5 t -96.9 142.95 13.23 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.531 0 O-C-N 121.243 -0.911 . . . . 0.0 109.369 179.763 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.546 ' CE2' HG21 ' A' ' 3' ' ' ILE . 9.2 m-85 -118.69 -168.19 1.5 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.302 -0.874 . . . . 0.0 109.758 -179.855 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.534 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 34.3 m -166.21 127.81 1.83 Allowed 'General case' 0 N--CA 1.489 1.495 0 N-CA-C 107.788 -1.19 . . . . 0.0 107.788 179.443 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.5 ' HA3' ' O ' ' A' ' 24' ' ' ALA . . . -149.53 -177.84 23.97 Favored Glycine 0 N--CA 1.489 2.202 0 C-N-CA 118.44 -1.838 . . . . 0.0 111.266 -178.636 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.543 ' O ' HG13 ' A' ' 23' ' ' VAL . 15.6 mtpt -104.45 168.27 9.2 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.808 -0.819 . . . . 0.0 108.929 179.929 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.926 HG22 HD13 ' A' ' 50' ' ' LEU . 72.4 t -87.98 101.37 11.49 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.612 0 O-C-N 121.156 -0.965 . . . . 0.0 108.423 179.478 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.665 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.1 p -111.11 11.12 21.96 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.275 -0.89 . . . . 0.0 110.286 -178.814 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.555 ' HB3' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -175.29 147.01 0.86 Allowed 'General case' 0 N--CA 1.495 1.803 0 O-C-N 120.956 -1.09 . . . . 0.0 110.255 179.75 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.4 HG21 HG22 ' A' ' 47' ' ' THR . 17.2 mt -139.28 151.71 23.17 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 N-CA-C 108.142 -1.059 . . . . 0.0 108.142 179.068 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 1.054 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -129.61 154.05 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.601 0 O-C-N 120.765 -1.209 . . . . 0.0 110.088 -179.089 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 1.1 m-20 -59.13 -41.7 88.88 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 120.866 -1.147 . . . . 0.0 109.327 179.173 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.054 ' CE1' HG21 ' A' ' 17' ' ' VAL . 14.0 p90 -91.3 27.14 2.0 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.313 -0.867 . . . . 0.0 110.22 -179.716 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.606 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 155.22 -153.58 24.88 Favored Glycine 0 N--CA 1.491 2.36 0 C-N-CA 118.898 -1.62 . . . . 0.0 111.063 -179.365 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.792 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -150.33 144.71 25.69 Favored 'General case' 0 N--CA 1.487 1.394 0 O-C-N 121.063 -1.257 . . . . 0.0 109.007 179.915 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.959 ' CE1' HD11 ' A' ' 32' ' ' LEU . 11.1 m-30 -108.41 162.11 14.41 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.401 -0.812 . . . . 0.0 109.214 -179.972 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.571 ' CG2' HG23 ' A' ' 33' ' ' VAL . 3.5 t -150.63 166.81 2.32 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.166 -0.958 . . . . 0.0 109.433 -179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.665 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -132.79 145.24 50.83 Favored 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.209 -0.932 . . . . 0.0 108.856 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.985 HD11 ' HB2' ' A' ' 29' ' ' LYS . 7.7 pt -98.83 -20.47 5.51 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 O-C-N 120.547 -1.346 . . . . 0.0 109.653 -179.829 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 81.11 -8.42 57.67 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 109.695 -1.362 . . . . 0.0 109.695 179.859 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -89.54 34.18 4.11 Favored Glycine 0 N--CA 1.49 2.272 0 N-CA-C 109.383 -1.487 . . . . 0.0 109.383 179.971 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.427 ' C ' ' HG2' ' A' ' 29' ' ' LYS . . . 87.79 -1.23 85.21 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 109.634 -1.387 . . . . 0.0 109.634 -179.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.985 ' HB2' HD11 ' A' ' 25' ' ' ILE . 5.8 mmtm -140.68 174.55 10.41 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.193 -1.181 . . . . 0.0 109.68 179.94 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.553 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 7.3 pt-20 -128.01 157.47 40.55 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 120.867 -1.146 . . . . 0.0 110.474 -179.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.812 ' CA ' HD12 ' A' ' 71' ' ' LEU . . . -105.83 -175.79 23.83 Favored Glycine 0 N--CA 1.487 2.042 0 N-CA-C 108.337 -1.905 . . . . 0.0 108.337 179.298 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.959 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.79 121.29 7.4 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 120.746 -1.444 . . . . 0.0 111.542 -179.794 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.792 ' HB ' ' HB3' ' A' ' 21' ' ' ALA . 26.0 t -95.86 62.9 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.387 0 N-CA-C 107.402 -1.333 . . . . 0.0 107.402 176.922 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.475 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.7 t-160 -48.08 155.02 0.5 Allowed 'General case' 0 C--N 1.303 -1.433 0 O-C-N 120.885 -1.135 . . . . 0.0 108.883 -179.274 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.576 HG23 ' H ' ' A' ' 36' ' ' SER . 3.0 tp -45.84 -52.09 3.0 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.513 0 O-C-N 121.218 -0.926 . . . . 0.0 110.315 -179.431 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.576 ' H ' HG23 ' A' ' 35' ' ' ILE . 0.0 OUTLIER -81.52 42.96 0.71 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.294 -0.879 . . . . 0.0 110.524 -179.33 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.972 ' C ' HD12 ' A' ' 38' ' ' ILE . 68.3 mt-30 -150.83 53.38 0.87 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.859 -1.151 . . . . 0.0 110.036 179.997 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.972 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.7 mp -124.53 -96.01 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 120.926 -1.109 . . . . 0.0 110.376 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.797 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -95.09 -39.9 9.9 Favored 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.492 -0.755 . . . . 0.0 109.674 -178.845 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.497 ' O ' ' HB2' ' A' ' 41' ' ' LYS . 9.9 p-10 174.74 -40.66 0.01 OUTLIER 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.418 -0.801 . . . . 0.0 109.475 -179.976 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.497 ' HB2' ' O ' ' A' ' 40' ' ' ASP . 0.2 OUTLIER 172.23 -18.39 0.0 OUTLIER 'General case' 0 N--CA 1.493 1.701 0 O-C-N 121.288 -0.883 . . . . 0.0 110.793 -179.763 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -75.43 6.93 4.01 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 120.821 -1.174 . . . . 0.0 110.51 -179.3 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.031 HG13 ' CD1' ' A' ' 49' ' ' TYR . 60.2 t -86.76 52.55 0.1 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.36 0 O-C-N 120.925 -1.109 . . . . 0.0 109.242 179.659 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.433 ' C ' ' O ' ' A' ' 43' ' ' VAL . 3.6 mm-40 -45.06 -25.05 0.29 Allowed 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.224 -0.922 . . . . 0.0 108.744 179.633 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.429 ' N ' ' C ' ' A' ' 43' ' ' VAL . 25.0 mmtp -119.66 122.7 42.09 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.537 -0.727 . . . . 0.0 109.157 179.706 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.606 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -78.98 -24.54 12.93 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.985 0 O-C-N 121.271 -0.893 . . . . 0.0 108.842 179.812 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.4 HG22 HG21 ' A' ' 16' ' ' ILE . 72.5 p -75.9 4.4 8.25 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.449 -0.782 . . . . 0.0 109.723 179.527 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 14.8 m-20 -102.75 -38.16 7.57 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.135 -0.978 . . . . 0.0 109.183 179.878 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 1.031 ' CD1' HG13 ' A' ' 43' ' ' VAL . 9.9 m-85 -89.43 -33.55 16.78 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.349 -0.844 . . . . 0.0 109.104 179.669 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.926 HD13 HG22 ' A' ' 13' ' ' VAL . 0.1 OUTLIER -98.86 135.54 40.15 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.412 -0.805 . . . . 0.0 109.443 -179.793 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.479 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.0 OUTLIER -138.89 122.5 17.41 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.556 -0.715 . . . . 0.0 109.6 -179.84 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . 0.504 ' CG ' ' O ' ' A' ' 52' ' ' MET . 5.1 ptm -48.6 105.79 0.09 Allowed 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.317 -0.864 . . . . 0.0 109.947 -179.925 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 133.92 -43.55 1.26 Allowed Glycine 0 N--CA 1.492 2.398 0 C-N-CA 119.832 -1.175 . . . . 0.0 110.471 179.361 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . 0.424 ' O ' HG23 ' A' ' 13' ' ' VAL . 15.8 mt-30 -69.32 146.15 52.43 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.01 -1.288 . . . . 0.0 110.107 -179.399 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.51 ' HA ' ' HA ' ' A' ' 12' ' ' LYS . 0.4 OUTLIER -122.53 140.08 53.18 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.355 -0.841 . . . . 0.0 109.115 179.526 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.416 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 24.8 m -146.73 155.95 48.37 Favored Pre-proline 0 N--CA 1.487 1.424 0 O-C-N 121.164 -0.96 . . . . 0.0 110.052 -179.592 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.534 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 37.2 Cg_endo -83.37 146.9 12.51 Favored 'Trans proline' 0 C--N 1.314 -1.261 0 C-N-CA 123.161 2.574 . . . . 0.0 110.428 179.591 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.945 ' O ' HG13 ' A' ' 8' ' ' VAL . 1.0 OUTLIER -141.29 -168.61 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.186 -0.946 . . . . 0.0 109.287 179.368 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.702 ' CG ' HG22 ' A' ' 8' ' ' VAL . 17.2 mtmt -134.3 134.14 41.54 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.385 -0.822 . . . . 0.0 109.779 179.979 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.651 HG11 HG22 ' A' ' 5' ' ' VAL . 47.6 t -63.49 87.43 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.721 0 O-C-N 121.392 -0.818 . . . . 0.0 109.197 179.632 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.575 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 4.9 tp -53.56 -37.78 63.24 Favored 'General case' 0 C--N 1.301 -1.518 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 179.644 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.575 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 2.7 pt-20 153.4 167.66 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.064 0 CA-C-O 121.765 0.793 . . . . 0.0 110.14 179.374 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.537 HG13 ' O ' ' A' ' 67' ' ' GLY . 49.1 t -151.52 130.29 2.97 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 O-C-N 121.494 -0.753 . . . . 0.0 109.37 179.155 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.424 ' O ' ' C ' ' A' ' 65' ' ' ARG . 14.6 p-10 -154.09 -177.38 6.38 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.236 -0.915 . . . . 0.0 109.382 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . 0.424 ' C ' ' O ' ' A' ' 64' ' ' ASP . 9.3 ptm180 -44.13 -44.26 7.53 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.186 -0.946 . . . . 0.0 108.973 179.837 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -105.35 57.13 0.68 Allowed 'General case' 0 N--CA 1.489 1.487 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 179.15 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.537 ' O ' HG13 ' A' ' 63' ' ' VAL . . . -175.08 92.41 0.09 OUTLIER Glycine 0 N--CA 1.489 2.202 0 N-CA-C 108.989 -1.645 . . . . 0.0 108.989 -179.662 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 4.3 mtt180 -88.54 100.08 12.8 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.25 -1.147 . . . . 0.0 108.989 -179.992 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.535 ' HA ' ' CG2' ' A' ' 63' ' ' VAL . 61.2 mt 52.42 78.42 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.474 -0.766 . . . . 0.0 109.511 -179.956 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.463 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 26.2 mmm180 -89.72 87.68 7.09 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 120.841 -1.162 . . . . 0.0 108.62 179.517 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.812 HD12 ' CA ' ' A' ' 31' ' ' GLY . 13.6 mt -89.16 163.64 15.35 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.324 -0.86 . . . . 0.0 109.607 -179.305 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.5 ' OG ' HD13 ' A' ' 61' ' ' LEU . 0.3 OUTLIER -133.43 107.65 8.19 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.442 -0.786 . . . . 0.0 109.724 -179.636 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.423 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.0 OUTLIER -44.92 140.31 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.249 -0.907 . . . . 0.0 108.77 179.713 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.416 ' HD3' ' HB2' ' A' ' 57' ' ' PRO . 0.0 OUTLIER -50.58 170.6 0.03 OUTLIER 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.15 -0.969 . . . . 0.0 109.424 179.973 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 3.8 tp10 46.51 61.85 2.58 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.149 -0.969 . . . . 0.0 109.048 -179.802 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.419 -179.646 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.518 0 CA-C-O 121.254 0.549 . . . . 0.0 109.548 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.683 ' C ' HD13 ' A' ' 3' ' ' ILE . 2.5 mp0 -95.7 -169.32 1.93 Allowed 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.272 -0.893 . . . . 0.0 109.605 -179.921 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.683 HD13 ' C ' ' A' ' 2' ' ' GLU . 0.0 OUTLIER -124.11 115.5 45.06 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 C-N-CA 119.472 -0.891 . . . . 0.0 110.21 -179.092 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -117.8 147.95 42.54 Favored 'General case' 0 N--CA 1.488 1.458 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 179.582 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.465 HG22 ' HA ' ' A' ' 62' ' ' GLU . 14.8 t -69.54 159.77 5.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 O-C-N 120.991 -1.068 . . . . 0.0 109.577 -179.745 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.451 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 71.06 7.32 62.36 Favored Glycine 0 N--CA 1.487 2.083 0 N-CA-C 108.998 -1.641 . . . . 0.0 108.998 -179.38 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -91.77 178.6 5.86 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.284 -1.127 . . . . 0.0 109.67 -179.818 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.537 ' HA ' ' HA ' ' A' ' 59' ' ' LYS . 68.1 t -114.97 144.84 21.64 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.305 -0.872 . . . . 0.0 109.448 -179.9 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.626 ' CD1' HG23 ' A' ' 60' ' ' VAL . 14.0 m-85 -143.94 128.42 17.99 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.023 -1.048 . . . . 0.0 110.355 -179.975 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -91.06 115.62 28.16 Favored 'General case' 0 C--N 1.298 -1.653 0 N-CA-C 107.467 -1.308 . . . . 0.0 107.467 178.15 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -113.6 141.3 16.87 Favored Glycine 0 N--CA 1.488 2.101 0 C-N-CA 119.119 -1.515 . . . . 0.0 110.626 -178.362 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.516 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.8 OUTLIER -89.56 162.07 15.86 Favored 'General case' 0 C--N 1.303 -1.452 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 178.724 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.741 HG22 HD13 ' A' ' 50' ' ' LEU . 58.2 t -87.86 105.39 15.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.592 0 O-C-N 120.986 -1.072 . . . . 0.0 108.368 179.616 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.918 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -111.7 -0.8 15.89 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.262 -0.899 . . . . 0.0 110.218 -178.859 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.527 ' CD ' ' O ' ' A' ' 14' ' ' THR . 0.3 OUTLIER -168.05 152.42 6.34 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.902 -1.123 . . . . 0.0 110.314 179.97 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.441 ' HA ' ' HA ' ' A' ' 21' ' ' ALA . 56.6 mt -145.37 150.03 16.14 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.65 0 N-CA-C 108.294 -1.002 . . . . 0.0 108.294 179.058 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 1.095 HG21 ' CE1' ' A' ' 19' ' ' PHE . 1.2 m -126.93 156.33 38.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.55 0 O-C-N 120.932 -1.105 . . . . 0.0 109.813 -179.076 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -60.37 -37.89 82.18 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.784 -1.197 . . . . 0.0 109.455 179.208 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.095 ' CE1' HG21 ' A' ' 17' ' ' VAL . 13.9 p90 -94.56 26.43 3.47 Favored 'General case' 0 N--CA 1.494 1.736 0 O-C-N 121.244 -0.91 . . . . 0.0 110.379 -179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.593 ' HA2' ' N ' ' A' ' 35' ' ' ILE . . . 155.54 -154.08 25.25 Favored Glycine 0 N--CA 1.491 2.322 0 C-N-CA 119.284 -1.436 . . . . 0.0 110.481 -179.792 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.726 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -152.27 146.23 25.25 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.043 -1.269 . . . . 0.0 109.439 -179.558 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.957 ' CE1' HD11 ' A' ' 32' ' ' LEU . 12.4 m-30 -108.04 158.54 17.31 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 121.354 -0.842 . . . . 0.0 109.145 179.53 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.788 ' CG2' HG23 ' A' ' 33' ' ' VAL . 7.7 t -145.85 163.75 10.69 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.166 -0.959 . . . . 0.0 109.151 179.99 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.918 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -137.1 146.55 45.25 Favored 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.017 -1.052 . . . . 0.0 110.119 -179.648 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.522 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.1 pt -106.77 22.22 3.69 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.735 0 O-C-N 120.779 -1.201 . . . . 0.0 108.667 178.985 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 147.66 -143.27 11.01 Favored Glycine 0 N--CA 1.492 2.38 0 N-CA-C 109.445 -1.462 . . . . 0.0 109.445 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -111.75 9.24 27.85 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.49 -1.444 . . . . 0.0 109.49 179.866 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -118.96 -67.78 0.31 Allowed Glycine 0 N--CA 1.49 2.273 0 N-CA-C 109.498 -1.441 . . . . 0.0 109.498 -179.984 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.522 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER -97.66 151.11 20.44 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.234 -1.157 . . . . 0.0 109.514 -179.97 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.573 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 3.5 pt-20 -134.68 153.4 52.01 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 120.847 -1.158 . . . . 0.0 110.224 -179.855 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -102.57 -173.51 27.0 Favored Glycine 0 N--CA 1.488 2.118 0 N-CA-C 108.504 -1.839 . . . . 0.0 108.504 179.347 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.957 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.31 119.02 6.55 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 120.993 -1.298 . . . . 0.0 110.692 179.514 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.83 HG12 HD11 ' A' ' 38' ' ' ILE . 8.4 t -96.59 63.56 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.665 -1.235 . . . . 0.0 107.665 177.588 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.551 ' HB3' ' CG ' ' A' ' 37' ' ' GLN . 4.4 t-80 -47.7 166.08 0.03 OUTLIER 'General case' 0 C--N 1.306 -1.308 0 O-C-N 120.879 -1.138 . . . . 0.0 108.279 -179.594 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.662 ' HA ' HG13 ' A' ' 46' ' ' VAL . 0.2 OUTLIER -55.19 -55.33 17.06 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.136 -0.977 . . . . 0.0 110.296 -179.256 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.626 ' H ' HG23 ' A' ' 35' ' ' ILE . 92.6 p -82.31 42.57 0.75 Allowed 'General case' 0 N--CA 1.494 1.763 0 O-C-N 121.018 -1.051 . . . . 0.0 110.334 -179.734 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.95 ' O ' HD13 ' A' ' 73' ' ' ILE . 20.8 mm-40 -145.27 44.46 1.32 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 120.938 -1.101 . . . . 0.0 109.598 179.959 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.925 HG21 ' CD2' ' A' ' 49' ' ' TYR . 1.8 mp -119.33 -91.66 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.456 0 O-C-N 121.253 -0.904 . . . . 0.0 108.978 179.742 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.825 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -118.93 157.79 27.0 Favored 'General case' 0 C--N 1.298 -1.654 0 N-CA-C 108.971 -0.752 . . . . 0.0 108.971 -179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.42 ' C ' ' O ' ' A' ' 39' ' ' ALA . 0.2 OUTLIER -43.06 -49.97 6.09 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.315 -0.866 . . . . 0.0 109.568 -179.674 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.41 ' O ' ' C ' ' A' ' 42' ' ' ARG . 0.0 OUTLIER -58.52 120.66 9.23 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.161 -0.962 . . . . 0.0 109.141 179.806 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.41 ' C ' ' O ' ' A' ' 41' ' ' LYS . 0.0 OUTLIER -44.35 123.97 3.8 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.316 -0.865 . . . . 0.0 109.601 -179.901 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.023 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 39.6 t -94.23 70.72 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 N-CA-C 108.388 -0.968 . . . . 0.0 108.388 179.314 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 25.5 tp10 -46.49 -22.5 0.27 Allowed 'General case' 0 N--CA 1.488 1.464 0 O-C-N 121.151 -0.968 . . . . 0.0 109.244 179.991 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.539 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 28.9 mttp -119.68 109.12 15.27 Favored 'General case' 0 N--CA 1.487 1.396 0 O-C-N 121.386 -0.821 . . . . 0.0 109.246 179.867 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.662 HG13 ' HA ' ' A' ' 35' ' ' ILE . 0.0 OUTLIER -77.52 -22.87 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.833 0 O-C-N 121.232 -0.918 . . . . 0.0 108.781 179.842 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 18.6 p -76.99 2.57 14.48 Favored 'General case' 0 C--N 1.299 -1.619 0 O-C-N 121.449 -0.782 . . . . 0.0 109.216 179.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.404 ' OD2' ' HD2' ' A' ' 45' ' ' LYS . 1.7 m-20 -101.42 -33.68 9.89 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.1 -1.0 . . . . 0.0 109.264 179.829 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 1.023 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 6.6 m-85 -94.98 -30.78 13.94 Favored 'General case' 0 N--CA 1.488 1.44 0 N-CA-C 108.755 -0.831 . . . . 0.0 108.755 179.575 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.741 HD13 HG22 ' A' ' 13' ' ' VAL . 0.2 OUTLIER -105.61 140.73 38.24 Favored 'General case' 0 N--CA 1.488 1.454 0 CA-C-O 121.536 0.684 . . . . 0.0 109.35 -179.731 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.511 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 2.0 tm0? -148.61 124.38 10.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.462 -0.774 . . . . 0.0 109.301 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 56.8 mtp -48.8 112.65 0.64 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.288 -0.883 . . . . 0.0 109.924 -179.755 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 113.11 -44.85 1.42 Allowed Glycine 0 N--CA 1.491 2.333 0 N-CA-C 110.187 -1.165 . . . . 0.0 110.187 179.692 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . 0.539 ' O ' HG23 ' A' ' 13' ' ' VAL . 15.5 mm100 -56.92 102.96 0.09 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.147 -1.208 . . . . 0.0 109.586 -179.727 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 2.2 mt-10 -65.18 137.14 57.43 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.188 -0.945 . . . . 0.0 109.125 179.853 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.7 m -135.48 132.13 19.7 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.229 -0.919 . . . . 0.0 109.841 -179.767 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.414 ' HG2' ' HG3' ' A' ' 74' ' ' LYS . 36.4 Cg_endo -79.96 142.63 15.72 Favored 'Trans proline' 0 C--N 1.311 -1.439 0 C-N-CA 122.461 2.107 . . . . 0.0 110.129 179.464 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.892 ' CG2' HD12 ' A' ' 71' ' ' LEU . 0.9 OUTLIER -141.43 -173.74 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.511 0 O-C-N 121.232 -0.917 . . . . 0.0 109.246 179.665 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.571 ' N ' HG23 ' A' ' 58' ' ' VAL . 9.0 mtmm -142.35 111.26 6.33 Favored 'General case' 0 C--N 1.302 -1.492 0 O-C-N 121.295 -0.878 . . . . 0.0 110.248 -179.71 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.626 HG23 ' CD1' ' A' ' 9' ' ' TYR . 61.5 t -45.57 94.97 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 N-CA-C 108.23 -1.026 . . . . 0.0 108.23 178.857 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.579 HD13 ' OG ' ' A' ' 72' ' ' SER . 4.6 tp -75.89 -26.84 57.39 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.331 -0.855 . . . . 0.0 109.866 -178.991 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.523 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 8.9 pt-20 162.73 -171.88 0.01 OUTLIER 'General case' 0 N--CA 1.496 1.863 0 O-C-N 121.378 -0.827 . . . . 0.0 110.427 -179.825 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.505 ' O ' ' N ' ' A' ' 67' ' ' GLY . 49.0 t -143.49 -42.68 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 N-CA-C 109.017 -0.734 . . . . 0.0 109.017 179.644 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.447 ' O ' ' C ' ' A' ' 65' ' ' ARG . 0.3 OUTLIER -45.46 -45.94 13.34 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.405 -0.81 . . . . 0.0 109.926 -179.948 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . 0.447 ' C ' ' O ' ' A' ' 64' ' ' ASP . 11.2 ttm180 -41.71 -70.84 0.09 Allowed 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.293 -0.879 . . . . 0.0 109.677 -179.772 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -97.25 -52.23 3.9 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.228 -0.92 . . . . 0.0 109.248 179.864 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.505 ' N ' ' O ' ' A' ' 63' ' ' VAL . . . 110.88 -17.99 26.96 Favored Glycine 0 N--CA 1.49 2.237 0 N-CA-C 109.144 -1.583 . . . . 0.0 109.144 -179.81 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.473 ' O ' ' HB ' ' A' ' 69' ' ' ILE . 0.0 OUTLIER -98.31 51.87 1.02 Allowed 'General case' 0 N--CA 1.489 1.499 0 O-C-N 121.398 -1.06 . . . . 0.0 108.895 179.514 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.556 HG23 ' CD2' ' A' ' 71' ' ' LEU . 4.0 mt 62.13 109.28 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 121.493 -0.755 . . . . 0.0 109.392 179.909 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.5 ' CB ' ' O ' ' A' ' 62' ' ' GLU . 0.0 OUTLIER -106.09 92.62 4.22 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.458 -0.776 . . . . 0.0 109.376 179.947 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.892 HD12 ' CG2' ' A' ' 58' ' ' VAL . 0.3 OUTLIER -94.74 154.53 17.25 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.324 -0.86 . . . . 0.0 109.366 -179.94 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.579 ' OG ' HD13 ' A' ' 61' ' ' LEU . 0.6 OUTLIER -109.85 111.71 23.31 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.197 -0.94 . . . . 0.0 110.219 -179.231 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.95 HD13 ' O ' ' A' ' 37' ' ' GLN . 1.2 mp -56.96 128.21 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.478 0 N-CA-C 108.654 -0.869 . . . . 0.0 108.654 179.181 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.441 ' C ' ' O ' ' A' ' 73' ' ' ILE . 0.6 OUTLIER -39.44 -59.33 1.1 Allowed 'General case' 0 N--CA 1.494 1.751 0 O-C-N 121.357 -0.84 . . . . 0.0 110.351 -179.136 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -48.27 -45.67 34.93 Favored 'General case' 0 C--N 1.292 -1.898 0 O-C-N 121.498 -0.752 . . . . 0.0 109.439 -179.84 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.437 ' HB3' ' O ' ' A' ' 73' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 118.055 -0.974 . . . . 0.0 109.622 -179.991 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.587 0 N-CA-C 109.412 -0.588 . . . . 0.0 109.412 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.459 ' O ' ' O ' ' A' ' 3' ' ' ILE . 8.6 mt-10 54.43 40.9 32.14 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.246 -0.909 . . . . 0.0 109.381 179.882 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.498 HD13 ' CD ' ' A' ' 7' ' ' ARG . 0.3 OUTLIER 62.26 127.14 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.233 -0.917 . . . . 0.0 108.806 179.768 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.455 ' O ' ' HG3' ' A' ' 7' ' ' ARG . 1.6 pt-20 -129.17 -150.96 0.46 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.272 -0.892 . . . . 0.0 109.922 -179.408 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 1.076 HG22 HG11 ' A' ' 60' ' ' VAL . 2.2 t -80.36 163.55 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.575 0 O-C-N 121.351 -0.843 . . . . 0.0 109.714 -179.758 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.504 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 90.08 13.97 59.77 Favored Glycine 0 N--CA 1.489 2.201 0 N-CA-C 109.71 -1.356 . . . . 0.0 109.71 179.738 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.498 ' CD ' HD13 ' A' ' 3' ' ' ILE . 0.1 OUTLIER -133.79 -173.87 3.36 Favored 'General case' 0 N--CA 1.488 1.453 0 O-C-N 121.086 -1.243 . . . . 0.0 109.643 -179.333 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 8.8 t -90.05 134.13 29.98 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 N-CA-C 108.5 -0.926 . . . . 0.0 108.5 179.192 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.673 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 4.6 m-85 -122.28 133.21 54.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.043 -1.035 . . . . 0.0 109.998 -179.598 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.3 m -83.87 103.29 13.02 Favored 'General case' 0 C--N 1.3 -1.549 0 N-CA-C 107.846 -1.168 . . . . 0.0 107.846 178.546 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.31 119.82 5.11 Favored Glycine 0 N--CA 1.487 2.056 0 C-N-CA 119.884 -1.151 . . . . 0.0 110.737 -178.495 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.604 ' O ' HG13 ' A' ' 23' ' ' VAL . 2.0 mtmt -89.29 148.46 23.55 Favored 'General case' 0 N--CA 1.488 1.464 0 N-CA-C 107.704 -1.221 . . . . 0.0 107.704 178.77 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.646 HG22 ' CD2' ' A' ' 50' ' ' LEU . 3.8 t -86.85 117.6 31.42 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.664 0 O-C-N 120.597 -1.314 . . . . 0.0 108.656 -179.848 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.952 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.5 p -128.16 -3.41 5.67 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.419 -0.801 . . . . 0.0 109.933 -178.596 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.535 ' HG3' ' HB3' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -173.77 150.57 1.71 Allowed 'General case' 0 N--CA 1.496 1.851 0 O-C-N 121.128 -0.982 . . . . 0.0 109.872 179.396 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.502 HG22 ' N ' ' A' ' 17' ' ' VAL . 18.0 mt -136.31 161.49 37.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.374 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 1.055 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -139.97 153.34 22.69 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.804 0 O-C-N 120.59 -1.319 . . . . 0.0 110.623 -179.009 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 7.9 m-20 -59.22 -41.19 88.07 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 120.766 -1.209 . . . . 0.0 109.376 179.093 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.055 ' CE1' HG21 ' A' ' 17' ' ' VAL . 14.3 p90 -90.99 28.42 1.58 Allowed 'General case' 0 N--CA 1.493 1.716 0 O-C-N 121.356 -0.84 . . . . 0.0 110.096 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.797 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 149.7 -149.28 21.2 Favored Glycine 0 N--CA 1.492 2.402 0 C-N-CA 119.08 -1.533 . . . . 0.0 110.834 -179.717 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 1.047 ' HB1' HD12 ' A' ' 50' ' ' LEU . . . -153.64 147.79 25.73 Favored 'General case' 0 C--N 1.303 -1.424 0 O-C-N 120.967 -1.313 . . . . 0.0 109.263 -179.974 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.972 ' CE1' HD11 ' A' ' 32' ' ' LEU . 11.9 m-30 -106.7 158.35 17.03 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.4 -0.813 . . . . 0.0 109.083 179.641 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.757 ' CG2' HG23 ' A' ' 33' ' ' VAL . 15.6 t -150.12 162.11 4.03 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.291 -0.881 . . . . 0.0 109.185 -179.464 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.952 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -133.57 136.5 44.97 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.147 -0.97 . . . . 0.0 109.494 -179.631 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.49 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.7 pt -110.87 51.81 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 120.917 -1.115 . . . . 0.0 109.47 179.98 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 120.71 -166.85 13.84 Favored Glycine 0 N--CA 1.49 2.281 0 N-CA-C 109.483 -1.447 . . . . 0.0 109.483 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -104.06 20.21 41.37 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 109.537 -1.425 . . . . 0.0 109.537 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -126.16 -36.79 0.52 Allowed Glycine 0 N--CA 1.49 2.286 0 N-CA-C 109.738 -1.345 . . . . 0.0 109.738 -179.954 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.49 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.6 OUTLIER -134.21 146.04 49.75 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.157 -1.201 . . . . 0.0 109.501 -179.787 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.72 ' O ' HD13 ' A' ' 69' ' ' ILE . 1.0 OUTLIER -120.49 149.83 41.78 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 120.804 -1.185 . . . . 0.0 110.46 -179.57 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.725 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -102.69 -178.1 26.99 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.627 -1.789 . . . . 0.0 108.627 179.198 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.972 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -148.56 119.79 7.8 Favored 'General case' 0 N--CA 1.488 1.464 0 O-C-N 120.863 -1.375 . . . . 0.0 110.67 179.744 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.778 ' HB ' ' HB3' ' A' ' 21' ' ' ALA . 59.4 t -94.4 62.26 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.486 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 177.776 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.457 ' HB2' HD23 ' A' ' 32' ' ' LEU . 4.0 t-80 -50.16 159.39 0.45 Allowed 'General case' 0 C--N 1.303 -1.431 0 O-C-N 120.888 -1.132 . . . . 0.0 108.637 -179.53 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.582 HG23 ' H ' ' A' ' 36' ' ' SER . 1.6 tp -48.53 -52.94 7.58 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.169 -0.957 . . . . 0.0 110.342 -179.614 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.582 ' H ' HG23 ' A' ' 35' ' ' ILE . 1.9 t -81.84 44.85 0.86 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.12 -0.987 . . . . 0.0 110.536 -179.448 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.778 ' C ' HD12 ' A' ' 38' ' ' ILE . 46.8 mt-30 -150.36 37.03 0.67 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 120.783 -1.198 . . . . 0.0 109.88 179.935 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.887 HG21 ' CD2' ' A' ' 49' ' ' TYR . 1.8 mp -114.77 -96.69 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 120.932 -1.105 . . . . 0.0 110.285 -179.58 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.772 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -97.46 51.75 1.09 Allowed 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.447 -0.783 . . . . 0.0 109.43 -179.17 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.541 ' CB ' ' O ' ' A' ' 39' ' ' ALA . 5.0 m-20 82.28 -41.88 0.13 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.782 -0.574 . . . . 0.0 110.106 179.843 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.442 ' CB ' ' O ' ' A' ' 40' ' ' ASP . 0.0 OUTLIER 171.05 -22.95 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.528 0 O-C-N 120.883 -1.136 . . . . 0.0 110.767 -179.691 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.6 mtm180 -79.49 77.98 6.03 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.878 -1.139 . . . . 0.0 110.974 -178.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.113 HG13 ' CD1' ' A' ' 49' ' ' TYR . 59.1 t -144.32 63.73 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 121.313 -0.867 . . . . 0.0 108.756 178.68 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.446 ' C ' ' O ' ' A' ' 43' ' ' VAL . 20.9 tp10 -38.57 -29.27 0.03 OUTLIER 'General case' 0 N--CA 1.494 1.739 0 O-C-N 121.569 -0.707 . . . . 0.0 110.538 -179.264 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.487 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 3.5 mttm -133.03 132.37 41.75 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.915 -1.115 . . . . 0.0 109.978 -179.552 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.797 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -79.65 -25.74 12.35 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.268 -1.012 . . . . 0.0 108.268 179.18 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 10.5 p -77.2 4.45 10.44 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.653 -0.654 . . . . 0.0 109.355 179.325 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.487 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 2.8 m-20 -106.53 -30.16 9.22 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.147 -0.97 . . . . 0.0 108.621 179.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 1.113 ' CD1' HG13 ' A' ' 43' ' ' VAL . 19.0 m-85 -92.14 -30.91 15.71 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.576 -0.703 . . . . 0.0 109.264 179.764 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 1.047 HD12 ' HB1' ' A' ' 21' ' ' ALA . 0.6 OUTLIER -106.08 143.48 34.15 Favored 'General case' 0 N--CA 1.492 1.644 0 C-N-CA 119.32 -0.952 . . . . 0.0 109.633 179.857 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.515 ' O ' ' CB ' ' A' ' 13' ' ' VAL . 4.1 tt0 -130.69 129.69 42.92 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.273 -0.892 . . . . 0.0 108.999 179.455 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 10.2 mtt -63.57 118.33 8.04 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.142 -0.973 . . . . 0.0 109.674 -179.895 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 105.12 -23.05 31.66 Favored Glycine 0 N--CA 1.492 2.372 0 N-CA-C 109.691 -1.364 . . . . 0.0 109.691 179.871 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . 0.499 ' CG ' ' HB3' ' A' ' 51' ' ' GLN . 4.9 mt-30 -73.31 -172.61 1.17 Allowed 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.23 -1.159 . . . . 0.0 109.647 -179.915 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.463 ' HG2' ' HA ' ' A' ' 12' ' ' LYS . 5.6 mt-10 -156.76 128.75 7.29 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.214 -0.929 . . . . 0.0 109.518 -179.899 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.411 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 14.6 m -128.5 145.63 56.71 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.223 -0.923 . . . . 0.0 109.721 -179.89 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.411 ' HD3' ' HA ' ' A' ' 56' ' ' VAL . 36.3 Cg_endo -79.79 139.93 14.28 Favored 'Trans proline' 0 C--N 1.311 -1.429 0 C-N-CA 122.644 2.229 . . . . 0.0 110.155 179.718 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.818 ' CG2' HD22 ' A' ' 71' ' ' LEU . 1.0 OUTLIER -142.49 -177.96 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 O-C-N 121.162 -0.961 . . . . 0.0 109.777 -179.844 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.418 ' N ' HG23 ' A' ' 58' ' ' VAL . 5.3 mttm -127.0 116.52 20.88 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.443 -0.786 . . . . 0.0 109.465 179.804 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 1.076 HG11 HG22 ' A' ' 5' ' ' VAL . 13.6 t -51.31 99.34 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.302 -1.459 0 O-C-N 121.166 -0.959 . . . . 0.0 109.353 179.704 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.611 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 9.8 tp -75.74 -16.01 60.2 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.327 -0.858 . . . . 0.0 109.573 -179.666 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.611 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 2.3 tt0 92.71 -175.83 0.01 OUTLIER 'General case' 0 N--CA 1.5 2.061 0 N-CA-C 109.349 -0.611 . . . . 0.0 109.349 -179.769 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.663 HG13 ' O ' ' A' ' 68' ' ' ARG . 0.9 OUTLIER -122.24 -167.19 0.46 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.62 0 O-C-N 120.993 -1.067 . . . . 0.0 109.852 -179.457 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.629 ' H ' HG12 ' A' ' 63' ' ' VAL . 9.6 p-10 -135.33 -139.83 0.17 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.376 -0.827 . . . . 0.0 109.64 -179.635 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 3.0 tpm_? -67.43 -29.34 68.8 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.146 -0.971 . . . . 0.0 109.901 -179.657 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . 0.46 ' HB3' ' HG2' ' A' ' 68' ' ' ARG . 2.8 tt0 -89.64 -174.12 4.2 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.003 -1.06 . . . . 0.0 109.434 -179.913 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -109.86 45.69 1.28 Allowed Glycine 0 N--CA 1.49 2.271 0 N-CA-C 109.748 -1.341 . . . . 0.0 109.748 -179.82 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.663 ' O ' HG13 ' A' ' 63' ' ' VAL . 9.6 mmm180 -105.03 91.51 3.83 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.149 -1.206 . . . . 0.0 109.448 179.816 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.72 HD13 ' O ' ' A' ' 30' ' ' GLU . 2.4 mt -47.37 120.0 0.66 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.129 -0.982 . . . . 0.0 109.362 179.928 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.493 ' NH1' ' HB2' ' A' ' 68' ' ' ARG . 7.1 mmt-85 -94.5 100.57 12.53 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.208 -0.933 . . . . 0.0 109.718 179.86 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.818 HD22 ' CG2' ' A' ' 58' ' ' VAL . 12.0 mt -90.7 146.36 24.07 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 121.264 -0.897 . . . . 0.0 108.725 179.612 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.25 90.01 3.17 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.199 -0.938 . . . . 0.0 110.071 -179.333 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -50.27 133.23 10.24 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.328 -0.858 . . . . 0.0 108.983 179.752 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.411 ' O ' ' C ' ' A' ' 75' ' ' GLU . 4.1 tttp -73.98 167.51 21.35 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.232 -0.918 . . . . 0.0 109.33 -179.932 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.411 ' C ' ' O ' ' A' ' 74' ' ' LYS . 5.1 mt-10 -45.06 -40.11 6.39 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.198 -0.939 . . . . 0.0 109.385 -179.985 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.557 0 CA-C-O 117.927 -1.035 . . . . 0.0 109.514 179.993 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.59 0 CA-C-O 121.254 0.549 . . . . 0.0 109.539 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER 51.86 -171.64 0.03 OUTLIER 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.207 -0.933 . . . . 0.0 109.465 -179.993 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.643 HG21 ' OH ' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -130.72 -161.63 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.341 0 O-C-N 121.346 -0.846 . . . . 0.0 109.26 -179.499 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -134.9 135.65 41.74 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.312 -0.868 . . . . 0.0 109.013 179.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.418 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 4.0 t -67.24 157.45 6.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.564 0 O-C-N 121.194 -0.941 . . . . 0.0 109.35 -179.853 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.418 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 85.24 -5.74 82.06 Favored Glycine 0 N--CA 1.487 2.072 0 N-CA-C 109.001 -1.64 . . . . 0.0 109.001 -179.391 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 5.4 ttm180 -85.04 159.41 20.22 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.21 -1.171 . . . . 0.0 109.519 179.926 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 46.6 t -92.08 138.69 19.32 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.154 -0.966 . . . . 0.0 109.465 179.876 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.643 ' OH ' HG21 ' A' ' 3' ' ' ILE . 10.3 m-85 -119.53 -177.24 3.33 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.142 -0.974 . . . . 0.0 109.975 179.956 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -143.58 111.86 6.29 Favored 'General case' 0 C--N 1.3 -1.577 0 N-CA-C 107.403 -1.332 . . . . 0.0 107.403 178.885 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -125.09 153.34 17.94 Favored Glycine 0 N--CA 1.49 2.245 0 C-N-CA 119.009 -1.567 . . . . 0.0 110.809 -178.224 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.495 ' O ' HG13 ' A' ' 23' ' ' VAL . 16.1 mttm -95.93 166.07 11.96 Favored 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 108.421 -0.955 . . . . 0.0 108.421 178.938 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.081 HG22 HD13 ' A' ' 50' ' ' LEU . 79.3 t -88.46 105.23 15.45 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 121.062 -1.023 . . . . 0.0 108.323 179.404 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.53 ' O ' ' CD ' ' A' ' 15' ' ' ARG . 1.7 p -117.57 6.27 12.48 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.269 -0.895 . . . . 0.0 110.077 -179.014 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.53 ' CD ' ' O ' ' A' ' 14' ' ' THR . 0.0 OUTLIER -169.69 149.25 3.8 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 121.08 -1.013 . . . . 0.0 109.935 179.867 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.494 HG22 ' N ' ' A' ' 17' ' ' VAL . 19.5 mt -141.99 163.49 19.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.761 0 N-CA-C 108.558 -0.904 . . . . 0.0 108.558 179.479 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 1.045 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -143.48 153.41 16.35 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.8 -1.188 . . . . 0.0 110.205 -179.43 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.6 OUTLIER -58.21 -42.7 86.8 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 120.784 -1.198 . . . . 0.0 109.324 179.276 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.045 ' CE1' HG21 ' A' ' 17' ' ' VAL . 12.1 p90 -90.61 29.42 1.31 Allowed 'General case' 0 N--CA 1.492 1.655 0 O-C-N 121.217 -0.927 . . . . 0.0 110.351 -179.558 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.56 ' HA2' ' N ' ' A' ' 35' ' ' ILE . . . 150.47 -152.08 24.01 Favored Glycine 0 N--CA 1.494 2.54 0 C-N-CA 119.102 -1.523 . . . . 0.0 110.936 179.939 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.711 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -152.78 148.81 27.66 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 120.992 -1.299 . . . . 0.0 108.979 -179.897 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.959 ' CE1' HD11 ' A' ' 32' ' ' LEU . 11.1 m-30 -107.81 163.81 12.79 Favored 'General case' 0 C--N 1.298 -1.657 0 O-C-N 121.345 -0.847 . . . . 0.0 108.753 179.571 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.938 ' CG2' HG23 ' A' ' 33' ' ' VAL . 22.7 t -149.5 165.49 3.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.093 -1.004 . . . . 0.0 109.204 -179.93 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.591 ' HA ' ' HA ' ' A' ' 30' ' ' GLU . . . -132.42 141.44 48.86 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.057 -1.027 . . . . 0.0 110.592 -179.108 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.518 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.1 pt -110.91 -93.0 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.585 0 O-C-N 121.079 -1.013 . . . . 0.0 108.81 179.083 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -70.38 -163.34 4.5 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 109.321 -1.511 . . . . 0.0 109.321 179.547 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -84.42 -23.98 48.85 Favored Glycine 0 N--CA 1.491 2.331 0 N-CA-C 109.848 -1.301 . . . . 0.0 109.848 -179.796 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -115.03 -13.91 8.85 Favored Glycine 0 N--CA 1.491 2.353 0 N-CA-C 109.975 -1.25 . . . . 0.0 109.975 -179.741 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.518 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.3 OUTLIER -104.95 142.7 34.3 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.121 -1.223 . . . . 0.0 109.625 -179.973 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.743 ' O ' HG21 ' A' ' 69' ' ' ILE . 1.4 pp20? -133.14 149.42 52.08 Favored 'General case' 0 C--N 1.303 -1.447 0 O-C-N 120.924 -1.11 . . . . 0.0 110.328 179.946 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.618 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -98.08 -172.68 32.79 Favored Glycine 0 N--CA 1.489 2.174 0 N-CA-C 108.251 -1.939 . . . . 0.0 108.251 179.194 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.959 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.65 119.76 6.74 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 120.842 -1.387 . . . . 0.0 111.047 179.737 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.938 HG23 ' CG2' ' A' ' 23' ' ' VAL . 49.3 t -95.47 61.3 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.438 0 N-CA-C 107.395 -1.335 . . . . 0.0 107.395 177.32 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.507 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.6 t-80 -49.11 160.82 0.18 Allowed 'General case' 0 C--N 1.303 -1.432 0 O-C-N 120.846 -1.159 . . . . 0.0 108.331 -179.373 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.56 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.6 tp -52.96 -41.29 40.11 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.606 0 O-C-N 121.029 -1.045 . . . . 0.0 109.986 -179.731 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.485 ' O ' ' HG2' ' A' ' 37' ' ' GLN . 49.9 m -81.59 30.29 0.36 Allowed 'General case' 0 N--CA 1.495 1.792 0 O-C-N 121.086 -1.009 . . . . 0.0 110.922 -179.425 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.968 ' C ' HD12 ' A' ' 38' ' ' ILE . 6.3 mt-30 -149.22 65.32 1.02 Allowed 'General case' 0 N--CA 1.492 1.654 0 O-C-N 120.653 -1.28 . . . . 0.0 110.174 -179.842 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.989 HG12 HG11 ' A' ' 43' ' ' VAL . 1.6 mp -123.54 -99.37 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.639 0 O-C-N 120.87 -1.144 . . . . 0.0 109.843 179.489 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.781 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -111.92 -142.49 0.38 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.16 -0.962 . . . . 0.0 109.33 -179.544 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.475 ' O ' ' CB ' ' A' ' 41' ' ' LYS . 2.2 t70 -43.65 -51.88 6.76 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.128 -0.982 . . . . 0.0 109.721 -179.921 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.475 ' CB ' ' O ' ' A' ' 40' ' ' ASP . 0.8 OUTLIER 165.7 -22.62 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.248 -0.907 . . . . 0.0 109.985 -179.703 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 1.7 mmp_? -77.18 77.24 3.72 Favored 'General case' 0 N--CA 1.493 1.697 0 O-C-N 121.127 -0.983 . . . . 0.0 110.676 -179.119 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.066 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 72.4 t -137.51 49.74 0.34 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.739 0 O-C-N 121.117 -0.989 . . . . 0.0 108.874 178.673 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 29.4 mp0 -45.01 -31.0 1.15 Allowed 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.344 -0.847 . . . . 0.0 109.397 -179.777 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.504 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 0.3 OUTLIER -112.17 114.78 27.79 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.202 -0.936 . . . . 0.0 109.386 179.873 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.555 HG21 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -73.18 -22.66 19.55 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.83 0 N-CA-C 108.415 -0.957 . . . . 0.0 108.415 179.746 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 3.0 p -77.31 4.41 10.76 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.535 -0.728 . . . . 0.0 109.387 179.492 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.504 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 2.4 m-20 -103.93 -29.89 10.66 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.156 -0.965 . . . . 0.0 108.75 179.566 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 1.066 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 32.3 m-85 -96.49 -30.11 13.52 Favored 'General case' 0 C--N 1.302 -1.472 0 O-C-N 121.616 -0.678 . . . . 0.0 109.337 -179.949 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 1.081 HD13 HG22 ' A' ' 13' ' ' VAL . 0.1 OUTLIER -104.07 133.98 48.1 Favored 'General case' 0 N--CA 1.489 1.497 0 CA-C-O 121.816 0.817 . . . . 0.0 109.774 -179.695 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.497 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.0 OUTLIER -136.21 123.49 21.85 Favored 'General case' 0 N--CA 1.491 1.609 0 N-CA-C 108.943 -0.762 . . . . 0.0 108.943 -179.912 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . 0.426 ' HA ' ' O ' ' A' ' 13' ' ' VAL . 3.1 mtt -52.44 110.01 0.45 Allowed 'General case' 0 N--CA 1.493 1.69 0 O-C-N 121.18 -0.95 . . . . 0.0 110.772 -179.189 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 122.54 -9.87 9.25 Favored Glycine 0 N--CA 1.496 2.648 0 C-N-CA 119.894 -1.146 . . . . 0.0 110.606 178.868 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -80.96 175.66 10.5 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.146 -1.208 . . . . 0.0 110.174 -179.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 -142.72 117.72 10.01 Favored 'General case' 0 N--CA 1.49 1.537 0 N-CA-C 108.698 -0.853 . . . . 0.0 108.698 179.564 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.3 m -135.95 145.42 52.54 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 120.993 -1.067 . . . . 0.0 110.635 -179.207 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.487 ' HG2' ' CD ' ' A' ' 74' ' ' LYS . 37.2 Cg_endo -82.98 155.64 15.07 Favored 'Trans proline' 0 C--N 1.314 -1.278 0 C-N-CA 122.873 2.382 . . . . 0.0 109.486 178.806 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.995 HG21 ' HB3' ' A' ' 71' ' ' LEU . 1.2 m -150.48 -173.74 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.561 0 O-C-N 120.823 -1.173 . . . . 0.0 110.206 179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.437 ' N ' HG23 ' A' ' 58' ' ' VAL . 0.3 OUTLIER -123.18 129.2 51.09 Favored 'General case' 0 N--CA 1.489 1.491 0 N-CA-C 108.726 -0.842 . . . . 0.0 108.726 179.628 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.637 ' CG2' ' CE1' ' A' ' 9' ' ' TYR . 89.0 t -59.38 91.55 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.27 -0.894 . . . . 0.0 110.071 -179.375 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.938 HD23 ' HG2' ' A' ' 70' ' ' ARG . 14.2 tp -60.17 -18.31 47.04 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.245 -0.909 . . . . 0.0 109.228 179.593 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.599 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 1.6 pt-20 97.89 -161.79 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.149 0 CA-C-O 121.676 0.75 . . . . 0.0 109.901 -179.964 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.883 HG13 ' O ' ' A' ' 67' ' ' GLY . 41.4 t -140.68 119.24 10.55 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 109.211 -0.663 . . . . 0.0 109.211 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.425 ' O ' ' C ' ' A' ' 65' ' ' ARG . 20.8 p-10 -97.17 -158.07 0.64 Allowed 'General case' 0 N--CA 1.492 1.631 0 O-C-N 121.222 -0.924 . . . . 0.0 109.255 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . 0.425 ' C ' ' O ' ' A' ' 64' ' ' ASP . 4.5 mtp85 -44.3 -75.4 0.03 OUTLIER 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.249 -0.907 . . . . 0.0 108.876 179.727 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 4.2 pt20 -103.26 123.94 47.69 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.245 -0.909 . . . . 0.0 108.799 179.087 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.883 ' O ' HG13 ' A' ' 63' ' ' VAL . . . 151.07 104.66 0.29 Allowed Glycine 0 N--CA 1.487 2.069 0 N-CA-C 109.151 -1.58 . . . . 0.0 109.151 -179.58 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 3.5 ptm180 -88.42 125.42 34.72 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.399 -1.059 . . . . 0.0 109.279 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.743 HG21 ' O ' ' A' ' 30' ' ' GLU . 21.7 mt 45.15 86.43 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 O-C-N 121.392 -0.817 . . . . 0.0 109.182 -179.639 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.938 ' HG2' HD23 ' A' ' 61' ' ' LEU . 4.0 tpt180 -89.51 88.21 7.35 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 121.028 -1.045 . . . . 0.0 109.554 -179.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.995 ' HB3' HG21 ' A' ' 58' ' ' VAL . 12.6 mt -89.87 140.74 29.31 Favored 'General case' 0 N--CA 1.488 1.434 0 O-C-N 121.137 -0.977 . . . . 0.0 109.057 179.69 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.478 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.4 OUTLIER -115.79 109.61 17.9 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.301 -0.875 . . . . 0.0 109.781 -179.572 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.603 HG22 ' O ' ' A' ' 38' ' ' ILE . 0.1 OUTLIER -42.4 126.32 0.69 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.651 0 O-C-N 121.364 -0.835 . . . . 0.0 108.925 179.918 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.704 ' HD2' ' HB2' ' A' ' 76' ' ' ALA . 0.0 OUTLIER -61.94 -158.32 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.444 0 O-C-N 121.167 -0.958 . . . . 0.0 109.46 -179.66 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 4.2 tp10 -101.72 47.41 0.9 Allowed 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.343 -0.848 . . . . 0.0 109.615 -179.762 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.704 ' HB2' ' HD2' ' A' ' 74' ' ' LYS . . . . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 118.078 -0.963 . . . . 0.0 109.358 179.951 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.41 ' O ' ' HB2' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.573 0 N-CA-C 109.465 -0.568 . . . . 0.0 109.465 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.532 ' C ' HD13 ' A' ' 3' ' ' ILE . 2.9 mm-40 67.34 -176.13 0.2 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.162 -0.961 . . . . 0.0 109.537 179.888 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.608 HG21 ' OH ' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -130.37 -161.08 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.352 0 O-C-N 121.297 -0.877 . . . . 0.0 109.578 -179.564 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -127.64 116.63 20.59 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.36 -0.837 . . . . 0.0 109.01 179.8 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.53 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 20.1 t -52.06 164.56 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.177 -0.952 . . . . 0.0 109.67 -179.706 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.53 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 85.29 -4.89 84.89 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.078 -1.609 . . . . 0.0 109.078 -179.486 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 60.2 ttt-85 -95.51 157.77 15.75 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.262 -1.14 . . . . 0.0 109.724 -179.827 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.513 HG13 ' O ' ' A' ' 58' ' ' VAL . 72.9 t -90.45 153.93 3.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 121.306 -0.871 . . . . 0.0 109.368 179.944 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.608 ' OH ' HG21 ' A' ' 3' ' ' ILE . 14.7 m-85 -133.96 -171.56 2.77 Favored 'General case' 0 N--CA 1.492 1.653 0 O-C-N 121.033 -1.042 . . . . 0.0 110.225 -179.62 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.453 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 24.8 m -159.29 120.45 3.26 Favored 'General case' 0 N--CA 1.489 1.484 0 N-CA-C 107.244 -1.391 . . . . 0.0 107.244 179.243 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.524 ' CA ' ' O ' ' A' ' 24' ' ' ALA . . . -131.92 164.59 23.66 Favored Glycine 0 N--CA 1.49 2.27 0 C-N-CA 118.759 -1.686 . . . . 0.0 111.077 -178.323 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.564 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.3 OUTLIER -101.76 168.37 9.49 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 179.385 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.569 HG23 ' O ' ' A' ' 54' ' ' GLN . 96.0 t -88.01 99.34 8.68 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.656 0 O-C-N 120.719 -1.238 . . . . 0.0 108.475 179.753 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.778 HG21 ' CB ' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -105.24 -3.1 23.27 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.351 -0.843 . . . . 0.0 110.191 -178.8 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.57 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 1.8 mpp_? -165.82 155.44 12.28 Favored 'General case' 0 N--CA 1.493 1.721 0 O-C-N 120.946 -1.096 . . . . 0.0 110.19 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.519 HG21 HG22 ' A' ' 47' ' ' THR . 21.3 mt -144.43 157.89 15.01 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 N-CA-C 108.528 -0.915 . . . . 0.0 108.528 179.575 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 1.039 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -140.09 155.85 24.38 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.757 0 O-C-N 120.664 -1.273 . . . . 0.0 110.196 -178.995 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 18.4 t0 -60.69 -41.21 94.68 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 120.63 -1.294 . . . . 0.0 109.456 179.472 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.039 ' CE1' HG21 ' A' ' 17' ' ' VAL . 12.4 p90 -89.73 24.61 2.29 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 121.186 -0.947 . . . . 0.0 110.039 -179.774 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.805 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 154.76 -149.07 20.27 Favored Glycine 0 N--CA 1.493 2.445 0 C-N-CA 119.166 -1.492 . . . . 0.0 110.958 -179.682 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.842 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -154.94 148.05 24.79 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 121.217 -1.166 . . . . 0.0 108.465 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.961 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.9 m-30 -108.75 160.88 15.61 Favored 'General case' 0 C--N 1.3 -1.575 0 N-CA-C 108.791 -0.818 . . . . 0.0 108.791 179.693 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.564 HG13 ' O ' ' A' ' 12' ' ' LYS . 3.2 t -150.82 165.33 2.53 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.08 -1.012 . . . . 0.0 109.335 179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.778 ' CB ' HG21 ' A' ' 14' ' ' THR . . . -127.08 150.46 49.46 Favored 'General case' 0 N--CA 1.493 1.688 0 O-C-N 121.066 -1.021 . . . . 0.0 109.864 -179.574 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.512 HG13 ' O ' ' A' ' 29' ' ' LYS . 0.8 OUTLIER -113.32 24.13 4.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.704 0 O-C-N 121.102 -0.999 . . . . 0.0 109.397 179.646 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 128.83 -165.65 21.57 Favored Glycine 0 N--CA 1.491 2.315 0 N-CA-C 109.617 -1.393 . . . . 0.0 109.617 179.945 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -92.26 89.47 1.4 Allowed Glycine 0 N--CA 1.489 2.215 0 N-CA-C 109.501 -1.44 . . . . 0.0 109.501 179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 158.34 -58.96 0.34 Allowed Glycine 0 N--CA 1.49 2.282 0 N-CA-C 109.34 -1.504 . . . . 0.0 109.34 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.512 ' O ' HG13 ' A' ' 25' ' ' ILE . 20.8 mmmt -119.7 153.7 35.21 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.362 -1.081 . . . . 0.0 109.319 179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.572 ' O ' HD13 ' A' ' 69' ' ' ILE . 0.0 OUTLIER -129.7 151.95 49.73 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 120.887 -1.133 . . . . 0.0 110.448 -179.305 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.959 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -99.17 -174.53 31.57 Favored Glycine 0 N--CA 1.489 2.217 0 N-CA-C 108.48 -1.848 . . . . 0.0 108.48 179.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.961 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.23 121.81 8.0 Favored 'General case' 0 N--CA 1.487 1.422 0 O-C-N 120.764 -1.433 . . . . 0.0 111.46 179.946 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.957 HG13 ' CD1' ' A' ' 73' ' ' ILE . 52.7 t -94.44 62.37 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.46 0 N-CA-C 107.695 -1.224 . . . . 0.0 107.695 177.274 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.494 ' CB ' ' OE1' ' A' ' 37' ' ' GLN . 3.3 t-80 -50.43 155.13 1.1 Allowed 'General case' 0 C--N 1.304 -1.411 0 O-C-N 120.862 -1.149 . . . . 0.0 108.804 -179.37 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.563 HG23 ' N ' ' A' ' 36' ' ' SER . 4.1 tp -46.64 -49.92 5.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.361 -0.837 . . . . 0.0 110.765 -179.528 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.563 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.0 OUTLIER -81.5 41.84 0.65 Allowed 'General case' 0 N--CA 1.494 1.736 0 O-C-N 120.952 -1.093 . . . . 0.0 110.524 -179.434 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.995 ' C ' HD12 ' A' ' 38' ' ' ILE . 17.2 mt-30 -150.38 51.44 0.89 Allowed 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.875 -1.141 . . . . 0.0 110.016 179.847 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.995 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.7 mp -127.27 -96.5 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 120.935 -1.103 . . . . 0.0 110.312 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.794 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -100.11 53.12 0.9 Allowed 'General case' 0 N--CA 1.489 1.496 0 O-C-N 121.563 -0.711 . . . . 0.0 109.899 -179.01 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.561 ' CB ' ' O ' ' A' ' 39' ' ' ALA . 11.7 t0 82.54 -44.92 0.15 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.787 -0.571 . . . . 0.0 109.967 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.431 ' HB2' ' O ' ' A' ' 40' ' ' ASP . 0.1 OUTLIER 172.97 -25.59 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.035 -1.041 . . . . 0.0 110.572 -179.62 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.423 ' O ' ' OH ' ' A' ' 49' ' ' TYR . 0.1 OUTLIER -76.43 78.58 3.15 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.136 -0.977 . . . . 0.0 110.846 -178.763 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.123 HG13 ' CD1' ' A' ' 49' ' ' TYR . 54.1 t -144.61 67.03 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 N-CA-C 108.631 -0.877 . . . . 0.0 108.631 178.512 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 71.7 tt0 -45.26 -26.36 0.49 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.434 -0.791 . . . . 0.0 110.13 -179.295 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -131.54 131.64 43.53 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.067 -1.021 . . . . 0.0 109.991 -179.6 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.805 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -80.04 -26.2 11.94 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.897 0 N-CA-C 108.083 -1.08 . . . . 0.0 108.083 178.992 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.519 HG22 HG21 ' A' ' 16' ' ' ILE . 7.3 p -80.36 6.58 11.72 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 178.926 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 -105.3 -25.01 12.59 Favored 'General case' 0 N--CA 1.49 1.556 0 N-CA-C 107.839 -1.171 . . . . 0.0 107.839 179.23 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 1.123 ' CD1' HG13 ' A' ' 43' ' ' VAL . 26.0 m-85 -97.57 -33.61 11.28 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 109.039 -0.726 . . . . 0.0 109.039 179.74 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.9 HD11 HG21 ' A' ' 33' ' ' VAL . 0.7 OUTLIER -104.38 143.08 33.48 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.198 -0.939 . . . . 0.0 109.449 179.292 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.503 ' HB3' ' HG3' ' A' ' 54' ' ' GLN . 1.3 tm0? -133.86 134.94 43.34 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.824 -0.806 . . . . 0.0 108.824 179.423 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 7.0 mtt -54.99 102.54 0.07 Allowed 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.142 -0.973 . . . . 0.0 109.733 -179.734 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 126.84 -38.09 2.25 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 119.784 -1.198 . . . . 0.0 110.186 179.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . 0.569 ' O ' HG23 ' A' ' 13' ' ' VAL . 19.3 mm-40 -59.58 128.95 39.58 Favored 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.24 -1.153 . . . . 0.0 110.056 -179.579 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.489 ' HA ' ' HA ' ' A' ' 12' ' ' LYS . 61.8 mt-10 -108.89 131.96 54.5 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.34 -0.85 . . . . 0.0 108.9 179.375 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 17.1 m -137.34 153.44 74.71 Favored Pre-proline 0 N--CA 1.49 1.575 0 O-C-N 121.086 -1.009 . . . . 0.0 110.177 -179.69 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.453 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.9 Cg_endo -79.69 155.89 24.2 Favored 'Trans proline' 0 C--N 1.311 -1.445 0 C-N-CA 122.937 2.425 . . . . 0.0 110.09 179.57 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.803 HG21 ' HB3' ' A' ' 71' ' ' LEU . 1.0 OUTLIER -147.94 -174.73 0.39 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.383 0 O-C-N 121.047 -1.033 . . . . 0.0 109.469 179.927 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.513 ' N ' HG23 ' A' ' 58' ' ' VAL . 1.7 mttp -136.38 119.97 17.12 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.452 -0.78 . . . . 0.0 109.384 179.854 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.594 ' CG2' ' CE1' ' A' ' 9' ' ' TYR . 60.8 t -48.39 95.46 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.654 0 O-C-N 121.303 -0.873 . . . . 0.0 109.281 179.824 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.662 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 11.7 tp -74.46 -27.31 60.53 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 121.38 -0.825 . . . . 0.0 109.351 -179.655 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.662 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 8.2 tp10 136.42 158.28 0.0 OUTLIER 'General case' 0 N--CA 1.506 2.342 0 N-CA-C 108.67 -0.863 . . . . 0.0 108.67 179.89 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.714 HG22 ' HA ' ' A' ' 69' ' ' ILE . 6.3 t -88.66 129.5 39.67 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 121.034 -1.041 . . . . 0.0 109.089 179.84 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 48.8 p-10 -69.38 -176.09 0.91 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.303 -0.873 . . . . 0.0 109.978 -179.579 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -73.73 -4.41 34.35 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.406 -0.809 . . . . 0.0 109.717 -179.857 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . 0.451 ' O ' ' HG3' ' A' ' 66' ' ' GLN . 1.0 OUTLIER -90.17 9.02 30.03 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.175 -0.953 . . . . 0.0 109.4 -179.957 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 70.2 6.7 58.14 Favored Glycine 0 N--CA 1.489 2.188 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.534 ' O ' HG13 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -92.15 152.08 20.07 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.171 -1.193 . . . . 0.0 109.315 179.897 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.714 ' HA ' HG22 ' A' ' 63' ' ' VAL . 0.8 OUTLIER -83.25 121.13 35.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.227 -0.92 . . . . 0.0 109.881 -179.56 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.448 ' CB ' ' O ' ' A' ' 62' ' ' GLU . 2.4 tpt180 -89.77 97.39 11.16 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.24 -0.913 . . . . 0.0 109.039 179.593 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.959 HD12 ' HA3' ' A' ' 31' ' ' GLY . 23.5 mt -89.59 143.48 26.78 Favored 'General case' 0 C--N 1.304 -1.413 0 O-C-N 121.304 -0.873 . . . . 0.0 109.6 -179.502 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.491 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.5 OUTLIER -100.38 123.5 44.68 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.39 -0.819 . . . . 0.0 109.737 -179.594 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.957 ' CD1' HG13 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -63.3 123.65 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.418 -0.801 . . . . 0.0 109.226 179.988 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.428 ' HD3' ' HB2' ' A' ' 57' ' ' PRO . 0.1 OUTLIER -67.14 178.82 1.33 Allowed 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.221 -0.925 . . . . 0.0 109.397 179.859 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -87.72 42.48 1.05 Allowed 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.362 -0.836 . . . . 0.0 109.616 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.526 0 CA-C-O 118.044 -0.979 . . . . 0.0 109.512 179.879 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.507 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.468 ' O ' ' O ' ' A' ' 3' ' ' ILE . 3.1 tt0 -92.09 80.46 5.1 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.298 -0.876 . . . . 0.0 109.739 -179.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.479 HG23 ' N ' ' A' ' 4' ' ' GLU . 0.4 OUTLIER -45.17 169.77 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 N-CA-C 109.037 -0.727 . . . . 0.0 109.037 179.196 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.479 ' N ' HG23 ' A' ' 3' ' ' ILE . 0.6 OUTLIER -123.73 140.36 53.06 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.006 -1.059 . . . . 0.0 109.604 -179.87 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.548 HG12 ' N ' ' A' ' 6' ' ' GLY . 24.1 t -67.4 165.42 2.04 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.232 -0.917 . . . . 0.0 109.332 179.932 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.548 ' N ' HG12 ' A' ' 5' ' ' VAL . . . 75.6 1.61 66.6 Favored Glycine 0 N--CA 1.488 2.131 0 N-CA-C 108.886 -1.686 . . . . 0.0 108.886 -179.295 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.472 ' HD3' HD11 ' A' ' 3' ' ' ILE . 2.4 ttt180 -81.86 170.15 16.0 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.277 -1.131 . . . . 0.0 109.429 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.464 ' HA ' ' O ' ' A' ' 58' ' ' VAL . 78.8 t -108.54 115.85 50.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.185 -0.947 . . . . 0.0 109.801 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.464 ' CE1' ' CG2' ' A' ' 60' ' ' VAL . 5.1 m-85 -92.18 -168.74 2.06 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.325 -0.859 . . . . 0.0 109.148 179.692 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.545 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 21.3 m -151.48 115.85 5.07 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.917 -1.142 . . . . 0.0 107.917 178.69 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.536 ' CA ' ' O ' ' A' ' 24' ' ' ALA . . . -129.16 152.8 19.57 Favored Glycine 0 N--CA 1.487 2.035 0 C-N-CA 119.148 -1.501 . . . . 0.0 110.844 -178.57 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.49 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -93.61 167.7 11.5 Favored 'General case' 0 C--N 1.304 -1.412 0 N-CA-C 108.239 -1.023 . . . . 0.0 108.239 179.006 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.745 HG13 HD23 ' A' ' 50' ' ' LEU . 58.4 t -88.35 106.28 16.43 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.754 0 C-N-CA 119.164 -1.014 . . . . 0.0 108.34 179.736 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.832 HG21 ' CB ' ' A' ' 24' ' ' ALA . 0.5 OUTLIER -111.07 -3.28 15.55 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.341 -0.85 . . . . 0.0 110.226 -178.577 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.548 ' CD ' ' OG1' ' A' ' 14' ' ' THR . 0.0 OUTLIER -173.45 150.73 1.86 Allowed 'General case' 0 N--CA 1.495 1.808 0 O-C-N 120.98 -1.075 . . . . 0.0 110.007 179.479 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.465 HG21 HG22 ' A' ' 47' ' ' THR . 13.1 mt -136.73 161.38 36.42 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.78 0 N-CA-C 108.43 -0.952 . . . . 0.0 108.43 179.525 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 1.032 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.9 OUTLIER -138.65 153.89 26.22 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.768 0 O-C-N 120.653 -1.28 . . . . 0.0 110.225 -179.63 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 3.6 m-20 -58.59 -43.69 89.61 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 120.771 -1.205 . . . . 0.0 109.495 179.196 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.032 ' CE1' HG21 ' A' ' 17' ' ' VAL . 11.6 p90 -89.98 27.9 1.49 Allowed 'General case' 0 N--CA 1.495 1.782 0 O-C-N 121.22 -0.925 . . . . 0.0 110.251 -179.54 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.677 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 153.67 -153.68 25.0 Favored Glycine 0 N--CA 1.492 2.375 0 C-N-CA 118.914 -1.613 . . . . 0.0 111.249 -179.731 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.761 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -151.75 147.69 26.99 Favored 'General case' 0 C--N 1.305 -1.349 0 O-C-N 121.109 -1.23 . . . . 0.0 109.056 -179.737 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.972 ' CE1' HD11 ' A' ' 32' ' ' LEU . 12.2 m-30 -108.25 160.12 16.09 Favored 'General case' 0 C--N 1.299 -1.623 0 N-CA-C 108.894 -0.78 . . . . 0.0 108.894 179.571 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.694 ' CG2' HG23 ' A' ' 33' ' ' VAL . 24.0 t -150.41 166.58 2.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.06 -1.025 . . . . 0.0 109.666 -179.837 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.832 ' CB ' HG21 ' A' ' 14' ' ' THR . . . -130.99 144.99 51.89 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.183 -0.948 . . . . 0.0 109.714 -179.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.553 HD13 HD11 ' A' ' 71' ' ' LEU . 2.2 pt -116.18 45.31 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.731 0 O-C-N 120.906 -1.121 . . . . 0.0 109.399 179.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 125.58 -162.36 19.84 Favored Glycine 0 N--CA 1.491 2.355 0 N-CA-C 109.731 -1.348 . . . . 0.0 109.731 179.974 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -107.19 48.49 0.95 Allowed Glycine 0 N--CA 1.49 2.289 0 N-CA-C 109.743 -1.343 . . . . 0.0 109.743 -179.837 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -160.02 -46.88 0.02 OUTLIER Glycine 0 N--CA 1.491 2.341 0 N-CA-C 109.224 -1.55 . . . . 0.0 109.224 179.916 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.488 ' O ' HG13 ' A' ' 25' ' ' ILE . 56.2 mmtt -121.21 149.29 43.06 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.406 -1.055 . . . . 0.0 108.833 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.546 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 10.7 pt-20 -124.47 152.75 42.97 Favored 'General case' 0 C--N 1.305 -1.348 0 O-C-N 120.918 -1.114 . . . . 0.0 110.975 -179.35 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.87 ' CA ' HD12 ' A' ' 71' ' ' LEU . . . -100.72 -176.54 29.62 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 108.359 -1.896 . . . . 0.0 108.359 179.165 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.972 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.26 120.88 7.48 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.863 -1.375 . . . . 0.0 110.913 179.645 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.954 HG11 ' CD1' ' A' ' 50' ' ' LEU . 61.8 t -96.19 63.11 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.517 0 N-CA-C 107.89 -1.152 . . . . 0.0 107.89 177.712 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.44 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.1 t-80 -50.45 156.62 0.84 Allowed 'General case' 0 C--N 1.304 -1.406 0 O-C-N 120.837 -1.165 . . . . 0.0 108.623 -179.48 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.561 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.2 OUTLIER -46.65 -48.97 6.85 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.554 0 O-C-N 121.113 -0.992 . . . . 0.0 109.575 -179.793 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.537 ' N ' HG23 ' A' ' 35' ' ' ILE . 4.9 p -81.59 40.39 0.58 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.287 -0.883 . . . . 0.0 110.389 -179.841 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.56 ' C ' HD12 ' A' ' 38' ' ' ILE . 71.4 mt-30 -148.93 30.63 0.79 Allowed 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.714 -1.241 . . . . 0.0 110.069 179.969 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.824 HG21 ' CD2' ' A' ' 49' ' ' TYR . 1.8 mp -104.65 -96.32 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.016 -1.053 . . . . 0.0 109.602 179.68 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.792 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -109.23 -150.71 0.46 Allowed 'General case' 0 C--N 1.3 -1.585 0 O-C-N 121.463 -0.773 . . . . 0.0 109.502 -179.588 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.496 ' O ' ' HB2' ' A' ' 41' ' ' LYS . 8.7 m-20 -46.35 -56.68 5.49 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.31 -0.869 . . . . 0.0 109.891 -179.796 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.496 ' HB2' ' O ' ' A' ' 40' ' ' ASP . 22.4 tttt 170.65 -7.53 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.766 0 O-C-N 121.298 -0.876 . . . . 0.0 111.046 -179.716 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 2.2 mtm105 -80.73 41.31 0.56 Allowed 'General case' 0 N--CA 1.493 1.687 0 O-C-N 120.742 -1.224 . . . . 0.0 110.583 -179.449 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.064 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 87.4 t -106.09 47.5 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.571 0 O-C-N 120.749 -1.219 . . . . 0.0 109.466 179.494 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.434 ' C ' ' O ' ' A' ' 43' ' ' VAL . 0.4 OUTLIER -45.33 -27.22 0.63 Allowed 'General case' 0 N--CA 1.489 1.494 0 N-CA-C 108.477 -0.935 . . . . 0.0 108.477 179.568 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.446 ' HB3' ' CG ' ' A' ' 48' ' ' ASP . 0.0 OUTLIER -115.44 113.44 23.72 Favored 'General case' 0 C--N 1.303 -1.435 0 N-CA-C 108.695 -0.854 . . . . 0.0 108.695 179.239 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.677 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -73.67 -25.35 20.66 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.793 0 N-CA-C 108.566 -0.902 . . . . 0.0 108.566 -179.981 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.465 HG22 HG21 ' A' ' 16' ' ' ILE . 61.1 p -77.68 5.72 8.73 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.471 -0.768 . . . . 0.0 109.414 179.279 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.446 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 13.3 m-20 -101.29 -32.7 10.37 Favored 'General case' 0 N--CA 1.49 1.551 0 N-CA-C 108.073 -1.084 . . . . 0.0 108.073 179.292 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 1.064 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 19.5 m-85 -90.43 -36.23 14.69 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 108.899 -0.778 . . . . 0.0 108.899 179.502 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.954 ' CD1' HG11 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -101.61 158.01 16.41 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.292 -0.88 . . . . 0.0 110.527 179.789 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.423 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 16.8 tp60 -149.35 127.6 12.11 Favored 'General case' 0 N--CA 1.489 1.497 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.503 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 5.6 mtt -59.69 111.82 1.58 Allowed 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.124 -0.985 . . . . 0.0 110.19 -179.463 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 120.8 -25.43 7.19 Favored Glycine 0 N--CA 1.493 2.476 0 C-N-CA 119.874 -1.155 . . . . 0.0 110.383 179.301 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 9.6 mt-30 -74.95 177.09 6.57 Favored 'General case' 0 N--CA 1.492 1.64 0 O-C-N 121.082 -1.246 . . . . 0.0 110.323 -179.434 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.418 ' HA ' ' HA ' ' A' ' 12' ' ' LYS . 0.1 OUTLIER -139.13 126.53 21.59 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 108.651 -0.87 . . . . 0.0 108.651 179.76 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.2 m -138.01 144.98 45.97 Favored Pre-proline 0 N--CA 1.489 1.505 0 O-C-N 120.947 -1.096 . . . . 0.0 110.5 -179.293 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.545 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 37.1 Cg_endo -81.81 153.11 17.2 Favored 'Trans proline' 0 C--N 1.314 -1.28 0 C-N-CA 122.951 2.434 . . . . 0.0 110.117 179.418 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.806 HG21 ' HB3' ' A' ' 71' ' ' LEU . 0.8 OUTLIER -144.39 -168.86 0.31 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.1 -1.0 . . . . 0.0 109.344 179.457 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.651 ' N ' HG23 ' A' ' 58' ' ' VAL . 5.6 mttt -133.87 136.85 44.62 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.33 -0.856 . . . . 0.0 109.298 -179.981 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.521 ' HA ' HD23 ' A' ' 71' ' ' LEU . 86.2 t -65.39 86.87 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.35 -0.844 . . . . 0.0 109.025 179.675 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.504 ' O ' ' HB2' ' A' ' 62' ' ' GLU . 4.6 tp -56.32 -33.3 65.46 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.449 -0.782 . . . . 0.0 109.401 -179.825 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.504 ' HB2' ' O ' ' A' ' 61' ' ' LEU . 0.8 OUTLIER 167.62 157.76 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.769 0 O-C-N 121.468 -0.77 . . . . 0.0 110.118 -179.952 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.494 ' HA ' ' O ' ' A' ' 66' ' ' GLN . 46.6 t -150.15 -52.44 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.473 -0.767 . . . . 0.0 109.21 179.162 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.425 ' C ' ' O ' ' A' ' 63' ' ' VAL . 0.5 OUTLIER -44.47 -50.81 9.22 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.301 -0.875 . . . . 0.0 109.324 -179.937 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . 0.523 ' CB ' ' OE1' ' A' ' 66' ' ' GLN . 0.1 OUTLIER -68.01 -37.32 81.29 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.239 -0.913 . . . . 0.0 108.913 179.597 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . 0.523 ' OE1' ' CB ' ' A' ' 65' ' ' ARG . 2.0 pm0 -128.37 112.76 14.76 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.479 -0.763 . . . . 0.0 109.08 179.598 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -74.39 5.32 28.95 Favored Glycine 0 N--CA 1.491 2.317 0 N-CA-C 110.5 -1.04 . . . . 0.0 110.5 -179.498 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.471 ' O ' ' O ' ' A' ' 69' ' ' ILE . 7.9 mtt180 -89.79 39.17 0.94 Allowed 'General case' 0 N--CA 1.488 1.434 0 O-C-N 120.746 -1.444 . . . . 0.0 109.496 179.878 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.525 HG21 ' O ' ' A' ' 30' ' ' GLU . 61.9 mt 36.87 95.55 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.784 0 CA-C-O 121.181 0.515 . . . . 0.0 110.437 179.445 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.467 ' HG2' HD23 ' A' ' 61' ' ' LEU . 10.0 tpt180 -89.88 81.5 6.31 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.16 -0.963 . . . . 0.0 109.625 179.777 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.87 HD12 ' CA ' ' A' ' 31' ' ' GLY . 20.8 mt -92.23 143.75 26.1 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.214 -0.929 . . . . 0.0 109.276 179.893 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.445 ' O ' ' C ' ' A' ' 73' ' ' ILE . 2.1 m -125.73 117.01 22.53 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.289 -0.882 . . . . 0.0 109.744 -179.69 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.445 ' C ' ' O ' ' A' ' 72' ' ' SER . 0.1 OUTLIER -44.22 136.91 1.14 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.274 -0.891 . . . . 0.0 108.785 179.68 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.444 ' CD ' ' HE3' ' A' ' 59' ' ' LYS . 0.1 OUTLIER -48.12 170.99 0.02 OUTLIER 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.191 -0.943 . . . . 0.0 109.532 -179.714 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER 46.7 44.03 13.43 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.248 -0.908 . . . . 0.0 109.466 -179.964 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.619 0 CA-C-O 118.011 -0.995 . . . . 0.0 109.41 179.823 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.44 ' O ' ' O ' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.49 1.575 0 N-CA-C 109.511 -0.552 . . . . 0.0 109.511 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.44 ' O ' ' O ' ' A' ' 1' ' ' ALA . 4.6 mt-10 49.15 -178.13 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.659 0 O-C-N 121.207 -0.933 . . . . 0.0 109.72 179.879 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.521 HG21 ' OH ' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -127.48 -164.52 0.41 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.414 0 O-C-N 121.399 -0.813 . . . . 0.0 109.66 -179.511 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 9.0 tt0 -126.25 119.13 26.64 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.496 -0.753 . . . . 0.0 109.201 179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.666 HG22 HG11 ' A' ' 60' ' ' VAL . 3.0 t -56.4 157.13 1.17 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.27 -0.894 . . . . 0.0 109.402 -179.924 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . 83.73 -1.31 88.92 Favored Glycine 0 N--CA 1.488 2.123 0 N-CA-C 109.137 -1.585 . . . . 0.0 109.137 -179.387 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 8.0 ttt85 -89.25 156.05 19.0 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.217 -1.166 . . . . 0.0 109.915 -179.802 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.686 HG22 ' HG2' ' A' ' 59' ' ' LYS . 40.8 t -93.39 134.95 29.44 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.439 -0.788 . . . . 0.0 109.265 179.92 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.521 ' OH ' HG21 ' A' ' 3' ' ' ILE . 13.3 m-85 -116.64 -174.25 2.53 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.173 -0.954 . . . . 0.0 110.239 -179.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.468 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 5.5 m -155.89 111.77 3.05 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 107.263 -1.384 . . . . 0.0 107.263 179.258 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.434 ' CA ' ' O ' ' A' ' 24' ' ' ALA . . . -126.58 153.66 18.85 Favored Glycine 0 N--CA 1.489 2.183 0 C-N-CA 118.906 -1.616 . . . . 0.0 111.04 -178.095 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.5 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -89.71 164.12 14.82 Favored 'General case' 0 C--N 1.303 -1.448 0 N-CA-C 108.22 -1.03 . . . . 0.0 108.22 179.128 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.705 ' CG2' HD22 ' A' ' 50' ' ' LEU . 99.4 t -88.08 95.96 5.56 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.616 0 O-C-N 120.753 -1.217 . . . . 0.0 108.336 179.703 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.743 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.1 p -96.53 -1.9 46.17 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.5 -0.75 . . . . 0.0 109.865 -178.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.544 ' CD ' ' OG1' ' A' ' 14' ' ' THR . 0.0 OUTLIER -173.37 143.21 1.06 Allowed 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.174 -0.954 . . . . 0.0 109.687 179.982 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.792 HG21 HG22 ' A' ' 47' ' ' THR . 8.8 mt -131.56 159.16 43.26 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.753 0 N-CA-C 108.199 -1.037 . . . . 0.0 108.199 179.323 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 1.005 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -135.44 153.83 34.15 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 O-C-N 120.634 -1.291 . . . . 0.0 110.42 -178.474 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 5.3 m-20 -61.3 -39.69 91.41 Favored 'General case' 0 N--CA 1.492 1.63 0 O-C-N 120.569 -1.332 . . . . 0.0 109.376 179.416 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.005 ' CE1' HG21 ' A' ' 17' ' ' VAL . 15.5 p90 -90.86 23.42 3.15 Favored 'General case' 0 N--CA 1.494 1.733 0 O-C-N 121.364 -0.835 . . . . 0.0 110.107 -179.736 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.601 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 155.16 -152.28 23.81 Favored Glycine 0 N--CA 1.492 2.43 0 C-N-CA 119.214 -1.47 . . . . 0.0 110.822 -179.402 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.826 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -151.42 145.01 24.94 Favored 'General case' 0 C--N 1.304 -1.412 0 O-C-N 120.759 -1.436 . . . . 0.0 109.31 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.961 ' CE1' HD11 ' A' ' 32' ' ' LEU . 12.4 m-30 -107.18 156.78 18.46 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.802 -0.814 . . . . 0.0 108.802 179.559 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.5 HG13 ' O ' ' A' ' 12' ' ' LYS . 7.2 t -150.44 162.13 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 121.045 -1.035 . . . . 0.0 109.793 -179.533 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.743 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -128.17 144.49 51.12 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.283 -0.886 . . . . 0.0 109.06 179.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.602 HD11 ' HB3' ' A' ' 29' ' ' LYS . 1.8 pt -103.4 2.94 10.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.745 0 O-C-N 120.775 -1.203 . . . . 0.0 109.915 -179.794 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 118.1 175.15 16.69 Favored Glycine 0 N--CA 1.49 2.297 0 C-N-CA 119.711 -1.233 . . . . 0.0 110.248 179.386 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -55.71 93.55 0.02 OUTLIER Glycine 0 N--CA 1.489 2.216 0 N-CA-C 109.476 -1.45 . . . . 0.0 109.476 179.873 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.408 ' O ' ' HG2' ' A' ' 29' ' ' LYS . . . 165.52 -42.02 0.28 Allowed Glycine 0 N--CA 1.488 2.139 0 N-CA-C 109.094 -1.602 . . . . 0.0 109.094 -179.943 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.602 ' HB3' HD11 ' A' ' 25' ' ' ILE . 0.0 OUTLIER -173.31 171.9 3.92 Favored 'General case' 0 N--CA 1.488 1.428 0 O-C-N 121.328 -1.101 . . . . 0.0 109.683 179.631 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.657 ' O ' HD13 ' A' ' 69' ' ' ILE . 0.3 OUTLIER -128.44 149.11 50.71 Favored 'General case' 0 C--N 1.301 -1.513 0 O-C-N 120.937 -1.102 . . . . 0.0 110.092 -179.661 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . . . . . . . . . . . -98.7 -178.3 32.3 Favored Glycine 0 N--CA 1.486 2.02 0 N-CA-C 108.216 -1.954 . . . . 0.0 108.216 179.106 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.961 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -148.87 116.53 6.24 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 120.827 -1.396 . . . . 0.0 110.541 179.604 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 1.07 HG21 HD11 ' A' ' 50' ' ' LEU . 91.9 t -89.95 59.35 0.22 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 177.75 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.509 ' HB2' HD23 ' A' ' 32' ' ' LEU . 4.5 t-80 -47.28 156.19 0.27 Allowed 'General case' 0 C--N 1.304 -1.408 0 O-C-N 120.739 -1.225 . . . . 0.0 108.551 -179.463 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.569 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.2 OUTLIER -49.81 -47.25 22.5 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 O-C-N 121.163 -0.96 . . . . 0.0 109.49 -179.713 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.509 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.3 OUTLIER -81.22 39.79 0.53 Allowed 'General case' 0 N--CA 1.492 1.672 0 O-C-N 121.413 -0.804 . . . . 0.0 110.399 -179.925 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.791 ' C ' HD12 ' A' ' 38' ' ' ILE . 47.1 mm-40 -147.98 34.15 0.83 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 120.934 -1.104 . . . . 0.0 109.27 179.826 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.809 HG21 ' CD2' ' A' ' 49' ' ' TYR . 1.6 mp -112.48 -97.11 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.623 0 O-C-N 121.248 -0.908 . . . . 0.0 109.916 -179.613 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.773 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -100.42 16.31 24.95 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.311 -0.868 . . . . 0.0 109.825 -179.402 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.572 ' CB ' ' O ' ' A' ' 39' ' ' ALA . 7.5 t70 83.85 -57.43 0.13 Allowed 'General case' 0 N--CA 1.494 1.738 0 O-C-N 121.751 -0.593 . . . . 0.0 109.7 179.889 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 18.9 mttm -59.78 -179.58 0.1 Allowed 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.203 -0.936 . . . . 0.0 109.194 179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.411 ' O ' ' N ' ' A' ' 44' ' ' GLU . 3.3 mmt180 -79.88 92.26 5.48 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.3 -0.875 . . . . 0.0 109.503 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.001 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 2.5 t -58.55 95.31 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.251 0 N-CA-C 107.763 -1.199 . . . . 0.0 107.763 179.326 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.451 ' C ' ' O ' ' A' ' 43' ' ' VAL . 3.2 mp0 -40.32 -25.06 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.639 -0.663 . . . . 0.0 109.923 -179.59 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.538 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.8 OUTLIER -151.28 121.56 7.28 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.146 -0.971 . . . . 0.0 110.021 -179.813 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.601 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -71.71 -26.92 26.71 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.819 0 N-CA-C 107.891 -1.151 . . . . 0.0 107.891 178.959 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.792 HG22 HG21 ' A' ' 16' ' ' ILE . 58.6 p -79.14 6.02 10.64 Favored 'General case' 0 N--CA 1.488 1.472 0 N-CA-C 109.054 -0.721 . . . . 0.0 109.054 178.892 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.48 ' OD2' ' HB2' ' A' ' 45' ' ' LYS . 26.6 m-20 -106.25 -26.9 11.34 Favored 'General case' 0 N--CA 1.489 1.479 0 N-CA-C 107.991 -1.115 . . . . 0.0 107.991 179.204 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 1.001 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 12.9 m-85 -92.54 -34.83 13.9 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 108.643 -0.873 . . . . 0.0 108.643 179.247 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 1.07 HD11 HG21 ' A' ' 33' ' ' VAL . 4.6 mt -109.57 152.9 24.9 Favored 'General case' 0 N--CA 1.492 1.635 0 C-N-CA 119.473 -0.891 . . . . 0.0 109.752 179.637 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.482 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.9 OUTLIER -128.19 138.68 52.58 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.39 -0.819 . . . . 0.0 108.982 179.437 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 22.6 mtp -63.17 114.19 3.61 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.217 -0.927 . . . . 0.0 109.716 -179.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 109.38 -23.85 21.72 Favored Glycine 0 N--CA 1.491 2.325 0 N-CA-C 110.103 -1.199 . . . . 0.0 110.103 179.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . 0.462 ' HG3' ' HB3' ' A' ' 51' ' ' GLN . 1.5 mt-30 -74.5 147.78 41.57 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.098 -1.236 . . . . 0.0 109.791 -179.718 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.475 ' HA ' ' HA ' ' A' ' 12' ' ' LYS . 0.3 OUTLIER -107.06 146.95 30.57 Favored 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.329 -0.857 . . . . 0.0 109.37 179.889 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.456 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 18.8 m -150.6 140.03 13.52 Favored Pre-proline 0 N--CA 1.489 1.494 0 O-C-N 121.079 -1.013 . . . . 0.0 109.944 -179.882 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.468 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 37.2 Cg_endo -82.96 151.85 14.33 Favored 'Trans proline' 0 C--N 1.315 -1.21 0 C-N-CA 122.786 2.324 . . . . 0.0 110.137 179.311 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.85 ' CG2' HD12 ' A' ' 71' ' ' LEU . 0.9 OUTLIER -147.72 -171.22 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.667 0 O-C-N 121.167 -0.958 . . . . 0.0 109.299 179.511 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.686 ' HG2' HG22 ' A' ' 8' ' ' VAL . 10.8 mttt -138.59 121.7 16.84 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.079 -1.013 . . . . 0.0 109.955 -179.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.706 ' HA ' HD13 ' A' ' 71' ' ' LEU . 35.2 t -51.04 91.35 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.662 0 O-C-N 121.294 -0.879 . . . . 0.0 108.944 179.251 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.704 HD13 ' OG ' ' A' ' 72' ' ' SER . 6.5 tp -66.42 -26.76 67.38 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.506 -0.746 . . . . 0.0 109.646 -179.616 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.537 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 21.2 tt0 162.54 153.06 0.01 OUTLIER 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.326 -0.859 . . . . 0.0 110.164 179.828 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.493 ' HA ' ' O ' ' A' ' 67' ' ' GLY . 74.7 t -151.2 -87.77 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.529 0 O-C-N 121.289 -0.882 . . . . 0.0 109.26 179.133 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.483 ' O ' ' O ' ' A' ' 63' ' ' VAL . 2.1 p-10 41.58 -167.7 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.834 0 O-C-N 121.36 -0.838 . . . . 0.0 110.155 179.648 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 1.2 ttt-85 -64.65 -29.17 70.17 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.12 -0.987 . . . . 0.0 108.969 179.967 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 3.0 mm-40 -104.86 74.06 1.11 Allowed 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.391 -0.818 . . . . 0.0 108.955 179.542 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.493 ' O ' ' HA ' ' A' ' 63' ' ' VAL . . . 157.28 103.47 0.2 Allowed Glycine 0 N--CA 1.487 2.045 0 N-CA-C 109.114 -1.594 . . . . 0.0 109.114 -179.557 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.433 ' O ' ' CG ' ' A' ' 68' ' ' ARG . 0.0 OUTLIER -89.01 96.63 10.81 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.333 -1.098 . . . . 0.0 109.295 -179.818 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.72 HG22 ' O ' ' A' ' 69' ' ' ILE . 42.4 mt 45.37 64.92 0.16 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.429 0 O-C-N 121.463 -0.773 . . . . 0.0 110.189 179.722 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.471 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 0.0 OUTLIER -90.01 83.89 6.13 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.025 -1.047 . . . . 0.0 108.905 179.342 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.85 HD12 ' CG2' ' A' ' 58' ' ' VAL . 2.4 mm? -89.18 164.05 15.16 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.267 -0.896 . . . . 0.0 109.935 -179.314 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.704 ' OG ' HD13 ' A' ' 61' ' ' LEU . 0.4 OUTLIER -119.33 112.71 19.78 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.522 -0.736 . . . . 0.0 109.366 -179.87 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.57 HD12 HG13 ' A' ' 33' ' ' VAL . 0.1 OUTLIER -55.63 136.08 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.577 0 O-C-N 121.271 -0.893 . . . . 0.0 109.336 -179.67 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.442 ' C ' ' O ' ' A' ' 73' ' ' ILE . 0.0 OUTLIER -41.48 -39.14 1.44 Allowed 'General case' 0 N--CA 1.494 1.727 0 O-C-N 121.351 -0.843 . . . . 0.0 109.814 -179.481 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.549 ' H ' HG23 ' A' ' 73' ' ' ILE . 1.2 tt0 -90.72 45.85 1.29 Allowed 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.877 -0.786 . . . . 0.0 108.877 179.627 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.494 0 CA-C-O 118.032 -0.985 . . . . 0.0 109.412 -179.65 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.572 0 CA-C-O 121.287 0.565 . . . . 0.0 109.491 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -93.75 -159.55 0.7 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.184 -0.947 . . . . 0.0 109.315 179.865 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.866 ' H ' HD12 ' A' ' 3' ' ' ILE . 0.1 OUTLIER -144.86 -164.73 0.18 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 O-C-N 121.199 -0.938 . . . . 0.0 109.319 -179.655 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 24.0 tt0 -149.1 152.2 35.75 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.308 -0.87 . . . . 0.0 109.475 179.973 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.602 HG22 HG11 ' A' ' 60' ' ' VAL . 6.5 t -61.16 168.4 0.61 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.205 -0.934 . . . . 0.0 109.042 179.868 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.567 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 70.74 10.33 67.29 Favored Glycine 0 N--CA 1.49 2.254 0 N-CA-C 108.935 -1.666 . . . . 0.0 108.935 -179.466 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -109.92 176.14 5.18 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.365 -1.079 . . . . 0.0 109.421 -179.888 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . . . . . . . . . 24.1 t -91.37 123.58 43.57 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.199 -0.938 . . . . 0.0 109.011 179.621 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.706 ' OH ' HD13 ' A' ' 3' ' ' ILE . 4.2 m-85 -110.87 130.69 55.51 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.124 -0.985 . . . . 0.0 110.012 -179.849 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 11.0 m -80.45 100.49 8.53 Favored 'General case' 0 C--N 1.301 -1.525 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 178.335 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -79.47 126.0 7.25 Favored Glycine 0 N--CA 1.487 2.072 0 C-N-CA 119.87 -1.157 . . . . 0.0 110.487 -178.539 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.586 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -89.75 148.12 23.44 Favored 'General case' 0 N--CA 1.488 1.468 0 N-CA-C 107.795 -1.187 . . . . 0.0 107.795 178.794 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.856 HG13 ' CD1' ' A' ' 50' ' ' LEU . 22.8 t -87.85 112.21 23.23 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 O-C-N 120.568 -1.332 . . . . 0.0 108.97 -179.648 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.989 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.7 OUTLIER -122.8 -6.09 8.55 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.437 -0.789 . . . . 0.0 110.216 -178.916 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.462 ' HD2' ' O ' ' A' ' 14' ' ' THR . 0.9 OUTLIER -164.68 153.66 12.93 Favored 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.916 -1.115 . . . . 0.0 110.06 -179.949 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.443 HG22 ' N ' ' A' ' 17' ' ' VAL . 12.2 mt -141.08 161.57 22.62 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.815 0 N-CA-C 108.437 -0.949 . . . . 0.0 108.437 179.438 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 1.025 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -140.15 153.44 22.39 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 120.881 -1.137 . . . . 0.0 109.982 -179.58 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 8.2 t70 -58.45 -41.78 85.9 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 120.778 -1.202 . . . . 0.0 109.145 179.405 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.025 ' CE1' HG21 ' A' ' 17' ' ' VAL . 15.5 p90 -90.3 29.31 1.27 Allowed 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.381 -0.825 . . . . 0.0 110.077 -179.743 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.543 ' HA2' ' N ' ' A' ' 35' ' ' ILE . . . 149.81 -148.86 20.57 Favored Glycine 0 N--CA 1.491 2.341 0 C-N-CA 118.964 -1.589 . . . . 0.0 110.976 -179.766 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.752 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -154.94 148.83 25.66 Favored 'General case' 0 N--CA 1.488 1.457 0 O-C-N 121.233 -1.157 . . . . 0.0 108.917 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.977 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.5 m-30 -106.94 162.46 13.81 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.339 -0.851 . . . . 0.0 108.954 179.682 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.942 ' CG2' HG23 ' A' ' 33' ' ' VAL . 22.5 t -149.03 160.87 5.38 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.08 -1.013 . . . . 0.0 109.64 -179.64 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.989 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -133.8 135.92 44.14 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.306 -0.871 . . . . 0.0 109.55 -179.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.792 HD13 HD11 ' A' ' 71' ' ' LEU . 1.2 pt -108.81 -97.28 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.683 0 O-C-N 120.818 -1.176 . . . . 0.0 109.509 179.932 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.411 ' O ' ' C ' ' A' ' 27' ' ' GLY . . . 159.56 -58.05 0.32 Allowed Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.656 ' HA3' HD11 ' A' ' 3' ' ' ILE . . . -43.93 -34.55 3.03 Favored Glycine 0 N--CA 1.491 2.302 0 N-CA-C 109.541 -1.423 . . . . 0.0 109.541 179.943 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.447 ' O ' ' CG ' ' A' ' 29' ' ' LYS . . . -122.58 -69.85 0.25 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.274 -1.53 . . . . 0.0 109.274 179.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.483 ' O ' HG13 ' A' ' 25' ' ' ILE . 4.4 mtmt -164.15 -107.7 0.01 OUTLIER 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.232 -1.158 . . . . 0.0 109.674 179.847 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.556 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 6.4 mt-10 -127.48 150.87 49.47 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.741 -1.224 . . . . 0.0 111.004 -179.151 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.76 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -102.33 -172.96 27.25 Favored Glycine 0 N--CA 1.488 2.104 0 N-CA-C 108.22 -1.952 . . . . 0.0 108.22 178.967 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.977 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.14 121.8 8.05 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 120.737 -1.449 . . . . 0.0 110.951 179.743 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 1.004 HG12 HD11 ' A' ' 38' ' ' ILE . 61.1 t -95.3 61.36 0.25 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 N-CA-C 107.553 -1.277 . . . . 0.0 107.553 177.523 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.472 ' HB2' HD23 ' A' ' 32' ' ' LEU . 2.6 t-80 -48.88 158.13 0.35 Allowed 'General case' 0 C--N 1.304 -1.37 0 O-C-N 120.893 -1.13 . . . . 0.0 108.653 -179.462 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.543 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.9 tp -46.66 -51.01 5.05 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.524 0 O-C-N 121.188 -0.945 . . . . 0.0 109.864 -179.464 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.533 ' N ' HG23 ' A' ' 35' ' ' ILE . 42.6 p -81.99 44.51 0.85 Allowed 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.302 -0.874 . . . . 0.0 110.372 -179.639 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.929 ' C ' HD12 ' A' ' 38' ' ' ILE . 3.6 mm100 -144.29 33.61 1.2 Allowed 'General case' 0 N--CA 1.49 1.554 0 O-C-N 120.903 -1.123 . . . . 0.0 110.214 -179.839 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 1.004 HD11 HG12 ' A' ' 33' ' ' VAL . 1.6 mp -120.29 -98.49 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 120.833 -1.167 . . . . 0.0 110.214 179.887 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.771 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -98.05 41.12 1.14 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.459 -0.776 . . . . 0.0 109.45 -179.206 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.567 ' CB ' ' O ' ' A' ' 39' ' ' ALA . 16.7 t70 82.96 -62.92 0.12 Allowed 'General case' 0 N--CA 1.491 1.616 0 N-CA-C 109.149 -0.686 . . . . 0.0 109.149 -179.499 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -168.79 -0.13 0.02 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.066 -1.021 . . . . 0.0 111.774 -179.492 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -81.45 20.41 0.88 Allowed 'General case' 0 N--CA 1.491 1.596 0 O-C-N 120.518 -1.364 . . . . 0.0 110.357 -179.806 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.119 HG13 ' CD1' ' A' ' 49' ' ' TYR . 58.7 t -102.41 67.43 0.27 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.387 0 O-C-N 120.889 -1.132 . . . . 0.0 109.41 -179.948 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.416 ' C ' ' O ' ' A' ' 43' ' ' VAL . 14.0 mt-10 -45.78 -24.27 0.36 Allowed 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.354 -0.841 . . . . 0.0 108.988 179.488 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.456 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 4.7 mmtp -134.97 123.71 23.76 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.327 -0.858 . . . . 0.0 109.4 179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.54 HG11 ' HA2' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -73.68 -23.47 19.3 Favored 'Isoleucine or valine' 0 N--CA 1.498 1.928 0 O-C-N 121.131 -0.981 . . . . 0.0 108.643 179.647 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 8.3 p -75.4 1.39 14.03 Favored 'General case' 0 C--N 1.301 -1.521 0 O-C-N 121.482 -0.761 . . . . 0.0 109.389 179.198 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.456 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 0.9 OUTLIER -102.17 -35.59 8.84 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.149 -0.969 . . . . 0.0 109.245 -179.999 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 1.119 ' CD1' HG13 ' A' ' 43' ' ' VAL . 3.9 m-85 -90.83 -28.72 18.0 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.35 -0.844 . . . . 0.0 108.972 179.791 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.856 ' CD1' HG13 ' A' ' 13' ' ' VAL . 0.2 OUTLIER -109.72 140.9 43.06 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.495 -0.753 . . . . 0.0 109.565 -179.575 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.728 ' C ' HG11 ' A' ' 13' ' ' VAL . 2.3 mp0 -150.62 131.93 14.57 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.398 -0.814 . . . . 0.0 109.476 179.854 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -61.84 107.61 0.87 Allowed 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.273 -0.892 . . . . 0.0 109.955 -179.929 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 132.33 -31.97 2.91 Favored Glycine 0 N--CA 1.491 2.321 0 C-N-CA 119.729 -1.224 . . . . 0.0 110.306 179.55 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 6.2 mt-30 -80.3 162.28 24.65 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.033 -1.275 . . . . 0.0 109.818 -179.668 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 5.0 mt-10 -125.28 138.66 54.09 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.681 -0.859 . . . . 0.0 108.681 179.518 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.434 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 17.2 m -140.58 143.92 34.44 Favored Pre-proline 0 N--CA 1.491 1.605 0 O-C-N 121.017 -1.052 . . . . 0.0 110.008 -179.461 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.434 ' HD3' ' HA ' ' A' ' 56' ' ' VAL . 36.3 Cg_endo -79.05 145.93 19.85 Favored 'Trans proline' 0 C--N 1.31 -1.454 0 C-N-CA 122.59 2.193 . . . . 0.0 110.241 179.704 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.69 ' CG2' HD22 ' A' ' 71' ' ' LEU . 1.0 OUTLIER -148.21 -174.84 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.196 -0.94 . . . . 0.0 109.901 -179.878 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.458 ' N ' HG23 ' A' ' 58' ' ' VAL . 3.0 mtpt -123.51 135.66 54.15 Favored 'General case' 0 N--CA 1.488 1.447 0 O-C-N 121.52 -0.737 . . . . 0.0 109.239 179.606 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.602 HG11 HG22 ' A' ' 5' ' ' VAL . 96.1 t -67.1 91.72 0.16 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.528 0 O-C-N 121.33 -0.856 . . . . 0.0 109.229 179.95 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.576 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 5.9 tp -65.11 -16.96 64.05 Favored 'General case' 0 C--N 1.305 -1.358 0 O-C-N 121.315 -0.866 . . . . 0.0 109.773 -179.552 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.576 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 20.6 mt-10 96.47 -176.83 0.01 OUTLIER 'General case' 0 N--CA 1.504 2.239 0 N-CA-C 109.409 -0.589 . . . . 0.0 109.409 -179.782 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.501 HG22 ' HA ' ' A' ' 69' ' ' ILE . 82.8 t -114.58 129.85 69.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.178 -0.951 . . . . 0.0 109.741 -179.606 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -119.75 -30.0 4.88 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.27 -0.894 . . . . 0.0 109.603 179.946 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.09 -79.59 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.209 -0.932 . . . . 0.0 109.436 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 1.1 tt0 -151.15 -45.82 0.12 Allowed 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.106 -0.996 . . . . 0.0 109.105 179.786 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -162.43 24.95 0.22 Allowed Glycine 0 N--CA 1.489 2.212 0 N-CA-C 109.26 -1.536 . . . . 0.0 109.26 179.999 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.449 ' O ' ' CG ' ' A' ' 68' ' ' ARG . 0.1 OUTLIER -99.05 105.67 17.82 Favored 'General case' 0 N--CA 1.491 1.616 0 O-C-N 121.291 -1.123 . . . . 0.0 109.367 -179.907 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.775 HD13 HD11 ' A' ' 25' ' ' ILE . 82.2 mt -47.64 120.53 0.76 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.203 -0.936 . . . . 0.0 109.606 -179.926 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.548 ' CB ' ' O ' ' A' ' 62' ' ' GLU . 1.2 tpt180 -93.74 91.76 7.16 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.157 -0.964 . . . . 0.0 108.955 179.403 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.792 HD11 HD13 ' A' ' 25' ' ' ILE . 31.3 mt -89.51 150.19 22.56 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.34 -0.85 . . . . 0.0 109.024 -179.96 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.467 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.4 OUTLIER -123.24 108.08 12.41 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.273 -0.892 . . . . 0.0 110.049 -179.259 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.469 ' HA ' HG12 ' A' ' 58' ' ' VAL . 0.0 OUTLIER -48.61 140.83 2.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.604 0 O-C-N 121.227 -0.921 . . . . 0.0 108.911 179.886 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 11.3 mmtt -47.19 151.53 0.68 Allowed 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.318 -0.864 . . . . 0.0 109.744 -179.684 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 46.4 73.44 0.18 Allowed 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.321 -0.862 . . . . 0.0 109.521 179.97 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.629 ' HB2' ' O ' ' A' ' 38' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 118.012 -0.994 . . . . 0.0 109.506 -179.956 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.538 0 N-CA-C 109.508 -0.553 . . . . 0.0 109.508 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.47 ' O ' ' O ' ' A' ' 3' ' ' ILE . 91.5 mt-10 -121.81 -22.4 5.79 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.19 -0.943 . . . . 0.0 109.839 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.527 HG23 ' N ' ' A' ' 4' ' ' GLU . 0.4 OUTLIER 53.52 170.96 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.298 -1.65 0 N-CA-C 108.708 -0.849 . . . . 0.0 108.708 -179.821 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.527 ' N ' HG23 ' A' ' 3' ' ' ILE . 1.3 mt-10 -150.52 162.99 39.54 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.984 -1.072 . . . . 0.0 110.042 -179.833 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.661 HG22 HG11 ' A' ' 60' ' ' VAL . 2.5 t -70.05 161.96 4.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.545 0 O-C-N 121.348 -0.845 . . . . 0.0 109.204 179.838 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.459 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 86.54 9.99 74.34 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 109.253 -1.539 . . . . 0.0 109.253 -179.585 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.404 ' HD3' ' CD1' ' A' ' 3' ' ' ILE . 1.7 ttt180 -107.53 178.18 4.61 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.29 -1.124 . . . . 0.0 109.437 -179.997 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.545 HG22 ' HG2' ' A' ' 59' ' ' LYS . 41.3 t -90.0 127.65 42.45 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.199 -0.938 . . . . 0.0 108.82 179.565 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.87 ' CD2' HD13 ' A' ' 25' ' ' ILE . 2.8 m-30 -114.75 135.12 54.52 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.154 -0.966 . . . . 0.0 110.158 -179.335 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -73.82 100.74 3.54 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 106.837 -1.542 . . . . 0.0 106.837 177.448 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -82.26 122.73 5.82 Favored Glycine 0 N--CA 1.488 2.119 0 C-N-CA 120.009 -1.091 . . . . 0.0 111.368 -177.302 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.518 ' O ' HG13 ' A' ' 23' ' ' VAL . 2.4 mttt -96.07 143.24 27.39 Favored 'General case' 0 N--CA 1.487 1.385 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 177.988 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.014 HG13 HD23 ' A' ' 50' ' ' LEU . 24.9 t -88.1 107.66 17.74 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.687 0 O-C-N 120.802 -1.186 . . . . 0.0 108.934 -179.648 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.886 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.0 OUTLIER -116.93 -7.95 11.34 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.454 -0.778 . . . . 0.0 109.813 -179.07 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.485 ' HB3' ' HB2' ' A' ' 22' ' ' PHE . 0.9 OUTLIER -161.48 148.22 14.45 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.054 -1.029 . . . . 0.0 110.158 -179.899 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.616 HG21 HG22 ' A' ' 47' ' ' THR . 11.8 mt -137.05 157.38 35.48 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.756 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 179.005 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 1.045 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -136.3 153.4 31.28 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.621 0 O-C-N 120.749 -1.22 . . . . 0.0 110.034 -179.192 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 4.0 t0 -59.07 -41.94 89.15 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 120.69 -1.257 . . . . 0.0 109.331 179.228 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.045 ' CE1' HG21 ' A' ' 17' ' ' VAL . 12.9 p90 -91.16 27.24 1.93 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.3 -0.875 . . . . 0.0 110.361 -179.525 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.553 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 154.4 -154.9 25.83 Favored Glycine 0 N--CA 1.492 2.419 0 C-N-CA 118.895 -1.621 . . . . 0.0 110.829 -179.505 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.759 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -148.45 143.97 27.1 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.042 -1.27 . . . . 0.0 108.853 179.914 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.97 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.0 m-30 -105.94 154.77 20.11 Favored 'General case' 0 C--N 1.298 -1.658 0 O-C-N 121.254 -0.904 . . . . 0.0 108.825 179.748 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.81 ' CG2' HG23 ' A' ' 33' ' ' VAL . 35.2 t -144.04 161.81 15.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.507 0 O-C-N 121.066 -1.021 . . . . 0.0 109.783 -179.273 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.886 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -137.2 148.81 46.79 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.157 -0.964 . . . . 0.0 109.515 -179.731 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.87 HD13 ' CD2' ' A' ' 9' ' ' TYR . 2.7 pt -126.47 161.59 32.3 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 121.006 -1.059 . . . . 0.0 109.044 179.642 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -79.37 143.79 26.34 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.381 -1.488 . . . . 0.0 109.381 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 124.04 2.14 8.59 Favored Glycine 0 N--CA 1.491 2.333 0 N-CA-C 109.752 -1.339 . . . . 0.0 109.752 -179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 87.5 29.23 22.33 Favored Glycine 0 N--CA 1.489 2.225 0 N-CA-C 109.404 -1.478 . . . . 0.0 109.404 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.496 ' O ' HG13 ' A' ' 25' ' ' ILE . 1.7 mtpp -142.08 163.22 33.47 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.344 -1.092 . . . . 0.0 109.313 179.887 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.533 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 17.3 mt-10 -134.99 153.46 52.08 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 120.998 -1.063 . . . . 0.0 110.334 -179.786 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.663 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -107.3 -175.78 22.64 Favored Glycine 0 N--CA 1.489 2.204 0 N-CA-C 108.813 -1.715 . . . . 0.0 108.813 179.43 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.97 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.49 119.29 6.6 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 120.875 -1.368 . . . . 0.0 110.736 179.72 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 1.093 HG21 HD11 ' A' ' 50' ' ' LEU . 96.3 t -93.84 61.14 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.543 0 N-CA-C 107.868 -1.16 . . . . 0.0 107.868 177.71 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.474 ' HB2' HD23 ' A' ' 32' ' ' LEU . 6.6 t-80 -47.7 156.45 0.31 Allowed 'General case' 0 C--N 1.302 -1.472 0 O-C-N 120.906 -1.122 . . . . 0.0 108.417 -179.571 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.589 ' O ' HD13 ' A' ' 38' ' ' ILE . 3.1 tp -49.62 -43.37 18.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.558 0 O-C-N 121.154 -0.966 . . . . 0.0 110.321 -179.536 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.438 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.4 OUTLIER -81.25 34.29 0.36 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 121.182 -0.949 . . . . 0.0 110.94 -179.34 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.921 ' C ' HD12 ' A' ' 38' ' ' ILE . 71.4 mt-30 -150.81 58.4 0.92 Allowed 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.709 -1.244 . . . . 0.0 110.14 179.956 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.981 HG21 HG21 ' A' ' 43' ' ' VAL . 1.7 mp -122.08 -97.86 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 120.984 -1.073 . . . . 0.0 109.569 179.746 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.749 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -123.67 172.37 8.86 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.298 -0.876 . . . . 0.0 109.382 -179.809 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 7.1 t70 -51.62 -53.16 41.43 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.244 -0.91 . . . . 0.0 109.373 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -55.43 150.52 11.61 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.323 -0.861 . . . . 0.0 109.517 -179.996 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 5.4 mmt180 -65.79 128.9 37.84 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.3 -0.875 . . . . 0.0 109.487 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.167 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 66.9 t -108.65 55.75 0.14 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.287 -0.883 . . . . 0.0 109.046 179.641 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.424 ' O ' ' HG3' ' A' ' 44' ' ' GLU . 13.8 tp10 -45.38 -26.59 0.56 Allowed 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.162 -0.961 . . . . 0.0 108.467 179.662 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.48 ' HB3' ' CG ' ' A' ' 48' ' ' ASP . 4.2 mptt -108.0 105.63 15.5 Favored 'General case' 0 C--N 1.305 -1.358 0 N-CA-C 108.655 -0.869 . . . . 0.0 108.655 179.28 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.553 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -75.22 -25.52 18.2 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.921 0 O-C-N 121.399 -0.813 . . . . 0.0 109.09 -179.681 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.616 HG22 HG21 ' A' ' 16' ' ' ILE . 62.7 p -77.55 6.22 7.55 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.413 -0.805 . . . . 0.0 109.464 179.181 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.48 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 58.9 m-20 -101.7 -32.32 10.37 Favored 'General case' 0 N--CA 1.49 1.546 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 179.426 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 1.167 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 15.9 m-85 -92.45 -34.85 13.95 Favored 'General case' 0 C--N 1.305 -1.368 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.494 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 1.093 HD11 HG21 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -100.0 156.62 17.06 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.322 -0.861 . . . . 0.0 110.571 -179.854 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.503 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 61.8 mt-30 -146.85 126.57 13.42 Favored 'General case' 0 N--CA 1.489 1.509 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.798 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . 0.525 ' CG ' ' O ' ' A' ' 52' ' ' MET . 3.2 ptp -60.81 98.59 0.07 Allowed 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.15 -0.969 . . . . 0.0 109.94 -179.654 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 132.21 -25.44 3.86 Favored Glycine 0 N--CA 1.493 2.45 0 C-N-CA 119.719 -1.229 . . . . 0.0 110.368 179.467 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 89.0 mm-40 -79.19 150.49 31.65 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.105 -1.232 . . . . 0.0 110.402 -179.358 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 6.2 mt-10 -116.9 113.71 22.84 Favored 'General case' 0 N--CA 1.491 1.593 0 N-CA-C 108.575 -0.898 . . . . 0.0 108.575 179.088 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.405 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 17.7 m -115.24 150.23 44.06 Favored Pre-proline 0 N--CA 1.49 1.567 0 O-C-N 121.107 -0.996 . . . . 0.0 110.121 -179.205 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.405 ' HD3' ' HA ' ' A' ' 56' ' ' VAL . 36.2 Cg_endo -78.5 126.91 7.79 Favored 'Trans proline' 0 C--N 1.311 -1.438 0 C-N-CA 122.675 2.25 . . . . 0.0 110.24 179.744 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.963 ' CG2' HD22 ' A' ' 71' ' ' LEU . 1.3 m -131.9 -172.74 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.468 0 O-C-N 121.148 -0.97 . . . . 0.0 109.722 -179.992 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.545 ' HG2' HG22 ' A' ' 8' ' ' VAL . 9.8 mtmt -133.12 116.87 16.82 Favored 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.825 -0.806 . . . . 0.0 108.825 179.6 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.69 ' HA ' HD23 ' A' ' 71' ' ' LEU . 52.6 t -49.94 91.39 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.344 -0.848 . . . . 0.0 109.217 -179.744 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.592 ' O ' ' CG ' ' A' ' 62' ' ' GLU . 15.8 tp -64.93 -20.81 66.66 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.425 -0.797 . . . . 0.0 109.985 -179.379 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.592 ' CG ' ' O ' ' A' ' 61' ' ' LEU . 0.2 OUTLIER 89.35 -171.08 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.014 0 CA-C-O 121.219 0.533 . . . . 0.0 109.594 -179.73 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.793 HG22 ' O ' ' A' ' 68' ' ' ARG . 69.7 t -126.74 95.9 3.28 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.297 -0.877 . . . . 0.0 109.824 -179.759 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.425 ' C ' ' O ' ' A' ' 63' ' ' VAL . 0.0 OUTLIER -44.34 -73.15 0.05 OUTLIER 'General case' 0 N--CA 1.495 1.816 0 O-C-N 121.236 -0.915 . . . . 0.0 108.886 179.498 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . 0.598 ' O ' HG12 ' A' ' 63' ' ' VAL . 8.2 ptm180 -76.47 -141.55 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.094 -1.004 . . . . 0.0 108.925 179.276 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . 0.519 ' N ' ' HG3' ' A' ' 65' ' ' ARG . 2.7 mt-30 -123.48 102.23 7.77 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.943 -1.098 . . . . 0.0 109.419 179.767 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.678 ' H ' HG11 ' A' ' 63' ' ' VAL . . . -154.02 -100.02 0.18 Allowed Glycine 0 N--CA 1.492 2.407 0 N-CA-C 109.845 -1.302 . . . . 0.0 109.845 -179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.793 ' O ' HG22 ' A' ' 63' ' ' VAL . 0.1 OUTLIER -132.9 152.5 51.87 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.161 -1.199 . . . . 0.0 109.516 -179.893 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.6 ' HA ' HG23 ' A' ' 63' ' ' VAL . 1.3 mp -50.53 121.76 1.63 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.63 0 O-C-N 121.414 -0.804 . . . . 0.0 110.002 -179.529 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.442 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 7.4 mmt85 -90.38 116.31 28.23 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.2 -0.938 . . . . 0.0 109.106 179.408 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.963 HD22 ' CG2' ' A' ' 58' ' ' VAL . 11.1 mt -89.65 152.55 21.31 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.129 -0.982 . . . . 0.0 109.633 -179.754 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.457 ' HB2' ' O ' ' A' ' 59' ' ' LYS . 0.6 OUTLIER -115.95 93.68 4.35 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.301 -0.874 . . . . 0.0 109.838 -179.85 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.467 ' O ' ' O ' ' A' ' 74' ' ' LYS . 0.1 OUTLIER -48.8 141.14 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.202 -0.936 . . . . 0.0 109.251 179.762 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.467 ' O ' ' O ' ' A' ' 73' ' ' ILE . 0.1 OUTLIER -42.9 167.24 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.311 -0.868 . . . . 0.0 109.673 -179.789 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.464 ' CA ' ' OE1' ' A' ' 75' ' ' GLU . 0.1 OUTLIER 57.68 29.52 17.43 Favored 'General case' 0 N--CA 1.488 1.45 0 O-C-N 121.161 -0.962 . . . . 0.0 109.097 -179.986 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 117.996 -1.002 . . . . 0.0 109.55 179.975 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.586 0 N-CA-C 109.419 -0.585 . . . . 0.0 109.419 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.652 ' C ' HD13 ' A' ' 3' ' ' ILE . 2.4 tt0 60.21 -153.36 0.38 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.15 -0.969 . . . . 0.0 109.408 -179.956 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.652 HD13 ' C ' ' A' ' 2' ' ' GLU . 0.0 OUTLIER -133.39 -161.73 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.401 0 O-C-N 121.171 -0.956 . . . . 0.0 109.611 -179.436 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.473 ' O ' ' HG3' ' A' ' 7' ' ' ARG . 1.3 tp10 -104.95 131.09 52.9 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.433 -0.792 . . . . 0.0 108.887 179.364 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.773 HG22 ' CG1' ' A' ' 60' ' ' VAL . 12.5 t -79.6 165.68 2.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.224 -0.923 . . . . 0.0 109.809 -179.532 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.546 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 96.37 -0.55 61.79 Favored Glycine 0 N--CA 1.488 2.12 0 N-CA-C 109.376 -1.49 . . . . 0.0 109.376 -179.753 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.599 ' O ' HG23 ' A' ' 60' ' ' VAL . 0.0 OUTLIER -110.33 164.13 12.97 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.147 -1.208 . . . . 0.0 109.593 -179.546 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.891 HG13 ' O ' ' A' ' 58' ' ' VAL . 97.3 t -90.18 135.52 26.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.345 -0.847 . . . . 0.0 108.756 179.388 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.638 ' O ' HG22 ' A' ' 58' ' ' VAL . 6.4 m-85 -119.41 126.65 51.88 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 120.858 -1.151 . . . . 0.0 110.525 -179.673 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.449 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 0.2 OUTLIER -95.31 127.34 41.28 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 107.614 -1.254 . . . . 0.0 107.614 178.352 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -127.62 150.14 18.15 Favored Glycine 0 N--CA 1.486 2.025 0 C-N-CA 118.834 -1.651 . . . . 0.0 110.953 -178.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.509 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.1 OUTLIER -89.8 163.21 15.14 Favored 'General case' 0 C--N 1.306 -1.313 0 N-CA-C 107.603 -1.258 . . . . 0.0 107.603 178.624 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.945 HG22 HD13 ' A' ' 50' ' ' LEU . 69.8 t -88.42 107.9 18.15 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.673 0 O-C-N 121.006 -1.059 . . . . 0.0 108.445 179.812 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.635 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.3 p -118.51 -0.52 11.38 Favored 'General case' 0 C--N 1.301 -1.506 0 C-N-CA 119.544 -0.862 . . . . 0.0 110.167 -178.889 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.511 ' HB3' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -167.96 148.04 4.95 Favored 'General case' 0 N--CA 1.495 1.777 0 O-C-N 120.987 -1.071 . . . . 0.0 109.985 179.739 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.436 HG22 ' N ' ' A' ' 17' ' ' VAL . 30.6 mt -140.31 157.38 24.84 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.779 0 N-CA-C 108.581 -0.896 . . . . 0.0 108.581 179.232 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 1.014 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -135.38 152.98 32.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.918 -1.114 . . . . 0.0 109.751 -179.321 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 6.6 m-20 -60.41 -39.08 86.08 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 120.631 -1.293 . . . . 0.0 109.218 179.458 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.014 ' CE1' HG21 ' A' ' 17' ' ' VAL . 18.4 p90 -91.86 24.92 2.96 Favored 'General case' 0 N--CA 1.493 1.705 0 O-C-N 121.497 -0.752 . . . . 0.0 110.073 -179.678 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.618 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 156.07 -152.78 24.19 Favored Glycine 0 N--CA 1.491 2.344 0 C-N-CA 119.068 -1.539 . . . . 0.0 110.881 -179.188 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.75 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -151.91 145.65 25.05 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.853 -1.38 . . . . 0.0 108.843 179.636 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.959 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.3 m-30 -107.26 160.37 15.65 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 108.0 -1.111 . . . . 0.0 108.0 179.35 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.824 ' CG2' HG23 ' A' ' 33' ' ' VAL . 14.3 t -149.99 167.67 2.57 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.542 0 O-C-N 121.009 -1.057 . . . . 0.0 109.536 -179.228 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.635 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -131.62 147.43 52.52 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.137 -0.977 . . . . 0.0 109.278 179.942 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.52 HG13 ' O ' ' A' ' 29' ' ' LYS . 0.5 OUTLIER -109.54 -14.35 10.27 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.716 0 O-C-N 120.561 -1.337 . . . . 0.0 109.808 -179.995 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.484 ' O ' ' O ' ' A' ' 25' ' ' ILE . . . 59.31 128.07 0.01 OUTLIER Glycine 0 N--CA 1.492 2.4 0 N-CA-C 109.74 -1.344 . . . . 0.0 109.74 179.643 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 73.37 2.02 58.61 Favored Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.587 -1.405 . . . . 0.0 109.587 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.493 ' O ' HD11 ' A' ' 25' ' ' ILE . . . -156.79 33.36 0.57 Allowed Glycine 0 N--CA 1.49 2.265 0 N-CA-C 109.262 -1.535 . . . . 0.0 109.262 -179.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.52 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER 74.71 -156.11 0.05 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.456 -1.026 . . . . 0.0 109.807 179.857 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.582 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 7.2 mt-10 -120.18 153.05 36.81 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 120.814 -1.179 . . . . 0.0 110.811 -179.393 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.975 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -99.1 -172.8 31.39 Favored Glycine 0 N--CA 1.49 2.243 0 N-CA-C 108.555 -1.818 . . . . 0.0 108.555 179.061 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.959 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.83 120.19 6.85 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.824 -1.397 . . . . 0.0 111.082 179.6 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.824 HG23 ' CG2' ' A' ' 23' ' ' VAL . 48.6 t -95.15 61.79 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.468 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 177.276 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.486 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.1 t-160 -48.77 157.1 0.41 Allowed 'General case' 0 C--N 1.304 -1.401 0 O-C-N 120.785 -1.197 . . . . 0.0 108.908 -179.131 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.764 ' O ' HD13 ' A' ' 38' ' ' ILE . 0.4 OUTLIER -49.62 -47.09 21.3 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.583 0 O-C-N 121.297 -0.877 . . . . 0.0 110.237 -179.58 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.516 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.6 OUTLIER -80.48 33.33 0.3 Allowed 'General case' 0 N--CA 1.493 1.677 0 O-C-N 121.251 -0.906 . . . . 0.0 110.972 -179.133 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.894 ' C ' HD12 ' A' ' 38' ' ' ILE . 44.7 mm-40 -148.26 57.99 1.08 Allowed 'General case' 0 N--CA 1.494 1.752 0 O-C-N 120.823 -1.173 . . . . 0.0 109.735 179.691 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.98 ' CG2' HG21 ' A' ' 43' ' ' VAL . 1.5 mp -116.84 -99.56 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.686 0 O-C-N 120.942 -1.099 . . . . 0.0 110.075 -179.908 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.765 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -117.37 43.55 2.31 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.272 -0.892 . . . . 0.0 109.649 -179.341 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.45 ' O ' ' OD1' ' A' ' 40' ' ' ASP . 2.1 p30 42.62 27.57 0.1 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.39 -0.819 . . . . 0.0 109.074 -179.55 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.437 ' N ' ' O ' ' A' ' 39' ' ' ALA . 1.8 ttmt -124.35 -178.68 4.18 Favored 'General case' 0 N--CA 1.49 1.555 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 -179.91 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 3.8 mtp180 -77.35 77.5 3.88 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.205 -0.934 . . . . 0.0 109.639 179.969 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.127 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 72.1 t -87.73 49.58 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.324 0 O-C-N 121.103 -0.998 . . . . 0.0 108.322 179.266 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 23.0 mt-10 -44.4 -24.95 0.21 Allowed 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.349 -0.844 . . . . 0.0 109.032 179.828 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.49 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 68.7 mttt -110.8 104.44 13.07 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.454 -0.779 . . . . 0.0 109.14 179.831 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.618 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -72.19 -23.34 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.817 0 O-C-N 121.194 -0.941 . . . . 0.0 108.552 179.857 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 24.2 p -77.87 4.0 13.02 Favored 'General case' 0 C--N 1.3 -1.549 0 C-N-CA 119.827 -0.749 . . . . 0.0 109.294 179.21 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.49 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 1.8 m-20 -102.42 -33.78 9.41 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.151 -0.968 . . . . 0.0 108.824 179.598 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 1.127 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 23.5 m-85 -92.88 -33.05 14.37 Favored 'General case' 0 C--N 1.302 -1.459 0 N-CA-C 108.93 -0.767 . . . . 0.0 108.93 179.449 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.945 HD13 HG22 ' A' ' 13' ' ' VAL . 0.2 OUTLIER -102.23 138.19 39.49 Favored 'General case' 0 N--CA 1.49 1.544 0 N-CA-C 109.042 -0.725 . . . . 0.0 109.042 179.973 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.593 ' C ' HG11 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -142.32 142.35 32.5 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.48 -0.763 . . . . 0.0 109.41 -179.788 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -59.6 131.49 51.09 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.353 -0.842 . . . . 0.0 110.666 -179.394 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 90.45 -16.75 56.99 Favored Glycine 0 N--CA 1.494 2.53 0 N-CA-C 110.32 -1.112 . . . . 0.0 110.32 178.945 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . 0.425 ' CD ' ' HB2' ' A' ' 51' ' ' GLN . 6.7 mt-30 -70.46 169.4 14.14 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.173 -1.192 . . . . 0.0 109.886 -179.642 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.489 ' OE1' ' HE3' ' A' ' 12' ' ' LYS . 3.2 mt-10 -139.7 132.87 29.73 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.193 -0.942 . . . . 0.0 108.556 179.579 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.1 m -141.05 136.83 16.34 Favored Pre-proline 0 N--CA 1.49 1.545 0 O-C-N 120.916 -1.115 . . . . 0.0 110.402 -179.4 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.449 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.3 Cg_endo -80.2 144.4 16.48 Favored 'Trans proline' 0 C--N 1.313 -1.31 0 C-N-CA 122.524 2.149 . . . . 0.0 109.065 178.785 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.891 ' O ' HG13 ' A' ' 8' ' ' VAL . 1.5 m -144.13 -174.8 0.59 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 120.918 -1.114 . . . . 0.0 110.062 -179.612 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 4.1 mttt -121.9 135.14 54.87 Favored 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.516 -0.74 . . . . 0.0 109.357 179.891 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.773 ' CG1' HG22 ' A' ' 5' ' ' VAL . 58.9 t -64.55 100.08 0.26 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.526 0 O-C-N 121.275 -0.891 . . . . 0.0 109.002 179.734 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.616 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 2.8 tp -75.17 -15.23 60.58 Favored 'General case' 0 C--N 1.308 -1.239 0 O-C-N 121.216 -0.928 . . . . 0.0 109.723 -179.542 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.616 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 8.4 mt-10 105.88 -178.95 0.0 OUTLIER 'General case' 0 N--CA 1.504 2.258 0 N-CA-C 108.449 -0.945 . . . . 0.0 108.449 -179.333 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -111.01 169.85 3.75 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.043 -1.036 . . . . 0.0 109.671 -179.539 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.436 ' OD2' ' HB2' ' A' ' 68' ' ' ARG . 11.1 p30 -87.67 -167.86 2.03 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.218 -0.927 . . . . 0.0 109.565 -179.963 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -68.68 -10.71 57.91 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.317 -0.864 . . . . 0.0 109.793 -179.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 29.3 mt-30 -103.49 -95.44 0.31 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.201 -0.937 . . . . 0.0 109.549 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . -169.05 49.51 0.22 Allowed Glycine 0 N--CA 1.49 2.283 0 N-CA-C 109.732 -1.347 . . . . 0.0 109.732 -179.999 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.436 ' HB2' ' OD2' ' A' ' 64' ' ' ASP . 0.5 OUTLIER -107.7 94.43 5.08 Favored 'General case' 0 N--CA 1.492 1.646 0 O-C-N 121.172 -1.193 . . . . 0.0 109.3 179.842 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.51 ' CD1' ' HB3' ' A' ' 29' ' ' LYS . 2.9 mt -42.87 108.22 0.04 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.359 -0.838 . . . . 0.0 109.634 -179.877 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.522 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 0.0 OUTLIER -91.08 95.91 10.33 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.285 -0.884 . . . . 0.0 109.817 179.995 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.975 HD12 ' HA3' ' A' ' 31' ' ' GLY . 20.6 mt -93.35 153.54 18.48 Favored 'General case' 0 N--CA 1.488 1.463 0 O-C-N 121.206 -0.934 . . . . 0.0 108.916 179.577 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.485 ' OG ' HD13 ' A' ' 61' ' ' LEU . 0.4 OUTLIER -121.28 101.46 7.65 Favored 'General case' 0 C--N 1.302 -1.48 0 O-C-N 121.15 -0.969 . . . . 0.0 110.08 -179.622 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.624 HG22 ' O ' ' A' ' 38' ' ' ILE . 0.1 OUTLIER -45.28 137.96 1.35 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.525 0 O-C-N 121.2 -0.937 . . . . 0.0 108.96 179.838 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -49.02 151.39 1.29 Allowed 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.404 -0.81 . . . . 0.0 109.871 -179.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.408 ' O ' ' HA ' ' A' ' 39' ' ' ALA . 0.3 OUTLIER 57.19 40.11 28.33 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.273 -0.892 . . . . 0.0 109.604 179.762 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.474 ' HB2' ' O ' ' A' ' 73' ' ' ILE . . . . . . . . 0 N--CA 1.49 1.565 0 CA-C-O 118.019 -0.991 . . . . 0.0 109.453 179.824 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.569 0 CA-C-O 121.269 0.557 . . . . 0.0 109.534 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 18.3 pt-20 -81.79 -165.8 1.06 Allowed 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.159 -0.963 . . . . 0.0 109.542 -179.949 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.888 ' H ' HD12 ' A' ' 3' ' ' ILE . 0.1 OUTLIER -144.86 -179.16 0.97 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.406 0 O-C-N 121.288 -0.883 . . . . 0.0 109.518 -179.618 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -146.32 -174.37 4.43 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.433 -0.792 . . . . 0.0 109.349 179.858 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.553 ' HA ' HG11 ' A' ' 60' ' ' VAL . 4.6 t -76.04 162.86 4.19 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.175 -0.953 . . . . 0.0 109.135 179.885 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.489 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 77.43 -1.63 65.13 Favored Glycine 0 N--CA 1.489 2.184 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 -179.369 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.68 ' CD ' HG22 ' A' ' 3' ' ' ILE . 3.3 ttm105 -105.31 164.33 11.93 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.171 -1.193 . . . . 0.0 109.724 -179.705 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.582 HG13 ' O ' ' A' ' 58' ' ' VAL . 89.9 t -89.93 131.79 36.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.26 -0.9 . . . . 0.0 108.933 179.512 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.653 ' OH ' HD13 ' A' ' 3' ' ' ILE . 4.0 m-85 -107.78 179.33 4.26 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.183 -0.948 . . . . 0.0 110.031 -179.501 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -121.19 101.19 7.49 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 107.306 -1.368 . . . . 0.0 107.306 178.012 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -86.79 115.95 4.35 Favored Glycine 0 N--CA 1.486 2.024 0 C-N-CA 119.85 -1.167 . . . . 0.0 111.099 -177.865 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.562 ' O ' HG13 ' A' ' 23' ' ' VAL . 5.7 mtmt -88.66 152.04 22.07 Favored 'General case' 0 C--N 1.304 -1.387 0 N-CA-C 107.208 -1.404 . . . . 0.0 107.208 178.075 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.665 HG13 HD13 ' A' ' 50' ' ' LEU . 34.9 t -87.34 110.76 20.97 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.716 0 O-C-N 120.751 -1.218 . . . . 0.0 109.142 -179.07 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.973 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.5 OUTLIER -120.7 5.2 10.54 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.442 -0.786 . . . . 0.0 109.807 -179.227 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.529 ' CG ' ' O ' ' A' ' 14' ' ' THR . 3.5 mpp_? -176.15 152.5 1.16 Allowed 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.047 -1.033 . . . . 0.0 110.225 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.59 HG21 HG22 ' A' ' 47' ' ' THR . 35.0 mt -142.19 159.01 20.15 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 N-CA-C 108.522 -0.918 . . . . 0.0 108.522 179.209 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 1.033 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -137.19 153.65 29.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 120.82 -1.175 . . . . 0.0 109.872 -179.243 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 73.1 m-20 -59.13 -40.06 84.29 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 120.873 -1.142 . . . . 0.0 109.12 179.248 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.033 ' CE1' HG21 ' A' ' 17' ' ' VAL . 20.1 p90 -91.66 27.71 1.96 Allowed 'General case' 0 N--CA 1.493 1.699 0 O-C-N 121.431 -0.793 . . . . 0.0 110.148 -179.739 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.592 ' C ' HG22 ' A' ' 17' ' ' VAL . . . 151.82 -148.64 19.87 Favored Glycine 0 N--CA 1.492 2.386 0 C-N-CA 119.033 -1.556 . . . . 0.0 110.899 -179.559 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.75 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -155.32 148.46 24.71 Favored 'General case' 0 N--CA 1.486 1.34 0 O-C-N 121.241 -1.153 . . . . 0.0 108.846 -179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.947 ' CE1' HD11 ' A' ' 32' ' ' LEU . 11.6 m-30 -107.92 160.9 15.41 Favored 'General case' 0 C--N 1.3 -1.585 0 N-CA-C 108.813 -0.81 . . . . 0.0 108.813 179.58 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.795 ' CG2' HG23 ' A' ' 33' ' ' VAL . 20.4 t -149.39 162.25 4.6 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.129 -0.982 . . . . 0.0 109.49 -179.522 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.973 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -133.73 145.44 49.86 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.122 -0.986 . . . . 0.0 109.811 -179.694 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.515 ' O ' ' N ' ' A' ' 27' ' ' GLY . 3.2 pt -120.24 153.46 23.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.675 0 O-C-N 121.065 -1.022 . . . . 0.0 109.273 -179.872 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.458 ' C ' ' O ' ' A' ' 25' ' ' ILE . . . 38.81 -94.49 0.01 OUTLIER Glycine 0 N--CA 1.494 2.563 0 N-CA-C 109.919 -1.272 . . . . 0.0 109.919 179.469 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.515 ' N ' ' O ' ' A' ' 25' ' ' ILE . . . -172.63 -33.48 0.03 OUTLIER Glycine 0 N--CA 1.49 2.241 0 N-CA-C 109.859 -1.297 . . . . 0.0 109.859 179.816 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . -84.3 -9.41 81.97 Favored Glycine 0 N--CA 1.491 2.329 0 O-C-N 121.162 -1.199 . . . . 0.0 110.214 -179.69 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.562 ' HD2' HD11 ' A' ' 69' ' ' ILE . 2.5 mmmt -138.68 157.13 46.69 Favored 'General case' 0 N--CA 1.492 1.636 0 O-C-N 121.007 -1.29 . . . . 0.0 109.776 -179.938 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.539 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 0.0 OUTLIER -132.56 151.44 51.93 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.155 -0.966 . . . . 0.0 110.43 -179.861 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.831 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -104.72 -175.64 24.81 Favored Glycine 0 N--CA 1.49 2.292 0 N-CA-C 108.733 -1.747 . . . . 0.0 108.733 179.309 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.947 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -149.43 120.59 7.78 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 120.846 -1.385 . . . . 0.0 110.724 179.753 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.795 HG23 ' CG2' ' A' ' 23' ' ' VAL . 88.3 t -93.67 60.1 0.23 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 177.85 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.482 ' HB2' HD23 ' A' ' 32' ' ' LEU . 5.6 t-80 -47.6 158.42 0.19 Allowed 'General case' 0 C--N 1.303 -1.446 0 O-C-N 120.779 -1.201 . . . . 0.0 108.383 -179.533 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.676 ' O ' HD13 ' A' ' 38' ' ' ILE . 2.8 tp -47.76 -52.94 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.518 0 O-C-N 121.081 -1.012 . . . . 0.0 110.07 -179.276 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.578 ' H ' HG23 ' A' ' 35' ' ' ILE . 0.0 OUTLIER -81.48 39.41 0.53 Allowed 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.091 -1.005 . . . . 0.0 110.375 -179.631 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.924 ' C ' HD12 ' A' ' 38' ' ' ILE . 11.9 mm100 -144.83 50.41 1.26 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 120.926 -1.109 . . . . 0.0 109.641 -179.882 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.924 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.6 mp -120.08 -99.79 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 120.765 -1.209 . . . . 0.0 110.675 -179.484 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.788 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -111.72 -151.69 0.49 Allowed 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.211 -0.931 . . . . 0.0 110.269 -178.622 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -62.13 -65.15 0.73 Allowed 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.559 -0.713 . . . . 0.0 109.918 -179.628 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.474 ' HD2' ' OH ' ' A' ' 49' ' ' TYR . 4.6 ptpt -60.96 173.36 0.79 Allowed 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.121 -0.987 . . . . 0.0 109.318 -179.756 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 6.0 mmm180 -78.7 -2.06 37.44 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.295 -0.878 . . . . 0.0 110.138 -179.156 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.136 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 24.4 t 54.76 76.09 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.38 0 O-C-N 120.998 -1.064 . . . . 0.0 108.475 -179.527 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 46.9 mt-10 -46.97 -22.06 0.28 Allowed 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.328 -0.858 . . . . 0.0 109.718 -179.739 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.541 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.5 OUTLIER -128.28 117.78 22.09 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.113 -0.992 . . . . 0.0 109.858 -179.805 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.549 HG21 ' CA ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -77.65 -25.81 14.86 Favored 'Isoleucine or valine' 0 N--CA 1.499 1.987 0 O-C-N 121.199 -0.938 . . . . 0.0 108.701 179.485 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.59 HG22 HG21 ' A' ' 16' ' ' ILE . 63.5 p -77.1 3.73 11.85 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.383 -0.823 . . . . 0.0 109.307 179.237 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.404 ' OD2' ' CB ' ' A' ' 45' ' ' LYS . 99.1 m-20 -101.86 -24.36 14.04 Favored 'General case' 0 N--CA 1.49 1.527 0 N-CA-C 108.337 -0.986 . . . . 0.0 108.337 179.482 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 1.136 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 22.1 m-85 -100.29 -25.87 14.1 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 108.838 -0.801 . . . . 0.0 108.838 179.733 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.669 HD12 ' HB1' ' A' ' 21' ' ' ALA . 0.2 OUTLIER -111.25 142.74 43.06 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.245 -0.909 . . . . 0.0 109.391 179.465 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.508 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.2 OUTLIER -141.72 133.41 27.07 Favored 'General case' 0 N--CA 1.489 1.499 0 N-CA-C 108.858 -0.793 . . . . 0.0 108.858 179.537 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 9.9 mtm -54.78 97.49 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.137 -0.977 . . . . 0.0 110.077 -179.487 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 128.9 -36.0 2.51 Favored Glycine 0 N--CA 1.492 2.416 0 C-N-CA 119.847 -1.168 . . . . 0.0 110.304 179.341 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 5.2 mm-40 -57.5 162.47 2.89 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.066 -1.256 . . . . 0.0 109.695 -179.677 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.434 ' HG3' ' HA ' ' A' ' 12' ' ' LYS . 0.7 OUTLIER -137.55 125.93 23.34 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.412 -0.805 . . . . 0.0 109.184 179.819 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.406 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 16.0 m -130.25 139.26 35.09 Favored Pre-proline 0 N--CA 1.488 1.451 0 O-C-N 121.063 -1.023 . . . . 0.0 109.606 -179.837 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.471 ' O ' ' HB2' ' A' ' 74' ' ' LYS . 35.5 Cg_endo -78.44 134.13 12.33 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 122.503 2.135 . . . . 0.0 110.352 179.925 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.792 HG21 ' HB3' ' A' ' 71' ' ' LEU . 0.9 OUTLIER -127.41 179.17 3.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.152 -0.968 . . . . 0.0 109.782 -179.922 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.521 ' HG3' HG22 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -117.01 122.19 43.51 Favored 'General case' 0 N--CA 1.489 1.49 0 N-CA-C 108.85 -0.796 . . . . 0.0 108.85 179.639 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.649 ' HA ' HD23 ' A' ' 71' ' ' LEU . 91.2 t -53.25 94.95 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 O-C-N 121.189 -0.944 . . . . 0.0 109.528 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.604 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 13.4 tp -67.68 -14.97 63.39 Favored 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.279 -0.888 . . . . 0.0 109.221 179.793 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.604 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 0.6 OUTLIER 96.17 -171.29 0.0 OUTLIER 'General case' 0 N--CA 1.499 2.005 0 CA-C-O 121.244 0.545 . . . . 0.0 109.614 -179.916 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.738 HG13 ' O ' ' A' ' 68' ' ' ARG . 2.1 t -133.41 175.69 10.75 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.512 0 O-C-N 121.308 -0.87 . . . . 0.0 109.759 -179.418 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.587 ' H ' HG12 ' A' ' 63' ' ' VAL . 3.1 p-10 -108.15 -164.46 0.96 Allowed 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.307 -0.87 . . . . 0.0 109.358 179.962 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 11.5 mmm180 -79.21 7.37 7.75 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.036 -1.04 . . . . 0.0 109.822 -179.854 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -99.32 -46.59 5.47 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.172 -0.955 . . . . 0.0 109.387 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 120.78 23.44 2.78 Favored Glycine 0 N--CA 1.49 2.278 0 N-CA-C 109.506 -1.438 . . . . 0.0 109.506 179.93 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.738 ' O ' HG13 ' A' ' 63' ' ' VAL . 0.0 OUTLIER -91.07 99.49 12.51 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.327 -1.102 . . . . 0.0 109.334 -179.949 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.562 HD11 ' HD2' ' A' ' 29' ' ' LYS . 38.2 mt -46.17 121.19 0.67 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.18 -0.95 . . . . 0.0 109.412 179.918 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.572 ' HG2' HD23 ' A' ' 61' ' ' LEU . 0.1 OUTLIER -108.14 103.69 12.95 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.188 -0.945 . . . . 0.0 109.57 -179.944 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.831 HD12 ' HA3' ' A' ' 31' ' ' GLY . 81.4 mt -105.33 155.24 19.28 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.16 -0.963 . . . . 0.0 108.842 179.686 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.41 ' O ' ' C ' ' A' ' 73' ' ' ILE . 0.3 OUTLIER -121.32 97.21 5.41 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.115 -0.99 . . . . 0.0 110.362 -179.204 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.455 ' CG2' ' O ' ' A' ' 38' ' ' ILE . 0.2 OUTLIER -42.67 123.02 0.5 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.743 0 O-C-N 121.317 -0.864 . . . . 0.0 109.099 179.605 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.471 ' HB2' ' O ' ' A' ' 57' ' ' PRO . 0.8 OUTLIER -67.61 167.51 12.9 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.208 -0.933 . . . . 0.0 109.768 -179.651 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.406 ' O ' ' C ' ' A' ' 76' ' ' ALA . 6.2 mt-10 -64.09 -15.51 59.77 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.434 -0.791 . . . . 0.0 109.402 179.82 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.406 ' C ' ' O ' ' A' ' 75' ' ' GLU . . . . . . . . 0 N--CA 1.491 1.583 0 CA-C-O 118.019 -0.991 . . . . 0.0 109.67 179.937 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.551 0 N-CA-C 109.387 -0.597 . . . . 0.0 109.387 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.516 ' O ' ' CB ' ' A' ' 3' ' ' ILE . 3.3 mt-10 -103.64 -170.84 1.84 Allowed 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.247 -0.908 . . . . 0.0 109.573 -179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.561 HG21 ' OH ' ' A' ' 9' ' ' TYR . 0.3 OUTLIER 75.09 134.2 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 C-N-CA 119.228 -0.989 . . . . 0.0 108.893 -179.444 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.4 ' O ' ' HB2' ' A' ' 7' ' ' ARG . 0.6 OUTLIER -123.53 157.48 33.5 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.171 -0.956 . . . . 0.0 110.085 -179.628 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.566 HG12 ' N ' ' A' ' 6' ' ' GLY . 19.0 t -64.08 167.98 0.94 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.469 -0.769 . . . . 0.0 109.15 179.764 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.566 ' N ' HG12 ' A' ' 5' ' ' VAL . . . 74.67 2.77 65.15 Favored Glycine 0 N--CA 1.488 2.119 0 N-CA-C 108.97 -1.652 . . . . 0.0 108.97 -179.276 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.4 ' HB2' ' O ' ' A' ' 4' ' ' GLU . 1.1 ttm180 -88.96 -176.83 5.31 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.27 -1.135 . . . . 0.0 109.211 179.92 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.623 HG13 ' O ' ' A' ' 58' ' ' VAL . 55.3 t -102.5 119.54 50.99 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.148 -0.97 . . . . 0.0 108.945 179.602 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.646 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 3.0 m-85 -104.75 129.72 52.94 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.085 -1.009 . . . . 0.0 109.956 -179.561 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.5 m -74.49 98.08 3.25 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 178.398 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -77.73 120.45 5.51 Favored Glycine 0 N--CA 1.487 2.077 0 N-CA-C 110.384 -1.086 . . . . 0.0 110.384 -178.396 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.993 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.0 OUTLIER -92.47 150.51 20.74 Favored 'General case' 0 C--N 1.305 -1.362 0 N-CA-C 107.969 -1.123 . . . . 0.0 107.969 178.71 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.605 HG11 ' C ' ' A' ' 51' ' ' GLN . 20.7 t -89.49 106.12 16.7 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 O-C-N 120.908 -1.12 . . . . 0.0 108.991 -179.905 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 1.036 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -120.59 3.06 10.71 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.234 -0.916 . . . . 0.0 109.67 -179.506 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.517 ' HB3' ' HB2' ' A' ' 22' ' ' PHE . 5.0 mpp_? -173.31 153.48 2.43 Favored 'General case' 0 N--CA 1.495 1.818 0 O-C-N 121.174 -0.954 . . . . 0.0 109.821 179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.425 HG22 ' N ' ' A' ' 17' ' ' VAL . 14.7 mt -140.84 159.76 23.77 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.84 0 N-CA-C 108.661 -0.866 . . . . 0.0 108.661 179.562 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 1.06 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -139.67 155.55 25.25 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 120.822 -1.174 . . . . 0.0 110.285 -179.746 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -59.06 -44.48 91.84 Favored 'General case' 0 N--CA 1.492 1.645 0 O-C-N 120.967 -1.083 . . . . 0.0 109.803 179.449 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.06 ' CE1' HG21 ' A' ' 17' ' ' VAL . 8.2 p90 -90.42 24.62 2.53 Favored 'General case' 0 N--CA 1.495 1.776 0 O-C-N 121.107 -0.996 . . . . 0.0 110.377 -179.389 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.786 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 158.4 -152.28 23.41 Favored Glycine 0 N--CA 1.49 2.239 0 C-N-CA 118.977 -1.582 . . . . 0.0 111.044 -179.583 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.819 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -151.36 146.9 26.32 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.214 -1.168 . . . . 0.0 108.906 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.979 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.3 m-30 -106.73 157.93 17.35 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.259 -0.901 . . . . 0.0 108.992 179.754 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.993 HG13 ' O ' ' A' ' 12' ' ' LYS . 42.3 t -150.58 154.66 8.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.589 0 O-C-N 120.945 -1.097 . . . . 0.0 109.674 -178.834 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 1.036 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -121.87 138.21 54.48 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.89 -1.131 . . . . 0.0 109.319 179.662 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.563 HD12 ' CD2' ' A' ' 9' ' ' TYR . 2.5 pt -114.5 -172.4 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.733 0 O-C-N 121.166 -0.958 . . . . 0.0 109.239 -179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -91.35 178.4 41.53 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 109.242 -1.543 . . . . 0.0 109.242 179.625 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 87.48 -16.84 47.37 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 109.577 -1.409 . . . . 0.0 109.577 -179.94 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 104.38 12.38 29.07 Favored Glycine 0 N--CA 1.491 2.319 0 N-CA-C 109.619 -1.393 . . . . 0.0 109.619 179.999 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.495 ' O ' HG13 ' A' ' 25' ' ' ILE . 4.7 mttm -115.97 159.93 20.94 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.235 -1.156 . . . . 0.0 109.069 179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.52 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 0.4 OUTLIER -119.28 141.13 49.24 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.063 -1.023 . . . . 0.0 110.067 -179.757 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.9 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -91.93 -177.7 42.21 Favored Glycine 0 N--CA 1.488 2.137 0 N-CA-C 108.742 -1.743 . . . . 0.0 108.742 179.03 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.979 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -149.93 120.14 7.29 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 120.796 -1.414 . . . . 0.0 110.842 179.687 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.828 HG23 HG21 ' A' ' 23' ' ' VAL . 93.4 t -92.84 60.1 0.24 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 177.714 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.49 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.0 t-80 -48.76 156.51 0.47 Allowed 'General case' 0 N--CA 1.486 1.346 0 O-C-N 120.895 -1.128 . . . . 0.0 108.681 -179.375 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.553 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 2.7 tp -48.45 -48.92 13.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.296 -0.878 . . . . 0.0 110.623 -179.385 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.54 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.5 OUTLIER -81.25 40.93 0.58 Allowed 'General case' 0 N--CA 1.493 1.682 0 O-C-N 121.145 -0.972 . . . . 0.0 110.693 -179.396 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.946 ' C ' HD12 ' A' ' 38' ' ' ILE . 12.0 mt-30 -150.95 51.73 0.86 Allowed 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.713 -1.242 . . . . 0.0 110.047 179.88 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.946 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.7 mp -123.04 -97.91 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 120.886 -1.134 . . . . 0.0 110.094 -179.889 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.799 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -103.3 59.33 0.76 Allowed 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.432 -0.792 . . . . 0.0 108.999 -179.493 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.579 ' CB ' ' O ' ' A' ' 39' ' ' ALA . 9.8 t0 83.61 -43.05 0.09 Allowed 'General case' 0 N--CA 1.492 1.651 0 N-CA-C 108.903 -0.777 . . . . 0.0 108.903 -178.96 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.525 ' CB ' ' O ' ' A' ' 40' ' ' ASP . 0.2 OUTLIER 162.49 -20.05 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.364 -0.835 . . . . 0.0 110.044 179.825 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -73.63 80.62 1.51 Allowed 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.185 -0.947 . . . . 0.0 110.764 -179.171 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.945 HG13 ' CD1' ' A' ' 49' ' ' TYR . 50.1 t -140.32 82.14 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 121.106 -0.996 . . . . 0.0 109.169 178.839 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.417 ' C ' ' O ' ' A' ' 43' ' ' VAL . 29.3 tt0 -41.83 -29.53 0.21 Allowed 'General case' 0 N--CA 1.491 1.608 0 O-C-N 121.371 -0.83 . . . . 0.0 109.982 -179.61 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.483 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 1.1 mmtp -150.45 141.8 23.32 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.077 -1.015 . . . . 0.0 109.792 -179.933 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.786 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -74.12 -25.82 20.34 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.925 0 O-C-N 121.202 -0.936 . . . . 0.0 108.664 179.413 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.8 p -78.38 3.18 16.38 Favored 'General case' 0 C--N 1.301 -1.53 0 C-N-CA 119.745 -0.782 . . . . 0.0 109.108 179.372 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.443 ' OD2' ' HB2' ' A' ' 45' ' ' LYS . 4.7 m-20 -101.82 -29.4 11.88 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.171 -0.956 . . . . 0.0 108.749 179.62 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.945 ' CD1' HG13 ' A' ' 43' ' ' VAL . 20.4 m-85 -98.29 -27.5 14.1 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.571 -0.705 . . . . 0.0 109.129 179.765 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.648 HD21 HG21 ' A' ' 33' ' ' VAL . 0.2 OUTLIER -104.9 141.03 37.26 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.603 -0.686 . . . . 0.0 109.35 -179.73 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.605 ' C ' HG11 ' A' ' 13' ' ' VAL . 43.6 tt0 -136.46 132.34 35.24 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.488 -0.757 . . . . 0.0 109.641 -179.712 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 4.7 mtt -65.26 112.11 3.31 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.354 -0.841 . . . . 0.0 109.605 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 113.71 -23.07 13.78 Favored Glycine 0 N--CA 1.491 2.305 0 N-CA-C 109.6 -1.4 . . . . 0.0 109.6 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . 0.545 ' CG ' ' HB3' ' A' ' 51' ' ' GLN . 57.0 mm-40 -79.37 167.5 20.78 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.251 -1.147 . . . . 0.0 109.583 179.997 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.5 ' N ' ' OE1' ' A' ' 55' ' ' GLU . 1.3 mp0 -133.36 147.59 51.81 Favored 'General case' 0 N--CA 1.49 1.534 0 O-C-N 121.312 -0.867 . . . . 0.0 109.177 179.824 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.476 HG21 HD11 ' A' ' 73' ' ' ILE . 19.1 m -144.74 141.21 17.27 Favored Pre-proline 0 N--CA 1.491 1.596 0 O-C-N 121.156 -0.965 . . . . 0.0 109.771 -179.859 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 35.9 Cg_endo -78.54 126.39 7.45 Favored 'Trans proline' 0 C--N 1.312 -1.391 0 C-N-CA 122.575 2.183 . . . . 0.0 110.238 179.672 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.623 ' O ' HG13 ' A' ' 8' ' ' VAL . 1.0 OUTLIER -132.31 -170.98 0.73 Allowed 'Isoleucine or valine' 0 N--CA 1.491 1.612 0 O-C-N 121.191 -0.943 . . . . 0.0 109.516 179.843 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.535 ' N ' HG23 ' A' ' 58' ' ' VAL . 29.6 mtpt -134.43 127.01 30.68 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.414 -0.804 . . . . 0.0 109.459 179.801 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.646 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 26.2 t -53.42 89.9 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.504 0 O-C-N 121.281 -0.887 . . . . 0.0 109.018 179.688 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.595 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 16.2 tp -58.65 -19.6 40.6 Favored 'General case' 0 C--N 1.303 -1.423 0 O-C-N 121.241 -0.912 . . . . 0.0 109.605 -179.694 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.595 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 2.6 pt-20 95.54 -163.05 0.0 OUTLIER 'General case' 0 N--CA 1.502 2.134 0 CA-C-O 121.428 0.632 . . . . 0.0 109.869 179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.906 HG13 ' O ' ' A' ' 67' ' ' GLY . 55.3 t -142.42 147.6 20.99 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.615 0 O-C-N 121.561 -0.712 . . . . 0.0 109.453 -179.822 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . . . . . . . . . 10.9 p-10 -128.15 -151.31 0.47 Allowed 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.178 -0.952 . . . . 0.0 109.263 179.837 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 22.5 mtp180 -51.54 -57.23 9.66 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.166 -0.959 . . . . 0.0 108.976 179.67 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 6.6 mt-30 -118.99 124.85 47.99 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.289 -0.882 . . . . 0.0 108.941 179.46 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.906 ' O ' HG13 ' A' ' 63' ' ' VAL . . . 143.61 105.27 0.51 Allowed Glycine 0 N--CA 1.488 2.114 0 N-CA-C 109.324 -1.51 . . . . 0.0 109.324 -179.753 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.437 ' O ' ' C ' ' A' ' 69' ' ' ILE . 61.1 mtt-85 -88.79 120.98 30.69 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.338 -1.095 . . . . 0.0 109.206 -179.789 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.493 ' CD1' ' HB3' ' A' ' 29' ' ' LYS . 58.1 mt 42.82 84.36 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.296 -0.878 . . . . 0.0 109.352 -179.863 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.495 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 0.3 OUTLIER -89.92 111.34 22.37 Favored 'General case' 0 N--CA 1.488 1.432 0 O-C-N 120.901 -1.125 . . . . 0.0 108.981 179.893 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.9 HD12 ' HA3' ' A' ' 31' ' ' GLY . 18.8 mt -100.24 149.94 23.05 Favored 'General case' 0 C--N 1.303 -1.444 0 O-C-N 121.148 -0.97 . . . . 0.0 109.549 -179.797 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.458 ' O ' ' HB ' ' A' ' 58' ' ' VAL . 0.3 OUTLIER -114.67 106.7 14.54 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.375 -0.828 . . . . 0.0 109.565 -179.742 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.476 HD11 HG21 ' A' ' 56' ' ' VAL . 0.1 OUTLIER -65.84 135.24 28.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.506 0 O-C-N 121.261 -0.899 . . . . 0.0 109.229 -179.996 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -79.4 -149.54 0.05 Allowed 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.315 -0.866 . . . . 0.0 109.228 179.715 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -64.45 -44.2 91.88 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.154 -0.966 . . . . 0.0 109.497 179.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.489 1.515 0 CA-C-O 117.979 -1.01 . . . . 0.0 109.483 -179.87 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.605 0 N-CA-C 109.461 -0.57 . . . . 0.0 109.461 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.904 ' C ' HD13 ' A' ' 3' ' ' ILE . 0.5 OUTLIER 63.66 -175.76 0.16 Allowed 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.244 -0.91 . . . . 0.0 109.396 -179.892 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.904 HD13 ' C ' ' A' ' 2' ' ' GLU . 0.0 OUTLIER -134.62 123.8 42.85 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 O-C-N 121.12 -0.988 . . . . 0.0 110.238 -179.038 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -98.55 144.61 27.68 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 179.521 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.669 HG22 ' HA ' ' A' ' 62' ' ' GLU . 7.1 t -75.71 158.1 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.111 -0.993 . . . . 0.0 109.654 -179.667 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.417 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 76.62 2.15 74.27 Favored Glycine 0 N--CA 1.487 2.096 0 N-CA-C 109.16 -1.576 . . . . 0.0 109.16 -179.537 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . . . . . . . . . 3.8 ttt-85 -97.75 179.95 4.65 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.292 -1.122 . . . . 0.0 109.67 -179.873 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.739 HG22 ' HG3' ' A' ' 59' ' ' LYS . 71.6 t -119.36 143.68 30.01 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.591 0 O-C-N 121.275 -0.89 . . . . 0.0 109.019 179.821 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.587 ' CZ ' ' CG2' ' A' ' 3' ' ' ILE . 11.5 m-85 -136.53 129.51 31.06 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.059 -1.026 . . . . 0.0 110.77 -179.521 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.504 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 0.4 OUTLIER -97.58 112.05 24.07 Favored 'General case' 0 C--N 1.301 -1.536 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 178.149 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -113.48 151.97 18.16 Favored Glycine 0 N--CA 1.487 2.09 0 C-N-CA 119.134 -1.508 . . . . 0.0 110.59 -178.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.524 ' HG2' ' CG ' ' A' ' 55' ' ' GLU . 3.4 mtmm -89.63 162.32 15.68 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 107.91 -1.144 . . . . 0.0 107.91 178.876 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.56 HG22 HD13 ' A' ' 50' ' ' LEU . 60.3 t -88.16 97.56 6.83 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.637 0 O-C-N 120.994 -1.066 . . . . 0.0 108.203 179.651 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.718 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.6 p -103.43 -4.64 23.8 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.475 -0.765 . . . . 0.0 110.426 -178.642 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.551 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 0.0 OUTLIER -163.37 153.8 15.96 Favored 'General case' 0 N--CA 1.493 1.676 0 O-C-N 120.913 -1.117 . . . . 0.0 110.584 -179.699 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.402 ' HA ' ' HA ' ' A' ' 21' ' ' ALA . 19.8 mt -143.21 155.41 16.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.67 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 178.931 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 1.027 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.6 OUTLIER -135.54 154.96 35.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.59 0 O-C-N 120.837 -1.164 . . . . 0.0 110.055 -178.934 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 12.0 t0 -60.5 -40.44 91.41 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 120.687 -1.258 . . . . 0.0 109.323 179.43 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.027 ' CE1' HG21 ' A' ' 17' ' ' VAL . 15.5 p90 -90.2 23.14 2.98 Favored 'General case' 0 N--CA 1.493 1.702 0 O-C-N 121.356 -0.84 . . . . 0.0 110.289 -179.743 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.595 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 156.23 -149.42 20.35 Favored Glycine 0 N--CA 1.493 2.497 0 C-N-CA 119.294 -1.432 . . . . 0.0 110.975 -179.654 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.708 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -153.54 146.85 24.79 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.042 -1.27 . . . . 0.0 108.99 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.966 ' CE1' HD11 ' A' ' 32' ' ' LEU . 11.2 m-30 -109.35 155.89 20.67 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.395 -0.816 . . . . 0.0 109.175 179.974 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.768 ' CG2' HG23 ' A' ' 33' ' ' VAL . 7.0 t -144.23 168.23 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.706 0 O-C-N 120.93 -1.106 . . . . 0.0 109.145 179.795 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.718 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -138.05 150.92 47.36 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.06 -1.025 . . . . 0.0 110.743 -179.328 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.484 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.8 pt -122.0 111.04 29.09 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.661 0 O-C-N 121.182 -0.949 . . . . 0.0 108.951 179.315 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . 79.85 -86.08 1.27 Allowed Glycine 0 N--CA 1.49 2.242 0 N-CA-C 109.649 -1.38 . . . . 0.0 109.649 -179.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -179.43 -38.99 0.07 OUTLIER Glycine 0 N--CA 1.491 2.354 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -179.932 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.463 ' O ' ' OE2' ' A' ' 30' ' ' GLU . . . -80.23 -45.79 7.94 Favored Glycine 0 N--CA 1.492 2.381 0 N-CA-C 109.718 -1.353 . . . . 0.0 109.718 -179.723 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.832 ' HG2' HD11 ' A' ' 3' ' ' ILE . 0.0 OUTLIER -99.53 150.37 22.28 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.186 -1.185 . . . . 0.0 109.124 -179.997 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.544 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 5.2 mp0 -131.78 155.04 48.44 Favored 'General case' 0 N--CA 1.487 1.407 0 O-C-N 120.84 -1.162 . . . . 0.0 111.081 -179.468 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.789 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -105.72 -174.0 23.82 Favored Glycine 0 N--CA 1.49 2.291 0 N-CA-C 108.352 -1.899 . . . . 0.0 108.352 179.141 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.966 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.51 122.89 8.42 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 120.716 -1.461 . . . . 0.0 111.054 179.674 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.768 HG23 ' CG2' ' A' ' 23' ' ' VAL . 14.9 t -99.62 64.73 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.419 0 N-CA-C 107.746 -1.205 . . . . 0.0 107.746 177.333 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.499 ' HB3' ' HG3' ' A' ' 37' ' ' GLN . 3.6 t-80 -49.58 162.23 0.17 Allowed 'General case' 0 C--N 1.304 -1.395 0 O-C-N 120.835 -1.165 . . . . 0.0 108.746 -179.474 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.609 ' O ' HD13 ' A' ' 38' ' ' ILE . 0.3 OUTLIER -52.79 -52.05 31.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.578 0 O-C-N 121.214 -0.929 . . . . 0.0 110.329 -179.269 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.561 ' N ' HG23 ' A' ' 35' ' ' ILE . 11.5 m -81.42 32.46 0.35 Allowed 'General case' 0 N--CA 1.494 1.759 0 O-C-N 120.994 -1.066 . . . . 0.0 110.764 -179.351 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.894 ' C ' HD12 ' A' ' 38' ' ' ILE . 0.3 OUTLIER -138.24 48.24 1.97 Allowed 'General case' 0 N--CA 1.491 1.583 0 O-C-N 120.695 -1.253 . . . . 0.0 109.978 -179.955 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.894 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.5 mp -119.39 -99.39 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 120.956 -1.09 . . . . 0.0 110.019 179.917 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.806 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -97.68 -141.25 0.3 Allowed 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.317 -0.864 . . . . 0.0 109.09 -179.266 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.491 ' O ' ' HB2' ' A' ' 41' ' ' LYS . 0.2 OUTLIER -44.39 -57.21 3.67 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.054 -1.028 . . . . 0.0 108.994 179.791 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.491 ' HB2' ' O ' ' A' ' 40' ' ' ASP . 0.4 OUTLIER 173.32 -30.34 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.5 -0.75 . . . . 0.0 109.148 -179.994 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.438 ' O ' ' C ' ' A' ' 43' ' ' VAL . 11.5 mtm180 -48.03 -95.59 0.0 OUTLIER 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.368 -0.833 . . . . 0.0 110.034 -179.524 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 0.965 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 90.0 t 41.78 49.16 0.35 Allowed 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.334 -0.854 . . . . 0.0 109.06 -179.055 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.412 ' C ' ' O ' ' A' ' 43' ' ' VAL . 11.1 mt-10 -41.31 -30.66 0.19 Allowed 'General case' 0 N--CA 1.492 1.675 0 O-C-N 121.556 -0.715 . . . . 0.0 109.506 -179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.462 ' HB2' ' CG ' ' A' ' 48' ' ' ASP . 14.1 mttt -122.21 130.05 52.83 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.35 -0.844 . . . . 0.0 109.066 179.954 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.595 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -78.62 -24.31 13.32 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.895 0 O-C-N 121.19 -0.944 . . . . 0.0 108.932 -179.976 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 3.2 p -76.78 4.38 9.81 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.328 -0.858 . . . . 0.0 109.48 179.388 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.476 ' N ' ' OD1' ' A' ' 48' ' ' ASP . 2.0 m-20 -99.55 -37.43 9.17 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.156 -0.965 . . . . 0.0 108.727 179.515 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 0.965 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 18.0 m-85 -90.19 -32.69 16.5 Favored 'General case' 0 C--N 1.302 -1.477 0 N-CA-C 108.926 -0.768 . . . . 0.0 108.926 179.683 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.667 HD11 HG21 ' A' ' 33' ' ' VAL . 0.0 OUTLIER -99.21 140.38 33.45 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.532 -0.73 . . . . 0.0 109.223 179.938 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.493 ' H ' HG21 ' A' ' 13' ' ' VAL . 45.6 mt-30 -136.35 112.56 9.8 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.463 -0.773 . . . . 0.0 109.253 -179.821 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . 0.451 ' O ' ' CE ' ' A' ' 52' ' ' MET . 0.7 OUTLIER -52.49 94.59 0.01 OUTLIER 'General case' 0 N--CA 1.487 1.395 0 O-C-N 121.277 -0.889 . . . . 0.0 110.176 -179.769 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 143.37 -38.88 1.35 Allowed Glycine 0 N--CA 1.491 2.36 0 C-N-CA 119.771 -1.204 . . . . 0.0 110.428 179.508 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . . . . . . . . . 22.4 mt-30 -77.36 169.17 18.8 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.128 -1.219 . . . . 0.0 109.782 -179.42 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . 0.524 ' CG ' ' HG2' ' A' ' 12' ' ' LYS . 3.6 mt-10 -122.81 125.32 45.22 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.297 -0.877 . . . . 0.0 109.217 179.739 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.442 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 22.9 m -117.49 142.64 30.73 Favored Pre-proline 0 N--CA 1.489 1.523 0 O-C-N 121.187 -0.946 . . . . 0.0 109.97 -179.68 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.504 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.3 Cg_endo -80.28 153.66 21.43 Favored 'Trans proline' 0 C--N 1.313 -1.326 0 C-N-CA 122.753 2.302 . . . . 0.0 110.105 179.669 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.819 ' CG2' HD22 ' A' ' 71' ' ' LEU . 0.9 OUTLIER -150.47 -170.27 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.553 0 O-C-N 121.169 -0.957 . . . . 0.0 109.63 179.8 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.739 ' HG3' HG22 ' A' ' 8' ' ' VAL . 7.7 mtpt -140.75 124.44 17.03 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.398 -0.814 . . . . 0.0 109.663 179.799 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.572 ' HA ' HD23 ' A' ' 71' ' ' LEU . 43.0 t -52.6 89.57 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 O-C-N 121.415 -0.803 . . . . 0.0 108.991 179.365 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.789 HD12 ' OG ' ' A' ' 72' ' ' SER . 0.5 OUTLIER -63.62 -31.1 72.17 Favored 'General case' 0 C--N 1.304 -1.372 0 O-C-N 121.403 -0.811 . . . . 0.0 109.444 -179.596 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.669 ' HA ' HG22 ' A' ' 5' ' ' VAL . 2.1 mt-10 158.91 -167.7 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.828 0 CA-C-O 121.59 0.71 . . . . 0.0 110.194 -179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 32.1 t -145.83 135.66 17.98 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 N-CA-C 108.852 -0.796 . . . . 0.0 108.852 179.567 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.47 ' OD2' ' HB2' ' A' ' 68' ' ' ARG . 0.5 OUTLIER -84.96 -174.59 5.35 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 121.151 -0.968 . . . . 0.0 109.879 -179.782 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -73.61 -10.39 59.66 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.321 -0.862 . . . . 0.0 109.872 -179.678 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 82.2 mm-40 -89.68 12.89 15.6 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.183 -0.948 . . . . 0.0 109.586 -179.725 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 61.22 29.86 72.36 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.681 -1.368 . . . . 0.0 109.681 179.73 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.47 ' HB2' ' OD2' ' A' ' 64' ' ' ASP . 1.2 mmp_? -89.7 140.08 29.93 Favored 'General case' 0 N--CA 1.488 1.452 0 O-C-N 121.199 -1.177 . . . . 0.0 108.966 179.67 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.632 HG22 ' HG ' ' A' ' 71' ' ' LEU . 22.4 mt -82.49 107.72 14.67 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.423 0 O-C-N 121.243 -0.911 . . . . 0.0 109.85 -179.506 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.555 ' NH2' ' NE2' ' A' ' 37' ' ' GLN . 26.0 tpt85 -89.63 91.11 8.53 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 121.205 -0.934 . . . . 0.0 108.946 179.488 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.819 HD22 ' CG2' ' A' ' 58' ' ' VAL . 52.8 mt -89.96 161.08 16.06 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.252 -0.905 . . . . 0.0 110.112 -179.323 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.789 ' OG ' HD12 ' A' ' 61' ' ' LEU . 0.3 OUTLIER -124.36 116.58 22.82 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.481 -0.762 . . . . 0.0 110.028 -179.725 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.745 HD13 ' O ' ' A' ' 37' ' ' GLN . 1.3 mp -46.43 134.97 2.88 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.576 0 O-C-N 121.079 -1.013 . . . . 0.0 108.511 179.368 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER -74.67 -26.79 60.09 Favored 'General case' 0 N--CA 1.492 1.649 0 O-C-N 121.157 -0.964 . . . . 0.0 109.976 -179.334 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.413 ' CG ' ' O ' ' A' ' 75' ' ' GLU . 28.8 tt0 -81.72 7.95 11.22 Favored 'General case' 0 C--N 1.297 -1.699 0 O-C-N 121.281 -0.887 . . . . 0.0 109.406 179.613 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.518 ' N ' HG22 ' A' ' 73' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.476 0 CA-C-O 118.015 -0.993 . . . . 0.0 109.386 179.931 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.608 0 CA-C-O 121.342 0.591 . . . . 0.0 109.563 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.422 ' O ' ' C ' ' A' ' 3' ' ' ILE . 20.5 mp0 -114.31 82.56 1.73 Allowed 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.202 -0.937 . . . . 0.0 109.638 -179.809 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.921 HD12 ' OH ' ' A' ' 9' ' ' TYR . 0.2 OUTLIER -42.03 143.78 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.232 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -134.84 168.47 19.01 Favored 'General case' 0 N--CA 1.493 1.722 0 O-C-N 120.999 -1.063 . . . . 0.0 110.218 -179.312 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.559 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 16.7 t -77.36 168.14 2.1 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.614 0 O-C-N 121.284 -0.885 . . . . 0.0 109.299 179.901 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.559 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 80.23 6.63 89.12 Favored Glycine 0 N--CA 1.489 2.202 0 N-CA-C 108.854 -1.698 . . . . 0.0 108.854 -179.195 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.509 ' HG3' ' N ' ' A' ' 8' ' ' VAL . 4.5 tpt180 -102.6 156.16 17.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.389 -1.065 . . . . 0.0 109.424 -179.591 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.75 HG22 ' HG3' ' A' ' 59' ' ' LYS . 75.8 t -88.8 119.67 36.32 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.693 0 O-C-N 121.138 -0.976 . . . . 0.0 108.813 179.729 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.921 ' OH ' HD12 ' A' ' 3' ' ' ILE . 4.4 m-30 -105.22 129.47 53.59 Favored 'General case' 0 N--CA 1.495 1.793 0 O-C-N 121.113 -0.992 . . . . 0.0 110.066 -178.947 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 3.6 m -77.0 102.39 6.42 Favored 'General case' 0 C--N 1.302 -1.499 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 178.628 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -80.21 116.2 4.21 Favored Glycine 0 N--CA 1.486 2.027 0 C-N-CA 119.933 -1.127 . . . . 0.0 110.373 -178.995 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.632 ' O ' HG13 ' A' ' 23' ' ' VAL . 9.1 mttt -89.16 149.97 22.9 Favored 'General case' 0 N--CA 1.488 1.434 0 N-CA-C 107.819 -1.178 . . . . 0.0 107.819 178.655 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 1.029 HG22 ' CD2' ' A' ' 50' ' ' LEU . 85.8 t -86.83 106.69 16.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.539 0 O-C-N 120.956 -1.09 . . . . 0.0 109.059 -179.292 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 1.04 HG21 ' HB3' ' A' ' 24' ' ' ALA . 0.6 OUTLIER -113.99 -25.43 8.57 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.529 -0.732 . . . . 0.0 109.21 -179.492 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.537 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 5.6 mtp180 -143.86 152.23 40.9 Favored 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.262 -0.899 . . . . 0.0 109.967 179.762 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . . . . . . . . . 31.7 mt -139.85 154.42 23.82 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.726 0 N-CA-C 108.353 -0.98 . . . . 0.0 108.353 179.249 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 1.061 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.7 OUTLIER -134.83 154.3 36.4 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.603 0 O-C-N 120.782 -1.199 . . . . 0.0 110.313 -178.835 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 -59.28 -42.81 92.12 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 120.796 -1.19 . . . . 0.0 109.539 179.298 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.061 ' CE1' HG21 ' A' ' 17' ' ' VAL . 9.9 p90 -90.73 27.28 1.81 Allowed 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.17 -0.956 . . . . 0.0 110.065 -179.766 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.91 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 154.85 -153.01 24.49 Favored Glycine 0 N--CA 1.491 2.32 0 C-N-CA 119.012 -1.566 . . . . 0.0 111.141 -179.488 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.825 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -150.02 143.81 25.41 Favored 'General case' 0 C--N 1.305 -1.355 0 O-C-N 121.057 -1.26 . . . . 0.0 109.075 -179.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.98 ' CE1' HD11 ' A' ' 32' ' ' LEU . 9.5 m-30 -104.27 160.79 14.59 Favored 'General case' 0 C--N 1.298 -1.672 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.174 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.859 ' CG2' HG23 ' A' ' 33' ' ' VAL . 24.9 t -151.09 159.42 4.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.533 0 O-C-N 120.841 -1.162 . . . . 0.0 110.514 -178.613 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 1.04 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -138.14 143.04 40.14 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.24 -0.912 . . . . 0.0 109.142 179.618 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.927 HD11 ' CB ' ' A' ' 29' ' ' LYS . 11.9 pt -100.47 -34.77 4.18 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.728 0 O-C-N 120.825 -1.172 . . . . 0.0 109.001 179.742 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.43 ' N ' HG13 ' A' ' 25' ' ' ILE . . . 95.78 159.91 32.81 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 179.943 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 89.89 -13.04 65.57 Favored Glycine 0 N--CA 1.489 2.171 0 N-CA-C 109.358 -1.497 . . . . 0.0 109.358 -179.859 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 125.55 46.43 0.23 Allowed Glycine 0 N--CA 1.488 2.144 0 N-CA-C 109.81 -1.316 . . . . 0.0 109.81 179.787 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.927 ' CB ' HD11 ' A' ' 25' ' ' ILE . 0.0 OUTLIER -178.71 149.99 0.49 Allowed 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.031 -1.276 . . . . 0.0 110.088 179.709 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.617 ' O ' HD12 ' A' ' 69' ' ' ILE . 1.4 pm0 -136.04 156.6 48.49 Favored 'General case' 0 C--N 1.304 -1.395 0 O-C-N 121.059 -1.026 . . . . 0.0 110.194 -179.505 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.792 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -112.4 176.7 18.03 Favored Glycine 0 N--CA 1.488 2.129 0 N-CA-C 108.798 -1.721 . . . . 0.0 108.798 179.496 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.98 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -140.98 119.45 12.29 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 120.986 -1.302 . . . . 0.0 110.074 179.285 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.988 HG21 HD11 ' A' ' 50' ' ' LEU . 47.0 t -94.02 62.3 0.3 Allowed 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 N-CA-C 107.959 -1.126 . . . . 0.0 107.959 178.099 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.452 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.4 t-80 -48.56 156.18 0.47 Allowed 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.857 -1.152 . . . . 0.0 108.712 -179.53 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.618 HG23 ' H ' ' A' ' 36' ' ' SER . 3.2 tp -45.52 -53.96 1.78 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.365 -0.834 . . . . 0.0 110.899 -179.117 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.618 ' H ' HG23 ' A' ' 35' ' ' ILE . 5.3 t -81.27 41.4 0.6 Allowed 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.049 -1.032 . . . . 0.0 110.633 -179.254 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.995 ' C ' HD12 ' A' ' 38' ' ' ILE . 43.5 mt-30 -150.8 61.45 0.93 Allowed 'General case' 0 N--CA 1.492 1.637 0 O-C-N 120.782 -1.199 . . . . 0.0 110.598 -179.843 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.995 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.9 mp -129.37 -95.56 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.655 0 O-C-N 120.849 -1.157 . . . . 0.0 109.684 179.372 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.794 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -122.51 -161.25 0.93 Allowed 'General case' 0 C--N 1.3 -1.552 0 O-C-N 121.555 -0.715 . . . . 0.0 109.752 -179.251 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -60.02 -61.49 2.57 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.363 -0.836 . . . . 0.0 109.414 179.776 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -47.12 153.16 0.48 Allowed 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.226 -0.921 . . . . 0.0 109.24 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -67.71 -5.27 15.21 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.299 -0.876 . . . . 0.0 109.885 -179.635 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.074 HG13 ' CD1' ' A' ' 49' ' ' TYR . 75.7 t 48.78 51.63 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.505 0 O-C-N 120.996 -1.065 . . . . 0.0 109.016 -179.811 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . 0.453 ' C ' ' O ' ' A' ' 43' ' ' VAL . 0.3 OUTLIER -40.71 -32.24 0.2 Allowed 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.631 -0.668 . . . . 0.0 109.621 -179.99 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.475 ' HB3' ' OD1' ' A' ' 48' ' ' ASP . 2.7 mtmp? -111.69 118.23 35.08 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.417 -0.802 . . . . 0.0 109.514 -179.87 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.91 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -74.93 -26.59 19.42 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.831 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 179.509 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 7.9 p -78.93 5.36 11.76 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.36 -0.838 . . . . 0.0 109.176 179.215 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.475 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 3.2 m-20 -98.43 -37.24 9.68 Favored 'General case' 0 N--CA 1.49 1.549 0 N-CA-C 108.389 -0.967 . . . . 0.0 108.389 179.383 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 1.074 ' CD1' HG13 ' A' ' 43' ' ' VAL . 15.9 m-85 -90.28 -34.01 15.91 Favored 'General case' 0 C--N 1.304 -1.385 0 N-CA-C 108.924 -0.769 . . . . 0.0 108.924 179.626 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 1.029 ' CD2' HG22 ' A' ' 13' ' ' VAL . 0.0 OUTLIER -110.66 148.11 32.92 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.354 -0.841 . . . . 0.0 110.395 179.886 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.621 ' C ' HG11 ' A' ' 13' ' ' VAL . 2.3 tt0 -150.62 147.03 26.91 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.849 -0.797 . . . . 0.0 108.849 179.57 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 8.2 mtp -65.84 88.05 0.1 Allowed 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.098 -1.001 . . . . 0.0 109.743 -179.593 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 145.19 -20.81 1.92 Allowed Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.576 -1.41 . . . . 0.0 109.576 179.725 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . 0.406 ' HG2' ' HB3' ' A' ' 51' ' ' GLN . 19.7 mm-40 -80.86 168.86 18.28 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.309 -1.112 . . . . 0.0 110.008 -179.733 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -144.04 116.77 8.71 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.387 -0.821 . . . . 0.0 109.097 179.684 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 25.5 m -114.41 142.31 27.92 Favored Pre-proline 0 N--CA 1.492 1.649 0 O-C-N 121.13 -0.981 . . . . 0.0 109.359 179.984 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -78.93 142.39 17.45 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.351 2.034 . . . . 0.0 110.322 -179.993 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.627 HG21 HD13 ' A' ' 71' ' ' LEU . 0.8 OUTLIER -138.1 174.96 9.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.445 0 O-C-N 121.333 -0.855 . . . . 0.0 109.32 -179.886 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.75 ' HG3' HG22 ' A' ' 8' ' ' VAL . 0.1 OUTLIER -126.64 111.16 14.0 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.284 -0.885 . . . . 0.0 109.381 179.511 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.487 ' HA ' HD23 ' A' ' 71' ' ' LEU . 80.4 t -52.38 88.81 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.617 0 O-C-N 121.524 -0.735 . . . . 0.0 109.077 179.707 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.524 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 9.9 tp -67.19 -26.23 66.52 Favored 'General case' 0 C--N 1.3 -1.569 0 O-C-N 121.425 -0.797 . . . . 0.0 109.96 -179.387 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.524 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 2.6 mt-10 160.88 148.89 0.01 OUTLIER 'General case' 0 N--CA 1.497 1.906 0 O-C-N 121.252 -0.905 . . . . 0.0 110.11 179.663 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.687 HG13 ' H ' ' A' ' 69' ' ' ILE . 44.3 t -150.3 -106.16 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.416 -0.803 . . . . 0.0 109.226 179.377 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.487 ' O ' ' O ' ' A' ' 63' ' ' VAL . 0.3 OUTLIER 41.82 -169.2 0.0 OUTLIER 'General case' 0 N--CA 1.496 1.85 0 O-C-N 120.939 -1.101 . . . . 0.0 110.639 179.469 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 1.4 ptm180 -51.46 -50.35 59.97 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.277 -0.889 . . . . 0.0 109.544 -179.793 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 7.8 mt-30 -90.28 67.67 6.82 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.312 -0.868 . . . . 0.0 109.123 179.794 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.488 ' O ' ' HA ' ' A' ' 63' ' ' VAL . . . 164.95 101.79 0.16 Allowed Glycine 0 N--CA 1.487 2.05 0 N-CA-C 109.297 -1.521 . . . . 0.0 109.297 -179.715 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 53.6 mtt180 -89.45 84.03 6.39 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.34 -1.094 . . . . 0.0 109.601 -179.838 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.816 HG22 ' O ' ' A' ' 69' ' ' ILE . 16.3 mm 51.32 65.46 0.18 Allowed 'Isoleucine or valine' 0 N--CA 1.488 1.469 0 O-C-N 121.327 -0.858 . . . . 0.0 110.073 179.541 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -89.74 78.91 6.84 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 120.95 -1.094 . . . . 0.0 108.714 179.164 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.792 HD12 ' HA3' ' A' ' 31' ' ' GLY . 22.5 mt -89.36 145.55 25.28 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.263 -0.898 . . . . 0.0 109.216 -179.731 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -107.49 99.07 8.61 Favored 'General case' 0 C--N 1.302 -1.471 0 O-C-N 121.448 -0.782 . . . . 0.0 110.498 -178.927 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.736 ' O ' ' HB2' ' A' ' 76' ' ' ALA . 15.5 mm -51.69 137.95 9.72 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.316 -0.865 . . . . 0.0 109.295 179.697 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.471 ' C ' ' O ' ' A' ' 73' ' ' ILE . 0.2 OUTLIER -37.41 147.16 0.04 OUTLIER 'General case' 0 N--CA 1.497 1.897 0 O-C-N 121.587 -0.696 . . . . 0.0 110.102 -179.835 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 13.5 tt0 55.33 28.25 11.1 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.191 -0.943 . . . . 0.0 109.274 -179.938 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.736 ' HB2' ' O ' ' A' ' 73' ' ' ILE . . . . . . . . 0 N--CA 1.489 1.506 0 CA-C-O 118.024 -0.989 . . . . 0.0 109.544 -179.814 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.625 0 N-CA-C 109.367 -0.605 . . . . 0.0 109.367 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER 178.15 -168.36 0.07 Allowed 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.239 -0.913 . . . . 0.0 109.621 -179.862 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.637 HG21 ' OH ' ' A' ' 9' ' ' TYR . 0.0 OUTLIER -128.16 -163.28 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 121.321 -0.862 . . . . 0.0 109.272 -179.769 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.501 ' O ' ' HG3' ' A' ' 7' ' ' ARG . 0.8 OUTLIER -143.77 152.22 40.96 Favored 'General case' 0 N--CA 1.489 1.5 0 N-CA-C 108.808 -0.812 . . . . 0.0 108.808 179.393 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.526 ' CG1' ' N ' ' A' ' 6' ' ' GLY . 8.7 t -80.48 163.86 3.27 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.566 0 O-C-N 121.077 -1.014 . . . . 0.0 109.551 -179.795 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.526 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 95.45 4.17 60.97 Favored Glycine 0 N--CA 1.489 2.207 0 N-CA-C 109.48 -1.448 . . . . 0.0 109.48 179.97 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.501 ' HG3' ' O ' ' A' ' 4' ' ' GLU . 0.0 OUTLIER -111.64 171.25 7.6 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.159 -1.201 . . . . 0.0 109.823 -179.541 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.968 HG13 ' O ' ' A' ' 58' ' ' VAL . 75.9 t -97.28 141.48 15.71 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 N-CA-C 108.471 -0.937 . . . . 0.0 108.471 179.289 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.637 ' OH ' HG21 ' A' ' 3' ' ' ILE . 11.0 m-85 -120.87 127.7 52.13 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.036 -1.04 . . . . 0.0 110.502 -179.287 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . 0.494 ' HA ' ' HA ' ' A' ' 57' ' ' PRO . 5.6 m -97.04 109.22 22.02 Favored 'General case' 0 C--N 1.299 -1.606 0 N-CA-C 107.906 -1.146 . . . . 0.0 107.906 178.501 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -110.77 150.1 17.74 Favored Glycine 0 N--CA 1.487 2.095 0 C-N-CA 119.472 -1.347 . . . . 0.0 110.495 -178.837 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.446 ' O ' HG13 ' A' ' 23' ' ' VAL . 0.8 OUTLIER -89.81 163.02 15.21 Favored 'General case' 0 C--N 1.304 -1.394 0 N-CA-C 108.033 -1.099 . . . . 0.0 108.033 179.08 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.828 ' CG2' HD22 ' A' ' 50' ' ' LEU . 41.6 t -89.0 103.27 13.8 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.638 0 O-C-N 121.096 -1.002 . . . . 0.0 108.754 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.747 HG21 ' CB ' ' A' ' 24' ' ' ALA . 0.5 OUTLIER -106.6 -12.46 15.57 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.282 -0.886 . . . . 0.0 109.779 -179.198 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.496 ' HD2' ' O ' ' A' ' 14' ' ' THR . 0.5 OUTLIER -159.26 153.9 24.42 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.054 -1.029 . . . . 0.0 110.41 -179.662 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.473 HG21 HG22 ' A' ' 47' ' ' THR . 11.1 mt -139.69 157.65 26.85 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 N-CA-C 108.188 -1.041 . . . . 0.0 108.188 179.255 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 1.026 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -137.75 153.7 28.22 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 120.697 -1.252 . . . . 0.0 110.128 -178.947 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -60.69 -40.66 93.01 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 120.594 -1.316 . . . . 0.0 109.232 179.186 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.026 ' CE1' HG21 ' A' ' 17' ' ' VAL . 16.3 p90 -90.04 24.17 2.55 Favored 'General case' 0 N--CA 1.495 1.779 0 O-C-N 121.273 -0.892 . . . . 0.0 110.19 -179.717 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.796 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 155.82 -153.5 24.8 Favored Glycine 0 N--CA 1.494 2.506 0 C-N-CA 119.091 -1.528 . . . . 0.0 111.272 -179.405 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.955 ' HB1' HD12 ' A' ' 50' ' ' LEU . . . -149.78 145.35 26.58 Favored 'General case' 0 N--CA 1.487 1.397 0 O-C-N 121.116 -1.226 . . . . 0.0 108.931 179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.973 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.2 m-30 -107.78 145.25 33.81 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.337 -0.852 . . . . 0.0 109.232 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.901 ' CG2' HG23 ' A' ' 33' ' ' VAL . 48.9 t -133.33 167.52 26.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.715 0 O-C-N 121.134 -0.979 . . . . 0.0 109.597 -179.681 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.747 ' CB ' HG21 ' A' ' 14' ' ' THR . . . -136.64 135.29 38.17 Favored 'General case' 0 N--CA 1.493 1.699 0 O-C-N 120.884 -1.135 . . . . 0.0 110.78 -179.42 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.528 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.1 pt -113.25 93.83 2.77 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 120.94 -1.1 . . . . 0.0 108.863 178.961 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . . . . . . . . . . . -47.82 121.27 6.77 Favored Glycine 0 N--CA 1.491 2.352 0 N-CA-C 109.678 -1.369 . . . . 0.0 109.678 -179.816 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 100.6 71.62 0.96 Allowed Glycine 0 N--CA 1.491 2.313 0 N-CA-C 109.775 -1.33 . . . . 0.0 109.775 179.808 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . 0.464 ' O ' ' CB ' ' A' ' 29' ' ' LYS . . . 136.87 -56.33 0.69 Allowed Glycine 0 N--CA 1.49 2.296 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 179.695 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.528 ' O ' HG13 ' A' ' 25' ' ' ILE . 0.0 OUTLIER 167.87 -155.41 0.01 OUTLIER 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.123 -1.222 . . . . 0.0 109.406 -179.757 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 1.048 ' O ' HD13 ' A' ' 69' ' ' ILE . 4.6 pt-20 -111.08 150.48 29.31 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 120.771 -1.206 . . . . 0.0 109.988 -179.934 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.682 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -97.95 -175.4 33.47 Favored Glycine 0 N--CA 1.49 2.251 0 N-CA-C 108.03 -2.028 . . . . 0.0 108.03 178.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.973 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -151.13 121.04 7.09 Favored 'General case' 0 C--N 1.304 -1.41 0 O-C-N 120.89 -1.359 . . . . 0.0 111.39 179.645 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.901 HG23 ' CG2' ' A' ' 23' ' ' VAL . 71.8 t -94.67 61.81 0.27 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.512 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 177.286 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.517 ' O ' ' CD1' ' A' ' 38' ' ' ILE . 3.1 t-80 -49.54 152.83 1.27 Allowed 'General case' 0 C--N 1.304 -1.384 0 O-C-N 120.89 -1.131 . . . . 0.0 108.814 -179.165 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.578 ' O ' HD13 ' A' ' 38' ' ' ILE . 0.4 OUTLIER -46.96 -49.01 7.62 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.372 -0.83 . . . . 0.0 109.982 -179.591 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.516 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.3 OUTLIER -81.6 40.42 0.58 Allowed 'General case' 0 N--CA 1.494 1.732 0 O-C-N 121.21 -0.931 . . . . 0.0 110.327 -179.819 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.775 ' C ' HD12 ' A' ' 38' ' ' ILE . 14.7 mm-40 -147.88 31.9 0.86 Allowed 'General case' 0 N--CA 1.49 1.539 0 O-C-N 120.849 -1.157 . . . . 0.0 109.388 -179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.844 HG21 ' CD2' ' A' ' 49' ' ' TYR . 1.6 mp -111.22 -98.74 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.442 0 O-C-N 121.13 -0.981 . . . . 0.0 109.992 -179.581 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.776 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -104.6 179.24 4.33 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.323 -0.861 . . . . 0.0 109.38 -179.706 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.425 ' C ' ' O ' ' A' ' 39' ' ' ALA . 8.9 t0 -42.41 -55.19 3.51 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.444 -0.785 . . . . 0.0 109.367 179.947 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.491 ' HD2' ' OH ' ' A' ' 49' ' ' TYR . 3.1 ptpt -66.42 169.18 7.79 Favored 'General case' 0 N--CA 1.491 1.617 0 O-C-N 121.219 -0.925 . . . . 0.0 109.257 179.792 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.497 ' O ' ' HB ' ' A' ' 43' ' ' VAL . 1.1 mmt85 -79.67 -3.11 45.83 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.247 -0.908 . . . . 0.0 109.971 -179.558 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.047 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 24.1 t 63.27 82.28 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.486 1.375 0 O-C-N 121.151 -0.968 . . . . 0.0 109.553 179.803 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 2.5 tt0 -49.02 -22.61 0.92 Allowed 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.442 -0.786 . . . . 0.0 109.426 179.619 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.539 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 1.3 mmpt? -130.11 113.05 14.03 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 121.315 -0.866 . . . . 0.0 109.945 -179.58 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.796 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -76.64 -26.05 16.33 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.924 0 O-C-N 121.233 -0.917 . . . . 0.0 108.839 179.563 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.473 HG22 HG21 ' A' ' 16' ' ' ILE . 52.9 p -76.56 3.74 10.78 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.838 . . . . 0.0 109.35 179.396 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.464 ' OD2' ' CB ' ' A' ' 45' ' ' LYS . 98.5 m-20 -103.88 -30.26 10.46 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.143 -0.973 . . . . 0.0 108.515 179.716 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 1.047 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 16.3 m-85 -91.24 -31.58 16.09 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 108.885 -0.783 . . . . 0.0 108.885 179.501 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.955 HD12 ' HB1' ' A' ' 21' ' ' ALA . 1.3 mt -108.23 155.22 20.71 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.278 -0.889 . . . . 0.0 109.418 179.446 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.497 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 5.9 tp60 -141.53 138.43 32.72 Favored 'General case' 0 N--CA 1.488 1.467 0 N-CA-C 108.69 -0.855 . . . . 0.0 108.69 179.321 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 9.4 mtt -63.3 112.82 2.87 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.144 -0.973 . . . . 0.0 109.908 -179.497 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 108.3 -22.66 26.53 Favored Glycine 0 N--CA 1.492 2.378 0 N-CA-C 109.955 -1.258 . . . . 0.0 109.955 179.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . 0.492 ' CG ' ' HB3' ' A' ' 51' ' ' GLN . 35.3 mt-30 -68.94 162.6 26.34 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.173 -1.193 . . . . 0.0 109.89 -179.757 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 -114.32 141.82 47.11 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 121.359 -0.838 . . . . 0.0 109.033 179.6 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.445 ' O ' HG23 ' A' ' 56' ' ' VAL . 31.7 m -144.13 131.04 10.31 Favored Pre-proline 0 N--CA 1.49 1.54 0 O-C-N 120.948 -1.095 . . . . 0.0 110.25 -179.823 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.494 ' HA ' ' HA ' ' A' ' 10' ' ' THR . 36.6 Cg_endo -80.65 154.14 20.51 Favored 'Trans proline' 0 C--N 1.316 -1.176 0 C-N-CA 122.65 2.233 . . . . 0.0 109.765 179.405 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.968 ' O ' HG13 ' A' ' 8' ' ' VAL . 0.9 OUTLIER -150.89 -169.73 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.035 -1.041 . . . . 0.0 109.625 179.733 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.625 ' N ' HG23 ' A' ' 58' ' ' VAL . 0.0 OUTLIER -135.68 138.53 42.89 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.469 -0.769 . . . . 0.0 109.205 179.557 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.629 ' CG2' ' CD1' ' A' ' 9' ' ' TYR . 5.1 t -73.16 83.3 0.43 Allowed 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.334 -0.854 . . . . 0.0 108.853 179.758 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.534 ' O ' ' CB ' ' A' ' 62' ' ' GLU . 4.6 tp -58.96 -28.56 66.41 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.427 -0.796 . . . . 0.0 109.767 -179.565 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.534 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 0.0 OUTLIER 163.16 138.45 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.746 0 O-C-N 121.221 -0.924 . . . . 0.0 110.34 179.602 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.49 HG13 ' H ' ' A' ' 69' ' ' ILE . 42.2 t -150.21 -106.34 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.574 0 O-C-N 121.444 -0.785 . . . . 0.0 109.275 179.247 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.435 ' N ' HG12 ' A' ' 63' ' ' VAL . 2.6 p30 41.05 -161.86 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.917 -1.114 . . . . 0.0 110.345 179.601 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . 0.401 ' N ' ' OD1' ' A' ' 64' ' ' ASP . 3.2 ttm105 -45.35 -66.08 0.45 Allowed 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.423 -0.798 . . . . 0.0 109.804 -179.729 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 10.6 mt-30 -89.31 89.36 7.87 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.191 -0.943 . . . . 0.0 109.031 179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . 0.457 ' HA3' ' HA ' ' A' ' 63' ' ' VAL . . . 163.98 102.8 0.17 Allowed Glycine 0 N--CA 1.485 1.919 0 N-CA-C 108.841 -1.703 . . . . 0.0 108.841 -179.584 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . . . . . . . . . 10.3 mtt180 -88.15 72.35 9.13 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.347 -1.09 . . . . 0.0 109.15 -179.797 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 1.048 HD13 ' O ' ' A' ' 30' ' ' GLU . 35.0 mt 53.24 68.97 0.13 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.524 -0.735 . . . . 0.0 109.636 179.878 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.454 ' HB2' ' O ' ' A' ' 62' ' ' GLU . 3.4 mmm180 -89.77 78.25 6.93 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.14 -0.975 . . . . 0.0 108.692 179.437 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.682 HD12 ' HA3' ' A' ' 31' ' ' GLY . 19.4 mt -89.12 155.16 19.61 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.277 -0.889 . . . . 0.0 109.28 -179.65 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -129.16 117.55 20.96 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.509 -0.744 . . . . 0.0 110.001 -179.145 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.634 HG23 ' H ' ' A' ' 75' ' ' GLU . 0.0 OUTLIER -56.07 133.05 20.19 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 121.223 -0.923 . . . . 0.0 109.037 179.883 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -43.31 -32.6 0.83 Allowed 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.467 -0.771 . . . . 0.0 110.05 -179.302 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.634 ' H ' HG23 ' A' ' 73' ' ' ILE . 2.7 mt-10 -89.98 41.29 1.04 Allowed 'General case' 0 C--N 1.292 -1.904 0 N-CA-C 108.917 -0.772 . . . . 0.0 108.917 179.707 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.488 1.462 0 CA-C-O 118.034 -0.984 . . . . 0.0 109.363 -179.774 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.491 1.585 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.48 ' O ' ' O ' ' A' ' 3' ' ' ILE . 18.3 tt0 -59.19 -17.95 32.12 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.199 -0.938 . . . . 0.0 109.395 -179.949 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.597 HG23 ' OH ' ' A' ' 9' ' ' TYR . 0.3 OUTLIER 59.37 150.05 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.299 -1.595 0 N-CA-C 108.868 -0.79 . . . . 0.0 108.868 179.758 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . 0.545 ' O ' ' HG3' ' A' ' 7' ' ' ARG . 3.2 tt0 -150.39 -170.19 3.59 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.038 -1.039 . . . . 0.0 109.426 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.984 HG22 HG11 ' A' ' 60' ' ' VAL . 2.3 t -81.8 161.85 3.57 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.116 -0.99 . . . . 0.0 109.296 179.68 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.47 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 90.23 13.24 60.53 Favored Glycine 0 N--CA 1.49 2.293 0 N-CA-C 110.02 -1.232 . . . . 0.0 110.02 179.404 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.545 ' HG3' ' O ' ' A' ' 4' ' ' GLU . 0.0 OUTLIER -124.07 -174.74 3.07 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.102 -1.234 . . . . 0.0 109.669 -179.838 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.458 HG13 ' O ' ' A' ' 58' ' ' VAL . 23.9 t -89.62 135.19 26.74 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.425 0 N-CA-C 107.929 -1.137 . . . . 0.0 107.929 178.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.673 ' CD1' ' CG2' ' A' ' 60' ' ' VAL . 4.0 m-85 -122.64 136.79 54.98 Favored 'General case' 0 C--N 1.301 -1.504 0 O-C-N 121.037 -1.04 . . . . 0.0 110.195 -178.848 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 7.0 m -90.34 102.66 15.39 Favored 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 107.407 -1.331 . . . . 0.0 107.407 178.125 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.472 ' HA3' HG11 ' A' ' 23' ' ' VAL . . . -79.54 128.39 8.51 Favored Glycine 0 N--CA 1.488 2.114 0 C-N-CA 119.843 -1.17 . . . . 0.0 110.794 -178.197 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.58 ' O ' HG13 ' A' ' 23' ' ' VAL . 6.1 mttt -89.08 147.61 24.14 Favored 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 178.29 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.729 HG13 HD12 ' A' ' 50' ' ' LEU . 17.1 t -86.42 104.2 13.61 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.715 0 O-C-N 120.384 -1.447 . . . . 0.0 108.708 -179.289 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.914 HG21 ' HB3' ' A' ' 24' ' ' ALA . 1.5 p -111.29 -9.15 14.3 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.697 -0.627 . . . . 0.0 109.858 -178.888 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.551 ' CB ' ' HB2' ' A' ' 22' ' ' PHE . 1.1 mpp_? -166.76 157.82 12.41 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.026 -1.046 . . . . 0.0 110.256 -179.944 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.556 HG21 HG22 ' A' ' 47' ' ' THR . 14.7 mt -144.1 153.66 15.51 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.777 0 N-CA-C 108.317 -0.994 . . . . 0.0 108.317 179.057 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 1.061 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.9 OUTLIER -133.67 155.46 40.17 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.556 0 O-C-N 120.835 -1.165 . . . . 0.0 109.884 -179.413 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 12.3 t0 -59.34 -41.74 89.89 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 120.753 -1.217 . . . . 0.0 109.345 179.444 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.061 ' CE1' HG21 ' A' ' 17' ' ' VAL . 12.8 p90 -91.33 26.56 2.2 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.346 -0.846 . . . . 0.0 110.296 -179.609 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.772 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 156.25 -152.99 24.37 Favored Glycine 0 N--CA 1.493 2.456 0 C-N-CA 119.108 -1.52 . . . . 0.0 111.174 -179.669 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.912 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -152.24 144.54 23.99 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.259 -1.142 . . . . 0.0 109.017 -179.657 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.972 ' CE1' HD11 ' A' ' 32' ' ' LEU . 9.6 m-30 -105.28 152.72 22.55 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.171 -0.956 . . . . 0.0 109.244 179.954 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.801 ' CG2' HG23 ' A' ' 33' ' ' VAL . 35.5 t -145.35 162.95 12.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.595 0 O-C-N 121.266 -0.896 . . . . 0.0 109.385 -179.476 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.914 ' HB3' HG21 ' A' ' 14' ' ' THR . . . -135.18 130.72 35.79 Favored 'General case' 0 N--CA 1.493 1.693 0 O-C-N 120.852 -1.155 . . . . 0.0 110.089 -179.066 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.526 HG13 ' O ' ' A' ' 29' ' ' LYS . 1.0 OUTLIER -114.88 85.81 0.86 Allowed 'Isoleucine or valine' 0 N--CA 1.492 1.673 0 O-C-N 120.938 -1.101 . . . . 0.0 109.157 179.504 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.419 ' C ' ' O ' ' A' ' 25' ' ' ILE . . . -43.15 151.78 0.36 Allowed Glycine 0 N--CA 1.491 2.311 0 N-CA-C 109.702 -1.359 . . . . 0.0 109.702 -179.818 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 80.03 49.81 5.81 Favored Glycine 0 N--CA 1.489 2.186 0 N-CA-C 109.495 -1.442 . . . . 0.0 109.495 179.982 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 153.36 -74.66 0.24 Allowed Glycine 0 N--CA 1.491 2.321 0 N-CA-C 109.826 -1.309 . . . . 0.0 109.826 179.974 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.585 ' HD2' HD11 ' A' ' 69' ' ' ILE . 0.1 OUTLIER -171.8 -160.69 0.17 Allowed 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.141 -1.211 . . . . 0.0 109.421 -179.674 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.753 ' O ' HD13 ' A' ' 69' ' ' ILE . 2.8 mt-10 -105.91 148.46 27.59 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 120.725 -1.234 . . . . 0.0 109.628 179.772 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.481 ' O ' ' O ' ' A' ' 23' ' ' VAL . . . -98.97 -179.36 31.71 Favored Glycine 0 N--CA 1.488 2.149 0 N-CA-C 108.452 -1.859 . . . . 0.0 108.452 179.342 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.972 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.64 117.37 5.82 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 120.814 -1.404 . . . . 0.0 110.652 179.577 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.912 ' HB ' ' HB3' ' A' ' 21' ' ' ALA . 30.1 t -91.23 61.06 0.29 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.567 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 177.51 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.568 ' HB2' HD23 ' A' ' 32' ' ' LEU . 3.7 t-80 -50.73 156.28 0.98 Allowed 'General case' 0 C--N 1.304 -1.394 0 O-C-N 120.964 -1.085 . . . . 0.0 108.624 -179.384 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.556 ' N ' ' HA2' ' A' ' 20' ' ' GLY . 0.9 OUTLIER -48.87 -47.35 16.39 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.59 0 O-C-N 121.171 -0.956 . . . . 0.0 109.789 -179.954 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.541 ' N ' HG23 ' A' ' 35' ' ' ILE . 37.4 t -81.42 40.2 0.56 Allowed 'General case' 0 N--CA 1.493 1.71 0 O-C-N 121.158 -0.964 . . . . 0.0 110.647 -179.498 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.932 ' C ' HD12 ' A' ' 38' ' ' ILE . 35.9 mt-30 -150.51 43.35 0.84 Allowed 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.851 -1.155 . . . . 0.0 110.032 179.814 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 0.932 HD12 ' C ' ' A' ' 37' ' ' GLN . 1.6 mp -120.68 -98.97 0.07 OUTLIER 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.086 -1.008 . . . . 0.0 109.521 179.719 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.765 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -112.79 153.0 28.49 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.244 -0.91 . . . . 0.0 109.636 -179.725 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . 0.404 ' C ' ' O ' ' A' ' 39' ' ' ALA . 4.4 t70 -44.21 -45.14 8.28 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.298 -0.876 . . . . 0.0 109.189 179.958 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.442 ' O ' ' C ' ' A' ' 42' ' ' ARG . 0.3 OUTLIER -68.01 122.45 18.25 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.286 -0.884 . . . . 0.0 109.225 179.766 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.442 ' C ' ' O ' ' A' ' 41' ' ' LYS . 0.7 OUTLIER -41.26 126.24 2.68 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.427 -0.795 . . . . 0.0 109.759 -179.844 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.024 HG22 ' CZ ' ' A' ' 49' ' ' TYR . 17.7 t -88.11 85.81 2.52 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.263 0 N-CA-C 108.355 -0.98 . . . . 0.0 108.355 179.567 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 9.5 mt-10 -44.91 -21.33 0.05 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.544 -0.722 . . . . 0.0 110.316 -179.686 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.539 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 5.7 mttt -139.1 117.5 12.01 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 121.013 -1.054 . . . . 0.0 110.191 -179.433 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.772 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -72.52 -27.61 26.27 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.065 0 N-CA-C 108.664 -0.865 . . . . 0.0 108.664 179.38 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . 0.556 HG22 HG21 ' A' ' 16' ' ' ILE . 81.9 p -75.97 1.26 15.79 Favored 'General case' 0 C--N 1.301 -1.526 0 C-N-CA 119.798 -0.761 . . . . 0.0 109.15 179.439 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.469 ' OD1' ' HB3' ' A' ' 45' ' ' LYS . 2.1 m-20 -97.71 -35.35 10.59 Favored 'General case' 0 N--CA 1.492 1.652 0 O-C-N 121.291 -0.881 . . . . 0.0 109.041 179.696 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 1.024 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 7.0 m-85 -91.46 -27.38 18.31 Favored 'General case' 0 N--CA 1.489 1.48 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 179.404 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.874 HD21 HG21 ' A' ' 33' ' ' VAL . 0.2 OUTLIER -104.46 140.31 38.13 Favored 'General case' 0 N--CA 1.488 1.452 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 179.598 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.563 ' O ' HG21 ' A' ' 13' ' ' VAL . 4.1 tp-100 -132.41 124.46 28.69 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.198 -0.939 . . . . 0.0 109.788 -179.768 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . 0.474 ' O ' ' HG3' ' A' ' 52' ' ' MET . 23.6 ptp -58.42 130.07 45.01 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.381 -0.824 . . . . 0.0 109.869 179.94 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 93.86 -31.17 6.75 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 110.039 -1.224 . . . . 0.0 110.039 179.598 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . 0.485 ' HB2' ' HB3' ' A' ' 51' ' ' GLN . 56.8 mt-30 -77.97 -172.94 2.91 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.129 -1.218 . . . . 0.0 109.817 -179.62 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 27.2 mt-10 -143.56 157.06 44.72 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.441 -0.787 . . . . 0.0 108.943 179.704 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.1 m -140.0 140.91 25.29 Favored Pre-proline 0 C--N 1.303 -1.423 0 O-C-N 121.143 -0.973 . . . . 0.0 109.581 -179.781 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.444 ' O ' ' HB3' ' A' ' 74' ' ' LYS . 36.3 Cg_endo -79.24 130.38 9.17 Favored 'Trans proline' 0 C--N 1.311 -1.403 0 C-N-CA 122.438 2.092 . . . . 0.0 109.9 179.551 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.911 HG21 HD12 ' A' ' 71' ' ' LEU . 1.1 m -143.18 -170.02 0.4 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.087 -1.008 . . . . 0.0 109.99 -179.631 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.537 ' N ' HG23 ' A' ' 58' ' ' VAL . 0.5 OUTLIER -135.08 126.81 29.12 Favored 'General case' 0 C--N 1.301 -1.51 0 N-CA-C 108.697 -0.853 . . . . 0.0 108.697 179.672 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.984 HG11 HG22 ' A' ' 5' ' ' VAL . 36.2 t -51.74 97.36 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.278 -0.889 . . . . 0.0 109.306 -179.757 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.94 HD23 ' HG2' ' A' ' 70' ' ' ARG . 18.1 tp -67.36 -16.39 64.22 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.148 -0.97 . . . . 0.0 108.98 179.891 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.553 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 5.2 mt-10 91.62 -168.49 0.01 OUTLIER 'General case' 0 N--CA 1.499 2.002 0 CA-C-O 121.582 0.706 . . . . 0.0 110.114 179.687 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.714 HG22 ' O ' ' A' ' 68' ' ' ARG . 58.2 t -137.55 159.73 34.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.481 0 O-C-N 121.484 -0.76 . . . . 0.0 109.477 -179.519 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.487 ' N ' HG12 ' A' ' 63' ' ' VAL . 9.0 p-10 -90.28 -161.28 0.78 Allowed 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.348 -0.845 . . . . 0.0 109.295 179.762 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -81.79 41.01 0.63 Allowed 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.214 -0.929 . . . . 0.0 110.058 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 5.1 tt0 -129.21 -51.02 1.2 Allowed 'General case' 0 N--CA 1.49 1.562 0 O-C-N 120.938 -1.101 . . . . 0.0 109.555 -179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 125.92 26.94 1.19 Allowed Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.879 -1.288 . . . . 0.0 109.879 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.714 ' O ' HG22 ' A' ' 63' ' ' VAL . 7.9 ptp180 -101.91 120.11 39.87 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.204 -1.174 . . . . 0.0 109.266 179.725 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.753 HD13 ' O ' ' A' ' 30' ' ' GLU . 1.5 mt -66.11 118.68 9.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.327 -0.858 . . . . 0.0 109.961 -179.636 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.94 ' HG2' HD23 ' A' ' 61' ' ' LEU . 6.9 tpt180 -105.2 115.39 30.19 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.17 -0.956 . . . . 0.0 109.419 179.657 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.911 HD12 HG21 ' A' ' 58' ' ' VAL . 3.4 mm? -106.37 147.35 29.34 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.217 -0.927 . . . . 0.0 109.654 -179.704 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.502 ' OG ' HD13 ' A' ' 61' ' ' LEU . 0.4 OUTLIER -112.14 106.26 14.83 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.393 -0.817 . . . . 0.0 109.704 -179.93 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.472 HD11 HG22 ' A' ' 33' ' ' VAL . 0.9 OUTLIER -52.02 144.19 3.2 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.108 -0.995 . . . . 0.0 109.303 -179.871 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.444 ' HB3' ' O ' ' A' ' 57' ' ' PRO . 1.0 OUTLIER -51.64 -176.7 0.0 OUTLIER 'General case' 0 N--CA 1.491 1.615 0 O-C-N 121.371 -0.831 . . . . 0.0 109.843 -179.692 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . . . . . . . . . 27.7 mm-40 -43.64 -41.61 4.78 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.412 -0.805 . . . . 0.0 109.449 179.896 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . 0.473 ' O ' ' HA ' ' A' ' 39' ' ' ALA . . . . . . . . 0 N--CA 1.489 1.51 0 CA-C-O 117.997 -1.001 . . . . 0.0 109.381 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.476 ' O ' ' CB ' ' A' ' 2' ' ' GLU . . . . . . . . 0 N--CA 1.489 1.502 0 CA-C-O 121.293 0.568 . . . . 0.0 109.494 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLU . . . . . 0.476 ' CB ' ' O ' ' A' ' 1' ' ' ALA . 2.3 mm-40 165.0 -36.42 0.0 OUTLIER 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.31 -0.868 . . . . 0.0 109.35 -179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' ILE . . . . . 0.831 HD13 ' OH ' ' A' ' 9' ' ' TYR . 0.1 OUTLIER -156.42 154.64 6.05 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.959 0 C-N-CA 119.731 -0.788 . . . . 0.0 109.249 -179.681 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -121.88 170.58 9.65 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.204 -0.935 . . . . 0.0 109.485 -179.929 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.749 HG22 HG12 ' A' ' 60' ' ' VAL . 3.4 t -62.64 163.47 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.375 -0.828 . . . . 0.0 109.413 179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . 0.51 ' N ' ' CG1' ' A' ' 5' ' ' VAL . . . 88.28 4.29 77.67 Favored Glycine 0 N--CA 1.488 2.157 0 N-CA-C 109.247 -1.541 . . . . 0.0 109.247 -179.604 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ARG . . . . . 0.468 ' HD3' HG22 ' A' ' 3' ' ' ILE . 5.6 ttt-85 -112.88 176.51 4.99 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.153 -1.204 . . . . 0.0 109.835 -179.733 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' VAL . . . . . 0.795 HG22 ' HG3' ' A' ' 59' ' ' LYS . 71.3 t -104.83 129.81 56.83 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.593 0 O-C-N 121.352 -0.843 . . . . 0.0 109.306 179.79 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' TYR . . . . . 0.831 ' OH ' HD13 ' A' ' 3' ' ' ILE . 3.1 m-85 -106.27 -174.67 2.59 Favored 'General case' 0 N--CA 1.492 1.632 0 O-C-N 121.147 -0.97 . . . . 0.0 109.836 -179.943 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' THR . . . . . . . . . . . . . 11.4 m -147.28 110.79 4.92 Favored 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 107.304 -1.369 . . . . 0.0 107.304 178.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.43 ' HA2' ' HA ' ' A' ' 25' ' ' ILE . . . -121.26 143.24 15.96 Favored Glycine 0 N--CA 1.488 2.122 0 C-N-CA 118.868 -1.634 . . . . 0.0 110.908 -178.194 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' LYS . . . . . 0.45 ' O ' HG13 ' A' ' 23' ' ' VAL . 8.8 mttp -90.43 165.58 13.75 Favored 'General case' 0 C--N 1.303 -1.45 0 N-CA-C 108.021 -1.103 . . . . 0.0 108.021 178.802 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' VAL . . . . . 0.834 HG22 HD13 ' A' ' 50' ' ' LEU . 39.1 t -88.27 102.89 13.16 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.744 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.487 179.426 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.774 HG21 ' CB ' ' A' ' 24' ' ' ALA . 0.1 OUTLIER -101.75 -7.98 22.11 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 121.292 -0.88 . . . . 0.0 109.494 -179.351 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' ARG . . . . . 0.504 ' CG ' ' C ' ' A' ' 14' ' ' THR . 0.0 OUTLIER -167.64 147.24 5.02 Favored 'General case' 0 N--CA 1.496 1.85 0 O-C-N 121.151 -0.968 . . . . 0.0 109.613 -179.599 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' ILE . . . . . 0.532 HG22 ' N ' ' A' ' 17' ' ' VAL . 62.1 mt -131.13 163.34 37.26 Favored 'Isoleucine or valine' 0 N--CA 1.497 1.89 0 N-CA-C 108.101 -1.074 . . . . 0.0 108.101 178.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' VAL . . . . . 1.059 HG21 ' CE1' ' A' ' 19' ' ' PHE . 0.8 OUTLIER -138.82 154.38 26.31 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 120.726 -1.234 . . . . 0.0 110.425 -179.559 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 0.5 OUTLIER -59.23 -43.16 92.34 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.843 -1.161 . . . . 0.0 109.812 179.531 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' PHE . . . . . 1.059 ' CE1' HG21 ' A' ' 17' ' ' VAL . 6.4 p90 -92.12 25.6 2.81 Favored 'General case' 0 N--CA 1.495 1.808 0 O-C-N 121.249 -0.907 . . . . 0.0 110.266 -179.384 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' GLY . . . . . 0.864 ' C ' HG11 ' A' ' 46' ' ' VAL . . . 157.66 -154.79 25.84 Favored Glycine 0 N--CA 1.493 2.486 0 C-N-CA 119.033 -1.556 . . . . 0.0 110.98 -179.71 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' ALA . . . . . 0.772 ' HB3' ' HB ' ' A' ' 33' ' ' VAL . . . -149.61 145.97 27.05 Favored 'General case' 0 N--CA 1.486 1.345 0 O-C-N 121.089 -1.242 . . . . 0.0 108.995 -179.759 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' PHE . . . . . 0.967 ' CE1' HD11 ' A' ' 32' ' ' LEU . 10.8 m-30 -106.87 158.2 17.19 Favored 'General case' 0 C--N 1.298 -1.672 0 O-C-N 121.316 -0.865 . . . . 0.0 108.738 179.481 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' VAL . . . . . 0.908 ' CG2' HG23 ' A' ' 33' ' ' VAL . 37.6 t -148.34 166.34 4.56 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.069 -1.02 . . . . 0.0 109.755 -179.507 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' ALA . . . . . 0.774 ' CB ' HG21 ' A' ' 14' ' ' THR . . . -137.91 144.65 41.4 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.287 -0.883 . . . . 0.0 109.539 -179.764 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ILE . . . . . 0.535 ' CG1' ' O ' ' A' ' 29' ' ' LYS . 5.5 pt -104.28 -20.72 5.65 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.771 0 O-C-N 120.625 -1.297 . . . . 0.0 108.562 179.253 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' GLY . . . . . 0.469 ' O ' ' O ' ' A' ' 25' ' ' ILE . . . 59.73 142.07 0.01 OUTLIER Glycine 0 N--CA 1.489 2.193 0 N-CA-C 110.004 -1.238 . . . . 0.0 110.004 179.34 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 82.59 15.21 74.1 Favored Glycine 0 N--CA 1.489 2.227 0 N-CA-C 109.934 -1.266 . . . . 0.0 109.934 179.592 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' GLY . . . . . . . . . . . . . . . 178.9 -52.74 0.09 OUTLIER Glycine 0 N--CA 1.491 2.313 0 C-N-CA 119.625 -1.274 . . . . 0.0 110.18 179.905 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' LYS . . . . . 0.535 ' O ' ' CG1' ' A' ' 25' ' ' ILE . 0.4 OUTLIER -173.9 -161.78 0.13 Allowed 'General case' 0 N--CA 1.492 1.674 0 O-C-N 121.069 -1.254 . . . . 0.0 110.06 -179.519 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' GLU . . . . . 0.568 ' HA ' ' HA ' ' A' ' 24' ' ' ALA . 12.6 mp0 -123.39 153.24 40.65 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 120.836 -1.165 . . . . 0.0 110.109 -179.833 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' GLY . . . . . 0.56 ' HA3' HD12 ' A' ' 71' ' ' LEU . . . -103.67 -175.48 25.92 Favored Glycine 0 N--CA 1.49 2.244 0 N-CA-C 108.8 -1.72 . . . . 0.0 108.8 179.521 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' LEU . . . . . 0.967 HD11 ' CE1' ' A' ' 22' ' ' PHE . 0.5 OUTLIER -150.57 119.82 6.81 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 120.97 -1.312 . . . . 0.0 110.552 179.624 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . 0.908 HG23 ' CG2' ' A' ' 23' ' ' VAL . 25.2 t -96.84 63.21 0.28 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 N-CA-C 107.944 -1.132 . . . . 0.0 107.944 177.736 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' HIS . . . . . 0.532 ' O ' ' CD1' ' A' ' 38' ' ' ILE . 7.7 t-80 -48.64 162.57 0.1 Allowed 'General case' 0 C--N 1.304 -1.382 0 O-C-N 120.741 -1.224 . . . . 0.0 108.359 -179.627 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.636 ' O ' HD13 ' A' ' 38' ' ' ILE . 0.4 OUTLIER -55.5 -45.79 78.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.012 -1.055 . . . . 0.0 110.53 -179.49 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' SER . . . . . 0.489 ' N ' HG23 ' A' ' 35' ' ' ILE . 0.9 OUTLIER -80.05 23.77 0.45 Allowed 'General case' 0 N--CA 1.494 1.77 0 O-C-N 121.153 -0.967 . . . . 0.0 110.795 -179.338 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' GLN . . . . . 0.992 ' C ' HD12 ' A' ' 38' ' ' ILE . 3.4 mm100 -138.74 64.18 1.49 Allowed 'General case' 0 N--CA 1.491 1.618 0 O-C-N 120.883 -1.136 . . . . 0.0 109.293 179.546 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ILE . . . . . 1.069 HG21 HG21 ' A' ' 43' ' ' VAL . 1.8 mp -129.35 -94.59 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.042 -1.036 . . . . 0.0 109.704 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' ALA . . . . . 0.803 ' N ' HG22 ' A' ' 38' ' ' ILE . . . -114.98 -168.4 1.38 Allowed 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.455 -0.778 . . . . 0.0 109.852 -179.346 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' ASP . . . . . . . . . . . . . 4.6 m-20 -65.8 -58.06 6.51 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.4 -0.813 . . . . 0.0 109.417 179.867 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' LYS . . . . . 0.452 ' HA ' ' HE2' ' A' ' 41' ' ' LYS . 0.1 OUTLIER -65.41 125.97 26.79 Favored 'General case' 0 N--CA 1.489 1.5 0 O-C-N 121.359 -0.838 . . . . 0.0 109.227 179.939 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' ARG . . . . . 0.438 ' C ' ' O ' ' A' ' 41' ' ' LYS . 4.8 mtt180 -44.22 133.8 5.2 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.259 -0.901 . . . . 0.0 108.97 179.793 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' VAL . . . . . 1.069 HG21 HG21 ' A' ' 38' ' ' ILE . 44.3 t -97.3 82.39 1.14 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 121.2 -0.937 . . . . 0.0 109.06 -179.809 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' GLU . . . . . . . . . . . . . 94.3 mt-10 -53.98 -19.02 4.06 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.365 -0.834 . . . . 0.0 109.114 179.8 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' LYS . . . . . 0.543 ' O ' ' CG1' ' A' ' 43' ' ' VAL . 0.2 OUTLIER -121.68 108.19 13.25 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.436 -0.79 . . . . 0.0 109.748 -179.569 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' VAL . . . . . 0.864 HG11 ' C ' ' A' ' 20' ' ' GLY . 0.0 OUTLIER -76.3 -24.76 16.26 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.843 0 O-C-N 121.331 -0.856 . . . . 0.0 109.179 179.972 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' THR . . . . . . . . . . . . . 6.2 p -78.28 5.95 9.28 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.364 -0.835 . . . . 0.0 109.541 179.873 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' ASP . . . . . 0.457 ' CG ' ' HB3' ' A' ' 45' ' ' LYS . 10.2 m-20 -104.35 -37.59 7.17 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.136 -0.977 . . . . 0.0 108.716 179.548 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' TYR . . . . . 1.028 ' CZ ' HG22 ' A' ' 43' ' ' VAL . 11.7 m-85 -89.84 -38.01 14.05 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.739 -0.837 . . . . 0.0 108.739 179.532 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' LEU . . . . . 0.834 HD13 HG22 ' A' ' 13' ' ' VAL . 0.2 OUTLIER -96.45 136.02 37.52 Favored 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.435 -0.791 . . . . 0.0 109.301 -179.931 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' GLN . . . . . 0.52 ' O ' ' HB ' ' A' ' 13' ' ' VAL . 0.9 OUTLIER -129.72 132.57 46.66 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.659 -0.651 . . . . 0.0 109.372 -179.517 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' MET . . . . . . . . . . . . . 11.5 mtt -57.31 113.52 1.79 Allowed 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.313 -0.867 . . . . 0.0 109.661 -179.902 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 106.14 -34.09 6.0 Favored Glycine 0 N--CA 1.492 2.42 0 N-CA-C 109.636 -1.385 . . . . 0.0 109.636 179.904 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' GLN . . . . . 0.472 ' O ' HG23 ' A' ' 13' ' ' VAL . 6.9 mt-30 -54.4 143.02 24.94 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.32 -1.106 . . . . 0.0 110.025 -179.722 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' GLU . . . . . . . . . . . . . 23.4 mt-10 -104.15 129.39 51.88 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.313 -0.867 . . . . 0.0 108.898 179.368 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.405 ' HA ' ' HD3' ' A' ' 57' ' ' PRO . 33.2 m -132.78 134.48 24.65 Favored Pre-proline 0 N--CA 1.488 1.473 0 O-C-N 120.99 -1.069 . . . . 0.0 110.085 -179.617 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' PRO . . . . . 0.471 ' O ' ' HB2' ' A' ' 74' ' ' LYS . 37.0 Cg_endo -81.72 143.51 13.38 Favored 'Trans proline' 0 C--N 1.314 -1.283 0 C-N-CA 122.705 2.27 . . . . 0.0 110.015 179.341 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' VAL . . . . . 0.737 HG21 HD13 ' A' ' 71' ' ' LEU . 0.9 OUTLIER -135.31 -177.87 2.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 O-C-N 121.062 -1.024 . . . . 0.0 109.322 179.676 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . 0.795 ' HG3' HG22 ' A' ' 8' ' ' VAL . 0.0 OUTLIER -131.72 110.78 11.13 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.277 -0.889 . . . . 0.0 109.212 179.737 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' VAL . . . . . 0.749 HG12 HG22 ' A' ' 5' ' ' VAL . 25.1 t -49.67 90.41 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.374 -0.829 . . . . 0.0 109.112 179.852 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.546 ' N ' ' O ' ' A' ' 59' ' ' LYS . 4.5 tp -82.28 -22.17 35.86 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.383 -0.823 . . . . 0.0 109.735 -179.31 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' GLU . . . . . 0.496 ' O ' ' HB3' ' A' ' 70' ' ' ARG . 1.9 tp10 179.91 113.58 0.05 OUTLIER 'General case' 0 N--CA 1.493 1.713 0 O-C-N 121.237 -0.915 . . . . 0.0 109.842 -179.932 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 50.9 t -146.61 -59.9 0.1 OUTLIER 'Isoleucine or valine' 0 N--CA 1.491 1.598 0 O-C-N 121.114 -0.991 . . . . 0.0 109.628 179.724 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' ASP . . . . . 0.512 ' OD1' ' N ' ' A' ' 65' ' ' ARG . 38.6 p-10 -58.52 -15.5 11.47 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.256 -0.903 . . . . 0.0 109.575 -179.804 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' ARG . . . . . 0.512 ' N ' ' OD1' ' A' ' 64' ' ' ASP . 0.0 OUTLIER -63.79 -67.95 0.39 Allowed 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.1 -1.0 . . . . 0.0 109.352 -179.986 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' GLN . . . . . . . . . . . . . 3.9 mm100 -122.57 -39.49 2.54 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.263 -0.898 . . . . 0.0 109.23 179.712 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' GLY . . . . . . . . . . . . . . . 115.21 31.0 2.13 Favored Glycine 0 N--CA 1.489 2.22 0 N-CA-C 109.782 -1.327 . . . . 0.0 109.782 179.787 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' ARG . . . . . 0.479 ' O ' ' C ' ' A' ' 69' ' ' ILE . 3.2 mtt180 -95.01 35.67 1.26 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.059 -1.26 . . . . 0.0 109.179 179.837 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.607 HG22 ' O ' ' A' ' 69' ' ' ILE . 19.9 mt 31.65 76.97 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.8 0 CA-C-O 121.183 0.516 . . . . 0.0 110.844 179.742 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.496 ' HB3' ' O ' ' A' ' 62' ' ' GLU . 0.0 OUTLIER -101.32 72.12 1.41 Allowed 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.118 -0.989 . . . . 0.0 108.971 179.433 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' LEU . . . . . 0.737 HD13 HG21 ' A' ' 58' ' ' VAL . 23.4 mt -89.62 146.71 24.36 Favored 'General case' 0 N--CA 1.489 1.48 0 O-C-N 121.325 -0.859 . . . . 0.0 109.477 -179.703 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' SER . . . . . 0.508 ' CB ' ' HB2' ' A' ' 59' ' ' LYS . 0.3 OUTLIER -100.66 110.63 22.77 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.336 -0.852 . . . . 0.0 109.546 179.931 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.602 HD13 ' O ' ' A' ' 37' ' ' GLN . 1.9 mp -62.68 127.11 22.23 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.658 0 O-C-N 121.496 -0.752 . . . . 0.0 109.733 -179.738 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' LYS . . . . . 0.522 ' O ' ' CG ' ' A' ' 75' ' ' GLU . 0.0 OUTLIER -62.67 -160.12 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.301 -0.874 . . . . 0.0 109.29 179.666 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' GLU . . . . . 0.522 ' CG ' ' O ' ' A' ' 74' ' ' LYS . 22.9 pt-20 40.71 32.55 0.16 Allowed 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.47 -0.769 . . . . 0.0 109.448 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.49 1.533 0 CA-C-O 117.996 -1.002 . . . . 0.0 109.406 -179.831 . . . . . . . . 0 0 . 1 stop_ save_